assay_id,assay_cell_type,assay_type,cell_id,assay_test_type,description,confidence_score,src_assay_id,assay_category,tid,assay_tax_id,curated_by,src_id,chembl_id,bao_format,tissue_id,variant_id
1,,B,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,8,,,12052,,Autocuration,1,CHEMBL615117,BAO_0000019,,
2,,F,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,0,,,22226,,Autocuration,1,CHEMBL615118,BAO_0000219,,
3,,B,,,,0,,,22226,,Autocuration,1,CHEMBL615119,BAO_0000019,,
4,,B,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,4,,,104729,9913.0,Autocuration,1,CHEMBL615120,BAO_0000249,,
5,143B,F,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,,,80001,9606.0,Intermediate,1,CHEMBL615121,BAO_0000219,,
6,143B,F,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,,,80001,9606.0,Intermediate,1,CHEMBL615122,BAO_0000219,,
7,143B,F,163.0,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,1,,,80001,10090.0,Intermediate,1,CHEMBL615123,BAO_0000219,,
8,143B,F,163.0,,In vitro cell cytotoxicity was determined against 143B cell line,1,,,80001,9606.0,Expert,1,CHEMBL615124,BAO_0000219,,
9,143B,F,163.0,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,1,,,80001,9606.0,Intermediate,1,CHEMBL615125,BAO_0000219,,
10,143B,F,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,,,80001,9606.0,Intermediate,1,CHEMBL615126,BAO_0000219,,
11,143B,F,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,,,80001,9606.0,Intermediate,1,CHEMBL615127,BAO_0000219,,
12,143B,F,163.0,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,1,,,80001,9606.0,Expert,1,CHEMBL615128,BAO_0000219,,
13,,F,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,,50185,1280.0,Intermediate,1,CHEMBL857900,BAO_0000218,,
14,,F,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,,50185,1280.0,Intermediate,1,CHEMBL615129,BAO_0000218,,
15,,F,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,,50185,1280.0,Intermediate,1,CHEMBL615130,BAO_0000218,,
16,,F,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,,50185,1280.0,Intermediate,1,CHEMBL615131,BAO_0000218,,
17,,A,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,9,,,100122,10116.0,Expert,1,CHEMBL884521,BAO_0000357,,
18,,B,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),8,,,12054,,Autocuration,1,CHEMBL615132,BAO_0000357,,
19,,B,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,8,,,12054,,Autocuration,1,CHEMBL615133,BAO_0000019,,
20,,B,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),8,,,12054,,Autocuration,1,CHEMBL615134,BAO_0000357,,
21,,B,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),8,,,12054,,Autocuration,1,CHEMBL615135,BAO_0000357,,
22,,B,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),8,,,12054,,Autocuration,1,CHEMBL615136,BAO_0000357,,
23,,B,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,8,,,12054,,Autocuration,1,CHEMBL615137,BAO_0000357,,
24,,B,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,8,,,12054,,Autocuration,1,CHEMBL615138,BAO_0000357,,
25,,B,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",0,,,22226,,Autocuration,1,CHEMBL836324,BAO_0000219,,
26,,B,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,8,,,12054,9986.0,Autocuration,1,CHEMBL615139,BAO_0000357,,
27,,B,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),8,,,12054,9986.0,Autocuration,1,CHEMBL615140,BAO_0000357,,
28,,B,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,8,,,12426,,Autocuration,1,CHEMBL615141,BAO_0000219,,
29,,B,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,8,,,12054,3847.0,Autocuration,1,CHEMBL615142,BAO_0000357,,
30,,B,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,8,,,12054,3847.0,Autocuration,1,CHEMBL615143,BAO_0000357,,
31,,B,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,8,,,12054,3847.0,Autocuration,1,CHEMBL615144,BAO_0000357,,
32,,B,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,8,,,12054,3847.0,Autocuration,1,CHEMBL872867,BAO_0000357,,
33,,B,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,8,,,12054,3847.0,Autocuration,1,CHEMBL615145,BAO_0000357,,
34,,B,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,8,,,12054,3847.0,Autocuration,1,CHEMBL615146,BAO_0000357,,
35,,B,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,8,,,12054,3847.0,Autocuration,1,CHEMBL615147,BAO_0000357,,
36,,A,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,0,,,22226,10116.0,Autocuration,1,CHEMBL615148,BAO_0000019,,
37,,B,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,0,,,22226,562.0,Autocuration,1,CHEMBL615149,BAO_0000019,,
38,,B,,,Dissociation constant with dimeric 16S rRNA RNA construct B,0,,,22226,,Autocuration,1,CHEMBL615150,BAO_0000019,,
39,,B,,,Dissociation constant towards 16S rRNA construct A,3,,,22222,,Intermediate,1,CHEMBL615151,BAO_0000225,,
40,,B,,,Dissociation constant towards 16S rRNA construct B,3,,,22222,,Intermediate,1,CHEMBL615152,BAO_0000225,,
41,,B,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,3,,,100263,562.0,Expert,1,CHEMBL615153,BAO_0000225,,
42,,B,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,3,,,100263,562.0,Expert,1,CHEMBL615154,BAO_0000225,,
43,,B,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),8,,,13053,,Autocuration,1,CHEMBL615155,BAO_0000019,,
44,,B,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),8,,,13053,,Autocuration,1,CHEMBL615156,BAO_0000019,,
45,,B,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,8,,,20001,9606.0,Autocuration,1,CHEMBL615157,BAO_0000019,,
46,,B,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,8,,,20001,9606.0,Autocuration,1,CHEMBL615158,BAO_0000019,,
47,,B,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",9,,,12971,10116.0,Expert,1,CHEMBL615159,BAO_0000019,,
48,,B,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",9,,,12971,10116.0,Expert,1,CHEMBL615172,BAO_0000019,,
49,,B,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",9,,,12971,10116.0,Expert,1,CHEMBL615173,BAO_0000019,,
50,,B,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",9,,,12971,10116.0,Expert,1,CHEMBL615174,BAO_0000019,,
51,,B,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),8,,,13053,,Autocuration,1,CHEMBL884518,BAO_0000019,,
52,,B,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),8,,,11512,,Autocuration,1,CHEMBL615175,BAO_0000357,,
53,,B,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,8,,,11512,,Autocuration,1,CHEMBL615176,BAO_0000357,,
54,,B,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,8,,,11512,,Autocuration,1,CHEMBL615177,BAO_0000357,,
55,,B,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,5,,,104740,10116.0,Autocuration,1,CHEMBL615178,BAO_0000249,,
56,1A9,F,506.0,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,1,,,80002,9606.0,Intermediate,1,CHEMBL615179,BAO_0000219,,
57,Oocytes,F,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,7,,,104835,10116.0,Autocuration,1,CHEMBL615180,BAO_0000219,,
58,Oocytes,F,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,7,,,104821,10116.0,Autocuration,1,CHEMBL615181,BAO_0000219,,
59,Oocytes,F,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,7,,,104848,10116.0,Autocuration,1,CHEMBL615182,BAO_0000219,,
60,1A9,F,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,1,,,80002,9606.0,Expert,1,CHEMBL615183,BAO_0000219,,
61,1A9,F,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,1,,,80002,9606.0,Intermediate,1,CHEMBL615184,BAO_0000219,,
62,1A9,F,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line,1,,,80002,9606.0,Intermediate,1,CHEMBL615185,BAO_0000219,,
63,1A9,F,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,1,,,80002,9606.0,Intermediate,1,CHEMBL615186,BAO_0000219,,
64,1A9,F,506.0,,Effective dose of compound against replication of 1A9 cell line was evaluated,1,,,80002,9606.0,Intermediate,1,CHEMBL615187,BAO_0000219,,
65,1A9,F,506.0,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,1,,,80002,9606.0,Expert,1,CHEMBL885343,BAO_0000219,,
66,1A9,F,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),1,,,80002,9606.0,Intermediate,1,CHEMBL615188,BAO_0000219,,
67,1A9,F,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,1,,,80002,9606.0,Intermediate,1,CHEMBL615189,BAO_0000219,,
68,1A9,F,506.0,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,1,,,80002,9606.0,Intermediate,1,CHEMBL615190,BAO_0000219,,
69,1A9,F,506.0,,Inhibitory activity against Taxol resistant 1A9 cell lines,1,,,80002,9606.0,Intermediate,1,CHEMBL615191,BAO_0000219,,
70,1A9,F,506.0,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,1,,,80002,9606.0,Expert,1,CHEMBL615192,BAO_0000219,,
71,1A9,F,506.0,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,1,,,80002,9606.0,Expert,1,CHEMBL827083,BAO_0000219,,
72,1A9,F,506.0,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,1,,,80002,9606.0,Expert,1,CHEMBL615193,BAO_0000219,,
73,1A9,F,506.0,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,1,,,80002,9606.0,Intermediate,1,CHEMBL615194,BAO_0000219,,
74,1A9,F,506.0,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,1,,,80002,9606.0,Intermediate,1,CHEMBL615195,BAO_0000219,,
75,1A9,F,506.0,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,1,,,80002,9606.0,Intermediate,1,CHEMBL615196,BAO_0000219,,
76,Jurkat,F,503.0,,Inhibitory concentration against Jurkat cells,1,,,81072,9606.0,Intermediate,1,CHEMBL615197,BAO_0000219,,
77,,F,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,0,,,22226,,Intermediate,1,CHEMBL615198,BAO_0000019,,
78,,A,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,9,,,100121,10116.0,Expert,1,CHEMBL615199,BAO_0000357,,
79,,B,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",8,,,11231,,Expert,1,CHEMBL615200,BAO_0000357,,
80,,B,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",8,,,11231,,Expert,1,CHEMBL615201,BAO_0000357,,
81,,B,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",8,,,11231,,Expert,1,CHEMBL615202,BAO_0000357,,
82,,B,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",8,,,11231,5476.0,Autocuration,1,CHEMBL615203,BAO_0000251,,
83,,B,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",8,,,11231,5476.0,Autocuration,1,CHEMBL615204,BAO_0000251,,
84,,B,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",8,,,11231,4932.0,Autocuration,1,CHEMBL615205,BAO_0000251,,
85,,B,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",8,,,11231,4932.0,Autocuration,1,CHEMBL615206,BAO_0000251,,
86,,B,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",8,,,12083,9823.0,Autocuration,1,CHEMBL615207,BAO_0000251,2107.0,
87,,B,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",8,,,11231,10116.0,Autocuration,1,CHEMBL827084,BAO_0000019,,
88,,B,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",8,,,11231,10116.0,Autocuration,1,CHEMBL615208,BAO_0000019,,
89,,B,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",8,,,11231,10116.0,Autocuration,1,CHEMBL615209,BAO_0000019,,
90,,B,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",9,,,12083,10116.0,Autocuration,1,CHEMBL615210,BAO_0000251,2107.0,
91,,B,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",9,,,12083,10116.0,Autocuration,1,CHEMBL615211,BAO_0000251,2107.0,
92,,B,,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",9,,,12083,10116.0,Autocuration,1,CHEMBL615212,BAO_0000251,2107.0,
93,,B,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),8,,,11377,,Expert,1,CHEMBL615213,BAO_0000357,,
94,,B,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,8,,,11377,,Expert,1,CHEMBL615273,BAO_0000357,,
95,HepG2,F,726.0,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,,,81020,9606.0,Expert,1,CHEMBL615274,BAO_0000219,,
96,HepG2,F,726.0,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,1,,,81020,9606.0,Intermediate,1,CHEMBL615275,BAO_0000219,,
97,HepG2,F,726.0,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,1,,,81020,9606.0,Intermediate,1,CHEMBL615276,BAO_0000219,,
98,HepG2,F,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,1,,,81020,9606.0,Intermediate,1,CHEMBL615277,BAO_0000219,,
99,HepG2,F,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,1,,,81020,9606.0,Intermediate,1,CHEMBL615326,BAO_0000219,,
100,,F,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,,,50606,10407.0,Expert,1,CHEMBL883130,BAO_0000218,,
101,HepG2,F,726.0,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,1,,,81020,9606.0,Intermediate,1,CHEMBL884519,BAO_0000219,,
102,HepG2,F,726.0,,Concentration required to inhibit 50% of 2.2.15 cell line,1,,,81020,9606.0,Intermediate,1,CHEMBL615327,BAO_0000219,,
103,HepG2,A,726.0,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,1,,,81020,9606.0,Intermediate,1,CHEMBL615328,BAO_0000219,,
104,2.2.15,F,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,1,,,50587,9606.0,Intermediate,1,CHEMBL615329,BAO_0000218,,
105,2.2.15,F,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,1,,,50587,9606.0,Intermediate,1,CHEMBL615330,BAO_0000218,,
106,2.2.15,F,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",1,,,50606,10407.0,Expert,1,CHEMBL615331,BAO_0000218,,
107,2.2.15,F,,,In vitro anti-HBV activity in 2.2.15 cells,1,,,50587,9606.0,Intermediate,1,CHEMBL615332,BAO_0000218,,
108,2.2.15,F,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,1,,,50587,9606.0,Intermediate,1,CHEMBL615333,BAO_0000218,,
109,2.2.15,F,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,1,,,50587,9606.0,Intermediate,1,CHEMBL615334,BAO_0000218,,
110,2.2.15,F,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,1,,,50587,9606.0,Intermediate,1,CHEMBL615335,BAO_0000218,,
111,2.2.15,F,,,Cytotoxicity in 2.2.15 cells,1,,,50587,9606.0,Intermediate,1,CHEMBL615336,BAO_0000218,,
112,2.2.15,F,,,Cytotoxicity in 2.2.15 cells; Not determined,1,,,50587,9606.0,Intermediate,1,CHEMBL615337,BAO_0000218,,
113,2.2.15,F,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,1,,,50587,9606.0,Intermediate,1,CHEMBL615338,BAO_0000218,,
114,2.2.15,F,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,1,,,50587,9606.0,Intermediate,1,CHEMBL615339,BAO_0000218,,
115,2.2.15,F,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,1,,,50587,9606.0,Intermediate,1,CHEMBL615340,BAO_0000218,,
116,HepG2,F,726.0,,Antiviral activity against HBV was determined in 2.215 cell line,1,,,81020,9606.0,Intermediate,1,CHEMBL615341,BAO_0000219,,
117,,B,,,Inhibition of 20-HETE synthesis in human renal microsomes,0,,,22226,9606.0,Autocuration,1,CHEMBL615342,BAO_0000251,,
118,,B,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,0,,,22226,,Autocuration,1,CHEMBL615343,BAO_0000019,,
119,2008,F,388.0,,Inhibitory concentration against 2008 (ovarian) cells,1,,,80612,9606.0,Intermediate,1,CHEMBL615344,BAO_0000219,,
120,2008,F,388.0,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,1,,,80612,9606.0,Intermediate,1,CHEMBL615345,BAO_0000219,,
121,2008,F,388.0,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),1,,,80612,9606.0,Intermediate,1,CHEMBL615346,BAO_0000219,,
122,2008,F,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,1,,,80612,9606.0,Intermediate,1,CHEMBL615347,BAO_0000219,,
123,2008,F,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,1,,,80612,9606.0,Intermediate,1,CHEMBL615348,BAO_0000219,,
124,2008/R,F,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line,1,,,80613,9606.0,Intermediate,1,CHEMBL827085,BAO_0000219,,
125,2008/R,F,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,1,,,80613,9606.0,Intermediate,1,CHEMBL615349,BAO_0000219,,
126,2008/S,F,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line,1,,,80614,9606.0,Intermediate,1,CHEMBL615350,BAO_0000219,,
127,2008/S,F,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,1,,,80614,9606.0,Intermediate,1,CHEMBL615351,BAO_0000219,,
128,,B,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,2,,,100256,9606.0,Expert,1,CHEMBL615352,BAO_0000220,,
129,,B,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,2,,,100256,9606.0,Intermediate,1,CHEMBL615353,BAO_0000220,,
130,,B,,,Inhibition of chymotrypsin-like activity of 20S proteasome,2,,,100256,,Expert,1,CHEMBL615354,BAO_0000220,,
131,,B,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,2,,,100256,,Expert,1,CHEMBL615355,BAO_0000220,,
132,,B,,,Inhibitory activity against 20S proteosome,2,,,100256,,Intermediate,1,CHEMBL615356,BAO_0000220,,
133,,B,,,Compound was tested for inhibitory activity against tryptase,0,,,22226,9606.0,Autocuration,1,CHEMBL615357,BAO_0000019,,
134,HepG2,F,726.0,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,1,,,81020,9606.0,Intermediate,1,CHEMBL615358,BAO_0000219,,
135,HepG2,F,726.0,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,1,,,81020,9606.0,Intermediate,1,CHEMBL827086,BAO_0000219,,
136,,B,,,Compound was tested for the inhibition of Alpha-glucosidase,0,,,22226,,Autocuration,1,CHEMBL615359,BAO_0000019,,
137,,B,,,Inhibitory concentration against human neutrophil elastase (HNE),8,,,235,,Autocuration,1,CHEMBL615360,BAO_0000357,,
138,,F,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,0,,,22226,10116.0,Autocuration,1,CHEMBL615361,BAO_0000218,948.0,
139,,F,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,8,,,19640,,Autocuration,1,CHEMBL615362,BAO_0000019,,
140,,F,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,8,,,19640,,Expert,1,CHEMBL615363,BAO_0000019,,
141,,B,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,8,,,19640,,Autocuration,1,CHEMBL615364,BAO_0000357,,
142,,F,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,8,,,19640,,Expert,1,CHEMBL615365,BAO_0000019,,
143,P338,F,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,1,,,80360,10090.0,Intermediate,1,CHEMBL615366,BAO_0000219,,
144,P338,F,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,1,,,80360,10090.0,Intermediate,1,CHEMBL615367,BAO_0000219,,
145,PBL,F,554.0,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,1,,,80384,9606.0,Intermediate,1,CHEMBL615368,BAO_0000219,,
146,,F,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,0,,,22226,9940.0,Autocuration,1,CHEMBL615369,BAO_0000019,,
147,,F,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,0,,,22226,9940.0,Autocuration,1,CHEMBL615370,BAO_0000019,,
148,,B,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),8,,,191,,Autocuration,1,CHEMBL615673,BAO_0000357,,
149,,F,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,0,,,22226,9606.0,Autocuration,1,CHEMBL615674,BAO_0000019,,
150,,F,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,0,,,22226,9606.0,Autocuration,1,CHEMBL615675,BAO_0000019,,
151,CCRF-CEM,F,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,0,,,22226,9606.0,Autocuration,1,CHEMBL615676,BAO_0000219,,
152,CCRF-CEM,F,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,0,,,22226,9606.0,Autocuration,1,CHEMBL615677,BAO_0000219,,
153,CCRF-CEM,F,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,0,,,22226,9606.0,Autocuration,1,CHEMBL615678,BAO_0000219,,
154,CCRF-CEM,F,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,0,,,22226,9606.0,Autocuration,1,CHEMBL615679,BAO_0000219,,
155,,F,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,0,,,22226,9606.0,Autocuration,1,CHEMBL615680,BAO_0000019,,
156,,F,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,0,,,22226,9606.0,Autocuration,1,CHEMBL615681,BAO_0000019,,
157,,B,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,6,,,104290,,Autocuration,1,CHEMBL857972,BAO_0000249,,
158,,F,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,1,,,50264,1314.0,Intermediate,1,CHEMBL857899,BAO_0000218,,
159,,F,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),1,,,50527,10335.0,Intermediate,1,CHEMBL615371,BAO_0000218,,
160,HEL,F,468.0,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,1,,,50527,10335.0,Expert,1,CHEMBL615372,BAO_0000218,,
161,,F,,,Antiviral activity against 07/1 strain of VZV; ND: No data,1,,,50527,10335.0,Intermediate,1,CHEMBL615373,BAO_0000218,,
162,,F,,,Antiviral activity against 07/1 strain of VZV; ND=No data,1,,,50527,10335.0,Intermediate,1,CHEMBL615374,BAO_0000218,,
163,,F,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",1,,,50145,561.0,Intermediate,1,CHEMBL615375,BAO_0000218,,
164,,B,,,Ratio of Ki at A2 to Ki at A1 receptors,0,,,22226,,Autocuration,1,CHEMBL615376,BAO_0000019,,
165,,B,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",8,,,11143,5476.0,Expert,1,CHEMBL615377,BAO_0000249,,
166,,B,,,"Inhibition of 1,3-beta-glucan synthase",8,,,18077,284593.0,Expert,1,CHEMBL615378,BAO_0000357,,
167,1-87 tumor cell line,F,832.0,,Inhibition of growth of 1-87 human tumor cell line,1,,,80609,9606.0,Intermediate,1,CHEMBL615379,BAO_0000219,,
168,,B,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,9,,,12166,10116.0,Expert,1,CHEMBL615380,BAO_0000219,,
169,,B,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),9,,,100171,3847.0,Autocuration,1,CHEMBL615381,BAO_0000357,,
170,,B,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,9,,,100171,3847.0,Autocuration,1,CHEMBL615382,BAO_0000357,,
171,,B,,,% inhibition against soybean 1-lipoxygenase (SLO),9,,,100171,3847.0,Autocuration,1,CHEMBL615383,BAO_0000357,,
172,,B,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,9,,,100171,3847.0,Autocuration,1,CHEMBL615384,BAO_0000357,,
173,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,9,,,100171,3847.0,Autocuration,1,CHEMBL615385,BAO_0000357,,
174,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,9,,,100171,3847.0,Autocuration,1,CHEMBL615386,BAO_0000357,,
175,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,9,,,100171,3847.0,Autocuration,1,CHEMBL615387,BAO_0000357,,
176,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,9,,,100171,3847.0,Autocuration,1,CHEMBL615388,BAO_0000357,,
177,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,9,,,100171,3847.0,Autocuration,1,CHEMBL615214,BAO_0000357,,
178,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,9,,,100171,3847.0,Autocuration,1,CHEMBL827087,BAO_0000357,,
179,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,9,,,100171,3847.0,Autocuration,1,CHEMBL615215,BAO_0000357,,
180,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,9,,,100171,3847.0,Autocuration,1,CHEMBL615216,BAO_0000357,,
181,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,9,,,100171,3847.0,Autocuration,1,CHEMBL615217,BAO_0000357,,
182,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,9,,,100171,3847.0,Autocuration,1,CHEMBL615218,BAO_0000357,,
183,,B,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,9,,,100171,3847.0,Autocuration,1,CHEMBL615219,BAO_0000357,,
184,,B,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,0,,,22226,10090.0,Autocuration,1,CHEMBL615220,BAO_0000019,,
185,C3H 10T1/2,F,294.0,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),1,,,80049,10090.0,Intermediate,1,CHEMBL615221,BAO_0000219,,
186,,F,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,0,,,22226,,Intermediate,1,CHEMBL615222,BAO_0000019,,
187,,B,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),8,,,11489,,Autocuration,1,CHEMBL615223,BAO_0000357,,
188,,B,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),8,,,11862,,Autocuration,1,CHEMBL615224,BAO_0000357,,
189,,B,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,8,,,11862,,Autocuration,1,CHEMBL615225,BAO_0000357,,
190,,B,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,8,,,11489,,Autocuration,1,CHEMBL615226,BAO_0000357,,
191,,B,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,8,,,11862,,Autocuration,1,CHEMBL615227,BAO_0000357,,
192,,F,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,9,,,12347,9913.0,Expert,1,CHEMBL615228,BAO_0000019,,
193,,B,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,9,,,100120,10116.0,Expert,1,CHEMBL615229,BAO_0000357,,
194,,B,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,9,,,100120,10116.0,Expert,1,CHEMBL615230,BAO_0000357,2369.0,
195,,B,,,Inhibition of rat adrenal 11-beta-hydroxylase,9,,,100120,10116.0,Expert,1,CHEMBL615231,BAO_0000357,,
196,,B,,,Inhibition of rat adrenal 11-beta-hydroxylase,9,,,100120,10116.0,Expert,1,CHEMBL884520,BAO_0000357,,
197,,B,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,9,,,100120,10116.0,Expert,1,CHEMBL615232,BAO_0000357,,
198,,B,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,8,,,10328,,Autocuration,1,CHEMBL615233,BAO_0000019,,
199,,B,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,8,,,11490,,Autocuration,1,CHEMBL827088,BAO_0000357,,
200,,B,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,8,,,11490,,Autocuration,1,CHEMBL615234,BAO_0000357,,
201,,F,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,8,,,11134,,Autocuration,1,CHEMBL615235,BAO_0000019,,
202,,B,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,8,,,12052,,Autocuration,1,CHEMBL615236,BAO_0000019,,
203,,B,,,Compound was tested in vitro for inhibition of 12-LO human platelet,8,,,11134,,Autocuration,1,CHEMBL615237,BAO_0000019,,
204,,F,,,Inhibitory concentration against human platelet 12-lipoxygenase,8,,,11134,,Autocuration,1,CHEMBL615238,BAO_0000019,,
205,,B,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,8,,,11134,,Autocuration,1,CHEMBL615239,BAO_0000019,,
206,,F,,,Inhibitory concentration against human platelet 12-lipoxygenase,9,,,11134,9606.0,Autocuration,1,CHEMBL615240,BAO_0000019,,
207,,B,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,8,,,11835,,Expert,1,CHEMBL615241,BAO_0000019,,
208,,B,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,8,,,11601,,Expert,1,CHEMBL615242,BAO_0000357,,
209,,B,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),8,,,11134,,Autocuration,1,CHEMBL615243,BAO_0000019,,
210,,B,,,Inhibitory activity against human platelet 12-lipoxygenase,8,,,11134,,Autocuration,1,CHEMBL615244,BAO_0000019,,
211,,B,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,8,,,11134,,Autocuration,1,CHEMBL615245,BAO_0000019,,
212,,B,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),8,,,11134,,Autocuration,1,CHEMBL615246,BAO_0000019,,
213,,B,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,8,,,11134,,Autocuration,1,CHEMBL615247,BAO_0000019,,
214,,B,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,8,,,11134,,Autocuration,1,CHEMBL615248,BAO_0000019,,
215,,B,,,Inhibitory activity towards porcine 12-lipoxygenase,8,,,11601,,Autocuration,1,CHEMBL615249,BAO_0000357,,
216,,B,,,Tested for inhibition against porcine 12-LO,8,,,11601,,Autocuration,1,CHEMBL615250,BAO_0000357,,
217,,B,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,8,,,12052,,Autocuration,1,CHEMBL615251,BAO_0000019,,
218,,B,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,8,,,12052,,Autocuration,1,CHEMBL615252,BAO_0000019,,
219,,B,,,In vitro inhibition of rat platelet 12-lipoxygenase,8,,,12052,,Expert,1,CHEMBL828340,BAO_0000019,,
220,,B,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,8,,,12052,,Autocuration,1,CHEMBL615253,BAO_0000019,,
221,,B,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,8,,,12052,,Autocuration,1,CHEMBL615254,BAO_0000019,,
222,,B,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,8,,,12052,,Autocuration,1,CHEMBL615255,BAO_0000019,,
223,,B,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,8,,,12052,,Autocuration,1,CHEMBL615256,BAO_0000019,,
224,,B,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,8,,,12052,,Autocuration,1,CHEMBL615257,BAO_0000019,,
225,,B,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,8,,,12052,,Autocuration,1,CHEMBL615258,BAO_0000019,,
226,41M,F,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,1,,,80007,9606.0,Intermediate,1,CHEMBL615259,BAO_0000219,,
227,41M,F,621.0,,In vitro antitumor activity against 41M cell line.,1,,,80007,9606.0,Expert,1,CHEMBL615260,BAO_0000219,,
228,41M,F,621.0,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,1,,,80007,9606.0,Intermediate,1,CHEMBL615261,BAO_0000219,,
229,41M,F,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,1,,,80007,9606.0,Intermediate,1,CHEMBL615262,BAO_0000219,,
230,41M,F,621.0,,In vitro antitumor activity against 41McisR cell line.,1,,,80007,9606.0,Expert,1,CHEMBL615263,BAO_0000219,,
231,41M,F,621.0,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,1,,,80007,9606.0,Expert,1,CHEMBL838393,BAO_0000219,,
232,41M,F,621.0,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,1,,,80007,9606.0,Intermediate,1,CHEMBL615264,BAO_0000219,,
233,,B,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),9,,,84,9606.0,Expert,1,CHEMBL615265,BAO_0000357,,
234,,B,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),9,,,68,9606.0,Expert,1,CHEMBL615266,BAO_0000357,,
235,,B,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),8,,,68,,Expert,1,CHEMBL615267,BAO_0000357,,
236,,B,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,8,,,10201,,Expert,1,CHEMBL615268,BAO_0000357,,
237,,B,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,8,,,10201,,Expert,1,CHEMBL615269,BAO_0000357,,
238,,B,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,8,,,10201,,Expert,1,CHEMBL615270,BAO_0000357,,
239,,B,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",8,,,12220,,Autocuration,1,CHEMBL615271,BAO_0000357,,
240,,B,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",8,,,11303,562.0,Autocuration,1,CHEMBL615272,BAO_0000357,,
241,,B,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",8,,,11303,562.0,Autocuration,1,CHEMBL615103,BAO_0000357,,
242,,B,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",8,,,11303,562.0,Autocuration,1,CHEMBL615104,BAO_0000357,,
243,,B,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",8,,,12220,,Autocuration,1,CHEMBL615105,BAO_0000357,,
244,,B,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",8,,,12220,,Autocuration,1,CHEMBL872866,BAO_0000357,,
245,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615106,BAO_0000357,,
246,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",8,,,11303,9823.0,Autocuration,1,CHEMBL615107,BAO_0000019,,
247,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615108,BAO_0000357,,
248,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615109,BAO_0000357,,
249,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615110,BAO_0000357,,
250,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL840105,BAO_0000019,,
251,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615111,BAO_0000019,,
252,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615112,BAO_0000019,,
253,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615113,BAO_0000019,,
254,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",8,,,11303,9823.0,Autocuration,1,CHEMBL615114,BAO_0000019,,
255,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615115,BAO_0000357,,
256,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",8,,,11303,9823.0,Autocuration,1,CHEMBL615116,BAO_0000019,,
257,,B,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",8,,,11303,,Autocuration,1,CHEMBL615698,BAO_0000357,,
258,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",0,,,22226,9823.0,Autocuration,1,CHEMBL615699,BAO_0000019,,
259,,B,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",0,,,22226,9823.0,Autocuration,1,CHEMBL615700,BAO_0000019,,
260,,B,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,8,,,100249,4932.0,Expert,1,CHEMBL615701,BAO_0000357,,
261,,B,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,0,,,22226,10116.0,Autocuration,1,CHEMBL615702,BAO_0000019,,
262,,B,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,0,,,22226,10116.0,Autocuration,1,CHEMBL615703,BAO_0000019,,
263,,B,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",0,,,22226,10116.0,Autocuration,1,CHEMBL615704,BAO_0000019,,
264,,F,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",6,,,104698,,Autocuration,1,CHEMBL615705,BAO_0000019,,
265,,F,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",6,,,104698,,Autocuration,1,CHEMBL615706,BAO_0000019,,
266,,F,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,9,,,20033,10141.0,Intermediate,1,CHEMBL615707,BAO_0000221,2116.0,
267,,F,,,Stimulatory activity of intragastric pressure was tested in the rat,8,,,10623,,Expert,1,CHEMBL615708,BAO_0000019,,
268,,B,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,8,,,121,,Autocuration,1,CHEMBL615709,BAO_0000357,,
269,,F,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),0,,,22226,10116.0,Autocuration,1,CHEMBL615710,BAO_0000218,,
270,,F,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,8,,,12688,,Autocuration,1,CHEMBL615711,BAO_0000019,,
271,,B,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,9,,,121,9606.0,Expert,1,CHEMBL615712,BAO_0000357,,
272,,B,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,9,,,121,9606.0,Expert,1,CHEMBL836325,BAO_0000357,,
273,,F,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,8,,,12198,,Autocuration,1,CHEMBL615713,BAO_0000019,,
274,,B,,,Inhibition constant of high-affinity 5-HT uptake,8,,,12198,,Autocuration,1,CHEMBL615714,BAO_0000357,,
275,,F,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,8,,,12198,,Autocuration,1,CHEMBL615715,BAO_0000019,,
276,,F,,,Maximum rate was determined for high affinity transport of 5-HT,8,,,12198,,Autocuration,1,CHEMBL615716,BAO_0000019,,
277,,F,,,Compound was tested for agonistic activity against 5-HT uptake,4,,,104714,,Autocuration,1,CHEMBL615717,BAO_0000019,,
278,,B,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,8,,,10577,,Expert,1,CHEMBL881818,BAO_0000019,,
279,,B,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,8,,,105,9913.0,Expert,1,CHEMBL884540,BAO_0000357,,
280,,B,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,5,,,104744,10116.0,Autocuration,1,CHEMBL615718,BAO_0000224,,
281,,B,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,4,,,104744,,Autocuration,1,CHEMBL615719,BAO_0000224,,
282,,B,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,4,,,104744,,Autocuration,1,CHEMBL615720,BAO_0000249,,
283,,B,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,4,,,104744,,Autocuration,1,CHEMBL615721,BAO_0000249,,
284,,B,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,4,,,104744,,Autocuration,1,CHEMBL615722,BAO_0000019,,
285,,F,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,8,,,51,,Autocuration,1,CHEMBL615723,BAO_0000019,,
286,,B,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615724,BAO_0000221,10000000.0,
287,,B,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615725,BAO_0000221,10000000.0,
288,,B,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615726,BAO_0000221,10000000.0,
289,,F,,In vivo,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),8,,,10576,,Autocuration,1,CHEMBL615727,BAO_0000218,,
290,,F,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,9,,,105570,10141.0,Intermediate,1,CHEMBL615728,BAO_0000019,,
291,CHO,B,449.0,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,8,,,279,,Autocuration,1,CHEMBL857971,BAO_0000219,,
292,,B,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL615729,BAO_0000357,,
293,,F,,,Efficacy against 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL615730,BAO_0000019,,
294,,F,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,8,,,12687,,Expert,1,CHEMBL615731,BAO_0000019,,
295,,F,,,Relative potency towards 5-HT2A receptor of rat tail artery,8,,,12687,,Expert,1,CHEMBL615732,BAO_0000019,,
296,,F,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,8,,,12687,,Expert,1,CHEMBL615733,BAO_0000019,,
297,,F,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,8,,,12687,,Expert,1,CHEMBL615734,BAO_0000019,,
298,,F,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,8,,,12687,,Autocuration,1,CHEMBL615735,BAO_0000019,,
299,,F,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,8,,,12687,,Expert,1,CHEMBL615736,BAO_0000019,,
300,,F,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,9,,,20033,10141.0,Intermediate,1,CHEMBL615737,BAO_0000221,2116.0,
301,,F,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),9,,,20033,10141.0,Intermediate,1,CHEMBL615738,BAO_0000221,2116.0,
302,,F,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,9,,,20033,10141.0,Intermediate,1,CHEMBL615739,BAO_0000221,2116.0,
303,,B,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,8,,,10623,,Autocuration,1,CHEMBL615278,BAO_0000357,,
304,,F,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,9,,,10623,10116.0,Expert,1,CHEMBL615279,BAO_0000019,,
305,,B,,,Binding affinity against 5-hydroxytryptamine 4 receptor,8,,,168,,Expert,1,CHEMBL615280,BAO_0000357,,
306,,B,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,0,,,22226,9031.0,Autocuration,1,CHEMBL615281,BAO_0000019,,
307,,F,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,0,,,22226,9606.0,Autocuration,1,CHEMBL615282,BAO_0000019,,
308,,F,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,0,,,22226,9606.0,Autocuration,1,CHEMBL615283,BAO_0000019,,
309,HL-60,B,649.0,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,1,,,80156,9606.0,Autocuration,1,CHEMBL615284,BAO_0000219,,
310,,B,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,0,,,22226,9606.0,Autocuration,1,CHEMBL615285,BAO_0000019,,
311,,B,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,0,,,22226,9606.0,Autocuration,1,CHEMBL615286,BAO_0000019,,
312,Oocytes,B,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,7,,,104703,9606.0,Autocuration,1,CHEMBL615287,BAO_0000219,,
313,,F,,,Chymotryptic inhibitory activity against 26S proteasome,2,,,100256,,Intermediate,1,CHEMBL615288,BAO_0000220,,
314,,B,,,Inhibitory activity against 26S proteasome degradation of IkB,2,,,100256,,Intermediate,1,CHEMBL615289,BAO_0000220,,
315,A2780,F,478.0,,In vitro inhibition of 2780/DOX ovarian cancer cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL615290,BAO_0000219,,
316,A2780,F,478.0,,In vitro inhibition of 2780/S ovarian cancer cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL884522,BAO_0000219,,
317,,F,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,0,,,22226,9606.0,Autocuration,1,CHEMBL615291,BAO_0000019,,
318,,B,,,Association constant for binding to AATT 28-mer AATT hairpin,3,,,22222,,Intermediate,1,CHEMBL615292,BAO_0000225,,
319,,B,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,3,,,22222,,Intermediate,1,CHEMBL615293,BAO_0000225,,
320,,B,,,Reaction Rate Parameter for 28-mer AATT hairpin,3,,,22222,,Intermediate,1,CHEMBL615294,BAO_0000225,,
321,,B,,,Reaction Rate Parameter for 28-mer AATT hairpin,3,,,22222,,Intermediate,1,CHEMBL615295,BAO_0000225,,
322,,F,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),0,,,22226,9606.0,Autocuration,1,CHEMBL825021,BAO_0000019,,
323,,F,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),0,,,22226,9606.0,Autocuration,1,CHEMBL615296,BAO_0000019,,
324,,F,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,0,,,22226,9606.0,Autocuration,1,CHEMBL615297,BAO_0000019,,
325,,F,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,0,,,22226,10029.0,Autocuration,1,CHEMBL615298,BAO_0000019,,
326,,F,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,0,,,22226,10029.0,Autocuration,1,CHEMBL615299,BAO_0000019,,
327,,F,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,0,,,22226,10029.0,Autocuration,1,CHEMBL615300,BAO_0000019,,
328,,B,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,8,,,241,,Autocuration,1,CHEMBL615301,BAO_0000357,,
329,,B,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,9,,,241,9606.0,Expert,1,CHEMBL615302,BAO_0000357,,
330,,B,,,Selectivity ratio of ID50 in liver and heart,0,,,22226,10116.0,Autocuration,1,CHEMBL615303,BAO_0000019,,
331,,B,,,"Selectivity, ratio of relative ID50 in liver and heart",8,,,12132,,Autocuration,1,CHEMBL615304,BAO_0000019,,
332,,B,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,8,,,12132,,Autocuration,1,CHEMBL615305,BAO_0000019,,
333,,B,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,,,12132,,Autocuration,1,CHEMBL615306,BAO_0000218,,
334,,B,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,,,12132,,Autocuration,1,CHEMBL615307,BAO_0000218,,
335,,B,,In vivo,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,,,12132,,Autocuration,1,CHEMBL615308,BAO_0000218,,
336,,F,,In vivo,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,,,12132,,Autocuration,1,CHEMBL615309,BAO_0000218,,
337,,B,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",0,,,22226,,Autocuration,1,CHEMBL615310,BAO_0000019,,
338,,B,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,8,,,12132,,Autocuration,1,CHEMBL615311,BAO_0000019,,
339,,B,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",0,,,22226,9606.0,Autocuration,1,CHEMBL615312,BAO_0000019,,
340,,B,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,8,,,12132,,Autocuration,1,CHEMBL615313,BAO_0000019,,
341,,F,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,8,,,12132,,Autocuration,1,CHEMBL615314,BAO_0000019,,
342,,B,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",8,,,12132,,Autocuration,1,CHEMBL615315,BAO_0000019,,
343,,B,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",0,,,22226,10116.0,Autocuration,1,CHEMBL615316,BAO_0000218,,
344,,B,,In vivo,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,8,,,12132,,Autocuration,1,CHEMBL615317,BAO_0000218,,
345,,B,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",8,,,12132,,Autocuration,1,CHEMBL615318,BAO_0000218,,
346,,B,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",0,,,22226,10116.0,Autocuration,1,CHEMBL615319,BAO_0000218,,
347,,B,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",8,,,12132,,Autocuration,1,CHEMBL615320,BAO_0000019,,
348,,F,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",8,,,12132,,Autocuration,1,CHEMBL615321,BAO_0000019,,
349,,B,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",0,,,22226,10116.0,Autocuration,1,CHEMBL615322,BAO_0000019,,
350,,B,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,8,,,19690,562.0,Autocuration,1,CHEMBL615323,BAO_0000357,,
351,,B,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,8,,,19690,562.0,Autocuration,1,CHEMBL615407,BAO_0000357,,
352,,B,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,8,,,19690,562.0,Autocuration,1,CHEMBL857267,BAO_0000357,,
353,,B,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,8,,,19690,562.0,Autocuration,1,CHEMBL615408,BAO_0000357,,
354,,B,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,8,,,19690,,Autocuration,1,CHEMBL615409,BAO_0000357,,
355,,B,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,8,,,19690,,Autocuration,1,CHEMBL615410,BAO_0000357,,
356,,B,,,Inhibition constant against 3-dehydroquinate synthase,8,,,19690,,Autocuration,1,CHEMBL615411,BAO_0000357,,
357,,B,,,Association rate constant against 3-dehydroquinate synthase,8,,,19690,,Autocuration,1,CHEMBL615412,BAO_0000357,,
358,,B,,,Rate constant against 3-dehydroquinate synthase,8,,,19690,,Autocuration,1,CHEMBL615413,BAO_0000357,,
359,,B,,,Inhibitory activity against fuc-TVII,0,,,22226,,Autocuration,1,CHEMBL615414,BAO_0000019,,
360,,B,,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,,,12236,10116.0,Autocuration,1,CHEMBL615415,BAO_0000251,2107.0,
361,,B,,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,,,12236,10116.0,Autocuration,1,CHEMBL615416,BAO_0000251,2107.0,
362,,B,,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,,,12236,10116.0,Autocuration,1,CHEMBL615417,BAO_0000251,2107.0,
363,,B,,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,,,12236,10116.0,Autocuration,1,CHEMBL615418,BAO_0000251,2107.0,
364,,B,,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,9,,,12236,10116.0,Autocuration,1,CHEMBL615419,BAO_0000251,2107.0,
365,,B,,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,9,,,12236,10116.0,Autocuration,1,CHEMBL615420,BAO_0000251,2107.0,
366,,B,,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,9,,,12236,10116.0,Autocuration,1,CHEMBL615421,BAO_0000251,2107.0,
367,,B,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,9,,,12236,10116.0,Autocuration,1,CHEMBL615422,BAO_0000251,2107.0,
368,,B,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,9,,,12236,10116.0,Autocuration,1,CHEMBL615423,BAO_0000251,2107.0,
369,,B,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,9,,,12236,10116.0,Autocuration,1,CHEMBL872868,BAO_0000251,2107.0,
370,,B,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,9,,,12236,10116.0,Autocuration,1,CHEMBL615424,BAO_0000251,2107.0,
371,,B,,,Inhibitory activity against 3-phosphoglycerate kinase.,4,,,104832,,Autocuration,1,CHEMBL825022,BAO_0000224,,
372,,B,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,4,,,104832,,Autocuration,1,CHEMBL615425,BAO_0000224,,
373,,B,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",4,,,104832,,Autocuration,1,CHEMBL615426,BAO_0000224,,
374,,B,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,9,,,10612,9606.0,Expert,1,CHEMBL615427,BAO_0000357,,
375,3677 melanoma cell line,F,844.0,,Cytotoxicity on 3677 melanoma cells,1,,,80616,9606.0,Intermediate,1,CHEMBL615428,BAO_0000219,,
376,3677 melanoma cell line,F,844.0,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,1,,,80616,9606.0,Intermediate,1,CHEMBL615429,BAO_0000219,,
377,MC-38,F,700.0,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,1,,,80617,10090.0,Intermediate,1,CHEMBL615430,BAO_0000219,,
378,,F,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,0,,,22226,9606.0,Intermediate,1,CHEMBL615431,BAO_0000019,,
379,B16,F,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,0,,,22226,,Autocuration,1,CHEMBL615432,BAO_0000218,,
380,B16,F,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,0,,,22226,,Autocuration,1,CHEMBL615433,BAO_0000218,,
381,,F,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,9,,,12464,12131.0,Expert,1,CHEMBL615434,BAO_0000019,,
382,,F,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,1,,,50085,169066.0,Intermediate,1,CHEMBL615435,BAO_0000218,,
383,,F,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,1,,,50679,169066.0,Intermediate,1,CHEMBL615436,BAO_0000218,,
384,,F,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,1,,,50679,169066.0,Intermediate,1,CHEMBL615437,BAO_0000218,,
385,,F,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,9,,,12464,12131.0,Expert,1,CHEMBL615438,BAO_0000019,,
386,,F,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,9,,,12464,12131.0,Expert,1,CHEMBL615439,BAO_0000019,,
387,,F,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,9,,,12464,12131.0,Expert,1,CHEMBL615440,BAO_0000019,,
388,,F,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,9,,,12464,12131.0,Expert,1,CHEMBL615441,BAO_0000019,,
389,,F,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,1,,,50665,12059.0,Intermediate,1,CHEMBL615641,BAO_0000218,,
390,,F,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,1,,,50665,12059.0,Intermediate,1,CHEMBL872065,BAO_0000218,,
391,,F,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,1,,,50665,12059.0,Intermediate,1,CHEMBL825023,BAO_0000218,,
392,,F,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,1,,,50665,12059.0,Intermediate,1,CHEMBL615642,BAO_0000218,,
393,,B,,,Inhibition of human rhinovirus 3C protease,8,,,12464,147712.0,Expert,1,CHEMBL615643,BAO_0000357,,
394,,B,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,0,,,22226,9606.0,Autocuration,1,CHEMBL615644,BAO_0000019,,
395,3EM 37,F,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),1,,,80619,10090.0,Intermediate,1,CHEMBL615645,BAO_0000218,,
396,3EM 37,F,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),1,,,80619,10090.0,Intermediate,1,CHEMBL615646,BAO_0000218,,
397,3EM 37,F,833.0,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),1,,,80619,10090.0,Intermediate,1,CHEMBL615647,BAO_0000218,,
398,3EM 37,F,833.0,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),1,,,80619,10090.0,Intermediate,1,CHEMBL615648,BAO_0000218,,
399,3EM 37,F,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,1,,,80619,10090.0,Intermediate,1,CHEMBL615649,BAO_0000218,,
400,3EM 37,F,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,1,,,80619,10090.0,Intermediate,1,CHEMBL615650,BAO_0000218,,
401,3LL cell line,F,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,,,80620,10090.0,Intermediate,1,CHEMBL615651,BAO_0000218,,
402,3LL cell line,F,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,,,80620,10090.0,Intermediate,1,CHEMBL615652,BAO_0000218,,
403,3LL cell line,F,847.0,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,1,,,80620,10090.0,Expert,1,CHEMBL615653,BAO_0000218,,
404,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615654,BAO_0000219,,
405,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615655,BAO_0000219,,
406,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL825024,BAO_0000219,,
407,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615656,BAO_0000219,,
408,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615657,BAO_0000219,,
409,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615658,BAO_0000219,,
410,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615659,BAO_0000219,,
411,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615660,BAO_0000219,,
412,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615661,BAO_0000219,,
413,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615662,BAO_0000219,,
414,3LL cell line,F,847.0,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,1,,,80620,10090.0,Intermediate,1,CHEMBL615663,BAO_0000219,,
415,3LL cell line,F,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,1,,,80620,10090.0,Intermediate,1,CHEMBL615664,BAO_0000219,,
416,3LL cell line,F,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,1,,,80620,10090.0,Intermediate,1,CHEMBL615665,BAO_0000219,,
417,3LL cell line,F,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,,,80620,10090.0,Intermediate,1,CHEMBL615666,BAO_0000219,,
418,3LL cell line,F,847.0,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615667,BAO_0000219,,
419,3LL cell line,F,847.0,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615668,BAO_0000219,,
420,3LL cell line,F,847.0,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615669,BAO_0000219,,
421,3LL cell line,F,847.0,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615670,BAO_0000219,,
422,3LL cell line,F,847.0,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL836739,BAO_0000219,,
423,3LL cell line,F,847.0,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615671,BAO_0000219,,
424,3LL cell line,F,847.0,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615672,BAO_0000219,,
425,3LL cell line,F,847.0,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615791,BAO_0000219,,
426,3LL cell line,F,847.0,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615792,BAO_0000219,,
427,3LL cell line,F,847.0,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615793,BAO_0000219,,
428,3LL cell line,F,847.0,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615794,BAO_0000219,,
429,3LL cell line,F,847.0,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,1,,,80620,10090.0,Intermediate,1,CHEMBL615795,BAO_0000219,,
430,3LLD122,F,971.0,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,1,,,80621,9606.0,Intermediate,1,CHEMBL615590,BAO_0000219,,
431,,F,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,0,,,22226,,Autocuration,1,CHEMBL615591,BAO_0000218,,
432,,F,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,0,,,22226,,Autocuration,1,CHEMBL615592,BAO_0000218,,
433,,F,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,0,,,22226,,Autocuration,1,CHEMBL615593,BAO_0000218,,
434,,F,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,0,,,22226,,Autocuration,1,CHEMBL615594,BAO_0000218,,
435,NIH3T3,F,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,,,80951,10090.0,Intermediate,1,CHEMBL615595,BAO_0000219,,
436,NIH3T3,F,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,,,80951,10090.0,Intermediate,1,CHEMBL615596,BAO_0000219,,
437,NIH3T3,F,723.0,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,8,,,11169,,Expert,1,CHEMBL615597,BAO_0000219,,
438,NIH3T3,F,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,1,,,80951,10090.0,Intermediate,1,CHEMBL615598,BAO_0000219,,
439,NIH3T3,F,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,1,,,80951,10090.0,Intermediate,1,CHEMBL615599,BAO_0000219,,
440,NIH3T3,F,723.0,,Effective dose against murine 3T3 fibroblasts cells,1,,,80951,10090.0,Expert,1,CHEMBL615600,BAO_0000219,,
441,NIH3T3,F,723.0,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,1,,,80951,10090.0,Expert,1,CHEMBL615601,BAO_0000219,,
442,NIH3T3,F,723.0,,Cytotoxic effect on 3T3 cells,1,,,80951,10090.0,Expert,1,CHEMBL615602,BAO_0000219,,
443,NIH3T3,F,723.0,,Cytotoxic effect on 3T3 cells,1,,,80951,10090.0,Expert,1,CHEMBL615603,BAO_0000219,,
444,NIH3T3,F,723.0,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,1,,,80951,10090.0,Intermediate,1,CHEMBL615604,BAO_0000219,,
445,NIH3T3,F,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,,,80951,10090.0,Intermediate,1,CHEMBL615605,BAO_0000219,,
446,NIH3T3,F,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,1,,,80951,10090.0,Intermediate,1,CHEMBL615606,BAO_0000219,,
447,NIH3T3,F,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,1,,,80951,10090.0,Expert,1,CHEMBL884526,BAO_0000219,,
448,NIH3T3,F,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,1,,,80951,10090.0,Expert,1,CHEMBL615607,BAO_0000219,,
449,NIH3T3,F,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,1,,,80951,10090.0,Intermediate,1,CHEMBL615608,BAO_0000219,,
450,NIH3T3,F,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,1,,,80951,10090.0,Expert,1,CHEMBL615609,BAO_0000219,,
451,NIH3T3,F,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,1,,,80951,10090.0,Expert,1,CHEMBL615682,BAO_0000219,,
452,NIH3T3,F,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,1,,,80951,10090.0,Intermediate,1,CHEMBL615683,BAO_0000219,,
453,NIH3T3,F,723.0,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,1,,,80951,10090.0,Expert,1,CHEMBL615684,BAO_0000218,,
454,,F,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,7,,,104860,10090.0,Autocuration,1,CHEMBL615685,BAO_0000219,,
455,NIH3T3,F,723.0,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,1,,,80951,10090.0,Expert,1,CHEMBL615686,BAO_0000219,,
456,NIH3T3,F,723.0,,Inhibitory activity against 3T3 cell line,1,,,80951,10090.0,Intermediate,1,CHEMBL615687,BAO_0000219,,
457,NIH3T3,F,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,1,,,80951,10090.0,Intermediate,1,CHEMBL884523,BAO_0000219,,
458,,F,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,8,,,11169,,Expert,1,CHEMBL615688,BAO_0000019,,
459,NIH3T3,F,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,1,,,80951,10090.0,Intermediate,1,CHEMBL615689,BAO_0000219,,
460,NIH3T3,F,723.0,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,1,,,80951,10090.0,Intermediate,1,CHEMBL615690,BAO_0000219,,
461,,F,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,8,,,11169,,Expert,1,CHEMBL615691,BAO_0000019,,
462,,F,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,8,,,11169,,Expert,1,CHEMBL615692,BAO_0000019,,
463,NIH3T3,F,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,,,80951,10090.0,Intermediate,1,CHEMBL615693,BAO_0000219,,
464,NIH3T3,F,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,1,,,80951,10090.0,Expert,1,CHEMBL615324,BAO_0000219,,
465,NIH3T3,F,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,,,9,9606.0,Expert,1,CHEMBL615325,BAO_0000219,,
466,NIH3T3,F,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,,,9,9606.0,Expert,1,CHEMBL615490,BAO_0000219,,
467,NIH3T3,F,723.0,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,9,,,188,9606.0,Expert,1,CHEMBL615491,BAO_0000219,,
468,NIH3T3,F,723.0,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),9,,,188,9606.0,Expert,1,CHEMBL615492,BAO_0000219,,
469,NIH3T3,F,723.0,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,1,,,80951,10090.0,Intermediate,1,CHEMBL615493,BAO_0000219,,
470,NIH3T3,F,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,1,,,80951,10090.0,Intermediate,1,CHEMBL615494,BAO_0000219,,
471,NIH3T3,F,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,1,,,80951,10090.0,Intermediate,1,CHEMBL615495,BAO_0000219,,
472,NIH3T3,F,723.0,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,1,,,80951,10090.0,Intermediate,1,CHEMBL615496,BAO_0000219,,
473,NIH3T3,F,723.0,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,1,,,80951,10090.0,Intermediate,1,CHEMBL615497,BAO_0000219,,
474,NIH3T3,F,723.0,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,1,,,80951,10090.0,Expert,1,CHEMBL615498,BAO_0000219,,
475,NIH3T3,A,723.0,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,1,,,80951,10090.0,Intermediate,1,CHEMBL615499,BAO_0000219,,
476,NIH3T3,F,723.0,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,1,,,80951,10090.0,Expert,1,CHEMBL835522,BAO_0000219,,
477,NIH3T3,F,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,1,,,80951,10090.0,Intermediate,1,CHEMBL615500,BAO_0000219,,
478,NIH3T3,F,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,,80951,10090.0,Intermediate,1,CHEMBL615501,BAO_0000219,,
479,NIH3T3,F,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,,80951,10090.0,Intermediate,1,CHEMBL615502,BAO_0000219,,
480,NIH3T3,F,723.0,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,,80951,10090.0,Intermediate,1,CHEMBL615503,BAO_0000219,,
481,NIH3T3,F,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,,80951,10090.0,Intermediate,1,CHEMBL615504,BAO_0000219,,
482,NIH3T3,F,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,,,80951,10090.0,Intermediate,1,CHEMBL615505,BAO_0000219,,
483,NIH3T3,F,723.0,,Inhibition of swiss 3T3 mouse fibroblast proliferation,1,,,80951,10090.0,Expert,1,CHEMBL615506,BAO_0000219,,
484,NIH3T3,F,723.0,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,1,,,80951,10090.0,Intermediate,1,CHEMBL615507,BAO_0000219,,
485,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615508,BAO_0000218,,
486,3T3-L1,F,620.0,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,1,,,80006,10090.0,Intermediate,1,CHEMBL615509,BAO_0000219,,
487,3T3-L1,F,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,1,,,80006,10090.0,Intermediate,1,CHEMBL615510,BAO_0000219,,
488,3T3-L1,F,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,1,,,80006,10090.0,Intermediate,1,CHEMBL615511,BAO_0000219,,
489,3T3-L1,F,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,1,,,80006,10090.0,Intermediate,1,CHEMBL615512,BAO_0000219,,
490,3T3-L1,F,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",1,,,80006,10090.0,Intermediate,1,CHEMBL615513,BAO_0000218,,
491,3T3-L1,F,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",1,,,80006,10090.0,Intermediate,1,CHEMBL615514,BAO_0000218,,
492,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,1,,,80006,,Intermediate,1,CHEMBL615515,BAO_0000219,,
493,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,,,80006,,Intermediate,1,CHEMBL615516,BAO_0000219,,
494,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,,80006,,Intermediate,1,CHEMBL615517,BAO_0000219,,
495,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,,,80006,,Intermediate,1,CHEMBL615518,BAO_0000219,,
496,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,,80006,,Intermediate,1,CHEMBL615519,BAO_0000219,,
497,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615520,BAO_0000218,,
498,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615521,BAO_0000218,,
499,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615522,BAO_0000218,,
500,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615523,BAO_0000218,,
501,3T3-L1,F,620.0,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,,,80006,,Expert,1,CHEMBL615524,BAO_0000218,,
502,3T3-L1,F,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,,80006,,Expert,1,CHEMBL615525,BAO_0000218,,
503,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615526,BAO_0000218,,
504,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615527,BAO_0000218,,
505,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615528,BAO_0000218,,
506,3T3-L1,F,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,,80006,,Expert,1,CHEMBL615529,BAO_0000218,,
507,3T3-L1,F,620.0,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,,80006,,Expert,1,CHEMBL615530,BAO_0000218,,
508,3T3-L1,F,620.0,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,,,80006,,Expert,1,CHEMBL615531,BAO_0000218,,
509,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,,,80006,,Intermediate,1,CHEMBL615532,BAO_0000219,,
510,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,,,80006,,Intermediate,1,CHEMBL615533,BAO_0000219,,
511,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,,,80006,,Intermediate,1,CHEMBL615534,BAO_0000219,,
512,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615535,BAO_0000218,,
513,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615536,BAO_0000218,,
514,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615537,BAO_0000218,,
515,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,,,80006,,Intermediate,1,CHEMBL615538,BAO_0000218,,
516,3T3-L1,F,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,,,80006,,Intermediate,1,CHEMBL836166,BAO_0000218,,
517,3T3-L1,F,620.0,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,8,,,11214,,Expert,1,CHEMBL615539,BAO_0000219,,
518,3T3-L1,F,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,1,,,80006,10090.0,Intermediate,1,CHEMBL615540,BAO_0000219,,
519,3T3-L1,F,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,8,,,11214,,Expert,1,CHEMBL615541,BAO_0000219,,
520,3T3-L1,F,620.0,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,1,,,80006,10090.0,Expert,1,CHEMBL615542,BAO_0000219,,
521,3T3-L1,F,620.0,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,1,,,80006,10090.0,Intermediate,1,CHEMBL615543,BAO_0000219,,
522,3T3-L1,F,620.0,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,1,,,80006,10090.0,Expert,1,CHEMBL615544,BAO_0000219,,
523,3T3-L1,F,620.0,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,,,80006,10090.0,Expert,1,CHEMBL615545,BAO_0000219,,
524,3T3-L1,F,620.0,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,,,80006,10090.0,Expert,1,CHEMBL615546,BAO_0000219,,
525,3T3-L1,F,620.0,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,1,,,80006,10090.0,Expert,1,CHEMBL615547,BAO_0000219,,
526,3T3-L1,F,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,1,,,80006,10090.0,Expert,1,CHEMBL615548,BAO_0000219,,
527,3T3-L1,F,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,1,,,80006,10090.0,Expert,1,CHEMBL615549,BAO_0000219,,
528,3T3-L1,F,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,1,,,80006,10090.0,Expert,1,CHEMBL615550,BAO_0000219,,
529,3Y1 cell line,F,1118.0,,Inhibitory activity against rat fibroblast (3Y1) cell line,1,,,80622,10116.0,Intermediate,1,CHEMBL615551,BAO_0000219,,
530,3Y1 cell line,F,1118.0,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1,,,80622,10116.0,Expert,1,CHEMBL615552,BAO_0000219,,
531,3Y1 cell line,F,1118.0,,Cytotoxicity in 3Y1 cells.,1,,,80622,10116.0,Expert,1,CHEMBL615553,BAO_0000219,,
532,3Y1 cell line,F,1118.0,,Cytostatic effect in 3Y1 cells.,1,,,80622,10116.0,Expert,1,CHEMBL615554,BAO_0000219,,
533,3Y1 cell line,F,1118.0,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1,,,80622,10116.0,Intermediate,1,CHEMBL615555,BAO_0000219,,
534,3Y1 cell line,F,1118.0,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1,,,80622,10116.0,Expert,1,CHEMBL615556,BAO_0000219,,
535,,B,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,0,,,22226,,Autocuration,1,CHEMBL615557,BAO_0000019,,
536,,B,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,0,,,22226,,Autocuration,1,CHEMBL615558,BAO_0000019,,
537,,B,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,0,,,22226,,Autocuration,1,CHEMBL872066,BAO_0000019,,
538,,B,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,9,,,11607,9823.0,Expert,1,CHEMBL615559,BAO_0000019,,
539,,B,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,8,,,11607,,Autocuration,1,CHEMBL615560,BAO_0000019,,
540,,B,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,8,,,11607,,Autocuration,1,CHEMBL615561,BAO_0000019,,
541,,B,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,8,,,11607,,Expert,1,CHEMBL857062,BAO_0000019,,
542,,B,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),8,,,11607,,Expert,1,CHEMBL615562,BAO_0000019,,
543,,B,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,8,,,11607,,Autocuration,1,CHEMBL615563,BAO_0000019,,
544,,B,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),8,,,11607,,Autocuration,1,CHEMBL615564,BAO_0000357,,
545,,B,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,8,,,11607,,Autocuration,1,CHEMBL615565,BAO_0000019,,
546,,B,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,8,,,11607,,Autocuration,1,CHEMBL615566,BAO_0000019,,
547,,B,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,9,,,11607,9823.0,Expert,1,CHEMBL615567,BAO_0000019,,
548,,B,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,8,,,11607,,Autocuration,1,CHEMBL615568,BAO_0000019,,
549,,B,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),8,,,11607,,Autocuration,1,CHEMBL615569,BAO_0000357,,
550,,B,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,8,,,11607,,Autocuration,1,CHEMBL615570,BAO_0000019,,
551,,B,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),8,,,11607,,Autocuration,1,CHEMBL615571,BAO_0000019,,
552,,B,,,Binding affinity against melatonin (MT1) receptor (pC1),4,,,104733,,Autocuration,1,CHEMBL615572,BAO_0000224,,
553,,B,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,0,,,22226,,Autocuration,1,CHEMBL615573,BAO_0000019,,
554,,B,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,0,,,22226,,Autocuration,1,CHEMBL615574,BAO_0000019,,
555,,B,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,0,,,22226,,Autocuration,1,CHEMBL615575,BAO_0000019,,
556,,B,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,8,,,10619,,Autocuration,1,CHEMBL615576,BAO_0000357,,
557,,B,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,8,,,10619,,Autocuration,1,CHEMBL615577,BAO_0000357,,
558,,B,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,8,,,51,,Autocuration,1,CHEMBL615578,BAO_0000221,10000000.0,
559,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,8,,,51,,Expert,1,CHEMBL615579,BAO_0000357,,
560,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor,8,,,51,,Expert,1,CHEMBL615580,BAO_0000357,,
561,,B,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,8,,,51,,Expert,1,CHEMBL615581,BAO_0000019,,
562,,B,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615582,BAO_0000221,10000000.0,
563,,B,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615583,BAO_0000221,10000000.0,
564,,B,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615584,BAO_0000221,10000000.0,
565,,B,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL833691,BAO_0000221,10000000.0,
566,,B,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615585,BAO_0000221,10000000.0,
567,,B,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615586,BAO_0000221,10000000.0,
568,,B,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL884524,BAO_0000221,10000000.0,
569,,B,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615587,BAO_0000221,10000000.0,
570,,B,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",8,,,51,,Autocuration,1,CHEMBL615588,BAO_0000221,10000000.0,
571,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,9,,,10576,10116.0,Expert,1,CHEMBL615589,BAO_0000249,,
572,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,8,,,51,9913.0,Expert,1,CHEMBL615442,BAO_0000221,10000000.0,
573,,B,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,8,,,51,,Autocuration,1,CHEMBL615443,BAO_0000221,10000000.0,
574,,B,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615444,BAO_0000221,10000000.0,
575,,B,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,8,,,51,,Expert,1,CHEMBL615445,BAO_0000221,10000000.0,
576,,B,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615446,BAO_0000221,10000000.0,
577,CHO,B,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,8,,,51,,Autocuration,1,CHEMBL615447,BAO_0000219,,
578,,B,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,,,51,,Expert,1,CHEMBL615448,BAO_0000221,10000000.0,
579,,B,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,8,,,51,,Expert,1,CHEMBL615449,BAO_0000221,10000000.0,
580,CHO,B,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,,,51,,Autocuration,1,CHEMBL615450,BAO_0000219,,
581,,B,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",8,,,51,,Expert,1,CHEMBL615451,BAO_0000221,10000000.0,
582,,B,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,8,,,51,,Autocuration,1,CHEMBL615452,BAO_0000357,,
583,,B,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615453,BAO_0000221,10000000.0,
584,,B,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615454,BAO_0000221,10000000.0,
585,,B,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615455,BAO_0000221,10000000.0,
586,,B,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615456,BAO_0000221,10000000.0,
587,,B,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL615457,BAO_0000221,10000000.0,
588,,B,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,8,,,51,,Expert,1,CHEMBL615458,BAO_0000218,10000000.0,
589,,B,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,,,51,,Expert,1,CHEMBL615459,BAO_0000221,10000000.0,
590,CHO,B,449.0,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",9,,,51,9606.0,Expert,1,CHEMBL615460,BAO_0000219,,
591,,F,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,8,,,51,10141.0,Autocuration,1,CHEMBL615461,BAO_0000019,,
592,,F,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,8,,,51,10141.0,Autocuration,1,CHEMBL615462,BAO_0000019,,
593,,F,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,8,,,51,10141.0,Autocuration,1,CHEMBL615463,BAO_0000221,10000000.0,
594,,B,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,8,,,51,10141.0,Autocuration,1,CHEMBL615464,BAO_0000221,2116.0,
595,,B,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,8,,,51,10141.0,Autocuration,1,CHEMBL615465,BAO_0000221,2116.0,
596,,B,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,8,,,51,10141.0,Autocuration,1,CHEMBL615466,BAO_0000221,2116.0,
597,,B,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,8,,,51,10141.0,Autocuration,1,CHEMBL615467,BAO_0000221,2116.0,
598,,B,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,8,,,51,10141.0,Autocuration,1,CHEMBL615468,BAO_0000221,2116.0,
599,,B,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,8,,,51,10141.0,Autocuration,1,CHEMBL615469,BAO_0000221,2116.0,
600,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,,,51,10141.0,Autocuration,1,CHEMBL615470,BAO_0000357,,
601,,B,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,8,,,51,10141.0,Autocuration,1,CHEMBL615471,BAO_0000357,,
602,,B,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,8,,,51,10141.0,Autocuration,1,CHEMBL615472,BAO_0000357,,
603,,B,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,8,,,106,10141.0,Autocuration,1,CHEMBL883242,BAO_0000221,10000000.0,
604,,F,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,8,,,106,10141.0,Autocuration,1,CHEMBL615473,BAO_0000221,10000000.0,
605,CHO,B,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),8,,,11863,10029.0,Autocuration,1,CHEMBL615474,BAO_0000218,,
606,,B,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615475,BAO_0000357,,
607,HeLa,F,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,8,,,51,,Autocuration,1,CHEMBL615476,BAO_0000219,,
608,HeLa,F,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,8,,,51,,Autocuration,1,CHEMBL615477,BAO_0000219,,
609,,F,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615478,BAO_0000019,,
610,CHO,F,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615160,BAO_0000219,,
611,CHO,F,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,8,,,51,,Expert,1,CHEMBL615161,BAO_0000219,,
612,CHO,F,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,8,,,51,,Autocuration,1,CHEMBL615162,BAO_0000219,,
613,CHO,F,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,8,,,51,,Autocuration,1,CHEMBL615163,BAO_0000219,,
614,CHO,B,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,,,51,,Expert,1,CHEMBL615164,BAO_0000219,,
615,CHO,B,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,,,51,,Expert,1,CHEMBL615165,BAO_0000219,,
616,CHO,B,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,8,,,51,,Autocuration,1,CHEMBL615166,BAO_0000219,,
617,,F,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,8,,,51,,Autocuration,1,CHEMBL615167,BAO_0000219,,
618,HeLa,B,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,9,,,51,9606.0,Expert,1,CHEMBL615168,BAO_0000219,,
619,HeLa,B,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,9,,,51,9606.0,Expert,1,CHEMBL615169,BAO_0000219,,
620,CHO,B,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL615170,BAO_0000219,,
621,CHO,B,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,9,,,51,9606.0,Expert,1,CHEMBL615171,BAO_0000219,,
622,,F,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615694,BAO_0000019,,
623,,F,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615695,BAO_0000019,,
624,,F,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",8,,,51,,Autocuration,1,CHEMBL615696,BAO_0000019,,
625,CHO,F,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,8,,,51,,Autocuration,1,CHEMBL615697,BAO_0000219,,
626,CHO,F,449.0,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),9,,,51,9606.0,Expert,1,CHEMBL859410,BAO_0000219,,
627,CHO,F,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),8,,,51,,Autocuration,1,CHEMBL615841,BAO_0000219,,
628,CHO,F,449.0,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),9,,,51,9606.0,Expert,1,CHEMBL615842,BAO_0000219,,
629,CHO,F,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,8,,,51,,Autocuration,1,CHEMBL835003,BAO_0000219,,
630,CHO,F,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),8,,,51,,Autocuration,1,CHEMBL615843,BAO_0000219,,
631,CHO,F,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),9,,,51,9606.0,Expert,1,CHEMBL615979,BAO_0000219,,
632,CHO,F,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),8,,,51,,Autocuration,1,CHEMBL615980,BAO_0000219,,
633,CHO,F,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),9,,,51,9606.0,Expert,1,CHEMBL615981,BAO_0000219,,
634,,F,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,9,,,51,9606.0,Expert,1,CHEMBL615982,BAO_0000019,,
635,,F,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9,,,51,9606.0,Expert,1,CHEMBL615983,BAO_0000019,,
636,,F,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",9,,,51,9606.0,Expert,1,CHEMBL615984,BAO_0000019,,
637,,F,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",9,,,51,9606.0,Expert,1,CHEMBL615985,BAO_0000019,,
638,CHO,F,449.0,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,8,,,51,,Autocuration,1,CHEMBL615986,BAO_0000219,,
639,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,8,,,51,,Autocuration,1,CHEMBL615987,BAO_0000219,,
640,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,8,,,51,,Autocuration,1,CHEMBL615988,BAO_0000219,,
641,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,8,,,51,,Expert,1,CHEMBL615989,BAO_0000219,,
642,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,8,,,51,,Autocuration,1,CHEMBL615990,BAO_0000219,,
643,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,8,,,51,,Autocuration,1,CHEMBL615991,BAO_0000219,,
644,CHO,F,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,8,,,51,,Autocuration,1,CHEMBL615992,BAO_0000219,,
645,CHO,F,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,8,,,51,,Autocuration,1,CHEMBL615993,BAO_0000219,,
646,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,8,,,51,,Expert,1,CHEMBL615994,BAO_0000219,,
647,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,8,,,51,,Autocuration,1,CHEMBL615995,BAO_0000219,,
648,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,8,,,51,,Autocuration,1,CHEMBL615996,BAO_0000219,,
649,CHO,F,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,8,,,51,,Autocuration,1,CHEMBL615997,BAO_0000219,,
650,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,,,51,,Autocuration,1,CHEMBL615998,BAO_0000019,,
651,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,,,51,,Autocuration,1,CHEMBL615999,BAO_0000019,,
652,,F,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,8,,,51,,Autocuration,1,CHEMBL616000,BAO_0000019,,
653,HEK293,F,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,8,,,51,,Autocuration,1,CHEMBL616001,BAO_0000219,,
654,,F,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",9,,,51,9606.0,Expert,1,CHEMBL616002,BAO_0000019,,
655,,F,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",8,,,51,,Expert,1,CHEMBL616003,BAO_0000019,,
656,,F,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL616004,BAO_0000019,,
657,,F,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,9,,,51,9606.0,Expert,1,CHEMBL616005,BAO_0000019,,
658,,F,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",8,,,51,,Autocuration,1,CHEMBL616006,BAO_0000019,,
659,,F,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",8,,,51,,Expert,1,CHEMBL616007,BAO_0000019,,
660,,F,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",8,,,51,,Autocuration,1,CHEMBL616008,BAO_0000019,,
661,,F,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",8,,,51,,Autocuration,1,CHEMBL616009,BAO_0000019,,
662,,F,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",8,,,51,,Expert,1,CHEMBL616010,BAO_0000019,,
663,,F,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",9,,,51,9606.0,Expert,1,CHEMBL616011,BAO_0000019,,
664,,F,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",9,,,51,9606.0,Expert,1,CHEMBL615740,BAO_0000019,,
665,,F,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",8,,,51,,Autocuration,1,CHEMBL615741,BAO_0000019,,
666,,F,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",8,,,51,,Expert,1,CHEMBL615742,BAO_0000019,,
667,,F,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",8,,,51,,Autocuration,1,CHEMBL615743,BAO_0000019,,
668,CHO,F,449.0,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,8,,,51,,Autocuration,1,CHEMBL615744,BAO_0000219,,
669,CHO,F,449.0,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,8,,,51,,Expert,1,CHEMBL615745,BAO_0000219,,
670,,B,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,8,,,51,,Autocuration,1,CHEMBL615746,BAO_0000357,,
671,,B,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,8,,,51,,Autocuration,1,CHEMBL615747,BAO_0000357,,
672,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,,,51,,Autocuration,1,CHEMBL615748,BAO_0000019,,
673,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",8,,,51,,Autocuration,1,CHEMBL615749,BAO_0000019,,
674,,F,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,8,,,51,,Autocuration,1,CHEMBL615750,BAO_0000019,,
675,,F,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL616259,BAO_0000019,,
676,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,,,51,,Autocuration,1,CHEMBL616260,BAO_0000019,,
677,,F,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,9,,,51,9606.0,Expert,1,CHEMBL616261,BAO_0000019,,
678,,F,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9,,,51,9606.0,Expert,1,CHEMBL616262,BAO_0000019,,
679,,F,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",9,,,51,9606.0,Expert,1,CHEMBL616263,BAO_0000019,,
680,,F,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,9,,,51,9606.0,Expert,1,CHEMBL616264,BAO_0000019,,
681,,F,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,9,,,51,9606.0,Expert,1,CHEMBL616265,BAO_0000019,,
682,,F,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9,,,51,9606.0,Expert,1,CHEMBL616266,BAO_0000019,,
683,,F,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",9,,,51,9606.0,Expert,1,CHEMBL616267,BAO_0000019,,
684,,F,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,9,,,51,9606.0,Expert,1,CHEMBL616268,BAO_0000019,,
685,,B,,,Inhibition of human 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL616269,BAO_0000357,,
686,CHO,B,449.0,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,,,51,,Autocuration,1,CHEMBL884528,BAO_0000219,,
687,HEK293,B,722.0,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,9,,,105,,Expert,1,CHEMBL616270,BAO_0000219,,
688,CHO,B,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,8,,,51,,Autocuration,1,CHEMBL616271,BAO_0000219,,
689,CHO,F,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616272,BAO_0000219,,
690,,B,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,8,,,51,,Expert,1,CHEMBL616273,BAO_0000357,,
691,,B,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL616274,BAO_0000357,,
692,CHO,B,449.0,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,8,,,51,,Autocuration,1,CHEMBL616275,BAO_0000219,,
693,CHO,B,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,,,51,,Autocuration,1,CHEMBL616276,BAO_0000219,,
694,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,0,,,22226,10116.0,Autocuration,1,CHEMBL616277,BAO_0000218,,
695,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,0,,,22226,10116.0,Autocuration,1,CHEMBL616278,BAO_0000218,,
696,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,0,,,22226,10116.0,Autocuration,1,CHEMBL616279,BAO_0000218,,
697,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,0,,,22226,10116.0,Autocuration,1,CHEMBL616280,BAO_0000218,,
698,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,0,,,22226,10116.0,Autocuration,1,CHEMBL616281,BAO_0000218,,
699,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,0,,,22226,10116.0,Autocuration,1,CHEMBL616282,BAO_0000218,,
700,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,0,,,22226,10116.0,Autocuration,1,CHEMBL616283,BAO_0000218,,
701,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,0,,,22226,10116.0,Autocuration,1,CHEMBL616284,BAO_0000218,,
702,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,0,,,22226,10116.0,Autocuration,1,CHEMBL616285,BAO_0000218,,
703,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,0,,,22226,10116.0,Autocuration,1,CHEMBL616286,BAO_0000218,,
704,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,0,,,22226,10116.0,Autocuration,1,CHEMBL616287,BAO_0000218,,
705,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,0,,,22226,10116.0,Autocuration,1,CHEMBL616288,BAO_0000218,,
706,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,0,,,22226,10116.0,Autocuration,1,CHEMBL616289,BAO_0000218,,
707,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,0,,,22226,10116.0,Autocuration,1,CHEMBL615610,BAO_0000218,,
708,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,0,,,22226,10116.0,Autocuration,1,CHEMBL615611,BAO_0000218,,
709,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,0,,,22226,10116.0,Autocuration,1,CHEMBL615612,BAO_0000218,,
710,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,0,,,22226,10116.0,Autocuration,1,CHEMBL615613,BAO_0000218,,
711,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,0,,,22226,10116.0,Autocuration,1,CHEMBL615614,BAO_0000218,,
712,,F,,In vivo,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,0,,,22226,10116.0,Autocuration,1,CHEMBL615615,BAO_0000218,,
713,,B,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,4,,,105093,,Autocuration,1,CHEMBL615616,BAO_0000019,,
714,,B,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,8,,,11923,,Autocuration,1,CHEMBL615617,BAO_0000249,1898.0,
715,,B,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,8,,,10577,,Autocuration,1,CHEMBL615618,BAO_0000019,,
716,,B,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,8,,,10577,,Autocuration,1,CHEMBL615619,BAO_0000019,,
717,,B,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,8,,,10577,,Expert,1,CHEMBL615620,BAO_0000019,,
718,,B,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",8,,,55,,Autocuration,1,CHEMBL615621,BAO_0000357,,
719,,B,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",8,,,55,,Autocuration,1,CHEMBL615622,BAO_0000357,,
720,,F,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),8,,,12166,,Autocuration,1,CHEMBL615623,BAO_0000019,,
721,,F,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,8,,,12166,,Autocuration,1,CHEMBL615624,BAO_0000019,,
722,,F,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,8,,,12166,,Autocuration,1,CHEMBL615625,BAO_0000019,,
723,,F,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,8,,,12166,,Autocuration,1,CHEMBL767045,BAO_0000019,,
724,,F,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,8,,,55,10141.0,Autocuration,1,CHEMBL615626,BAO_0000019,,
725,,F,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,8,,,55,10141.0,Autocuration,1,CHEMBL615627,BAO_0000019,,
726,,B,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,8,,,55,10141.0,Autocuration,1,CHEMBL615628,BAO_0000019,,
727,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,8,,,55,10141.0,Autocuration,1,CHEMBL615629,BAO_0000357,,
728,,B,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,9,,,55,9606.0,Expert,1,CHEMBL615630,BAO_0000357,,
729,,B,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],8,,,55,,Autocuration,1,CHEMBL615631,BAO_0000219,,
730,,F,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,8,,,17087,,Autocuration,1,CHEMBL615632,BAO_0000218,,
731,,B,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,8,,,17087,,Autocuration,1,CHEMBL615633,BAO_0000357,,
732,,F,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,8,,,17087,,Autocuration,1,CHEMBL615634,BAO_0000218,,
733,,B,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,8,,,55,9823.0,Expert,1,CHEMBL615635,BAO_0000019,,
734,,B,,,In vitro inhibition of rat 5-Lipoxygenase,8,,,12166,,Expert,1,CHEMBL615636,BAO_0000357,,
735,,B,,,Inhibitory activity against 5-Lipoxygenase,9,,,12166,10116.0,Expert,1,CHEMBL615637,BAO_0000357,,
736,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,8,,,12166,,Expert,1,CHEMBL615638,BAO_0000219,,
737,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),8,,,12166,,Autocuration,1,CHEMBL615639,BAO_0000219,,
738,RBL-1,B,702.0,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,8,,,12166,,Autocuration,1,CHEMBL615640,BAO_0000219,,
739,,B,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,8,,,12166,,Autocuration,1,CHEMBL615796,BAO_0000019,,
740,,B,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],8,,,12166,,Autocuration,1,CHEMBL615845,BAO_0000219,,
741,,B,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,8,,,12166,,Autocuration,1,CHEMBL615846,BAO_0000357,,
742,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,8,,,12166,,Autocuration,1,CHEMBL615847,BAO_0000219,,
743,,B,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL615848,BAO_0000357,,
744,,B,,,Ratio of IC50 against 5-LO and COX,0,,,22226,10116.0,Autocuration,1,CHEMBL615849,BAO_0000019,,
745,,B,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,8,,,12166,,Autocuration,1,CHEMBL615850,BAO_0000357,,
746,,B,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,8,,,12166,,Autocuration,1,CHEMBL615851,BAO_0000357,,
747,,B,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,8,,,12166,,Autocuration,1,CHEMBL615852,BAO_0000219,,
748,,F,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,8,,,12166,,Autocuration,1,CHEMBL615853,BAO_0000019,,
749,,B,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,8,,,120,,Autocuration,1,CHEMBL884527,BAO_0000357,2367.0,
750,,B,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,0,,,22226,8932.0,Autocuration,1,CHEMBL872871,BAO_0000019,,
751,,B,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,0,,,22226,8932.0,Autocuration,1,CHEMBL615854,BAO_0000019,,
752,,B,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,0,,,22226,8932.0,Autocuration,1,CHEMBL767046,BAO_0000019,,
753,,B,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,8,,,10732,,Autocuration,1,CHEMBL615855,BAO_0000357,,
754,,F,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,9,,,12198,10116.0,Expert,1,CHEMBL615856,BAO_0000019,,
755,,F,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),9,,,12198,10116.0,Expert,1,CHEMBL615857,BAO_0000019,,
756,,F,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),9,,,12198,10116.0,Expert,1,CHEMBL615858,BAO_0000019,,
757,,B,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,8,,,10576,,Expert,1,CHEMBL615859,BAO_0000221,10000000.0,
758,,B,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,8,,,51,,Autocuration,1,CHEMBL615860,BAO_0000357,,
759,,B,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,0,,,22226,9986.0,Autocuration,1,CHEMBL615861,BAO_0000019,,
760,,B,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,0,,,22226,9986.0,Autocuration,1,CHEMBL615862,BAO_0000019,,
761,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,0,,,22226,9986.0,Autocuration,1,CHEMBL615863,BAO_0000019,,
762,,B,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,0,,,22226,9986.0,Autocuration,1,CHEMBL615864,BAO_0000019,,
763,,B,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,4,,,104744,,Autocuration,1,CHEMBL615865,BAO_0000221,10000000.0,
764,,B,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,4,,,104744,,Autocuration,1,CHEMBL615866,BAO_0000221,10000000.0,
765,,B,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,4,,,104744,,Autocuration,1,CHEMBL615867,BAO_0000221,10000000.0,
766,,B,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,4,,,104744,,Autocuration,1,CHEMBL615868,BAO_0000249,,
767,,B,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,5,,,104744,10116.0,Autocuration,1,CHEMBL615869,BAO_0000249,,
768,,B,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,5,,,104744,10116.0,Autocuration,1,CHEMBL615870,BAO_0000019,,
769,,B,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,5,,,104744,10116.0,Autocuration,1,CHEMBL615871,BAO_0000019,,
770,,B,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,4,,,104744,,Autocuration,1,CHEMBL615872,BAO_0000224,,
771,,B,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,4,,,104744,,Autocuration,1,CHEMBL833492,BAO_0000221,10000000.0,
772,,B,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,4,,,104744,,Autocuration,1,CHEMBL615873,BAO_0000221,10000000.0,
773,,B,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,4,,,104744,,Autocuration,1,CHEMBL615479,BAO_0000224,,
774,,B,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,4,,,104744,,Autocuration,1,CHEMBL615480,BAO_0000019,,
775,,B,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,5,,,104744,10116.0,Autocuration,1,CHEMBL615481,BAO_0000249,,
776,,B,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,4,,,104744,,Autocuration,1,CHEMBL872869,BAO_0000019,,
777,,B,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,4,,,104744,,Autocuration,1,CHEMBL615482,BAO_0000019,,
778,,B,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,4,,,104744,,Autocuration,1,CHEMBL615483,BAO_0000221,955.0,
779,,B,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,4,,,104744,,Autocuration,1,CHEMBL615484,BAO_0000221,955.0,
780,,B,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,4,,,104744,,Autocuration,1,CHEMBL615485,BAO_0000019,,
781,,B,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,5,,,104744,10116.0,Autocuration,1,CHEMBL615486,BAO_0000224,,
782,,B,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,4,,,104744,,Autocuration,1,CHEMBL615487,BAO_0000224,,
783,,B,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,4,,,104744,,Autocuration,1,CHEMBL615488,BAO_0000224,,
784,,B,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,4,,,104744,,Autocuration,1,CHEMBL615489,BAO_0000224,,
785,,B,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,4,,,104744,,Autocuration,1,CHEMBL615389,BAO_0000224,,
786,,B,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,4,,,104744,,Autocuration,1,CHEMBL615390,BAO_0000019,,
787,,B,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,4,,,104744,,Autocuration,1,CHEMBL615391,BAO_0000019,,
788,,B,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,4,,,104744,,Autocuration,1,CHEMBL615392,BAO_0000224,,
789,,B,,,Affinity for 5-hydroxytryptamine 1 receptor,0,,,22226,10116.0,Autocuration,1,CHEMBL615393,BAO_0000019,,
790,,B,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,4,,,104744,,Autocuration,1,CHEMBL615394,BAO_0000221,955.0,
791,,B,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,4,,,104744,,Autocuration,1,CHEMBL615395,BAO_0000221,955.0,
792,,B,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,4,,,104744,,Autocuration,1,CHEMBL615396,BAO_0000224,,
793,,B,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,4,,,104744,,Autocuration,1,CHEMBL615397,BAO_0000221,955.0,
794,,B,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,4,,,104744,,Autocuration,1,CHEMBL615398,BAO_0000019,,
795,,B,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,0,,,22226,10116.0,Autocuration,1,CHEMBL615399,BAO_0000019,,
796,,B,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,4,,,104744,,Autocuration,1,CHEMBL615400,BAO_0000019,,
797,,B,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,5,,,104744,10116.0,Autocuration,1,CHEMBL615401,BAO_0000019,,
798,,B,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,0,,,22226,10116.0,Autocuration,1,CHEMBL615402,BAO_0000019,,
799,,B,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,4,,,104744,,Autocuration,1,CHEMBL615403,BAO_0000019,,
800,,B,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,4,,,104744,,Autocuration,1,CHEMBL615404,BAO_0000221,955.0,
801,,B,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,4,,,104744,,Autocuration,1,CHEMBL615781,BAO_0000019,,
802,,B,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,4,,,104744,,Autocuration,1,CHEMBL615782,BAO_0000220,955.0,
803,,B,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,4,,,104744,,Autocuration,1,CHEMBL615783,BAO_0000221,955.0,
804,,B,,,Compound was tested for binding affinity against 5-HT1 receptor,0,,,22226,,Autocuration,1,CHEMBL873481,BAO_0000019,,
805,,B,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,0,,,22226,,Autocuration,1,CHEMBL615784,BAO_0000019,,
806,,B,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,8,,,10576,,Expert,1,CHEMBL615785,BAO_0000357,,
807,,F,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",8,,,10576,,Autocuration,1,CHEMBL615786,BAO_0000249,,
808,,F,,In vivo,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,8,,,10576,,Autocuration,1,CHEMBL615787,BAO_0000218,,
809,,F,,In vivo,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,8,,,10576,,Autocuration,1,CHEMBL615788,BAO_0000218,,
810,,F,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL767044,BAO_0000019,,
811,,F,,In vivo,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,8,,,10576,,Autocuration,1,CHEMBL615789,BAO_0000218,,
812,,F,,In vivo,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,8,,,10576,,Autocuration,1,CHEMBL615790,BAO_0000218,,
813,,F,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,8,,,10576,,Autocuration,1,CHEMBL615813,BAO_0000019,,
814,,F,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,8,,,10576,,Autocuration,1,CHEMBL615814,BAO_0000219,,
815,,F,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,8,,,51,,Expert,1,CHEMBL615815,BAO_0000219,,
816,,F,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,8,,,10576,,Autocuration,1,CHEMBL615816,BAO_0000219,,
817,,B,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,8,,,10576,,Expert,1,CHEMBL615817,BAO_0000249,,
818,,B,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL615818,BAO_0000221,10000000.0,
819,,B,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL615819,BAO_0000221,10000000.0,
820,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,8,,,10576,,Expert,1,CHEMBL615820,BAO_0000249,,
821,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,9,,,10576,10116.0,Expert,1,CHEMBL615821,BAO_0000221,10000000.0,
822,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,9,,,10576,10116.0,Expert,1,CHEMBL615822,BAO_0000221,10000000.0,
823,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL615823,BAO_0000221,10000000.0,
824,,B,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,9,,,10576,10116.0,Expert,1,CHEMBL615824,BAO_0000221,10000000.0,
825,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,9,,,10576,10116.0,Expert,1,CHEMBL615825,BAO_0000221,10000000.0,
826,,B,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL615826,BAO_0000357,,
827,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL615827,BAO_0000249,,
828,,B,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL615828,BAO_0000249,10000000.0,
829,,B,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Expert,1,CHEMBL615829,BAO_0000221,10000000.0,
830,,B,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL615830,BAO_0000221,10000000.0,
831,,B,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,8,,,10576,,Expert,1,CHEMBL615831,BAO_0000221,10000000.0,
832,,B,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL615832,BAO_0000357,,
833,,B,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL615833,BAO_0000019,,
834,,B,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL615834,BAO_0000221,10000000.0,
835,,B,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,8,,,10576,,Intermediate,1,CHEMBL615835,BAO_0000249,,
836,,B,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,8,,,10576,,Autocuration,1,CHEMBL615836,BAO_0000249,10000000.0,
837,,B,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,9,,,10576,10116.0,Expert,1,CHEMBL615837,BAO_0000019,,
838,,B,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,9,,,10576,10116.0,Expert,1,CHEMBL615838,BAO_0000019,,
839,,B,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",8,,,10576,,Expert,1,CHEMBL615839,BAO_0000249,,
840,,B,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL884525,BAO_0000019,,
841,,B,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,8,,,10576,,Autocuration,1,CHEMBL615840,BAO_0000249,,
842,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Expert,1,CHEMBL615405,BAO_0000221,10000000.0,
843,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,8,,,10576,,Expert,1,CHEMBL615406,BAO_0000019,,
844,,B,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,8,,,10576,,Expert,1,CHEMBL615900,BAO_0000221,10000000.0,
845,,B,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,8,,,10576,,Expert,1,CHEMBL615901,BAO_0000221,10000000.0,
846,,B,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,8,,,10576,,Expert,1,CHEMBL615902,BAO_0000357,,
847,,B,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,8,,,10576,,Autocuration,1,CHEMBL615903,BAO_0000221,10000000.0,
848,,B,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,8,,,10576,,Autocuration,1,CHEMBL615904,BAO_0000357,,
849,,B,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,8,,,10576,,Expert,1,CHEMBL615905,BAO_0000357,,
850,,B,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,8,,,10576,,Autocuration,1,CHEMBL615906,BAO_0000019,,
851,,F,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,8,,,10576,,Autocuration,1,CHEMBL615907,BAO_0000019,,
852,,B,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,8,,,10576,,Expert,1,CHEMBL615908,BAO_0000019,,
853,,B,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL615909,BAO_0000221,10000000.0,
854,,B,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",8,,,10576,,Autocuration,1,CHEMBL615910,BAO_0000019,,
855,,B,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",8,,,10576,,Autocuration,1,CHEMBL615911,BAO_0000019,,
856,,B,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",8,,,10576,,Autocuration,1,CHEMBL615912,BAO_0000019,,
857,,B,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL615913,BAO_0000019,,
858,,B,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL615914,BAO_0000357,,
859,,B,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,8,,,10576,,Autocuration,1,CHEMBL615915,BAO_0000221,10000000.0,
860,,B,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,8,,,10576,,Autocuration,1,CHEMBL615916,BAO_0000357,,
861,,B,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,8,,,10576,,Expert,1,CHEMBL615917,BAO_0000357,,
862,,B,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,8,,,10576,,Expert,1,CHEMBL615918,BAO_0000357,,
863,,B,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,8,,,10576,,Expert,1,CHEMBL615919,BAO_0000249,10000000.0,
864,,B,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,9,,,10576,10116.0,Expert,1,CHEMBL615920,BAO_0000221,10000000.0,
865,,B,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL615921,BAO_0000357,,
866,,B,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),8,,,10576,,Expert,1,CHEMBL615922,BAO_0000357,,
867,,F,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",9,,,10576,10116.0,Expert,1,CHEMBL881290,BAO_0000249,,
868,,B,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",8,,,10576,,Autocuration,1,CHEMBL615923,BAO_0000221,10000000.0,
869,,F,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL615924,BAO_0000221,10000000.0,
870,,F,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL615925,BAO_0000221,10000000.0,
871,,B,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL615926,BAO_0000357,,
872,,B,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL615927,BAO_0000019,,
873,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,,,10576,,Autocuration,1,CHEMBL615928,BAO_0000221,10000000.0,
874,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,9,,,10576,10116.0,Expert,1,CHEMBL615929,BAO_0000357,,
875,,B,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL615930,BAO_0000221,10000000.0,
876,CHO,B,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,8,,,51,,Autocuration,1,CHEMBL615931,BAO_0000219,,
877,CHO,F,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615932,BAO_0000219,,
878,CHO,F,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615933,BAO_0000219,,
879,,B,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615934,BAO_0000357,,
880,,B,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,8,,,51,,Autocuration,1,CHEMBL615935,BAO_0000357,,
881,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",8,,,51,,Autocuration,1,CHEMBL615936,BAO_0000019,,
882,CHO,B,449.0,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,8,,,51,,Autocuration,1,CHEMBL615937,BAO_0000219,,
883,,B,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615938,BAO_0000357,,
884,,B,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),8,,,51,,Autocuration,1,CHEMBL615797,BAO_0000357,,
885,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615798,BAO_0000357,,
886,,B,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,8,,,51,,Autocuration,1,CHEMBL872870,BAO_0000357,,
887,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,8,,,51,,Autocuration,1,CHEMBL615799,BAO_0000357,,
888,,B,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615800,BAO_0000357,,
889,HEK293,F,722.0,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,8,,,51,,Autocuration,1,CHEMBL615801,BAO_0000219,,
890,,B,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,8,,,51,,Autocuration,1,CHEMBL615802,BAO_0000019,,
891,,B,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,8,,,51,,Autocuration,1,CHEMBL615803,BAO_0000357,,
892,,F,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",8,,,51,,Expert,1,CHEMBL835002,BAO_0000019,,
893,,F,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",8,,,51,,Autocuration,1,CHEMBL615804,BAO_0000019,,
894,HeLa,B,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,8,,,51,,Expert,1,CHEMBL615805,BAO_0000219,,
895,CHO,B,449.0,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615806,BAO_0000219,,
896,,B,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,9,,,51,9606.0,Expert,1,CHEMBL615807,BAO_0000357,,
897,,B,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,8,,,51,,Autocuration,1,CHEMBL615808,BAO_0000357,,
898,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL615809,BAO_0000357,,
899,HeLa,B,308.0,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,8,,,51,,Autocuration,1,CHEMBL615810,BAO_0000219,,
900,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615811,BAO_0000357,,
901,CHO,B,449.0,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,8,,,51,,Autocuration,1,CHEMBL615812,BAO_0000219,,
902,CHO,B,449.0,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,,,51,,Autocuration,1,CHEMBL615751,BAO_0000219,,
903,,B,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615752,BAO_0000357,,
904,CHO,B,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,8,,,51,,Expert,1,CHEMBL615753,BAO_0000219,,
905,CHO,B,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,8,,,51,,Autocuration,1,CHEMBL615754,BAO_0000219,,
906,,B,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615755,BAO_0000357,,
907,CHO,B,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,9,,,51,9606.0,Expert,1,CHEMBL615756,BAO_0000219,,
908,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615757,BAO_0000019,,
909,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,8,,,51,,Autocuration,1,CHEMBL615758,BAO_0000357,,
910,,B,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,8,,,51,,Expert,1,CHEMBL615759,BAO_0000357,,
911,,B,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615760,BAO_0000357,,
912,HeLa,B,308.0,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,8,,,51,,Expert,1,CHEMBL615761,BAO_0000219,,
913,,B,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,8,,,51,,Autocuration,1,CHEMBL872104,BAO_0000357,,
914,,B,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615762,BAO_0000357,,
915,,B,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615763,BAO_0000357,,
916,,B,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,8,,,51,,Autocuration,1,CHEMBL615764,BAO_0000357,,
917,Cell line,B,1167.0,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),8,,,51,,Autocuration,1,CHEMBL615765,BAO_0000219,,
918,,B,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),8,,,51,,Autocuration,1,CHEMBL615766,BAO_0000019,,
919,,B,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615767,BAO_0000357,,
920,,B,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Expert,1,CHEMBL615768,BAO_0000357,,
921,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615769,BAO_0000357,,
922,,B,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,8,,,51,,Expert,1,CHEMBL615770,BAO_0000357,,
923,,B,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615771,BAO_0000357,,
924,,B,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,8,,,51,,Expert,1,CHEMBL615772,BAO_0000357,,
925,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL615773,BAO_0000357,,
926,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,8,,,51,,Expert,1,CHEMBL615774,BAO_0000357,,
927,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL615775,BAO_0000357,,
928,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,8,,,51,,Autocuration,1,CHEMBL615776,BAO_0000357,,
929,,B,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Expert,1,CHEMBL615777,BAO_0000357,,
930,,B,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,8,,,51,,Autocuration,1,CHEMBL615778,BAO_0000219,,
931,,B,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,9,,,51,9606.0,Expert,1,CHEMBL615779,BAO_0000357,,
932,,B,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,8,,,51,,Autocuration,1,CHEMBL615780,BAO_0000357,,
933,,B,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616298,BAO_0000357,,
934,,B,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616299,BAO_0000357,,
935,CHO-K1,B,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,8,,,51,,Autocuration,1,CHEMBL616300,BAO_0000219,,
936,CHO-K1,F,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,8,,,51,,Expert,1,CHEMBL616301,BAO_0000219,,
937,,B,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616302,BAO_0000019,,
938,,B,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),8,,,51,,Autocuration,1,CHEMBL616117,BAO_0000019,,
939,,B,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),8,,,51,,Autocuration,1,CHEMBL616118,BAO_0000019,,
940,,B,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,8,,,51,,Autocuration,1,CHEMBL616119,BAO_0000019,,
941,HeLa,B,308.0,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,9,,,51,9606.0,Expert,1,CHEMBL616120,BAO_0000219,,
942,,B,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616121,BAO_0000357,,
943,,B,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,8,,,51,,Autocuration,1,CHEMBL616122,BAO_0000357,,
944,,B,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616123,BAO_0000357,,
945,,B,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL616124,BAO_0000357,,
946,,B,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,8,,,51,,Expert,1,CHEMBL616125,BAO_0000357,,
947,,B,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,8,,,51,10116.0,Expert,1,CHEMBL616126,BAO_0000357,,
948,CHO,B,449.0,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL616127,BAO_0000219,,
949,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,8,,,51,,Expert,1,CHEMBL616128,BAO_0000019,,
950,,B,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,8,,,51,,Autocuration,1,CHEMBL616129,BAO_0000357,,
951,,B,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,8,,,51,,Expert,1,CHEMBL616130,BAO_0000357,,
952,,B,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,8,,,51,,Autocuration,1,CHEMBL616131,BAO_0000357,,
953,HeLa,B,308.0,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,8,,,51,,Autocuration,1,CHEMBL616132,BAO_0000219,,
954,HeLa,B,308.0,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,9,,,51,9606.0,Expert,1,CHEMBL616133,BAO_0000219,,
955,,B,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL616134,BAO_0000357,,
956,,B,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,8,,,51,,Autocuration,1,CHEMBL616135,BAO_0000357,,
957,,B,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,9,,,51,9606.0,Expert,1,CHEMBL616136,BAO_0000357,,
958,,B,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,8,,,51,,Autocuration,1,CHEMBL616137,BAO_0000019,,
959,,B,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,8,,,51,,Autocuration,1,CHEMBL872105,BAO_0000019,,
960,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,8,,,51,,Autocuration,1,CHEMBL616138,BAO_0000357,,
961,,B,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL616139,BAO_0000357,,
962,,F,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",8,,,51,,Autocuration,1,CHEMBL616140,BAO_0000019,,
963,,B,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,8,,,51,,Expert,1,CHEMBL616141,BAO_0000019,,
964,,B,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL616142,BAO_0000357,,
965,,B,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,8,,,51,,Autocuration,1,CHEMBL616143,BAO_0000357,,
966,HeLa,B,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,8,,,51,,Autocuration,1,CHEMBL616144,BAO_0000219,,
967,HeLa,B,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,8,,,51,,Autocuration,1,CHEMBL616145,BAO_0000219,,
968,HeLa,B,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,8,,,51,,Autocuration,1,CHEMBL616012,BAO_0000219,,
969,HeLa,B,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,8,,,51,,Autocuration,1,CHEMBL616013,BAO_0000219,,
970,,F,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",8,,,51,,Autocuration,1,CHEMBL616014,BAO_0000019,,
971,,F,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",8,,,51,,Autocuration,1,CHEMBL616015,BAO_0000019,,
972,,F,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",8,,,51,,Autocuration,1,CHEMBL616016,BAO_0000019,,
973,,F,,In vivo,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,8,,,51,,Autocuration,1,CHEMBL616017,BAO_0000218,,
974,,B,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,8,,,51,,Autocuration,1,CHEMBL616018,BAO_0000019,,
975,,F,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,8,,,51,,Autocuration,1,CHEMBL616019,BAO_0000019,,
976,,F,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,8,,,51,,Autocuration,1,CHEMBL616020,BAO_0000019,,
977,,B,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL858018,BAO_0000357,,
978,HEK293,F,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,8,,,51,,Autocuration,1,CHEMBL616021,BAO_0000219,,
979,,F,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",8,,,51,,Expert,1,CHEMBL616022,BAO_0000019,,
980,,F,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",8,,,51,,Autocuration,1,CHEMBL616023,BAO_0000019,,
981,,F,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",8,,,51,,Autocuration,1,CHEMBL616024,BAO_0000019,,
982,,F,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",8,,,51,,Autocuration,1,CHEMBL616025,BAO_0000019,,
983,CHO,F,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,8,,,51,,Autocuration,1,CHEMBL616026,BAO_0000219,,
984,,F,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",8,,,51,,Autocuration,1,CHEMBL616027,BAO_0000019,,
985,,F,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",9,,,51,9606.0,Expert,1,CHEMBL616028,BAO_0000019,,
986,,F,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,9,,,51,9606.0,Expert,1,CHEMBL616029,BAO_0000019,,
987,CHO,B,449.0,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,8,,,51,,Expert,1,CHEMBL616030,BAO_0000219,,
988,,B,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,8,,,51,,Expert,1,CHEMBL616031,BAO_0000019,,
989,,F,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,9,,,51,9606.0,Expert,1,CHEMBL616032,BAO_0000019,,
990,,F,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,9,,,51,9606.0,Expert,1,CHEMBL616033,BAO_0000019,,
991,,F,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,,,51,,Autocuration,1,CHEMBL616034,BAO_0000019,,
992,,F,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,,,51,,Autocuration,1,CHEMBL616035,BAO_0000019,,
993,,F,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616036,BAO_0000019,,
994,,F,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,,,51,,Autocuration,1,CHEMBL616037,BAO_0000019,,
995,,F,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,,,51,,Autocuration,1,CHEMBL616038,BAO_0000019,,
996,,F,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,8,,,51,,Autocuration,1,CHEMBL616039,BAO_0000019,,
997,,F,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616040,BAO_0000019,,
998,HeLa,F,308.0,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9,,,51,9606.0,Expert,1,CHEMBL616041,BAO_0000219,,
999,HeLa,F,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9,,,51,9606.0,Expert,1,CHEMBL616042,BAO_0000219,,
1000,HeLa,F,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9,,,51,9606.0,Expert,1,CHEMBL616043,BAO_0000219,,
1001,,F,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",8,,,51,,Autocuration,1,CHEMBL616044,BAO_0000019,,
1002,,F,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",8,,,51,,Autocuration,1,CHEMBL616045,BAO_0000019,,
1003,HEK293,F,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,8,,,51,,Autocuration,1,CHEMBL616046,BAO_0000219,,
1004,CHO,F,449.0,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),8,,,51,,Autocuration,1,CHEMBL616047,BAO_0000219,,
1005,CHO,F,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,8,,,51,,Autocuration,1,CHEMBL616048,BAO_0000219,,
1006,CHO,F,449.0,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),9,,,51,9606.0,Expert,1,CHEMBL616049,BAO_0000219,,
1007,CHO,F,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),8,,,51,,Autocuration,1,CHEMBL616050,BAO_0000219,,
1008,,F,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,8,,,51,,Expert,1,CHEMBL616051,BAO_0000219,,
1009,,F,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,8,,,51,,Autocuration,1,CHEMBL616212,BAO_0000219,,
1010,,F,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",8,,,51,,Autocuration,1,CHEMBL616213,BAO_0000019,,
1011,,B,,In vitro,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,8,,,51,,Expert,1,CHEMBL616214,BAO_0000219,,
1012,,B,,In vitro,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,8,,,51,,Expert,1,CHEMBL616215,BAO_0000219,,
1013,,B,,,Binding activity radioligand.,8,,,51,,Autocuration,1,CHEMBL616216,BAO_0000357,,
1014,,B,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,8,,,51,,Autocuration,1,CHEMBL616217,BAO_0000019,,
1015,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616218,BAO_0000357,,
1016,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616219,BAO_0000357,,
1017,,B,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616220,BAO_0000357,,
1018,,B,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Expert,1,CHEMBL833493,BAO_0000357,,
1019,,B,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616221,BAO_0000357,,
1020,CHO,B,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,9,,,51,9606.0,Expert,1,CHEMBL616222,BAO_0000219,,
1021,,F,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616223,BAO_0000019,,
1022,,F,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,8,,,51,,Autocuration,1,CHEMBL616224,BAO_0000019,,
1023,,B,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,8,,,51,,Expert,1,CHEMBL616225,BAO_0000019,,
1024,HEK293,B,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,9,,,51,9606.0,Expert,1,CHEMBL616226,BAO_0000219,,
1025,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,8,,,51,,Autocuration,1,CHEMBL616227,BAO_0000219,,
1026,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL616228,BAO_0000219,,
1027,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,8,,,51,,Autocuration,1,CHEMBL616229,BAO_0000219,,
1028,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,8,,,51,,Autocuration,1,CHEMBL616230,BAO_0000219,,
1029,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,8,,,51,,Autocuration,1,CHEMBL616231,BAO_0000219,,
1030,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL616232,BAO_0000357,,
1031,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,8,,,51,,Autocuration,1,CHEMBL616233,BAO_0000219,,
1032,HEK293,B,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,8,,,51,,Autocuration,1,CHEMBL857973,BAO_0000219,,
1033,,B,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,8,,,51,,Autocuration,1,CHEMBL616234,BAO_0000219,,
1034,,B,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616235,BAO_0000357,,
1035,HeLa,B,308.0,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,8,,,51,,Expert,1,CHEMBL616236,BAO_0000219,,
1036,,B,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,8,,,51,,Expert,1,CHEMBL616237,BAO_0000019,,
1037,HEK293,B,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,8,,,51,,Autocuration,1,CHEMBL616238,BAO_0000219,,
1038,HEK293,B,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,8,,,51,,Autocuration,1,CHEMBL616239,BAO_0000219,,
1039,,B,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,8,,,51,,Autocuration,1,CHEMBL616240,BAO_0000219,,
1040,HeLa,B,308.0,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,9,,,51,9606.0,Expert,1,CHEMBL616241,BAO_0000219,,
1041,HEK293,B,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,8,,,51,,Autocuration,1,CHEMBL616242,BAO_0000219,,
1042,HEK293,B,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",8,,,51,,Autocuration,1,CHEMBL616243,BAO_0000219,,
1043,,B,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,9,,,51,,Expert,1,CHEMBL616244,BAO_0000357,,
1044,,B,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,9,,,51,9606.0,Autocuration,1,CHEMBL616245,BAO_0000357,,
1045,,B,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,8,,,106,,Autocuration,1,CHEMBL616246,BAO_0000357,,
1046,,B,,,Binding affinity against 5-HT1D receptor,8,,,105,,Autocuration,1,CHEMBL616247,BAO_0000357,,
1047,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,,,105,,Autocuration,1,CHEMBL616248,BAO_0000357,,
1048,,B,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,8,,,107,,Autocuration,1,CHEMBL616249,BAO_0000357,,
1049,,B,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,8,,,10576,9606.0,Autocuration,1,CHEMBL616250,BAO_0000357,,
1050,,B,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616251,BAO_0000357,,
1051,,F,,In vivo,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,8,,,11863,,Autocuration,1,CHEMBL616252,BAO_0000218,,
1052,,F,,In vivo,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,8,,,11863,,Autocuration,1,CHEMBL616253,BAO_0000218,,
1053,,F,,In vivo,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,8,,,11863,,Autocuration,1,CHEMBL616254,BAO_0000218,,
1054,,F,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,9,,,11863,10090.0,Expert,1,CHEMBL616255,BAO_0000218,,
1055,,F,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,9,,,11863,10090.0,Expert,1,CHEMBL832872,BAO_0000218,,
1056,,F,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,9,,,11863,10090.0,Expert,1,CHEMBL616256,BAO_0000218,,
1057,,F,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,9,,,11863,10090.0,Expert,1,CHEMBL616257,BAO_0000218,,
1058,,F,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,9,,,11863,10090.0,Expert,1,CHEMBL616258,BAO_0000218,,
1059,,F,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,9,,,11863,10090.0,Expert,1,CHEMBL616384,BAO_0000218,,
1060,,B,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,8,,,11863,,Autocuration,1,CHEMBL616385,BAO_0000221,10000000.0,
1061,,B,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,8,,,11863,,Expert,1,CHEMBL616386,BAO_0000357,,
1062,,B,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,9,,,11863,10090.0,Expert,1,CHEMBL616387,BAO_0000221,10000000.0,
1063,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,8,,,11863,,Autocuration,1,CHEMBL616388,BAO_0000221,10000000.0,
1064,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,9,,,11863,10090.0,Expert,1,CHEMBL616389,BAO_0000221,10000000.0,
1065,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,8,,,11863,,Autocuration,1,CHEMBL616390,BAO_0000221,10000000.0,
1066,,B,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,8,,,11863,,Autocuration,1,CHEMBL616391,BAO_0000357,,
1067,,B,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,9,,,11863,10090.0,Expert,1,CHEMBL616392,BAO_0000221,10000000.0,
1068,,B,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,8,,,51,9823.0,Autocuration,1,CHEMBL616393,BAO_0000357,,
1069,,B,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,8,,,51,9823.0,Autocuration,1,CHEMBL616394,BAO_0000357,,
1070,,B,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,8,,,51,9823.0,Autocuration,1,CHEMBL616395,BAO_0000019,,
1071,,B,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,8,,,51,9823.0,Autocuration,1,CHEMBL616396,BAO_0000357,,
1072,,B,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,8,,,51,9823.0,Autocuration,1,CHEMBL872907,BAO_0000019,,
1073,,B,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,8,,,51,9823.0,Autocuration,1,CHEMBL616397,BAO_0000019,,
1074,,B,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,8,,,51,9823.0,Autocuration,1,CHEMBL616398,BAO_0000019,,
1075,,B,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,8,,,51,9823.0,Expert,1,CHEMBL616399,BAO_0000357,,
1076,,B,,,Binding activity radioligand.,8,,,51,9823.0,Autocuration,1,CHEMBL857065,BAO_0000357,,
1077,,B,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,8,,,51,9823.0,Expert,1,CHEMBL616400,BAO_0000019,,
1078,,B,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,8,,,51,9823.0,Autocuration,1,CHEMBL616401,BAO_0000019,,
1079,,B,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,8,,,10624,,Expert,1,CHEMBL616402,BAO_0000019,,
1080,,B,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,8,,,51,9823.0,Expert,1,CHEMBL616403,BAO_0000019,,
1081,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,8,,,51,9823.0,Autocuration,1,CHEMBL616404,BAO_0000221,10000000.0,
1082,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,8,,,51,9823.0,Autocuration,1,CHEMBL616405,BAO_0000249,,
1083,,B,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,8,,,51,9823.0,Autocuration,1,CHEMBL616406,BAO_0000019,,
1084,,F,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,8,,,51,9823.0,Expert,1,CHEMBL616407,BAO_0000019,,
1085,,B,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,8,,,51,9986.0,Autocuration,1,CHEMBL616408,BAO_0000019,,
1086,,B,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,9,,,10576,10116.0,Expert,1,CHEMBL616409,BAO_0000249,,
1087,,B,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",9,,,10576,10116.0,Expert,1,CHEMBL616410,BAO_0000221,10000000.0,
1088,,B,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,8,,,10576,,Autocuration,1,CHEMBL616411,BAO_0000357,,
1089,,F,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",9,,,10576,10116.0,Expert,1,CHEMBL616412,BAO_0000249,,
1090,,F,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",9,,,10576,10116.0,Expert,1,CHEMBL616413,BAO_0000249,10000000.0,
1091,,B,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,,,10576,,Autocuration,1,CHEMBL616414,BAO_0000221,10000000.0,
1092,,B,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,9,,,10576,10116.0,Expert,1,CHEMBL616415,BAO_0000221,10000000.0,
1093,,B,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,8,,,10576,,Autocuration,1,CHEMBL616416,BAO_0000019,,
1094,,B,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL616417,BAO_0000357,,
1095,,B,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,8,,,10576,,Autocuration,1,CHEMBL616418,BAO_0000357,,
1096,,B,,In vitro,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,8,,,10576,,Autocuration,1,CHEMBL616419,BAO_0000219,,
1097,,B,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL616420,BAO_0000357,,
1098,,B,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,8,,,10576,,Autocuration,1,CHEMBL616421,BAO_0000249,,
1099,,B,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,8,,,10576,,Autocuration,1,CHEMBL616422,BAO_0000249,,
1100,,B,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,8,,,10576,,Expert,1,CHEMBL616423,BAO_0000249,,
1101,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,9,,,10576,10116.0,Expert,1,CHEMBL616424,BAO_0000357,,
1102,,B,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,8,,,10576,,Expert,1,CHEMBL616425,BAO_0000357,,
1103,,B,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,8,,,10576,,Expert,1,CHEMBL616426,BAO_0000357,,
1104,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,8,,,10576,,Autocuration,1,CHEMBL616427,BAO_0000221,10000000.0,
1105,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,8,,,10576,,Autocuration,1,CHEMBL616428,BAO_0000221,10000000.0,
1106,,B,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL616290,BAO_0000221,10000000.0,
1107,,B,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL616052,BAO_0000357,,
1108,,B,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616053,BAO_0000357,,
1109,,B,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL616054,BAO_0000249,,
1110,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616055,BAO_0000357,,
1111,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,8,,,10576,,Autocuration,1,CHEMBL616056,BAO_0000357,,
1112,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,8,,,10576,,Expert,1,CHEMBL616057,BAO_0000019,,
1113,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,9,,,10576,10116.0,Expert,1,CHEMBL616058,BAO_0000221,955.0,
1114,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,8,,,10576,,Autocuration,1,CHEMBL616059,BAO_0000221,955.0,
1115,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL616060,BAO_0000249,,
1116,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,9,,,10576,10116.0,Expert,1,CHEMBL616061,BAO_0000221,10000000.0,
1117,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,8,,,10576,,Expert,1,CHEMBL616062,BAO_0000221,10000000.0,
1118,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL616063,BAO_0000249,,
1119,,B,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",8,,,10576,,Autocuration,1,CHEMBL616064,BAO_0000249,2435.0,
1120,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,9,,,10576,10116.0,Expert,1,CHEMBL616065,BAO_0000249,,
1121,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,9,,,10576,10116.0,Expert,1,CHEMBL616066,BAO_0000249,,
1122,,B,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL616067,BAO_0000221,10000000.0,
1123,,B,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,8,,,10576,,Autocuration,1,CHEMBL616068,BAO_0000221,10000000.0,
1124,,B,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,8,,,10576,,Intermediate,1,CHEMBL616069,BAO_0000221,10000000.0,
1125,,B,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,8,,,10576,,Expert,1,CHEMBL616070,BAO_0000249,,
1126,,B,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL616071,BAO_0000221,10000000.0,
1127,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL616072,BAO_0000221,10000000.0,
1128,,B,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,8,,,10576,,Autocuration,1,CHEMBL616073,BAO_0000221,10000000.0,
1129,,B,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,8,,,10576,,Autocuration,1,CHEMBL616074,BAO_0000221,10000000.0,
1130,,B,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,8,,,10576,,Expert,1,CHEMBL616075,BAO_0000019,,
1131,,B,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616076,BAO_0000357,,
1132,,B,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,9,,,10576,10116.0,Expert,1,CHEMBL616077,BAO_0000019,,
1133,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,9,,,10576,10116.0,Expert,1,CHEMBL616078,BAO_0000019,,
1134,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,9,,,10576,10116.0,Expert,1,CHEMBL616079,BAO_0000019,,
1135,CHO-K1,B,485.0,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,9,,,10576,10116.0,Expert,1,CHEMBL616080,BAO_0000219,,
1136,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616081,BAO_0000357,,
1137,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,9,,,10576,10116.0,Expert,1,CHEMBL616082,BAO_0000221,10000000.0,
1138,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,8,,,10576,,Autocuration,1,CHEMBL616083,BAO_0000221,10000000.0,
1139,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,8,,,10576,,Autocuration,1,CHEMBL616084,BAO_0000019,,
1140,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,8,,,10576,,Expert,1,CHEMBL616085,BAO_0000019,,
1141,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL616086,BAO_0000019,,
1142,,B,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",8,,,10576,,Autocuration,1,CHEMBL616087,BAO_0000221,10000000.0,
1143,,B,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,8,,,10576,,Expert,1,CHEMBL616088,BAO_0000357,,
1144,,B,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,8,,,10576,,Autocuration,1,CHEMBL616089,BAO_0000019,,
1145,,B,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,9,,,10576,10116.0,Expert,1,CHEMBL616090,BAO_0000357,,
1146,,B,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL616091,BAO_0000357,,
1147,,B,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",8,,,10576,,Autocuration,1,CHEMBL616092,BAO_0000249,2435.0,
1148,,B,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),8,,,10576,,Autocuration,1,CHEMBL616093,BAO_0000357,,
1149,,B,,In vivo,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),8,,,10576,,Autocuration,1,CHEMBL616094,BAO_0000218,,
1150,,B,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,8,,,10576,,Autocuration,1,CHEMBL616095,BAO_0000221,955.0,
1151,,B,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL616096,BAO_0000357,,
1152,,B,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,8,,,10576,,Expert,1,CHEMBL616097,BAO_0000249,,
1153,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,9,,,10576,10116.0,Expert,1,CHEMBL616098,BAO_0000249,,
1154,,B,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL616099,BAO_0000221,10000000.0,
1155,,B,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL616100,BAO_0000221,10000000.0,
1156,,B,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,8,,,10576,,Expert,1,CHEMBL616101,BAO_0000357,,
1157,,B,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,8,,,10576,,Expert,1,CHEMBL616102,BAO_0000249,,
1158,,B,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616103,BAO_0000357,,
1159,,B,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,8,,,10576,,Expert,1,CHEMBL616104,BAO_0000019,,
1160,,B,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",8,,,10576,,Expert,1,CHEMBL616105,BAO_0000019,,
1161,,B,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL616106,BAO_0000019,,
1162,,B,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,8,,,10576,,Autocuration,1,CHEMBL616107,BAO_0000019,,
1163,,B,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,8,,,10576,,Expert,1,CHEMBL616108,BAO_0000357,,
1164,,B,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,8,,,10576,,Expert,1,CHEMBL616109,BAO_0000221,10000000.0,
1165,,B,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,8,,,10576,,Autocuration,1,CHEMBL616110,BAO_0000357,,
1166,CHO,B,449.0,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,8,,,10576,,Expert,1,CHEMBL616111,BAO_0000219,,
1167,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL616112,BAO_0000019,,
1168,,B,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,8,,,10576,,Autocuration,1,CHEMBL616113,BAO_0000221,10000000.0,
1169,,B,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616114,BAO_0000019,,
1170,,B,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616115,BAO_0000019,,
1171,,B,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616116,BAO_0000357,,
1172,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL615844,BAO_0000221,955.0,
1173,,B,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,8,,,10576,,Expert,1,CHEMBL615939,BAO_0000221,10000000.0,
1174,,B,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,8,,,10576,,Expert,1,CHEMBL615940,BAO_0000019,,
1175,,B,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,8,,,10576,,Expert,1,CHEMBL615941,BAO_0000221,10000000.0,
1176,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,8,,,10576,,Autocuration,1,CHEMBL615942,BAO_0000221,10000000.0,
1177,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL615943,BAO_0000221,10000000.0,
1178,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,8,,,10576,,Autocuration,1,CHEMBL615944,BAO_0000221,10000000.0,
1179,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,8,,,10576,,Autocuration,1,CHEMBL615945,BAO_0000221,10000000.0,
1180,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,8,,,10576,,Autocuration,1,CHEMBL615946,BAO_0000221,10000000.0,
1181,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,8,,,10576,,Autocuration,1,CHEMBL615947,BAO_0000221,10000000.0,
1182,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,8,,,10576,,Autocuration,1,CHEMBL615948,BAO_0000221,10000000.0,
1183,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,8,,,10576,,Autocuration,1,CHEMBL615949,BAO_0000221,10000000.0,
1184,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,8,,,10576,,Autocuration,1,CHEMBL615950,BAO_0000221,10000000.0,
1185,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,8,,,10576,,Autocuration,1,CHEMBL615951,BAO_0000221,10000000.0,
1186,,B,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,8,,,10576,,Autocuration,1,CHEMBL615952,BAO_0000221,10000000.0,
1187,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,8,,,10576,,Autocuration,1,CHEMBL615953,BAO_0000221,10000000.0,
1188,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,8,,,10576,,Autocuration,1,CHEMBL615954,BAO_0000221,10000000.0,
1189,,B,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,9,,,10576,10116.0,Expert,1,CHEMBL615955,BAO_0000221,10000000.0,
1190,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,8,,,10576,,Autocuration,1,CHEMBL615956,BAO_0000221,10000000.0,
1191,,B,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,8,,,10576,,Autocuration,1,CHEMBL615957,BAO_0000221,10000000.0,
1192,,B,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,8,,,10576,,Expert,1,CHEMBL615958,BAO_0000019,,
1193,,B,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,8,,,10576,,Expert,1,CHEMBL615959,BAO_0000019,,
1194,,B,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),8,,,10576,,Autocuration,1,CHEMBL615960,BAO_0000019,,
1195,,B,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),8,,,10576,,Autocuration,1,CHEMBL615961,BAO_0000019,,
1196,,B,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,8,,,10576,,Expert,1,CHEMBL615962,BAO_0000221,955.0,
1197,,B,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,8,,,10576,,Expert,1,CHEMBL615963,BAO_0000019,,
1198,,B,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,8,,,10576,,Autocuration,1,CHEMBL615964,BAO_0000019,,
1199,,B,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,8,,,10576,,Autocuration,1,CHEMBL615965,BAO_0000019,,
1200,CHO,B,449.0,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,8,,,10576,,Expert,1,CHEMBL615966,BAO_0000219,,
1201,,B,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,8,,,10576,,Expert,1,CHEMBL615967,BAO_0000249,,
1202,,B,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL615968,BAO_0000019,,
1203,CHO,B,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),8,,,10576,,Autocuration,1,CHEMBL615969,BAO_0000218,,
1204,,B,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),8,,,10576,,Autocuration,1,CHEMBL615970,BAO_0000218,,
1205,,B,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,9,,,10576,10116.0,Expert,1,CHEMBL615971,BAO_0000357,,
1206,,B,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,8,,,10576,,Expert,1,CHEMBL615972,BAO_0000249,,
1207,,B,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,8,,,10576,,Autocuration,1,CHEMBL615973,BAO_0000249,,
1208,,B,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,8,,,10576,,Autocuration,1,CHEMBL615974,BAO_0000249,,
1209,CHO,B,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,9,,,51,9606.0,Expert,1,CHEMBL615975,BAO_0000219,,
1210,,B,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,8,,,10576,,Expert,1,CHEMBL615976,BAO_0000249,,
1211,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,9,,,10576,10116.0,Expert,1,CHEMBL872106,BAO_0000221,10000000.0,
1212,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL615977,BAO_0000357,,
1213,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,8,,,10576,,Autocuration,1,CHEMBL615978,BAO_0000357,,
1214,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,8,,,10576,,Autocuration,1,CHEMBL616166,BAO_0000357,,
1215,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,8,,,10576,,Autocuration,1,CHEMBL616167,BAO_0000357,,
1216,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,8,,,10576,,Autocuration,1,CHEMBL616168,BAO_0000357,,
1217,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,8,,,10576,,Autocuration,1,CHEMBL616169,BAO_0000357,,
1218,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,8,,,10576,,Autocuration,1,CHEMBL616170,BAO_0000357,,
1219,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,8,,,10576,,Autocuration,1,CHEMBL616171,BAO_0000357,,
1220,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,8,,,10576,,Autocuration,1,CHEMBL616172,BAO_0000357,,
1221,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,8,,,10576,,Autocuration,1,CHEMBL616173,BAO_0000357,,
1222,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,8,,,10576,,Autocuration,1,CHEMBL616174,BAO_0000357,,
1223,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,8,,,10576,,Autocuration,1,CHEMBL616175,BAO_0000357,,
1224,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,8,,,10576,,Autocuration,1,CHEMBL616176,BAO_0000357,,
1225,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,8,,,10576,,Autocuration,1,CHEMBL616177,BAO_0000357,,
1226,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,8,,,10576,,Autocuration,1,CHEMBL616178,BAO_0000357,,
1227,,B,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,8,,,10576,,Autocuration,1,CHEMBL616179,BAO_0000019,,
1228,,B,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616180,BAO_0000357,,
1229,,B,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL616181,BAO_0000357,,
1230,,B,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,8,,,10576,,Autocuration,1,CHEMBL616182,BAO_0000019,,
1231,,B,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616183,BAO_0000221,10000000.0,
1232,,B,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,8,,,10576,,Expert,1,CHEMBL615874,BAO_0000019,,
1233,CHO-K1,B,485.0,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,9,,,10576,10116.0,Expert,1,CHEMBL615875,BAO_0000219,,
1234,,B,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,8,,,10576,,Autocuration,1,CHEMBL615876,BAO_0000019,,
1235,,B,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,8,,,10576,,Autocuration,1,CHEMBL615877,BAO_0000019,,
1236,,B,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),8,,,10576,,Autocuration,1,CHEMBL615878,BAO_0000357,,
1237,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,8,,,10576,,Expert,1,CHEMBL615879,BAO_0000357,,
1238,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,8,,,10576,,Expert,1,CHEMBL615880,BAO_0000357,,
1239,,B,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",8,,,10576,,Autocuration,1,CHEMBL615881,BAO_0000019,,
1240,,B,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",9,,,10576,10116.0,Expert,1,CHEMBL615882,BAO_0000019,,
1241,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,8,,,10576,,Autocuration,1,CHEMBL615883,BAO_0000218,,
1242,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),8,,,10576,,Autocuration,1,CHEMBL615884,BAO_0000218,,
1243,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),8,,,10576,,Autocuration,1,CHEMBL615885,BAO_0000218,,
1244,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),8,,,10576,,Autocuration,1,CHEMBL615886,BAO_0000218,,
1245,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),8,,,10576,,Autocuration,1,CHEMBL615887,BAO_0000218,,
1246,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),8,,,10576,,Autocuration,1,CHEMBL615888,BAO_0000218,,
1247,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),8,,,10576,,Autocuration,1,CHEMBL615889,BAO_0000218,,
1248,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),8,,,10576,,Autocuration,1,CHEMBL615890,BAO_0000218,,
1249,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),8,,,10576,,Autocuration,1,CHEMBL615891,BAO_0000218,,
1250,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),8,,,10576,,Autocuration,1,CHEMBL615892,BAO_0000218,,
1251,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),8,,,10576,,Autocuration,1,CHEMBL615893,BAO_0000218,,
1252,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),8,,,10576,,Autocuration,1,CHEMBL615894,BAO_0000218,,
1253,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),8,,,10576,,Autocuration,1,CHEMBL615895,BAO_0000218,,
1254,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),8,,,10576,,Autocuration,1,CHEMBL615896,BAO_0000218,,
1255,,F,,In vivo,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,8,,,10576,,Autocuration,1,CHEMBL615897,BAO_0000218,,
1256,,F,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",9,,,10576,10116.0,Expert,1,CHEMBL615898,BAO_0000249,,
1257,,B,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,8,,,10576,,Autocuration,1,CHEMBL615899,BAO_0000019,,
1258,,B,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,8,,,10576,,Autocuration,1,CHEMBL616291,BAO_0000019,,
1259,,B,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,8,,,10576,,Autocuration,1,CHEMBL616292,BAO_0000357,,
1260,,F,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",8,,,10576,,Autocuration,1,CHEMBL616293,BAO_0000249,,
1261,,B,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Expert,1,CHEMBL616294,BAO_0000221,10000000.0,
1262,,B,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,8,,,10576,,Autocuration,1,CHEMBL616295,BAO_0000249,10000000.0,
1263,,B,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,8,,,10576,,Autocuration,1,CHEMBL616296,BAO_0000221,955.0,
1264,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616297,BAO_0000019,,
1265,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616605,BAO_0000019,,
1266,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616606,BAO_0000019,,
1267,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,8,,,10576,,Autocuration,1,CHEMBL616607,BAO_0000019,,
1268,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,8,,,10576,,Expert,1,CHEMBL616608,BAO_0000019,,
1269,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616609,BAO_0000019,,
1270,,F,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,9,,,10576,10116.0,Expert,1,CHEMBL616610,BAO_0000019,,
1271,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616611,BAO_0000019,,
1272,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,8,,,10576,,Expert,1,CHEMBL616612,BAO_0000019,,
1273,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616613,BAO_0000019,,
1274,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,8,,,10576,,Expert,1,CHEMBL616614,BAO_0000019,,
1275,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616615,BAO_0000019,,
1276,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,8,,,10576,,Expert,1,CHEMBL616616,BAO_0000019,,
1277,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616617,BAO_0000019,,
1278,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616618,BAO_0000019,,
1279,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616619,BAO_0000019,,
1280,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,8,,,10576,,Expert,1,CHEMBL616620,BAO_0000019,,
1281,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,8,,,10576,,Expert,1,CHEMBL616621,BAO_0000019,,
1282,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,8,,,10576,,Autocuration,1,CHEMBL616622,BAO_0000019,,
1283,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,8,,,10576,,Expert,1,CHEMBL616146,BAO_0000019,,
1284,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL832873,BAO_0000019,,
1285,,F,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,8,,,10576,,Autocuration,1,CHEMBL616147,BAO_0000019,,
1286,,F,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL872872,BAO_0000019,,
1287,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,8,,,10576,,Autocuration,1,CHEMBL616148,BAO_0000019,,
1288,,B,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,8,,,10576,,Autocuration,1,CHEMBL616149,BAO_0000221,10000000.0,
1289,,B,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,8,,,10576,,Expert,1,CHEMBL616150,BAO_0000221,10000000.0,
1290,,B,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,9,,,10576,10116.0,Expert,1,CHEMBL616151,BAO_0000249,,
1291,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,8,,,10576,,Expert,1,CHEMBL872873,BAO_0000221,10000000.0,
1292,,B,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,8,,,10576,,Autocuration,1,CHEMBL616670,BAO_0000221,10000000.0,
1293,,B,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,8,,,10576,,Autocuration,1,CHEMBL616671,BAO_0000221,10000000.0,
1294,,F,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",9,,,10576,10116.0,Expert,1,CHEMBL884861,BAO_0000249,,
1295,,B,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616672,BAO_0000357,,
1296,,B,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,8,,,10576,,Autocuration,1,CHEMBL616673,BAO_0000019,,
1297,,F,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL616674,BAO_0000019,,
1298,,B,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL616675,BAO_0000357,,
1299,,B,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,8,,,10576,,Autocuration,1,CHEMBL616676,BAO_0000221,10000000.0,
1300,,B,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,,,10576,,Autocuration,1,CHEMBL616677,BAO_0000221,10000000.0,
1301,,B,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,,,10576,,Autocuration,1,CHEMBL616678,BAO_0000221,10000000.0,
1302,,B,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL616679,BAO_0000357,,
1303,,B,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,8,,,10576,,Expert,1,CHEMBL616680,BAO_0000221,10000000.0,
1304,,B,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL616681,BAO_0000221,10000000.0,
1305,,B,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL616682,BAO_0000221,10000000.0,
1306,,B,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616683,BAO_0000221,10000000.0,
1307,,B,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616684,BAO_0000221,10000000.0,
1308,,B,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,8,,,10576,,Autocuration,1,CHEMBL616685,BAO_0000221,10000000.0,
1309,,B,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,8,,,10576,,Autocuration,1,CHEMBL616686,BAO_0000221,955.0,
1310,,B,,,Affinity for 5-hydroxytryptamine 1A receptor site,8,,,10576,,Autocuration,1,CHEMBL616687,BAO_0000357,,
1311,,B,,,Affinity for 5-hydroxytryptamine 1A receptor site,8,,,10576,,Autocuration,1,CHEMBL616688,BAO_0000357,,
1312,,B,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,8,,,10576,,Autocuration,1,CHEMBL616689,BAO_0000221,10000000.0,
1313,,B,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL616690,BAO_0000357,,
1314,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL616691,BAO_0000357,,
1315,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,9,,,10576,10116.0,Expert,1,CHEMBL616692,BAO_0000221,10000000.0,
1316,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,8,,,10576,,Expert,1,CHEMBL616693,BAO_0000249,,
1317,,B,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",9,,,10576,10116.0,Expert,1,CHEMBL616694,BAO_0000019,,
1318,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,8,,,10576,,Autocuration,1,CHEMBL616695,BAO_0000221,10000000.0,
1319,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,8,,,10576,,Autocuration,1,CHEMBL616696,BAO_0000357,,
1320,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,8,,,10576,,Autocuration,1,CHEMBL616697,BAO_0000357,,
1321,,B,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616698,BAO_0000357,,
1322,,B,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL616949,BAO_0000019,,
1323,,B,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,8,,,10576,,Autocuration,1,CHEMBL616950,BAO_0000221,10000000.0,
1324,,B,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,8,,,10576,,Autocuration,1,CHEMBL832875,BAO_0000357,,
1325,,B,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,8,,,10576,,Expert,1,CHEMBL616951,BAO_0000221,955.0,
1326,,B,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,8,,,10576,,Expert,1,CHEMBL616952,BAO_0000221,955.0,
1327,,B,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,8,,,10576,,Expert,1,CHEMBL616953,BAO_0000357,,
1328,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,8,,,10576,,Autocuration,1,CHEMBL616954,BAO_0000357,,
1329,,B,,,GTPgammaS radioligand binding assay,8,,,106,,Autocuration,1,CHEMBL616955,BAO_0000357,,
1330,,B,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,8,,,106,,Autocuration,1,CHEMBL616956,BAO_0000357,,
1331,,F,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,8,,,106,,Autocuration,1,CHEMBL616957,BAO_0000019,,
1332,,F,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,8,,,106,,Autocuration,1,CHEMBL616958,BAO_0000019,,
1333,,B,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616959,BAO_0000357,,
1334,,B,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,8,,,106,,Autocuration,1,CHEMBL616960,BAO_0000357,,
1335,,F,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,8,,,106,,Autocuration,1,CHEMBL616961,BAO_0000019,,
1336,HeLa,B,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,8,,,106,,Expert,1,CHEMBL616962,BAO_0000219,,
1337,HeLa,B,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,8,,,106,,Autocuration,1,CHEMBL616963,BAO_0000219,,
1338,,B,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,9,,,106,9606.0,Expert,1,CHEMBL616524,BAO_0000357,,
1339,CHO,B,449.0,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,8,,,106,,Autocuration,1,CHEMBL616525,BAO_0000219,,
1340,,B,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,8,,,106,,Autocuration,1,CHEMBL872908,BAO_0000019,,
1341,,B,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,8,,,106,,Autocuration,1,CHEMBL616526,BAO_0000019,,
1342,,B,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,9,,,106,9606.0,Expert,1,CHEMBL616527,BAO_0000357,,
1343,,B,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,8,,,106,,Expert,1,CHEMBL616528,BAO_0000219,,
1344,,B,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,8,,,106,,Autocuration,1,CHEMBL616529,BAO_0000357,,
1345,,B,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,8,,,106,,Autocuration,1,CHEMBL616530,BAO_0000357,,
1346,,B,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,8,,,106,,Expert,1,CHEMBL616531,BAO_0000357,,
1347,,B,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616532,BAO_0000357,,
1348,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616533,BAO_0000357,,
1349,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,8,,,106,,Expert,1,CHEMBL616534,BAO_0000357,,
1350,,B,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,8,,,106,,Expert,1,CHEMBL616535,BAO_0000357,,
1351,,B,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,8,,,106,,Autocuration,1,CHEMBL616536,BAO_0000357,,
1352,,B,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616537,BAO_0000357,,
1353,CHO-K1,F,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,8,,,106,,Expert,1,CHEMBL616538,BAO_0000219,,
1354,,F,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,8,,,106,,Expert,1,CHEMBL616539,BAO_0000019,,
1355,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,8,,,106,,Expert,1,CHEMBL616540,BAO_0000019,,
1356,,B,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,8,,,106,,Autocuration,1,CHEMBL616429,BAO_0000357,,
1357,,B,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,8,,,106,,Expert,1,CHEMBL616430,BAO_0000357,,
1358,,B,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,9,,,106,9606.0,Expert,1,CHEMBL616431,BAO_0000219,,
1359,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,9,,,106,9606.0,Expert,1,CHEMBL616432,BAO_0000357,,
1360,,B,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,9,,,106,9606.0,Expert,1,CHEMBL616433,BAO_0000357,,
1361,,B,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,9,,,106,9606.0,Expert,1,CHEMBL616434,BAO_0000357,,
1362,CHO,B,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,8,,,106,,Autocuration,1,CHEMBL616435,BAO_0000219,,
1363,,B,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,8,,,106,,Expert,1,CHEMBL616436,BAO_0000019,,
1364,HeLa,B,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,8,,,106,,Autocuration,1,CHEMBL616437,BAO_0000219,,
1365,HeLa,B,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,8,,,106,,Autocuration,1,CHEMBL616438,BAO_0000219,,
1366,HeLa,B,308.0,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,8,,,106,,Autocuration,1,CHEMBL616439,BAO_0000219,,
1367,,B,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,9,,,106,9606.0,Expert,1,CHEMBL616440,BAO_0000357,,
1368,CHO-K1,B,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,8,,,106,,Autocuration,1,CHEMBL616441,BAO_0000219,,
1369,,B,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,8,,,106,,Expert,1,CHEMBL616442,BAO_0000357,,
1370,,B,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,8,,,106,,Autocuration,1,CHEMBL616443,BAO_0000357,,
1371,CHO-K1,B,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,8,,,106,,Expert,1,CHEMBL616444,BAO_0000219,,
1372,,B,,,Binding activity against human 5-hydroxytryptamine 1B receptor,9,,,106,9606.0,Expert,1,CHEMBL616445,BAO_0000357,,
1373,,B,,,Binding activity against human 5-hydroxytryptamine 1B receptor,9,,,106,9606.0,Expert,1,CHEMBL616446,BAO_0000357,,
1374,CHO,B,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,9,,,106,9606.0,Expert,1,CHEMBL616447,BAO_0000219,,
1375,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,8,,,106,,Autocuration,1,CHEMBL616448,BAO_0000357,,
1376,CHO,B,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,8,,,106,,Autocuration,1,CHEMBL616449,BAO_0000219,,
1377,CHO,B,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,8,,,106,,Autocuration,1,CHEMBL616450,BAO_0000219,,
1378,CHO,B,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,8,,,106,,Autocuration,1,CHEMBL857974,BAO_0000219,,
1379,CHO,B,449.0,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,8,,,106,,Autocuration,1,CHEMBL616451,BAO_0000219,,
1380,CHO,B,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,8,,,106,,Autocuration,1,CHEMBL616452,BAO_0000219,,
1381,CHO,B,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,8,,,106,,Autocuration,1,CHEMBL616453,BAO_0000219,,
1382,CHO,B,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,8,,,106,,Autocuration,1,CHEMBL616454,BAO_0000219,,
1383,,B,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,9,,,106,9606.0,Expert,1,CHEMBL616455,BAO_0000357,,
1384,CHO,B,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,8,,,106,,Autocuration,1,CHEMBL616456,BAO_0000219,,
1385,,B,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,8,,,106,,Autocuration,1,CHEMBL616457,BAO_0000357,,
1386,CHO,B,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,8,,,106,,Autocuration,1,CHEMBL616458,BAO_0000219,,
1387,CHO,B,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",8,,,106,,Autocuration,1,CHEMBL616459,BAO_0000219,,
1388,,F,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,8,,,106,,Expert,1,CHEMBL616460,BAO_0000019,,
1389,,F,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,8,,,106,,Expert,1,CHEMBL616461,BAO_0000019,,
1390,CHO,F,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",8,,,106,,Autocuration,1,CHEMBL616462,BAO_0000219,,
1391,CHO,F,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",8,,,106,,Autocuration,1,CHEMBL616463,BAO_0000219,,
1392,,F,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",8,,,105,,Autocuration,1,CHEMBL616464,BAO_0000019,,
1393,CHO,B,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,8,,,105,,Autocuration,1,CHEMBL616465,BAO_0000219,,
1394,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,8,,,17105,,Autocuration,1,CHEMBL832874,BAO_0000357,,
1395,,F,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,8,,,106,9986.0,Autocuration,1,CHEMBL616184,BAO_0000019,,
1396,,B,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,8,,,106,9986.0,Autocuration,1,CHEMBL616185,BAO_0000019,,
1397,,B,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",8,,,106,9986.0,Intermediate,1,CHEMBL616186,BAO_0000019,,
1398,,B,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,8,,,106,9986.0,Autocuration,1,CHEMBL616187,BAO_0000019,,
1399,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,8,,,10577,,Expert,1,CHEMBL616188,BAO_0000357,,
1400,,B,,,Binding affinity for 5-hydroxytryptamine 1B receptor,9,,,10577,,Intermediate,1,CHEMBL873475,BAO_0000357,,
1401,,B,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,9,,,10577,10116.0,Expert,1,CHEMBL616189,BAO_0000019,2435.0,
1402,,B,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,8,,,10577,,Expert,1,CHEMBL616190,BAO_0000357,,
1403,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,8,,,10576,,Autocuration,1,CHEMBL616191,BAO_0000357,,
1404,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,8,,,10576,,Autocuration,1,CHEMBL616192,BAO_0000357,,
1405,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,8,,,10576,,Autocuration,1,CHEMBL616193,BAO_0000357,,
1406,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,8,,,10576,,Autocuration,1,CHEMBL616194,BAO_0000357,,
1407,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,8,,,10576,,Autocuration,1,CHEMBL616195,BAO_0000357,,
1408,,B,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,8,,,10576,,Autocuration,1,CHEMBL616196,BAO_0000357,,
1409,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,8,,,10576,,Autocuration,1,CHEMBL616197,BAO_0000249,10000000.0,
1410,,B,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,8,,,10576,,Intermediate,1,CHEMBL616198,BAO_0000019,,
1411,,B,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,8,,,10576,,Autocuration,1,CHEMBL616199,BAO_0000221,10000000.0,
1412,,B,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,8,,,10576,,Expert,1,CHEMBL616200,BAO_0000221,10000000.0,
1413,,B,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL616201,BAO_0000221,10000000.0,
1414,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,8,,,10576,,Expert,1,CHEMBL616202,BAO_0000221,10000000.0,
1415,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,8,,,10576,,Expert,1,CHEMBL616203,BAO_0000221,10000000.0,
1416,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,8,,,10576,,Expert,1,CHEMBL616204,BAO_0000221,10000000.0,
1417,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,8,,,10576,,Expert,1,CHEMBL616205,BAO_0000221,10000000.0,
1418,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,8,,,10576,,Expert,1,CHEMBL616206,BAO_0000221,10000000.0,
1419,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,8,,,10576,,Expert,1,CHEMBL616207,BAO_0000249,,
1420,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,8,,,10576,,Autocuration,1,CHEMBL616208,BAO_0000249,,
1421,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,8,,,10576,,Autocuration,1,CHEMBL616209,BAO_0000249,,
1422,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,8,,,10576,,Expert,1,CHEMBL616210,BAO_0000357,,
1423,,B,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,8,,,10576,,Expert,1,CHEMBL616211,BAO_0000221,10000000.0,
1424,,B,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,8,,,10576,,Autocuration,1,CHEMBL616504,BAO_0000221,10000000.0,
1425,,B,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL616505,BAO_0000221,10000000.0,
1426,,F,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616506,BAO_0000019,,
1427,,B,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,8,,,10576,,Autocuration,1,CHEMBL872107,BAO_0000221,10000000.0,
1428,,B,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,9,,,10576,10116.0,Expert,1,CHEMBL616507,BAO_0000221,10000000.0,
1429,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,8,,,10576,,Autocuration,1,CHEMBL616303,BAO_0000249,,
1430,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,8,,,10576,,Autocuration,1,CHEMBL616304,BAO_0000221,10000000.0,
1431,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL616305,BAO_0000221,10000000.0,
1432,,F,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,8,,,10576,,Intermediate,1,CHEMBL616306,BAO_0000221,10000000.0,
1433,,B,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616307,BAO_0000357,,
1434,,B,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,9,,,10576,10116.0,Expert,1,CHEMBL881829,BAO_0000221,10000000.0,
1435,,B,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,8,,,10576,,Expert,1,CHEMBL616308,BAO_0000357,,
1436,,B,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,8,,,10576,,Autocuration,1,CHEMBL616309,BAO_0000019,,
1437,,B,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,8,,,10576,,Expert,1,CHEMBL616310,BAO_0000019,,
1438,CHO,B,449.0,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,8,,,10576,,Autocuration,1,CHEMBL616311,BAO_0000219,,
1439,,B,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL616312,BAO_0000357,,
1440,,B,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,8,,,10576,,Autocuration,1,CHEMBL616313,BAO_0000357,,
1441,,B,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL616314,BAO_0000221,10000000.0,
1442,,B,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL616315,BAO_0000221,10000000.0,
1443,,B,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,8,,,10576,,Autocuration,1,CHEMBL616567,BAO_0000221,10000000.0,
1444,,B,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,8,,,10576,,Autocuration,1,CHEMBL616568,BAO_0000221,10000000.0,
1445,,B,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,8,,,10576,,Intermediate,1,CHEMBL616569,BAO_0000019,,
1446,,B,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,8,,,10576,,Expert,1,CHEMBL616570,BAO_0000357,,
1447,,B,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,8,,,10576,,Autocuration,1,CHEMBL616571,BAO_0000357,,
1448,,B,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,8,,,10576,,Autocuration,1,CHEMBL616572,BAO_0000221,10000000.0,
1449,,B,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,8,,,10576,,Expert,1,CHEMBL616573,BAO_0000249,,
1450,,B,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,9,,,10576,10116.0,Expert,1,CHEMBL616574,BAO_0000357,,
1451,,B,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,8,,,10576,,Expert,1,CHEMBL616575,BAO_0000221,10000000.0,
1452,,B,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,8,,,10576,,Autocuration,1,CHEMBL872108,BAO_0000221,10000000.0,
1453,,B,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,8,,,10576,,Autocuration,1,CHEMBL616576,BAO_0000357,,
1454,,B,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,8,,,10576,,Autocuration,1,CHEMBL616577,BAO_0000249,,
1455,,B,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,8,,,10576,,Autocuration,1,CHEMBL616578,BAO_0000249,,
1456,,B,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,8,,,10576,,Expert,1,CHEMBL616579,BAO_0000357,,
1457,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,9,,,10576,10116.0,Expert,1,CHEMBL616580,BAO_0000019,,
1458,,B,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,8,,,10576,,Autocuration,1,CHEMBL616581,BAO_0000019,,
1459,,B,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL616582,BAO_0000221,10000000.0,
1460,,B,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,8,,,10576,,Expert,1,CHEMBL616583,BAO_0000221,10000000.0,
1461,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,9,,,10576,10116.0,Expert,1,CHEMBL616584,BAO_0000221,10000000.0,
1462,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,,,10576,,Expert,1,CHEMBL616585,BAO_0000357,,
1463,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,9,,,10576,10116.0,Expert,1,CHEMBL616586,BAO_0000221,10000000.0,
1464,,B,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL616587,BAO_0000221,10000000.0,
1465,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,8,,,10576,,Autocuration,1,CHEMBL616588,BAO_0000221,10000000.0,
1466,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,8,,,10576,,Autocuration,1,CHEMBL616589,BAO_0000221,10000000.0,
1467,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,8,,,10576,,Expert,1,CHEMBL616590,BAO_0000221,10000000.0,
1468,CHO,B,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",8,,,10576,,Expert,1,CHEMBL616591,BAO_0000219,,
1469,,B,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,8,,,10576,,Expert,1,CHEMBL616592,BAO_0000357,,
1470,,B,,,The inhibition activity of 5-HT1A at 1 uM,8,,,10576,,Autocuration,1,CHEMBL616593,BAO_0000357,,
1471,CHO-K1,B,485.0,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",8,,,10576,,Expert,1,CHEMBL616594,BAO_0000219,,
1472,,B,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,8,,,10576,,Expert,1,CHEMBL616595,BAO_0000249,,
1473,,B,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,8,,,10576,,Autocuration,1,CHEMBL616596,BAO_0000357,,
1474,,B,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,8,,,10576,,Autocuration,1,CHEMBL616597,BAO_0000221,10000000.0,
1475,,B,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,8,,,10576,,Expert,1,CHEMBL616598,BAO_0000221,10000000.0,
1476,,F,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,9,,,10576,10116.0,Expert,1,CHEMBL616599,BAO_0000249,,
1477,,F,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",9,,,10576,10116.0,Expert,1,CHEMBL616600,BAO_0000249,10000000.0,
1478,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,8,,,10576,,Autocuration,1,CHEMBL616601,BAO_0000019,,
1479,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,8,,,10576,,Autocuration,1,CHEMBL616602,BAO_0000019,,
1480,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,8,,,10576,,Autocuration,1,CHEMBL616603,BAO_0000019,,
1481,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,8,,,10576,,Autocuration,1,CHEMBL616604,BAO_0000019,,
1482,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,8,,,10576,,Autocuration,1,CHEMBL616316,BAO_0000249,,
1483,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,8,,,10576,,Autocuration,1,CHEMBL616317,BAO_0000249,,
1484,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,9,,,10576,10116.0,Expert,1,CHEMBL616318,BAO_0000019,,
1485,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,8,,,10576,,Autocuration,1,CHEMBL616319,BAO_0000221,10000000.0,
1486,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,8,,,10576,,Autocuration,1,CHEMBL616320,BAO_0000221,10000000.0,
1487,,B,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,9,,,10576,10116.0,Expert,1,CHEMBL616321,BAO_0000221,10000000.0,
1488,,F,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,8,,,10576,,Autocuration,1,CHEMBL616322,BAO_0000019,,
1489,,F,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,8,,,10576,,Autocuration,1,CHEMBL616323,BAO_0000019,,
1490,,B,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,8,,,10576,,Autocuration,1,CHEMBL616324,BAO_0000357,,
1491,,B,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,8,,,10576,,Autocuration,1,CHEMBL616325,BAO_0000221,10000000.0,
1492,,B,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,8,,,10576,,Autocuration,1,CHEMBL616326,BAO_0000221,10000000.0,
1493,,B,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,8,,,10576,,Autocuration,1,CHEMBL616327,BAO_0000221,10000000.0,
1494,,B,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,8,,,10576,,Autocuration,1,CHEMBL616328,BAO_0000357,,
1495,,B,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),8,,,10576,,Autocuration,1,CHEMBL858110,BAO_0000249,,
1496,,F,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),8,,,10576,,Autocuration,1,CHEMBL616329,BAO_0000249,,
1497,,B,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),8,,,10576,,Autocuration,1,CHEMBL616330,BAO_0000249,,
1498,,F,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),8,,,10576,,Autocuration,1,CHEMBL616331,BAO_0000249,,
1499,,F,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,8,,,10576,,Autocuration,1,CHEMBL616332,BAO_0000249,,
1500,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,8,,,10576,,Autocuration,1,CHEMBL857063,BAO_0000249,955.0,
1501,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,8,,,10576,,Autocuration,1,CHEMBL616333,BAO_0000019,,
1502,,F,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL616334,BAO_0000019,,
1503,,B,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL616335,BAO_0000221,10000000.0,
1504,,B,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,8,,,10576,,Autocuration,1,CHEMBL616336,BAO_0000019,,
1505,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL616337,BAO_0000249,,
1506,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,8,,,10576,,Autocuration,1,CHEMBL616338,BAO_0000019,,
1507,,B,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,8,,,10576,,Autocuration,1,CHEMBL616339,BAO_0000221,10000000.0,
1508,,B,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,8,,,10576,,Autocuration,1,CHEMBL616340,BAO_0000221,10000000.0,
1509,,B,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,8,,,10576,,Autocuration,1,CHEMBL616341,BAO_0000357,,
1510,,B,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,9,,,10576,10116.0,Expert,1,CHEMBL616342,BAO_0000357,,
1511,,B,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,9,,,10576,10116.0,Expert,1,CHEMBL616343,BAO_0000019,,
1512,,B,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,8,,,10576,,Expert,1,CHEMBL616344,BAO_0000019,,
1513,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,8,,,10576,,Expert,1,CHEMBL616345,BAO_0000357,,
1514,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,8,,,10576,,Expert,1,CHEMBL616346,BAO_0000019,,
1515,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,8,,,10576,,Autocuration,1,CHEMBL616347,BAO_0000221,10000000.0,
1516,,B,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,8,,,10576,,Expert,1,CHEMBL616348,BAO_0000019,,
1517,,B,,,Binding affinity at 5-hydroxytryptamine 1A receptor,8,,,10576,,Expert,1,CHEMBL616349,BAO_0000357,,
1518,,B,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,9,,,10576,10116.0,Expert,1,CHEMBL616152,BAO_0000249,,
1519,,B,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,8,,,10576,,Autocuration,1,CHEMBL616153,BAO_0000249,,
1520,,B,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",8,,,10576,,Expert,1,CHEMBL616154,BAO_0000019,,
1521,,B,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,8,,,10576,,Autocuration,1,CHEMBL616155,BAO_0000019,,
1522,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,9,,,10576,10116.0,Expert,1,CHEMBL616156,BAO_0000221,10000000.0,
1523,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,9,,,10576,10116.0,Expert,1,CHEMBL616157,BAO_0000221,10000000.0,
1524,,B,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,8,,,10576,,Autocuration,1,CHEMBL616158,BAO_0000221,10000000.0,
1525,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,8,,,10576,,Autocuration,1,CHEMBL616159,BAO_0000357,,
1526,,B,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,8,,,10576,,Expert,1,CHEMBL616160,BAO_0000357,,
1527,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,8,,,10576,,Autocuration,1,CHEMBL616161,BAO_0000019,,
1528,,F,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,8,,,10576,,Autocuration,1,CHEMBL616162,BAO_0000019,,
1529,,B,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,9,,,12687,10116.0,Expert,1,CHEMBL616163,BAO_0000357,,
1530,,B,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,8,,,10626,,Expert,1,CHEMBL616164,BAO_0000249,,
1531,,B,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,8,,,10576,,Autocuration,1,CHEMBL616165,BAO_0000221,955.0,
1532,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,8,,,51,10116.0,Autocuration,1,CHEMBL616355,BAO_0000019,,
1533,,F,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,8,,,10576,,Autocuration,1,CHEMBL616356,BAO_0000019,,
1534,,B,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,8,,,10576,,Autocuration,1,CHEMBL616357,BAO_0000221,955.0,
1535,,B,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",8,,,10576,,Autocuration,1,CHEMBL616358,BAO_0000019,,
1536,,B,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616359,BAO_0000357,,
1537,,B,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,8,,,51,,Expert,1,CHEMBL616360,BAO_0000357,,
1538,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,,,51,,Expert,1,CHEMBL616361,BAO_0000357,,
1539,,B,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616362,BAO_0000357,,
1540,,B,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,8,,,51,,Autocuration,1,CHEMBL616363,BAO_0000249,,
1541,,B,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,8,,,51,,Autocuration,1,CHEMBL616364,BAO_0000357,,
1542,,B,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616365,BAO_0000357,,
1543,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,8,,,51,,Expert,1,CHEMBL616366,BAO_0000357,,
1544,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,8,,,51,,Expert,1,CHEMBL872906,BAO_0000357,,
1545,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,8,,,51,,Autocuration,1,CHEMBL616367,BAO_0000357,,
1546,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616368,BAO_0000357,,
1547,,B,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,8,,,51,,Autocuration,1,CHEMBL616369,BAO_0000357,,
1548,,B,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,9,,,51,9606.0,Expert,1,CHEMBL616370,BAO_0000357,,
1549,,B,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,9,,,51,9606.0,Expert,1,CHEMBL616371,BAO_0000357,,
1550,CHO,B,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,,,51,,Autocuration,1,CHEMBL616372,BAO_0000219,,
1551,,B,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,8,,,51,,Expert,1,CHEMBL616373,BAO_0000219,,
1552,,B,,In vivo,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,8,,,51,,Autocuration,1,CHEMBL616374,BAO_0000218,,
1553,,B,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,8,,,51,,Autocuration,1,CHEMBL616375,BAO_0000221,10000000.0,
1554,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,8,,,51,,Autocuration,1,CHEMBL616376,BAO_0000357,,
1555,,B,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,8,,,51,,Expert,1,CHEMBL857064,BAO_0000357,,
1556,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,8,,,51,,Autocuration,1,CHEMBL616377,BAO_0000357,,
1557,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,8,,,51,,Autocuration,1,CHEMBL616378,BAO_0000357,,
1558,,B,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,8,,,51,,Autocuration,1,CHEMBL616379,BAO_0000357,,
1559,,B,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616380,BAO_0000357,,
1560,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,8,,,11863,,Autocuration,1,CHEMBL616381,BAO_0000357,,
1561,,B,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616382,BAO_0000357,,
1562,,B,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,8,,,11863,,Autocuration,1,CHEMBL616383,BAO_0000357,,
1563,CHO,B,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,9,,,11863,10090.0,Expert,1,CHEMBL616350,BAO_0000219,,
1564,,B,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616351,BAO_0000357,,
1565,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,8,,,11863,,Autocuration,1,CHEMBL616352,BAO_0000357,,
1566,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616353,BAO_0000357,,
1567,,B,,,Binding affinity against serotonergic 5-HT1a receptor,8,,,11863,,Autocuration,1,CHEMBL616354,BAO_0000357,,
1568,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,8,,,11863,,Autocuration,1,CHEMBL616508,BAO_0000357,,
1569,,B,,,Binding affinity for 5-hydroxytryptamine 1A receptor,9,,,11863,10090.0,Expert,1,CHEMBL616559,BAO_0000357,,
1570,,B,,,Binding affinity at 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616560,BAO_0000357,,
1571,,B,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",8,,,11863,,Autocuration,1,CHEMBL616561,BAO_0000357,,
1572,CHO,B,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,,,11863,,Autocuration,1,CHEMBL616562,BAO_0000219,,
1573,CHO,B,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,8,,,11863,,Autocuration,1,CHEMBL616563,BAO_0000219,,
1574,,B,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616564,BAO_0000357,,
1575,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,8,,,11863,,Autocuration,1,CHEMBL616565,BAO_0000357,,
1576,,B,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616566,BAO_0000218,,
1577,,B,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,8,,,11863,,Autocuration,1,CHEMBL616989,BAO_0000357,,
1578,,B,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL857975,BAO_0000357,,
1579,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor,9,,,11863,10090.0,Expert,1,CHEMBL616990,BAO_0000357,,
1580,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,8,,,11863,,Autocuration,1,CHEMBL616991,BAO_0000357,,
1581,,B,,,Tested against 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616992,BAO_0000357,,
1582,,B,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,8,,,11863,,Autocuration,1,CHEMBL616993,BAO_0000357,,
1583,,B,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,8,,,106,9986.0,Expert,1,CHEMBL616994,BAO_0000019,,
1584,,B,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,8,,,106,9986.0,Autocuration,1,CHEMBL616995,BAO_0000019,,
1585,HEK293,B,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,9,,,105571,9593.0,Intermediate,1,CHEMBL616996,BAO_0000219,,
1586,,F,,In vivo,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,8,,,106,10141.0,Autocuration,1,CHEMBL616997,BAO_0000218,,
1587,,F,,In vivo,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,8,,,106,10141.0,Autocuration,1,CHEMBL616998,BAO_0000218,,
1588,,F,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,8,,,106,10141.0,Autocuration,1,CHEMBL616999,BAO_0000019,,
1589,,F,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,8,,,106,10141.0,Autocuration,1,CHEMBL617000,BAO_0000019,,
1590,,F,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,8,,,106,10141.0,Autocuration,1,CHEMBL617001,BAO_0000019,,
1591,,F,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,8,,,106,10141.0,Autocuration,1,CHEMBL858111,BAO_0000019,,
1592,,F,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,8,,,106,,Autocuration,1,CHEMBL617002,BAO_0000019,,
1593,,F,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),8,,,106,,Autocuration,1,CHEMBL617003,BAO_0000019,,
1594,,F,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),8,,,106,,Autocuration,1,CHEMBL617004,BAO_0000019,,
1595,,F,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,9,,,106,9606.0,Expert,1,CHEMBL617005,BAO_0000019,,
1596,CHO-K1,F,485.0,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,9,,,106,9606.0,Expert,1,CHEMBL616623,BAO_0000219,,
1597,CHO,F,449.0,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,8,,,106,,Autocuration,1,CHEMBL616624,BAO_0000219,,
1598,,B,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL883243,BAO_0000357,,
1599,,F,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,8,,,106,,Autocuration,1,CHEMBL616625,BAO_0000019,,
1600,CHO,F,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",8,,,106,,Expert,1,CHEMBL616626,BAO_0000219,,
1601,CHO,F,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,8,,,106,,Autocuration,1,CHEMBL616627,BAO_0000219,,
1602,CHO,F,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,8,,,106,,Autocuration,1,CHEMBL616628,BAO_0000219,,
1603,CHO,F,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,8,,,106,,Autocuration,1,CHEMBL616629,BAO_0000219,,
1604,CHO,F,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,8,,,106,,Autocuration,1,CHEMBL616630,BAO_0000219,,
1605,,F,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",8,,,106,,Expert,1,CHEMBL616631,BAO_0000019,,
1606,,F,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",8,,,106,,Autocuration,1,CHEMBL616632,BAO_0000019,,
1607,,B,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,9,,,106,9606.0,Expert,1,CHEMBL616633,BAO_0000357,,
1608,CHO,B,449.0,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,8,,,106,,Expert,1,CHEMBL616634,BAO_0000219,,
1609,,B,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,8,,,106,,Autocuration,1,CHEMBL616635,BAO_0000357,,
1610,,B,,,Binding affinity against 5-hydroxytryptamine 1B receptor,9,,,106,9606.0,Expert,1,CHEMBL885358,BAO_0000357,,
1611,CHO,B,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,9,,,106,9606.0,Expert,1,CHEMBL616636,BAO_0000219,,
1612,CHO,B,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,8,,,106,,Expert,1,CHEMBL616637,BAO_0000219,,
1613,,B,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616638,BAO_0000357,,
1614,CHO,B,449.0,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,8,,,106,,Expert,1,CHEMBL616639,BAO_0000219,,
1615,CHO,B,449.0,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,8,,,106,,Expert,1,CHEMBL616640,BAO_0000219,,
1616,CHO,B,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,8,,,106,,Expert,1,CHEMBL616641,BAO_0000219,,
1617,CHO,B,449.0,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,8,,,106,,Expert,1,CHEMBL616642,BAO_0000219,,
1618,CHO,B,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,8,,,106,,Expert,1,CHEMBL616643,BAO_0000219,,
1619,,B,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),8,,,106,,Autocuration,1,CHEMBL616644,BAO_0000357,,
1620,,B,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,8,,,106,,Autocuration,1,CHEMBL616645,BAO_0000357,,
1621,,F,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),8,,,105,9986.0,Autocuration,1,CHEMBL616646,BAO_0000019,,
1622,,F,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),8,,,105,9986.0,Expert,1,CHEMBL616647,BAO_0000019,,
1623,,B,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),8,,,105,,Autocuration,1,CHEMBL616509,BAO_0000357,,
1624,,B,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),8,,,105,,Autocuration,1,CHEMBL616510,BAO_0000357,,
1625,,B,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616511,BAO_0000357,,
1626,,B,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,8,,,105,9913.0,Expert,1,CHEMBL616512,BAO_0000357,,
1627,,B,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,8,,,105,9913.0,Autocuration,1,CHEMBL616513,BAO_0000357,,
1628,,B,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,8,,,105,9913.0,Autocuration,1,CHEMBL616514,BAO_0000019,2435.0,
1629,,B,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,8,,,105,9913.0,Expert,1,CHEMBL616515,BAO_0000357,,
1630,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,8,,,105,9913.0,Autocuration,1,CHEMBL616516,BAO_0000019,,
1631,,B,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,8,,,105,9913.0,Autocuration,1,CHEMBL616517,BAO_0000357,,
1632,,B,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,8,,,105,9913.0,Autocuration,1,CHEMBL616518,BAO_0000357,,
1633,,B,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,8,,,105,9913.0,Autocuration,1,CHEMBL616519,BAO_0000357,,
1634,,B,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,8,,,105,9913.0,Autocuration,1,CHEMBL616520,BAO_0000357,,
1635,,B,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,8,,,105,9913.0,Autocuration,1,CHEMBL616521,BAO_0000357,,
1636,,B,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,8,,,105,9913.0,Autocuration,1,CHEMBL616522,BAO_0000357,,
1637,,B,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,8,,,105,9913.0,Autocuration,1,CHEMBL884531,BAO_0000357,,
1638,,B,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,8,,,105,9913.0,Autocuration,1,CHEMBL616523,BAO_0000357,,
1639,,B,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,8,,,105,9913.0,Autocuration,1,CHEMBL616731,BAO_0000019,2435.0,
1640,,B,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,8,,,105,9913.0,Autocuration,1,CHEMBL616732,BAO_0000019,,
1641,,B,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,8,,,105,9913.0,Autocuration,1,CHEMBL616733,BAO_0000357,,
1642,,B,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,8,,,105,9913.0,Autocuration,1,CHEMBL616734,BAO_0000357,,
1643,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,8,,,105,9913.0,Autocuration,1,CHEMBL616735,BAO_0000249,,
1644,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,8,,,105,9913.0,Autocuration,1,CHEMBL616736,BAO_0000249,,
1645,,F,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,8,,,105,9913.0,Expert,1,CHEMBL616737,BAO_0000019,,
1646,,B,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,8,,,105,9913.0,Autocuration,1,CHEMBL616738,BAO_0000019,,
1647,,F,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,8,,,105,9913.0,Expert,1,CHEMBL616739,BAO_0000019,,
1648,,F,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,8,,,105,9913.0,Expert,1,CHEMBL616740,BAO_0000019,,
1649,,F,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,8,,,105,9913.0,Expert,1,CHEMBL616741,BAO_0000019,,
1650,HEK293,B,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,8,,,105,9593.0,Autocuration,1,CHEMBL616742,BAO_0000219,,
1651,,B,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,9,,,105570,10141.0,Intermediate,1,CHEMBL616743,BAO_0000019,,
1652,,B,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,9,,,105570,10141.0,Intermediate,1,CHEMBL616744,BAO_0000019,,
1653,,F,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,9,,,105570,10141.0,Intermediate,1,CHEMBL616745,BAO_0000019,,
1654,,F,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,9,,,105570,10141.0,Intermediate,1,CHEMBL616746,BAO_0000019,,
1655,,F,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,9,,,105570,10141.0,Intermediate,1,CHEMBL616747,BAO_0000019,,
1656,,F,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,9,,,105570,10141.0,Intermediate,1,CHEMBL616748,BAO_0000019,,
1657,,F,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,9,,,105570,10141.0,Intermediate,1,CHEMBL616648,BAO_0000019,,
1658,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor,9,,,105570,10141.0,Intermediate,1,CHEMBL616649,BAO_0000357,,
1659,,B,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,9,,,105570,10141.0,Intermediate,1,CHEMBL616650,BAO_0000357,,
1660,,F,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,9,,,105570,10141.0,Intermediate,1,CHEMBL616651,BAO_0000218,,
1661,,F,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,9,,,105570,10141.0,Intermediate,1,CHEMBL616652,BAO_0000218,,
1662,,F,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,9,,,105570,10141.0,Intermediate,1,CHEMBL616653,BAO_0000218,,
1663,,F,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,9,,,105570,10141.0,Intermediate,1,CHEMBL616654,BAO_0000218,,
1664,,B,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,9,,,105570,10141.0,Intermediate,1,CHEMBL616655,BAO_0000019,,
1665,,B,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,9,,,105570,10141.0,Intermediate,1,CHEMBL616656,BAO_0000357,,
1666,,B,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,8,,,105,10141.0,Autocuration,1,CHEMBL616657,BAO_0000019,,
1667,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,9,,,105570,10141.0,Intermediate,1,CHEMBL616658,BAO_0000357,2435.0,
1668,,B,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,9,,,105570,10141.0,Intermediate,1,CHEMBL616659,BAO_0000357,,
1669,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor,8,,,51,,Autocuration,1,CHEMBL616660,BAO_0000357,,
1670,,B,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,8,,,106,,Autocuration,1,CHEMBL616661,BAO_0000357,,
1671,,F,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,8,,,105,,Expert,1,CHEMBL616662,BAO_0000019,,
1672,,F,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616663,BAO_0000019,,
1673,,F,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616664,BAO_0000019,,
1674,CHO,F,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",9,,,105,9606.0,Expert,1,CHEMBL881820,BAO_0000219,,
1675,CHO,F,449.0,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",8,,,105,,Autocuration,1,CHEMBL616665,BAO_0000219,,
1676,CHO,B,449.0,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,8,,,105,,Expert,1,CHEMBL616666,BAO_0000219,,
1677,CHO,B,449.0,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616667,BAO_0000219,,
1678,CHO,F,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",8,,,105,,Expert,1,CHEMBL616668,BAO_0000219,,
1679,CHO,F,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",9,,,105,9606.0,Expert,1,CHEMBL616669,BAO_0000219,,
1680,CHO,F,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",8,,,105,,Expert,1,CHEMBL617040,BAO_0000219,,
1681,CHO,F,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",8,,,105,,Autocuration,1,CHEMBL617041,BAO_0000219,,
1682,CHO,F,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",8,,,105,,Expert,1,CHEMBL617042,BAO_0000219,,
1683,CHO,F,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",8,,,105,,Expert,1,CHEMBL617043,BAO_0000219,,
1684,,F,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL617044,BAO_0000019,,
1685,CHO,F,449.0,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,8,,,105,,Expert,1,CHEMBL617045,BAO_0000219,,
1686,CHO,F,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",9,,,105,9606.0,Expert,1,CHEMBL617046,BAO_0000219,,
1687,CHO,F,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",9,,,105,9606.0,Expert,1,CHEMBL617047,BAO_0000219,,
1688,,F,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",8,,,105,,Expert,1,CHEMBL617048,BAO_0000019,,
1689,,F,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",8,,,105,,Autocuration,1,CHEMBL616897,BAO_0000019,,
1690,,F,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",9,,,105,9606.0,Expert,1,CHEMBL616898,BAO_0000019,,
1691,CHO,F,449.0,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,9,,,105,9606.0,Expert,1,CHEMBL858201,BAO_0000219,,
1692,,F,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616899,BAO_0000019,,
1693,,B,,In vitro,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),8,,,105,,Autocuration,1,CHEMBL616900,BAO_0000219,,
1694,CHO,B,449.0,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,8,,,105,,Expert,1,CHEMBL616901,BAO_0000219,,
1695,,B,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,8,,,105,,Autocuration,1,CHEMBL616902,BAO_0000357,,
1696,CHO,B,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9,,,105,9606.0,Expert,1,CHEMBL616903,BAO_0000219,,
1697,CHO,B,449.0,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,8,,,105,,Expert,1,CHEMBL616904,BAO_0000219,,
1698,,B,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616905,BAO_0000357,,
1699,CHO,B,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,8,,,105,,Expert,1,CHEMBL616906,BAO_0000219,,
1700,CHO,B,449.0,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,8,,,105,,Expert,1,CHEMBL616907,BAO_0000219,,
1701,CHO,B,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,8,,,105,,Expert,1,CHEMBL616908,BAO_0000219,,
1702,CHO,B,449.0,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9,,,105,9606.0,Expert,1,CHEMBL616909,BAO_0000219,,
1703,CHO,B,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9,,,105,9606.0,Expert,1,CHEMBL616910,BAO_0000219,,
1704,CHO,B,449.0,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,8,,,105,,Expert,1,CHEMBL616911,BAO_0000219,,
1705,CHO,B,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,8,,,105,,Expert,1,CHEMBL616912,BAO_0000219,,
1706,,B,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),8,,,105,,Autocuration,1,CHEMBL616913,BAO_0000357,,
1707,CHO,B,449.0,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,9,,,105,9606.0,Expert,1,CHEMBL616914,BAO_0000219,,
1708,CHO,B,449.0,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,8,,,105,,Autocuration,1,CHEMBL616915,BAO_0000219,,
1709,,B,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,8,,,105,,Autocuration,1,CHEMBL616916,BAO_0000019,,
1710,,B,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,9,,,105,9606.0,Expert,1,CHEMBL616917,BAO_0000357,,
1711,,B,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",8,,,105,,Autocuration,1,CHEMBL616918,BAO_0000357,,
1712,,B,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,8,,,105,,Expert,1,CHEMBL616919,BAO_0000219,,
1713,,B,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,8,,,105,,Autocuration,1,CHEMBL616920,BAO_0000357,,
1714,,B,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,8,,,105,,Autocuration,1,CHEMBL872914,BAO_0000357,,
1715,,B,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,8,,,105,,Autocuration,1,CHEMBL616921,BAO_0000357,,
1716,,B,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,8,,,105,,Expert,1,CHEMBL616922,BAO_0000357,,
1717,,B,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616923,BAO_0000357,,
1718,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,8,,,105,,Expert,1,CHEMBL616924,BAO_0000357,,
1719,,B,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,8,,,105,,Expert,1,CHEMBL875909,BAO_0000357,,
1720,,B,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,8,,,105,,Autocuration,1,CHEMBL616925,BAO_0000357,,
1721,,B,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,8,,,105,,Autocuration,1,CHEMBL616926,BAO_0000357,,
1722,,B,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616927,BAO_0000357,,
1723,CHO-K1,F,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,8,,,105,,Expert,1,CHEMBL616928,BAO_0000219,,
1724,,B,,In vitro,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),9,,,105,9606.0,Expert,1,CHEMBL616929,BAO_0000219,,
1725,,B,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,9,,,105,9606.0,Expert,1,CHEMBL616930,BAO_0000357,,
1726,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,8,,,105,,Expert,1,CHEMBL616931,BAO_0000019,,
1727,,B,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,8,,,105,,Autocuration,1,CHEMBL616932,BAO_0000357,,
1728,,B,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,8,,,105,,Expert,1,CHEMBL616933,BAO_0000357,,
1729,,B,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,9,,,105,9606.0,Expert,1,CHEMBL616934,BAO_0000219,,
1730,,B,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,9,,,105,9606.0,Expert,1,CHEMBL616935,BAO_0000357,,
1731,,B,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,8,,,105,,Autocuration,1,CHEMBL616936,BAO_0000357,,
1732,,B,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,9,,,105,9606.0,Expert,1,CHEMBL616937,BAO_0000357,,
1733,,B,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,9,,,105,9606.0,Expert,1,CHEMBL616938,BAO_0000357,,
1734,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616939,BAO_0000019,,
1735,,B,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,8,,,105,,Expert,1,CHEMBL616940,BAO_0000019,,
1736,,B,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,9,,,105,9606.0,Expert,1,CHEMBL616941,BAO_0000357,,
1737,CHO-K1,B,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,8,,,105,,Autocuration,1,CHEMBL616942,BAO_0000219,,
1738,CHO-K1,B,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,8,,,105,,Autocuration,1,CHEMBL616943,BAO_0000219,,
1739,CHO,B,449.0,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,4,,,104802,,Autocuration,1,CHEMBL616944,BAO_0000219,,
1740,,F,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",8,,,105,,Autocuration,1,CHEMBL616945,BAO_0000019,,
1741,,B,,,Binding activity radioligand.,8,,,105,,Autocuration,1,CHEMBL616946,BAO_0000357,,
1742,,B,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,8,,,105,,Autocuration,1,CHEMBL616947,BAO_0000019,,
1743,CHO-K1,B,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,8,,,105,,Expert,1,CHEMBL616948,BAO_0000219,,
1744,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616851,BAO_0000357,,
1745,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616852,BAO_0000357,,
1746,,B,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616853,BAO_0000357,,
1747,,B,,,Binding activity against human 5-hydroxytryptamine 1D receptor,9,,,105,9606.0,Expert,1,CHEMBL616854,BAO_0000357,,
1748,CHO,B,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,9,,,105,9606.0,Expert,1,CHEMBL616855,BAO_0000219,,
1749,CHO,B,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,8,,,105,,Autocuration,1,CHEMBL616856,BAO_0000219,,
1750,CHO,B,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,8,,,105,,Autocuration,1,CHEMBL616857,BAO_0000219,,
1751,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL616858,BAO_0000357,,
1752,CHO,B,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,8,,,105,,Autocuration,1,CHEMBL616859,BAO_0000219,,
1753,CHO,B,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,8,,,105,,Autocuration,1,CHEMBL616860,BAO_0000219,,
1754,HEK293,B,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,8,,,105,,Autocuration,1,CHEMBL616861,BAO_0000219,,
1755,HEK293,B,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,8,,,105,,Autocuration,1,CHEMBL616541,BAO_0000219,,
1756,HEK293,B,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,8,,,105,,Autocuration,1,CHEMBL616542,BAO_0000219,,
1757,CHO,B,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,8,,,105,,Autocuration,1,CHEMBL616543,BAO_0000219,,
1758,,B,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,9,,,105,9606.0,Expert,1,CHEMBL616544,BAO_0000357,,
1759,CHO,B,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,8,,,105,,Autocuration,1,CHEMBL616545,BAO_0000219,,
1760,,B,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,8,,,105,,Autocuration,1,CHEMBL616546,BAO_0000357,,
1761,CHO,B,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,8,,,105,,Autocuration,1,CHEMBL616547,BAO_0000219,,
1762,CHO,B,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",8,,,105,,Autocuration,1,CHEMBL616548,BAO_0000219,,
1763,,F,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,8,,,105,,Expert,1,CHEMBL616549,BAO_0000019,,
1764,,F,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,8,,,105,,Expert,1,CHEMBL616550,BAO_0000019,,
1765,,B,,,Binding affinity against 5-HT2C receptor,8,,,108,,Autocuration,1,CHEMBL857066,BAO_0000357,,
1766,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor,8,,,108,,Autocuration,1,CHEMBL616551,BAO_0000357,,
1767,,B,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,8,,,10577,,Autocuration,1,CHEMBL616552,BAO_0000357,,
1768,,F,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,8,,,10577,,Autocuration,1,CHEMBL832876,BAO_0000019,,
1769,,B,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",8,,,10577,,Expert,1,CHEMBL616553,BAO_0000019,,
1770,,B,,,Binding affinity towards 5-HT1B was determined,8,,,10577,,Autocuration,1,CHEMBL616554,BAO_0000357,,
1771,,B,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,8,,,10577,,Expert,1,CHEMBL616555,BAO_0000019,,
1772,,B,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",8,,,10577,,Expert,1,CHEMBL616556,BAO_0000019,,
1773,,B,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",8,,,10577,,Autocuration,1,CHEMBL616557,BAO_0000019,,
1774,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,8,,,10577,,Expert,1,CHEMBL616558,BAO_0000019,,
1775,,B,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,9,,,10577,10116.0,Expert,1,CHEMBL616749,BAO_0000019,,
1776,,B,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,8,,,10577,,Autocuration,1,CHEMBL616750,BAO_0000357,,
1777,,B,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",8,,,10577,,Autocuration,1,CHEMBL616751,BAO_0000357,,
1778,,B,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,8,,,10577,,Autocuration,1,CHEMBL616752,BAO_0000249,,
1779,,B,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,8,,,10577,,Autocuration,1,CHEMBL616753,BAO_0000019,2435.0,
1780,,B,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,9,,,10577,10116.0,Expert,1,CHEMBL616754,BAO_0000357,,
1781,,B,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,8,,,10577,,Autocuration,1,CHEMBL616755,BAO_0000019,,
1782,,B,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,8,,,10577,,Autocuration,1,CHEMBL616756,BAO_0000019,2435.0,
1783,,B,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,8,,,10577,,Autocuration,1,CHEMBL616757,BAO_0000019,2435.0,
1784,,B,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,8,,,10577,,Autocuration,1,CHEMBL616758,BAO_0000357,2435.0,
1785,,B,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,8,,,10577,,Autocuration,1,CHEMBL616759,BAO_0000249,,
1786,,B,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,8,,,10577,,Autocuration,1,CHEMBL616760,BAO_0000357,,
1787,,B,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,8,,,10577,,Autocuration,1,CHEMBL616761,BAO_0000019,2435.0,
1788,,B,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,8,,,10577,,Autocuration,1,CHEMBL616762,BAO_0000019,2435.0,
1789,,B,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,8,,,10577,,Autocuration,1,CHEMBL616763,BAO_0000019,,
1790,,B,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,8,,,10577,,Expert,1,CHEMBL872909,BAO_0000357,,
1791,,B,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,8,,,10577,,Autocuration,1,CHEMBL616764,BAO_0000357,,
1792,,B,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,9,,,10577,10116.0,Expert,1,CHEMBL616765,BAO_0000357,,
1793,,B,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,8,,,10577,,Autocuration,1,CHEMBL616766,BAO_0000357,2435.0,
1794,,B,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,8,,,10577,,Autocuration,1,CHEMBL616767,BAO_0000357,2435.0,
1795,,B,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,8,,,10577,,Autocuration,1,CHEMBL616768,BAO_0000357,,
1796,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,8,,,10577,,Autocuration,1,CHEMBL616769,BAO_0000357,,
1797,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,8,,,10577,,Autocuration,1,CHEMBL616770,BAO_0000019,,
1798,,B,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,8,,,10577,,Autocuration,1,CHEMBL616771,BAO_0000019,,
1799,,B,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,8,,,10577,,Autocuration,1,CHEMBL616772,BAO_0000019,2435.0,
1800,,B,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,8,,,10577,,Expert,1,CHEMBL616773,BAO_0000019,,
1801,,B,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,8,,,10577,,Autocuration,1,CHEMBL616774,BAO_0000019,,
1802,,B,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,8,,,10577,,Autocuration,1,CHEMBL616775,BAO_0000357,,
1803,,B,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,8,,,10577,,Autocuration,1,CHEMBL616776,BAO_0000249,,
1804,,B,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,8,,,10577,,Autocuration,1,CHEMBL616777,BAO_0000357,,
1805,,B,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,8,,,10577,,Autocuration,1,CHEMBL616778,BAO_0000357,,
1806,,B,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,9,,,10577,10116.0,Expert,1,CHEMBL616779,BAO_0000249,,
1807,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,9,,,10577,10116.0,Expert,1,CHEMBL616780,BAO_0000357,,
1808,,B,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,8,,,10577,,Autocuration,1,CHEMBL616781,BAO_0000019,,
1809,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,8,,,10577,,Autocuration,1,CHEMBL616782,BAO_0000357,,
1810,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,8,,,10577,,Autocuration,1,CHEMBL616783,BAO_0000357,,
1811,,B,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,8,,,10577,,Expert,1,CHEMBL616784,BAO_0000019,2435.0,
1812,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,8,,,10577,,Autocuration,1,CHEMBL616785,BAO_0000357,,
1813,,B,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,8,,,10577,,Autocuration,1,CHEMBL857067,BAO_0000249,955.0,
1814,,B,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,8,,,10577,,Autocuration,1,CHEMBL616786,BAO_0000019,,
1815,,B,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,8,,,10577,,Autocuration,1,CHEMBL616787,BAO_0000249,955.0,
1816,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,8,,,10577,,Autocuration,1,CHEMBL616788,BAO_0000357,,
1817,,B,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,8,,,10577,,Autocuration,1,CHEMBL616789,BAO_0000357,,
1818,,B,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,9,,,10577,10116.0,Expert,1,CHEMBL616790,BAO_0000019,,
1819,,B,,,Binding affinity at 5-hydroxytryptamine 1B receptor,8,,,10577,,Expert,1,CHEMBL616791,BAO_0000357,,
1820,,B,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,8,,,10577,,Autocuration,1,CHEMBL616792,BAO_0000019,,
1821,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,9,,,10577,10116.0,Expert,1,CHEMBL616793,BAO_0000249,,
1822,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,8,,,10577,,Autocuration,1,CHEMBL616794,BAO_0000357,,
1823,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,8,,,10577,,Autocuration,1,CHEMBL616795,BAO_0000357,,
1824,,B,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,4,,,104686,,Autocuration,1,CHEMBL616796,BAO_0000019,,
1825,,B,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616797,BAO_0000357,,
1826,,B,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,8,,,106,,Autocuration,1,CHEMBL616798,BAO_0000249,,
1827,,B,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,8,,,106,,Autocuration,1,CHEMBL616799,BAO_0000357,,
1828,,B,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,8,,,106,,Autocuration,1,CHEMBL616800,BAO_0000357,,
1829,,B,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616801,BAO_0000357,,
1830,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,8,,,106,,Autocuration,1,CHEMBL616802,BAO_0000357,,
1831,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,8,,,106,,Autocuration,1,CHEMBL616803,BAO_0000357,,
1832,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,8,,,106,,Expert,1,CHEMBL857068,BAO_0000357,,
1833,,B,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,8,,,106,,Autocuration,1,CHEMBL616804,BAO_0000357,,
1834,,B,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,8,,,106,,Autocuration,1,CHEMBL616805,BAO_0000357,,
1835,,B,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616806,BAO_0000357,,
1836,,B,,,Binding affinity against 5-hydroxytryptamine 1B receptor,8,,,106,,Autocuration,1,CHEMBL616807,BAO_0000357,,
1837,,B,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,8,,,106,,Autocuration,1,CHEMBL616808,BAO_0000357,,
1838,,B,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,8,,,106,,Autocuration,1,CHEMBL616809,BAO_0000357,,
1839,,B,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,8,,,106,,Autocuration,1,CHEMBL616810,BAO_0000357,,
1840,,B,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,4,,,104802,,Autocuration,1,CHEMBL616811,BAO_0000224,,
1841,,B,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,8,,,108,9913.0,Autocuration,1,CHEMBL616812,BAO_0000357,,
1842,,B,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,8,,,108,9823.0,Autocuration,1,CHEMBL616813,BAO_0000357,,
1843,,B,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,8,,,108,9823.0,Autocuration,1,CHEMBL616814,BAO_0000357,,
1844,,B,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,8,,,108,9823.0,Autocuration,1,CHEMBL616815,BAO_0000357,,
1845,,B,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,8,,,108,9823.0,Autocuration,1,CHEMBL616816,BAO_0000357,,
1846,,B,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,8,,,108,9823.0,Autocuration,1,CHEMBL616817,BAO_0000357,,
1847,,B,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,8,,,108,9823.0,Autocuration,1,CHEMBL616818,BAO_0000357,,
1848,,B,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,8,,,108,9823.0,Expert,1,CHEMBL616819,BAO_0000357,,
1849,,B,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,8,,,108,9823.0,Expert,1,CHEMBL616820,BAO_0000357,,
1850,,B,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,8,,,108,9823.0,Expert,1,CHEMBL616821,BAO_0000019,,
1851,,B,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,8,,,108,9823.0,Autocuration,1,CHEMBL616822,BAO_0000357,,
1852,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,8,,,108,9986.0,Autocuration,1,CHEMBL616823,BAO_0000019,,
1853,,B,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,9,,,12689,10116.0,Autocuration,1,CHEMBL616824,BAO_0000357,,
1854,,B,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,9,,,12689,10116.0,Autocuration,1,CHEMBL616825,BAO_0000357,,
1855,,B,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,9,,,12689,10116.0,Autocuration,1,CHEMBL616826,BAO_0000357,,
1856,,B,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,9,,,12689,10116.0,Expert,1,CHEMBL616827,BAO_0000019,,
1857,,B,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,9,,,12689,10116.0,Autocuration,1,CHEMBL616828,BAO_0000357,,
1858,,B,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,9,,,12689,10116.0,Autocuration,1,CHEMBL616829,BAO_0000357,,
1859,,B,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,9,,,12689,10116.0,Autocuration,1,CHEMBL616830,BAO_0000019,,
1860,,B,,,Binding affinity against 5-hydroxytryptamine 1C receptor,9,,,12689,10116.0,Expert,1,CHEMBL616831,BAO_0000357,,
1861,,B,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",9,,,12689,10116.0,Autocuration,1,CHEMBL616832,BAO_0000019,,
1862,,B,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",9,,,12689,10116.0,Autocuration,1,CHEMBL616833,BAO_0000019,,
1863,,B,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",9,,,12689,10116.0,Expert,1,CHEMBL616834,BAO_0000019,,
1864,,B,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",9,,,12689,10116.0,Autocuration,1,CHEMBL829595,BAO_0000019,,
1865,,B,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,9,,,12689,10116.0,Autocuration,1,CHEMBL616835,BAO_0000357,,
1866,,B,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,9,,,12689,10116.0,Autocuration,1,CHEMBL872910,BAO_0000249,,
1867,,B,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,8,,,12689,,Expert,1,CHEMBL616836,BAO_0000357,,
1868,,B,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,9,,,12689,10116.0,Autocuration,1,CHEMBL616837,BAO_0000357,,
1869,,B,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,9,,,12689,10116.0,Autocuration,1,CHEMBL616466,BAO_0000019,,
1870,HEK293,B,722.0,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,9,,,12689,10116.0,Autocuration,1,CHEMBL616467,BAO_0000219,,
1871,,B,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,8,,,108,,Autocuration,1,CHEMBL616468,BAO_0000357,,
1872,,B,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL616469,BAO_0000357,,
1873,,B,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL616470,BAO_0000357,,
1874,,B,,,Binding affinity against 5-hydroxytryptamine 1C receptor,8,,,12689,,Autocuration,1,CHEMBL616471,BAO_0000357,,
1875,,B,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,8,,,12689,,Autocuration,1,CHEMBL616472,BAO_0000357,,
1876,,B,,,Binding affinity against 5-hydroxytryptamine 1C receptor,8,,,12689,,Autocuration,1,CHEMBL616473,BAO_0000357,,
1877,,B,,,Binding affinity against serotonergic 5-HT1c receptor,8,,,12689,,Autocuration,1,CHEMBL616474,BAO_0000357,,
1878,,B,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,8,,,12689,,Autocuration,1,CHEMBL616475,BAO_0000357,,
1879,,B,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,8,,,12689,,Autocuration,1,CHEMBL616476,BAO_0000357,,
1880,,B,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),8,,,105,9986.0,Autocuration,1,CHEMBL616477,BAO_0000019,,
1881,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,4,,,104686,,Autocuration,1,CHEMBL616478,BAO_0000224,,
1882,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,4,,,104686,,Autocuration,1,CHEMBL616479,BAO_0000224,,
1883,,B,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,4,,,104686,,Autocuration,1,CHEMBL616480,BAO_0000019,,
1884,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,5,,,104686,10116.0,Autocuration,1,CHEMBL616481,BAO_0000019,,
1885,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,5,,,104686,10116.0,Autocuration,1,CHEMBL616482,BAO_0000249,,
1886,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,5,,,104686,10116.0,Autocuration,1,CHEMBL884713,BAO_0000221,955.0,
1887,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,4,,,104686,,Autocuration,1,CHEMBL616483,BAO_0000224,,
1888,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,4,,,104686,,Autocuration,1,CHEMBL616484,BAO_0000224,,
1889,,B,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,4,,,104686,,Autocuration,1,CHEMBL616485,BAO_0000019,,
1890,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,4,,,104686,,Autocuration,1,CHEMBL616486,BAO_0000224,,
1891,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,4,,,104686,,Autocuration,1,CHEMBL616487,BAO_0000224,,
1892,,B,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,4,,,104686,,Autocuration,1,CHEMBL616488,BAO_0000224,,
1893,,B,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,,,104686,,Autocuration,1,CHEMBL616489,BAO_0000019,,
1894,,B,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,,,104686,,Autocuration,1,CHEMBL616490,BAO_0000019,,
1895,,B,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,4,,,104686,,Autocuration,1,CHEMBL616491,BAO_0000019,,
1896,,B,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,4,,,104686,,Autocuration,1,CHEMBL616492,BAO_0000019,,
1897,,B,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,,,104686,,Autocuration,1,CHEMBL616493,BAO_0000019,,
1898,,B,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,4,,,104686,,Autocuration,1,CHEMBL616494,BAO_0000019,,
1899,,B,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,4,,,104686,,Autocuration,1,CHEMBL616495,BAO_0000019,,
1900,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,4,,,104686,,Autocuration,1,CHEMBL616496,BAO_0000019,,
1901,,B,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,,,104686,,Autocuration,1,CHEMBL616497,BAO_0000019,,
1902,,B,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,4,,,104686,,Autocuration,1,CHEMBL616498,BAO_0000019,,
1903,,B,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,4,,,104686,,Autocuration,1,CHEMBL616499,BAO_0000019,,
1904,,B,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,4,,,104686,,Autocuration,1,CHEMBL616500,BAO_0000019,,
1905,,B,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,5,,,104686,10116.0,Autocuration,1,CHEMBL616501,BAO_0000221,955.0,
1906,,B,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,4,,,104686,,Autocuration,1,CHEMBL616502,BAO_0000221,955.0,
1907,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,4,,,104686,,Autocuration,1,CHEMBL884529,BAO_0000249,,
1908,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,4,,,104686,,Autocuration,1,CHEMBL616503,BAO_0000249,,
1909,,B,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL616964,BAO_0000224,,
1910,,B,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,4,,,104686,,Autocuration,1,CHEMBL616965,BAO_0000249,,
1911,,B,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,4,,,104686,,Autocuration,1,CHEMBL616966,BAO_0000224,,
1912,,B,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,4,,,104686,,Autocuration,1,CHEMBL616967,BAO_0000224,,
1913,,B,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL616968,BAO_0000224,,
1914,,B,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,4,,,104686,,Autocuration,1,CHEMBL616969,BAO_0000224,,
1915,,B,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,4,,,104686,,Autocuration,1,CHEMBL884530,BAO_0000019,,
1916,,B,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL616970,BAO_0000224,,
1917,,B,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,4,,,104686,,Autocuration,1,CHEMBL616971,BAO_0000224,,
1918,,B,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",4,,,104686,,Autocuration,1,CHEMBL616972,BAO_0000224,,
1919,,B,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,4,,,104686,,Autocuration,1,CHEMBL616973,BAO_0000224,,
1920,,B,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,4,,,104686,,Autocuration,1,CHEMBL616974,BAO_0000224,,
1921,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,4,,,104686,,Autocuration,1,CHEMBL616975,BAO_0000019,,
1922,,B,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,4,,,104686,,Autocuration,1,CHEMBL616976,BAO_0000019,,
1923,,B,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,4,,,104686,,Autocuration,1,CHEMBL616977,BAO_0000224,,
1924,,B,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,4,,,104686,,Autocuration,1,CHEMBL616978,BAO_0000224,,
1925,,B,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,4,,,104686,,Autocuration,1,CHEMBL616979,BAO_0000224,,
1926,,B,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL616980,BAO_0000224,,
1927,,B,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,4,,,104686,,Autocuration,1,CHEMBL616981,BAO_0000249,,
1928,,B,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,4,,,104686,,Autocuration,1,CHEMBL616982,BAO_0000249,,
1929,,B,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,4,,,104686,,Autocuration,1,CHEMBL616983,BAO_0000224,,
1930,,B,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,4,,,104686,,Autocuration,1,CHEMBL616984,BAO_0000019,,
1931,,B,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL616985,BAO_0000224,,
1932,,B,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,4,,,104686,,Autocuration,1,CHEMBL616986,BAO_0000224,,
1933,,B,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,4,,,104686,,Autocuration,1,CHEMBL616987,BAO_0000224,,
1934,,B,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,4,,,104686,,Autocuration,1,CHEMBL616988,BAO_0000019,,
1935,,B,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,4,,,104686,,Autocuration,1,CHEMBL617243,BAO_0000019,,
1936,,B,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,4,,,104686,,Autocuration,1,CHEMBL617244,BAO_0000019,,
1937,CHO-K1,B,485.0,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,5,,,104686,10116.0,Autocuration,1,CHEMBL617245,BAO_0000219,,
1938,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,4,,,104686,,Autocuration,1,CHEMBL617246,BAO_0000249,,
1939,,B,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),4,,,104686,,Autocuration,1,CHEMBL617546,BAO_0000224,,
1940,,B,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),4,,,104686,,Autocuration,1,CHEMBL617547,BAO_0000249,,
1941,,B,,In vitro,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,4,,,104686,,Autocuration,1,CHEMBL617548,BAO_0000219,,
1942,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617549,BAO_0000224,,
1943,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,4,,,104686,,Autocuration,1,CHEMBL617550,BAO_0000224,,
1944,,B,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,4,,,104686,,Autocuration,1,CHEMBL617551,BAO_0000224,,
1945,,B,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,4,,,104686,,Autocuration,1,CHEMBL617552,BAO_0000249,,
1946,,B,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,4,,,104686,,Autocuration,1,CHEMBL617553,BAO_0000249,,
1947,,F,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,4,,,104686,,Autocuration,1,CHEMBL617554,BAO_0000019,1515.0,
1948,,B,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617555,BAO_0000019,,
1949,,B,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,4,,,104686,,Autocuration,1,CHEMBL617556,BAO_0000224,,
1950,,B,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,8,,,10624,,Autocuration,1,CHEMBL617557,BAO_0000357,,
1951,,B,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,8,,,10624,,Autocuration,1,CHEMBL617558,BAO_0000357,,
1952,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,8,,,17106,,Expert,1,CHEMBL617559,BAO_0000357,,
1953,,B,,,Binding affinity for 5-hydroxytryptamine 1D receptor,9,,,17106,,Expert,1,CHEMBL617560,BAO_0000357,,
1954,,B,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,8,,,17106,,Autocuration,1,CHEMBL617561,BAO_0000249,,
1955,,B,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,8,,,17106,,Autocuration,1,CHEMBL617562,BAO_0000249,,
1956,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,8,,,17106,,Autocuration,1,CHEMBL617563,BAO_0000357,2435.0,
1957,,F,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,8,,,17106,,Autocuration,1,CHEMBL617564,BAO_0000019,,
1958,,B,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,8,,,17106,,Expert,1,CHEMBL617565,BAO_0000019,,
1959,,B,,,Binding activity radioligand.,8,,,17106,,Autocuration,1,CHEMBL856076,BAO_0000357,,
1960,,B,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,8,,,17106,,Autocuration,1,CHEMBL617566,BAO_0000019,,
1961,,B,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,8,,,17106,,Expert,1,CHEMBL875911,BAO_0000019,,
1962,,B,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,8,,,17106,,Autocuration,1,CHEMBL617567,BAO_0000019,,
1963,,B,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,8,,,17106,,Autocuration,1,CHEMBL617568,BAO_0000249,,
1964,,B,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,8,,,17106,,Expert,1,CHEMBL617569,BAO_0000019,,
1965,,B,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,8,,,17106,,Expert,1,CHEMBL617570,BAO_0000249,,
1966,,B,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,8,,,17106,,Autocuration,1,CHEMBL617571,BAO_0000357,,
1967,,B,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,8,,,105,9823.0,Autocuration,1,CHEMBL617572,BAO_0000357,,
1968,,B,,,The compound was tested for intrinsic activity against 5-HT1D receptor,8,,,105,9986.0,Expert,1,CHEMBL617573,BAO_0000357,,
1969,,B,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,8,,,105,9986.0,Autocuration,1,CHEMBL617574,BAO_0000019,,
1970,,B,,,The compound was tested for binding affinity against 5-HT1D receptor,8,,,105,9986.0,Expert,1,CHEMBL617575,BAO_0000357,,
1971,,B,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,8,,,10578,,Autocuration,1,CHEMBL617576,BAO_0000357,,
1972,,F,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,8,,,10578,,Autocuration,1,CHEMBL617577,BAO_0000019,,
1973,,F,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,8,,,10578,,Autocuration,1,CHEMBL617578,BAO_0000019,,
1974,,B,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,8,,,10578,,Autocuration,1,CHEMBL617579,BAO_0000357,,
1975,,B,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,8,,,10578,,Expert,1,CHEMBL617580,BAO_0000019,,
1976,,B,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,8,,,10578,,Autocuration,1,CHEMBL617581,BAO_0000249,,
1977,,B,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,8,,,10578,,Autocuration,1,CHEMBL617582,BAO_0000357,,
1978,,B,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,8,,,10578,,Expert,1,CHEMBL617583,BAO_0000019,,
1979,,B,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,8,,,105,,Autocuration,1,CHEMBL617584,BAO_0000357,,
1980,,B,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL617585,BAO_0000357,,
1981,,B,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,8,,,105,,Autocuration,1,CHEMBL875912,BAO_0000357,,
1982,,B,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL617586,BAO_0000357,,
1983,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,8,,,105,,Autocuration,1,CHEMBL617587,BAO_0000357,,
1984,,B,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,8,,,105,,Autocuration,1,CHEMBL617588,BAO_0000357,,
1985,,B,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL857980,BAO_0000357,,
1986,,B,,,Tested against 5-hydroxytryptamine 1D receptor,8,,,105,,Autocuration,1,CHEMBL617589,BAO_0000357,,
1987,,B,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,8,,,105,,Autocuration,1,CHEMBL617590,BAO_0000357,,
1988,HEK293,B,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,8,,,105,,Autocuration,1,CHEMBL617591,BAO_0000219,,
1989,,B,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,9,,,105,9606.0,Expert,1,CHEMBL617592,BAO_0000357,,
1990,,B,,,,8,,,105,,Autocuration,1,CHEMBL617593,BAO_0000357,,
1991,CHO-K1,B,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,8,,,106,,Autocuration,1,CHEMBL617594,BAO_0000219,,
1992,CHO-K1,B,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,8,,,105,,Autocuration,1,CHEMBL617595,BAO_0000219,,
1993,HEK293,B,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,8,,,105,,Autocuration,1,CHEMBL617596,BAO_0000219,,
1994,HEK293,B,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,8,,,105,,Autocuration,1,CHEMBL617597,BAO_0000219,,
1995,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,8,,,105,,Autocuration,1,CHEMBL617598,BAO_0000019,,
1996,,B,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,8,,,105,,Autocuration,1,CHEMBL872916,BAO_0000357,,
1997,,B,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,8,,,105,,Expert,1,CHEMBL617599,BAO_0000357,,
1998,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,8,,,105,,Autocuration,1,CHEMBL617091,BAO_0000357,,
1999,CHO-K1,B,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",8,,,105,,Expert,1,CHEMBL617092,BAO_0000219,,
2000,CHO-K1,B,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,8,,,105,,Autocuration,1,CHEMBL617093,BAO_0000219,,
2001,,F,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,8,,,105,,Autocuration,1,CHEMBL617094,BAO_0000019,,
2002,,F,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,8,,,105,,Autocuration,1,CHEMBL617095,BAO_0000019,,
2003,,F,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,8,,,105,,Autocuration,1,CHEMBL617096,BAO_0000019,,
2004,,F,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,8,,,105,,Autocuration,1,CHEMBL617097,BAO_0000019,,
2005,,F,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,8,,,105,,Autocuration,1,CHEMBL617098,BAO_0000019,,
2006,,B,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,8,,,105,,Autocuration,1,CHEMBL617301,BAO_0000357,,
2007,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,8,,,105,,Autocuration,1,CHEMBL617302,BAO_0000357,,
2008,,B,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,8,,,105,,Autocuration,1,CHEMBL617303,BAO_0000357,,
2009,,B,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,8,,,105,,Expert,1,CHEMBL617304,BAO_0000357,,
2010,CHO,B,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",8,,,105,,Expert,1,CHEMBL617305,BAO_0000219,,
2011,,B,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,9,,,105,9606.0,Autocuration,1,CHEMBL617306,BAO_0000219,,
2012,,B,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,8,,,17106,,Autocuration,1,CHEMBL617307,BAO_0000357,,
2013,,B,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,8,,,105,9986.0,Autocuration,1,CHEMBL617308,BAO_0000019,,
2014,,B,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,8,,,105,,Autocuration,1,CHEMBL617309,BAO_0000357,,
2015,,B,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,8,,,105,,Autocuration,1,CHEMBL617310,BAO_0000357,,
2016,,B,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,8,,,105,,Autocuration,1,CHEMBL617311,BAO_0000357,,
2017,,B,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,8,,,105,,Autocuration,1,CHEMBL617312,BAO_0000357,,
2018,,B,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,8,,,105,,Autocuration,1,CHEMBL617313,BAO_0000357,,
2019,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,8,,,105,,Expert,1,CHEMBL617314,BAO_0000357,,
2020,,F,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,8,,,106,,Autocuration,1,CHEMBL617315,BAO_0000019,,
2021,HEK293,B,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,8,,,106,,Autocuration,1,CHEMBL617316,BAO_0000219,,
2022,HEK293,B,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,8,,,106,,Autocuration,1,CHEMBL617317,BAO_0000219,,
2023,CHO,B,449.0,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",8,,,106,,Autocuration,1,CHEMBL617318,BAO_0000219,,
2024,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,8,,,106,,Autocuration,1,CHEMBL617319,BAO_0000019,,
2025,,B,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,9,,,106,,Expert,1,CHEMBL617320,BAO_0000357,,
2026,,B,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,9,,,106,,Expert,1,CHEMBL617321,BAO_0000357,,
2027,,B,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,9,,,106,,Expert,1,CHEMBL617322,BAO_0000357,,
2028,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,8,,,106,,Autocuration,1,CHEMBL616862,BAO_0000357,,
2029,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,8,,,106,,Autocuration,1,CHEMBL616863,BAO_0000357,,
2030,CHO,B,449.0,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,8,,,106,,Autocuration,1,CHEMBL616864,BAO_0000219,,
2031,CHO-K1,B,485.0,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,8,,,106,,Autocuration,1,CHEMBL616865,BAO_0000219,,
2032,CHO-K1,B,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,8,,,106,,Autocuration,1,CHEMBL616866,BAO_0000219,,
2033,,F,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,8,,,106,,Autocuration,1,CHEMBL616867,BAO_0000019,,
2034,CHO-K1,B,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",8,,,106,,Expert,1,CHEMBL616868,BAO_0000219,,
2035,,B,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,8,,,105,,Expert,1,CHEMBL616869,BAO_0000357,,
2036,CHO,B,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",8,,,106,,Expert,1,CHEMBL616870,BAO_0000219,,
2037,CHO-K1,F,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,8,,,105,,Autocuration,1,CHEMBL616871,BAO_0000219,,
2038,CHO-K1,F,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,8,,,105,,Autocuration,1,CHEMBL616872,BAO_0000219,,
2039,CHO-K1,F,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,8,,,105,,Autocuration,1,CHEMBL616873,BAO_0000219,,
2040,CHO-K1,F,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,8,,,105,,Autocuration,1,CHEMBL616838,BAO_0000219,,
2041,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,8,,,105,,Autocuration,1,CHEMBL616839,BAO_0000357,,
2042,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,8,,,106,9986.0,Autocuration,1,CHEMBL616840,BAO_0000019,,
2043,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,8,,,105,,Autocuration,1,CHEMBL616841,BAO_0000357,,
2044,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,8,,,105,,Autocuration,1,CHEMBL616842,BAO_0000357,,
2045,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,8,,,105,,Expert,1,CHEMBL857976,BAO_0000357,,
2046,CHO,B,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,8,,,10618,,Autocuration,1,CHEMBL616843,BAO_0000219,,
2047,,B,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,9,,,10618,9606.0,Expert,1,CHEMBL616844,BAO_0000357,,
2048,,B,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,8,,,10618,,Autocuration,1,CHEMBL616845,BAO_0000357,,
2049,,B,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,9,,,10618,9606.0,Expert,1,CHEMBL616846,BAO_0000357,,
2050,,B,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,8,,,10618,,Autocuration,1,CHEMBL616847,BAO_0000357,,
2051,,B,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,8,,,10618,,Autocuration,1,CHEMBL616848,BAO_0000019,,
2052,,B,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,8,,,10618,,Autocuration,1,CHEMBL616849,BAO_0000357,,
2053,,B,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,8,,,10618,,Autocuration,1,CHEMBL872911,BAO_0000357,,
2054,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,8,,,10618,,Autocuration,1,CHEMBL616850,BAO_0000019,,
2055,CHO,B,449.0,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,9,,,10618,9606.0,Expert,1,CHEMBL616699,BAO_0000219,,
2056,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,8,,,10618,,Autocuration,1,CHEMBL616700,BAO_0000357,,
2057,CHO,B,449.0,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,8,,,10618,,Autocuration,1,CHEMBL616701,BAO_0000219,,
2058,CHO,B,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,8,,,10618,,Autocuration,1,CHEMBL616702,BAO_0000219,,
2059,CHO,B,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,8,,,10618,,Autocuration,1,CHEMBL616703,BAO_0000219,,
2060,,B,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,8,,,10618,,Autocuration,1,CHEMBL616704,BAO_0000357,,
2061,CHO,B,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,8,,,10618,,Autocuration,1,CHEMBL616705,BAO_0000219,,
2062,,B,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,8,,,10618,,Autocuration,1,CHEMBL616706,BAO_0000357,,
2063,CHO,B,449.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,8,,,10618,,Autocuration,1,CHEMBL616707,BAO_0000219,,
2064,,B,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,8,,,10618,,Autocuration,1,CHEMBL616708,BAO_0000357,,
2065,,B,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,8,,,10618,,Autocuration,1,CHEMBL616709,BAO_0000357,,
2066,CHO,B,449.0,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,8,,,10618,,Autocuration,1,CHEMBL616710,BAO_0000219,,
2067,CHO,B,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,8,,,10618,,Autocuration,1,CHEMBL616711,BAO_0000219,,
2068,CHO,B,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",8,,,10618,,Autocuration,1,CHEMBL616712,BAO_0000219,,
2069,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,8,,,10618,,Autocuration,1,CHEMBL616713,BAO_0000357,,
2070,,B,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,8,,,10618,,Autocuration,1,CHEMBL616714,BAO_0000357,,
2071,,B,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,8,,,10618,,Autocuration,1,CHEMBL616715,BAO_0000357,,
2072,,B,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,8,,,10618,,Autocuration,1,CHEMBL616716,BAO_0000357,,
2073,,F,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",8,,,279,,Autocuration,1,CHEMBL616717,BAO_0000019,,
2074,,F,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",8,,,279,,Expert,1,CHEMBL616718,BAO_0000019,,
2075,,F,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,8,,,279,,Autocuration,1,CHEMBL875905,BAO_0000019,,
2076,,F,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,8,,,279,,Autocuration,1,CHEMBL616719,BAO_0000019,,
2077,,F,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",8,,,279,,Expert,1,CHEMBL616720,BAO_0000019,,
2078,,B,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,8,,,279,,Autocuration,1,CHEMBL616721,BAO_0000357,,
2079,CHO,B,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,8,,,279,,Autocuration,1,CHEMBL616722,BAO_0000219,,
2080,,B,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),8,,,279,,Autocuration,1,CHEMBL616723,BAO_0000357,,
2081,CHO,B,449.0,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,8,,,279,,Autocuration,1,CHEMBL616724,BAO_0000219,,
2082,,B,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,8,,,279,,Autocuration,1,CHEMBL616725,BAO_0000357,,
2083,,B,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,8,,,279,,Autocuration,1,CHEMBL616726,BAO_0000357,,
2084,,B,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,8,,,279,,Autocuration,1,CHEMBL616727,BAO_0000357,,
2085,,B,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,8,,,279,,Autocuration,1,CHEMBL616728,BAO_0000357,,
2086,,B,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,8,,,279,,Autocuration,1,CHEMBL616729,BAO_0000357,,
2087,,B,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,8,,,279,,Expert,1,CHEMBL616730,BAO_0000019,,
2088,,B,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,8,,,279,,Autocuration,1,CHEMBL617125,BAO_0000357,,
2089,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,8,,,279,,Autocuration,1,CHEMBL857977,BAO_0000357,,
2090,CHO,B,449.0,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,8,,,279,,Autocuration,1,CHEMBL617126,BAO_0000219,,
2091,CHO,B,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,8,,,279,,Autocuration,1,CHEMBL617127,BAO_0000219,,
2092,,B,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,8,,,279,,Autocuration,1,CHEMBL617128,BAO_0000357,,
2093,CHO,B,449.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,8,,,279,,Autocuration,1,CHEMBL617129,BAO_0000219,,
2094,,B,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,8,,,279,,Autocuration,1,CHEMBL617130,BAO_0000357,,
2095,CHO,B,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,8,,,279,,Autocuration,1,CHEMBL617131,BAO_0000219,,
2096,CHO,B,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",8,,,279,,Autocuration,1,CHEMBL617132,BAO_0000219,,
2097,CHO,B,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",8,,,279,,Autocuration,1,CHEMBL617133,BAO_0000219,,
2098,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,8,,,279,,Autocuration,1,CHEMBL617134,BAO_0000357,,
2099,,B,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,8,,,279,,Autocuration,1,CHEMBL617135,BAO_0000357,,
2100,,B,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,8,,,279,,Autocuration,1,CHEMBL617136,BAO_0000357,,
2101,,B,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",4,,,104686,,Autocuration,1,CHEMBL617137,BAO_0000019,,
2102,,B,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",4,,,104686,,Autocuration,1,CHEMBL617138,BAO_0000019,,
2103,,B,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",4,,,104686,,Autocuration,1,CHEMBL617139,BAO_0000019,,
2104,,B,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617140,BAO_0000019,,
2105,,F,,In vivo,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",4,,,104686,,Autocuration,1,CHEMBL617141,BAO_0000218,,
2106,,F,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,,,104686,,Autocuration,1,CHEMBL858112,BAO_0000019,,
2107,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,8,,,17005,,Intermediate,1,CHEMBL617142,BAO_0000019,,
2108,,B,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",0,,,22226,9913.0,Autocuration,1,CHEMBL617143,BAO_0000019,,
2109,,B,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,0,,,22226,9913.0,Autocuration,1,CHEMBL617144,BAO_0000019,,
2110,,B,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,0,,,22226,9913.0,Autocuration,1,CHEMBL617145,BAO_0000019,,
2111,,B,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,0,,,22226,,Autocuration,1,CHEMBL617146,BAO_0000019,,
2112,,B,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,4,,,104784,10141.0,Autocuration,1,CHEMBL617147,BAO_0000019,,
2113,,B,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,4,,,104784,10141.0,Autocuration,1,CHEMBL617148,BAO_0000019,,
2114,,B,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,4,,,104784,10141.0,Autocuration,1,CHEMBL617149,BAO_0000019,,
2115,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,4,,,104784,,Autocuration,1,CHEMBL617150,BAO_0000224,,
2116,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,4,,,104784,,Autocuration,1,CHEMBL617151,BAO_0000224,,
2117,,B,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617201,BAO_0000224,,
2118,,B,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,8,,,10209,,Autocuration,1,CHEMBL617202,BAO_0000357,,
2119,,B,,In vivo,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,4,,,104826,,Autocuration,1,CHEMBL617203,BAO_0000218,,
2120,,B,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,4,,,104826,,Autocuration,1,CHEMBL617204,BAO_0000019,,
2121,,B,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,4,,,104826,,Autocuration,1,CHEMBL617205,BAO_0000224,,
2122,,B,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,5,,,104826,10090.0,Autocuration,1,CHEMBL617206,BAO_0000019,,
2123,,B,,In vivo,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,4,,,104826,,Autocuration,1,CHEMBL617207,BAO_0000218,,
2124,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,5,,,104826,10090.0,Autocuration,1,CHEMBL617208,BAO_0000019,,
2125,,B,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,4,,,104826,,Autocuration,1,CHEMBL617209,BAO_0000224,,
2126,,B,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,4,,,104826,,Autocuration,1,CHEMBL617210,BAO_0000224,,
2127,,B,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,4,,,104826,,Autocuration,1,CHEMBL617211,BAO_0000224,,
2128,,B,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,5,,,104826,10090.0,Autocuration,1,CHEMBL617212,BAO_0000019,,
2129,,B,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,4,,,104784,9823.0,Autocuration,1,CHEMBL617213,BAO_0000224,,
2130,,B,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,4,,,104784,9823.0,Autocuration,1,CHEMBL617214,BAO_0000224,,
2131,,B,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,0,,,22226,,Autocuration,1,CHEMBL617215,BAO_0000221,,
2132,,B,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,0,,,22226,,Autocuration,1,CHEMBL617216,BAO_0000221,,
2133,,B,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,8,,,17005,9823.0,Autocuration,1,CHEMBL617217,BAO_0000357,,
2134,,B,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617218,BAO_0000019,,
2135,,B,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL872913,BAO_0000019,,
2136,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,4,,,104826,,Autocuration,1,CHEMBL617219,BAO_0000019,,
2137,,B,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL873482,BAO_0000224,,
2138,,B,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,5,,,104686,10116.0,Autocuration,1,CHEMBL617220,BAO_0000019,,
2139,,B,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,4,,,104686,,Autocuration,1,CHEMBL617221,BAO_0000019,,
2140,,B,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,4,,,104686,,Autocuration,1,CHEMBL617222,BAO_0000019,,
2141,,F,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,4,,,104686,,Autocuration,1,CHEMBL875906,BAO_0000019,,
2142,,B,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,4,,,104686,,Autocuration,1,CHEMBL617223,BAO_0000019,,
2143,,B,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617224,BAO_0000224,,
2144,,B,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,5,,,104686,10116.0,Autocuration,1,CHEMBL617225,BAO_0000224,,
2145,,B,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,4,,,104686,,Autocuration,1,CHEMBL617226,BAO_0000224,,
2146,,B,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,4,,,104686,,Autocuration,1,CHEMBL617227,BAO_0000224,,
2147,,B,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,4,,,104686,,Autocuration,1,CHEMBL617228,BAO_0000224,,
2148,,B,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,4,,,104686,,Autocuration,1,CHEMBL617229,BAO_0000224,,
2149,,B,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,4,,,104686,,Autocuration,1,CHEMBL617230,BAO_0000224,,
2150,,B,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",4,,,104686,,Autocuration,1,CHEMBL617231,BAO_0000224,,
2151,,B,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,4,,,104686,,Autocuration,1,CHEMBL617232,BAO_0000224,,
2152,,B,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617233,BAO_0000224,,
2153,,B,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,4,,,104686,,Autocuration,1,CHEMBL617234,BAO_0000224,,
2154,,F,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,4,,,104686,,Autocuration,1,CHEMBL617235,BAO_0000019,,
2155,,F,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,4,,,104686,,Autocuration,1,CHEMBL617236,BAO_0000019,,
2156,,B,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,4,,,104686,,Autocuration,1,CHEMBL617237,BAO_0000221,10000000.0,
2157,,B,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,4,,,104686,,Autocuration,1,CHEMBL617238,BAO_0000221,10000000.0,
2158,,B,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,5,,,104686,10116.0,Autocuration,1,CHEMBL617239,BAO_0000221,955.0,
2159,,B,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,4,,,104686,,Autocuration,1,CHEMBL617240,BAO_0000019,,
2160,,B,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,4,,,104686,,Autocuration,1,CHEMBL617241,BAO_0000249,,
2161,,B,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,4,,,104686,,Autocuration,1,CHEMBL875907,BAO_0000249,,
2162,,B,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,4,,,104686,,Autocuration,1,CHEMBL617242,BAO_0000019,,
2163,,F,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,4,,,104686,,Autocuration,1,CHEMBL617152,BAO_0000019,,
2164,,B,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,5,,,104686,10116.0,Autocuration,1,CHEMBL617153,BAO_0000221,955.0,
2165,,B,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,5,,,104686,10116.0,Autocuration,1,CHEMBL617154,BAO_0000249,,
2166,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,4,,,104686,,Autocuration,1,CHEMBL617155,BAO_0000221,955.0,
2167,,F,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,4,,,104686,,Autocuration,1,CHEMBL617156,BAO_0000019,,
2168,,F,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,4,,,104686,,Autocuration,1,CHEMBL617157,BAO_0000019,,
2169,,F,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,,,104686,,Autocuration,1,CHEMBL617158,BAO_0000019,,
2170,,F,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,4,,,104686,,Autocuration,1,CHEMBL617159,BAO_0000019,,
2171,,F,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,4,,,104686,,Autocuration,1,CHEMBL617160,BAO_0000019,,
2172,,F,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,,,104686,,Autocuration,1,CHEMBL858113,BAO_0000019,,
2173,,B,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,4,,,104686,,Autocuration,1,CHEMBL617247,BAO_0000220,955.0,
2174,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,4,,,104686,,Autocuration,1,CHEMBL617248,BAO_0000019,,
2175,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,4,,,104686,,Autocuration,1,CHEMBL617249,BAO_0000249,955.0,
2176,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,4,,,104686,,Autocuration,1,CHEMBL617250,BAO_0000019,,
2177,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,4,,,104686,,Autocuration,1,CHEMBL617251,BAO_0000019,,
2178,,B,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL617252,BAO_0000019,,
2179,,B,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,4,,,104686,,Autocuration,1,CHEMBL617006,BAO_0000019,,
2180,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,4,,,104686,,Autocuration,1,CHEMBL617007,BAO_0000019,,
2181,,F,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",4,,,104686,,Autocuration,1,CHEMBL617008,BAO_0000019,,
2182,,B,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,4,,,104686,,Autocuration,1,CHEMBL617009,BAO_0000019,,
2183,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,5,,,104686,10116.0,Autocuration,1,CHEMBL617010,BAO_0000224,,
2184,,B,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL857978,BAO_0000019,,
2185,,B,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL617011,BAO_0000019,,
2186,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,5,,,104686,10116.0,Autocuration,1,CHEMBL617012,BAO_0000019,,
2187,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,4,,,104686,,Autocuration,1,CHEMBL617013,BAO_0000224,,
2188,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,4,,,104686,,Autocuration,1,CHEMBL617014,BAO_0000249,,
2189,,B,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617015,BAO_0000019,,
2190,,B,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,4,,,104686,,Autocuration,1,CHEMBL617016,BAO_0000019,,
2191,,B,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,4,,,104686,,Autocuration,1,CHEMBL617017,BAO_0000224,,
2192,,B,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,4,,,104686,,Autocuration,1,CHEMBL617018,BAO_0000221,955.0,
2193,,F,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,4,,,104686,,Autocuration,1,CHEMBL617019,BAO_0000019,,
2194,,B,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,4,,,105075,,Autocuration,1,CHEMBL617020,BAO_0000019,,
2195,,B,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,4,,,105075,,Autocuration,1,CHEMBL617021,BAO_0000019,,
2196,,B,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,4,,,105075,,Autocuration,1,CHEMBL617022,BAO_0000019,,
2197,,B,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,4,,,105075,,Autocuration,1,CHEMBL617023,BAO_0000019,,
2198,,B,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,4,,,105075,,Autocuration,1,CHEMBL617024,BAO_0000019,,
2199,,B,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,4,,,105075,,Autocuration,1,CHEMBL617025,BAO_0000019,,
2200,,B,,,Hill coefficient of compound was determined,4,,,105075,,Autocuration,1,CHEMBL617026,BAO_0000224,,
2201,,B,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,0,,,22226,,Autocuration,1,CHEMBL617027,BAO_0000019,,
2202,,B,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,5,,,104686,10116.0,Autocuration,1,CHEMBL617028,BAO_0000019,,
2203,,B,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,8,,,12687,,Expert,1,CHEMBL617029,BAO_0000019,,
2204,,B,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,8,,,12687,,Expert,1,CHEMBL875908,BAO_0000019,,
2205,,B,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),8,,,12687,,Autocuration,1,CHEMBL617030,BAO_0000357,,
2206,,B,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),8,,,12687,,Autocuration,1,CHEMBL617031,BAO_0000019,,
2207,,B,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,8,,,12687,,Autocuration,1,CHEMBL617032,BAO_0000019,,
2208,,B,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,5,,,104686,10116.0,Autocuration,1,CHEMBL617033,BAO_0000224,,
2209,,B,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",4,,,104686,,Autocuration,1,CHEMBL617034,BAO_0000224,,
2210,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,4,,,104686,,Autocuration,1,CHEMBL617035,BAO_0000224,,
2211,,B,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",4,,,104686,,Autocuration,1,CHEMBL617036,BAO_0000019,,
2212,,B,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617037,BAO_0000224,,
2213,,B,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,0,,,22226,,Autocuration,1,CHEMBL617038,BAO_0000219,,
2214,,B,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",4,,,104784,,Autocuration,1,CHEMBL617039,BAO_0000219,,
2215,,B,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617161,BAO_0000224,,
2216,,B,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617162,BAO_0000224,,
2217,,B,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617163,BAO_0000224,,
2218,,B,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617164,BAO_0000224,,
2219,,B,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,4,,,104784,,Autocuration,1,CHEMBL617165,BAO_0000249,,
2220,,B,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,4,,,104784,,Autocuration,1,CHEMBL617166,BAO_0000224,,
2221,,B,,,Binding affinity towards 5-HT2 receptor,4,,,104784,,Autocuration,1,CHEMBL617167,BAO_0000224,,
2222,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL872912,BAO_0000224,,
2223,,B,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,4,,,104784,,Autocuration,1,CHEMBL617168,BAO_0000224,,
2224,,B,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,4,,,104686,,Autocuration,1,CHEMBL617169,BAO_0000224,,
2225,,B,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617170,BAO_0000224,,
2226,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,4,,,104784,,Autocuration,1,CHEMBL617171,BAO_0000224,,
2227,,B,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,4,,,104784,,Autocuration,1,CHEMBL617172,BAO_0000224,,
2228,,B,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617173,BAO_0000224,,
2229,,B,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,0,,,22226,,Autocuration,1,CHEMBL617174,BAO_0000019,,
2230,,B,,,5-hydroxytryptamine 2 receptor binding affinity,4,,,104784,,Autocuration,1,CHEMBL617175,BAO_0000224,,
2231,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,8,,,17005,,Autocuration,1,CHEMBL617176,BAO_0000357,,
2232,,B,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,8,,,17005,,Autocuration,1,CHEMBL617177,BAO_0000357,,
2233,,B,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,4,,,104784,,Autocuration,1,CHEMBL617178,BAO_0000224,,
2234,,B,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,4,,,104784,,Autocuration,1,CHEMBL617179,BAO_0000224,,
2235,,B,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,4,,,104784,,Autocuration,1,CHEMBL617180,BAO_0000224,,
2236,,B,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,8,,,17005,,Autocuration,1,CHEMBL617181,BAO_0000357,,
2237,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor,8,,,17005,,Autocuration,1,CHEMBL617182,BAO_0000357,,
2238,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor,8,,,17005,,Autocuration,1,CHEMBL617183,BAO_0000357,,
2239,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,8,,,17005,,Autocuration,1,CHEMBL617184,BAO_0000357,,
2240,,B,,,Binding affinity against serotonergic 5-HT2 receptor,8,,,17005,,Autocuration,1,CHEMBL617185,BAO_0000357,,
2241,,B,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,8,,,17005,,Autocuration,1,CHEMBL617186,BAO_0000357,,
2242,,B,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,8,,,17005,,Autocuration,1,CHEMBL617187,BAO_0000357,,
2243,,B,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,8,,,17005,,Autocuration,1,CHEMBL617188,BAO_0000357,,
2244,,B,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,8,,,17005,,Autocuration,1,CHEMBL617189,BAO_0000218,,
2245,,B,,,Inhibitory activity against cloned human 5-HT2 receptor,5,,,104784,9606.0,Autocuration,1,CHEMBL617190,BAO_0000224,,
2246,CHO,B,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",5,,,104784,9606.0,Autocuration,1,CHEMBL617191,BAO_0000219,,
2247,CHO,B,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",5,,,104784,9606.0,Autocuration,1,CHEMBL617192,BAO_0000219,,
2248,CHO,B,449.0,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",5,,,104784,9606.0,Autocuration,1,CHEMBL617193,BAO_0000219,,
2249,CHO,B,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",5,,,104784,9606.0,Autocuration,1,CHEMBL617194,BAO_0000219,,
2250,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,4,,,104784,,Autocuration,1,CHEMBL617195,BAO_0000224,,
2251,,B,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,4,,,104784,,Autocuration,1,CHEMBL881830,BAO_0000224,,
2252,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,8,,,17005,,Autocuration,1,CHEMBL617196,BAO_0000357,,
2253,,B,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,4,,,104686,,Autocuration,1,CHEMBL617197,BAO_0000224,,
2254,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,8,,,17005,,Expert,1,CHEMBL617198,BAO_0000357,,
2255,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,8,,,17005,,Expert,1,CHEMBL873476,BAO_0000357,,
2256,,B,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,8,,,17005,,Expert,1,CHEMBL617199,BAO_0000019,,
2257,,B,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,8,,,107,10141.0,Autocuration,1,CHEMBL617200,BAO_0000357,,
2258,,B,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,8,,,51,,Autocuration,1,CHEMBL617484,BAO_0000357,,
2259,,B,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,8,,,107,,Autocuration,1,CHEMBL617485,BAO_0000357,,
2260,,B,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,8,,,51,,Autocuration,1,CHEMBL617486,BAO_0000357,,
2261,,B,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL858022,BAO_0000357,,
2262,CHO,B,449.0,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,8,,,107,,Autocuration,1,CHEMBL617049,BAO_0000219,,
2263,CHO,F,449.0,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,9,,,107,9606.0,Expert,1,CHEMBL617050,BAO_0000219,,
2264,,F,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,8,,,107,,Autocuration,1,CHEMBL617051,BAO_0000219,,
2265,,F,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,8,,,107,,Autocuration,1,CHEMBL617052,BAO_0000219,,
2266,,F,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,8,,,107,,Autocuration,1,CHEMBL617053,BAO_0000219,,
2267,CHO,B,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",8,,,107,,Autocuration,1,CHEMBL617054,BAO_0000219,,
2268,CHO,B,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",8,,,107,,Autocuration,1,CHEMBL617055,BAO_0000219,,
2269,,B,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,8,,,107,,Autocuration,1,CHEMBL882924,BAO_0000357,,
2270,,B,,,Inhibition of human 5-hydroxytryptamine 2A receptor,9,,,107,9606.0,Expert,1,CHEMBL617056,BAO_0000357,,
2271,CHO,B,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,8,,,107,,Autocuration,1,CHEMBL617057,BAO_0000219,,
2272,,B,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,8,,,107,,Expert,1,CHEMBL617058,BAO_0000219,,
2273,,B,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),8,,,107,,Autocuration,1,CHEMBL617059,BAO_0000357,,
2274,CHO,B,449.0,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,8,,,107,,Autocuration,1,CHEMBL617060,BAO_0000219,,
2275,CHO,B,449.0,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,8,,,107,,Expert,1,CHEMBL617061,BAO_0000219,,
2276,L929,B,307.0,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,8,,,107,,Expert,1,CHEMBL617062,BAO_0000219,,
2277,CHO,B,449.0,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,8,,,107,,Expert,1,CHEMBL617063,BAO_0000219,,
2278,,F,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,8,,,107,,Autocuration,1,CHEMBL617064,BAO_0000019,,
2279,,F,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,8,,,107,,Autocuration,1,CHEMBL617065,BAO_0000019,,
2280,CHO,B,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,8,,,107,,Autocuration,1,CHEMBL617066,BAO_0000219,,
2281,CHO,B,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,8,,,107,,Autocuration,1,CHEMBL617067,BAO_0000219,,
2282,,F,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,8,,,107,,Autocuration,1,CHEMBL617068,BAO_0000019,,
2283,,F,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,8,,,107,,Autocuration,1,CHEMBL617069,BAO_0000019,,
2284,,F,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL617070,BAO_0000019,,
2285,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,8,,,107,,Autocuration,1,CHEMBL617071,BAO_0000357,,
2286,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL872915,BAO_0000357,,
2287,,B,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,8,,,107,,Autocuration,1,CHEMBL617072,BAO_0000357,,
2288,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,8,,,107,,Autocuration,1,CHEMBL617073,BAO_0000357,,
2289,,B,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,8,,,107,,Autocuration,1,CHEMBL617074,BAO_0000357,,
2290,CHO,B,449.0,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,8,,,107,,Expert,1,CHEMBL617075,BAO_0000219,,
2291,,B,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617076,BAO_0000357,,
2292,,B,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,9,,,107,9606.0,Expert,1,CHEMBL617077,BAO_0000019,,
2293,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,8,,,107,,Expert,1,CHEMBL617078,BAO_0000357,,
2294,,B,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,9,,,107,9606.0,Expert,1,CHEMBL617079,BAO_0000357,,
2295,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,8,,,107,,Autocuration,1,CHEMBL617080,BAO_0000357,,
2296,CHO,B,449.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,8,,,107,,Expert,1,CHEMBL617081,BAO_0000219,,
2297,,B,,,Binding affinity towards human 5-HT2A receptor in BEK cells,8,,,107,,Expert,1,CHEMBL617082,BAO_0000219,,
2298,,B,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617083,BAO_0000357,,
2299,,B,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,8,,,107,,Autocuration,1,CHEMBL617084,BAO_0000357,,
2300,,B,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,9,,,107,9606.0,Expert,1,CHEMBL617085,BAO_0000357,,
2301,,B,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,8,,,107,,Autocuration,1,CHEMBL617086,BAO_0000357,,
2302,,B,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,8,,,107,,Autocuration,1,CHEMBL617087,BAO_0000219,,
2303,,B,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617088,BAO_0000357,,
2304,,B,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617089,BAO_0000357,,
2305,,B,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",8,,,107,,Expert,1,CHEMBL617090,BAO_0000019,,
2306,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL617513,BAO_0000357,,
2307,HEK293,B,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL617514,BAO_0000219,,
2308,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617515,BAO_0000019,,
2309,,B,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,8,,,107,,Autocuration,1,CHEMBL617516,BAO_0000357,,
2310,,B,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,9,,,107,9606.0,Expert,1,CHEMBL617517,BAO_0000357,,
2311,CHO,B,449.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,9,,,107,9606.0,Expert,1,CHEMBL617518,BAO_0000219,,
2312,,B,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617519,BAO_0000357,,
2313,,B,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,9,,,107,9606.0,Expert,1,CHEMBL617520,BAO_0000357,,
2314,,B,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,8,,,107,,Autocuration,1,CHEMBL617521,BAO_0000357,,
2315,,B,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,9,,,107,9606.0,Expert,1,CHEMBL617522,BAO_0000357,,
2316,,B,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,8,,,107,,Autocuration,1,CHEMBL617523,BAO_0000357,,
2317,,B,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,8,,,107,,Autocuration,1,CHEMBL617524,BAO_0000357,,
2318,,B,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,4,,,104686,,Autocuration,1,CHEMBL617525,BAO_0000019,,
2319,,B,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,5,,,104686,10116.0,Autocuration,1,CHEMBL617526,BAO_0000019,,
2320,,B,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,4,,,104686,,Autocuration,1,CHEMBL617527,BAO_0000224,,
2321,,B,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,4,,,104686,,Autocuration,1,CHEMBL617528,BAO_0000019,,
2322,,B,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,4,,,104686,,Autocuration,1,CHEMBL617529,BAO_0000019,,
2323,,B,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,4,,,104686,,Autocuration,1,CHEMBL617530,BAO_0000224,,
2324,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,4,,,104686,,Autocuration,1,CHEMBL617531,BAO_0000019,,
2325,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,4,,,104686,,Autocuration,1,CHEMBL617532,BAO_0000019,,
2326,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,4,,,104686,,Autocuration,1,CHEMBL617533,BAO_0000019,,
2327,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,4,,,104686,,Autocuration,1,CHEMBL617534,BAO_0000019,,
2328,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,4,,,104686,,Autocuration,1,CHEMBL617535,BAO_0000224,,
2329,,B,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,4,,,104686,,Autocuration,1,CHEMBL617536,BAO_0000224,,
2330,,B,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617537,BAO_0000224,,
2331,,B,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617538,BAO_0000224,,
2332,,B,,In vitro,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,4,,,104686,,Autocuration,1,CHEMBL617539,BAO_0000219,,
2333,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL617540,BAO_0000224,,
2334,,B,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,5,,,104686,10116.0,Autocuration,1,CHEMBL617541,BAO_0000224,,
2335,,B,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617542,BAO_0000224,,
2336,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,4,,,104686,,Autocuration,1,CHEMBL617543,BAO_0000224,,
2337,CHO-K1,B,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,5,,,104686,10116.0,Autocuration,1,CHEMBL617544,BAO_0000219,,
2338,CHO-K1,B,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,5,,,104686,10116.0,Autocuration,1,CHEMBL617545,BAO_0000219,,
2339,,B,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,5,,,104686,10116.0,Autocuration,1,CHEMBL617413,BAO_0000019,,
2340,,B,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,4,,,104686,,Autocuration,1,CHEMBL617414,BAO_0000019,,
2341,,B,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,5,,,104686,10116.0,Autocuration,1,CHEMBL617415,BAO_0000019,,
2342,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617416,BAO_0000224,,
2343,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,4,,,104686,,Autocuration,1,CHEMBL617417,BAO_0000224,,
2344,,B,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",4,,,104686,,Autocuration,1,CHEMBL617418,BAO_0000019,,
2345,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,4,,,104686,,Autocuration,1,CHEMBL617419,BAO_0000019,,
2346,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,4,,,104686,,Autocuration,1,CHEMBL617420,BAO_0000224,,
2347,,B,,,Affinity for 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL617421,BAO_0000224,,
2348,,B,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,4,,,104686,,Autocuration,1,CHEMBL617422,BAO_0000224,,
2349,,B,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,4,,,104686,,Autocuration,1,CHEMBL617423,BAO_0000019,,
2350,,B,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,4,,,104686,,Autocuration,1,CHEMBL617424,BAO_0000019,,
2351,,B,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,4,,,104686,,Autocuration,1,CHEMBL617425,BAO_0000019,,
2352,,B,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),4,,,104686,,Autocuration,1,CHEMBL617426,BAO_0000224,,
2353,,B,,In vivo,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),4,,,104686,,Autocuration,1,CHEMBL617427,BAO_0000218,,
2354,,B,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,4,,,104686,,Autocuration,1,CHEMBL617428,BAO_0000221,955.0,
2355,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,4,,,104686,,Autocuration,1,CHEMBL617429,BAO_0000224,,
2356,,B,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,4,,,104686,,Autocuration,1,CHEMBL617430,BAO_0000019,,
2357,,B,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,4,,,104686,,Autocuration,1,CHEMBL617431,BAO_0000019,,
2358,,B,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,4,,,104686,,Autocuration,1,CHEMBL617432,BAO_0000019,1870.0,
2359,,B,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617433,BAO_0000224,,
2360,,B,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617434,BAO_0000224,,
2361,,B,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL617435,BAO_0000224,,
2362,,B,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,4,,,104686,,Autocuration,1,CHEMBL617436,BAO_0000019,,
2363,,B,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,5,,,104686,10116.0,Autocuration,1,CHEMBL617437,BAO_0000019,2435.0,
2364,,B,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",4,,,104686,,Autocuration,1,CHEMBL617438,BAO_0000019,,
2365,,B,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",4,,,104686,,Autocuration,1,CHEMBL617439,BAO_0000019,,
2366,,B,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617440,BAO_0000224,,
2367,,B,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617441,BAO_0000224,,
2368,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,5,,,104686,10116.0,Autocuration,1,CHEMBL872918,BAO_0000019,,
2369,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,5,,,104686,10116.0,Autocuration,1,CHEMBL617442,BAO_0000019,,
2370,,B,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,4,,,104686,,Autocuration,1,CHEMBL617443,BAO_0000019,,
2371,,B,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,4,,,104686,,Autocuration,1,CHEMBL617444,BAO_0000019,,
2372,,B,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,4,,,104686,,Autocuration,1,CHEMBL617445,BAO_0000019,,
2373,,B,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,4,,,104686,,Autocuration,1,CHEMBL617446,BAO_0000019,,
2374,,B,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,4,,,104686,,Autocuration,1,CHEMBL617447,BAO_0000249,,
2375,,B,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,4,,,104686,,Autocuration,1,CHEMBL617448,BAO_0000019,,
2376,,B,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,4,,,104686,,Autocuration,1,CHEMBL617449,BAO_0000019,,
2377,,B,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,4,,,104686,,Autocuration,1,CHEMBL617450,BAO_0000019,,
2378,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,4,,,104686,,Autocuration,1,CHEMBL617451,BAO_0000019,,
2379,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,4,,,104686,,Autocuration,1,CHEMBL617452,BAO_0000019,,
2380,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,4,,,104686,,Autocuration,1,CHEMBL617453,BAO_0000019,,
2381,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,4,,,104686,,Autocuration,1,CHEMBL617660,BAO_0000019,,
2382,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,4,,,104686,,Autocuration,1,CHEMBL617661,BAO_0000019,,
2383,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,4,,,104686,,Autocuration,1,CHEMBL617662,BAO_0000019,,
2384,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,4,,,104686,,Autocuration,1,CHEMBL872919,BAO_0000019,,
2385,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,4,,,104686,,Autocuration,1,CHEMBL617663,BAO_0000019,,
2386,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,4,,,104686,,Autocuration,1,CHEMBL617664,BAO_0000019,,
2387,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,4,,,104686,,Autocuration,1,CHEMBL617665,BAO_0000019,,
2388,,B,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,4,,,104686,,Autocuration,1,CHEMBL617666,BAO_0000019,,
2389,,B,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,4,,,104686,,Autocuration,1,CHEMBL617667,BAO_0000019,,
2390,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,4,,,104686,,Autocuration,1,CHEMBL617668,BAO_0000249,,
2391,,B,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,4,,,104686,,Autocuration,1,CHEMBL617669,BAO_0000249,,
2392,,B,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617670,BAO_0000224,,
2393,,B,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL617671,BAO_0000224,,
2394,,B,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617672,BAO_0000224,,
2395,,B,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,4,,,104686,,Autocuration,1,CHEMBL617673,BAO_0000019,,
2396,,B,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,4,,,104686,,Autocuration,1,CHEMBL617674,BAO_0000224,,
2397,,B,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,4,,,104686,,Autocuration,1,CHEMBL617675,BAO_0000019,,
2398,,B,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,4,,,104686,,Autocuration,1,CHEMBL617676,BAO_0000019,,
2399,,B,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,4,,,104686,,Autocuration,1,CHEMBL617677,BAO_0000019,,
2400,,B,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,5,,,104686,,Autocuration,1,CHEMBL617678,BAO_0000019,,
2401,,B,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,4,,,104686,,Autocuration,1,CHEMBL617679,BAO_0000224,,
2402,,B,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,4,,,104686,,Autocuration,1,CHEMBL617680,BAO_0000224,,
2403,,B,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,4,,,104686,,Autocuration,1,CHEMBL617681,BAO_0000019,,
2404,,B,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,4,,,104686,,Autocuration,1,CHEMBL617682,BAO_0000221,955.0,
2405,,B,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,4,,,104686,,Autocuration,1,CHEMBL617683,BAO_0000224,,
2406,,B,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,4,,,104686,,Autocuration,1,CHEMBL617684,BAO_0000224,,
2407,,B,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,5,,,104686,10116.0,Autocuration,1,CHEMBL617685,BAO_0000224,,
2408,,B,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,4,,,104686,,Autocuration,1,CHEMBL617686,BAO_0000019,,
2409,,B,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,4,,,104686,,Autocuration,1,CHEMBL617687,BAO_0000224,,
2410,,B,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,4,,,104686,,Autocuration,1,CHEMBL617688,BAO_0000224,,
2411,,F,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,,,104686,,Autocuration,1,CHEMBL617689,BAO_0000019,,
2412,,F,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,4,,,104686,,Autocuration,1,CHEMBL617690,BAO_0000019,,
2413,,F,,In vivo,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",4,,,104686,,Autocuration,1,CHEMBL617691,BAO_0000218,,
2414,,F,,In vivo,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",4,,,104686,,Autocuration,1,CHEMBL617692,BAO_0000218,,
2415,,F,,In vivo,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",4,,,104686,,Autocuration,1,CHEMBL617693,BAO_0000218,,
2416,,F,,In vivo,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",4,,,104686,,Autocuration,1,CHEMBL617694,BAO_0000218,,
2417,,B,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,8,,,12687,,Expert,1,CHEMBL857985,BAO_0000221,955.0,
2418,,B,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617695,BAO_0000019,,
2419,,B,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,8,,,12687,,Autocuration,1,CHEMBL617696,BAO_0000019,,
2420,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,8,,,12687,,Autocuration,1,CHEMBL617697,BAO_0000357,,
2421,,B,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,9,,,12687,10116.0,Expert,1,CHEMBL617257,BAO_0000019,,
2422,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617258,BAO_0000357,,
2423,,B,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,8,,,12687,,Expert,1,CHEMBL617259,BAO_0000019,,
2424,,B,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,8,,,12687,,Autocuration,1,CHEMBL617260,BAO_0000357,,
2425,,B,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL617261,BAO_0000357,,
2426,,B,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,8,,,12687,,Autocuration,1,CHEMBL617262,BAO_0000019,,
2427,,B,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,8,,,12687,,Expert,1,CHEMBL617263,BAO_0000019,,
2428,,B,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,8,,,12687,,Autocuration,1,CHEMBL617264,BAO_0000019,,
2429,,B,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL617265,BAO_0000019,,
2430,,B,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617266,BAO_0000249,,
2431,,B,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,8,,,12687,,Autocuration,1,CHEMBL617267,BAO_0000019,,
2432,,B,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,8,,,12687,,Expert,1,CHEMBL617268,BAO_0000019,,
2433,CHO,B,449.0,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,8,,,12687,,Autocuration,1,CHEMBL617269,BAO_0000219,,
2434,,B,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,8,,,12687,,Expert,1,CHEMBL617323,BAO_0000357,,
2435,,B,,,Serotonergic activity of the compound.,8,,,12687,,Autocuration,1,CHEMBL617324,BAO_0000357,,
2436,,B,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,8,,,12687,,Autocuration,1,CHEMBL617325,BAO_0000249,,
2437,,B,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,9,,,12687,10116.0,Expert,1,CHEMBL617326,BAO_0000019,,
2438,,B,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,8,,,12687,,Expert,1,CHEMBL617327,BAO_0000249,,
2439,,F,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617328,BAO_0000019,,
2440,,F,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617329,BAO_0000019,,
2441,,F,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617330,BAO_0000019,,
2442,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,,,12687,,Autocuration,1,CHEMBL617331,BAO_0000357,,
2443,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,8,,,12687,,Autocuration,1,CHEMBL617332,BAO_0000357,,
2444,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,8,,,107,,Expert,1,CHEMBL617333,BAO_0000357,,
2445,,B,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,8,,,107,,Autocuration,1,CHEMBL617334,BAO_0000357,,
2446,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,8,,,107,,Autocuration,1,CHEMBL617335,BAO_0000357,,
2447,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,8,,,107,,Autocuration,1,CHEMBL617336,BAO_0000357,,
2448,,B,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,8,,,107,,Autocuration,1,CHEMBL617337,BAO_0000357,,
2449,,B,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,9,,,107,9606.0,Expert,1,CHEMBL617338,BAO_0000357,,
2450,,B,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617339,BAO_0000357,,
2451,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,8,,,107,,Expert,1,CHEMBL617340,BAO_0000357,,
2452,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,8,,,107,,Autocuration,1,CHEMBL617341,BAO_0000357,,
2453,,B,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,8,,,107,,Expert,1,CHEMBL617342,BAO_0000357,,
2454,,B,,,Affinity for 5-hydroxytryptamine 2A receptor,8,,,107,,Expert,1,CHEMBL617343,BAO_0000357,,
2455,NIH3T3,B,723.0,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,8,,,107,,Expert,1,CHEMBL617344,BAO_0000219,,
2456,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,8,,,107,,Expert,1,CHEMBL617345,BAO_0000357,,
2457,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,8,,,107,,Expert,1,CHEMBL617346,BAO_0000357,,
2458,,B,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617347,BAO_0000357,,
2459,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,8,,,107,,Autocuration,1,CHEMBL617348,BAO_0000357,,
2460,,B,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,8,,,107,,Autocuration,1,CHEMBL617349,BAO_0000357,,
2461,,F,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617350,BAO_0000019,,
2462,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,8,,,107,,Expert,1,CHEMBL872339,BAO_0000357,,
2463,,B,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,8,,,107,,Autocuration,1,CHEMBL617351,BAO_0000357,,
2464,,B,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,8,,,107,,Expert,1,CHEMBL617352,BAO_0000357,,
2465,,B,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617353,BAO_0000357,,
2466,,B,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617354,BAO_0000357,,
2467,,B,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617355,BAO_0000357,,
2468,CHO,B,449.0,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,8,,,107,10090.0,Expert,1,CHEMBL617356,BAO_0000219,,
2469,,B,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617357,BAO_0000357,,
2470,,B,,,Binding affinity at 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617358,BAO_0000357,,
2471,,B,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,8,,,107,,Expert,1,CHEMBL617359,BAO_0000357,,
2472,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,8,,,107,,Autocuration,1,CHEMBL617360,BAO_0000357,,
2473,,B,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,8,,,107,,Autocuration,1,CHEMBL875913,BAO_0000357,,
2474,,B,,,Affinity against 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617361,BAO_0000357,,
2475,,B,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,9,,,107,9606.0,Expert,1,CHEMBL617362,BAO_0000357,,
2476,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,8,,,107,,Autocuration,1,CHEMBL617363,BAO_0000357,,
2477,,B,,,Tested against 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617364,BAO_0000357,,
2478,,B,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,4,,,105075,,Autocuration,1,CHEMBL617365,BAO_0000224,,
2479,,B,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,4,,,105075,,Autocuration,1,CHEMBL617366,BAO_0000224,,
2480,,B,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,4,,,105075,,Autocuration,1,CHEMBL617367,BAO_0000224,,
2481,,B,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,4,,,105075,,Autocuration,1,CHEMBL617368,BAO_0000224,,
2482,,B,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),8,,,107,,Autocuration,1,CHEMBL617369,BAO_0000357,,
2483,HEK293,B,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,9,,,227,9606.0,Expert,1,CHEMBL617370,BAO_0000219,,
2484,CHO,F,449.0,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,9,,,227,9606.0,Expert,1,CHEMBL617371,BAO_0000219,,
2485,,B,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),8,,,227,,Autocuration,1,CHEMBL617372,BAO_0000357,,
2486,,B,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,9,,,227,9606.0,Expert,1,CHEMBL617373,BAO_0000357,,
2487,,F,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,8,,,227,,Autocuration,1,CHEMBL617374,BAO_0000019,,
2488,,F,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,8,,,227,,Autocuration,1,CHEMBL617375,BAO_0000019,,
2489,,F,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,8,,,227,,Autocuration,1,CHEMBL617376,BAO_0000019,,
2490,,F,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,8,,,227,,Autocuration,1,CHEMBL617377,BAO_0000019,,
2491,,F,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,8,,,227,,Autocuration,1,CHEMBL617378,BAO_0000019,,
2492,,F,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,8,,,227,,Autocuration,1,CHEMBL617379,BAO_0000019,,
2493,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,8,,,227,,Autocuration,1,CHEMBL617380,BAO_0000357,,
2494,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,8,,,227,,Autocuration,1,CHEMBL617381,BAO_0000357,,
2495,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,8,,,227,,Autocuration,1,CHEMBL617382,BAO_0000357,,
2496,,B,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617383,BAO_0000357,,
2497,,B,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,8,,,107,,Expert,1,CHEMBL617384,BAO_0000357,,
2498,,B,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,8,,,107,,Expert,1,CHEMBL617385,BAO_0000357,,
2499,,B,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,8,,,107,,Autocuration,1,CHEMBL617386,BAO_0000019,,
2500,,B,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,8,,,107,,Autocuration,1,CHEMBL617387,BAO_0000019,,
2501,NIH3T3,B,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,8,,,107,,Autocuration,1,CHEMBL617388,BAO_0000219,,
2502,CHO,F,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,8,,,107,,Autocuration,1,CHEMBL617389,BAO_0000219,,
2503,CHO,F,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9,,,107,9606.0,Expert,1,CHEMBL617390,BAO_0000219,,
2504,,B,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,4,,,104817,,Autocuration,1,CHEMBL617391,BAO_0000224,,
2505,,B,,,Binding activity radioligand.,8,,,107,,Autocuration,1,CHEMBL617392,BAO_0000357,,
2506,,B,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,8,,,107,,Autocuration,1,CHEMBL617393,BAO_0000019,,
2507,L929,B,307.0,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,8,,,107,,Autocuration,1,CHEMBL617394,BAO_0000219,,
2508,L929,B,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,8,,,107,,Expert,1,CHEMBL617395,BAO_0000219,,
2509,L929,B,307.0,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,8,,,107,,Expert,1,CHEMBL617396,BAO_0000219,,
2510,L929,B,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,8,,,107,,Autocuration,1,CHEMBL617397,BAO_0000219,,
2511,,B,,,Binding affinity against 5-HT2A receptor,8,,,107,,Autocuration,1,CHEMBL617398,BAO_0000357,,
2512,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor,8,,,107,,Autocuration,1,CHEMBL617399,BAO_0000357,,
2513,HEK293,B,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL617400,BAO_0000219,,
2514,HEK293,B,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,8,,,107,,Autocuration,1,CHEMBL617401,BAO_0000219,,
2515,HEK293,B,722.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,9,,,107,9606.0,Expert,1,CHEMBL617402,BAO_0000219,,
2516,HEK293,B,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9,,,107,9606.0,Expert,1,CHEMBL617403,BAO_0000219,,
2517,,B,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,8,,,107,,Expert,1,CHEMBL617404,BAO_0000357,,
2518,HEK293,B,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9,,,107,9606.0,Expert,1,CHEMBL857981,BAO_0000219,,
2519,HEK293,B,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9,,,107,9606.0,Expert,1,CHEMBL617405,BAO_0000219,,
2520,HEK293,B,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,9,,,107,9606.0,Expert,1,CHEMBL617253,BAO_0000219,,
2521,,B,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,8,,,107,,Expert,1,CHEMBL617254,BAO_0000357,,
2522,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL617255,BAO_0000219,,
2523,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL617256,BAO_0000219,,
2524,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,8,,,107,,Autocuration,1,CHEMBL616874,BAO_0000219,,
2525,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,9,,,107,9606.0,Expert,1,CHEMBL616875,BAO_0000219,,
2526,HEK293,B,722.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,8,,,107,,Expert,1,CHEMBL616876,BAO_0000219,,
2527,HEK293,B,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",8,,,107,,Expert,1,CHEMBL616877,BAO_0000219,,
2528,HEK293,B,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,9,,,107,9606.0,Expert,1,CHEMBL616878,BAO_0000219,,
2529,HEK293,B,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,8,,,107,,Expert,1,CHEMBL616879,BAO_0000219,,
2530,HEK293,B,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,8,,,107,,Expert,1,CHEMBL616880,BAO_0000219,,
2531,HEK293,B,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9,,,107,9606.0,Expert,1,CHEMBL616881,BAO_0000219,,
2532,NIH3T3,B,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,8,,,107,,Autocuration,1,CHEMBL616882,BAO_0000219,,
2533,NIH3T3,B,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,8,,,107,,Autocuration,1,CHEMBL616883,BAO_0000219,,
2534,NIH3T3,B,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,8,,,107,,Autocuration,1,CHEMBL616884,BAO_0000219,,
2535,HEK293,B,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,8,,,107,,Autocuration,1,CHEMBL616885,BAO_0000219,,
2536,CHO-K1,B,485.0,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,8,,,107,,Autocuration,1,CHEMBL616886,BAO_0000219,,
2537,CHO-K1,B,485.0,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,8,,,107,,Expert,1,CHEMBL616887,BAO_0000219,,
2538,,B,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,9,,,107,9606.0,Expert,1,CHEMBL616888,BAO_0000357,,
2539,HEK293,B,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,8,,,107,,Autocuration,1,CHEMBL616889,BAO_0000219,,
2540,HEK293,B,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,8,,,107,,Autocuration,1,CHEMBL616890,BAO_0000219,,
2541,CHO,B,449.0,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,9,,,107,9606.0,Expert,1,CHEMBL616891,BAO_0000219,,
2542,HEK293,B,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,8,,,107,,Autocuration,1,CHEMBL616892,BAO_0000219,,
2543,HEK293,B,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",8,,,107,,Autocuration,1,CHEMBL616893,BAO_0000219,,
2544,NIH3T3,F,723.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,8,,,10620,,Autocuration,1,CHEMBL616894,BAO_0000219,,
2545,NIH3T3,B,723.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,8,,,107,,Expert,1,CHEMBL616895,BAO_0000219,,
2546,,F,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,8,,,10620,,Autocuration,1,CHEMBL616896,BAO_0000019,,
2547,,B,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,8,,,10621,,Autocuration,1,CHEMBL617099,BAO_0000357,,
2548,,B,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,8,,,10621,,Autocuration,1,CHEMBL617100,BAO_0000357,,
2549,,B,,,Binding affinity against rabbit aorta 5-HT2A receptor,8,,,107,9986.0,Autocuration,1,CHEMBL884532,BAO_0000357,,
2550,,B,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,8,,,107,9986.0,Expert,1,CHEMBL617101,BAO_0000357,,
2551,,B,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,8,,,107,9986.0,Expert,1,CHEMBL617102,BAO_0000357,,
2552,,B,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,8,,,107,9986.0,Autocuration,1,CHEMBL617103,BAO_0000019,,
2553,,B,,,The compound was tested for binding affinity against 5-HT2A receptor,8,,,107,9986.0,Expert,1,CHEMBL617104,BAO_0000357,,
2554,CHO-K1,B,485.0,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,8,,,10576,,Autocuration,1,CHEMBL857979,BAO_0000219,,
2555,,B,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,8,,,12687,,Autocuration,1,CHEMBL857502,BAO_0000019,,
2556,,B,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,8,,,12687,,Autocuration,1,CHEMBL617105,BAO_0000019,,
2557,,B,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,8,,,12687,,Autocuration,1,CHEMBL858021,BAO_0000019,945.0,
2558,,B,,,Binding affinity for 5-HT 2A in rat stomach fundus,9,,,12687,10116.0,Expert,1,CHEMBL875910,BAO_0000019,945.0,
2559,,B,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,8,,,12687,,Autocuration,1,CHEMBL617106,BAO_0000019,,
2560,NIH3T3,B,723.0,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,8,,,12687,,Expert,1,CHEMBL617107,BAO_0000219,,
2561,,F,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617108,BAO_0000019,,
2562,,F,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617109,BAO_0000019,,
2563,,B,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617110,BAO_0000357,,
2564,,B,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,8,,,12687,,Autocuration,1,CHEMBL617111,BAO_0000357,,
2565,,F,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,9,,,12687,10116.0,Expert,1,CHEMBL617112,BAO_0000019,,
2566,,B,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617113,BAO_0000357,,
2567,,B,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617114,BAO_0000357,,
2568,,B,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617115,BAO_0000357,,
2569,,F,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,8,,,12687,,Autocuration,1,CHEMBL617116,BAO_0000219,,
2570,,F,,,Efficacy at 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617117,BAO_0000019,,
2571,,B,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),8,,,12687,,Autocuration,1,CHEMBL617118,BAO_0000357,,
2572,,B,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),9,,,12687,10116.0,Expert,1,CHEMBL617119,BAO_0000357,,
2573,,B,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),9,,,12687,10116.0,Expert,1,CHEMBL617120,BAO_0000357,,
2574,,F,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,9,,,12687,10116.0,Expert,1,CHEMBL617121,BAO_0000219,,
2575,,F,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,8,,,12687,,Autocuration,1,CHEMBL617122,BAO_0000219,,
2576,,B,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617123,BAO_0000019,,
2577,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,8,,,12687,,Expert,1,CHEMBL617124,BAO_0000019,,
2578,,B,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,8,,,12687,,Expert,1,CHEMBL617600,BAO_0000249,,
2579,,B,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,8,,,12687,,Expert,1,CHEMBL617601,BAO_0000357,,
2580,,B,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,8,,,12687,,Expert,1,CHEMBL882923,BAO_0000019,,
2581,,B,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617602,BAO_0000357,,
2582,,B,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,8,,,12687,,Autocuration,1,CHEMBL617603,BAO_0000019,,
2583,,B,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617604,BAO_0000357,,
2584,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,8,,,12687,,Expert,1,CHEMBL617605,BAO_0000019,,
2585,,B,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,8,,,12687,,Expert,1,CHEMBL617606,BAO_0000019,,
2586,,B,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL617607,BAO_0000019,,
2587,,B,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,,,12687,,Autocuration,1,CHEMBL617455,BAO_0000249,,
2588,,B,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,9,,,12687,10116.0,Expert,1,CHEMBL617456,BAO_0000019,,
2589,,B,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),8,,,12687,,Expert,1,CHEMBL617457,BAO_0000357,,
2590,,B,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL617458,BAO_0000357,,
2591,,B,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,9,,,12687,10116.0,Expert,1,CHEMBL617459,BAO_0000019,,
2592,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,8,,,12687,,Expert,1,CHEMBL617460,BAO_0000357,,
2593,,B,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",8,,,12687,,Expert,1,CHEMBL617461,BAO_0000357,,
2594,,B,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,9,,,12687,10116.0,Expert,1,CHEMBL617462,BAO_0000019,,
2595,,B,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,8,,,12687,,Autocuration,1,CHEMBL617463,BAO_0000357,,
2596,,B,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",8,,,12687,,Autocuration,1,CHEMBL617464,BAO_0000019,,
2597,,B,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",8,,,12687,,Autocuration,1,CHEMBL617465,BAO_0000019,,
2598,,B,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,8,,,12687,,Expert,1,CHEMBL617466,BAO_0000019,,
2599,,B,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,8,,,12687,,Autocuration,1,CHEMBL617467,BAO_0000019,,
2600,,B,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,8,,,12687,,Expert,1,CHEMBL617468,BAO_0000019,,
2601,,B,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,8,,,12687,,Autocuration,1,CHEMBL617469,BAO_0000019,,
2602,,B,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617470,BAO_0000019,,
2603,,B,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,8,,,12687,,Autocuration,1,CHEMBL617471,BAO_0000019,,
2604,NIH3T3,B,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,8,,,12687,,Expert,1,CHEMBL617472,BAO_0000219,,
2605,,B,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,8,,,12687,,Expert,1,CHEMBL617473,BAO_0000357,,
2606,,B,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617474,BAO_0000019,,
2607,,B,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617475,BAO_0000019,,
2608,,B,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,8,,,12687,,Autocuration,1,CHEMBL617476,BAO_0000221,955.0,
2609,,B,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,8,,,12687,,Expert,1,CHEMBL617477,BAO_0000357,,
2610,NIH3T3,B,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Expert,1,CHEMBL617478,BAO_0000219,,
2611,,F,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",8,,,12687,,Autocuration,1,CHEMBL617479,BAO_0000221,,
2612,,B,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,8,,,12687,,Autocuration,1,CHEMBL617480,BAO_0000357,,
2613,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor,8,,,12687,,Expert,1,CHEMBL617481,BAO_0000357,,
2614,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,8,,,12687,,Expert,1,CHEMBL617482,BAO_0000019,,
2615,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,8,,,12687,,Autocuration,1,CHEMBL617483,BAO_0000019,,
2616,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,8,,,12687,,Autocuration,1,CHEMBL621528,BAO_0000357,,
2617,NIH3T3,B,723.0,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL621529,BAO_0000219,,
2618,,B,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,8,,,12687,,Expert,1,CHEMBL621530,BAO_0000357,,
2619,,B,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,,,12687,,Expert,1,CHEMBL621531,BAO_0000357,,
2620,,B,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL621532,BAO_0000019,,
2621,,B,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,8,,,12687,,Expert,1,CHEMBL621533,BAO_0000357,,
2622,CHO,B,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,8,,,12687,,Expert,1,CHEMBL621534,BAO_0000219,,
2623,,B,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,8,,,12687,,Autocuration,1,CHEMBL621535,BAO_0000019,,
2624,,B,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,8,,,12687,,Autocuration,1,CHEMBL621536,BAO_0000357,,
2625,,B,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL621537,BAO_0000357,,
2626,,B,,,Binding affinity for 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL621538,BAO_0000357,,
2627,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,8,,,12687,,Autocuration,1,CHEMBL621539,BAO_0000019,,
2628,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,8,,,12687,,Autocuration,1,CHEMBL621540,BAO_0000019,,
2629,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,8,,,12687,,Autocuration,1,CHEMBL621541,BAO_0000019,,
2630,,B,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,8,,,12687,,Autocuration,1,CHEMBL621542,BAO_0000019,,
2631,,B,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,8,,,12687,,Expert,1,CHEMBL621543,BAO_0000357,,
2632,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,8,,,12687,,Expert,1,CHEMBL621544,BAO_0000357,,
2633,,B,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,9,,,12687,10116.0,Expert,1,CHEMBL621545,BAO_0000357,,
2634,,B,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,,,12687,,Autocuration,1,CHEMBL621546,BAO_0000357,,
2635,,B,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,8,,,12687,,Autocuration,1,CHEMBL621547,BAO_0000357,,
2636,NIH3T3,B,723.0,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Expert,1,CHEMBL618692,BAO_0000219,,
2637,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL618693,BAO_0000357,,
2638,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,8,,,12687,,Autocuration,1,CHEMBL872922,BAO_0000357,,
2639,,B,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,8,,,12687,,Autocuration,1,CHEMBL618694,BAO_0000357,,
2640,,B,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,9,,,12687,10116.0,Expert,1,CHEMBL618695,BAO_0000357,,
2641,,B,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,8,,,12687,,Autocuration,1,CHEMBL618696,BAO_0000357,,
2642,,B,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,8,,,12687,,Expert,1,CHEMBL618697,BAO_0000357,,
2643,,B,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,8,,,12687,,Autocuration,1,CHEMBL618892,BAO_0000357,,
2644,,B,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,8,,,12687,,Autocuration,1,CHEMBL618893,BAO_0000357,,
2645,,B,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL618894,BAO_0000357,,
2646,NIH3T3,B,723.0,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,8,,,12687,,Expert,1,CHEMBL618895,BAO_0000219,,
2647,,B,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,9,,,12687,10116.0,Expert,1,CHEMBL618896,BAO_0000357,,
2648,,B,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,8,,,12687,,Autocuration,1,CHEMBL618897,BAO_0000019,5383.0,
2649,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,8,,,12687,,Autocuration,1,CHEMBL618898,BAO_0000357,,
2650,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,8,,,12687,,Autocuration,1,CHEMBL618899,BAO_0000357,,
2651,,B,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,8,,,12687,,Autocuration,1,CHEMBL618900,BAO_0000357,,
2652,,B,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,8,,,12687,,Autocuration,1,CHEMBL618901,BAO_0000019,,
2653,,B,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL618902,BAO_0000357,,
2654,,B,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL618903,BAO_0000221,10000000.0,
2655,,B,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL618904,BAO_0000357,,
2656,,B,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,8,,,12687,,Autocuration,1,CHEMBL618905,BAO_0000357,,
2657,,B,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,8,,,12687,,Autocuration,1,CHEMBL618906,BAO_0000357,,
2658,NIH3T3,B,723.0,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,8,,,12687,,Expert,1,CHEMBL618907,BAO_0000219,,
2659,,B,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,8,,,12687,,Autocuration,1,CHEMBL618908,BAO_0000019,,
2660,,B,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617909,BAO_0000357,,
2661,,B,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,8,,,12687,,Expert,1,CHEMBL617910,BAO_0000019,,
2662,,B,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,8,,,12687,,Autocuration,1,CHEMBL617911,BAO_0000221,955.0,
2663,,B,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,,,12687,,Autocuration,1,CHEMBL872923,BAO_0000249,,
2664,,B,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,,,12687,,Autocuration,1,CHEMBL617912,BAO_0000249,,
2665,,B,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,9,,,12687,10116.0,Expert,1,CHEMBL617913,BAO_0000019,,
2666,,B,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,,,12687,,Expert,1,CHEMBL617914,BAO_0000249,,
2667,,B,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,,,12687,,Autocuration,1,CHEMBL617915,BAO_0000249,,
2668,,B,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,8,,,12687,,Autocuration,1,CHEMBL617916,BAO_0000249,,
2669,,B,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,9,,,12687,10116.0,Expert,1,CHEMBL617917,BAO_0000019,,
2670,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,8,,,12687,,Expert,1,CHEMBL617918,BAO_0000019,,
2671,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,8,,,12687,,Autocuration,1,CHEMBL617919,BAO_0000019,,
2672,,B,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,9,,,12687,10116.0,Expert,1,CHEMBL617920,BAO_0000019,,
2673,,B,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,9,,,12687,10116.0,Expert,1,CHEMBL617921,BAO_0000019,,
2674,,B,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",5,,,105102,10116.0,Expert,1,CHEMBL617922,BAO_0000224,,
2675,,B,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,8,,,12687,,Autocuration,1,CHEMBL617923,BAO_0000357,,
2676,,B,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,8,,,12687,,Autocuration,1,CHEMBL617924,BAO_0000357,,
2677,,B,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,8,,,12687,,Autocuration,1,CHEMBL617925,BAO_0000357,,
2678,,B,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,9,,,12687,10116.0,Expert,1,CHEMBL617926,BAO_0000357,,
2679,,B,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,8,,,12687,,Autocuration,1,CHEMBL617927,BAO_0000357,,
2680,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,8,,,12687,,Autocuration,1,CHEMBL617928,BAO_0000357,,
2681,,B,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617929,BAO_0000019,,
2682,,B,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,8,,,12687,,Expert,1,CHEMBL617930,BAO_0000019,,
2683,,B,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,8,,,12687,,Autocuration,1,CHEMBL617931,BAO_0000019,,
2684,,B,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,8,,,12687,,Autocuration,1,CHEMBL617932,BAO_0000019,,
2685,CHO,B,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,8,,,12687,,Autocuration,1,CHEMBL617933,BAO_0000219,,
2686,,B,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,8,,,12687,,Autocuration,1,CHEMBL617934,BAO_0000019,,
2687,,B,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,8,,,12687,,Autocuration,1,CHEMBL617935,BAO_0000019,,
2688,,B,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,8,,,12687,,Autocuration,1,CHEMBL617936,BAO_0000357,,
2689,,B,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,8,,,12687,,Autocuration,1,CHEMBL617937,BAO_0000019,,
2690,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,8,,,12687,,Autocuration,1,CHEMBL617938,BAO_0000019,,
2691,,B,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,8,,,12687,,Autocuration,1,CHEMBL617939,BAO_0000218,,
2692,,B,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,8,,,12687,,Autocuration,1,CHEMBL617940,BAO_0000218,,
2693,,B,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,8,,,12687,,Autocuration,1,CHEMBL617941,BAO_0000218,,
2694,,B,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,8,,,12687,,Expert,1,CHEMBL617942,BAO_0000357,,
2695,,B,,,Ratio of pKi of 5-HT2A to that of D2 receptor,8,,,12687,,Expert,1,CHEMBL617943,BAO_0000357,,
2696,,B,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,4,,,105093,,Expert,1,CHEMBL617944,BAO_0000224,,
2697,,B,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,4,,,105093,,Expert,1,CHEMBL617945,BAO_0000224,,
2698,,B,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,4,,,105075,,Expert,1,CHEMBL617946,BAO_0000224,,
2699,,B,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,8,,,12687,,Autocuration,1,CHEMBL617947,BAO_0000357,,
2700,,B,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,8,,,12687,,Expert,1,CHEMBL617948,BAO_0000357,,
2701,,F,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,8,,,12687,,Autocuration,1,CHEMBL858116,BAO_0000019,,
2702,,F,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,8,,,12687,,Autocuration,1,CHEMBL617949,BAO_0000019,,
2703,,F,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,8,,,12687,,Autocuration,1,CHEMBL617950,BAO_0000019,,
2704,,F,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,8,,,12687,,Expert,1,CHEMBL617951,BAO_0000019,1515.0,
2705,,F,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,8,,,12687,,Expert,1,CHEMBL617952,BAO_0000019,1515.0,
2706,,F,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,8,,,12687,,Autocuration,1,CHEMBL617953,BAO_0000019,1515.0,
2707,,B,,,Binding activity radioligand.,8,,,12687,,Autocuration,1,CHEMBL617954,BAO_0000357,,
2708,,B,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,8,,,12687,,Expert,1,CHEMBL617955,BAO_0000019,,
2709,,B,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,8,,,12687,,Autocuration,1,CHEMBL857071,BAO_0000019,,
2710,,B,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,8,,,12687,,Expert,1,CHEMBL617270,BAO_0000019,,
2711,N1E-115,B,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,8,,,12687,,Autocuration,1,CHEMBL617271,BAO_0000219,,
2712,N1E-115,B,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,8,,,12687,,Autocuration,1,CHEMBL617272,BAO_0000219,,
2713,,B,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,8,,,12687,,Autocuration,1,CHEMBL617273,BAO_0000019,,
2714,,F,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,9,,,12687,10116.0,Expert,1,CHEMBL617274,BAO_0000019,,
2715,,B,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617275,BAO_0000357,,
2716,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617276,BAO_0000357,,
2717,,B,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617277,BAO_0000357,,
2718,,B,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,8,,,108,,Expert,1,CHEMBL617278,BAO_0000019,,
2719,,B,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,8,,,108,,Expert,1,CHEMBL617279,BAO_0000019,,
2720,,B,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,8,,,108,,Expert,1,CHEMBL617280,BAO_0000019,,
2721,,B,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617281,BAO_0000357,,
2722,,B,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617282,BAO_0000357,,
2723,,B,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,8,,,108,,Expert,1,CHEMBL617283,BAO_0000019,,
2724,,B,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,8,,,108,,Expert,1,CHEMBL617284,BAO_0000019,,
2725,HEK293,B,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL617285,BAO_0000219,,
2726,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617286,BAO_0000019,,
2727,,B,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,9,,,108,9606.0,Expert,1,CHEMBL617287,BAO_0000357,,
2728,,B,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,8,,,108,,Expert,1,CHEMBL617288,BAO_0000357,,
2729,,B,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,8,,,108,,Autocuration,1,CHEMBL617289,BAO_0000357,,
2730,,B,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL872917,BAO_0000357,,
2731,,B,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,8,,,108,,Autocuration,1,CHEMBL617290,BAO_0000357,,
2732,CHO,B,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,8,,,108,,Autocuration,1,CHEMBL617291,BAO_0000219,,
2733,CHO,B,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,8,,,108,,Autocuration,1,CHEMBL617292,BAO_0000219,,
2734,NIH3T3,B,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,8,,,108,,Autocuration,1,CHEMBL617293,BAO_0000219,,
2735,CHO,F,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9,,,108,9606.0,Expert,1,CHEMBL617294,BAO_0000219,,
2736,,B,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,8,,,108,,Expert,1,CHEMBL617295,BAO_0000019,,
2737,,B,,,Binding activity radioligand.,8,,,108,,Autocuration,1,CHEMBL617296,BAO_0000357,,
2738,,B,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,8,,,108,,Autocuration,1,CHEMBL617297,BAO_0000019,,
2739,CHO,B,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,8,,,108,,Expert,1,CHEMBL617298,BAO_0000219,,
2740,CHO,B,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,8,,,108,,Expert,1,CHEMBL617299,BAO_0000219,,
2741,CHO,B,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,8,,,108,,Autocuration,1,CHEMBL617300,BAO_0000219,,
2742,,B,,,Binding affinity against 5-HT2C receptor,8,,,108,,Autocuration,1,CHEMBL617454,BAO_0000357,,
2743,HEK293,B,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL617505,BAO_0000219,,
2744,HEK293,B,722.0,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,9,,,108,9606.0,Expert,1,CHEMBL617506,BAO_0000219,,
2745,HEK293,B,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,9,,,108,9606.0,Expert,1,CHEMBL617507,BAO_0000219,,
2746,,B,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,8,,,108,,Expert,1,CHEMBL617508,BAO_0000357,,
2747,HEK293,B,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,9,,,108,9606.0,Expert,1,CHEMBL857982,BAO_0000219,,
2748,HEK293,B,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,9,,,108,9606.0,Expert,1,CHEMBL617509,BAO_0000219,,
2749,HEK293,B,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,9,,,108,9606.0,Expert,1,CHEMBL617510,BAO_0000219,,
2750,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,8,,,108,,Autocuration,1,CHEMBL617511,BAO_0000357,,
2751,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL617512,BAO_0000219,,
2752,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL617749,BAO_0000219,,
2753,HEK293,B,722.0,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,8,,,108,,Autocuration,1,CHEMBL617750,BAO_0000219,,
2754,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,8,,,108,,Autocuration,1,CHEMBL617751,BAO_0000219,,
2755,HEK293,B,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,8,,,108,,Expert,1,CHEMBL617752,BAO_0000219,,
2756,HEK293,B,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",8,,,108,,Autocuration,1,CHEMBL617753,BAO_0000219,,
2757,HEK293,B,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",8,,,108,,Expert,1,CHEMBL617754,BAO_0000219,,
2758,HEK293,B,722.0,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,9,,,108,9606.0,Expert,1,CHEMBL617755,BAO_0000219,,
2759,HEK293,B,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",8,,,108,,Autocuration,1,CHEMBL617756,BAO_0000219,,
2760,HEK293,B,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,8,,,108,,Expert,1,CHEMBL617757,BAO_0000219,,
2761,HEK293,B,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,8,,,108,,Expert,1,CHEMBL617758,BAO_0000219,,
2762,NIH3T3,B,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,8,,,108,,Autocuration,1,CHEMBL617759,BAO_0000219,,
2763,HEK293,B,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,8,,,108,,Autocuration,1,CHEMBL617760,BAO_0000219,,
2764,CHO-K1,B,485.0,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,8,,,108,,Expert,1,CHEMBL617761,BAO_0000219,,
2765,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor,9,,,108,9606.0,Expert,1,CHEMBL617762,BAO_0000357,,
2766,,B,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617763,BAO_0000357,,
2767,HEK293,B,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,8,,,108,,Autocuration,1,CHEMBL857983,BAO_0000219,,
2768,HEK293,B,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,8,,,108,,Autocuration,1,CHEMBL617764,BAO_0000219,,
2769,HeLa,B,308.0,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,8,,,108,,Autocuration,1,CHEMBL617765,BAO_0000219,,
2770,,F,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,8,,,108,,Autocuration,1,CHEMBL617766,BAO_0000019,,
2771,,F,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,8,,,108,,Autocuration,1,CHEMBL617767,BAO_0000221,10000000.0,
2772,HEK293,B,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,8,,,108,,Autocuration,1,CHEMBL617768,BAO_0000219,,
2773,HEK293,B,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",8,,,108,,Autocuration,1,CHEMBL617769,BAO_0000219,,
2774,,B,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,8,,,11864,,Autocuration,1,CHEMBL858023,BAO_0000357,,
2775,,B,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,8,,,11864,,Autocuration,1,CHEMBL617770,BAO_0000019,945.0,
2776,,B,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,8,,,11864,,Autocuration,1,CHEMBL617771,BAO_0000019,945.0,
2777,A9,F,625.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,8,,,11864,,Autocuration,1,CHEMBL617772,BAO_0000219,,
2778,NIH3T3,B,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,8,,,11864,,Autocuration,1,CHEMBL617773,BAO_0000219,,
2779,NIH3T3,B,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,8,,,11864,,Autocuration,1,CHEMBL617850,BAO_0000219,,
2780,NIH3T3,B,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,8,,,11864,,Autocuration,1,CHEMBL617851,BAO_0000219,,
2781,,F,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,8,,,11864,,Autocuration,1,CHEMBL617852,BAO_0000019,,
2782,,B,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,8,,,12689,10090.0,Autocuration,1,CHEMBL858024,BAO_0000019,945.0,
2783,,B,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,9,,,12689,10116.0,Expert,1,CHEMBL617853,BAO_0000019,945.0,
2784,,B,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,8,,,108,,Expert,1,CHEMBL617854,BAO_0000357,,
2785,,B,,,Binding affinity for 5-hydroxytryptamine 2C receptor,8,,,108,9823.0,Expert,1,CHEMBL873477,BAO_0000357,,
2786,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,8,,,108,,Expert,1,CHEMBL617855,BAO_0000357,,
2787,,B,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,8,,,108,,Expert,1,CHEMBL617856,BAO_0000019,,
2788,,B,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,8,,,108,,Autocuration,1,CHEMBL617857,BAO_0000019,,
2789,,B,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,8,,,108,,Autocuration,1,CHEMBL617858,BAO_0000249,,
2790,,B,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617859,BAO_0000357,,
2791,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617860,BAO_0000357,,
2792,,B,,,Binding activity radioligand.,8,,,108,,Autocuration,1,CHEMBL617861,BAO_0000357,,
2793,,B,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,8,,,108,,Expert,1,CHEMBL617862,BAO_0000019,,
2794,,B,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,8,,,108,,Autocuration,1,CHEMBL617863,BAO_0000019,,
2795,,B,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,8,,,108,,Autocuration,1,CHEMBL617864,BAO_0000249,,
2796,,B,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,8,,,108,,Autocuration,1,CHEMBL617649,BAO_0000249,,
2797,,F,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,8,,,108,9823.0,Expert,1,CHEMBL617650,BAO_0000019,,
2798,,F,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,8,,,108,9823.0,Expert,1,CHEMBL617651,BAO_0000019,,
2799,,B,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,8,,,108,9823.0,Autocuration,1,CHEMBL617652,BAO_0000357,,
2800,,B,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,8,,,108,9823.0,Autocuration,1,CHEMBL857072,BAO_0000019,,
2801,,B,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,8,,,108,9823.0,Autocuration,1,CHEMBL617653,BAO_0000357,,
2802,,B,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,8,,,12687,,Autocuration,1,CHEMBL617654,BAO_0000019,,
2803,,F,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,8,,,12689,,Autocuration,1,CHEMBL617655,BAO_0000019,,
2804,,B,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,8,,,12689,,Expert,1,CHEMBL617656,BAO_0000357,,
2805,,B,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,8,,,12689,,Autocuration,1,CHEMBL617657,BAO_0000357,,
2806,,B,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,8,,,12689,,Autocuration,1,CHEMBL617658,BAO_0000357,,
2807,,B,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,9,,,12689,10116.0,Expert,1,CHEMBL617659,BAO_0000357,,
2808,,B,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,9,,,12689,10116.0,Expert,1,CHEMBL617838,BAO_0000357,,
2809,,B,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,9,,,12689,10116.0,Expert,1,CHEMBL617839,BAO_0000249,,
2810,,B,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,8,,,12689,,Autocuration,1,CHEMBL617840,BAO_0000357,,
2811,,B,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,8,,,12689,,Autocuration,1,CHEMBL617841,BAO_0000019,,
2812,,B,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,8,,,12689,,Autocuration,1,CHEMBL875915,BAO_0000019,,
2813,,B,,In vitro,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,8,,,12689,,Expert,1,CHEMBL617842,BAO_0000219,,
2814,NIH3T3,B,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,8,,,12689,,Expert,1,CHEMBL617843,BAO_0000219,,
2815,,B,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,8,,,12689,,Expert,1,CHEMBL617844,BAO_0000357,,
2816,,B,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,8,,,12689,,Expert,1,CHEMBL617845,BAO_0000357,,
2817,NIH3T3,B,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,8,,,12689,,Expert,1,CHEMBL617846,BAO_0000219,,
2818,,B,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,8,,,12689,,Autocuration,1,CHEMBL617847,BAO_0000357,,
2819,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor,8,,,12689,,Expert,1,CHEMBL617848,BAO_0000357,,
2820,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,8,,,12689,,Autocuration,1,CHEMBL617849,BAO_0000357,,
2821,,B,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,,,12689,,Expert,1,CHEMBL621507,BAO_0000357,,
2822,,B,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,8,,,12689,,Expert,1,CHEMBL621508,BAO_0000357,,
2823,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,8,,,12689,,Autocuration,1,CHEMBL621509,BAO_0000019,,
2824,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,8,,,12689,,Autocuration,1,CHEMBL621510,BAO_0000019,,
2825,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,8,,,12689,,Autocuration,1,CHEMBL621511,BAO_0000019,,
2826,A9,B,625.0,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,8,,,12689,,Expert,1,CHEMBL621512,BAO_0000219,,
2827,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,8,,,12689,,Autocuration,1,CHEMBL621513,BAO_0000357,,
2828,,B,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,8,,,12689,,Expert,1,CHEMBL621514,BAO_0000357,,
2829,,B,,In vitro,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,8,,,12689,,Expert,1,CHEMBL621515,BAO_0000219,,
2830,,B,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,8,,,12689,,Autocuration,1,CHEMBL621516,BAO_0000219,,
2831,,B,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,8,,,12689,,Autocuration,1,CHEMBL621517,BAO_0000019,5383.0,
2832,,B,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,8,,,12689,,Autocuration,1,CHEMBL621518,BAO_0000357,,
2833,,B,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,8,,,12689,,Autocuration,1,CHEMBL621519,BAO_0000019,,
2834,,B,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,8,,,12689,,Autocuration,1,CHEMBL621520,BAO_0000357,,
2835,,B,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,8,,,12689,,Autocuration,1,CHEMBL621521,BAO_0000357,,
2836,,B,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,8,,,12689,,Autocuration,1,CHEMBL621522,BAO_0000357,,
2837,,B,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,8,,,12689,,Expert,1,CHEMBL621523,BAO_0000219,,
2838,,B,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,8,,,12689,,Autocuration,1,CHEMBL621524,BAO_0000357,,
2839,,B,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,9,,,12689,10116.0,Expert,1,CHEMBL621525,BAO_0000357,,
2840,,B,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,8,,,12689,,Autocuration,1,CHEMBL872921,BAO_0000357,,
2841,,B,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,8,,,12689,,Autocuration,1,CHEMBL621526,BAO_0000357,,
2842,,B,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,8,,,12689,,Expert,1,CHEMBL621527,BAO_0000219,,
2843,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,9,,,12689,10116.0,Expert,1,CHEMBL617865,BAO_0000019,,
2844,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,8,,,12689,,Autocuration,1,CHEMBL617866,BAO_0000357,,
2845,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,8,,,12689,,Autocuration,1,CHEMBL617867,BAO_0000019,,
2846,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,8,,,12689,,Autocuration,1,CHEMBL617487,BAO_0000357,,
2847,,B,,,Binding affinity for 5-hydroxytryptamine 2C receptor,8,,,12689,,Expert,1,CHEMBL617488,BAO_0000357,,
2848,,B,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,8,,,12689,,Autocuration,1,CHEMBL617489,BAO_0000357,,
2849,,B,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,8,,,12689,,Autocuration,1,CHEMBL617490,BAO_0000019,,
2850,,B,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,8,,,12689,,Autocuration,1,CHEMBL617491,BAO_0000019,,
2851,,B,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,8,,,12689,,Autocuration,1,CHEMBL617492,BAO_0000019,,
2852,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,8,,,12689,,Autocuration,1,CHEMBL617493,BAO_0000019,,
2853,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,8,,,12689,,Autocuration,1,CHEMBL617494,BAO_0000357,,
2854,,B,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,9,,,12689,10116.0,Expert,1,CHEMBL617495,BAO_0000019,,
2855,,B,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,8,,,12689,,Autocuration,1,CHEMBL617496,BAO_0000357,,
2856,CHO-K1,B,485.0,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,8,,,12689,,Autocuration,1,CHEMBL617497,BAO_0000219,,
2857,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,,,12689,,Autocuration,1,CHEMBL617498,BAO_0000357,,
2858,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,8,,,12689,,Autocuration,1,CHEMBL617499,BAO_0000357,,
2859,,F,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,8,,,12689,,Autocuration,1,CHEMBL617500,BAO_0000019,,
2860,,B,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617501,BAO_0000357,,
2861,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,8,,,108,,Expert,1,CHEMBL617502,BAO_0000357,,
2862,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,8,,,227,,Autocuration,1,CHEMBL617503,BAO_0000357,,
2863,,B,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,8,,,227,,Autocuration,1,CHEMBL617504,BAO_0000357,,
2864,,B,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,8,,,227,,Autocuration,1,CHEMBL617406,BAO_0000357,,
2865,,B,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,9,,,227,9606.0,Expert,1,CHEMBL617407,BAO_0000019,,
2866,,B,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,8,,,227,,Autocuration,1,CHEMBL617408,BAO_0000357,,
2867,,B,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,8,,,227,,Autocuration,1,CHEMBL617409,BAO_0000357,,
2868,,B,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,8,,,227,,Autocuration,1,CHEMBL617410,BAO_0000357,,
2869,,B,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,8,,,227,,Autocuration,1,CHEMBL617411,BAO_0000357,,
2870,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,8,,,227,,Autocuration,1,CHEMBL617412,BAO_0000019,,
2871,,B,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,9,,,227,9606.0,Expert,1,CHEMBL617774,BAO_0000357,,
2872,HEK293,B,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,9,,,227,9606.0,Expert,1,CHEMBL617775,BAO_0000219,,
2873,HEK293,B,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,9,,,227,9606.0,Expert,1,CHEMBL617776,BAO_0000219,,
2874,CHO,F,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9,,,227,9606.0,Expert,1,CHEMBL617777,BAO_0000219,,
2875,CHO,F,449.0,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9,,,227,9606.0,Expert,1,CHEMBL617778,BAO_0000219,,
2876,HEK293,B,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",8,,,227,,Autocuration,1,CHEMBL617779,BAO_0000219,,
2877,HEK293,B,722.0,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,8,,,227,,Expert,1,CHEMBL617780,BAO_0000219,,
2878,HEK293,B,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",8,,,227,,Autocuration,1,CHEMBL617781,BAO_0000219,,
2879,HEK293,B,722.0,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,9,,,227,9606.0,Expert,1,CHEMBL617782,BAO_0000219,,
2880,HEK293,B,722.0,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,9,,,227,9606.0,Expert,1,CHEMBL617783,BAO_0000219,,
2881,,B,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,8,,,227,,Autocuration,1,CHEMBL617784,BAO_0000357,,
2882,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,8,,,227,,Autocuration,1,CHEMBL617785,BAO_0000219,,
2883,HEK293,B,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,8,,,227,,Expert,1,CHEMBL857984,BAO_0000219,,
2884,HEK293,B,722.0,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,8,,,227,,Expert,1,CHEMBL617786,BAO_0000219,,
2885,HEK293,B,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,8,,,227,,Expert,1,CHEMBL617787,BAO_0000219,,
2886,HEK293,B,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,9,,,227,9606.0,Expert,1,CHEMBL617788,BAO_0000219,,
2887,HEK293,B,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,9,,,227,9606.0,Expert,1,CHEMBL617789,BAO_0000219,,
2888,HEK293,B,722.0,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,8,,,227,,Autocuration,1,CHEMBL617790,BAO_0000219,,
2889,CHO-K1,B,485.0,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,8,,,227,,Expert,1,CHEMBL617791,BAO_0000219,,
2890,,B,,,Binding affinity against 5-hydroxytryptamine 2B receptor,8,,,227,,Expert,1,CHEMBL617608,BAO_0000357,,
2891,HEK293,B,722.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,8,,,227,,Autocuration,1,CHEMBL617609,BAO_0000219,,
2892,HEK293,B,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,8,,,227,,Autocuration,1,CHEMBL617610,BAO_0000219,,
2893,HEK293,B,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,8,,,227,,Autocuration,1,CHEMBL617611,BAO_0000219,,
2894,HEK293,B,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",8,,,227,,Autocuration,1,CHEMBL617612,BAO_0000219,,
2895,HEK293,B,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",8,,,227,,Autocuration,1,CHEMBL617613,BAO_0000219,,
2896,,B,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,8,,,227,9986.0,Autocuration,1,CHEMBL617614,BAO_0000019,,
2897,,B,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,8,,,12688,,Expert,1,CHEMBL617615,BAO_0000019,945.0,
2898,,B,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,8,,,12688,,Expert,1,CHEMBL858114,BAO_0000357,945.0,
2899,,B,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,8,,,12688,,Autocuration,1,CHEMBL617616,BAO_0000357,945.0,
2900,,F,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,9,,,12688,10116.0,Expert,1,CHEMBL617617,BAO_0000019,945.0,
2901,,F,,,Antagonistic against 5-hydroxytryptamine 2B receptor,9,,,12688,10116.0,Expert,1,CHEMBL875914,BAO_0000019,,
2902,,F,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,8,,,12688,,Autocuration,1,CHEMBL617618,BAO_0000019,945.0,
2903,,B,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,9,,,12688,10116.0,Expert,1,CHEMBL617619,BAO_0000357,945.0,
2904,,F,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,8,,,12688,,Autocuration,1,CHEMBL617620,BAO_0000019,,
2905,,F,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,8,,,12688,,Autocuration,1,CHEMBL617621,BAO_0000019,,
2906,,F,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,8,,,12688,,Autocuration,1,CHEMBL617622,BAO_0000019,,
2907,,B,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,9,,,12688,10116.0,Expert,1,CHEMBL617623,BAO_0000357,945.0,
2908,,B,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,9,,,12688,10116.0,Expert,1,CHEMBL617624,BAO_0000357,945.0,
2909,,B,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,9,,,12688,10116.0,Expert,1,CHEMBL617625,BAO_0000357,945.0,
2910,,B,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,9,,,12688,10116.0,Expert,1,CHEMBL617626,BAO_0000357,945.0,
2911,,F,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,8,,,12688,,Autocuration,1,CHEMBL617627,BAO_0000019,945.0,
2912,,F,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,8,,,12688,,Expert,1,CHEMBL617628,BAO_0000019,945.0,
2913,,F,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,8,,,12688,,Autocuration,1,CHEMBL617629,BAO_0000019,945.0,
2914,,F,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,8,,,12688,,Autocuration,1,CHEMBL858115,BAO_0000019,945.0,
2915,,F,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,9,,,12688,10116.0,Expert,1,CHEMBL617630,BAO_0000019,945.0,
2916,,F,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,8,,,12688,,Autocuration,1,CHEMBL617631,BAO_0000019,1515.0,
2917,,B,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,8,,,12688,,Autocuration,1,CHEMBL617632,BAO_0000357,,
2918,,B,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,8,,,12688,,Expert,1,CHEMBL617633,BAO_0000357,,
2919,,B,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,8,,,12688,,Autocuration,1,CHEMBL617634,BAO_0000357,,
2920,,B,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,8,,,12688,,Autocuration,1,CHEMBL617635,BAO_0000357,,
2922,,F,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,9,,,12688,10116.0,Autocuration,1,CHEMBL617637,BAO_0000019,945.0,
2923,,B,,,Binding affinity against 5-hydroxytryptamine 1A receptor,8,,,227,,Autocuration,1,CHEMBL617638,BAO_0000357,,
2924,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,8,,,227,,Autocuration,1,CHEMBL617639,BAO_0000357,,
2925,,B,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,8,,,227,,Autocuration,1,CHEMBL617640,BAO_0000357,,
2926,,B,,,Evaluated for the binding affinity to 5-HT 2B receptor,8,,,227,,Autocuration,1,CHEMBL617641,BAO_0000357,,
2927,,B,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,8,,,227,,Autocuration,1,CHEMBL617642,BAO_0000357,,
2928,,B,,,Binding affinities against 5-hydroxytryptamine 2B receptor,8,,,227,,Autocuration,1,CHEMBL617643,BAO_0000357,,
2929,,B,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,8,,,227,,Autocuration,1,CHEMBL617644,BAO_0000357,,
2930,,B,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,8,,,227,,Autocuration,1,CHEMBL617645,BAO_0000357,,
2931,,B,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,8,,,108,,Expert,1,CHEMBL617646,BAO_0000357,,
2932,,B,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,8,,,108,9913.0,Autocuration,1,CHEMBL617647,BAO_0000357,,
2933,,B,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,8,,,108,9913.0,Autocuration,1,CHEMBL617648,BAO_0000357,,
2934,,B,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,8,,,108,9913.0,Autocuration,1,CHEMBL617875,BAO_0000357,,
2935,,B,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,8,,,108,9913.0,Autocuration,1,CHEMBL617876,BAO_0000357,,
2936,,B,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,8,,,108,9913.0,Expert,1,CHEMBL617877,BAO_0000357,,
2937,,B,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,8,,,108,9913.0,Expert,1,CHEMBL617878,BAO_0000357,,
2938,,B,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,8,,,108,9913.0,Autocuration,1,CHEMBL617879,BAO_0000357,,
2939,,B,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,8,,,108,10141.0,Autocuration,1,CHEMBL617880,BAO_0000019,,
2940,,B,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,9,,,20033,10141.0,Intermediate,1,CHEMBL617881,BAO_0000357,2435.0,
2941,,B,,,Binding affinity against 5-HT1A receptor,8,,,51,,Autocuration,1,CHEMBL857073,BAO_0000357,,
2942,CHO,F,449.0,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,8,,,108,,Expert,1,CHEMBL617882,BAO_0000219,,
2943,CHO,F,449.0,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,9,,,108,9606.0,Expert,1,CHEMBL617883,BAO_0000219,,
2944,,F,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,8,,,108,,Autocuration,1,CHEMBL617884,BAO_0000219,,
2945,CHO,B,449.0,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,8,,,108,,Autocuration,1,CHEMBL617885,BAO_0000219,,
2946,CHO,B,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",8,,,108,,Autocuration,1,CHEMBL617886,BAO_0000219,,
2947,,B,,,Inhibition of human 5-hydroxytryptamine 2C receptor,9,,,108,9606.0,Expert,1,CHEMBL617887,BAO_0000357,,
2948,,B,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),8,,,108,,Autocuration,1,CHEMBL617888,BAO_0000357,,
2949,,B,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,8,,,108,,Autocuration,1,CHEMBL617889,BAO_0000019,,
2950,,B,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617890,BAO_0000357,,
2951,,B,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,8,,,108,,Autocuration,1,CHEMBL617891,BAO_0000357,,
2952,,B,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,8,,,108,,Autocuration,1,CHEMBL617892,BAO_0000357,,
2953,CHO,B,449.0,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,8,,,108,,Expert,1,CHEMBL617893,BAO_0000219,,
2954,CHO,B,449.0,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,8,,,108,,Expert,1,CHEMBL617894,BAO_0000219,,
2955,CHO,B,449.0,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,8,,,108,,Expert,1,CHEMBL617895,BAO_0000219,,
2956,CHO,B,449.0,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL617896,BAO_0000219,,
2957,,B,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,9,,,108,9606.0,Expert,1,CHEMBL617897,BAO_0000357,,
2958,,F,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,8,,,108,,Autocuration,1,CHEMBL617898,BAO_0000019,,
2959,,F,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,8,,,108,,Autocuration,1,CHEMBL617899,BAO_0000019,,
2960,CHO,B,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,8,,,108,10116.0,Expert,1,CHEMBL617900,BAO_0000219,,
2961,,F,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,8,,,108,,Autocuration,1,CHEMBL617901,BAO_0000019,,
2962,,F,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,8,,,108,,Autocuration,1,CHEMBL617902,BAO_0000019,,
2963,,F,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL617903,BAO_0000019,,
2964,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,8,,,108,,Autocuration,1,CHEMBL617904,BAO_0000357,,
2965,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL617905,BAO_0000357,,
2966,,B,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,8,,,108,,Autocuration,1,CHEMBL617906,BAO_0000357,,
2967,,B,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,8,,,108,,Autocuration,1,CHEMBL617907,BAO_0000357,,
2968,,B,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,8,,,108,,Autocuration,1,CHEMBL617908,BAO_0000357,,
2969,CHO,B,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,8,,,108,,Expert,1,CHEMBL620617,BAO_0000219,,
2970,,B,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,9,,,108,9606.0,Expert,1,CHEMBL620618,BAO_0000019,,
2971,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,8,,,108,,Expert,1,CHEMBL620619,BAO_0000357,,
2972,,B,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,9,,,108,9606.0,Expert,1,CHEMBL620620,BAO_0000357,,
2973,,B,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,8,,,108,,Autocuration,1,CHEMBL620621,BAO_0000357,,
2974,,B,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,7,,,104698,10116.0,Autocuration,1,CHEMBL872920,BAO_0000249,,
2975,,B,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,6,,,104698,,Autocuration,1,CHEMBL620622,BAO_0000223,,
2976,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,7,,,104698,10116.0,Autocuration,1,CHEMBL620623,BAO_0000019,,
2977,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,6,,,104698,,Autocuration,1,CHEMBL620624,BAO_0000019,,
2978,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,6,,,104698,,Autocuration,1,CHEMBL620625,BAO_0000019,,
2979,,B,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,6,,,104698,,Autocuration,1,CHEMBL620626,BAO_0000219,,
2980,,B,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,6,,,104698,,Autocuration,1,CHEMBL621307,BAO_0000019,,
2981,,B,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,6,,,104698,,Autocuration,1,CHEMBL621308,BAO_0000019,,
2982,,B,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,6,,,104698,,Autocuration,1,CHEMBL621309,BAO_0000223,,
2983,,B,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,6,,,104698,,Autocuration,1,CHEMBL621310,BAO_0000223,,
2984,,B,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,6,,,104698,,Autocuration,1,CHEMBL621311,BAO_0000223,,
2985,,B,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",6,,,104698,,Autocuration,1,CHEMBL621502,BAO_0000249,,
2986,,B,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",6,,,104698,,Autocuration,1,CHEMBL621503,BAO_0000249,,
2987,,B,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,6,,,104698,,Autocuration,1,CHEMBL621504,BAO_0000249,,
2988,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,6,,,104698,,Autocuration,1,CHEMBL621505,BAO_0000223,,
2989,,B,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,6,,,104698,,Autocuration,1,CHEMBL621506,BAO_0000019,,
2990,,B,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,6,,,104698,,Autocuration,1,CHEMBL619781,BAO_0000223,,
2991,,B,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,6,,,104698,,Autocuration,1,CHEMBL619782,BAO_0000223,,
2992,,B,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,6,,,104698,,Autocuration,1,CHEMBL619783,BAO_0000019,,
2993,,B,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL619784,BAO_0000019,,
2994,,B,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,6,,,104698,,Autocuration,1,CHEMBL619785,BAO_0000249,,
2995,,B,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,6,,,104698,,Autocuration,1,CHEMBL619786,BAO_0000223,,
2996,,B,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,6,,,104698,,Autocuration,1,CHEMBL619787,BAO_0000019,,
2997,,B,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,6,,,104698,,Autocuration,1,CHEMBL872925,BAO_0000019,,
2998,,B,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,6,,,104698,,Autocuration,1,CHEMBL619788,BAO_0000019,,
2999,,B,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,6,,,104698,,Autocuration,1,CHEMBL619789,BAO_0000249,,
3000,,B,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,6,,,104698,,Autocuration,1,CHEMBL619790,BAO_0000249,,
3001,,B,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,6,,,104698,,Autocuration,1,CHEMBL619791,BAO_0000019,,
3002,,B,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,6,,,104698,,Autocuration,1,CHEMBL619792,BAO_0000019,,
3003,,B,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,6,,,104698,,Autocuration,1,CHEMBL619793,BAO_0000249,,
3004,,B,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL619794,BAO_0000223,,
3005,,B,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,6,,,104698,,Autocuration,1,CHEMBL619795,BAO_0000221,955.0,
3006,,B,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,6,,,104698,,Autocuration,1,CHEMBL619796,BAO_0000019,,
3007,,B,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,6,,,104698,,Autocuration,1,CHEMBL620448,BAO_0000223,,
3008,,B,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,6,,,104698,,Autocuration,1,CHEMBL620449,BAO_0000223,,
3009,,B,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,6,,,104698,,Autocuration,1,CHEMBL620450,BAO_0000223,,
3010,,B,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,6,,,104698,,Autocuration,1,CHEMBL620451,BAO_0000223,,
3011,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,6,,,104698,,Autocuration,1,CHEMBL620631,BAO_0000223,,
3012,,B,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,6,,,104698,,Autocuration,1,CHEMBL620632,BAO_0000019,,
3013,,B,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,6,,,104698,,Autocuration,1,CHEMBL620633,BAO_0000019,,
3014,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,6,,,104698,,Autocuration,1,CHEMBL620634,BAO_0000223,,
3015,,B,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,6,,,104698,,Autocuration,1,CHEMBL620635,BAO_0000019,,
3016,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620636,BAO_0000218,,
3017,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620637,BAO_0000218,,
3018,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620638,BAO_0000218,,
3019,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620639,BAO_0000218,,
3020,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620640,BAO_0000218,,
3021,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620641,BAO_0000218,,
3022,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620642,BAO_0000218,,
3023,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620643,BAO_0000218,,
3024,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620644,BAO_0000218,,
3025,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620645,BAO_0000218,,
3026,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620646,BAO_0000218,,
3027,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620647,BAO_0000218,,
3028,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620648,BAO_0000218,,
3029,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620649,BAO_0000218,,
3030,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620650,BAO_0000218,,
3031,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620651,BAO_0000218,,
3032,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL872875,BAO_0000218,,
3033,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL620652,BAO_0000218,,
3034,,F,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,6,,,104698,,Autocuration,1,CHEMBL620653,BAO_0000019,,
3035,,B,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,6,,,104698,,Autocuration,1,CHEMBL857076,BAO_0000019,,
3036,,B,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL620654,BAO_0000019,,
3037,,B,,,Binding activity radioligand.,6,,,104698,,Autocuration,1,CHEMBL620655,BAO_0000223,,
3038,,B,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,6,,,104698,,Autocuration,1,CHEMBL620656,BAO_0000249,,
3039,,B,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,6,,,104698,,Autocuration,1,CHEMBL620657,BAO_0000249,,
3040,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,8,,,108,,Autocuration,1,CHEMBL620658,BAO_0000357,,
3041,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,8,,,108,,Autocuration,1,CHEMBL620659,BAO_0000357,,
3042,,B,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,8,,,108,,Autocuration,1,CHEMBL620660,BAO_0000357,,
3043,,B,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL620661,BAO_0000357,,
3044,,B,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL620662,BAO_0000357,,
3045,,B,,,Affinity for 5-hydroxytryptamine 2C receptor,8,,,108,,Expert,1,CHEMBL620663,BAO_0000357,,
3046,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,8,,,108,,Autocuration,1,CHEMBL620664,BAO_0000357,,
3047,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,8,,,108,,Expert,1,CHEMBL620665,BAO_0000357,,
3048,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,8,,,108,,Autocuration,1,CHEMBL620666,BAO_0000357,,
3049,,B,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,8,,,108,,Autocuration,1,CHEMBL620667,BAO_0000357,,
3050,,B,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,8,,,108,,Expert,1,CHEMBL620668,BAO_0000357,,
3051,,B,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,8,,,108,,Autocuration,1,CHEMBL620669,BAO_0000357,,
3052,,B,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,8,,,108,,Expert,1,CHEMBL620670,BAO_0000357,,
3053,,B,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL620671,BAO_0000357,,
3054,,B,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,8,,,108,,Autocuration,1,CHEMBL620672,BAO_0000357,,
3055,,B,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,8,,,108,,Autocuration,1,CHEMBL620673,BAO_0000357,,
3056,,B,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL620674,BAO_0000357,,
3057,,B,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL620675,BAO_0000357,,
3058,,B,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,8,,,108,,Autocuration,1,CHEMBL620676,BAO_0000357,,
3059,,B,,,Affinity against 5-hydroxytryptamine 2C receptor,8,,,108,,Autocuration,1,CHEMBL621382,BAO_0000357,,
3060,,B,,,Binding affinity against 5-hydroxytryptamine 2C receptor,9,,,108,9606.0,Expert,1,CHEMBL621383,BAO_0000357,,
3061,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,8,,,108,,Autocuration,1,CHEMBL621384,BAO_0000357,,
3062,,B,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,8,,,144,9913.0,Autocuration,1,CHEMBL621385,BAO_0000357,,
3063,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,8,,,144,9913.0,Autocuration,1,CHEMBL617989,BAO_0000357,,
3064,,F,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,4,,,104714,10141.0,Expert,1,CHEMBL617990,BAO_0000019,,
3065,,B,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,4,,,104714,10141.0,Autocuration,1,CHEMBL875085,BAO_0000221,2116.0,
3066,,F,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,4,,,104714,10141.0,Autocuration,1,CHEMBL617991,BAO_0000019,,
3067,,F,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,4,,,104714,10141.0,Autocuration,1,CHEMBL617992,BAO_0000019,,
3068,,B,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,4,,,104714,10141.0,Autocuration,1,CHEMBL617993,BAO_0000221,2116.0,
3069,,B,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,4,,,104714,10141.0,Autocuration,1,CHEMBL617994,BAO_0000221,2116.0,
3070,,F,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL617995,BAO_0000019,,
3071,,F,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL617996,BAO_0000019,,
3072,,F,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL617997,BAO_0000019,,
3073,,F,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,4,,,104714,10141.0,Autocuration,1,CHEMBL617998,BAO_0000019,,
3074,,F,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL617999,BAO_0000019,,
3075,,F,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL618000,BAO_0000019,,
3076,,F,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",4,,,104714,10141.0,Autocuration,1,CHEMBL617815,BAO_0000221,2116.0,
3077,,F,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",4,,,104714,10141.0,Autocuration,1,CHEMBL617816,BAO_0000221,2116.0,
3078,,F,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,4,,,104714,10141.0,Autocuration,1,CHEMBL617817,BAO_0000221,2116.0,
3079,,B,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,4,,,104714,10141.0,Autocuration,1,CHEMBL617818,BAO_0000221,2116.0,
3080,,B,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,4,,,104714,10141.0,Autocuration,1,CHEMBL617819,BAO_0000221,2116.0,
3081,,B,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,4,,,104714,10141.0,Autocuration,1,CHEMBL617820,BAO_0000223,,
3082,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,4,,,104714,10141.0,Autocuration,1,CHEMBL617821,BAO_0000221,2116.0,
3083,,F,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),4,,,104714,10141.0,Autocuration,1,CHEMBL617822,BAO_0000221,2116.0,
3084,,F,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),4,,,104714,10141.0,Autocuration,1,CHEMBL617823,BAO_0000221,2116.0,
3085,,F,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,4,,,104714,10141.0,Autocuration,1,CHEMBL617824,BAO_0000221,2116.0,
3086,,F,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,4,,,104714,10141.0,Autocuration,1,CHEMBL617825,BAO_0000221,2116.0,
3087,,F,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,4,,,104714,10141.0,Autocuration,1,CHEMBL617826,BAO_0000221,2116.0,
3088,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,4,,,104714,10141.0,Autocuration,1,CHEMBL617827,BAO_0000221,2116.0,
3089,,F,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),4,,,104714,10141.0,Autocuration,1,CHEMBL617828,BAO_0000221,2116.0,
3090,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,4,,,104714,10141.0,Autocuration,1,CHEMBL617829,BAO_0000221,2116.0,
3091,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,4,,,104714,10141.0,Autocuration,1,CHEMBL617830,BAO_0000221,2116.0,
3092,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,4,,,104714,10141.0,Autocuration,1,CHEMBL617831,BAO_0000221,2116.0,
3093,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,4,,,104714,10141.0,Autocuration,1,CHEMBL617832,BAO_0000221,2116.0,
3094,,B,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,0,,,22226,10141.0,Autocuration,1,CHEMBL617833,BAO_0000019,,
3095,,B,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,8,,,51,,Autocuration,1,CHEMBL617834,BAO_0000357,,
3096,,B,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,5,,,104714,9606.0,Expert,1,CHEMBL617835,BAO_0000223,,
3097,,B,,,Binding affinity towards 5-HT3 receptor,4,,,104714,,Autocuration,1,CHEMBL617836,BAO_0000223,,
3098,,B,,,Binding activity radioligand.,4,,,104714,,Autocuration,1,CHEMBL617837,BAO_0000223,,
3099,,B,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,4,,,104714,,Autocuration,1,CHEMBL620392,BAO_0000019,,
3100,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,4,,,104714,,Autocuration,1,CHEMBL620393,BAO_0000223,,
3101,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,4,,,104714,,Autocuration,1,CHEMBL620394,BAO_0000223,,
3102,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,4,,,104714,,Autocuration,1,CHEMBL620395,BAO_0000223,,
3103,,B,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,0,,,22226,,Autocuration,1,CHEMBL620396,BAO_0000019,,
3104,NG108-15,B,433.0,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,4,,,105030,,Expert,1,CHEMBL620582,BAO_0000219,,
3105,,B,,In vivo,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",4,,,105030,,Autocuration,1,CHEMBL620583,BAO_0000218,,
3106,,B,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),4,,,105030,,Autocuration,1,CHEMBL620584,BAO_0000019,,
3107,,B,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,4,,,105030,,Autocuration,1,CHEMBL620585,BAO_0000224,,
3108,,B,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,4,,,105030,,Autocuration,1,CHEMBL620586,BAO_0000224,,
3109,,B,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),4,,,105030,,Autocuration,1,CHEMBL620587,BAO_0000019,,
3110,,B,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,4,,,105030,,Autocuration,1,CHEMBL620588,BAO_0000019,,
3111,,F,,,5-hydroxytryptamine 3 receptor agonism in mouse,4,,,105030,,Autocuration,1,CHEMBL620589,BAO_0000218,,
3112,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,4,,,105030,,Autocuration,1,CHEMBL620590,BAO_0000219,,
3113,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,4,,,105030,,Autocuration,1,CHEMBL617956,BAO_0000019,,
3114,,B,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,4,,,105030,,Autocuration,1,CHEMBL617957,BAO_0000019,,
3115,,B,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,4,,,105030,,Autocuration,1,CHEMBL617958,BAO_0000224,,
3116,,B,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,4,,,105030,,Autocuration,1,CHEMBL617959,BAO_0000219,,
3117,,B,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,4,,,105030,,Autocuration,1,CHEMBL617960,BAO_0000219,,
3118,,B,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,4,,,105030,,Autocuration,1,CHEMBL617961,BAO_0000224,,
3119,,B,,In vitro,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,4,,,105030,,Autocuration,1,CHEMBL617962,BAO_0000219,,
3120,N1E-115,B,339.0,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,4,,,105030,,Autocuration,1,CHEMBL617963,BAO_0000219,,
3121,,B,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,8,,,11765,,Autocuration,1,CHEMBL617964,BAO_0000019,,
3122,,B,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,8,,,11765,,Autocuration,1,CHEMBL617965,BAO_0000219,,
3123,,B,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,9,,,10630,10090.0,Autocuration,1,CHEMBL617966,BAO_0000357,,
3124,,B,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,8,,,17106,,Autocuration,1,CHEMBL857074,BAO_0000019,,
3125,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,8,,,144,9823.0,Autocuration,1,CHEMBL617967,BAO_0000357,,
3126,,B,,,Binding activity radioligand.,8,,,144,9823.0,Autocuration,1,CHEMBL617968,BAO_0000357,,
3127,,B,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,4,,,104714,9986.0,Autocuration,1,CHEMBL617969,BAO_0000223,,
3128,,B,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,4,,,104714,9986.0,Autocuration,1,CHEMBL617970,BAO_0000223,,
3129,,B,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,4,,,104714,9986.0,Autocuration,1,CHEMBL617971,BAO_0000223,,
3130,,B,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,4,,,104714,9986.0,Autocuration,1,CHEMBL617972,BAO_0000019,,
3131,,F,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),4,,,104714,9986.0,Autocuration,1,CHEMBL617973,BAO_0000019,,
3132,,F,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),4,,,104714,9986.0,Autocuration,1,CHEMBL617974,BAO_0000019,,
3133,,F,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),4,,,104714,9986.0,Autocuration,1,CHEMBL617975,BAO_0000221,2116.0,
3134,,F,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),4,,,104714,9986.0,Autocuration,1,CHEMBL617976,BAO_0000019,,
3135,,F,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),4,,,104714,9986.0,Autocuration,1,CHEMBL617977,BAO_0000019,,
3136,,F,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),4,,,104714,9986.0,Autocuration,1,CHEMBL617978,BAO_0000019,,
3137,,F,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),4,,,104714,9986.0,Autocuration,1,CHEMBL617979,BAO_0000019,,
3138,CHO,B,449.0,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,4,,,104714,9986.0,Autocuration,1,CHEMBL617980,BAO_0000219,,
3139,,B,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL617981,BAO_0000019,,
3140,,B,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),8,,,12020,,Autocuration,1,CHEMBL617982,BAO_0000019,,
3141,,B,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),8,,,12020,,Autocuration,1,CHEMBL617983,BAO_0000357,,
3142,,B,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,7,,,104698,10116.0,Autocuration,1,CHEMBL617984,BAO_0000019,,
3143,,B,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",6,,,104698,,Autocuration,1,CHEMBL617985,BAO_0000019,,
3144,,F,,In vivo,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",6,,,104698,,Autocuration,1,CHEMBL617986,BAO_0000218,948.0,
3145,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",6,,,104698,,Autocuration,1,CHEMBL617987,BAO_0000019,948.0,
3146,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",6,,,104698,,Autocuration,1,CHEMBL617988,BAO_0000019,948.0,
3147,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",6,,,104698,,Autocuration,1,CHEMBL617792,BAO_0000019,948.0,
3148,,F,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",6,,,104698,,Autocuration,1,CHEMBL617793,BAO_0000019,948.0,
3149,,F,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",6,,,104698,,Autocuration,1,CHEMBL617794,BAO_0000019,,
3150,,F,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",6,,,104698,,Autocuration,1,CHEMBL617795,BAO_0000019,,
3151,,F,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",6,,,104698,,Autocuration,1,CHEMBL617796,BAO_0000019,,
3152,,F,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",6,,,104698,,Autocuration,1,CHEMBL617797,BAO_0000019,,
3153,,F,,In vivo,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),7,,,104698,10116.0,Autocuration,1,CHEMBL617798,BAO_0000218,,
3154,,F,,In vivo,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),6,,,104698,,Autocuration,1,CHEMBL617799,BAO_0000218,,
3155,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,7,,,104698,10116.0,Autocuration,1,CHEMBL617800,BAO_0000218,,
3156,,F,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,7,,,104698,10116.0,Autocuration,1,CHEMBL617801,BAO_0000019,,
3157,,F,,In vivo,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,7,,,104698,10116.0,Autocuration,1,CHEMBL617802,BAO_0000218,,
3158,,F,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),7,,,104698,10116.0,Autocuration,1,CHEMBL617803,BAO_0000019,,
3159,,B,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,6,,,104698,,Autocuration,1,CHEMBL617804,BAO_0000019,,
3160,,B,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL617805,BAO_0000019,,
3161,,B,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,6,,,104698,,Autocuration,1,CHEMBL617806,BAO_0000223,,
3162,,B,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,6,,,104698,,Autocuration,1,CHEMBL617807,BAO_0000019,,
3163,,B,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,6,,,104698,,Autocuration,1,CHEMBL617808,BAO_0000019,,
3164,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,6,,,104698,,Autocuration,1,CHEMBL617809,BAO_0000249,,
3165,,B,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,6,,,104698,,Autocuration,1,CHEMBL617810,BAO_0000019,,
3166,,B,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,6,,,104698,,Autocuration,1,CHEMBL617811,BAO_0000249,955.0,
3167,,B,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,6,,,104698,,Autocuration,1,CHEMBL617812,BAO_0000221,955.0,
3168,,B,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,6,,,104698,,Autocuration,1,CHEMBL617813,BAO_0000249,,
3169,,B,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,6,,,104698,,Autocuration,1,CHEMBL617814,BAO_0000249,,
3170,,B,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,6,,,104698,,Autocuration,1,CHEMBL617698,BAO_0000019,,
3171,,B,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,7,,,104698,10116.0,Autocuration,1,CHEMBL617699,BAO_0000019,,
3172,,B,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,7,,,104698,10116.0,Autocuration,1,CHEMBL617700,BAO_0000019,,
3173,,B,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL617701,BAO_0000223,,
3174,,B,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,6,,,104698,,Autocuration,1,CHEMBL617702,BAO_0000019,,
3175,,B,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",6,,,104698,,Autocuration,1,CHEMBL617703,BAO_0000249,,
3176,,B,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL617704,BAO_0000019,,
3177,,B,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,6,,,104698,,Autocuration,1,CHEMBL617705,BAO_0000223,,
3178,,B,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL617706,BAO_0000223,,
3179,NG108-15,B,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),6,,,104698,,Autocuration,1,CHEMBL617707,BAO_0000219,,
3180,NG108-15,B,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,6,,,104698,,Autocuration,1,CHEMBL617708,BAO_0000219,,
3181,,B,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,6,,,104698,,Autocuration,1,CHEMBL617709,BAO_0000019,,
3182,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,6,,,104698,,Autocuration,1,CHEMBL617710,BAO_0000019,,
3183,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,6,,,104698,,Autocuration,1,CHEMBL882925,BAO_0000019,,
3184,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,6,,,104698,,Autocuration,1,CHEMBL617711,BAO_0000019,,
3185,,F,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,6,,,104698,,Autocuration,1,CHEMBL617712,BAO_0000019,,
3186,,F,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,7,,,104698,10116.0,Autocuration,1,CHEMBL617713,BAO_0000019,,
3187,,F,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",6,,,104698,,Autocuration,1,CHEMBL617714,BAO_0000019,,
3188,,F,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,6,,,104698,,Autocuration,1,CHEMBL617715,BAO_0000218,,
3189,,F,,In vivo,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,6,,,104698,,Autocuration,1,CHEMBL617716,BAO_0000218,,
3190,,F,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,6,,,104698,,Autocuration,1,CHEMBL617717,BAO_0000218,,
3191,,F,,In vivo,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617718,BAO_0000218,,
3192,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617719,BAO_0000218,,
3193,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),6,,,104698,,Autocuration,1,CHEMBL617720,BAO_0000218,,
3194,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,7,,,104698,10116.0,Autocuration,1,CHEMBL617721,BAO_0000218,,
3195,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617722,BAO_0000218,,
3196,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,6,,,104698,,Autocuration,1,CHEMBL617723,BAO_0000218,,
3197,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617724,BAO_0000218,,
3198,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617725,BAO_0000218,,
3199,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617726,BAO_0000218,,
3200,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617727,BAO_0000218,,
3201,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617728,BAO_0000218,,
3202,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617729,BAO_0000218,,
3203,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617730,BAO_0000218,,
3204,,F,,In vivo,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617731,BAO_0000218,,
3205,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617732,BAO_0000218,,
3206,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617733,BAO_0000218,,
3207,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617734,BAO_0000218,,
3208,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,6,,,104698,,Autocuration,1,CHEMBL872874,BAO_0000218,,
3209,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,6,,,104698,,Autocuration,1,CHEMBL617735,BAO_0000218,,
3210,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,6,,,104698,,Autocuration,1,CHEMBL617736,BAO_0000218,,
3211,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,6,,,104698,,Autocuration,1,CHEMBL617737,BAO_0000218,,
3212,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,6,,,104698,,Autocuration,1,CHEMBL617738,BAO_0000218,,
3213,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617739,BAO_0000218,,
3214,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617740,BAO_0000218,,
3215,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617741,BAO_0000218,,
3216,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617742,BAO_0000218,,
3217,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617743,BAO_0000218,,
3218,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617744,BAO_0000218,,
3219,,F,,In vivo,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,6,,,104698,,Autocuration,1,CHEMBL617745,BAO_0000218,,
3220,,F,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",6,,,104698,,Autocuration,1,CHEMBL617746,BAO_0000218,,
3221,,F,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",6,,,104698,,Autocuration,1,CHEMBL617747,BAO_0000218,,
3222,,F,,In vivo,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,6,,,104698,,Autocuration,1,CHEMBL617748,BAO_0000218,,
3223,,F,,In vivo,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,6,,,104698,,Autocuration,1,CHEMBL618909,BAO_0000218,,
3224,,F,,In vivo,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,6,,,104698,,Autocuration,1,CHEMBL618910,BAO_0000218,,
3225,,F,,In vivo,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,6,,,104698,,Autocuration,1,CHEMBL618911,BAO_0000218,,
3226,,F,,In vivo,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,6,,,104698,,Autocuration,1,CHEMBL618912,BAO_0000218,,
3227,,F,,In vivo,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),6,,,104698,,Autocuration,1,CHEMBL618913,BAO_0000218,,
3228,,F,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,6,,,104698,,Autocuration,1,CHEMBL618914,BAO_0000019,,
3229,,F,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,6,,,104698,,Autocuration,1,CHEMBL618915,BAO_0000019,,
3230,,B,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL618916,BAO_0000223,,
3231,,F,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,6,,,104698,,Autocuration,1,CHEMBL618917,BAO_0000019,,
3232,,B,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,7,,,104698,,Intermediate,1,CHEMBL618918,BAO_0000221,10000000.0,
3233,,B,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,7,,,104698,10116.0,Autocuration,1,CHEMBL618919,BAO_0000019,,
3234,,B,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL618920,BAO_0000019,,
3235,,B,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,6,,,104698,,Autocuration,1,CHEMBL618921,BAO_0000223,,
3236,,B,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,6,,,104698,,Autocuration,1,CHEMBL618922,BAO_0000019,,
3237,,B,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,6,,,104698,,Autocuration,1,CHEMBL618923,BAO_0000019,,
3238,,B,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,6,,,104698,,Autocuration,1,CHEMBL618924,BAO_0000019,,
3239,,B,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,6,,,104698,,Autocuration,1,CHEMBL618925,BAO_0000019,,
3240,,B,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,6,,,104698,,Autocuration,1,CHEMBL618926,BAO_0000019,,
3241,,F,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,9,,,20033,10141.0,Intermediate,1,CHEMBL618927,BAO_0000221,2116.0,
3242,,F,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,9,,,20033,10141.0,Intermediate,1,CHEMBL618928,BAO_0000221,2116.0,
3243,,F,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",9,,,20033,10141.0,Intermediate,1,CHEMBL618929,BAO_0000221,2116.0,
3244,,F,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",9,,,20033,10141.0,Intermediate,1,CHEMBL618930,BAO_0000221,2116.0,
3245,,F,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",9,,,20033,10141.0,Intermediate,1,CHEMBL618931,BAO_0000221,2116.0,
3246,,F,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",9,,,20033,10141.0,Intermediate,1,CHEMBL619594,BAO_0000221,2116.0,
3247,,F,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",9,,,20033,10141.0,Intermediate,1,CHEMBL619595,BAO_0000221,2116.0,
3248,,F,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,9,,,20033,10141.0,Intermediate,1,CHEMBL619596,BAO_0000221,2116.0,
3249,,F,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,9,,,20033,10141.0,Intermediate,1,CHEMBL619755,BAO_0000221,2116.0,
3250,,F,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,9,,,20033,10141.0,Intermediate,1,CHEMBL619756,BAO_0000221,2116.0,
3251,,F,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,9,,,20033,10141.0,Intermediate,1,CHEMBL619757,BAO_0000221,2116.0,
3252,,F,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,9,,,20033,10141.0,Intermediate,1,CHEMBL619758,BAO_0000221,2116.0,
3253,,F,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",9,,,20033,10141.0,Intermediate,1,CHEMBL619759,BAO_0000221,2116.0,
3254,,F,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",9,,,20033,10141.0,Intermediate,1,CHEMBL619760,BAO_0000221,2116.0,
3255,,F,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",9,,,20033,10141.0,Intermediate,1,CHEMBL619761,BAO_0000221,2116.0,
3256,,F,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,9,,,20033,10141.0,Intermediate,1,CHEMBL619762,BAO_0000221,2116.0,
3257,,F,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",9,,,20033,10141.0,Intermediate,1,CHEMBL619763,BAO_0000221,2116.0,
3258,,F,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",9,,,20033,10141.0,Intermediate,1,CHEMBL617868,BAO_0000221,2116.0,
3259,,B,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,9,,,20033,10141.0,Intermediate,1,CHEMBL617869,BAO_0000357,,
3260,,B,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,9,,,20033,10141.0,Intermediate,1,CHEMBL882926,BAO_0000249,2435.0,
3261,,B,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,9,,,20033,10141.0,Intermediate,1,CHEMBL617870,BAO_0000249,2435.0,
3262,,B,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,9,,,20033,10141.0,Intermediate,1,CHEMBL617871,BAO_0000357,2435.0,
3263,,B,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,9,,,20033,10141.0,Intermediate,1,CHEMBL617872,BAO_0000357,2435.0,
3264,,B,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,9,,,20033,10141.0,Intermediate,1,CHEMBL617873,BAO_0000357,2435.0,
3265,,B,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,9,,,20033,10141.0,Intermediate,1,CHEMBL617874,BAO_0000357,2435.0,
3266,,F,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,9,,,20033,10141.0,Intermediate,1,CHEMBL619067,BAO_0000221,2116.0,
3267,,F,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,9,,,20033,10141.0,Intermediate,1,CHEMBL619068,BAO_0000221,2116.0,
3268,,F,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,9,,,20033,10141.0,Intermediate,1,CHEMBL619069,BAO_0000221,2116.0,
3269,,B,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,9,,,20033,10141.0,Intermediate,1,CHEMBL619070,BAO_0000357,,
3270,,B,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,9,,,20033,10141.0,Intermediate,1,CHEMBL619071,BAO_0000357,,
3271,,F,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,9,,,20033,10141.0,Intermediate,1,CHEMBL619072,BAO_0000019,,
3272,,F,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,9,,,20033,10141.0,Intermediate,1,CHEMBL619073,BAO_0000019,,
3273,,F,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,9,,,20033,10141.0,Intermediate,1,CHEMBL619074,BAO_0000019,,
3274,,B,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,9,,,20033,10141.0,Intermediate,1,CHEMBL619075,BAO_0000357,,
3275,,B,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,9,,,20033,10141.0,Intermediate,1,CHEMBL619076,BAO_0000357,2435.0,
3276,,B,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,9,,,20033,10141.0,Intermediate,1,CHEMBL619077,BAO_0000357,2435.0,
3277,,B,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,9,,,20033,10141.0,Intermediate,1,CHEMBL619078,BAO_0000249,2435.0,
3278,,B,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,9,,,20033,10141.0,Intermediate,1,CHEMBL619079,BAO_0000249,2435.0,
3279,,B,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,9,,,20033,10141.0,Intermediate,1,CHEMBL619080,BAO_0000221,2116.0,
3280,,B,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,9,,,20033,10141.0,Expert,1,CHEMBL619081,BAO_0000357,,
3281,,B,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,9,,,20033,10141.0,Intermediate,1,CHEMBL619082,BAO_0000357,,
3282,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,9,,,20033,10141.0,Intermediate,1,CHEMBL619083,BAO_0000357,,
3283,,B,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,9,,,20033,10141.0,Intermediate,1,CHEMBL619084,BAO_0000357,,
3284,,F,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,9,,,20033,10141.0,Intermediate,1,CHEMBL859397,BAO_0000221,2116.0,
3285,,F,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,9,,,20033,10141.0,Intermediate,1,CHEMBL619085,BAO_0000221,2116.0,
3286,,F,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,9,,,20033,10141.0,Intermediate,1,CHEMBL619086,BAO_0000221,2116.0,
3287,,F,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,9,,,20033,10141.0,Intermediate,1,CHEMBL619087,BAO_0000221,2116.0,
3288,,F,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,9,,,20033,10141.0,Intermediate,1,CHEMBL619088,BAO_0000221,2116.0,
3289,,B,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,9,,,20033,10141.0,Intermediate,1,CHEMBL619089,BAO_0000357,,
3290,,B,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,8,,,168,10141.0,Autocuration,1,CHEMBL619090,BAO_0000357,,
3291,,F,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,9,,,20033,10141.0,Intermediate,1,CHEMBL619091,BAO_0000019,,
3292,,B,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,9,,,20033,10141.0,Intermediate,1,CHEMBL619092,BAO_0000357,,
3293,,B,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,9,,,20033,10141.0,Intermediate,1,CHEMBL619093,BAO_0000019,,
3294,HEK293,B,722.0,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,8,,,168,10141.0,Autocuration,1,CHEMBL619094,BAO_0000219,,
3295,,B,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,9,,,20033,10141.0,Intermediate,1,CHEMBL619095,BAO_0000019,,
3296,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,9,,,20033,10141.0,Intermediate,1,CHEMBL857988,BAO_0000357,,
3297,,B,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,9,,,20033,10141.0,Intermediate,1,CHEMBL619096,BAO_0000357,,
3298,,B,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,9,,,20033,10141.0,Intermediate,1,CHEMBL619097,BAO_0000357,2435.0,
3299,,B,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,9,,,20033,10141.0,Intermediate,1,CHEMBL619098,BAO_0000221,10000000.0,
3300,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,9,,,20033,10141.0,Intermediate,1,CHEMBL619751,BAO_0000357,,
3301,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,9,,,20033,10141.0,Intermediate,1,CHEMBL619752,BAO_0000357,,
3302,,F,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,9,,,20033,10141.0,Intermediate,1,CHEMBL875096,BAO_0000221,2116.0,
3303,,B,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,8,,,108,,Autocuration,1,CHEMBL619004,BAO_0000357,,
3304,,B,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,8,,,168,,Autocuration,1,CHEMBL619005,BAO_0000357,,
3305,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,8,,,168,,Autocuration,1,CHEMBL619006,BAO_0000019,,
3306,HeLa,B,308.0,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,8,,,168,,Autocuration,1,CHEMBL619007,BAO_0000219,,
3307,,B,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,8,,,168,,Autocuration,1,CHEMBL619008,BAO_0000357,,
3308,,B,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,8,,,168,,Autocuration,1,CHEMBL619009,BAO_0000357,,
3309,HeLa,B,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",8,,,168,,Autocuration,1,CHEMBL619010,BAO_0000219,,
3310,,B,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,8,,,10622,,Autocuration,1,CHEMBL619011,BAO_0000357,,
3311,,B,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,8,,,10622,,Autocuration,1,CHEMBL619012,BAO_0000357,,
3312,,B,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,8,,,10622,,Autocuration,1,CHEMBL619013,BAO_0000219,,
3313,,B,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,8,,,10622,,Autocuration,1,CHEMBL619014,BAO_0000357,,
3314,,F,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,8,,,11249,,Autocuration,1,CHEMBL857503,BAO_0000019,2081.0,
3315,,F,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,8,,,11249,,Autocuration,1,CHEMBL619015,BAO_0000019,2081.0,
3316,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,8,,,11249,,Autocuration,1,CHEMBL619016,BAO_0000357,,
3317,,B,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,8,,,11249,,Autocuration,1,CHEMBL619017,BAO_0000221,10000000.0,
3318,,B,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,8,,,168,9823.0,Autocuration,1,CHEMBL619018,BAO_0000221,10000000.0,
3319,,B,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,8,,,168,9986.0,Autocuration,1,CHEMBL619019,BAO_0000019,,
3320,,B,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,9,,,10623,10116.0,Expert,1,CHEMBL619020,BAO_0000357,,
3321,,F,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,8,,,10623,,Autocuration,1,CHEMBL619021,BAO_0000019,,
3322,,B,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,8,,,10623,,Autocuration,1,CHEMBL619022,BAO_0000357,,
3323,,B,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,8,,,10623,,Autocuration,1,CHEMBL619023,BAO_0000357,,
3324,,F,,,lntrinsic activity relative to 5-HT receptor,8,,,10623,,Autocuration,1,CHEMBL619024,BAO_0000019,,
3325,,F,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,8,,,10623,,Autocuration,1,CHEMBL619025,BAO_0000019,,
3326,,F,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,8,,,10623,,Expert,1,CHEMBL619026,BAO_0000019,,
3327,,F,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,8,,,10623,,Autocuration,1,CHEMBL619027,BAO_0000019,,
3328,,F,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,8,,,10623,,Autocuration,1,CHEMBL619028,BAO_0000019,,
3329,,F,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,8,,,10623,,Autocuration,1,CHEMBL619029,BAO_0000019,,
3330,,F,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,8,,,10623,,Autocuration,1,CHEMBL619030,BAO_0000019,,
3331,,B,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,8,,,10623,,Expert,1,CHEMBL619031,BAO_0000357,,
3332,,F,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,8,,,10623,,Autocuration,1,CHEMBL619032,BAO_0000019,,
3333,,B,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,9,,,10623,10116.0,Expert,1,CHEMBL619033,BAO_0000357,,
3334,,B,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,8,,,10623,,Autocuration,1,CHEMBL619034,BAO_0000357,,
3335,,B,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,8,,,10623,,Autocuration,1,CHEMBL619035,BAO_0000357,,
3336,,B,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,8,,,10623,,Autocuration,1,CHEMBL619036,BAO_0000357,,
3337,,B,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,9,,,10623,10116.0,Expert,1,CHEMBL619037,BAO_0000019,,
3338,,B,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,8,,,10623,,Autocuration,1,CHEMBL619038,BAO_0000249,2435.0,
3339,,B,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,8,,,10623,,Autocuration,1,CHEMBL619039,BAO_0000249,,
3340,,B,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,8,,,10623,,Expert,1,CHEMBL619040,BAO_0000249,,
3341,,B,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,9,,,10623,10116.0,Expert,1,CHEMBL619041,BAO_0000019,2435.0,
3342,,B,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,8,,,10623,,Autocuration,1,CHEMBL619042,BAO_0000019,2435.0,
3343,,B,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,8,,,10623,,Expert,1,CHEMBL619043,BAO_0000249,2435.0,
3344,,B,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,8,,,10623,,Expert,1,CHEMBL619044,BAO_0000019,2435.0,
3345,,B,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,8,,,10623,,Expert,1,CHEMBL619045,BAO_0000249,2435.0,
3346,,B,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,8,,,10623,,Expert,1,CHEMBL619046,BAO_0000249,2435.0,
3347,,B,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,8,,,10623,,Expert,1,CHEMBL619047,BAO_0000249,,
3348,,F,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,8,,,10623,,Autocuration,1,CHEMBL619048,BAO_0000221,955.0,
3349,,F,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,8,,,10623,,Autocuration,1,CHEMBL859398,BAO_0000019,,
3350,,F,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,8,,,10623,,Autocuration,1,CHEMBL619049,BAO_0000019,,
3351,,F,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,8,,,10623,,Autocuration,1,CHEMBL857886,BAO_0000019,,
3352,,F,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,8,,,10623,,Autocuration,1,CHEMBL619050,BAO_0000019,,
3353,,F,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,8,,,10623,,Autocuration,1,CHEMBL620591,BAO_0000019,,
3354,,B,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,9,,,10623,10116.0,Expert,1,CHEMBL620592,BAO_0000357,,
3355,,B,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,8,,,10623,,Expert,1,CHEMBL620593,BAO_0000249,2435.0,
3356,,F,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,9,,,10623,10116.0,Expert,1,CHEMBL620594,BAO_0000019,,
3357,,F,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,8,,,10623,,Expert,1,CHEMBL875079,BAO_0000019,,
3358,,F,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,8,,,10623,,Expert,1,CHEMBL620595,BAO_0000019,,
3359,,F,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,9,,,10623,10116.0,Expert,1,CHEMBL620596,BAO_0000019,,
3360,,F,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,8,,,10623,,Autocuration,1,CHEMBL620597,BAO_0000019,,
3361,,F,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,8,,,10623,,Expert,1,CHEMBL620598,BAO_0000019,,
3362,,F,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),8,,,10623,,Expert,1,CHEMBL620599,BAO_0000218,,
3363,,F,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,8,,,10623,,Autocuration,1,CHEMBL620600,BAO_0000019,,
3364,,F,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,8,,,168,10116.0,Autocuration,1,CHEMBL620601,BAO_0000019,,
3365,,F,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,8,,,168,,Autocuration,1,CHEMBL620602,BAO_0000019,,
3366,,B,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,8,,,168,,Autocuration,1,CHEMBL620603,BAO_0000357,,
3367,,B,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,8,,,168,,Autocuration,1,CHEMBL620604,BAO_0000357,,
3368,,B,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,8,,,168,,Autocuration,1,CHEMBL620605,BAO_0000357,,
3369,,B,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,8,,,168,,Autocuration,1,CHEMBL620606,BAO_0000357,,
3370,,F,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,8,,,168,,Autocuration,1,CHEMBL620607,BAO_0000019,,
3371,,B,,,In vitro binding affinity towards 5-HT4 receptor was determined,8,,,168,,Autocuration,1,CHEMBL620608,BAO_0000357,,
3372,,F,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,8,,,168,,Autocuration,1,CHEMBL620609,BAO_0000019,,
3373,,F,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,8,,,168,,Autocuration,1,CHEMBL620610,BAO_0000019,,
3374,,B,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,8,,,168,,Autocuration,1,CHEMBL620611,BAO_0000357,,
3375,,B,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,8,,,168,,Autocuration,1,CHEMBL620612,BAO_0000357,,
3376,,B,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,8,,,168,,Autocuration,1,CHEMBL620613,BAO_0000357,,
3377,,B,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,8,,,168,,Autocuration,1,CHEMBL620614,BAO_0000357,,
3378,,B,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,8,,,168,,Expert,1,CHEMBL620615,BAO_0000357,,
3379,,B,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,6,,,104698,,Autocuration,1,CHEMBL857075,BAO_0000249,,
3380,,B,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,6,,,104698,,Autocuration,1,CHEMBL620616,BAO_0000249,,
3381,,B,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,6,,,104698,,Autocuration,1,CHEMBL619411,BAO_0000249,,
3382,,B,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,6,,,104698,,Autocuration,1,CHEMBL619412,BAO_0000019,,
3383,,B,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL619413,BAO_0000019,,
3384,,B,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,6,,,104698,,Autocuration,1,CHEMBL619414,BAO_0000221,10000000.0,
3385,,B,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,6,,,104698,,Autocuration,1,CHEMBL619415,BAO_0000019,,
3386,,B,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,6,,,104698,,Autocuration,1,CHEMBL619416,BAO_0000019,,
3387,,F,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,6,,,104698,,Autocuration,1,CHEMBL619417,BAO_0000019,,
3388,,B,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL619418,BAO_0000223,,
3389,,B,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL619419,BAO_0000223,,
3390,,B,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,6,,,104698,,Autocuration,1,CHEMBL619420,BAO_0000019,,
3391,,B,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,6,,,104698,,Autocuration,1,CHEMBL619421,BAO_0000249,,
3392,,B,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,7,,,104698,10116.0,Autocuration,1,CHEMBL619422,BAO_0000019,,
3393,,B,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,6,,,104698,,Autocuration,1,CHEMBL619423,BAO_0000019,,
3394,,B,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,6,,,104698,,Autocuration,1,CHEMBL875080,BAO_0000019,,
3395,,B,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,6,,,104698,,Autocuration,1,CHEMBL619424,BAO_0000019,,
3396,,B,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,6,,,104698,,Autocuration,1,CHEMBL619425,BAO_0000249,,
3397,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,6,,,104698,,Autocuration,1,CHEMBL619426,BAO_0000223,,
3398,,B,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,6,,,104698,,Autocuration,1,CHEMBL619427,BAO_0000223,,
3399,,B,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,7,,,104698,10116.0,Autocuration,1,CHEMBL619645,BAO_0000223,,
3400,,B,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",9,,,10576,,Expert,1,CHEMBL619646,BAO_0000249,,
3401,,F,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,8,,,12020,,Autocuration,1,CHEMBL619647,BAO_0000221,955.0,
3402,,F,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,8,,,12020,,Autocuration,1,CHEMBL619648,BAO_0000019,,
3403,,F,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,8,,,12020,,Autocuration,1,CHEMBL619165,BAO_0000019,,
3404,,F,,In vivo,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,8,,,12020,,Autocuration,1,CHEMBL620719,BAO_0000218,,
3405,,B,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,8,,,12020,,Autocuration,1,CHEMBL872924,BAO_0000019,,
3406,,B,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,8,,,12020,,Autocuration,1,CHEMBL620720,BAO_0000357,,
3407,,B,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,8,,,12020,,Autocuration,1,CHEMBL620721,BAO_0000019,,
3408,,B,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,8,,,12020,,Autocuration,1,CHEMBL620722,BAO_0000019,,
3409,,B,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",6,,,104698,,Autocuration,1,CHEMBL620723,BAO_0000019,,
3410,,B,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,8,,,12020,,Autocuration,1,CHEMBL620724,BAO_0000019,,
3411,,B,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,6,,,104698,,Autocuration,1,CHEMBL620725,BAO_0000249,,
3412,,F,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,9,,,12020,10116.0,Autocuration,1,CHEMBL620726,BAO_0000019,,
3413,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,8,,,144,,Expert,1,CHEMBL620727,BAO_0000357,,
3414,,B,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,4,,,104714,,Autocuration,1,CHEMBL620728,BAO_0000223,,
3415,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,0,,,22226,,Autocuration,1,CHEMBL620729,BAO_0000019,,
3416,,F,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,4,,,104714,,Autocuration,1,CHEMBL858288,BAO_0000019,,
3417,,B,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,4,,,104714,,Autocuration,1,CHEMBL620730,BAO_0000223,,
3418,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,4,,,104714,,Autocuration,1,CHEMBL620731,BAO_0000223,,
3419,,F,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL620732,BAO_0000019,,
3420,,F,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL618042,BAO_0000019,,
3421,,F,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL618043,BAO_0000019,,
3422,,B,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,4,,,104714,,Autocuration,1,CHEMBL618044,BAO_0000223,,
3423,,F,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,4,,,104714,,Autocuration,1,CHEMBL618045,BAO_0000019,,
3424,,B,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,4,,,104714,,Autocuration,1,CHEMBL618046,BAO_0000223,,
3425,,F,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,4,,,104714,,Autocuration,1,CHEMBL618047,BAO_0000019,,
3426,,F,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,4,,,104714,,Autocuration,1,CHEMBL875084,BAO_0000019,,
3427,,F,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,4,,,104714,,Autocuration,1,CHEMBL618048,BAO_0000019,,
3428,,B,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,4,,,104714,,Autocuration,1,CHEMBL618049,BAO_0000223,,
3429,,F,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,4,,,104714,,Autocuration,1,CHEMBL619764,BAO_0000019,,
3430,,F,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,4,,,104714,,Autocuration,1,CHEMBL619765,BAO_0000019,,
3431,,F,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,4,,,104714,,Autocuration,1,CHEMBL619766,BAO_0000019,,
3432,,B,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,4,,,104714,,Autocuration,1,CHEMBL619767,BAO_0000223,,
3433,,B,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,4,,,104714,,Autocuration,1,CHEMBL619768,BAO_0000223,,
3434,,F,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,4,,,104714,,Autocuration,1,CHEMBL619769,BAO_0000019,,
3435,,B,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,4,,,104714,,Autocuration,1,CHEMBL619770,BAO_0000223,,
3436,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,4,,,104714,,Autocuration,1,CHEMBL619771,BAO_0000223,,
3437,,B,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,4,,,104714,,Autocuration,1,CHEMBL619772,BAO_0000219,,
3438,,B,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,4,,,104714,,Autocuration,1,CHEMBL619773,BAO_0000223,,
3439,NG108-15,B,433.0,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,4,,,104714,,Autocuration,1,CHEMBL619774,BAO_0000219,,
3440,,B,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,4,,,104714,,Autocuration,1,CHEMBL875083,BAO_0000019,,
3441,NG108-15,B,433.0,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,4,,,104714,,Autocuration,1,CHEMBL620718,BAO_0000219,,
3442,,B,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,4,,,104714,,Autocuration,1,CHEMBL618127,BAO_0000223,,
3443,,B,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,4,,,104714,,Autocuration,1,CHEMBL618128,BAO_0000223,,
3444,,B,,In vitro,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,4,,,104714,,Autocuration,1,CHEMBL618129,BAO_0000219,,
3445,,B,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,4,,,104714,,Autocuration,1,CHEMBL618130,BAO_0000223,,
3446,,F,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,4,,,104714,,Autocuration,1,CHEMBL618131,BAO_0000019,,
3447,,F,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL618132,BAO_0000019,,
3448,,F,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL618133,BAO_0000019,,
3449,,F,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,4,,,104714,10141.0,Autocuration,1,CHEMBL618134,BAO_0000019,,
3450,,F,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL618135,BAO_0000019,,
3451,,B,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,4,,,104714,,Autocuration,1,CHEMBL618136,BAO_0000223,,
3452,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,4,,,104714,,Autocuration,1,CHEMBL618137,BAO_0000223,,
3453,,B,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,4,,,104714,,Autocuration,1,CHEMBL618138,BAO_0000223,,
3454,,B,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,4,,,104714,,Autocuration,1,CHEMBL618139,BAO_0000223,,
3455,,B,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,4,,,104714,,Autocuration,1,CHEMBL618140,BAO_0000223,,
3456,,B,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,4,,,104714,,Autocuration,1,CHEMBL618141,BAO_0000223,,
3457,,B,,,Binding affinity for 5-hydroxytryptamine 2C receptor,8,,,108,,Expert,1,CHEMBL873478,BAO_0000357,,
3458,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,6,,,104698,,Autocuration,1,CHEMBL618142,BAO_0000223,,
3459,,B,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,8,,,144,,Autocuration,1,CHEMBL618143,BAO_0000357,,
3460,,B,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,8,,,144,,Autocuration,1,CHEMBL618144,BAO_0000357,,
3461,,B,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,8,,,144,,Autocuration,1,CHEMBL618145,BAO_0000357,,
3462,,B,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,4,,,104714,,Autocuration,1,CHEMBL618146,BAO_0000223,,
3463,,B,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,4,,,104714,,Autocuration,1,CHEMBL618147,BAO_0000223,,
3464,,B,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,4,,,104714,,Autocuration,1,CHEMBL618148,BAO_0000223,,
3465,,B,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,8,,,144,,Autocuration,1,CHEMBL618149,BAO_0000019,,
3466,,B,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,8,,,144,,Autocuration,1,CHEMBL872927,BAO_0000357,,
3467,,B,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,8,,,144,,Autocuration,1,CHEMBL618150,BAO_0000357,,
3468,,B,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,8,,,144,,Autocuration,1,CHEMBL618151,BAO_0000357,,
3469,,B,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,8,,,144,,Autocuration,1,CHEMBL875094,BAO_0000357,,
3470,,B,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,8,,,144,,Autocuration,1,CHEMBL618152,BAO_0000019,,
3471,,B,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,8,,,144,,Autocuration,1,CHEMBL618153,BAO_0000357,,
3472,,B,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,8,,,144,,Autocuration,1,CHEMBL618888,BAO_0000357,,
3473,,F,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,8,,,144,,Autocuration,1,CHEMBL618889,BAO_0000019,,
3474,,B,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,8,,,144,,Autocuration,1,CHEMBL618890,BAO_0000357,,
3475,,B,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,8,,,144,,Autocuration,1,CHEMBL618891,BAO_0000019,,
3476,,B,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,8,,,144,,Autocuration,1,CHEMBL619054,BAO_0000019,,
3477,,B,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,4,,,104714,,Autocuration,1,CHEMBL619055,BAO_0000223,,
3478,,B,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,8,,,144,,Autocuration,1,CHEMBL619056,BAO_0000357,,
3479,,F,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,8,,,144,,Autocuration,1,CHEMBL619057,BAO_0000019,,
3480,,B,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,8,,,144,,Autocuration,1,CHEMBL619058,BAO_0000357,,
3481,Oocytes,F,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,9,,,12020,10116.0,Expert,1,CHEMBL619059,BAO_0000219,,
3482,Oocytes,F,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,9,,,12020,10116.0,Expert,1,CHEMBL619060,BAO_0000219,,
3483,Oocytes,F,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,9,,,12020,10116.0,Expert,1,CHEMBL875095,BAO_0000219,,
3484,,F,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,9,,,20033,10141.0,Intermediate,1,CHEMBL619061,BAO_0000221,2116.0,
3485,,F,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,9,,,20033,10141.0,Intermediate,1,CHEMBL619062,BAO_0000221,2116.0,
3486,,F,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,9,,,20033,10141.0,Intermediate,1,CHEMBL619063,BAO_0000019,,
3487,,B,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,9,,,20033,10141.0,Intermediate,1,CHEMBL619064,BAO_0000221,2116.0,
3488,,B,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,9,,,20033,10141.0,Intermediate,1,CHEMBL619065,BAO_0000357,,
3489,,B,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,9,,,20033,10141.0,Intermediate,1,CHEMBL619066,BAO_0000221,2116.0,
3490,,B,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,8,,,10209,,Autocuration,1,CHEMBL619775,BAO_0000221,2116.0,
3491,,B,,,Affinity against 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL619776,BAO_0000357,,
3492,,B,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,4,,,104841,10141.0,Autocuration,1,CHEMBL619777,BAO_0000224,,
3493,,B,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,4,,,104841,10141.0,Autocuration,1,CHEMBL619778,BAO_0000224,,
3494,,B,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,4,,,104841,10141.0,Autocuration,1,CHEMBL619779,BAO_0000221,2116.0,
3495,,B,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",4,,,104841,10141.0,Autocuration,1,CHEMBL619780,BAO_0000224,,
3496,,B,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",4,,,104841,10141.0,Autocuration,1,CHEMBL619166,BAO_0000224,,
3497,,F,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,4,,,104841,10141.0,Autocuration,1,CHEMBL619167,BAO_0000019,,
3498,,F,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,4,,,104841,10141.0,Autocuration,1,CHEMBL619168,BAO_0000019,,
3499,,B,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,9,,,168,9606.0,Expert,1,CHEMBL619169,BAO_0000219,2081.0,
3500,,B,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,9,,,168,9606.0,Expert,1,CHEMBL619170,BAO_0000219,2081.0,
3501,,F,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",5,,,104841,9606.0,Autocuration,1,CHEMBL619171,BAO_0000019,,
3502,,F,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",9,,,168,9606.0,Expert,1,CHEMBL619172,BAO_0000219,2081.0,
3503,,B,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,0,,,22226,10090.0,Autocuration,1,CHEMBL619173,BAO_0000019,,
3504,,B,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,0,,,22226,10090.0,Autocuration,1,CHEMBL619174,BAO_0000019,,
3505,,B,,,5-hydroxytryptamine receptor binding affinity was determined in rats,4,,,104705,,Autocuration,1,CHEMBL619175,BAO_0000019,,
3506,,B,,,Binding affinity at rat 5-hydroxytryptamine receptor.,4,,,104705,,Autocuration,1,CHEMBL619176,BAO_0000224,,
3507,,B,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,4,,,104705,,Autocuration,1,CHEMBL619177,BAO_0000019,,
3508,,B,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,4,,,104705,,Autocuration,1,CHEMBL619178,BAO_0000224,,
3509,,B,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,4,,,104705,,Autocuration,1,CHEMBL619179,BAO_0000224,,
3510,,F,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,4,,,104705,,Autocuration,1,CHEMBL619180,BAO_0000019,945.0,
3511,,F,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,4,,,104705,,Autocuration,1,CHEMBL619181,BAO_0000019,945.0,
3512,,F,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,4,,,104705,,Autocuration,1,CHEMBL619182,BAO_0000019,,
3513,,B,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,4,,,104705,,Autocuration,1,CHEMBL619183,BAO_0000224,,
3514,,B,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",4,,,104705,,Autocuration,1,CHEMBL619184,BAO_0000224,,
3515,,B,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,8,,,10576,,Autocuration,1,CHEMBL619185,BAO_0000221,10000000.0,
3516,,B,,,Binding affinity for rat 5-hydroxytryptamine transporter.,8,,,12198,,Expert,1,CHEMBL619186,BAO_0000357,,
3517,,B,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,4,,,104705,,Autocuration,1,CHEMBL619187,BAO_0000019,,
3518,,B,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,5,,,104705,10116.0,Autocuration,1,CHEMBL619188,BAO_0000019,,
3519,,B,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,5,,,104705,10116.0,Autocuration,1,CHEMBL619189,BAO_0000224,,
3520,,F,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,9,,,12198,10116.0,Expert,1,CHEMBL619190,BAO_0000019,955.0,
3521,,F,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,9,,,12198,10116.0,Expert,1,CHEMBL619191,BAO_0000221,2037.0,
3522,,B,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,5,,,104705,10116.0,Autocuration,1,CHEMBL619192,BAO_0000019,,
3523,,B,,,Percent binding affinity against 5-hydroxytryptamine receptor,5,,,104705,10116.0,Autocuration,1,CHEMBL619193,BAO_0000224,,
3524,,B,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,0,,,22226,,Autocuration,1,CHEMBL619194,BAO_0000019,,
3525,,B,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,5,,,104705,10116.0,Autocuration,1,CHEMBL619195,BAO_0000224,,
3526,,B,,,Affinity against 5-hydroxytryptamine receptor was determined,5,,,104705,10116.0,Autocuration,1,CHEMBL619196,BAO_0000224,,
3527,,B,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,5,,,104705,10116.0,Autocuration,1,CHEMBL619197,BAO_0000019,945.0,
3528,,B,,In vitro,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,9,,,121,9606.0,Expert,1,CHEMBL619198,BAO_0000219,,
3529,,B,,In vitro,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,9,,,121,9606.0,Expert,1,CHEMBL875081,BAO_0000219,,
3530,,B,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,8,,,18065,,Autocuration,1,CHEMBL884712,BAO_0000357,,
3531,,B,,,Inhibition of 5-hydroxytryptamine reuptake,8,,,121,,Expert,1,CHEMBL884710,BAO_0000357,,
3532,,F,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",8,,,18065,,Autocuration,1,CHEMBL619199,BAO_0000019,,
3533,,F,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",8,,,18065,,Autocuration,1,CHEMBL619200,BAO_0000019,,
3534,,F,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",8,,,18065,,Autocuration,1,CHEMBL619201,BAO_0000019,,
3535,,F,,,Tested for 5-hydroxytryptamine receptor uptake,8,,,18065,,Autocuration,1,CHEMBL619202,BAO_0000019,,
3536,CHO,B,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,9,,,51,9606.0,Expert,1,CHEMBL619203,BAO_0000219,,
3537,,F,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,9,,,51,9606.0,Expert,1,CHEMBL619204,BAO_0000019,,
3538,,B,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,8,,,10576,9606.0,Autocuration,1,CHEMBL619205,BAO_0000249,,
3539,,B,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,8,,,10576,,Autocuration,1,CHEMBL619206,BAO_0000357,,
3540,,B,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,8,,,10576,,Expert,1,CHEMBL619207,BAO_0000249,,
3541,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,8,,,10825,,Autocuration,1,CHEMBL619208,BAO_0000019,2435.0,
3542,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,8,,,10825,,Autocuration,1,CHEMBL619209,BAO_0000019,2435.0,
3543,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,8,,,10825,,Autocuration,1,CHEMBL619210,BAO_0000019,2435.0,
3544,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,8,,,10825,,Autocuration,1,CHEMBL619211,BAO_0000019,2435.0,
3545,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,8,,,10825,,Autocuration,1,CHEMBL619212,BAO_0000019,2435.0,
3546,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620681,BAO_0000019,2435.0,
3547,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620682,BAO_0000019,2435.0,
3548,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620683,BAO_0000019,2435.0,
3549,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620684,BAO_0000019,2435.0,
3550,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620685,BAO_0000019,2435.0,
3551,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620686,BAO_0000019,2435.0,
3552,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620687,BAO_0000019,349.0,
3553,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620688,BAO_0000019,349.0,
3554,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620689,BAO_0000019,349.0,
3555,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620690,BAO_0000019,349.0,
3556,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620691,BAO_0000019,349.0,
3557,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620692,BAO_0000019,349.0,
3558,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,8,,,10825,,Autocuration,1,CHEMBL620693,BAO_0000019,349.0,
3559,,B,,,Binding affinity against 5-hydroxytryptamine 4 receptor,8,,,168,,Expert,1,CHEMBL620694,BAO_0000357,,
3560,,F,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,8,,,168,,Autocuration,1,CHEMBL857986,BAO_0000019,,
3561,,B,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,8,,,168,,Autocuration,1,CHEMBL620695,BAO_0000357,,
3562,,B,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,8,,,168,,Expert,1,CHEMBL620696,BAO_0000357,,
3563,,B,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,8,,,168,,Autocuration,1,CHEMBL620697,BAO_0000357,,
3564,,B,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,8,,,168,,Autocuration,1,CHEMBL620698,BAO_0000357,,
3565,,B,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,8,,,168,,Autocuration,1,CHEMBL620699,BAO_0000357,,
3566,,B,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,8,,,168,,Autocuration,1,CHEMBL620700,BAO_0000357,,
3567,COS-7,B,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,8,,,168,,Autocuration,1,CHEMBL620701,BAO_0000219,,
3568,COS-7,B,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,8,,,168,,Autocuration,1,CHEMBL875082,BAO_0000219,,
3569,COS-7,B,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,8,,,168,,Autocuration,1,CHEMBL620702,BAO_0000219,,
3570,COS-7,B,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,8,,,168,,Autocuration,1,CHEMBL620703,BAO_0000219,,
3571,C6,B,673.0,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,8,,,168,,Autocuration,1,CHEMBL620704,BAO_0000219,,
3572,C6,B,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,8,,,168,,Expert,1,CHEMBL620705,BAO_0000219,,
3573,C6,B,673.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,8,,,168,,Expert,1,CHEMBL620706,BAO_0000219,,
3574,C6,B,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,8,,,168,,Expert,1,CHEMBL620707,BAO_0000219,,
3575,,B,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,8,,,10624,,Expert,1,CHEMBL620708,BAO_0000357,,
3576,,B,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,8,,,105,,Autocuration,1,CHEMBL620709,BAO_0000357,,
3577,,B,,,Binding affinity against 5-hydroxytryptamine 5A receptor,9,,,10624,9606.0,Expert,1,CHEMBL620710,BAO_0000357,,
3578,CHO,B,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,8,,,10624,,Autocuration,1,CHEMBL620711,BAO_0000219,,
3579,,B,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,9,,,10624,9606.0,Expert,1,CHEMBL620712,BAO_0000357,,
3580,,B,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,9,,,10624,9606.0,Expert,1,CHEMBL620713,BAO_0000357,,
3581,,B,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,9,,,10624,9606.0,Expert,1,CHEMBL620714,BAO_0000357,,
3582,,B,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,9,,,10624,9606.0,Expert,1,CHEMBL620715,BAO_0000357,,
3583,,B,,,Binding affinity towards 5-HT5A receptor,8,,,10624,,Autocuration,1,CHEMBL620716,BAO_0000357,,
3584,,B,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,8,,,10624,,Expert,1,CHEMBL620717,BAO_0000357,,
3585,,B,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,8,,,10624,,Autocuration,1,CHEMBL618072,BAO_0000357,,
3586,,B,,,Binding affinity towards cloned human 5-HT5A receptor was determined,8,,,10624,,Autocuration,1,CHEMBL857987,BAO_0000357,,
3587,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,8,,,10624,,Autocuration,1,CHEMBL618073,BAO_0000219,,
3588,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,8,,,10624,,Autocuration,1,CHEMBL618074,BAO_0000219,,
3589,HEK293,B,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),8,,,10624,,Autocuration,1,CHEMBL618075,BAO_0000219,,
3590,,B,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,9,,,10625,10090.0,Expert,1,CHEMBL618076,BAO_0000357,,
3591,,B,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,9,,,10625,10090.0,Expert,1,CHEMBL618077,BAO_0000357,,
3592,,B,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,9,,,10625,10090.0,Expert,1,CHEMBL618078,BAO_0000357,,
3593,,B,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,9,,,10625,10090.0,Expert,1,CHEMBL881821,BAO_0000357,,
3594,,B,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,9,,,10625,10090.0,Expert,1,CHEMBL618079,BAO_0000357,,
3595,,B,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,8,,,10625,,Expert,1,CHEMBL618080,BAO_0000357,,
3596,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,8,,,10576,,Autocuration,1,CHEMBL618081,BAO_0000219,,
3597,HEK293,B,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,8,,,10626,,Autocuration,1,CHEMBL618082,BAO_0000219,,
3598,,B,,,Binding affinity towards 5-HT5a receptor,8,,,10624,,Expert,1,CHEMBL618083,BAO_0000357,,
3599,,B,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,9,,,10624,9606.0,Expert,1,CHEMBL618084,BAO_0000357,,
3600,,B,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,8,,,10624,,Expert,1,CHEMBL618085,BAO_0000357,,
3601,,B,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,8,,,10624,,Expert,1,CHEMBL618086,BAO_0000357,,
3602,,B,,,Binding affinities against 5-hydroxytryptamine 5A receptor,8,,,10624,,Autocuration,1,CHEMBL875092,BAO_0000357,,
3603,,B,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,8,,,10624,,Autocuration,1,CHEMBL618087,BAO_0000357,,
3604,,B,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,8,,,10624,,Autocuration,1,CHEMBL872926,BAO_0000357,,
3605,,F,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,4,,,104714,10141.0,Autocuration,1,CHEMBL618088,BAO_0000019,,
3606,,B,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,4,,,104714,,Autocuration,1,CHEMBL618089,BAO_0000223,,
3607,,B,,,Inhibition of human 5-hydroxytryptamine 6 receptor,9,,,10627,9606.0,Expert,1,CHEMBL618090,BAO_0000357,,
3608,,B,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,9,,,10627,9606.0,Expert,1,CHEMBL618091,BAO_0000357,,
3609,,B,,,Inhibition against human 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL618092,BAO_0000357,,
3610,,B,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,9,,,10627,9606.0,Expert,1,CHEMBL618093,BAO_0000357,,
3611,HeLa,B,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,8,,,10627,,Expert,1,CHEMBL618094,BAO_0000219,,
3612,,B,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,9,,,10627,9606.0,Expert,1,CHEMBL618095,BAO_0000357,,
3613,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,9,,,10627,9606.0,Expert,1,CHEMBL875093,BAO_0000357,,
3614,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,9,,,10627,9606.0,Expert,1,CHEMBL618096,BAO_0000357,,
3615,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,9,,,10627,9606.0,Expert,1,CHEMBL618118,BAO_0000357,,
3616,,B,,,Binding affinity against 5-hydroxytryptamine 6 receptor,9,,,10627,9606.0,Expert,1,CHEMBL618119,BAO_0000357,,
3617,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,,,10627,,Expert,1,CHEMBL618120,BAO_0000357,,
3618,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL618121,BAO_0000357,,
3619,HEK293,B,722.0,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",8,,,10627,,Expert,1,CHEMBL618122,BAO_0000219,,
3620,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,8,,,10627,,Autocuration,1,CHEMBL618123,BAO_0000357,,
3621,HEK293,B,722.0,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,8,,,10627,,Expert,1,CHEMBL618124,BAO_0000219,,
3622,,B,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL618125,BAO_0000357,,
3623,HEK293,B,722.0,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,9,,,10627,9606.0,Expert,1,CHEMBL618126,BAO_0000219,,
3624,,B,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,8,,,10627,,Expert,1,CHEMBL618236,BAO_0000019,,
3625,,B,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,8,,,10627,,Expert,1,CHEMBL618237,BAO_0000019,,
3626,COS-7,B,643.0,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,8,,,10627,,Expert,1,CHEMBL618238,BAO_0000219,,
3627,,B,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,9,,,10627,9606.0,Expert,1,CHEMBL618239,BAO_0000357,,
3628,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL618240,BAO_0000019,,
3629,,B,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,8,,,10627,,Autocuration,1,CHEMBL618241,BAO_0000357,,
3630,HEK293,B,722.0,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,8,,,10627,,Autocuration,1,CHEMBL859399,BAO_0000219,,
3631,,F,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,8,,,10627,,Autocuration,1,CHEMBL618242,BAO_0000019,,
3632,,B,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL857991,BAO_0000357,,
3633,,B,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,8,,,10627,,Expert,1,CHEMBL619951,BAO_0000357,,
3634,HeLa,B,308.0,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,9,,,10627,9606.0,Expert,1,CHEMBL619952,BAO_0000219,,
3635,HeLa,B,308.0,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,9,,,10627,9606.0,Expert,1,CHEMBL619953,BAO_0000219,,
3636,HeLa,B,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,8,,,10627,,Autocuration,1,CHEMBL619954,BAO_0000219,,
3637,HeLa,B,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,8,,,10627,,Autocuration,1,CHEMBL619955,BAO_0000219,,
3638,HeLa,B,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,8,,,10627,,Autocuration,1,CHEMBL619956,BAO_0000219,,
3639,CHO,B,449.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,8,,,10627,,Autocuration,1,CHEMBL619957,BAO_0000219,,
3640,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,8,,,10627,,Autocuration,1,CHEMBL619958,BAO_0000219,,
3641,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,8,,,10627,,Autocuration,1,CHEMBL620627,BAO_0000219,,
3642,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,8,,,10627,,Autocuration,1,CHEMBL620628,BAO_0000219,,
3643,HeLa,B,308.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,8,,,10627,,Autocuration,1,CHEMBL620629,BAO_0000219,,
3644,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL620630,BAO_0000357,,
3645,HeLa,B,308.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,8,,,10627,,Autocuration,1,CHEMBL620782,BAO_0000219,,
3646,,B,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL620783,BAO_0000357,,
3647,,B,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,8,,,10627,,Expert,1,CHEMBL620784,BAO_0000357,,
3648,HeLa,B,308.0,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,8,,,10627,,Expert,1,CHEMBL620785,BAO_0000219,,
3649,,B,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),8,,,10627,,Autocuration,1,CHEMBL857992,BAO_0000357,,
3650,,B,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,8,,,10627,,Autocuration,1,CHEMBL620786,BAO_0000219,,
3651,HeLa,B,308.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,8,,,10627,,Autocuration,1,CHEMBL620787,BAO_0000219,,
3652,HeLa,B,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",8,,,10627,,Autocuration,1,CHEMBL620788,BAO_0000219,,
3653,HeLa,B,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",8,,,10627,,Autocuration,1,CHEMBL620789,BAO_0000219,,
3654,HeLa,B,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",8,,,10627,,Autocuration,1,CHEMBL620790,BAO_0000219,,
3655,CHO,B,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,8,,,10628,,Autocuration,1,CHEMBL620791,BAO_0000219,,
3656,,B,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,8,,,10628,,Autocuration,1,CHEMBL620792,BAO_0000019,,
3657,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,8,,,10628,,Autocuration,1,CHEMBL620793,BAO_0000357,,
3658,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,8,,,10628,,Autocuration,1,CHEMBL620794,BAO_0000357,,
3659,HeLa,B,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,9,,,10627,9606.0,Autocuration,1,CHEMBL620795,BAO_0000219,,
3660,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,,,10627,,Expert,1,CHEMBL620796,BAO_0000357,,
3661,,B,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,8,,,10627,,Autocuration,1,CHEMBL620797,BAO_0000357,,
3662,,F,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,9,,,10627,9606.0,Expert,1,CHEMBL620798,BAO_0000019,,
3663,,B,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,8,,,10627,,Autocuration,1,CHEMBL620799,BAO_0000357,,
3664,,B,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,8,,,10627,,Expert,1,CHEMBL620800,BAO_0000357,,
3665,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,8,,,10627,,Autocuration,1,CHEMBL620801,BAO_0000357,,
3666,,B,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL875100,BAO_0000357,,
3667,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,8,,,10627,,Autocuration,1,CHEMBL620802,BAO_0000357,,
3668,,F,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,8,,,10627,,Expert,1,CHEMBL620803,BAO_0000019,,
3669,,F,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,8,,,10627,,Expert,1,CHEMBL620804,BAO_0000019,,
3670,,B,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,8,,,10627,,Autocuration,1,CHEMBL620805,BAO_0000357,,
3671,,B,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL620806,BAO_0000357,,
3672,,B,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,8,,,10627,,Autocuration,1,CHEMBL620807,BAO_0000357,,
3673,,B,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,8,,,10627,,Autocuration,1,CHEMBL620808,BAO_0000357,,
3674,,B,,,Binding affinities against 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL620809,BAO_0000357,,
3675,,B,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL620810,BAO_0000357,,
3676,,B,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,9,,,10627,9606.0,Expert,1,CHEMBL620811,BAO_0000357,,
3677,,B,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,8,,,10627,,Autocuration,1,CHEMBL620812,BAO_0000357,,
3678,,B,,,Affinity against 5-hydroxytryptamine 6 receptor,8,,,10627,,Autocuration,1,CHEMBL620813,BAO_0000357,,
3679,,B,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],8,,,10627,,Autocuration,1,CHEMBL620814,BAO_0000357,,
3680,,B,,,Inhibition of human 5-hydroxytryptamine 7 receptor,9,,,10209,9606.0,Expert,1,CHEMBL620815,BAO_0000357,,
3681,HEK293,B,722.0,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,8,,,10209,,Autocuration,1,CHEMBL620816,BAO_0000219,,
3682,,B,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL620817,BAO_0000357,,
3683,,B,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),8,,,10209,,Autocuration,1,CHEMBL620818,BAO_0000357,,
3684,HEK293,B,722.0,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,8,,,10209,,Expert,1,CHEMBL620819,BAO_0000219,,
3685,,B,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,9,,,10209,9606.0,Expert,1,CHEMBL620820,BAO_0000357,,
3686,CHO,B,449.0,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,8,,,10209,,Autocuration,1,CHEMBL620821,BAO_0000219,,
3687,,B,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,9,,,10209,9606.0,Expert,1,CHEMBL620822,BAO_0000357,,
3688,,B,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,9,,,10209,9606.0,Expert,1,CHEMBL620823,BAO_0000357,,
3689,,B,,,Binding affinity against 5-hydroxytryptamine 7 receptor,9,,,10209,9606.0,Expert,1,CHEMBL620824,BAO_0000357,,
3690,CHO,B,449.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,8,,,10209,,Expert,1,CHEMBL620825,BAO_0000219,,
3691,,B,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,8,,,10209,,Autocuration,1,CHEMBL872930,BAO_0000357,,
3692,,B,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL620826,BAO_0000357,,
3693,,B,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,8,,,10209,,Autocuration,1,CHEMBL620827,BAO_0000357,,
3694,,B,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL620828,BAO_0000357,,
3695,,B,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL620829,BAO_0000357,,
3696,HEK293,B,722.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,8,,,10209,,Expert,1,CHEMBL620830,BAO_0000219,,
3697,,B,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,8,,,10209,,Expert,1,CHEMBL620831,BAO_0000019,,
3698,,B,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,8,,,10209,,Expert,1,CHEMBL620832,BAO_0000019,,
3699,,B,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,9,,,10209,9606.0,Expert,1,CHEMBL621548,BAO_0000357,,
3700,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL621549,BAO_0000019,,
3701,,B,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,8,,,10209,,Autocuration,1,CHEMBL621550,BAO_0000357,,
3702,CHO,B,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,8,,,10209,,Autocuration,1,CHEMBL621551,BAO_0000219,,
3703,,B,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,8,,,10209,,Autocuration,1,CHEMBL621552,BAO_0000019,,
3704,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL857077,BAO_0000357,,
3705,,B,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,8,,,10209,,Autocuration,1,CHEMBL618158,BAO_0000357,,
3706,COS-7,B,643.0,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,9,,,10209,9606.0,Expert,1,CHEMBL618159,BAO_0000219,,
3707,COS-7,B,643.0,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,8,,,10209,,Autocuration,1,CHEMBL875101,BAO_0000219,,
3708,HEK293,B,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,9,,,10209,9606.0,Expert,1,CHEMBL618160,BAO_0000219,,
3709,,B,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,8,,,10209,,Expert,1,CHEMBL618161,BAO_0000357,,
3710,HEK293,B,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,8,,,10209,,Expert,1,CHEMBL618162,BAO_0000219,,
3711,,B,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,8,,,10209,,Expert,1,CHEMBL618163,BAO_0000357,,
3712,,B,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,8,,,10209,,Autocuration,1,CHEMBL618164,BAO_0000357,,
3713,,B,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,8,,,10209,,Expert,1,CHEMBL618165,BAO_0000219,,
3714,HEK293,B,722.0,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,8,,,10209,,Autocuration,1,CHEMBL618166,BAO_0000219,,
3715,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,8,,,10209,,Autocuration,1,CHEMBL857989,BAO_0000219,,
3716,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,8,,,10209,,Autocuration,1,CHEMBL619888,BAO_0000219,,
3717,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,8,,,10209,,Autocuration,1,CHEMBL619889,BAO_0000219,,
3718,HEK293,B,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,8,,,10209,,Autocuration,1,CHEMBL619890,BAO_0000219,,
3719,CHO,B,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,8,,,10209,,Autocuration,1,CHEMBL619891,BAO_0000219,,
3720,HEK293,B,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),8,,,10209,,Autocuration,1,CHEMBL619892,BAO_0000219,,
3721,HEK293,B,722.0,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,9,,,10209,,Expert,1,CHEMBL619893,BAO_0000219,,
3722,HEK293,B,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),8,,,10209,,Autocuration,1,CHEMBL619894,BAO_0000219,,
3723,HEK293,B,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,9,,,10209,,Intermediate,1,CHEMBL619895,BAO_0000219,,
3724,,B,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,9,,,10209,,Intermediate,1,CHEMBL619896,BAO_0000357,,
3725,COS-7,B,643.0,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,8,,,10209,,Autocuration,1,CHEMBL619897,BAO_0000219,,
3726,HEK293,B,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,8,,,10209,,Autocuration,1,CHEMBL619898,BAO_0000219,,
3727,HEK293,B,722.0,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,8,,,10209,,Expert,1,CHEMBL619899,BAO_0000219,,
3728,HEK293,B,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),8,,,10209,,Autocuration,1,CHEMBL619900,BAO_0000219,,
3729,HEK293,B,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,9,,,10209,9606.0,Expert,1,CHEMBL619901,BAO_0000219,,
3730,HEK293,B,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,8,,,10209,,Autocuration,1,CHEMBL620580,BAO_0000219,,
3731,HEK293,B,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,8,,,10209,,Autocuration,1,CHEMBL620581,BAO_0000219,,
3732,HEK293,B,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",8,,,10209,,Autocuration,1,CHEMBL620733,BAO_0000219,,
3733,,B,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,9,,,10209,9606.0,Autocuration,1,CHEMBL620734,BAO_0000357,,
3734,,B,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,9,,,10022,10090.0,Expert,1,CHEMBL620735,BAO_0000357,,
3735,,B,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,8,,,10209,9986.0,Autocuration,1,CHEMBL620736,BAO_0000019,,
3736,CHO,B,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,8,,,11923,,Autocuration,1,CHEMBL620737,BAO_0000219,,
3737,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,8,,,11923,,Autocuration,1,CHEMBL620738,BAO_0000219,,
3738,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,8,,,11923,,Autocuration,1,CHEMBL620739,BAO_0000219,,
3739,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,8,,,11923,,Autocuration,1,CHEMBL620740,BAO_0000219,,
3740,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,8,,,11923,,Autocuration,1,CHEMBL620741,BAO_0000219,,
3741,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,8,,,11923,,Autocuration,1,CHEMBL620742,BAO_0000219,,
3742,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,8,,,11923,,Autocuration,1,CHEMBL620743,BAO_0000219,,
3743,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,8,,,11923,,Autocuration,1,CHEMBL620744,BAO_0000219,,
3744,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,8,,,11923,,Autocuration,1,CHEMBL620745,BAO_0000219,,
3745,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,8,,,11923,,Autocuration,1,CHEMBL620746,BAO_0000219,,
3746,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,8,,,11923,,Autocuration,1,CHEMBL620747,BAO_0000219,,
3747,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,8,,,11923,,Autocuration,1,CHEMBL620748,BAO_0000219,,
3748,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,8,,,11923,,Autocuration,1,CHEMBL620749,BAO_0000219,,
3749,,B,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,8,,,11923,,Expert,1,CHEMBL620750,BAO_0000357,,
3750,,B,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,9,,,11923,10116.0,Expert,1,CHEMBL620751,BAO_0000357,,
3751,,B,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,8,,,11923,,Expert,1,CHEMBL620752,BAO_0000357,,
3752,,B,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,8,,,11923,,Autocuration,1,CHEMBL872929,BAO_0000019,,
3753,,B,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,9,,,11923,10116.0,Expert,1,CHEMBL620753,BAO_0000357,,
3754,,B,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,9,,,11923,10116.0,Expert,1,CHEMBL620754,BAO_0000357,,
3755,CHO,B,449.0,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,9,,,11923,10116.0,Expert,1,CHEMBL620755,BAO_0000219,,
3756,,B,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,8,,,11923,,Autocuration,1,CHEMBL620756,BAO_0000357,,
3757,,B,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,8,,,11923,,Autocuration,1,CHEMBL620757,BAO_0000357,,
3758,CHO,B,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",8,,,11923,,Autocuration,1,CHEMBL620758,BAO_0000219,,
3759,CHO,B,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",8,,,11923,,Autocuration,1,CHEMBL620759,BAO_0000219,,
3760,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,8,,,11923,,Autocuration,1,CHEMBL620760,BAO_0000219,,
3761,CHO,B,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,8,,,11923,,Autocuration,1,CHEMBL620761,BAO_0000219,,
3762,,F,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,8,,,11923,,Autocuration,1,CHEMBL620762,BAO_0000221,2116.0,
3763,,F,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,8,,,11923,,Autocuration,1,CHEMBL620763,BAO_0000221,2116.0,
3764,,F,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,8,,,11923,,Autocuration,1,CHEMBL620764,BAO_0000221,2116.0,
3765,,B,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,9,,,11923,10116.0,Expert,1,CHEMBL857990,BAO_0000249,,
3766,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,8,,,11923,,Autocuration,1,CHEMBL620765,BAO_0000357,,
3767,,B,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,8,,,11923,,Expert,1,CHEMBL620766,BAO_0000357,,
3768,,B,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,8,,,11923,,Expert,1,CHEMBL620767,BAO_0000019,1898.0,
3769,,B,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,8,,,11923,,Autocuration,1,CHEMBL620768,BAO_0000357,,
3770,,B,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,8,,,11923,,Expert,1,CHEMBL619051,BAO_0000249,1898.0,
3771,,B,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,8,,,11923,,Expert,1,CHEMBL619052,BAO_0000357,,
3772,HEK293,F,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,9,,,11923,10116.0,Expert,1,CHEMBL619053,BAO_0000219,,
3773,HEK293,F,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,9,,,11923,10116.0,Expert,1,CHEMBL619703,BAO_0000219,,
3774,HEK293,F,722.0,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,9,,,11923,10116.0,Autocuration,1,CHEMBL619704,BAO_0000219,,
3775,,B,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,8,,,10209,,Expert,1,CHEMBL619851,BAO_0000357,,
3776,,B,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,8,,,10209,,Autocuration,1,CHEMBL619852,BAO_0000357,,
3777,,B,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,8,,,10209,,Autocuration,1,CHEMBL619853,BAO_0000357,,
3778,,B,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,9,,,10209,9606.0,Expert,1,CHEMBL619854,BAO_0000357,,
3779,,B,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,8,,,10209,,Expert,1,CHEMBL619855,BAO_0000357,,
3780,,B,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,8,,,10209,,Autocuration,1,CHEMBL619856,BAO_0000357,,
3781,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,8,,,10209,,Autocuration,1,CHEMBL619857,BAO_0000357,,
3782,,F,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,8,,,10209,,Expert,1,CHEMBL619858,BAO_0000019,,
3783,,B,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,8,,,10209,,Autocuration,1,CHEMBL619859,BAO_0000357,,
3784,,B,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,8,,,10209,,Autocuration,1,CHEMBL619860,BAO_0000357,,
3785,,B,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL619861,BAO_0000357,,
3786,,B,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,8,,,10209,,Expert,1,CHEMBL619862,BAO_0000357,,
3787,,B,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,8,,,10209,,Autocuration,1,CHEMBL619863,BAO_0000357,,
3788,,B,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,8,,,10209,,Autocuration,1,CHEMBL619864,BAO_0000357,,
3789,,B,,,Binding affinities against 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL872928,BAO_0000357,,
3790,,B,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,8,,,10209,,Autocuration,1,CHEMBL619865,BAO_0000357,,
3791,,B,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,8,,,10209,,Expert,1,CHEMBL619866,BAO_0000357,,
3792,,B,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,8,,,10209,,Autocuration,1,CHEMBL619867,BAO_0000357,,
3793,,B,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,8,,,10209,,Autocuration,1,CHEMBL619868,BAO_0000221,2116.0,
3794,,F,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,8,,,55,,Autocuration,1,CHEMBL619869,BAO_0000019,,
3795,,F,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,9,,,55,9606.0,Expert,1,CHEMBL619870,BAO_0000019,,
3796,,B,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,8,,,55,,Autocuration,1,CHEMBL619871,BAO_0000357,,
3797,,B,,,In vitro inhibition of human recombinant lipoxygenase enzyme,8,,,55,,Autocuration,1,CHEMBL619872,BAO_0000357,,
3798,,B,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,8,,,55,,Autocuration,1,CHEMBL619873,BAO_0000357,,
3799,,B,,,Inhibition of 5-lipoxygenase in human whole blood.,8,,,55,,Expert,1,CHEMBL619874,BAO_0000357,178.0,
3800,,B,,,Inhibition of 5-lipoxygenase in human whole blood.,8,,,55,,Expert,1,CHEMBL619875,BAO_0000357,178.0,
3801,,B,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,8,,,55,,Autocuration,1,CHEMBL619876,BAO_0000357,,
3802,,B,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),8,,,55,,Autocuration,1,CHEMBL619877,BAO_0000357,,
3803,,F,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,8,,,55,,Expert,1,CHEMBL619878,BAO_0000219,,
3804,,F,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,8,,,55,,Autocuration,1,CHEMBL619879,BAO_0000019,178.0,
3805,,B,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,8,,,55,,Autocuration,1,CHEMBL619880,BAO_0000357,,
3806,,B,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),8,,,55,,Autocuration,1,CHEMBL619881,BAO_0000357,,
3807,,B,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,8,,,55,,Expert,1,CHEMBL619882,BAO_0000357,,
3808,,B,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,8,,,55,,Autocuration,1,CHEMBL619883,BAO_0000357,,
3809,,B,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),9,,,55,9606.0,Expert,1,CHEMBL619884,BAO_0000357,178.0,
3810,,B,,,In vitro potency against human 5-Lipoxygenase,8,,,55,,Autocuration,1,CHEMBL619885,BAO_0000357,,
3811,,F,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,9,,,55,9606.0,Expert,1,CHEMBL619886,BAO_0000019,,
3812,,F,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,8,,,55,,Autocuration,1,CHEMBL619887,BAO_0000019,178.0,
3813,,F,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,8,,,55,,Autocuration,1,CHEMBL875097,BAO_0000019,,
3814,,B,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,8,,,55,,Autocuration,1,CHEMBL618001,BAO_0000219,,
3815,,B,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,8,,,55,,Autocuration,1,CHEMBL618002,BAO_0000219,,
3816,,B,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,8,,,55,,Autocuration,1,CHEMBL618003,BAO_0000219,,
3817,,B,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,8,,,55,,Autocuration,1,CHEMBL618004,BAO_0000219,,
3818,,B,,,Inhibition of human 5-lipoxygenase in human cells,8,,,55,,Autocuration,1,CHEMBL618005,BAO_0000219,,
3819,,B,,,Inhibition of human neutrophil 5-lipoxygenase,8,,,55,,Expert,1,CHEMBL618006,BAO_0000357,,
3820,,B,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,8,,,55,,Autocuration,1,CHEMBL875086,BAO_0000019,,
3821,,B,,,Inhibition of 5-lipoxygenase from human whole blood,8,,,55,,Expert,1,CHEMBL618007,BAO_0000357,178.0,
3822,,B,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,8,,,55,,Autocuration,1,CHEMBL618008,BAO_0000357,,
3823,,B,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,8,,,55,,Autocuration,1,CHEMBL618009,BAO_0000219,,
3824,,B,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,8,,,55,,Expert,1,CHEMBL618010,BAO_0000357,,
3825,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,8,,,55,,Autocuration,1,CHEMBL618011,BAO_0000357,,
3826,,B,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,8,,,55,,Expert,1,CHEMBL618012,BAO_0000357,,
3827,,B,,,Tested against 5-lipoxygenase,8,,,55,,Autocuration,1,CHEMBL882927,BAO_0000357,,
3828,,B,,,Tested for activity against 5-Lipoxygenase (5-LO),8,,,55,,Autocuration,1,CHEMBL618013,BAO_0000357,,
3829,,B,,,Tested for activity against 5-lipoxygenase,8,,,55,,Autocuration,1,CHEMBL618014,BAO_0000357,,
3830,,B,,,Tested for inhibition of 5-HPETE production by human 5-LO,8,,,55,,Autocuration,1,CHEMBL618015,BAO_0000357,,
3831,,F,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,8,,,55,,Autocuration,1,CHEMBL618016,BAO_0000019,,
3832,,B,,,Inhibition of Human 5-lipoxygenase,8,,,55,,Expert,1,CHEMBL618017,BAO_0000357,,
3833,,B,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,8,,,55,,Autocuration,1,CHEMBL618018,BAO_0000019,,
3834,,B,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],8,,,55,,Autocuration,1,CHEMBL875087,BAO_0000219,,
3835,,B,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],8,,,55,,Autocuration,1,CHEMBL618019,BAO_0000219,,
3836,,B,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,8,,,55,,Autocuration,1,CHEMBL618020,BAO_0000019,,
3837,,B,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,8,,,55,,Autocuration,1,CHEMBL618021,BAO_0000019,,
3838,,B,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),8,,,55,,Autocuration,1,CHEMBL618022,BAO_0000357,178.0,
3839,,B,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,8,,,55,,Autocuration,1,CHEMBL618023,BAO_0000357,,
3840,,B,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),8,,,55,,Autocuration,1,CHEMBL618024,BAO_0000357,,
3841,,B,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,8,,,55,,Expert,1,CHEMBL873950,BAO_0000019,,
3842,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,8,,,55,,Autocuration,1,CHEMBL618025,BAO_0000357,,
3843,,B,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,8,,,55,,Autocuration,1,CHEMBL618026,BAO_0000219,,
3844,,B,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,8,,,55,,Autocuration,1,CHEMBL618027,BAO_0000219,,
3845,,B,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,8,,,55,,Autocuration,1,CHEMBL618028,BAO_0000219,,
3846,,B,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,8,,,55,,Autocuration,1,CHEMBL618029,BAO_0000219,,
3847,,B,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,8,,,55,,Expert,1,CHEMBL618030,BAO_0000357,,
3848,,B,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,8,,,55,,Expert,1,CHEMBL618031,BAO_0000357,,
3849,,B,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,8,,,55,,Autocuration,1,CHEMBL618032,BAO_0000357,,
3850,,B,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,8,,,55,,Autocuration,1,CHEMBL618033,BAO_0000357,,
3851,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,8,,,55,,Autocuration,1,CHEMBL618034,BAO_0000357,,
3852,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,8,,,55,,Autocuration,1,CHEMBL875088,BAO_0000357,,
3853,,B,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,8,,,55,,Autocuration,1,CHEMBL618035,BAO_0000019,,
3854,,B,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,8,,,55,,Autocuration,1,CHEMBL618036,BAO_0000019,,
3855,,B,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,8,,,55,,Expert,1,CHEMBL618037,BAO_0000357,,
3856,,B,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,8,,,55,,Expert,1,CHEMBL618038,BAO_0000357,,
3857,,F,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,8,,,55,,Autocuration,1,CHEMBL618761,BAO_0000019,,
3858,,B,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,8,,,55,,Expert,1,CHEMBL618762,BAO_0000357,,
3859,,B,,,Inhibition of lipoxygenase at the concentration of 1 uM,8,,,55,,Expert,1,CHEMBL618763,BAO_0000357,,
3860,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,8,,,55,,Autocuration,1,CHEMBL618764,BAO_0000357,,
3861,,B,,,Inhibition of 5-Lipoxygenase (5-LOX),9,,,55,9606.0,Expert,1,CHEMBL618765,BAO_0000357,,
3862,,B,,,Inhibition of 5-lipoxygenase in mouse macrophages.,8,,,17087,,Expert,1,CHEMBL618766,BAO_0000357,,
3863,,B,,,Inhibition of 5-lipoxygenase in mouse macrophages.,8,,,17087,,Expert,1,CHEMBL618767,BAO_0000357,,
3864,,B,,,Inhibitory activity against lipoxygenase-2 in mice,8,,,17087,,Autocuration,1,CHEMBL619380,BAO_0000357,,
3865,,B,,,Inhibitory activity against murine lipoxygenase-2.,8,,,17087,,Expert,1,CHEMBL619381,BAO_0000357,,
3866,,B,,,Inhibition of 5-lipoxygenase from mouse macrophage,9,,,17087,10090.0,Expert,1,CHEMBL619382,BAO_0000357,,
3867,,B,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,8,,,17087,,Autocuration,1,CHEMBL619383,BAO_0000357,,
3868,,B,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,8,,,55,9823.0,Autocuration,1,CHEMBL619384,BAO_0000019,,
3869,,B,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,8,,,55,9823.0,Autocuration,1,CHEMBL619385,BAO_0000019,,
3870,,B,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,8,,,55,9986.0,Autocuration,1,CHEMBL882928,BAO_0000019,,
3871,,B,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,9,,,12166,10116.0,Expert,1,CHEMBL619386,BAO_0000019,,
3872,,B,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",8,,,12166,,Autocuration,1,CHEMBL619387,BAO_0000019,,
3873,,B,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",8,,,12166,,Autocuration,1,CHEMBL619388,BAO_0000019,,
3874,,B,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",8,,,12166,,Autocuration,1,CHEMBL619389,BAO_0000019,,
3875,,B,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),8,,,12166,,Expert,1,CHEMBL619390,BAO_0000019,,
3876,,B,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",8,,,12166,,Expert,1,CHEMBL619391,BAO_0000019,,
3877,,B,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,8,,,12166,,Autocuration,1,CHEMBL619392,BAO_0000019,,
3878,,B,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),8,,,12166,,Autocuration,1,CHEMBL619393,BAO_0000019,,
3879,,B,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,8,,,12166,,Autocuration,1,CHEMBL619394,BAO_0000019,,
3880,RBL-1,B,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",8,,,12166,,Autocuration,1,CHEMBL619395,BAO_0000219,,
3881,RBL-1,B,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",8,,,12166,,Autocuration,1,CHEMBL619396,BAO_0000219,,
3882,,B,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),8,,,12166,,Autocuration,1,CHEMBL619397,BAO_0000357,,
3883,,B,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",8,,,12166,,Autocuration,1,CHEMBL619398,BAO_0000357,,
3884,,B,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",8,,,12166,,Autocuration,1,CHEMBL619399,BAO_0000357,,
3885,,B,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,8,,,12166,,Autocuration,1,CHEMBL619400,BAO_0000357,,
3886,,B,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",8,,,12166,,Autocuration,1,CHEMBL619401,BAO_0000019,,
3887,,B,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",8,,,12166,,Autocuration,1,CHEMBL619402,BAO_0000019,,
3888,RBL-2H3,B,663.0,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,9,,,12166,10116.0,Expert,1,CHEMBL619403,BAO_0000219,,
3889,,B,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,8,,,12166,,Autocuration,1,CHEMBL619404,BAO_0000357,,
3890,,B,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,8,,,12166,,Autocuration,1,CHEMBL619405,BAO_0000357,,
3891,RBL-1,B,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,8,,,12166,,Expert,1,CHEMBL619406,BAO_0000219,,
3892,RBL-1,B,702.0,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,9,,,12166,10116.0,Expert,1,CHEMBL619407,BAO_0000219,,
3893,,B,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),8,,,12166,,Autocuration,1,CHEMBL619408,BAO_0000357,,
3894,RBL-1,B,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,8,,,12166,,Autocuration,1,CHEMBL619409,BAO_0000219,,
3895,RBL-1,B,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,8,,,12166,,Expert,1,CHEMBL619410,BAO_0000219,,
3896,RBL-1,B,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,8,,,12166,,Autocuration,1,CHEMBL619753,BAO_0000219,,
3897,RBL-1,B,702.0,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL619754,BAO_0000219,,
3898,,B,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,8,,,12166,,Expert,1,CHEMBL619903,BAO_0000357,,
3899,,B,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",8,,,12166,,Expert,1,CHEMBL619904,BAO_0000357,,
3900,,B,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,8,,,12166,,Expert,1,CHEMBL619905,BAO_0000357,,
3901,,B,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,8,,,12166,,Autocuration,1,CHEMBL619906,BAO_0000019,,
3902,,B,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,8,,,12166,,Autocuration,1,CHEMBL619907,BAO_0000019,,
3903,,B,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,8,,,12166,,Autocuration,1,CHEMBL619908,BAO_0000019,,
3904,,B,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,8,,,12166,,Autocuration,1,CHEMBL619909,BAO_0000019,,
3905,RBL-1,F,702.0,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,8,,,12166,,Expert,1,CHEMBL619910,BAO_0000219,,
3906,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,8,,,12166,,Expert,1,CHEMBL882929,BAO_0000219,,
3907,RBL-1,B,702.0,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,8,,,12166,,Expert,1,CHEMBL619911,BAO_0000219,,
3908,,B,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,8,,,12166,,Autocuration,1,CHEMBL619912,BAO_0000019,,
3909,,B,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,9,,,12166,10116.0,Expert,1,CHEMBL619913,BAO_0000357,,
3910,RBL-1,B,702.0,,In vitro inhibitory activity against RBL-1 5-LO,8,,,12166,,Expert,1,CHEMBL619914,BAO_0000219,,
3911,RBL-1,B,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),8,,,12166,,Autocuration,1,CHEMBL619915,BAO_0000219,,
3912,RBL-1,B,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),8,,,12166,,Autocuration,1,CHEMBL619916,BAO_0000219,,
3913,,B,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,8,,,12166,,Autocuration,1,CHEMBL619917,BAO_0000218,,
3914,,B,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,8,,,12166,,Autocuration,1,CHEMBL619918,BAO_0000357,,
3915,,B,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,8,,,12166,,Autocuration,1,CHEMBL619919,BAO_0000218,,
3916,RBL-1,B,702.0,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,8,,,12166,,Autocuration,1,CHEMBL883710,BAO_0000219,,
3917,,B,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,8,,,12166,,Autocuration,1,CHEMBL619920,BAO_0000019,178.0,
3918,,B,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,8,,,12166,,Expert,1,CHEMBL619921,BAO_0000357,,
3919,,F,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,8,,,12166,,Autocuration,1,CHEMBL619922,BAO_0000019,,
3920,,F,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,8,,,12166,,Autocuration,1,CHEMBL619923,BAO_0000219,,
3921,RBL-1,B,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,8,,,12166,,Expert,1,CHEMBL619924,BAO_0000219,,
3922,,B,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,8,,,12166,,Expert,1,CHEMBL619925,BAO_0000357,,
3923,RBL-1,B,702.0,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,8,,,12166,,Expert,1,CHEMBL619926,BAO_0000219,,
3924,RBL-1,B,702.0,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,8,,,12166,,Autocuration,1,CHEMBL619927,BAO_0000219,,
3925,RBL-1,B,702.0,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,8,,,12166,,Expert,1,CHEMBL619928,BAO_0000219,,
3926,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL619929,BAO_0000219,,
3927,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,8,,,12166,,Autocuration,1,CHEMBL875089,BAO_0000219,,
3928,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,8,,,12166,,Autocuration,1,CHEMBL619930,BAO_0000219,,
3929,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,8,,,12166,,Autocuration,1,CHEMBL619931,BAO_0000219,,
3930,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,8,,,12166,,Autocuration,1,CHEMBL619932,BAO_0000219,,
3931,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,8,,,12166,,Autocuration,1,CHEMBL619933,BAO_0000219,,
3932,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,8,,,12166,,Autocuration,1,CHEMBL619934,BAO_0000219,,
3933,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,8,,,12166,,Autocuration,1,CHEMBL619935,BAO_0000219,,
3934,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,8,,,12166,,Autocuration,1,CHEMBL619936,BAO_0000219,,
3935,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,8,,,12166,,Autocuration,1,CHEMBL619937,BAO_0000219,,
3936,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,8,,,12166,,Autocuration,1,CHEMBL619938,BAO_0000219,,
3937,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,8,,,12166,,Autocuration,1,CHEMBL619939,BAO_0000219,,
3938,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,8,,,12166,,Autocuration,1,CHEMBL619940,BAO_0000219,,
3939,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,8,,,12166,,Autocuration,1,CHEMBL875090,BAO_0000219,,
3940,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,8,,,12166,,Autocuration,1,CHEMBL619941,BAO_0000219,,
3941,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,8,,,12166,,Autocuration,1,CHEMBL619942,BAO_0000219,,
3942,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,8,,,12166,,Autocuration,1,CHEMBL883711,BAO_0000219,,
3943,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,8,,,12166,,Autocuration,1,CHEMBL619943,BAO_0000219,,
3944,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,8,,,12166,,Autocuration,1,CHEMBL619944,BAO_0000219,,
3945,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,8,,,12166,,Autocuration,1,CHEMBL619945,BAO_0000219,,
3946,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,8,,,12166,,Autocuration,1,CHEMBL619946,BAO_0000219,,
3947,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,8,,,12166,,Autocuration,1,CHEMBL619947,BAO_0000219,,
3948,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,8,,,12166,,Autocuration,1,CHEMBL619948,BAO_0000219,,
3949,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,8,,,12166,,Autocuration,1,CHEMBL619949,BAO_0000219,,
3950,,B,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,8,,,12166,,Expert,1,CHEMBL619950,BAO_0000019,,
3951,,B,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,8,,,12166,,Autocuration,1,CHEMBL618050,BAO_0000019,,
3952,RBL-2H3,F,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,8,,,12166,,Expert,1,CHEMBL875091,BAO_0000219,,
3953,RBL-2H3,F,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,8,,,12166,,Expert,1,CHEMBL618051,BAO_0000219,,
3954,RBL-1,B,702.0,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,9,,,12166,10116.0,Expert,1,CHEMBL618052,BAO_0000219,,
3955,,B,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,8,,,12166,,Autocuration,1,CHEMBL618053,BAO_0000019,,
3956,,B,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),8,,,12166,,Expert,1,CHEMBL618054,BAO_0000019,,
3957,RBL-1,B,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,9,,,12166,10116.0,Expert,1,CHEMBL618055,BAO_0000219,,
3958,RBL-1,B,702.0,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,8,,,12166,,Expert,1,CHEMBL618056,BAO_0000219,,
3959,,B,,,In vitro inhibitory activity against 5-lipoxygenase was determined,8,,,12166,,Autocuration,1,CHEMBL618057,BAO_0000357,,
3960,RBL-1,B,702.0,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,8,,,12166,,Autocuration,1,CHEMBL618058,BAO_0000219,,
3961,RBL-1,B,702.0,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,8,,,12166,,Expert,1,CHEMBL618059,BAO_0000219,,
3962,,F,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,9,,,12166,10116.0,Expert,1,CHEMBL618060,BAO_0000019,,
3963,RBL-1,B,702.0,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,8,,,12166,,Autocuration,1,CHEMBL618061,BAO_0000219,,
3964,,B,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,8,,,12166,,Autocuration,1,CHEMBL618062,BAO_0000019,,
3965,RBL-1,B,702.0,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,8,,,12166,,Expert,1,CHEMBL618063,BAO_0000219,,
3966,,B,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,8,,,12166,,Autocuration,1,CHEMBL618064,BAO_0000357,,
3967,RBL-1,B,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,9,,,12166,10116.0,Expert,1,CHEMBL618065,BAO_0000219,,
3968,RBL-1,B,702.0,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,9,,,12166,10116.0,Expert,1,CHEMBL618066,BAO_0000219,,
3969,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),8,,,12166,,Autocuration,1,CHEMBL618067,BAO_0000219,,
3970,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),8,,,12166,,Autocuration,1,CHEMBL618068,BAO_0000219,,
3971,RBL-1,B,702.0,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,9,,,12166,10116.0,Expert,1,CHEMBL618069,BAO_0000219,,
3972,RBL-1,B,702.0,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,8,,,12166,,Expert,1,CHEMBL618070,BAO_0000219,,
3973,,F,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,8,,,10825,,Autocuration,1,CHEMBL618071,BAO_0000019,349.0,
3974,,F,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,8,,,10825,,Autocuration,1,CHEMBL619247,BAO_0000019,349.0,
3975,,F,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,8,,,10825,,Autocuration,1,CHEMBL619248,BAO_0000019,,
3976,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,8,,,10576,,Autocuration,1,CHEMBL619249,BAO_0000221,10000000.0,
3977,,B,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,8,,,10576,,Autocuration,1,CHEMBL619250,BAO_0000221,10000000.0,
3978,,B,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,8,,,10577,,Autocuration,1,CHEMBL619251,BAO_0000019,,
3979,,F,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,8,,,55,9615.0,Autocuration,1,CHEMBL619252,BAO_0000019,178.0,
3980,,F,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,8,,,55,,Autocuration,1,CHEMBL619253,BAO_0000019,178.0,
3981,,B,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],8,,,12166,,Autocuration,1,CHEMBL619254,BAO_0000219,,
3982,,B,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,8,,,17140,,Expert,1,CHEMBL619255,BAO_0000219,,
3983,,B,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,8,,,17140,,Expert,1,CHEMBL619256,BAO_0000219,,
3984,,B,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),8,,,17140,,Autocuration,1,CHEMBL875418,BAO_0000219,,
3985,,B,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,8,,,17140,,Expert,1,CHEMBL619257,BAO_0000219,,
3986,,B,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,8,,,17140,,Autocuration,1,CHEMBL619258,BAO_0000219,,
3987,,B,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,8,,,17140,,Expert,1,CHEMBL619259,BAO_0000357,,
3988,,B,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,8,,,17140,,Expert,1,CHEMBL619260,BAO_0000357,,
3989,,F,,In vivo,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619261,BAO_0000218,178.0,
3990,,F,,In vivo,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619263,BAO_0000218,178.0,
3991,,F,,In vivo,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619264,BAO_0000218,178.0,
3992,,F,,In vivo,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619265,BAO_0000218,178.0,
3993,,F,,In vivo,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619266,BAO_0000218,178.0,
3994,,F,,In vivo,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619902,BAO_0000218,178.0,
3995,,F,,In vivo,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620058,BAO_0000218,178.0,
3996,,F,,In vivo,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620059,BAO_0000218,178.0,
3997,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620060,BAO_0000218,178.0,
3998,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620061,BAO_0000218,178.0,
3999,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620062,BAO_0000218,178.0,
4000,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620063,BAO_0000218,178.0,
4001,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620064,BAO_0000218,178.0,
4002,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620065,BAO_0000218,178.0,
4003,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620066,BAO_0000218,178.0,
4004,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620067,BAO_0000218,178.0,
4005,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620068,BAO_0000218,178.0,
4006,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620069,BAO_0000218,178.0,
4007,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620070,BAO_0000218,178.0,
4008,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620071,BAO_0000218,178.0,
4009,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620072,BAO_0000218,178.0,
4010,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620036,BAO_0000218,178.0,
4011,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL857702,BAO_0000218,178.0,
4012,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620037,BAO_0000218,178.0,
4013,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620038,BAO_0000218,178.0,
4014,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620039,BAO_0000218,178.0,
4015,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620040,BAO_0000218,178.0,
4016,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620041,BAO_0000218,178.0,
4017,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620042,BAO_0000218,178.0,
4018,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620043,BAO_0000218,178.0,
4019,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620044,BAO_0000218,178.0,
4020,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620045,BAO_0000218,178.0,
4021,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620046,BAO_0000218,178.0,
4022,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620047,BAO_0000218,178.0,
4023,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620048,BAO_0000218,178.0,
4024,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL857703,BAO_0000218,178.0,
4025,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620049,BAO_0000218,178.0,
4026,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620050,BAO_0000218,178.0,
4027,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL620051,BAO_0000218,178.0,
4028,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619213,BAO_0000218,178.0,
4029,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619214,BAO_0000218,178.0,
4030,,F,,In vivo,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619804,BAO_0000218,178.0,
4031,,F,,In vivo,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619805,BAO_0000218,178.0,
4032,,F,,In vivo,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619806,BAO_0000218,178.0,
4033,,F,,In vivo,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619807,BAO_0000218,178.0,
4034,,F,,In vivo,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,9615.0,Autocuration,1,CHEMBL619808,BAO_0000218,178.0,
4035,,B,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,8,,,55,9615.0,Autocuration,1,CHEMBL619809,BAO_0000218,,
4036,,B,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,8,,,55,9615.0,Autocuration,1,CHEMBL619810,BAO_0000218,,
4037,,B,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,8,,,55,9615.0,Autocuration,1,CHEMBL619811,BAO_0000218,,
4038,,B,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,8,,,55,9615.0,Autocuration,1,CHEMBL620769,BAO_0000218,,
4039,,B,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,8,,,55,9615.0,Autocuration,1,CHEMBL620770,BAO_0000218,,
4040,,B,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,8,,,55,9615.0,Autocuration,1,CHEMBL620771,BAO_0000218,,
4041,,B,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,8,,,55,9615.0,Autocuration,1,CHEMBL620772,BAO_0000218,,
4042,,B,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,8,,,55,9615.0,Autocuration,1,CHEMBL620773,BAO_0000218,,
4043,,B,,,Ability to inhibit 5-lipoxygenase in guinea pig,8,,,55,10141.0,Autocuration,1,CHEMBL620774,BAO_0000357,,
4044,,B,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),8,,,55,10141.0,Expert,1,CHEMBL620775,BAO_0000357,,
4045,,B,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,8,,,55,10141.0,Autocuration,1,CHEMBL620776,BAO_0000357,,
4046,,B,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",8,,,55,10141.0,Autocuration,1,CHEMBL620777,BAO_0000218,178.0,
4047,,B,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,8,,,55,10141.0,Autocuration,1,CHEMBL620778,BAO_0000357,,
4048,,B,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,8,,,55,10141.0,Autocuration,1,CHEMBL620779,BAO_0000357,,
4049,,B,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,8,,,55,10141.0,Expert,1,CHEMBL621500,BAO_0000019,,
4050,,B,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,8,,,55,10141.0,Expert,1,CHEMBL621501,BAO_0000019,,
4051,,B,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,8,,,55,10141.0,Autocuration,1,CHEMBL618098,BAO_0000019,,
4052,,B,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,8,,,55,10141.0,Autocuration,1,CHEMBL618099,BAO_0000019,,
4053,,B,,,Inhibitory activity against 5-lipoxygenase,8,,,55,10141.0,Autocuration,1,CHEMBL618100,BAO_0000357,,
4054,,B,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,8,,,55,10141.0,Autocuration,1,CHEMBL618101,BAO_0000357,,
4055,,B,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,8,,,55,10141.0,Autocuration,1,CHEMBL618102,BAO_0000357,,
4056,,B,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,8,,,55,10141.0,Autocuration,1,CHEMBL618103,BAO_0000357,,
4057,,B,,,Inhibitory activity uM,8,,,55,10141.0,Autocuration,1,CHEMBL618104,BAO_0000357,,
4058,,B,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,8,,,55,10141.0,Autocuration,1,CHEMBL883712,BAO_0000219,,
4059,,B,,,Inhibitory activity against 5-lipoxygenase at 10 uM,8,,,55,10141.0,Autocuration,1,CHEMBL618105,BAO_0000357,,
4060,,B,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,8,,,55,10141.0,Autocuration,1,CHEMBL618106,BAO_0000357,,
4061,,B,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,8,,,55,10141.0,Autocuration,1,CHEMBL618107,BAO_0000357,,
4062,,B,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,8,,,55,10141.0,Autocuration,1,CHEMBL618108,BAO_0000357,,
4063,,B,,,Inhibitory activity uM,8,,,55,10141.0,Autocuration,1,CHEMBL618109,BAO_0000357,,
4064,,B,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,8,,,55,10141.0,Autocuration,1,CHEMBL618110,BAO_0000357,,
4065,,B,,,Inhibitory activity uM,8,,,55,10141.0,Expert,1,CHEMBL618111,BAO_0000357,,
4066,,F,,,Inhibitory activity uM,8,,,55,10141.0,Autocuration,1,CHEMBL618112,BAO_0000019,,
4067,,B,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,8,,,55,10141.0,Autocuration,1,CHEMBL618113,BAO_0000019,,
4068,,B,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,8,,,55,10141.0,Autocuration,1,CHEMBL618114,BAO_0000357,,
4069,,F,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,8,,,55,10141.0,Expert,1,CHEMBL620871,BAO_0000221,2116.0,
4070,,B,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),8,,,55,,Autocuration,1,CHEMBL620872,BAO_0000357,,
4071,,B,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),8,,,55,,Autocuration,1,CHEMBL620873,BAO_0000357,,
4072,,B,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),8,,,55,,Autocuration,1,CHEMBL620874,BAO_0000357,,
4073,,B,,,In vitro inhibition of human 5-Lipoxygenase.,8,,,55,,Expert,1,CHEMBL620875,BAO_0000357,,
4074,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620876,BAO_0000251,2107.0,
4075,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620877,BAO_0000251,2107.0,
4076,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL857854,BAO_0000251,2107.0,
4077,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620878,BAO_0000251,2107.0,
4078,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620879,BAO_0000251,2107.0,
4079,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620880,BAO_0000251,2107.0,
4080,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620881,BAO_0000251,2107.0,
4081,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620882,BAO_0000251,2107.0,
4082,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620883,BAO_0000251,2107.0,
4083,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620884,BAO_0000251,2107.0,
4084,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620885,BAO_0000251,2107.0,
4085,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620886,BAO_0000251,2107.0,
4086,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620887,BAO_0000251,2107.0,
4087,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618039,BAO_0000251,2107.0,
4088,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618040,BAO_0000251,2107.0,
4089,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618041,BAO_0000251,2107.0,
4090,,B,,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",0,,,22226,10116.0,Autocuration,1,CHEMBL618216,BAO_0000251,2107.0,
4091,,B,,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",0,,,22226,10116.0,Autocuration,1,CHEMBL618217,BAO_0000251,2107.0,
4092,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618218,BAO_0000251,2107.0,
4093,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618219,BAO_0000251,2107.0,
4094,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618220,BAO_0000251,2107.0,
4095,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618221,BAO_0000251,2107.0,
4096,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618222,BAO_0000251,2107.0,
4097,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618223,BAO_0000251,2107.0,
4098,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618224,BAO_0000251,2107.0,
4099,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618225,BAO_0000251,2107.0,
4100,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618226,BAO_0000251,2107.0,
4101,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618227,BAO_0000251,2107.0,
4102,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618228,BAO_0000251,2107.0,
4103,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618229,BAO_0000251,2107.0,
4104,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618230,BAO_0000251,2107.0,
4105,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618231,BAO_0000251,2107.0,
4106,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618232,BAO_0000251,2107.0,
4107,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618233,BAO_0000251,2107.0,
4108,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618234,BAO_0000251,2107.0,
4109,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618235,BAO_0000251,2107.0,
4110,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618115,BAO_0000251,2107.0,
4111,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618116,BAO_0000251,2107.0,
4112,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL618117,BAO_0000251,2107.0,
4113,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619968,BAO_0000251,2107.0,
4114,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619969,BAO_0000251,2107.0,
4115,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619970,BAO_0000251,2107.0,
4116,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619971,BAO_0000251,2107.0,
4117,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619972,BAO_0000251,2107.0,
4118,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619973,BAO_0000251,2107.0,
4119,,B,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619974,BAO_0000251,2107.0,
4120,,B,,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619975,BAO_0000251,2107.0,
4121,,B,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619976,BAO_0000251,,
4122,,B,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",0,,,22226,10116.0,Autocuration,1,CHEMBL619977,BAO_0000251,2107.0,
4123,,B,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",0,,,22226,10116.0,Autocuration,1,CHEMBL619978,BAO_0000251,2107.0,
4124,,B,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",0,,,22226,10116.0,Autocuration,1,CHEMBL619979,BAO_0000251,2107.0,
4125,,B,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",0,,,22226,10116.0,Autocuration,1,CHEMBL619980,BAO_0000251,2107.0,
4126,,B,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",0,,,22226,10116.0,Autocuration,1,CHEMBL619981,BAO_0000251,2107.0,
4127,RPMI-8226,F,741.0,,In vitro inhibition of 7226/S myeloma cancer cell line,1,,,80433,9606.0,Intermediate,1,CHEMBL619982,BAO_0000219,,
4128,BEL-7404 tumor cell line,F,993.0,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),1,,,80698,9606.0,Intermediate,1,CHEMBL619983,BAO_0000219,,
4129,786-0,F,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,,,80640,9606.0,Intermediate,1,CHEMBL620031,BAO_0000219,,
4130,786-0,F,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,,,80640,9606.0,Intermediate,1,CHEMBL620032,BAO_0000219,,
4131,V79,F,505.0,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,1,,,81264,10029.0,Expert,1,CHEMBL620033,BAO_0000219,,
4132,V79,F,505.0,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,1,,,81264,10029.0,Expert,1,CHEMBL620034,BAO_0000219,,
4133,7800C1 cell line,F,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,1,,,80635,10116.0,Intermediate,1,CHEMBL620035,BAO_0000219,,
4134,7800C1 cell line,F,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,1,,,80635,10116.0,Intermediate,1,CHEMBL618318,BAO_0000219,,
4135,7800C1 cell line,F,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,1,,,80635,10116.0,Intermediate,1,CHEMBL618319,BAO_0000219,,
4136,7800C1 cell line,F,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,1,,,80635,10116.0,Intermediate,1,CHEMBL618320,BAO_0000219,,
4137,7800C1 cell line,F,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,1,,,80635,10116.0,Intermediate,1,CHEMBL618321,BAO_0000219,,
4138,7800C1 cell line,F,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,1,,,80635,10116.0,Intermediate,1,CHEMBL883118,BAO_0000219,,
4139,786-0,F,391.0,,In vitro antitumor activity against renal 786-0 tumor cell lines,1,,,80640,9606.0,Intermediate,1,CHEMBL883795,BAO_0000219,,
4140,786-0,F,391.0,,Cytotoxic activity against 786-0 Renal cancer cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL618322,BAO_0000219,,
4141,786-0,F,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,1,,,80640,9606.0,Intermediate,1,CHEMBL618323,BAO_0000219,,
4142,786-0,F,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,1,,,80640,9606.0,Intermediate,1,CHEMBL618324,BAO_0000219,,
4143,786-0,F,391.0,,In vitro antitumor activity against human renal 786-0 cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL618325,BAO_0000219,,
4144,786-0,F,391.0,,Inhibition of Renal cancer in 786-0 cancer cell lines,1,,,80640,9606.0,Intermediate,1,CHEMBL875416,BAO_0000219,,
4145,786-0,F,391.0,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,1,,,80640,9606.0,Intermediate,1,CHEMBL618326,BAO_0000219,,
4146,786-0,F,391.0,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,1,,,80640,9606.0,Intermediate,1,CHEMBL618327,BAO_0000219,,
4147,786-0,F,391.0,,inhibition of the growth of renal cancer(786-0) cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL619215,BAO_0000219,,
4148,786-0,F,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,,,80640,9606.0,Intermediate,1,CHEMBL619216,BAO_0000219,,
4149,786-0,F,391.0,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL619217,BAO_0000219,,
4150,786-0,F,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor,1,,,80640,9606.0,Intermediate,1,CHEMBL619218,BAO_0000219,,
4151,786-0,F,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,1,,,80640,9606.0,Intermediate,1,CHEMBL619219,BAO_0000219,,
4152,786-0,F,391.0,,The IC50 value was measured on 786-0 cell line in renal tumor type.,1,,,80640,9606.0,Intermediate,1,CHEMBL619220,BAO_0000219,,
4153,786-0,F,391.0,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,1,,,80640,9606.0,Intermediate,1,CHEMBL619221,BAO_0000219,,
4154,786-0,F,391.0,,Tested for cytotoxic activity against renal cancer 786-0 cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL619222,BAO_0000219,,
4155,786-0,F,391.0,,Compound was tested for growth inhibitory activity against 786-0 cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL857454,BAO_0000219,,
4156,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,8,,,12166,,Autocuration,1,CHEMBL619223,BAO_0000219,,
4157,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,8,,,12166,,Autocuration,1,CHEMBL619224,BAO_0000219,,
4158,,B,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,8,,,12166,,Autocuration,1,CHEMBL619225,BAO_0000019,,
4159,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),8,,,12166,,Expert,1,CHEMBL619226,BAO_0000219,,
4160,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),8,,,12166,,Expert,1,CHEMBL619227,BAO_0000219,,
4161,,B,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL619228,BAO_0000357,,
4162,,B,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,8,,,12166,,Autocuration,1,CHEMBL619229,BAO_0000219,,
4163,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,8,,,12166,,Autocuration,1,CHEMBL619230,BAO_0000219,,
4164,,B,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,8,,,12166,,Autocuration,1,CHEMBL619231,BAO_0000357,,
4165,,B,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",8,,,12166,,Autocuration,1,CHEMBL619232,BAO_0000357,,
4166,,B,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,8,,,12166,,Expert,1,CHEMBL619233,BAO_0000357,,
4167,,B,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL619234,BAO_0000357,,
4168,,B,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),8,,,12166,,Autocuration,1,CHEMBL619235,BAO_0000357,,
4169,,B,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",9,,,12166,10116.0,Expert,1,CHEMBL619236,BAO_0000019,,
4170,RBL-1,B,702.0,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,8,,,12166,,Autocuration,1,CHEMBL619237,BAO_0000219,,
4171,,B,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,8,,,12166,,Autocuration,1,CHEMBL619238,BAO_0000357,,
4172,,B,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,8,,,12166,,Expert,1,CHEMBL619239,BAO_0000357,,
4173,,B,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,8,,,12166,,Autocuration,1,CHEMBL619240,BAO_0000357,,
4174,,B,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,8,,,12166,,Autocuration,1,CHEMBL875417,BAO_0000019,,
4175,RBL-1,B,702.0,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),8,,,12166,,Autocuration,1,CHEMBL619241,BAO_0000219,,
4176,,F,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,8,,,12166,,Expert,1,CHEMBL619242,BAO_0000019,,
4177,RBL-1,B,702.0,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,8,,,12166,,Autocuration,1,CHEMBL883796,BAO_0000219,,
4178,,B,,,Tested for its inhibitory activity against 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL619243,BAO_0000357,,
4179,,B,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,8,,,12166,,Autocuration,1,CHEMBL619244,BAO_0000357,,
4180,,B,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",8,,,12166,,Expert,1,CHEMBL619245,BAO_0000019,,
4181,,B,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,8,,,12166,,Expert,1,CHEMBL619246,BAO_0000019,,
4182,RBL-1,B,702.0,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,8,,,12166,,Expert,1,CHEMBL619984,BAO_0000219,,
4183,RBL-1,B,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,8,,,12166,,Autocuration,1,CHEMBL619985,BAO_0000219,,
4184,RBL-1,B,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,8,,,12166,,Autocuration,1,CHEMBL619986,BAO_0000219,,
4185,RBL-1,B,702.0,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,8,,,12166,,Expert,1,CHEMBL619987,BAO_0000219,,
4186,,B,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,8,,,12166,,Autocuration,1,CHEMBL619988,BAO_0000218,,
4187,RBL-1,B,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,8,,,12166,,Autocuration,1,CHEMBL619989,BAO_0000219,,
4188,RBL-1,B,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,8,,,12166,,Autocuration,1,CHEMBL619990,BAO_0000219,,
4189,,B,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],8,,,12166,,Autocuration,1,CHEMBL619991,BAO_0000219,,
4190,,B,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),8,,,12166,,Autocuration,1,CHEMBL619992,BAO_0000219,,
4191,,B,,In vivo,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),8,,,12166,,Autocuration,1,CHEMBL619993,BAO_0000218,,
4192,RBL-2H3,F,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,8,,,12166,,Autocuration,1,CHEMBL619994,BAO_0000219,,
4193,RBL-2H3,F,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,8,,,12166,,Autocuration,1,CHEMBL619995,BAO_0000219,,
4194,,B,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],8,,,12166,,Autocuration,1,CHEMBL619996,BAO_0000019,,
4195,,B,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL619997,BAO_0000019,,
4196,,B,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,8,,,12166,,Expert,1,CHEMBL619998,BAO_0000019,,
4197,,B,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,8,,,12166,,Expert,1,CHEMBL619999,BAO_0000019,,
4198,,B,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,8,,,12166,,Autocuration,1,CHEMBL620000,BAO_0000019,,
4199,RBL-1,B,702.0,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,8,,,12166,,Autocuration,1,CHEMBL620001,BAO_0000219,,
4200,,B,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,9,,,12166,10116.0,Expert,1,CHEMBL620002,BAO_0000357,,
4201,RBL-1,B,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,8,,,12166,,Autocuration,1,CHEMBL620003,BAO_0000219,,
4202,RBL-1,F,702.0,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,8,,,12166,,Expert,1,CHEMBL620004,BAO_0000219,,
4203,,B,,,Compound was evaluated for the inhibition of 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL874063,BAO_0000357,,
4204,RBL-1,B,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,8,,,12166,,Autocuration,1,CHEMBL620005,BAO_0000219,,
4205,RBL-1,B,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,8,,,12166,,Autocuration,1,CHEMBL620006,BAO_0000219,,
4206,RBL-1,B,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,8,,,12166,,Autocuration,1,CHEMBL620007,BAO_0000219,,
4207,RBL-1,B,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,8,,,12166,,Autocuration,1,CHEMBL620008,BAO_0000219,,
4208,RBL-1,B,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,9,,,12166,10116.0,Expert,1,CHEMBL620009,BAO_0000219,,
4209,RBL-1,B,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,8,,,12166,,Autocuration,1,CHEMBL620010,BAO_0000219,,
4210,RBL-1,B,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,8,,,12166,,Autocuration,1,CHEMBL620011,BAO_0000219,,
4211,RBL-1,B,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,8,,,12166,,Autocuration,1,CHEMBL620677,BAO_0000219,,
4212,RBL-1,B,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,8,,,12166,,Autocuration,1,CHEMBL620678,BAO_0000219,,
4213,RBL-1,B,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,8,,,12166,,Autocuration,1,CHEMBL620679,BAO_0000219,,
4214,RBL-1,B,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,8,,,12166,,Autocuration,1,CHEMBL620680,BAO_0000219,,
4215,,B,,,Inhibitory activity against 5-lipoxygenase at 10 uM,9,,,12166,10116.0,Expert,1,CHEMBL620838,BAO_0000357,,
4216,,B,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,8,,,12166,,Autocuration,1,CHEMBL620839,BAO_0000357,,
4217,,B,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,8,,,12166,,Expert,1,CHEMBL620840,BAO_0000357,,
4218,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,8,,,12166,,Expert,1,CHEMBL620841,BAO_0000219,,
4219,RBL-1,B,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,8,,,12166,,Autocuration,1,CHEMBL620842,BAO_0000219,,
4220,RBL-1,B,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,8,,,12166,,Autocuration,1,CHEMBL620843,BAO_0000219,,
4221,RBL-1,B,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,8,,,12166,,Autocuration,1,CHEMBL620844,BAO_0000219,,
4222,RBL-1,B,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,8,,,12166,,Autocuration,1,CHEMBL620845,BAO_0000219,,
4223,,B,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,8,,,12166,,Autocuration,1,CHEMBL620846,BAO_0000019,,
4224,,B,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,8,,,12166,,Autocuration,1,CHEMBL873951,BAO_0000357,,
4225,,B,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,8,,,12166,,Autocuration,1,CHEMBL620847,BAO_0000357,,
4226,RBL-1,B,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,8,,,12166,,Autocuration,1,CHEMBL620848,BAO_0000219,,
4227,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,8,,,12166,,Autocuration,1,CHEMBL620849,BAO_0000219,,
4228,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,8,,,12166,,Autocuration,1,CHEMBL620850,BAO_0000219,,
4229,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,8,,,12166,,Autocuration,1,CHEMBL620851,BAO_0000219,,
4230,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,8,,,12166,,Autocuration,1,CHEMBL620852,BAO_0000219,,
4231,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,8,,,12166,,Autocuration,1,CHEMBL875098,BAO_0000219,,
4232,RBL-1,B,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,9,,,12166,10116.0,Expert,1,CHEMBL620853,BAO_0000219,,
4233,,B,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,8,,,12166,,Autocuration,1,CHEMBL620854,BAO_0000019,,
4234,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,8,,,12166,,Autocuration,1,CHEMBL620855,BAO_0000219,,
4235,RBL-1,B,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,8,,,12166,,Expert,1,CHEMBL839884,BAO_0000219,,
4236,RBL-1,B,702.0,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,8,,,12166,,Autocuration,1,CHEMBL620856,BAO_0000219,,
4237,RBL-1,B,702.0,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,8,,,12166,,Autocuration,1,CHEMBL620857,BAO_0000219,,
4238,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,8,,,12166,,Autocuration,1,CHEMBL620858,BAO_0000019,,
4239,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,8,,,12166,,Autocuration,1,CHEMBL620859,BAO_0000019,,
4240,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,8,,,12166,,Autocuration,1,CHEMBL620860,BAO_0000019,,
4241,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,8,,,12166,,Autocuration,1,CHEMBL620861,BAO_0000019,,
4242,,B,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),8,,,12166,,Expert,1,CHEMBL620862,BAO_0000357,,
4243,,B,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,8,,,12166,,Autocuration,1,CHEMBL620863,BAO_0000357,,
4244,,B,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,8,,,12166,,Autocuration,1,CHEMBL620864,BAO_0000019,,
4245,RBL-1,B,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,8,,,12166,,Autocuration,1,CHEMBL620865,BAO_0000219,,
4246,RBL-1,B,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,8,,,12166,,Autocuration,1,CHEMBL620866,BAO_0000219,,
4247,RBL-2H3,B,663.0,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,8,,,12166,,Autocuration,1,CHEMBL620867,BAO_0000219,,
4248,RBL-2H3,B,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,8,,,12166,,Autocuration,1,CHEMBL620868,BAO_0000219,,
4249,RBL-2H3,F,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,8,,,12166,,Autocuration,1,CHEMBL620869,BAO_0000219,,
4250,,F,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL873952,BAO_0000019,,
4251,,B,,,The compound was tested for inhibition of isolated 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL875099,BAO_0000357,,
4252,RBL-2H3,F,663.0,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,8,,,12166,,Autocuration,1,CHEMBL620870,BAO_0000219,,
4253,,B,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,8,,,12166,,Autocuration,1,CHEMBL618261,BAO_0000019,,
4254,,B,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,8,,,12166,,Autocuration,1,CHEMBL618262,BAO_0000019,,
4255,,B,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,8,,,12166,,Autocuration,1,CHEMBL619428,BAO_0000019,,
4256,,B,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,8,,,12166,,Autocuration,1,CHEMBL619429,BAO_0000019,,
4257,,B,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,8,,,12166,,Autocuration,1,CHEMBL619430,BAO_0000019,,
4258,RBL-1,B,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,8,,,12166,,Autocuration,1,CHEMBL620017,BAO_0000219,,
4259,RBL-1,B,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,8,,,12166,,Autocuration,1,CHEMBL620018,BAO_0000219,,
4260,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,8,,,12166,,Autocuration,1,CHEMBL620019,BAO_0000219,,
4261,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,8,,,12166,,Autocuration,1,CHEMBL620020,BAO_0000219,,
4262,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,8,,,12166,,Autocuration,1,CHEMBL620021,BAO_0000219,,
4263,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,8,,,12166,,Autocuration,1,CHEMBL620022,BAO_0000219,,
4264,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,8,,,12166,,Autocuration,1,CHEMBL620023,BAO_0000219,,
4265,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,8,,,12166,,Autocuration,1,CHEMBL620024,BAO_0000219,,
4266,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,8,,,12166,,Autocuration,1,CHEMBL620025,BAO_0000219,,
4267,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,8,,,12166,,Autocuration,1,CHEMBL620026,BAO_0000219,,
4268,RBL-1,F,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,8,,,12166,,Autocuration,1,CHEMBL620027,BAO_0000219,,
4269,,F,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,9,,,12166,10116.0,Expert,1,CHEMBL620028,BAO_0000019,,
4270,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL620029,BAO_0000357,,
4271,,B,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,8,,,12166,,Autocuration,1,CHEMBL620030,BAO_0000357,,
4272,RBL-1,B,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,8,,,12166,,Autocuration,1,CHEMBL875415,BAO_0000219,,
4273,RBL-1,B,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,8,,,12166,,Autocuration,1,CHEMBL618256,BAO_0000219,,
4274,RBL-1,B,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,8,,,12166,,Autocuration,1,CHEMBL618257,BAO_0000219,,
4275,RBL-1,B,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,8,,,12166,,Autocuration,1,CHEMBL618258,BAO_0000219,,
4276,RBL-1,B,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,8,,,12166,,Autocuration,1,CHEMBL618259,BAO_0000219,,
4277,,B,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,8,,,12166,,Autocuration,1,CHEMBL618260,BAO_0000019,,
4278,RBL-1,B,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,8,,,12166,,Autocuration,1,CHEMBL618215,BAO_0000219,,
4279,RBL-1,B,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,8,,,12166,,Autocuration,1,CHEMBL618390,BAO_0000219,,
4280,RBL-1,B,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,8,,,12166,,Autocuration,1,CHEMBL618391,BAO_0000219,,
4281,RBL-1,B,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,8,,,12166,,Autocuration,1,CHEMBL618392,BAO_0000219,,
4282,RBL-1,B,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,8,,,12166,,Autocuration,1,CHEMBL618393,BAO_0000219,,
4283,,B,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,8,,,12166,,Autocuration,1,CHEMBL618394,BAO_0000219,,
4284,RBL-1,B,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),8,,,12166,9606.0,Expert,1,CHEMBL618395,BAO_0000219,,
4285,RBL-1,B,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),9,,,12166,10116.0,Expert,1,CHEMBL618396,BAO_0000219,,
4286,RBL-1,B,702.0,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),9,,,12166,10116.0,Expert,1,CHEMBL858253,BAO_0000219,,
4287,,B,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,9,,,12166,10116.0,Autocuration,1,CHEMBL618397,BAO_0000019,,
4288,,B,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),8,,,12054,3847.0,Autocuration,1,CHEMBL618398,BAO_0000357,,
4289,,B,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",0,,,22226,,Autocuration,1,CHEMBL618399,BAO_0000019,,
4290,,B,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,8,,,55,,Expert,1,CHEMBL618400,BAO_0000357,,
4291,,B,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,8,,,55,,Autocuration,1,CHEMBL618401,BAO_0000357,,
4292,,B,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,8,,,55,,Autocuration,1,CHEMBL618402,BAO_0000357,,
4293,RBL-1,B,702.0,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,8,,,55,,Autocuration,1,CHEMBL876400,BAO_0000219,,
4294,,B,,,Inhibitory activity against 5-lipoxygenase.,8,,,55,,Expert,1,CHEMBL618403,BAO_0000357,,
4295,,B,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,8,,,55,,Autocuration,1,CHEMBL618404,BAO_0000357,,
4296,,B,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,8,,,55,,Autocuration,1,CHEMBL618405,BAO_0000357,,
4297,,B,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,8,,,55,,Autocuration,1,CHEMBL618406,BAO_0000357,,
4298,,F,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,8,,,55,,Expert,1,CHEMBL618407,BAO_0000019,,
4299,,B,,,Tested for the inhibitory activity against 5-lipoxygenase,8,,,55,,Autocuration,1,CHEMBL618408,BAO_0000357,,
4300,,B,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,8,,,55,,Autocuration,1,CHEMBL618409,BAO_0000357,,
4301,,B,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,8,,,55,,Autocuration,1,CHEMBL618410,BAO_0000357,,
4302,,B,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,8,,,55,,Autocuration,1,CHEMBL618411,BAO_0000357,,
4303,,B,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,8,,,55,,Autocuration,1,CHEMBL618412,BAO_0000357,,
4304,RBL-1,B,702.0,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,8,,,12166,,Autocuration,1,CHEMBL618413,BAO_0000219,,
4305,,B,,,,8,,,12166,,Autocuration,1,CHEMBL618414,BAO_0000357,,
4306,,B,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),8,,,10102,,Autocuration,1,CHEMBL618415,BAO_0000357,,
4307,,B,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,8,,,10102,,Autocuration,1,CHEMBL618416,BAO_0000019,,
4308,,B,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,8,,,10102,,Autocuration,1,CHEMBL876401,BAO_0000357,,
4309,,B,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,8,,,10102,,Expert,1,CHEMBL618417,BAO_0000357,,
4310,,B,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,8,,,10102,,Autocuration,1,CHEMBL618418,BAO_0000357,,
4311,,B,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",8,,,10102,,Autocuration,1,CHEMBL618419,BAO_0000357,,
4312,,B,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",8,,,10102,,Autocuration,1,CHEMBL618420,BAO_0000357,,
4313,,B,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,8,,,10102,,Autocuration,1,CHEMBL618421,BAO_0000357,,
4314,,B,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,8,,,11238,,Autocuration,1,CHEMBL618422,BAO_0000019,,
4315,,B,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),8,,,11238,,Autocuration,1,CHEMBL618423,BAO_0000019,,
4316,,B,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),8,,,11238,,Autocuration,1,CHEMBL618424,BAO_0000019,,
4317,,B,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,2,,,100284,,Intermediate,1,CHEMBL618425,BAO_0000220,,
4318,,F,,,The dark toxicity against 543 human galactophore carcinoma cells,0,,,22226,9606.0,Autocuration,1,CHEMBL618426,BAO_0000019,,
4319,Panel (56 tumour cell lines),F,390.0,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,1,,,80623,9606.0,Expert,1,CHEMBL618427,BAO_0000219,,
4320,5637,F,345.0,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,1,,,80008,9606.0,Expert,1,CHEMBL618428,BAO_0000219,,
4321,5637,F,345.0,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,1,,,80008,9606.0,Intermediate,1,CHEMBL618429,BAO_0000219,,
4322,5637,F,345.0,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",1,,,80008,9606.0,Intermediate,1,CHEMBL618430,BAO_0000219,,
4323,5637,F,345.0,,Growth inhibition against human 5637 cell lines,1,,,80008,9606.0,Expert,1,CHEMBL618431,BAO_0000219,,
4324,5637,F,345.0,,Antitumor activity against human bladder carcinoma 5637 cells.,1,,,80008,9606.0,Expert,1,CHEMBL883799,BAO_0000219,,
4325,5637,F,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,1,,,80008,9606.0,Intermediate,1,CHEMBL618432,BAO_0000219,,
4326,5637,F,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,1,,,80008,9606.0,Intermediate,1,CHEMBL618433,BAO_0000219,,
4327,,B,,,In vitro inhibition of bovine trypsin(Trp).,9,,,10443,9913.0,Expert,1,CHEMBL618434,BAO_0000357,,
4328,CV-1,B,407.0,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,8,,,240,9527.0,Expert,1,CHEMBL618435,BAO_0000219,,
4329,,B,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,8,,,10577,,Autocuration,1,CHEMBL876402,BAO_0000357,,
4330,,F,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,6,,,104698,,Autocuration,1,CHEMBL618436,BAO_0000019,,
4331,,F,,In vivo,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,0,,,22226,,Autocuration,1,CHEMBL618437,BAO_0000218,,
4332,,B,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,9,,,20033,10141.0,Intermediate,1,CHEMBL618438,BAO_0000357,,
4333,,A,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,8,,,17045,10116.0,Expert,1,CHEMBL883800,BAO_0000251,,
4334,,A,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,8,,,17045,10116.0,Expert,1,CHEMBL618439,BAO_0000251,,
4335,,F,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,0,,,22226,,Intermediate,1,CHEMBL618440,BAO_0000019,,
4336,,F,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,0,,,22226,,Intermediate,1,CHEMBL618441,BAO_0000019,,
4337,,B,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,8,,,11938,5691.0,Expert,1,CHEMBL618442,BAO_0000019,,
4338,,B,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,8,,,11938,5691.0,Autocuration,1,CHEMBL618443,BAO_0000019,,
4339,,B,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,8,,,11938,9940.0,Expert,1,CHEMBL619158,BAO_0000019,,
4340,,B,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,8,,,11938,9940.0,Autocuration,1,CHEMBL620974,BAO_0000019,,
4341,,B,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,8,,,11938,,Autocuration,1,CHEMBL620975,BAO_0000357,,
4342,,F,,,Average inhibitory concentration against 60 human cell lines was reported,0,,,22226,9606.0,Intermediate,1,CHEMBL620976,BAO_0000019,,
4343,,F,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,0,,,22226,9606.0,Expert,1,CHEMBL620977,BAO_0000019,,
4344,Panel NCI-60 (60 carcinoma cell lines),F,542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,1,,,80315,9606.0,Intermediate,1,CHEMBL620978,BAO_0000219,,
4345,Panel NCI-60 (60 carcinoma cell lines),F,542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,1,,,80315,9606.0,Intermediate,1,CHEMBL620979,BAO_0000219,,
4346,Panel NCI-60 (60 carcinoma cell lines),F,542.0,,In vitro mean growth inhibitory activity against 60-cell panel,1,,,80315,,Expert,1,CHEMBL620980,BAO_0000219,,
4347,Panel NCI-60 (60 carcinoma cell lines),F,542.0,,In vitro mean growth lethal concentration against 60-cell panel,1,,,80315,,Expert,1,CHEMBL620981,BAO_0000219,,
4348,Panel NCI-60 (60 carcinoma cell lines),F,542.0,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,1,,,80315,,Expert,1,CHEMBL620982,BAO_0000219,,
4349,Panel NCI-60 (60 carcinoma cell lines),F,542.0,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,1,,,80315,,Expert,1,CHEMBL620983,BAO_0000219,,
4350,,F,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,4,,,104775,,Autocuration,1,CHEMBL620984,BAO_0000019,,
4351,,F,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,4,,,104775,,Autocuration,1,CHEMBL620985,BAO_0000019,,
4352,,B,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,8,,,275,,Expert,1,CHEMBL620986,BAO_0000357,,
4353,,F,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,1,,,50425,5833.0,Expert,1,CHEMBL620987,BAO_0000218,,
4354,,F,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,1,,,50425,5833.0,Expert,1,CHEMBL620988,BAO_0000218,,
4355,,F,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,1,,,50425,5833.0,Expert,1,CHEMBL620989,BAO_0000218,,
4356,,F,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,1,,,50425,5833.0,Expert,1,CHEMBL620990,BAO_0000218,,
4357,,F,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,1,,,50425,5833.0,Intermediate,1,CHEMBL620991,BAO_0000218,,
4358,6C3HED,F,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,,,80628,10090.0,Intermediate,1,CHEMBL620992,BAO_0000218,,
4359,6C3HED,F,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,,,80628,10090.0,Intermediate,1,CHEMBL620993,BAO_0000218,,
4360,6C3HED,F,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,1,,,80628,10090.0,Intermediate,1,CHEMBL620994,BAO_0000218,,
4361,6C3HED,F,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,,,80628,10090.0,Intermediate,1,CHEMBL620995,BAO_0000218,,
4362,6C3HED,F,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,,,80628,10090.0,Intermediate,1,CHEMBL620996,BAO_0000218,,
4363,6C3HED,F,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,1,,,80628,10090.0,Intermediate,1,CHEMBL875581,BAO_0000218,,
4364,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,0,,,22224,10090.0,Autocuration,1,CHEMBL620997,BAO_0000218,,
4365,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,0,,,22224,10090.0,Autocuration,1,CHEMBL620998,BAO_0000218,,
4366,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),0,,,22224,10090.0,Autocuration,1,CHEMBL620999,BAO_0000218,,
4367,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,0,,,22224,10090.0,Autocuration,1,CHEMBL621000,BAO_0000218,,
4368,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,0,,,22224,10090.0,Autocuration,1,CHEMBL621001,BAO_0000218,,
4369,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,0,,,22224,10090.0,Autocuration,1,CHEMBL621002,BAO_0000218,,
4370,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,0,,,22224,10090.0,Autocuration,1,CHEMBL621003,BAO_0000218,,
4371,,F,,In vivo,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",0,,,22224,10090.0,Autocuration,1,CHEMBL621004,BAO_0000218,,
4372,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),0,,,22224,10090.0,Autocuration,1,CHEMBL621005,BAO_0000218,,
4373,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),0,,,22224,10090.0,Autocuration,1,CHEMBL621006,BAO_0000218,,
4374,,F,,In vivo,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,0,,,22224,10090.0,Autocuration,1,CHEMBL621007,BAO_0000218,,
4375,,F,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,0,,,22224,10090.0,Autocuration,1,CHEMBL621008,BAO_0000218,,
4376,,F,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,0,,,22224,10090.0,Autocuration,1,CHEMBL621009,BAO_0000218,,
4377,,F,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,0,,,22224,10090.0,Autocuration,1,CHEMBL857705,BAO_0000218,,
4378,,F,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,0,,,22224,10090.0,Autocuration,1,CHEMBL619828,BAO_0000218,,
4379,,F,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,0,,,22224,10090.0,Autocuration,1,CHEMBL619829,BAO_0000218,,
4380,,F,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,0,,,22224,10090.0,Autocuration,1,CHEMBL619830,BAO_0000218,,
4381,,F,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,0,,,22224,10090.0,Autocuration,1,CHEMBL619831,BAO_0000218,,
4382,,F,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,0,,,22224,10090.0,Autocuration,1,CHEMBL619832,BAO_0000218,,
4383,,A,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,0,,,22224,10090.0,Autocuration,1,CHEMBL619833,BAO_0000218,,
4384,,A,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,0,,,22224,10090.0,Autocuration,1,CHEMBL619834,BAO_0000218,,
4385,,A,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,0,,,22224,10090.0,Autocuration,1,CHEMBL619835,BAO_0000218,,
4386,,A,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,0,,,22224,10090.0,Autocuration,1,CHEMBL619836,BAO_0000218,,
4387,6C3HED,F,850.0,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",1,,,80628,10090.0,Intermediate,1,CHEMBL619837,BAO_0000218,,
4388,,F,,In vivo,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,0,,,22224,,Autocuration,1,CHEMBL619838,BAO_0000218,,
4389,,A,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,1,,,50594,10090.0,Intermediate,1,CHEMBL619839,BAO_0000218,,
4390,6C3HED,F,850.0,In vivo,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,1,,,80628,10090.0,Intermediate,1,CHEMBL619840,BAO_0000218,,
4391,6C3HED,F,850.0,In vivo,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,1,,,80628,10090.0,Intermediate,1,CHEMBL619841,BAO_0000218,,
4392,6C3HED,F,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),1,,,80628,10090.0,Expert,1,CHEMBL857704,BAO_0000218,,
4393,6C3HED,F,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),1,,,80628,10090.0,Intermediate,1,CHEMBL619842,BAO_0000218,,
4394,6C3HED,F,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),1,,,80628,10090.0,Expert,1,CHEMBL619843,BAO_0000218,,
4395,,B,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",0,,,22226,1280.0,Autocuration,1,CHEMBL619844,BAO_0000019,,
4396,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL857855,BAO_0000251,2107.0,
4397,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619845,BAO_0000251,2107.0,
4398,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619846,BAO_0000251,2107.0,
4399,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619847,BAO_0000251,2107.0,
4400,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL619848,BAO_0000251,2107.0,
4401,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620893,BAO_0000251,2107.0,
4402,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620894,BAO_0000251,2107.0,
4403,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620895,BAO_0000251,2107.0,
4404,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620896,BAO_0000251,2107.0,
4405,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620897,BAO_0000251,2107.0,
4406,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620898,BAO_0000251,2107.0,
4407,,B,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,0,,,22226,10116.0,Autocuration,1,CHEMBL620899,BAO_0000251,2107.0,
4408,,A,,In vivo,The apparent total plasma clearance in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620900,BAO_0000218,1969.0,
4409,,A,,In vivo,Compound was evaluated for Hepatic clearance in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620901,BAO_0000218,,
4410,,A,,In vivo,Lower clearance in monkey (i.v.) at 0.5 mpk,0,,,22224,9527.0,Autocuration,1,CHEMBL620902,BAO_0000218,,
4411,,A,,In vivo,Plasma clearance in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620903,BAO_0000218,,
4412,,A,,In vivo,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL620904,BAO_0000218,,
4413,,A,,In vivo,Plasma clearance of compound was determined in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620905,BAO_0000218,,
4414,,A,,In vivo,Plasma clearance was calculated in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620906,BAO_0000218,,
4415,,A,,In vivo,Plasma clearance in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL875420,BAO_0000218,,
4416,,A,,In vivo,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),0,,,22224,9527.0,Autocuration,1,CHEMBL620907,BAO_0000218,,
4417,,A,,In vivo,Plasma clearance was evaluated in rhesus,0,,,22224,9527.0,Autocuration,1,CHEMBL620908,BAO_0000218,,
4418,,A,,In vivo,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,0,,,22224,9527.0,Autocuration,1,CHEMBL620909,BAO_0000218,,
4419,,A,,In vivo,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,0,,,22224,9527.0,Autocuration,1,CHEMBL620910,BAO_0000218,,
4420,,A,,In vivo,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),0,,,22224,9527.0,Autocuration,1,CHEMBL620911,BAO_0000218,,
4421,,A,,In vivo,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),0,,,22224,9527.0,Autocuration,1,CHEMBL620912,BAO_0000218,,
4422,,A,,In vivo,Cmax 24 hr after 2 mg/kg oral administration in monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL620913,BAO_0000218,,
4423,,A,,In vivo,Cmax in monkey after administration of 1 mg/kg iv,0,,,22224,9527.0,Autocuration,1,CHEMBL620914,BAO_0000218,,
4424,,A,,In vivo,Cmax was determine after peroral administration at 10 mpk in Rhesus,0,,,22224,9527.0,Autocuration,1,CHEMBL620915,BAO_0000218,,
4425,,A,,In vivo,Cmax in cynomolgus monkey by iv administration,0,,,22224,9527.0,Autocuration,1,CHEMBL620916,BAO_0000218,,
4426,,A,,In vivo,Cmax in cynomolgus monkey by po administration,0,,,22224,9527.0,Autocuration,1,CHEMBL620917,BAO_0000218,,
4427,,A,,In vivo,Cmax value evaluated in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620918,BAO_0000218,,
4428,,A,,In vivo,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620919,BAO_0000218,,
4429,,A,,In vivo,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL620920,BAO_0000218,1969.0,
4430,,A,,In vivo,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL620921,BAO_0000218,1969.0,
4431,,A,,In vivo,Maximal plasma concentration in squirrel monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL620922,BAO_0000218,1969.0,
4432,,A,,In vivo,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,0,,,22224,9527.0,Autocuration,1,CHEMBL620923,BAO_0000218,,
4433,,A,,In vivo,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL620924,BAO_0000218,1969.0,
4434,,A,,In vivo,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),0,,,22224,9527.0,Autocuration,1,CHEMBL620925,BAO_0000218,,
4435,,A,,In vivo,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL620926,BAO_0000218,,
4436,,A,,In vivo,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL620927,BAO_0000218,,
4437,,A,,In vivo,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL620928,BAO_0000218,,
4438,,A,,In vivo,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL620929,BAO_0000218,,
4439,,A,,In vivo,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,0,,,22224,9527.0,Autocuration,1,CHEMBL620930,BAO_0000218,1969.0,
4440,,A,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,0,,,22224,9527.0,Autocuration,1,CHEMBL620931,BAO_0000218,,
4441,,A,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,0,,,22224,9527.0,Autocuration,1,CHEMBL620932,BAO_0000218,,
4442,,A,,In vivo,Absolute bioavailability was evaluated in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL620933,BAO_0000218,,
4443,,A,,In vivo,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,0,,,22224,9443.0,Autocuration,1,CHEMBL620934,BAO_0000218,,
4444,,A,,In vivo,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,0,,,22224,9443.0,Autocuration,1,CHEMBL620935,BAO_0000218,,
4445,,A,,In vivo,Bioavailability of compound was determined in rhesus monkey,0,,,22224,9544.0,Autocuration,1,CHEMBL620936,BAO_0000218,,
4446,,A,,In vivo,Bioavailability determined after oral administration in marmoset,0,,,22224,38020.0,Autocuration,1,CHEMBL620937,BAO_0000218,,
4447,,A,,In vivo,Oral bioavailability in cynomolgus monkey,0,,,22224,9541.0,Autocuration,1,CHEMBL620938,BAO_0000218,,
4448,,A,,In vivo,Bioavailability in monkey (p.o.) at 2.0 mpk,0,,,22224,9443.0,Autocuration,1,CHEMBL620939,BAO_0000218,,
4449,,A,,In vivo,Bioavailability was evaluated after oral administration in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL620940,BAO_0000218,,
4450,,A,,In vivo,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,0,,,22224,9541.0,Autocuration,1,CHEMBL620941,BAO_0000218,,
4451,,A,,In vivo,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),0,,,22224,9544.0,Autocuration,1,CHEMBL620942,BAO_0000218,,
4452,,A,,In vivo,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),0,,,22224,9544.0,Autocuration,1,CHEMBL620943,BAO_0000218,,
4453,,A,,In vivo,Bioavailability of the compound was determined in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL620944,BAO_0000218,,
4454,,A,,In vivo,Bioavailability in squirrel monkey (dose 5 mg/kg),0,,,22224,9521.0,Autocuration,1,CHEMBL620945,BAO_0000218,,
4455,,A,,In vivo,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),0,,,22224,9443.0,Autocuration,1,CHEMBL620946,BAO_0000218,,
4456,,A,,In vivo,Oral bioavailability in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL620947,BAO_0000218,,
4457,,A,,In vivo,Compound was tested for bioavailability in squirrel monkey,0,,,22224,9521.0,Autocuration,1,CHEMBL620948,BAO_0000218,,
4458,,A,,In vivo,Oral bioavailability in Rhesus monkey,0,,,22224,9544.0,Autocuration,1,CHEMBL620949,BAO_0000218,,
4459,,A,,In vivo,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),0,,,22224,9544.0,Autocuration,1,CHEMBL620950,BAO_0000218,,
4460,,A,,In vivo,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,0,,,22224,9541.0,Autocuration,1,CHEMBL620951,BAO_0000218,,
4461,,A,,In vivo,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,0,,,22224,9541.0,Autocuration,1,CHEMBL620952,BAO_0000218,,
4462,,A,,In vivo,Oral bioavailability in monkey (dose 5 mg/kg),0,,,22224,9443.0,Autocuration,1,CHEMBL875421,BAO_0000218,,
4463,,A,,In vivo,Oral bioavailability of compound at 5 mg/kg in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL620953,BAO_0000218,,
4464,,A,,In vivo,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL873491,BAO_0000218,,
4465,,A,,In vivo,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL620954,BAO_0000218,,
4466,,A,,,Plasma half life determined,1,,,50588,9615.0,Intermediate,1,CHEMBL620955,BAO_0000218,1969.0,
4467,,A,,,Plasma half life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618097,BAO_0000218,1969.0,
4468,,A,,,Plasma half-life in Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618268,BAO_0000218,1969.0,
4469,,A,,In vivo,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,,,50588,9615.0,Intermediate,1,CHEMBL618269,BAO_0000218,1969.0,
4470,,A,,In vivo,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),1,,,50588,9615.0,Intermediate,1,CHEMBL618270,BAO_0000218,1969.0,
4471,,A,,In vivo,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618271,BAO_0000218,,
4472,,A,,In vivo,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL873493,BAO_0000218,,
4473,,A,,,Tested for the half life period in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621031,BAO_0000218,,
4474,,A,,In vivo,Tested for the half life period in dog at dosage of 10 mpk,1,,,50588,9615.0,Intermediate,1,CHEMBL621032,BAO_0000218,,
4475,,A,,,The compound was tested for half life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621033,BAO_0000218,,
4476,,A,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",1,,,50588,9615.0,Intermediate,1,CHEMBL621034,BAO_0000218,1969.0,
4477,,A,,,The half life was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621035,BAO_0000218,,
4478,,A,,,The plasma half-life in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621036,BAO_0000218,1969.0,
4479,,A,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,1,,,50588,9615.0,Intermediate,1,CHEMBL621037,BAO_0000218,1969.0,
4480,,A,,,Half life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619812,BAO_0000218,,
4481,,A,,In vivo,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,1,,,50588,9615.0,Intermediate,1,CHEMBL619813,BAO_0000218,,
4482,,A,,In vivo,tmax upon peroral administration of 10.0 mg/Kg dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL873335,BAO_0000218,,
4483,,A,,In vivo,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL619814,BAO_0000218,,
4484,,A,,In vivo,Cmax in ferrets after 30 mg/kg oral dose,1,,,50506,9669.0,Expert,1,CHEMBL619815,BAO_0000218,,
4485,,F,,In vivo,Emesis in ferrets at 30 mg/kg oral dose,1,,,50506,9669.0,Expert,1,CHEMBL619816,BAO_0000218,,
4486,,A,,In vivo,Bioavailability in cynomolgus monkey,0,,,22224,9541.0,Autocuration,1,CHEMBL619817,BAO_0000218,,
4487,,A,,In vivo,Volume of distribution in cynomolgus,1,,,100710,9541.0,Intermediate,1,CHEMBL619818,BAO_0000218,,
4488,,A,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,0,,,22224,10141.0,Autocuration,1,CHEMBL619819,BAO_0000218,1969.0,
4489,,A,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,0,,,22224,10141.0,Autocuration,1,CHEMBL619820,BAO_0000218,,
4490,,A,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",0,,,22224,10141.0,Autocuration,1,CHEMBL875419,BAO_0000218,,
4491,,A,,In vivo,AUC in guinea pig after 3mg/kg oral dose,0,,,22224,10141.0,Autocuration,1,CHEMBL619821,BAO_0000218,1969.0,
4492,,A,,In vivo,Bioavailability in guinea pig was tested,0,,,22224,10141.0,Autocuration,1,CHEMBL619822,BAO_0000218,,
4493,,A,,In vivo,Tested for oral bioavailability in guinea pig at 5 mg/kg,0,,,22224,10141.0,Autocuration,1,CHEMBL619823,BAO_0000218,,
4494,,A,,In vivo,Tested for the oral bioavailability of the compound,0,,,22224,10141.0,Autocuration,1,CHEMBL619824,BAO_0000218,,
4495,,A,,In vivo,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,0,,,22224,10141.0,Autocuration,1,CHEMBL619825,BAO_0000218,,
4496,,A,,In vivo,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,0,,,22224,10141.0,Autocuration,1,CHEMBL619826,BAO_0000218,,
4497,,A,,In vivo,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,0,,,22224,10141.0,Autocuration,1,CHEMBL619827,BAO_0000218,2048.0,
4498,,A,,In vivo,Cmax in guinea pig after 3mg/kg oral dose,0,,,22224,10141.0,Autocuration,1,CHEMBL618167,BAO_0000218,,
4499,,A,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,0,,,22224,10141.0,Autocuration,1,CHEMBL618168,BAO_0000019,178.0,
4500,,A,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,0,,,22224,10141.0,Autocuration,1,CHEMBL618169,BAO_0000019,955.0,
4501,,A,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,0,,,22224,10141.0,Autocuration,1,CHEMBL618170,BAO_0000019,,
4502,,A,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,0,,,22224,10141.0,Autocuration,1,CHEMBL618171,BAO_0000019,160.0,
4503,,A,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,0,,,22224,10141.0,Autocuration,1,CHEMBL618172,BAO_0000019,2113.0,
4504,,A,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,0,,,22224,10141.0,Autocuration,1,CHEMBL618173,BAO_0000019,2107.0,
4505,,A,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,0,,,22224,10141.0,Autocuration,1,CHEMBL618174,BAO_0000019,,
4506,,A,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,0,,,22224,10141.0,Autocuration,1,CHEMBL875408,BAO_0000019,2106.0,
4507,,A,,In vivo,Elimination T1/2 in Guinea pig (PO dose),0,,,22224,10141.0,Autocuration,1,CHEMBL839827,BAO_0000218,,
4508,,A,,,Partition coefficient was measured as -log (counts per min ),0,,,22224,10141.0,Autocuration,1,CHEMBL618175,BAO_0000019,,
4509,,A,,In vivo,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,0,,,22224,10141.0,Autocuration,1,CHEMBL618176,BAO_0000218,,
4510,,A,,In vivo,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,0,,,22224,10141.0,Autocuration,1,CHEMBL618177,BAO_0000218,,
4511,,A,,In vivo,Elimination T1/2 in Guinea pig (PO dose),0,,,22224,10141.0,Autocuration,1,CHEMBL618178,BAO_0000218,,
4512,,A,,In vivo,"Tested for the half life period of the compound, intravenously",0,,,22224,10141.0,Autocuration,1,CHEMBL618179,BAO_0000218,,
4513,,A,,,Half-life was measured,0,,,22224,10141.0,Autocuration,1,CHEMBL873489,BAO_0000019,,
4514,,A,,,The time required for onset of inotropy after addition of a single dose of delta F75,0,,,22224,10141.0,Autocuration,1,CHEMBL618180,BAO_0000019,,
4515,,A,,In vivo,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,0,,,22224,10141.0,Autocuration,1,CHEMBL618181,BAO_0000218,,
4516,,A,,In vivo,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,0,,,22224,10141.0,Autocuration,1,CHEMBL618182,BAO_0000218,,
4517,,A,,In vivo,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,0,,,22224,10029.0,Autocuration,1,CHEMBL618183,BAO_0000218,,
4518,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618184,BAO_0000218,,
4519,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618185,BAO_0000218,,
4520,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618186,BAO_0000218,,
4521,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618187,BAO_0000218,,
4522,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL618188,BAO_0000218,,
4523,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL875409,BAO_0000218,,
4524,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618189,BAO_0000218,,
4525,,A,,In vivo,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618190,BAO_0000218,178.0,
4526,,A,,In vivo,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618191,BAO_0000218,178.0,
4527,,A,,In vivo,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618192,BAO_0000218,178.0,
4528,,A,,In vivo,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618193,BAO_0000218,10000001.0,
4529,,A,,In vivo,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618194,BAO_0000218,10000001.0,
4530,,A,,In vivo,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618195,BAO_0000218,10000001.0,
4531,,A,,In vivo,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618196,BAO_0000218,955.0,
4532,,A,,In vivo,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618197,BAO_0000218,955.0,
4533,,A,,In vivo,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618198,BAO_0000218,955.0,
4534,,A,,In vivo,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618199,BAO_0000218,948.0,
4535,,A,,In vivo,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618200,BAO_0000218,948.0,
4536,,A,,In vivo,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618201,BAO_0000218,948.0,
4537,,A,,In vivo,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618202,BAO_0000218,160.0,
4538,,A,,In vivo,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618203,BAO_0000218,160.0,
4539,,A,,In vivo,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618204,BAO_0000218,160.0,
4540,,A,,In vivo,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618205,BAO_0000218,2113.0,
4541,,A,,In vivo,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618206,BAO_0000218,2113.0,
4542,,A,,In vivo,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618207,BAO_0000218,2113.0,
4543,,A,,In vivo,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618208,BAO_0000218,2107.0,
4544,,A,,In vivo,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618932,BAO_0000218,2107.0,
4545,,A,,In vivo,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618933,BAO_0000218,2107.0,
4546,,A,,In vivo,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618934,BAO_0000218,2048.0,
4547,,A,,In vivo,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618935,BAO_0000218,2048.0,
4548,,A,,In vivo,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618936,BAO_0000218,2048.0,
4549,,A,,In vivo,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618937,BAO_0000218,2385.0,
4550,,A,,In vivo,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618938,BAO_0000218,2385.0,
4551,,A,,In vivo,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619104,BAO_0000218,2385.0,
4552,,A,,In vivo,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619105,BAO_0000218,2106.0,
4553,,A,,In vivo,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619106,BAO_0000218,2106.0,
4554,,A,,In vivo,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619107,BAO_0000218,2106.0,
4555,,A,,In vivo,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL875410,BAO_0000218,945.0,
4556,,A,,In vivo,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619108,BAO_0000218,945.0,
4557,,A,,In vivo,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619109,BAO_0000218,945.0,
4558,,A,,In vivo,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,,,50594,10090.0,Intermediate,1,CHEMBL619110,BAO_0000218,,
4559,,F,,In vivo,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,,,50594,10090.0,Intermediate,1,CHEMBL619111,BAO_0000218,,
4560,,A,,In vivo,MRT value at a dose of 10 mg/kg intravenous administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL619112,BAO_0000218,,
4561,,A,,In vivo,MRT value at a dose of 10 mg/kg peroral administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL619113,BAO_0000218,,
4562,,A,,In vivo,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL619114,BAO_0000218,,
4563,,F,,In vivo,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL619115,BAO_0000218,,
4564,A2780,F,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,1,,,81034,9606.0,Intermediate,1,CHEMBL619116,BAO_0000219,,
4565,A2780,F,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,1,,,81034,9606.0,Intermediate,1,CHEMBL619117,BAO_0000219,,
4566,A2780,F,478.0,,Compound was evaluated for cytotoxicity against A2780 cell lines.,1,,,81034,9606.0,Intermediate,1,CHEMBL619118,BAO_0000219,,
4567,A2780,F,478.0,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,1,,,81034,9606.0,Intermediate,1,CHEMBL619119,BAO_0000219,,
4568,A2780,F,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,,,81034,9606.0,Intermediate,1,CHEMBL619120,BAO_0000219,,
4569,A2780,F,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,,,81034,9606.0,Intermediate,1,CHEMBL619121,BAO_0000219,,
4570,A2780,F,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,,,81034,9606.0,Intermediate,1,CHEMBL619122,BAO_0000219,,
4571,A2780,F,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,,,81034,9606.0,Intermediate,1,CHEMBL619123,BAO_0000219,,
4572,A2780,F,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,,,81034,9606.0,Intermediate,1,CHEMBL619124,BAO_0000219,,
4573,A2780,F,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL619125,BAO_0000219,,
4574,A2780,F,478.0,,In vitro inhibitory activity against human tumor cell line A2780,1,,,81034,9606.0,Intermediate,1,CHEMBL875411,BAO_0000219,,
4575,A2780,F,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,1,,,81034,9606.0,Intermediate,1,CHEMBL619126,BAO_0000219,,
4576,A2780,F,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,,,81034,9606.0,Intermediate,1,CHEMBL619127,BAO_0000219,,
4577,A2780,F,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,,,81034,9606.0,Intermediate,1,CHEMBL619128,BAO_0000219,,
4578,A2780,F,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,,,81034,9606.0,Intermediate,1,CHEMBL619129,BAO_0000219,,
4579,A2780,F,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,1,,,81034,9606.0,Intermediate,1,CHEMBL619130,BAO_0000219,,
4580,A2780,F,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,1,,,81034,9606.0,Intermediate,1,CHEMBL619131,BAO_0000219,,
4581,A2780,F,478.0,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,1,,,81034,9606.0,Intermediate,1,CHEMBL619132,BAO_0000219,,
4582,A2780,F,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,,,81034,9606.0,Expert,1,CHEMBL619133,BAO_0000218,,
4583,A2780,F,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,,,81034,9606.0,Intermediate,1,CHEMBL619134,BAO_0000219,,
4584,A2780,F,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,,,81034,9606.0,Intermediate,1,CHEMBL619135,BAO_0000219,,
4585,A2780,F,478.0,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,1,,,81034,9606.0,Intermediate,1,CHEMBL619136,BAO_0000219,,
4586,A2780,F,478.0,,Relative resistance factor in A2780 cisplatin-resistant line,1,,,81034,9606.0,Intermediate,1,CHEMBL619137,BAO_0000219,,
4587,A2780,F,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,1,,,81034,9606.0,Intermediate,1,CHEMBL883713,BAO_0000219,,
4588,A2780,F,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,1,,,81034,9606.0,Intermediate,1,CHEMBL875412,BAO_0000219,,
4589,A2780,F,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,,,81034,9606.0,Expert,1,CHEMBL619138,BAO_0000218,,
4590,A2780,F,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,,,81034,9606.0,Expert,1,CHEMBL619262,BAO_0000218,,
4591,A2780,F,478.0,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,1,,,81034,9606.0,Intermediate,1,CHEMBL619139,BAO_0000219,,
4592,A2780,F,478.0,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,1,,,81034,9606.0,Intermediate,1,CHEMBL619140,BAO_0000219,,
4593,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,1,,,81034,9606.0,Intermediate,1,CHEMBL619141,BAO_0000219,,
4594,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,1,,,81034,9606.0,Intermediate,1,CHEMBL619142,BAO_0000219,,
4595,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,1,,,81034,9606.0,Intermediate,1,CHEMBL619143,BAO_0000219,,
4596,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,1,,,81034,9606.0,Intermediate,1,CHEMBL619144,BAO_0000219,,
4597,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,1,,,81034,9606.0,Intermediate,1,CHEMBL619145,BAO_0000219,,
4598,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,1,,,81034,9606.0,Intermediate,1,CHEMBL619146,BAO_0000219,,
4599,A2780,F,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,1,,,81034,9606.0,Intermediate,1,CHEMBL619147,BAO_0000219,,
4600,A2780,F,478.0,,Antiproliferative effect of compound on A2780/DX cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL619148,BAO_0000219,,
4601,A2780,F,478.0,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,1,,,81034,9606.0,Intermediate,1,CHEMBL619149,BAO_0000219,,
4602,A2780,F,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),1,,,81034,9606.0,Intermediate,1,CHEMBL619150,BAO_0000219,,
4603,A2780,F,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),1,,,81034,9606.0,Intermediate,1,CHEMBL619151,BAO_0000219,,
4604,A2780,F,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,1,,,81034,9606.0,Intermediate,1,CHEMBL883794,BAO_0000219,,
4605,A2780,F,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,1,,,81034,9606.0,Intermediate,1,CHEMBL619152,BAO_0000219,,
4606,A2780,F,478.0,,In vitro cytotoxicity against A2780ADR cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL619153,BAO_0000219,,
4607,A2780,F,478.0,,In vitro cytotoxicity against A2780CIS cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL619154,BAO_0000219,,
4608,A2780,F,478.0,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,1,,,81034,9606.0,Intermediate,1,CHEMBL619155,BAO_0000219,,
4609,A2780,F,478.0,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,1,,,81034,9606.0,Intermediate,1,CHEMBL619156,BAO_0000219,,
4610,A2780,F,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",1,,,81034,9606.0,Intermediate,1,CHEMBL619157,BAO_0000219,,
4611,A2780,F,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",1,,,81034,9606.0,Intermediate,1,CHEMBL619797,BAO_0000219,,
4612,,A,,In vivo,Oral bioavailability of compound in rhesus macaques,0,,,22224,9544.0,Autocuration,1,CHEMBL619798,BAO_0000218,,
4613,,A,,In vivo,Oral bioavailability in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL619799,BAO_0000218,,
4614,,A,,In vivo,Oral bioavailability evaluated in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL619800,BAO_0000218,,
4615,,A,,In vivo,Oral bioavailability in monkey (dose 1 mg/kg p.o.),0,,,22224,9443.0,Autocuration,1,CHEMBL619801,BAO_0000218,,
4616,,A,,In vivo,Oral bioavailability in Rhesus monkey,0,,,22224,9544.0,Autocuration,1,CHEMBL619802,BAO_0000218,,
4617,,A,,In vivo,Oral bioavailability was calculated in rhesus monkey,0,,,22224,9544.0,Autocuration,1,CHEMBL619803,BAO_0000218,,
4618,,A,,In vivo,Oral bioavailability in cynomolgus monkey,0,,,22224,9541.0,Autocuration,1,CHEMBL619965,BAO_0000218,,
4619,,A,,In vivo,Oral bioavailability in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL619966,BAO_0000218,,
4620,,A,,In vivo,Oral bioavailability in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL619967,BAO_0000218,,
4621,,A,,In vivo,Oral bioavailability in monkey (dose 1 mg/kg),0,,,22224,9443.0,Autocuration,1,CHEMBL620073,BAO_0000218,,
4622,,A,,In vivo,Oral bioavailability in monkey (dose 5 mg/kg),0,,,22224,9443.0,Autocuration,1,CHEMBL620074,BAO_0000218,,
4623,,A,,In vivo,Oral bioavailability in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL620075,BAO_0000218,,
4624,,A,,In vivo,Oral bioavailability in monkey,0,,,22224,9443.0,Autocuration,1,CHEMBL620076,BAO_0000218,,
4625,,A,,In vivo,Oral bioavailability in rhesus monkey,0,,,22224,9544.0,Autocuration,1,CHEMBL620077,BAO_0000218,,
4626,,A,,In vivo,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,0,,,22224,9544.0,Autocuration,1,CHEMBL620078,BAO_0000218,,
4627,,A,,In vivo,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,0,,,22224,9521.0,Autocuration,1,CHEMBL620079,BAO_0000218,,
4628,,A,,In vivo,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),0,,,22224,9443.0,Autocuration,1,CHEMBL620080,BAO_0000218,,
4629,,A,,In vivo,Oral bioavailability in Rhesus monkey,0,,,22224,9544.0,Autocuration,1,CHEMBL620081,BAO_0000218,,
4630,,A,,In vivo,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),0,,,22224,9544.0,Autocuration,1,CHEMBL620082,BAO_0000218,,
4631,,A,,In vivo,Oral bioavailability in monkey at 10 mg/kg of the compound,0,,,22224,9443.0,Autocuration,1,CHEMBL620083,BAO_0000218,,
4632,,A,,In vivo,Bioavailability in Rhesus monkey,0,,,22224,9544.0,Autocuration,1,CHEMBL620084,BAO_0000218,,
4633,,A,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL620085,BAO_0000218,,
4634,,A,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL874595,BAO_0000218,,
4635,,A,,In vivo,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL873352,BAO_0000218,,
4636,,A,,In vivo,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL620086,BAO_0000218,,
4637,,A,,In vivo,Mean residence time was determined after intravenous administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL620087,BAO_0000218,,
4638,,A,,In vivo,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL620088,BAO_0000218,,
4639,,A,,In vivo,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL620089,BAO_0000218,,
4640,,A,,In vivo,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),0,,,22224,9527.0,Autocuration,1,CHEMBL620090,BAO_0000218,,
4641,,A,,In vivo,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),0,,,22224,9527.0,Autocuration,1,CHEMBL620091,BAO_0000218,,
4642,,A,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),0,,,22224,9527.0,Autocuration,1,CHEMBL620092,BAO_0000251,,
4643,,A,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),0,,,22224,9527.0,Autocuration,1,CHEMBL620093,BAO_0000251,,
4644,,A,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),0,,,22224,9527.0,Autocuration,1,CHEMBL620094,BAO_0000251,,
4645,,A,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),0,,,22224,9527.0,Autocuration,1,CHEMBL620095,BAO_0000251,,
4646,,A,,In vivo,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL620096,BAO_0000218,,
4647,,A,,In vivo,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL620097,BAO_0000218,,
4648,,A,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,0,,,22224,9527.0,Autocuration,1,CHEMBL620098,BAO_0000019,,
4649,,A,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL620099,BAO_0000218,,
4650,,A,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL620100,BAO_0000218,,
4651,,A,,,Elimination Half-life of compound was determined in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620101,BAO_0000019,,
4652,,A,,,Half life of compound was determined in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL620102,BAO_0000019,,
4653,,A,,,Half life in monkey plasma,0,,,22224,9527.0,Autocuration,1,CHEMBL620103,BAO_0000366,1969.0,
4654,,A,,,Half life in monkey plasma; Not detected,0,,,22224,9527.0,Autocuration,1,CHEMBL620104,BAO_0000366,1969.0,
4655,,A,,In vivo,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,0,,,22224,9527.0,Autocuration,1,CHEMBL874596,BAO_0000218,,
4656,,A,,In vivo,Half-life 24 hr after 2 mg/kg iv administration in monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL873490,BAO_0000218,,
4657,,A,,,Terminal half life of the compound.,0,,,22224,9527.0,Autocuration,1,CHEMBL620105,BAO_0000019,,
4658,,A,,In vivo,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,0,,,22224,9527.0,Autocuration,1,CHEMBL620780,BAO_0000218,,
4659,,A,,In vivo,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),0,,,22224,9527.0,Autocuration,1,CHEMBL620781,BAO_0000218,,
4660,,A,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,0,,,22224,9527.0,Autocuration,1,CHEMBL620956,BAO_0000218,,
4661,,A,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL620957,BAO_0000218,1088.0,
4662,,A,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL620958,BAO_0000218,1088.0,
4663,,A,,In vivo,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,0,,,22224,9527.0,Autocuration,1,CHEMBL620959,BAO_0000218,,
4664,,A,,In vivo,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,0,,,22224,9527.0,Autocuration,1,CHEMBL620960,BAO_0000218,,
4665,,A,,In vivo,Volume of distribution was evaluated in rhesus,0,,,22224,9527.0,Autocuration,1,CHEMBL620961,BAO_0000218,,
4666,,A,,In vivo,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,0,,,22224,10029.0,Autocuration,1,CHEMBL620962,BAO_0000218,,
4667,,A,,In vivo,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,0,,,22224,10029.0,Autocuration,1,CHEMBL620963,BAO_0000218,,
4668,,A,,In vivo,Bioavailability in hamster was determined,0,,,22224,10029.0,Autocuration,1,CHEMBL620964,BAO_0000218,,
4669,,A,,In vivo,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,0,,,22224,10029.0,Autocuration,1,CHEMBL620965,BAO_0000218,,
4670,,A,,In vivo,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,0,,,22224,10029.0,Autocuration,1,CHEMBL620966,BAO_0000218,,
4671,,A,,,Half life of compound was determined in hamster blood,0,,,22224,10029.0,Autocuration,1,CHEMBL620967,BAO_0000221,178.0,
4672,,A,,,Michaelis-Menten constant of the compound.,0,,,22224,9823.0,Autocuration,1,CHEMBL620968,BAO_0000019,,
4673,,A,,,Vmax value was measured at 0 uM concentration of silyl ether.,0,,,22224,9823.0,Autocuration,1,CHEMBL874597,BAO_0000019,,
4674,,A,,,Vmax value was measured at 10 uM concentration of silyl ether.,0,,,22224,9823.0,Autocuration,1,CHEMBL620969,BAO_0000019,,
4675,,A,,,Vmax value was measured at 5 uM concentration of silyl ether.,0,,,22224,9823.0,Autocuration,1,CHEMBL620970,BAO_0000019,,
4676,,B,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,9,,,235,9606.0,Expert,1,CHEMBL620971,BAO_0000357,,
4677,,A,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,0,,,22224,9606.0,Autocuration,1,CHEMBL620972,BAO_0000218,,
4678,,A,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),0,,,22224,9606.0,Autocuration,1,CHEMBL620973,BAO_0000019,,
4679,,A,,,Active metabolite of ifosfamide determined in humans; A-Active,0,,,22224,9606.0,Autocuration,1,CHEMBL618243,BAO_0000019,,
4680,,A,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,0,,,22224,9606.0,Autocuration,1,CHEMBL618244,BAO_0000019,,
4681,,A,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,0,,,22224,9606.0,Autocuration,1,CHEMBL618245,BAO_0000019,,
4682,,A,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,0,,,22224,9606.0,Autocuration,1,CHEMBL618246,BAO_0000019,,
4683,,A,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,0,,,22224,9606.0,Autocuration,1,CHEMBL618247,BAO_0000019,,
4684,,A,,,Compound was evaluated for oral bioavailability in human,0,,,22224,9606.0,Autocuration,1,CHEMBL618248,BAO_0000218,,
4685,,A,,,Metabolite of ifosfamide determined in urine; NF-Not found,0,,,22224,9606.0,Autocuration,1,CHEMBL618249,BAO_0000019,1088.0,
4686,,A,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),0,,,22224,9606.0,Autocuration,1,CHEMBL618250,BAO_0000019,,
4687,,A,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,0,,,22224,9606.0,Autocuration,1,CHEMBL874598,BAO_0000019,,
4688,,A,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,0,,,22224,9606.0,Autocuration,1,CHEMBL618251,BAO_0000019,,
4689,,A,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,0,,,22224,9606.0,Autocuration,1,CHEMBL618252,BAO_0000019,,
4690,,A,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,0,,,22224,9606.0,Autocuration,1,CHEMBL618253,BAO_0000019,,
4691,,A,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),0,,,22224,9606.0,Autocuration,1,CHEMBL618254,BAO_0000019,,
4692,,A,,,Percent of compound in healthy individuals (Group D),0,,,22224,9606.0,Autocuration,1,CHEMBL618255,BAO_0000019,,
4693,,A,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL618983,BAO_0000251,2107.0,
4694,,A,,,Binding towards human plasma protein at 10 uM,0,,,22224,9606.0,Autocuration,1,CHEMBL618984,BAO_0000019,,
4695,,A,,,Binding towards human plasma protein at 100 uM,0,,,22224,9606.0,Autocuration,1,CHEMBL618985,BAO_0000019,,
4696,,A,,,Human plasma protein binding activity was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618986,BAO_0000019,,
4697,,A,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),0,,,22224,9606.0,Autocuration,1,CHEMBL618987,BAO_0000019,,
4698,,A,,,Percent binding of compound towards human plasma protein was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618988,BAO_0000019,,
4699,,A,,In vitro,Plasma clearance in human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL618989,BAO_0000251,2107.0,
4700,,A,,In vitro,In vitro intrinsic clearance in human liver microsome,0,,,22224,9606.0,Autocuration,1,CHEMBL618990,BAO_0000251,2107.0,
4701,,A,,In vitro,In vitro intrinsic clearance in human liver microsome,0,,,22224,9606.0,Autocuration,1,CHEMBL618991,BAO_0000251,2107.0,
4702,,A,,In vitro,In vitro microsome metabolism clearance in human was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL876725,BAO_0000251,,
4703,,A,,In vitro,In vitro microsome metabolism clearance in human was determined; High,0,,,22224,9606.0,Autocuration,1,CHEMBL618992,BAO_0000251,,
4704,,A,,In vitro,In vitro microsome metabolism clearance in human was determined; ND denotes no data,0,,,22224,9606.0,Autocuration,1,CHEMBL618993,BAO_0000251,,
4705,,A,,In vitro,Pharmacokinetic property (clearance) in human liver microsome,0,,,22224,9606.0,Autocuration,1,CHEMBL618994,BAO_0000251,2107.0,
4706,,A,,In vitro,Plasma clearance in human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL618995,BAO_0000251,2107.0,
4707,,A,,In vitro,In vitro clearance in human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL618996,BAO_0000251,2107.0,
4708,,A,,In vitro,Intrinsic clearance in human liver microsomes was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618997,BAO_0000251,2107.0,
4709,,A,,In vitro,Intrinsic clearance in human liver microsomes was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618998,BAO_0000251,2107.0,
4710,,A,,In vivo,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,0,,,22224,9606.0,Autocuration,1,CHEMBL618999,BAO_0000218,,
4711,,A,,In vivo,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,0,,,22224,9606.0,Autocuration,1,CHEMBL620223,BAO_0000218,,
4712,,A,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,0,,,22224,9606.0,Autocuration,1,CHEMBL620224,BAO_0000218,,
4713,,A,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,0,,,22224,9606.0,Autocuration,1,CHEMBL620225,BAO_0000019,,
4714,,A,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,0,,,22224,9606.0,Autocuration,1,CHEMBL620226,BAO_0000019,,
4715,,A,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,0,,,22224,9606.0,Autocuration,1,CHEMBL620227,BAO_0000019,1088.0,
4716,,A,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,0,,,22224,9606.0,Autocuration,1,CHEMBL876726,BAO_0000019,1088.0,
4717,,A,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,0,,,22224,9606.0,Autocuration,1,CHEMBL620228,BAO_0000019,1088.0,
4718,,A,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,0,,,22224,9606.0,Autocuration,1,CHEMBL620229,BAO_0000019,1088.0,
4719,,F,,In vivo,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620230,BAO_0000218,,
4720,,F,,In vivo,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620231,BAO_0000218,,
4721,,F,,In vivo,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620232,BAO_0000218,,
4722,,F,,In vivo,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620233,BAO_0000218,,
4723,,A,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),1,,,50594,10090.0,Intermediate,1,CHEMBL620234,BAO_0000218,,
4724,,A,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),1,,,50594,10090.0,Intermediate,1,CHEMBL620235,BAO_0000218,,
4725,,A,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),1,,,50594,10090.0,Intermediate,1,CHEMBL620236,BAO_0000218,,
4726,,A,,,In vitro metabolic potential in mouse liver microsomes,1,,,50594,10090.0,Intermediate,1,CHEMBL620237,BAO_0000218,2107.0,
4727,,A,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,1,,,50594,10090.0,Intermediate,1,CHEMBL620238,BAO_0000218,,
4728,,A,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),1,,,50594,10090.0,Intermediate,1,CHEMBL620239,BAO_0000218,2369.0,
4729,,A,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,1,,,50594,10090.0,Intermediate,1,CHEMBL620240,BAO_0000218,955.0,
4730,,A,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,1,,,50594,10090.0,Intermediate,1,CHEMBL620241,BAO_0000218,955.0,
4731,,A,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),1,,,50594,10090.0,Intermediate,1,CHEMBL876727,BAO_0000218,,
4732,,A,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),1,,,50594,10090.0,Intermediate,1,CHEMBL620242,BAO_0000218,2113.0,
4733,,A,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),1,,,50594,10090.0,Intermediate,1,CHEMBL620243,BAO_0000218,,
4734,,A,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620244,BAO_0000218,,
4735,,A,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,1,,,50594,10090.0,Intermediate,1,CHEMBL620245,BAO_0000218,1977.0,
4736,,A,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,1,,,50594,10090.0,Intermediate,1,CHEMBL620246,BAO_0000218,1977.0,
4737,,A,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,1,,,50594,10090.0,Intermediate,1,CHEMBL620247,BAO_0000218,1977.0,
4738,,A,,In vivo,Half life of compound was determined in plasma of mice at 24 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620248,BAO_0000218,1969.0,
4739,,A,,In vivo,Half life of compound was determined in plasma of mice at 40 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL873497,BAO_0000218,1969.0,
4740,,A,,In vivo,Half life of compound was determined in plasma of mice at 5 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620249,BAO_0000218,1969.0,
4741,,F,,In vivo,Half life after intraperitoneal administration in mice at 18 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620250,BAO_0000218,,
4742,,F,,In vivo,Half life after intraperitoneal administration in mice at 23 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620251,BAO_0000218,,
4743,,F,,In vivo,Half life after intraperitoneal administration in mice at 25 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620252,BAO_0000218,,
4744,,F,,In vivo,Half life after intraperitoneal administration in mice at 26 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620253,BAO_0000218,,
4745,,F,,In vivo,Half life after intravenous administration in mice at 23 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620254,BAO_0000218,,
4746,,A,,In vivo,Half life after intravenous administration in mice at 24 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620255,BAO_0000218,,
4747,,A,,In vivo,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,,,50594,10090.0,Intermediate,1,CHEMBL620256,BAO_0000218,,
4748,,A,,In vivo,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL876728,BAO_0000218,,
4749,,A,,In vivo,Maximum time required to reach Cp max was evaluated in mice after oral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL620257,BAO_0000218,,
4750,,A,,In vivo,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,,,50594,10090.0,Intermediate,1,CHEMBL620258,BAO_0000218,,
4751,,A,,In vivo,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",1,,,50594,10090.0,Intermediate,1,CHEMBL620259,BAO_0000218,,
4752,,A,,In vivo,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620260,BAO_0000218,,
4753,,A,,In vivo,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620261,BAO_0000218,178.0,
4754,,A,,In vivo,Half life at a dose of 10 mg/kg intravenous administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL620262,BAO_0000218,,
4755,,A,,In vivo,Half life at a dose of 10 mg/kg peroral administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL620263,BAO_0000218,,
4756,,A,,,Half life in ob/ob mice,1,,,50594,10090.0,Intermediate,1,CHEMBL620264,BAO_0000218,,
4757,,A,,In vivo,Half-life at a single subcutaneous administration of 40 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL620265,BAO_0000218,,
4758,,A,,,Half-life was measured in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL620266,BAO_0000218,,
4759,,A,,In vivo,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620267,BAO_0000218,,
4760,,A,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,1,,,50594,10090.0,Intermediate,1,CHEMBL619364,BAO_0000218,,
4761,,A,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,1,,,50594,10090.0,Intermediate,1,CHEMBL619365,BAO_0000218,,
4762,,A,,,T2 in brain of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL619366,BAO_0000218,955.0,
4763,,A,,,T2 in kidney of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL619367,BAO_0000218,2113.0,
4764,,A,,,T2 in liver of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL619368,BAO_0000218,2107.0,
4765,,A,,,T2 in lungs of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL619369,BAO_0000218,2048.0,
4766,,A,,,T2 in spleen of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL876729,BAO_0000218,2106.0,
4767,,A,,In vivo,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,,,50594,10090.0,Intermediate,1,CHEMBL619370,BAO_0000218,,
4768,,A,,In vivo,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",1,,,50594,10090.0,Intermediate,1,CHEMBL619371,BAO_0000218,,
4769,,A,,In vivo,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL619372,BAO_0000218,,
4770,,A,,In vivo,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL620012,BAO_0000218,,
4771,,A,,In vivo,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620013,BAO_0000218,,
4772,A2780,F,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,,,81034,9606.0,Intermediate,1,CHEMBL620014,BAO_0000219,,
4773,A2780,F,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,,,81034,9606.0,Intermediate,1,CHEMBL620015,BAO_0000219,,
4774,A2780,F,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,,,81034,9606.0,Intermediate,1,CHEMBL621010,BAO_0000219,,
4775,A2780,F,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,,,81034,9606.0,Intermediate,1,CHEMBL621011,BAO_0000219,,
4776,A2780,F,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,,,81034,9606.0,Intermediate,1,CHEMBL621012,BAO_0000219,,
4777,A2780,F,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,,,81034,9606.0,Intermediate,1,CHEMBL621013,BAO_0000219,,
4778,A2780,F,478.0,,In vitro cytotoxicity against A2780TAX cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL621014,BAO_0000219,,
4779,A2780cisR,F,481.0,,In vitro inhibitory activity against human tumor cell line A2780cis,1,,,80017,9606.0,Intermediate,1,CHEMBL618154,BAO_0000219,,
4780,A2780,F,478.0,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,1,,,81034,9606.0,Expert,1,CHEMBL618155,BAO_0000219,,
4781,A2780cisR,F,481.0,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,1,,,80017,9606.0,Intermediate,1,CHEMBL618156,BAO_0000219,,
4782,A2780cisR,F,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,,,80017,9606.0,Intermediate,1,CHEMBL618157,BAO_0000219,,
4783,A2780,F,478.0,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,1,,,81034,9606.0,Intermediate,1,CHEMBL618328,BAO_0000219,,
4784,A2780,F,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,1,,,81034,9606.0,Intermediate,1,CHEMBL618329,BAO_0000219,,
4785,A2780,F,478.0,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL618330,BAO_0000219,,
4786,A2780,F,478.0,,In vitro antitumor activity against A2780cisR cell line.,1,,,81034,9606.0,Expert,1,CHEMBL618331,BAO_0000219,,
4787,A2780,F,478.0,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),1,,,81034,9606.0,Intermediate,1,CHEMBL618332,BAO_0000219,,
4788,A2780,F,478.0,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,1,,,81034,9606.0,Expert,1,CHEMBL618333,BAO_0000219,,
4789,A2780cisR,F,481.0,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,1,,,80017,9606.0,Intermediate,1,CHEMBL618334,BAO_0000219,,
4790,A2780,F,478.0,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,1,,,81034,9606.0,Expert,1,CHEMBL618335,BAO_0000219,,
4791,,B,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,9,,,11736,10116.0,Expert,1,CHEMBL618336,BAO_0000019,,
4792,,F,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),8,,,11736,,Expert,1,CHEMBL618337,BAO_0000019,,
4793,,F,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),9,,,11736,10116.0,Expert,1,CHEMBL618338,BAO_0000019,,
4794,HEK293,F,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,9,,,278,9606.0,Expert,1,CHEMBL618339,BAO_0000219,,
4795,HEK293,F,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,9,,,278,9606.0,Expert,1,CHEMBL618340,BAO_0000219,,
4796,,B,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,9,,,11831,10090.0,Expert,1,CHEMBL618341,BAO_0000019,,
4797,,F,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),8,,,11831,,Expert,1,CHEMBL618342,BAO_0000019,,
4798,,F,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),9,,,11831,10090.0,Expert,1,CHEMBL618343,BAO_0000019,,
4799,,B,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,8,,,280,,Expert,1,CHEMBL621038,BAO_0000357,,
4800,T-cells,F,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),0,,,22226,9606.0,Autocuration,1,CHEMBL621039,BAO_0000219,,
4801,T-cells,F,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,0,,,22226,9606.0,Autocuration,1,CHEMBL621040,BAO_0000219,,
4802,A-375,F,455.0,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,1,,,80018,9606.0,Intermediate,1,CHEMBL621041,BAO_0000219,,
4803,A-375,F,455.0,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,1,,,80018,9606.0,Intermediate,1,CHEMBL621042,BAO_0000219,,
4804,A-375,F,455.0,,In vitro antitumor activity against A375cell line extracted form melanoma,1,,,80018,9606.0,Intermediate,1,CHEMBL621043,BAO_0000219,,
4805,A-375,F,455.0,,Inhibition of cell growth in (A375) melan cell line,1,,,80018,9606.0,Expert,1,CHEMBL621044,BAO_0000219,,
4806,A-375,F,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,1,,,80018,9606.0,Intermediate,1,CHEMBL621045,BAO_0000219,,
4807,A-375,F,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,1,,,80018,9606.0,Intermediate,1,CHEMBL621046,BAO_0000219,,
4808,A-375,F,455.0,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,1,,,80018,9606.0,Intermediate,1,CHEMBL621047,BAO_0000219,,
4809,A-427,F,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,1,,,80019,9606.0,Intermediate,1,CHEMBL621048,BAO_0000219,,
4810,A-427,F,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,1,,,80019,9606.0,Intermediate,1,CHEMBL883798,BAO_0000219,,
4811,A-427,F,797.0,,Cytotoxicity against lung carcinoma A427 tumor cell lines,1,,,80019,9606.0,Intermediate,1,CHEMBL621049,BAO_0000219,,
4812,A-427,F,797.0,,Inhibition of large cell lung carcinoma (A427),1,,,80019,9606.0,Intermediate,1,CHEMBL621050,BAO_0000219,,
4813,A-427,F,797.0,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,1,,,80019,9606.0,Intermediate,1,CHEMBL621051,BAO_0000219,,
4814,A-427,F,797.0,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,,,80019,9606.0,Intermediate,1,CHEMBL621052,BAO_0000219,,
4815,A-427,F,797.0,,Inhibitory concentration in human lung carcinoma A427 cell line,1,,,80019,9606.0,Intermediate,1,CHEMBL621053,BAO_0000219,,
4816,A-427,F,797.0,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,1,,,80019,9606.0,Intermediate,1,CHEMBL621054,BAO_0000219,,
4817,,A,,In vivo,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL621055,BAO_0000218,,
4818,,A,,In vivo,Tested for volume of distribution upon iv administration to african green monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL876398,BAO_0000218,,
4819,,A,,In vivo,Volume of distribution in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL621056,BAO_0000218,,
4820,,A,,In vivo,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,0,,,22224,9544.0,Autocuration,1,CHEMBL621057,BAO_0000218,,
4821,,A,,In vivo,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,0,,,22224,9544.0,Autocuration,1,CHEMBL621058,BAO_0000218,,
4822,,A,,In vivo,Pharmacokinetic property(Vdss) in cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL621059,BAO_0000218,,
4823,,A,,In vivo,The distribution volume after intravenous administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL621060,BAO_0000218,,
4824,,A,,In vivo,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL621061,BAO_0000218,,
4825,,A,,In vivo,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL621062,BAO_0000218,,
4826,,A,,In vivo,Volume displacement was calculated in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL621063,BAO_0000218,,
4827,,A,,In vivo,Volume of distribution in steady state was determined in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL621064,BAO_0000218,,
4828,,A,,In vivo,Volume of distribution of compound was determined in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL621065,BAO_0000218,,
4829,,A,,In vivo,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),0,,,22224,9527.0,Autocuration,1,CHEMBL621066,BAO_0000218,,
4830,,A,,In vivo,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),0,,,22224,9527.0,Autocuration,1,CHEMBL621067,BAO_0000218,,
4831,,A,,In vivo,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),0,,,22224,9527.0,Autocuration,1,CHEMBL621068,BAO_0000218,,
4832,,A,,In vivo,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL876399,BAO_0000218,,
4833,,A,,In vivo,Volume distribution in monkey after administration of 1 mg/kg iv,0,,,22224,9527.0,Autocuration,1,CHEMBL621069,BAO_0000218,,
4834,,A,,In vivo,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),0,,,22224,9527.0,Autocuration,1,CHEMBL621070,BAO_0000218,,
4835,,A,,In vivo,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL621071,BAO_0000218,,
4836,,A,,In vivo,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL621072,BAO_0000218,,
4837,,A,,In vivo,Oral systemic bioavailability upon iv administration to african green monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618209,BAO_0000218,,
4838,,A,,In vivo,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),0,,,22224,9527.0,Autocuration,1,CHEMBL618210,BAO_0000218,,
4839,,A,,,Baboon plasma free fraction. ,0,,,22224,9527.0,Autocuration,1,CHEMBL618211,BAO_0000019,,
4840,,A,,,Area under the curve was calculated in rhesus monkey after iv administration,0,,,22224,9527.0,Autocuration,1,CHEMBL618212,BAO_0000218,,
4841,,A,,,Area under the curve was calculated in rhesus monkey after peroral administration,0,,,22224,9527.0,Autocuration,1,CHEMBL618213,BAO_0000019,,
4842,,A,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,0,,,22224,9527.0,Autocuration,1,CHEMBL618214,BAO_0000019,,
4843,,A,,In vivo,Half life period in monkey after 5 mg/kg dose,0,,,22224,9527.0,Autocuration,1,CHEMBL873492,BAO_0000218,,
4844,,A,,In vivo,Half-life was determined in monkey after 3 mg/kg of i.v. dose,0,,,22224,9527.0,Autocuration,1,CHEMBL618272,BAO_0000218,,
4845,,A,,In vivo,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,0,,,22224,9527.0,Autocuration,1,CHEMBL618273,BAO_0000218,,
4846,,A,,In vivo,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618274,BAO_0000218,1969.0,
4847,,A,,In vivo,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL618275,BAO_0000218,,
4848,,A,,In vivo,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618276,BAO_0000218,,
4849,,A,,,Compound was evaluated for terminal half life in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618277,BAO_0000019,,
4850,,A,,In vivo,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618278,BAO_0000218,,
4851,,A,,In vivo,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,0,,,22224,9544.0,Autocuration,1,CHEMBL618279,BAO_0000218,1969.0,
4852,,A,,,Half life of compound was determined in squirrel monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618280,BAO_0000019,,
4853,,A,,In vivo,Half life after iv administration in cynomolgus monkey,0,,,22224,9541.0,Autocuration,1,CHEMBL618281,BAO_0000218,,
4854,,A,,In vivo,Half life in monkey plasma after administration of 1 mg/kg iv,0,,,22224,9527.0,Autocuration,1,CHEMBL618282,BAO_0000218,1969.0,
4855,,A,,,Half life was calculated in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618283,BAO_0000019,,
4856,,A,,,Half life in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618284,BAO_0000019,,
4857,,A,,In vivo,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),0,,,22224,9527.0,Autocuration,1,CHEMBL618285,BAO_0000218,,
4858,,A,,,Half life was evaluated in rhesus,0,,,22224,9527.0,Autocuration,1,CHEMBL618286,BAO_0000019,,
4859,,A,,In vivo,Half life period after oral administration (2.5 mg/kg) in monkey was determined,0,,,22224,9527.0,Autocuration,1,CHEMBL618287,BAO_0000218,,
4860,,A,,In vivo,Half life period was determine after peroral administration at 10 mpk in Rhesus,0,,,22224,9527.0,Autocuration,1,CHEMBL618288,BAO_0000218,,
4861,,A,,In vivo,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),0,,,22224,9527.0,Autocuration,1,CHEMBL876393,BAO_0000218,,
4862,,A,,In vivo,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,0,,,22224,9527.0,Autocuration,1,CHEMBL618289,BAO_0000218,,
4863,,A,,In vivo,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL618290,BAO_0000218,,
4864,,A,,,Half-life was calculated in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618291,BAO_0000019,,
4865,,A,,,Half-life in Squirrel monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618292,BAO_0000019,,
4866,,A,,,Half-life in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618293,BAO_0000019,,
4867,,A,,In vivo,Half-life was measured in monkey after an iv dose of 1 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL618294,BAO_0000218,,
4868,,A,,In vivo,Half-life period after intravenous administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL618295,BAO_0000218,,
4869,,A,,In vivo,Half-life period after oral administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL618296,BAO_0000218,,
4870,,A,,In vivo,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,0,,,22224,9527.0,Autocuration,1,CHEMBL618297,BAO_0000218,,
4871,,A,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,0,,,22224,9606.0,Autocuration,1,CHEMBL618298,BAO_0000019,1088.0,
4872,,A,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,0,,,22224,9606.0,Autocuration,1,CHEMBL618299,BAO_0000019,1088.0,
4873,,A,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,0,,,22224,9606.0,Autocuration,1,CHEMBL618300,BAO_0000019,1088.0,
4874,,A,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,0,,,22224,9606.0,Autocuration,1,CHEMBL618301,BAO_0000019,1088.0,
4875,,A,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618302,BAO_0000019,1088.0,
4876,,A,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL876394,BAO_0000019,1088.0,
4877,,A,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618303,BAO_0000019,1088.0,
4878,,A,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618304,BAO_0000019,1088.0,
4879,,A,,In vivo,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618305,BAO_0000218,,
4880,,A,,In vivo,Oral bioavailability in human,0,,,22224,9606.0,Autocuration,1,CHEMBL618306,BAO_0000218,,
4881,,A,,,Compound was tested for human plasma protein binding,0,,,22224,9606.0,Autocuration,1,CHEMBL618307,BAO_0000019,,
4882,,A,,,Compound was tested for human plasma protein binding; Not determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618308,BAO_0000019,,
4883,,A,,,Protein binding activity of compound in human plasma; % Free,0,,,22224,9606.0,Autocuration,1,CHEMBL618309,BAO_0000019,,
4884,,A,,,Unbound fraction (plasma),0,,,22224,9606.0,Autocuration,1,CHEMBL618310,BAO_0000019,,
4885,,A,,,Half life for the hydrolysis of compound in human blood serum,0,,,22224,9606.0,Autocuration,1,CHEMBL873353,BAO_0000366,1969.0,
4886,,A,,,Half life period in human plasma using phosphate buffer (0.08 M),0,,,22224,9606.0,Autocuration,1,CHEMBL618311,BAO_0000366,1969.0,
4887,,A,,,Half life period in human plasma using phosphate buffer (0.1 M),0,,,22224,9606.0,Autocuration,1,CHEMBL618312,BAO_0000366,1969.0,
4888,,A,,,Half-life in human plasma was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618313,BAO_0000366,1969.0,
4889,,A,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,0,,,22224,9606.0,Autocuration,1,CHEMBL618314,BAO_0000019,,
4890,,A,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),0,,,22224,9606.0,Autocuration,1,CHEMBL618315,BAO_0000019,,
4891,,A,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",0,,,22224,9606.0,Autocuration,1,CHEMBL618316,BAO_0000019,,
4892,,A,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",0,,,22224,9606.0,Autocuration,1,CHEMBL618317,BAO_0000019,,
4893,,A,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",0,,,22224,9606.0,Autocuration,1,CHEMBL620138,BAO_0000019,,
4894,,A,,,Partition coefficient (logP),0,,,22224,9606.0,Autocuration,1,CHEMBL858280,BAO_0000019,,
4895,,A,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,0,,,22224,9606.0,Autocuration,1,CHEMBL620139,BAO_0000019,,
4896,,A,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL620140,BAO_0000251,,
4897,,A,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),0,,,22224,9606.0,Autocuration,1,CHEMBL620141,BAO_0000019,,
4898,,A,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),0,,,22224,9606.0,Autocuration,1,CHEMBL620142,BAO_0000019,,
4899,,A,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),0,,,22224,9606.0,Autocuration,1,CHEMBL620143,BAO_0000019,,
4900,,A,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),0,,,22224,9606.0,Autocuration,1,CHEMBL620144,BAO_0000251,,
4901,,A,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),0,,,22224,9606.0,Autocuration,1,CHEMBL620145,BAO_0000251,,
4902,,A,,,Metabolism of compound in human microsomes; Trace,0,,,22224,9606.0,Autocuration,1,CHEMBL620146,BAO_0000251,,
4903,,A,,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL620147,BAO_0000251,2107.0,
4904,,A,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,0,,,22224,9606.0,Autocuration,1,CHEMBL620148,BAO_0000251,,
4905,,A,,,In vitro metabolic potential in human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL620149,BAO_0000251,2107.0,
4906,,A,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,0,,,22224,9606.0,Autocuration,1,CHEMBL876412,BAO_0000019,,
4907,,A,,,Tested for human plasma protein binding of the compound; Not tested,0,,,22224,9606.0,Autocuration,1,CHEMBL619352,BAO_0000019,,
4908,,A,,,Compound was tested for percent protein binding (PB) in human,0,,,22224,9606.0,Autocuration,1,CHEMBL619353,BAO_0000019,,
4909,,A,,,Protein binding in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL619354,BAO_0000019,1969.0,
4910,,A,,,Permeability coefficient (B to A) in Caco-2 cell,0,,,22224,9606.0,Autocuration,1,CHEMBL619355,BAO_0000019,,
4911,,A,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,0,,,22224,9606.0,Autocuration,1,CHEMBL619356,BAO_0000019,,
4912,,A,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),0,,,22224,9606.0,Autocuration,1,CHEMBL619357,BAO_0000019,,
4913,,A,,,In vitro rate of absorption observed as Caco-2 permeability in humans,0,,,22224,9606.0,Autocuration,1,CHEMBL619358,BAO_0000019,,
4914,Caco-2,A,495.0,,Cellular permeability of compound was determined in Caco-2 cells; High,0,,,22224,9606.0,Autocuration,1,CHEMBL619359,BAO_0000219,,
4915,Caco-2,A,495.0,,Permeability in Caco-2 cells of compound,0,,,22224,9606.0,Autocuration,1,CHEMBL619360,BAO_0000219,,
4916,,A,,,Permeability coefficient (A to B) in Caco-2 cell,0,,,22224,9606.0,Autocuration,1,CHEMBL619361,BAO_0000019,,
4917,,A,,,Permeability coefficient (B to A) in Caco-2 cell,0,,,22224,9606.0,Autocuration,1,CHEMBL619362,BAO_0000019,,
4918,,A,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),0,,,22224,9606.0,Autocuration,1,CHEMBL619363,BAO_0000019,,
4919,,A,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,0,,,22224,9606.0,Autocuration,1,CHEMBL618942,BAO_0000019,,
4920,,A,,,Compound was tested for protein binding in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL618943,BAO_0000019,,
4921,,A,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,0,,,22224,9606.0,Autocuration,1,CHEMBL618944,BAO_0000019,,
4922,,A,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,0,,,22224,9606.0,Autocuration,1,CHEMBL618945,BAO_0000019,1088.0,
4923,,A,,In vivo,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618946,BAO_0000218,,
4924,,A,,In vivo,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,,50594,10090.0,Intermediate,1,CHEMBL876413,BAO_0000218,,
4925,,A,,In vivo,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL618947,BAO_0000218,,
4926,,A,,In vivo,Time taken to reach maximum concentration in plasma upon oral administration in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL618948,BAO_0000218,1969.0,
4927,,A,,In vivo,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,50594,10090.0,Intermediate,1,CHEMBL618949,BAO_0000218,1969.0,
4928,,F,,In vivo,Tmax after intraperitoneal administration in mice at 23 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618950,BAO_0000218,,
4929,,A,,In vivo,Tmax after oral administration at 30 mg/kg in ICR mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL618951,BAO_0000218,,
4930,,A,,In vivo,Tmax after peroral administration in mice at 2.4 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618952,BAO_0000218,,
4931,,A,,In vivo,Tmax at a single subcutaneous administration of 40 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL618953,BAO_0000218,,
4932,,A,,In vivo,Tmax in brain of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618954,BAO_0000218,955.0,
4933,,A,,In vivo,Tmax in kidney of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618955,BAO_0000218,2113.0,
4934,,A,,In vivo,Tmax in liver of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618956,BAO_0000218,2107.0,
4935,,A,,In vivo,Tmax in lungs of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618957,BAO_0000218,2048.0,
4936,,F,,In vivo,Tmax in mice at 18 uM/kg i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL618958,BAO_0000218,,
4937,,F,,In vivo,Tmax in mice at 23 uM/kg i.v. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL618959,BAO_0000218,,
4938,,F,,In vivo,Tmax in mice at 25 uM/kg i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL618960,BAO_0000218,,
4939,,F,,In vivo,Tmax in mice at 26 uM/kg i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL876723,BAO_0000218,,
4940,,A,,In vivo,Tmax in spleen of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618961,BAO_0000218,2106.0,
4941,,A,,In vivo,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL618962,BAO_0000218,,
4942,,A,,In vivo,Tmax value at a dose of 10 mg/kg peroral administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL618963,BAO_0000218,,
4943,,A,,,Tmax value in IRC mice,1,,,50594,10090.0,Intermediate,1,CHEMBL618964,BAO_0000218,,
4944,,A,,In vivo,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,,50594,10090.0,Intermediate,1,CHEMBL618965,BAO_0000218,,
4945,,A,,In vivo,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,,50594,10090.0,Intermediate,1,CHEMBL618966,BAO_0000218,,
4946,,A,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),1,,,50594,10090.0,Intermediate,1,CHEMBL618967,BAO_0000218,1088.0,
4947,,A,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),1,,,50594,10090.0,Intermediate,1,CHEMBL618968,BAO_0000218,1088.0,
4948,,A,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),1,,,50594,10090.0,Intermediate,1,CHEMBL618969,BAO_0000218,1088.0,
4949,,A,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL618970,BAO_0000218,,
4950,,A,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL618971,BAO_0000218,,
4951,,A,,In vivo,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618972,BAO_0000218,,
4952,,A,,In vivo,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618973,BAO_0000218,,
4953,,A,,In vivo,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618974,BAO_0000218,,
4954,,A,,In vivo,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL618975,BAO_0000218,,
4955,,A,,In vivo,Vd in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL618976,BAO_0000218,,
4956,,A,,In vivo,Volume of distribution in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL618977,BAO_0000218,,
4957,,A,,In vivo,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,50594,10090.0,Intermediate,1,CHEMBL876724,BAO_0000218,,
4958,,A,,In vivo,Volume of distribution of compound in plasma was determined at 24 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618978,BAO_0000218,,
4959,,A,,In vivo,Volume of distribution of compound in plasma was determined at 40 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618979,BAO_0000218,,
4960,,A,,In vivo,Volume of distribution of compound in plasma was determined at 5 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL618980,BAO_0000218,,
4961,,A,,In vivo,Pharmacokinetic property (vdss) was measured in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL618981,BAO_0000218,,
4962,,A,,In vivo,Value distribution upon iv administration in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL618982,BAO_0000218,,
4963,,A,,In vivo,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL620150,BAO_0000218,,
4964,,A,,In vivo,Volume of distribution was evaluated in mice after intravenous administration,1,,,50594,10090.0,Intermediate,1,CHEMBL620151,BAO_0000218,,
4965,,A,,In vivo,Volume of distribution was evaluated in mice after oral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL620152,BAO_0000218,,
4966,,A,,In vivo,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620153,BAO_0000218,,
4967,,A,,In vivo,Steady state volume of distribution was determined in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL876395,BAO_0000218,,
4968,,A,,In vivo,Volume distribution (steady state) of compound was determined in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL620154,BAO_0000218,,
4969,,A,,In vivo,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620155,BAO_0000218,,
4970,,A,,In vivo,Vss value at a dose of 10 mg/kg intravenous administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL620156,BAO_0000218,,
4971,,A,,In vivo,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL620157,BAO_0000218,,
4972,,A,,In vivo,Biodistribution of compound (oxidized form) in in kidney tissue,1,,,50594,10090.0,Intermediate,1,CHEMBL620158,BAO_0000218,2113.0,
4973,,A,,In vivo,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,,,50594,10090.0,Intermediate,1,CHEMBL620159,BAO_0000218,178.0,
4974,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL620160,BAO_0000218,178.0,
4975,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL620161,BAO_0000218,178.0,
4976,A-427,F,797.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,1,,,80019,9606.0,Intermediate,1,CHEMBL620162,BAO_0000219,,
4977,A-431,F,500.0,,Inhibition of A431 human squamous cell carcinoma cell proliferation,1,,,80852,9606.0,Expert,1,CHEMBL620163,BAO_0000219,,
4978,A-431,F,500.0,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,1,,,80852,9606.0,Expert,1,CHEMBL620833,BAO_0000219,,
4979,A-431,F,500.0,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,1,,,80852,9606.0,Expert,1,CHEMBL876396,BAO_0000219,,
4980,A-431,F,500.0,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,1,,,80852,9606.0,Expert,1,CHEMBL620834,BAO_0000219,,
4981,A-431,F,500.0,,Inhibition of A431 human carcinoma cell proliferation,1,,,80852,9606.0,Expert,1,CHEMBL620835,BAO_0000219,,
4982,A-431,F,500.0,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,1,,,80852,9606.0,Expert,1,CHEMBL620836,BAO_0000219,,
4983,A-431,F,500.0,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,1,,,80852,9606.0,Intermediate,1,CHEMBL620837,BAO_0000219,,
4984,A-431,F,500.0,,In vitro cytotoxicity against epidermoid carcinoma cell line,1,,,80852,9606.0,Intermediate,1,CHEMBL621017,BAO_0000219,,
4985,A-431,F,500.0,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9,,,9,9606.0,Expert,1,CHEMBL621018,BAO_0000218,,
4986,A-431,F,500.0,,Antiproliferative activity of compound was measured on human tumor cell line A431.,1,,,80852,9606.0,Intermediate,1,CHEMBL621019,BAO_0000219,,
4987,A-431,F,500.0,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,1,,,80852,9606.0,Intermediate,1,CHEMBL621020,BAO_0000219,,
4988,A-431,F,500.0,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,1,,,80852,9606.0,Intermediate,1,CHEMBL621021,BAO_0000219,,
4989,A-431,F,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,8,,,9,,Expert,1,CHEMBL621022,BAO_0000219,,
4990,A-431,F,500.0,,Tested for antiproliferative activity against human A431 cells,1,,,80852,9606.0,Expert,1,CHEMBL621023,BAO_0000219,,
4991,A-431,F,500.0,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9,,,9,9606.0,Expert,1,CHEMBL621024,BAO_0000219,,
4992,A-431,F,500.0,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,1,,,80852,9606.0,Expert,1,CHEMBL621025,BAO_0000219,,
4993,A-431,F,500.0,,Inhibition of A431 cell proliferation,1,,,80852,9606.0,Expert,1,CHEMBL621026,BAO_0000219,,
4994,A-431,F,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells,1,,,80852,9606.0,Expert,1,CHEMBL621027,BAO_0000219,,
4995,A-431,F,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),1,,,80852,9606.0,Expert,1,CHEMBL876397,BAO_0000219,,
4996,A-431,F,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,1,,,80852,9606.0,Intermediate,1,CHEMBL883797,BAO_0000219,,
4997,A-431,F,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,1,,,80852,9606.0,Intermediate,1,CHEMBL621028,BAO_0000219,,
4998,A-431,F,500.0,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,1,,,80852,9606.0,Intermediate,1,CHEMBL621029,BAO_0000219,,
4999,A-431,F,500.0,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,1,,,80852,9606.0,Intermediate,1,CHEMBL621030,BAO_0000219,,
5000,A-431,F,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,8,,,9,,Expert,1,CHEMBL621147,BAO_0000219,,
5001,A-431,F,500.0,,In vivo antiproliferative activity against A431 cell line,1,,,80852,9606.0,Intermediate,1,CHEMBL621148,BAO_0000218,,
5002,A-431,F,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9,,,9,9606.0,Expert,1,CHEMBL621149,BAO_0000219,,
5003,A-431,F,500.0,,Inhibition of A431 human epidermoid carcinoma cell proliferation,1,,,80852,9606.0,Expert,1,CHEMBL621150,BAO_0000219,,
5004,A-431,F,500.0,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9,,,9,9606.0,Expert,1,CHEMBL621151,BAO_0000219,,
5005,A-431,F,500.0,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),1,,,80852,9606.0,Intermediate,1,CHEMBL621152,BAO_0000219,,
5006,A-431,F,500.0,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),1,,,80852,9606.0,Intermediate,1,CHEMBL621153,BAO_0000219,,
5007,A-431,F,500.0,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),1,,,80852,9606.0,Intermediate,1,CHEMBL884000,BAO_0000219,,
5008,,F,,,Inhibition of EGFR overexpressing A431 cell proliferation,9,,,9,9606.0,Expert,1,CHEMBL621154,BAO_0000019,,
5009,A-431,F,500.0,,Inhibition of A431 cell proliferation,1,,,80852,9606.0,Expert,1,CHEMBL621155,BAO_0000219,,
5010,A-431,F,500.0,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9,,,9,9606.0,Expert,1,CHEMBL621156,BAO_0000219,,
5011,A-431,F,500.0,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9,,,9,9606.0,Expert,1,CHEMBL621157,BAO_0000219,,
5012,A-431,F,500.0,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),8,,,9,,Expert,1,CHEMBL621158,BAO_0000219,,
5013,A-431,F,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,,,80852,9606.0,Intermediate,1,CHEMBL621159,BAO_0000219,,
5014,A-431,F,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,,,80852,9606.0,Intermediate,1,CHEMBL621160,BAO_0000219,,
5015,A-431,F,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,1,,,80852,9606.0,Intermediate,1,CHEMBL621161,BAO_0000219,,
5016,A-431,F,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,1,,,80852,9606.0,Intermediate,1,CHEMBL621162,BAO_0000219,,
5017,A-431,F,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,,,80852,9606.0,Intermediate,1,CHEMBL621163,BAO_0000219,,
5018,A-431,F,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,1,,,80852,9606.0,Intermediate,1,CHEMBL621164,BAO_0000219,,
5019,A-431,F,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,1,,,80852,9606.0,Intermediate,1,CHEMBL621165,BAO_0000219,,
5020,,A,,,Half-life period in cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL619159,BAO_0000019,,
5021,,A,,In vitro,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",0,,,22224,9527.0,Autocuration,1,CHEMBL619160,BAO_0000366,1969.0,
5022,,A,,In vivo,Longer half-life in monkey (i.v.) at 0.5 mpk,0,,,22224,9527.0,Autocuration,1,CHEMBL619161,BAO_0000218,,
5023,,A,,,Plasma half life in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL619162,BAO_0000366,1969.0,
5024,,A,,,Plasma half-life in rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL619163,BAO_0000366,1969.0,
5025,,A,,In vivo,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),0,,,22224,9527.0,Autocuration,1,CHEMBL619164,BAO_0000218,1969.0,
5026,,A,,In vivo,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),0,,,22224,9527.0,Autocuration,1,CHEMBL619320,BAO_0000218,1969.0,
5027,,A,,In vivo,Tested for half life upon iv administration to african green monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL619321,BAO_0000218,,
5028,,A,,In vivo,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL873336,BAO_0000218,,
5029,,A,,In vivo,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL619322,BAO_0000218,,
5030,,A,,In vivo,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL619323,BAO_0000218,,
5031,,A,,In vivo,The time for peak concentration value after oral administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL619324,BAO_0000218,,
5032,,A,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619325,BAO_0000019,,
5033,,A,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL876411,BAO_0000019,,
5034,,A,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619326,BAO_0000019,,
5035,,A,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619327,BAO_0000019,,
5036,,A,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619328,BAO_0000019,,
5037,,A,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619329,BAO_0000019,,
5038,,A,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619330,BAO_0000019,,
5039,,A,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619331,BAO_0000019,,
5040,,A,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619332,BAO_0000019,,
5041,,A,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619333,BAO_0000019,,
5042,,A,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619334,BAO_0000019,,
5043,,A,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619335,BAO_0000019,,
5044,,A,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619336,BAO_0000019,,
5045,,A,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619337,BAO_0000019,,
5046,,A,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619338,BAO_0000019,,
5047,,A,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,0,,,22224,9527.0,Autocuration,1,CHEMBL619339,BAO_0000019,,
5048,,A,,In vivo,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL619340,BAO_0000218,,
5049,,A,,In vivo,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL873496,BAO_0000218,1969.0,
5050,,A,,,AUC value in rat after IV administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL619341,BAO_0000218,1969.0,
5051,,A,,,AUC value in rat after oral administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL619342,BAO_0000218,1969.0,
5052,,A,,In vivo,Cmax value in rat after oral administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL619343,BAO_0000218,,
5053,,A,,In vivo,Bioavailability in rat after oral administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL619344,BAO_0000218,,
5054,,A,,In vivo,Tmax value in rat after oral administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL619345,BAO_0000218,,
5055,,A,,,Vc value in rat after IV administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL619346,BAO_0000218,,
5056,,A,,In vivo,Half life period in rat after IV administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL619347,BAO_0000218,,
5057,,A,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,0,,,22224,9557.0,Autocuration,1,CHEMBL619348,BAO_0000019,,
5058,,A,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),0,,,22224,9557.0,Autocuration,1,CHEMBL619349,BAO_0000019,,
5059,,A,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),0,,,22224,9557.0,Autocuration,1,CHEMBL619350,BAO_0000019,,
5060,,A,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,0,,,22224,9557.0,Autocuration,1,CHEMBL619351,BAO_0000019,,
5061,,A,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,0,,,22224,9557.0,Autocuration,1,CHEMBL875953,BAO_0000019,,
5062,,A,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,0,,,22224,9557.0,Autocuration,1,CHEMBL621716,BAO_0000019,,
5063,,A,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,0,,,22224,9557.0,Autocuration,1,CHEMBL621717,BAO_0000019,,
5064,,A,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,0,,,22224,9557.0,Autocuration,1,CHEMBL621718,BAO_0000019,,
5065,,A,,,Area under curve after 1 mpk peroral administration to beagles,0,,,22224,9615.0,Autocuration,1,CHEMBL621719,BAO_0000019,,
5066,,A,,,Area under curve after 2 mpk peroral administration to beagles,0,,,22224,9615.0,Autocuration,1,CHEMBL621720,BAO_0000019,,
5067,,A,,In vivo,Cmax value after 1 mpk peroral administration to beagles,0,,,22224,9615.0,Autocuration,1,CHEMBL621721,BAO_0000218,,
5068,,A,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,0,,,22224,9606.0,Autocuration,1,CHEMBL621722,BAO_0000019,1088.0,
5069,,A,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,0,,,22224,9606.0,Autocuration,1,CHEMBL621723,BAO_0000019,1088.0,
5070,,A,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,0,,,22224,9606.0,Autocuration,1,CHEMBL621724,BAO_0000019,1088.0,
5071,,A,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,0,,,22224,9606.0,Autocuration,1,CHEMBL623443,BAO_0000019,1088.0,
5072,,A,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,0,,,22224,9606.0,Autocuration,1,CHEMBL623444,BAO_0000019,1088.0,
5073,,A,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,0,,,22224,9606.0,Autocuration,1,CHEMBL623445,BAO_0000019,1088.0,
5074,,A,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,0,,,22224,9606.0,Autocuration,1,CHEMBL623446,BAO_0000019,1088.0,
5075,,A,,,Metabolic stability observed at 30 min after administration in human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL623447,BAO_0000251,2107.0,
5076,,A,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,0,,,22224,9606.0,Autocuration,1,CHEMBL623448,BAO_0000019,,
5077,,A,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,0,,,22224,9606.0,Autocuration,1,CHEMBL623449,BAO_0000019,,
5078,,A,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,0,,,22224,9606.0,Autocuration,1,CHEMBL623450,BAO_0000019,,
5079,,A,,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",0,,,22224,9606.0,Autocuration,1,CHEMBL623451,BAO_0000251,2107.0,
5080,,A,,,Metabolic stability (% remaining at 30 mins) in human S9.,0,,,22224,9606.0,Autocuration,1,CHEMBL623452,BAO_0000019,,
5081,,A,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,0,,,22224,9606.0,Autocuration,1,CHEMBL623453,BAO_0000019,,
5082,,A,,,Percent parent compound remaining after 20 min incubation with human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL623454,BAO_0000251,2107.0,
5083,,A,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,0,,,22224,9606.0,Autocuration,1,CHEMBL623455,BAO_0000251,2107.0,
5084,,A,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,0,,,22224,9606.0,Autocuration,1,CHEMBL624371,BAO_0000251,2107.0,
5085,,A,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL624372,BAO_0000218,,
5086,,A,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,0,,,22224,9606.0,Autocuration,1,CHEMBL624373,BAO_0000019,,
5087,,A,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,0,,,22224,9606.0,Autocuration,1,CHEMBL624374,BAO_0000019,,
5088,,A,,,The percent remaining in human plasma after 30 min was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL624556,BAO_0000019,,
5089,,A,,,Conversion rate of the prodrug in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL624557,BAO_0000366,1969.0,
5090,,A,,,Conversion rate of the prodrug in human plasma; ND means no data,0,,,22224,9606.0,Autocuration,1,CHEMBL624558,BAO_0000366,1969.0,
5091,,A,,,Half life of compound was determined in human blood,0,,,22224,9606.0,Autocuration,1,CHEMBL624559,BAO_0000221,178.0,
5092,,A,,,Half life of compound was determined in man with once daily dosing,0,,,22224,9606.0,Autocuration,1,CHEMBL624560,BAO_0000019,,
5093,,A,,In vitro,Half life in human microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL624561,BAO_0000251,,
5094,,A,,,Half life in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL624562,BAO_0000366,1969.0,
5095,,A,,,Half life in human plasma; Not detected,0,,,22224,9606.0,Autocuration,1,CHEMBL624563,BAO_0000366,1969.0,
5096,,A,,In vivo,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,0,,,22224,9606.0,Autocuration,1,CHEMBL624564,BAO_0000218,,
5097,,A,,In vitro,Half-life for oxidative metabolic stability was determined using rat liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL624565,BAO_0000251,2107.0,
5098,,A,,,Half-life in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL875152,BAO_0000366,1969.0,
5099,,A,,,Half-life of the parent prodrug in plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL624566,BAO_0000366,1969.0,
5100,,A,,In vitro,In vitro half life in human plasma was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL873805,BAO_0000366,1969.0,
5101,,A,,In vitro,The compound was tested In Vitro for half life in human liver microsomes.,0,,,22224,9606.0,Autocuration,1,CHEMBL624567,BAO_0000251,2107.0,
5102,,A,,In vivo,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,0,,,22224,9606.0,Autocuration,1,CHEMBL624568,BAO_0000218,,
5103,,A,,In vivo,Observed volume of distribution,0,,,22224,9606.0,Autocuration,1,CHEMBL624569,BAO_0000218,,
5104,,A,,In vivo,Oral bioavailability in human,0,,,22224,9606.0,Autocuration,1,CHEMBL624570,BAO_0000218,,
5105,,A,,,Tested for human plasma protein binding of the compound,0,,,22224,9606.0,Autocuration,1,CHEMBL624571,BAO_0000019,,
5106,,A,,,"First order rate constant, k was determined in human plasma",0,,,22224,9606.0,Autocuration,1,CHEMBL624572,BAO_0000019,,
5107,,A,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,0,,,22224,9606.0,Autocuration,1,CHEMBL624573,BAO_0000019,,
5108,,A,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,0,,,22224,9606.0,Autocuration,1,CHEMBL875153,BAO_0000019,,
5109,,A,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL624574,BAO_0000251,2107.0,
5110,,A,,,The compound was tested for the plasma binding in human,0,,,22224,9606.0,Autocuration,1,CHEMBL624575,BAO_0000019,,
5111,,A,,,Plasma protein binding (human),0,,,22224,9606.0,Autocuration,1,CHEMBL624576,BAO_0000019,,
5112,,A,,In vitro,Compound was evaluated for half-life in human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL624577,BAO_0000251,2107.0,
5113,,A,,In vitro,Half life measured in vitro for its stability in human blood,0,,,22224,9606.0,Autocuration,1,CHEMBL624578,BAO_0000221,178.0,
5114,,A,,,Half life in human serum,0,,,22224,9606.0,Autocuration,1,CHEMBL622796,BAO_0000019,1977.0,
5115,,A,,,Half life in human serum; ND=not determined,0,,,22224,9606.0,Autocuration,1,CHEMBL622797,BAO_0000019,1977.0,
5116,,A,,,Half life were determined in CEM-SS cell extract in decomposition step 1,0,,,22224,9606.0,Autocuration,1,CHEMBL622798,BAO_0000019,,
5117,,A,,,Half life were determined in CEM-SS cell extract in decomposition step 2,0,,,22224,9606.0,Autocuration,1,CHEMBL622799,BAO_0000019,,
5118,,A,,,Half life of the in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL622800,BAO_0000366,1969.0,
5119,,A,,In vitro,Half life period in human hepatic S9 fraction was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL622801,BAO_0000220,,
5120,,A,,In vitro,Half life period in human liver microsome was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL622802,BAO_0000251,2107.0,
5121,,A,,,Half life period was determined; 6-7,0,,,22224,9606.0,Autocuration,1,CHEMBL622803,BAO_0000019,,
5122,,A,,,Half life period was evaluated in human,0,,,22224,9606.0,Autocuration,1,CHEMBL875154,BAO_0000019,,
5123,,A,,,Half life time in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL622804,BAO_0000366,1969.0,
5124,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622805,BAO_0000218,955.0,
5125,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622611,BAO_0000218,948.0,
5126,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622612,BAO_0000218,948.0,
5127,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL875160,BAO_0000218,2113.0,
5128,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL622613,BAO_0000218,2113.0,
5129,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622614,BAO_0000218,2113.0,
5130,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622615,BAO_0000218,2107.0,
5131,,A,,In vivo,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,,,50594,10090.0,Intermediate,1,CHEMBL622616,BAO_0000218,2107.0,
5132,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622617,BAO_0000218,2107.0,
5133,,A,,In vivo,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,,,50594,10090.0,Intermediate,1,CHEMBL622618,BAO_0000218,2106.0,
5134,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL622619,BAO_0000218,2106.0,
5135,,A,,In vivo,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622620,BAO_0000218,2106.0,
5136,,A,,In vivo,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622621,BAO_0000218,955.0,
5137,,A,,In vivo,Biodistribution of compound (oxidized form) in blood tissue,1,,,50594,10090.0,Intermediate,1,CHEMBL622622,BAO_0000218,178.0,
5138,,A,,In vivo,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622623,BAO_0000218,178.0,
5139,,A,,In vivo,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL622624,BAO_0000218,178.0,
5140,,A,,In vivo,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622625,BAO_0000218,178.0,
5141,,A,,In vivo,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622626,BAO_0000218,178.0,
5142,,A,,In vivo,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL622627,BAO_0000218,178.0,
5143,,A,,In vivo,Biodistribution of compound (oxidized form) in brain tissue of mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622628,BAO_0000218,955.0,
5144,,A,,In vivo,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622629,BAO_0000218,955.0,
5145,,A,,In vivo,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622630,BAO_0000218,955.0,
5146,,A,,In vivo,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622631,BAO_0000218,955.0,
5147,,A,,In vivo,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL622632,BAO_0000218,955.0,
5148,,A,,In vivo,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL622633,BAO_0000218,955.0,
5149,,A,,In vivo,Biodistribution of compound (oxidized form) in heart tissue of mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622634,BAO_0000218,948.0,
5150,,A,,In vivo,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL622635,BAO_0000218,948.0,
5151,,A,,In vivo,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL875161,BAO_0000218,948.0,
5152,,A,,In vivo,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622636,BAO_0000218,948.0,
5153,,A,,In vivo,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL623335,BAO_0000218,948.0,
5154,,A,,In vivo,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL623336,BAO_0000218,948.0,
5155,,A,,In vivo,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL623337,BAO_0000218,2113.0,
5156,,A,,In vivo,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL623338,BAO_0000218,2113.0,
5157,,A,,In vivo,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL623339,BAO_0000218,2113.0,
5158,,A,,In vivo,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL623524,BAO_0000218,2113.0,
5159,,A,,In vivo,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL623525,BAO_0000218,2113.0,
5160,,A,,In vivo,Biodistribution of compound (oxidized form) in liver tissue,1,,,50594,10090.0,Intermediate,1,CHEMBL623526,BAO_0000218,2107.0,
5161,,A,,In vivo,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL623527,BAO_0000218,2107.0,
5162,,A,,In vivo,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL623528,BAO_0000218,2107.0,
5163,A-431,F,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,1,,,80852,9606.0,Intermediate,1,CHEMBL624615,BAO_0000219,,
5164,A-431,F,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,,,80852,9606.0,Intermediate,1,CHEMBL621672,BAO_0000219,,
5165,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",1,,,80852,,Expert,1,CHEMBL621673,BAO_0000218,,
5166,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",1,,,80852,,Expert,1,CHEMBL621674,BAO_0000218,,
5167,A-431,F,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,9,9606.0,Expert,1,CHEMBL884002,BAO_0000219,,
5168,A-431,F,500.0,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",1,,,80852,9606.0,Intermediate,1,CHEMBL621850,BAO_0000219,,
5169,A-431,F,500.0,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,1,,,80852,9606.0,Intermediate,1,CHEMBL621851,BAO_0000219,,
5170,A-431,F,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9,,,9,9606.0,Expert,1,CHEMBL621852,BAO_0000219,,
5171,A-431,F,500.0,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9,,,9,9606.0,Expert,1,CHEMBL621853,BAO_0000219,,
5172,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",1,,,80852,,Expert,1,CHEMBL621854,BAO_0000218,,
5173,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,,,80852,,Expert,1,CHEMBL621855,BAO_0000218,,
5174,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,,,80852,,Expert,1,CHEMBL623724,BAO_0000218,,
5175,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",1,,,80852,,Expert,1,CHEMBL623725,BAO_0000218,,
5176,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",1,,,80852,,Expert,1,CHEMBL623726,BAO_0000218,,
5177,A-431,F,500.0,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9,,,9,9606.0,Expert,1,CHEMBL623727,BAO_0000219,,
5178,A-431,F,500.0,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,8,,,9,,Expert,1,CHEMBL623728,BAO_0000219,,
5179,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",1,,,80852,,Expert,1,CHEMBL623729,BAO_0000218,,
5180,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,,,80852,,Expert,1,CHEMBL623730,BAO_0000218,,
5181,A-431,F,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,,,80852,,Expert,1,CHEMBL623731,BAO_0000218,,
5182,A-431,F,500.0,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",1,,,80852,10090.0,Expert,1,CHEMBL623732,BAO_0000218,,
5183,A-431,F,500.0,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",1,,,80852,10090.0,Expert,1,CHEMBL623733,BAO_0000218,,
5184,A-431,F,500.0,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,,,80852,10090.0,Expert,1,CHEMBL623734,BAO_0000218,,
5185,A-431,F,500.0,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,,,80852,10090.0,Expert,1,CHEMBL623735,BAO_0000218,,
5186,A-431,F,500.0,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,1,,,80852,9606.0,Expert,1,CHEMBL623736,BAO_0000219,,
5187,A-431,F,500.0,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,1,,,80852,9606.0,Intermediate,1,CHEMBL623737,BAO_0000219,,
5188,A-431,F,500.0,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,1,,,80852,9606.0,Intermediate,1,CHEMBL623738,BAO_0000219,,
5189,A-431,F,500.0,,Dose giving a 50% decrease in the living cell number (A437 cells),1,,,80852,9606.0,Intermediate,1,CHEMBL875168,BAO_0000219,,
5190,A549,F,646.0,,In vitro inhibitory concentration against proliferation of A459 cell line.,1,,,80682,9606.0,Expert,1,CHEMBL623739,BAO_0000219,,
5191,A549,F,646.0,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL623740,BAO_0000219,,
5192,A549,F,646.0,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,1,,,80682,9606.0,Intermediate,1,CHEMBL624424,BAO_0000219,,
5193,A498,F,624.0,,In vitro antitumor activity against renal A498 tumor cell lines,1,,,80021,9606.0,Intermediate,1,CHEMBL624425,BAO_0000219,,
5194,A498,F,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",1,,,80021,9606.0,Intermediate,1,CHEMBL624426,BAO_0000219,,
5195,A498,F,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",1,,,80021,9606.0,Intermediate,1,CHEMBL624427,BAO_0000219,,
5196,A498,F,624.0,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,1,,,80021,9606.0,Intermediate,1,CHEMBL624428,BAO_0000219,,
5197,A498,F,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL624429,BAO_0000219,,
5198,A498,F,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,1,,,80021,9606.0,Intermediate,1,CHEMBL624620,BAO_0000219,,
5199,A498,F,624.0,,Cytotoxicity on kidney carcinoma (A-498) cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL624621,BAO_0000219,,
5200,A498,F,624.0,,Compound was evaluated against Human cell line renal A498,1,,,80021,9606.0,Intermediate,1,CHEMBL624622,BAO_0000219,,
5201,A498,F,624.0,,Compound was tested for inhibition of A498 human renal cancer cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL624623,BAO_0000219,,
5202,A498,F,624.0,,Growth inhibitory activity against A498 human cancer cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL874365,BAO_0000219,,
5203,A498,F,624.0,,In vitro antitumor activity against human renal A498 cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL624624,BAO_0000219,,
5204,A498,F,624.0,,In vitro cytotoxic activity against renal (A498) cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL624625,BAO_0000219,,
5205,A498,F,624.0,,In vitro cytotoxic activity against human renal cancer (A498) cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL624626,BAO_0000219,,
5206,A498,F,624.0,,Tested for cytostatic activity against renal A498 cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL624627,BAO_0000219,,
5207,A498,F,624.0,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,1,,,80021,9606.0,Intermediate,1,CHEMBL883157,BAO_0000219,,
5208,A498,F,624.0,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,1,,,80021,9606.0,Expert,1,CHEMBL624628,BAO_0000219,,
5209,,A,,In vivo,Cmax value after 2 mpk peroral administration to beagles,0,,,22224,9615.0,Autocuration,1,CHEMBL624629,BAO_0000218,,
5210,,A,,In vivo,Bioavailability,0,,,22224,9615.0,Autocuration,1,CHEMBL623551,BAO_0000218,,
5211,,A,,In vivo,Bioavailability after 1 mpk peroral administration to beagles,0,,,22224,9615.0,Autocuration,1,CHEMBL623552,BAO_0000218,,
5212,,A,,In vivo,Bioavailability after 2 mpk peroral administration to beagles,0,,,22224,9615.0,Autocuration,1,CHEMBL623553,BAO_0000218,,
5213,,A,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,0,,,22224,9913.0,Autocuration,1,CHEMBL623554,BAO_0000019,,
5214,,A,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,0,,,22224,9913.0,Autocuration,1,CHEMBL623555,BAO_0000019,,
5215,,A,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,0,,,22224,9913.0,Autocuration,1,CHEMBL623556,BAO_0000019,,
5216,,A,,,Solubility against bovine alpha-chymotrypsin,0,,,22224,9913.0,Autocuration,1,CHEMBL623557,BAO_0000019,,
5217,,A,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,0,,,22224,9913.0,Autocuration,1,CHEMBL623558,BAO_0000019,,
5218,,A,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,0,,,22224,9913.0,Autocuration,1,CHEMBL623559,BAO_0000019,,
5219,,A,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,0,,,22224,9913.0,Autocuration,1,CHEMBL623560,BAO_0000221,2106.0,
5220,,A,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,0,,,22224,9913.0,Autocuration,1,CHEMBL623561,BAO_0000019,,
5221,,A,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,0,,,22224,9913.0,Autocuration,1,CHEMBL623562,BAO_0000019,,
5222,,A,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,0,,,22224,9913.0,Autocuration,1,CHEMBL623563,BAO_0000019,,
5223,,A,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,0,,,22224,9913.0,Autocuration,1,CHEMBL623564,BAO_0000221,2106.0,
5224,,A,,,Half life in presence of 2 mg/mL BSA at pH 8.8,0,,,22224,9913.0,Autocuration,1,CHEMBL873806,BAO_0000019,,
5225,,A,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,0,,,22224,9913.0,Autocuration,1,CHEMBL623565,BAO_0000019,,
5226,,A,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,0,,,22224,9913.0,Autocuration,1,CHEMBL623566,BAO_0000019,,
5227,,A,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,0,,,22224,9913.0,Autocuration,1,CHEMBL623567,BAO_0000019,,
5228,,A,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),0,,,22224,9913.0,Autocuration,1,CHEMBL623568,BAO_0000019,,
5229,,A,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL623569,BAO_0000218,1969.0,
5230,,A,,,AUC after administration at 100 mg/kg/day in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL623570,BAO_0000218,1969.0,
5231,,A,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,1,,,50588,9615.0,Intermediate,1,CHEMBL624254,BAO_0000218,1969.0,
5232,,A,,,AUC value after 15 mg/kg iv dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624255,BAO_0000218,1969.0,
5233,,A,,,AUC value after 30 mg/kg po dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624256,BAO_0000218,1969.0,
5234,,A,,,AUC value after administration of 4 mg/Kg oral dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624257,BAO_0000218,1969.0,
5235,,A,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624258,BAO_0000218,1969.0,
5236,,A,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,1,,,50588,9615.0,Intermediate,1,CHEMBL875277,BAO_0000218,,
5237,,A,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,1,,,50588,9615.0,Intermediate,1,CHEMBL622667,BAO_0000218,,
5238,,A,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622668,BAO_0000218,,
5239,,A,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622669,BAO_0000218,,
5240,,A,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622670,BAO_0000218,,
5241,,A,,,Area under curve determined in dogs after oral administration of 10 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622671,BAO_0000218,,
5242,,A,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622672,BAO_0000218,,
5243,,A,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,50588,9615.0,Expert,1,CHEMBL622673,BAO_0000218,,
5244,,A,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,1,,,50588,9615.0,Expert,1,CHEMBL622674,BAO_0000218,,
5245,,A,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL622675,BAO_0000218,,
5246,,A,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL622676,BAO_0000218,,
5247,,A,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL622677,BAO_0000218,,
5248,,A,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL622678,BAO_0000218,,
5249,,A,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,1,,,50588,9615.0,Intermediate,1,CHEMBL622679,BAO_0000218,,
5250,,A,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL622680,BAO_0000218,,
5251,,A,,,Area under curve was determine after peroral administration at 10 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622681,BAO_0000218,,
5252,,A,,,Area under curve was determine after peroral administration at 5 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL875278,BAO_0000218,,
5253,,A,,,Area under curve was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622682,BAO_0000218,,
5254,,A,,,Area under curve in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL622683,BAO_0000218,,
5255,,A,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL622684,BAO_0000218,,
5256,,A,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),1,,,50588,9615.0,Intermediate,1,CHEMBL622685,BAO_0000218,,
5257,,A,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,1,,,50588,9615.0,Intermediate,1,CHEMBL622686,BAO_0000218,,
5258,,A,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,50588,9615.0,Intermediate,1,CHEMBL618344,BAO_0000218,,
5259,,A,,,Area under curve value in dog at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL875582,BAO_0000218,,
5260,,A,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618345,BAO_0000218,,
5261,,A,,,Area under curve was determined after 0.3 mg/kg po administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618346,BAO_0000218,,
5262,,A,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618347,BAO_0000218,,
5263,,A,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618348,BAO_0000218,,
5264,,A,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,0,,,22224,9606.0,Autocuration,1,CHEMBL618349,BAO_0000019,,
5265,,A,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,0,,,22224,9606.0,Autocuration,1,CHEMBL618350,BAO_0000019,,
5266,,A,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,0,,,22224,9606.0,Autocuration,1,CHEMBL618351,BAO_0000019,,
5267,,A,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,0,,,22224,9606.0,Autocuration,1,CHEMBL618352,BAO_0000019,,
5268,,A,,,Time taken to reduce 50% of the concentration of compound in blood plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL873494,BAO_0000221,178.0,
5269,,A,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",0,,,22224,9606.0,Autocuration,1,CHEMBL618353,BAO_0000366,1969.0,
5270,,A,,,Half life in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL618354,BAO_0000366,1969.0,
5271,,A,,,Half life in human plasma was reported,0,,,22224,9606.0,Autocuration,1,CHEMBL875583,BAO_0000366,1969.0,
5272,,A,,,Half life in human serum,0,,,22224,9606.0,Autocuration,1,CHEMBL618355,BAO_0000019,1977.0,
5273,,A,,,Half life upon exposure to human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL618356,BAO_0000366,1969.0,
5274,,A,,In vitro,t1/2 in human microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL618357,BAO_0000251,,
5275,,A,,,Half life period in 80% human plasma at 37 degree Centigrade,0,,,22224,9606.0,Autocuration,1,CHEMBL618358,BAO_0000366,1969.0,
5276,,A,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),0,,,22224,9606.0,Autocuration,1,CHEMBL618359,BAO_0000221,14.0,
5277,,A,,In vitro,Half-life measured in in vitro Cathepsin B assay in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL618360,BAO_0000366,1969.0,
5278,,A,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,0,,,22224,9606.0,Autocuration,1,CHEMBL618361,BAO_0000019,,
5279,,A,,In vitro,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,0,,,22224,9606.0,Autocuration,1,CHEMBL618362,BAO_0000251,2107.0,
5280,,A,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",0,,,22224,9606.0,Autocuration,1,CHEMBL618363,BAO_0000366,1969.0,
5281,,A,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",0,,,22224,9606.0,Autocuration,1,CHEMBL618364,BAO_0000366,1969.0,
5282,,A,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",0,,,22224,9606.0,Autocuration,1,CHEMBL875584,BAO_0000366,1969.0,
5283,,A,,,Half-life in the CEM cell extracts,0,,,22224,9606.0,Autocuration,1,CHEMBL618365,BAO_0000019,,
5284,,A,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,0,,,22224,9606.0,Autocuration,1,CHEMBL873495,BAO_0000366,1969.0,
5285,,A,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,0,,,22224,9606.0,Autocuration,1,CHEMBL618366,BAO_0000366,1969.0,
5286,,A,,,Half-life was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618367,BAO_0000019,,
5287,,A,,,Half-life (human blood stability),0,,,22224,9606.0,Autocuration,1,CHEMBL618368,BAO_0000221,178.0,
5288,,A,,,Half-life (human blood stability); no data,0,,,22224,9606.0,Autocuration,1,CHEMBL618369,BAO_0000221,178.0,
5289,,A,,,Half-life in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL618370,BAO_0000366,1969.0,
5290,,A,,,CYP3A4 metabolism half-life (t1/2),0,,,22224,9606.0,Autocuration,1,CHEMBL618371,BAO_0000019,,
5291,,A,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),0,,,22224,9606.0,Autocuration,1,CHEMBL618372,BAO_0000221,178.0,
5292,,A,,In vitro,In vitro half life in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL618373,BAO_0000366,1969.0,
5293,,A,,In vitro,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",0,,,22224,9606.0,Autocuration,1,CHEMBL618374,BAO_0000366,1969.0,
5294,,A,,In vitro,In vitro hydrolysis in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL618375,BAO_0000366,1969.0,
5295,,A,,In vitro,In vitro hydrolysis in human plasma; no data,0,,,22224,9606.0,Autocuration,1,CHEMBL618376,BAO_0000366,1969.0,
5296,,A,,In vitro,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,0,,,22224,9606.0,Autocuration,1,CHEMBL618377,BAO_0000251,2107.0,
5297,,A,,,Plasma half life in human,0,,,22224,9606.0,Autocuration,1,CHEMBL618378,BAO_0000366,1969.0,
5298,,A,,,Stability after incubation with human plasma (at 37 degree C),0,,,22224,9606.0,Autocuration,1,CHEMBL618379,BAO_0000366,1969.0,
5299,,A,,,T1/2 was evaluated in human plasma,0,,,22224,9606.0,Autocuration,1,CHEMBL618380,BAO_0000366,1969.0,
5300,,A,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",0,,,22224,9606.0,Autocuration,1,CHEMBL618381,BAO_0000366,1969.0,
5301,,A,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",0,,,22224,9606.0,Autocuration,1,CHEMBL618382,BAO_0000366,1969.0,
5302,,A,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,0,,,22224,9606.0,Autocuration,1,CHEMBL618383,BAO_0000019,,
5303,,A,,In vitro,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,0,,,22224,9606.0,Autocuration,1,CHEMBL618384,BAO_0000019,,
5304,,A,,In vitro,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,0,,,22224,9606.0,Autocuration,1,CHEMBL618385,BAO_0000019,,
5305,,A,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,0,,,22224,9606.0,Autocuration,1,CHEMBL619099,BAO_0000366,1969.0,
5306,,A,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,0,,,22224,9606.0,Autocuration,1,CHEMBL619100,BAO_0000366,1969.0,
5307,,A,,,Time taken for 50% to be consumed by serum PON1 was determined,0,,,22224,9606.0,Autocuration,1,CHEMBL619101,BAO_0000019,,
5308,,A,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,0,,,22224,9606.0,Autocuration,1,CHEMBL619102,BAO_0000019,,
5309,,A,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,0,,,22224,9606.0,Autocuration,1,CHEMBL619103,BAO_0000251,2107.0,
5310,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL619268,BAO_0000218,,
5311,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL619269,BAO_0000218,,
5312,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL619270,BAO_0000218,,
5313,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL619271,BAO_0000218,,
5314,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL875585,BAO_0000218,,
5315,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL619272,BAO_0000218,,
5316,786-0,F,391.0,,Compound tested for growth inhibition of renal cancer cell line 786-0,1,,,80640,9606.0,Intermediate,1,CHEMBL619273,BAO_0000219,,
5317,786-0,F,391.0,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL619274,BAO_0000219,,
5318,786-0,F,391.0,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,1,,,80640,9606.0,Expert,1,CHEMBL619275,BAO_0000219,,
5319,786-0,F,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",1,,,80640,9606.0,Intermediate,1,CHEMBL619276,BAO_0000219,,
5320,786-0,F,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",1,,,80640,9606.0,Intermediate,1,CHEMBL619277,BAO_0000219,,
5321,786-0,F,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",1,,,80640,9606.0,Intermediate,1,CHEMBL619278,BAO_0000219,,
5322,786-0,F,391.0,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,1,,,80640,9606.0,Intermediate,1,CHEMBL619279,BAO_0000219,,
5323,786-0,F,391.0,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,1,,,80640,9606.0,Intermediate,1,CHEMBL858458,BAO_0000219,,
5324,786-0,F,391.0,,Cytotoxic effect on renal cancer line 786-0,1,,,80640,9606.0,Expert,1,CHEMBL619280,BAO_0000219,,
5325,786-0,F,391.0,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,1,,,80640,9606.0,Intermediate,1,CHEMBL619281,BAO_0000219,,
5326,786-0,F,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,,,80640,9606.0,Intermediate,1,CHEMBL619282,BAO_0000219,,
5327,786-0,F,391.0,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",1,,,80640,9606.0,Intermediate,1,CHEMBL619283,BAO_0000219,,
5328,786-0,F,391.0,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL619284,BAO_0000219,,
5329,786-0,F,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,,,80640,9606.0,Intermediate,1,CHEMBL619285,BAO_0000219,,
5330,786-0,F,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),1,,,80640,9606.0,Intermediate,1,CHEMBL619286,BAO_0000219,,
5331,786-0,F,391.0,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,1,,,80640,9606.0,Intermediate,1,CHEMBL619287,BAO_0000219,,
5332,786-0,F,391.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,,,80640,9606.0,Intermediate,1,CHEMBL857455,BAO_0000219,,
5333,786-0,F,391.0,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),1,,,80640,9606.0,Intermediate,1,CHEMBL883801,BAO_0000219,,
5334,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,1,,,80641,9606.0,Intermediate,1,CHEMBL619288,BAO_0000219,,
5335,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),1,,,80641,9606.0,Intermediate,1,CHEMBL619289,BAO_0000219,,
5336,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,1,,,80641,9606.0,Intermediate,1,CHEMBL619290,BAO_0000219,,
5337,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),1,,,80641,9606.0,Intermediate,1,CHEMBL619291,BAO_0000219,,
5338,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),1,,,80641,9606.0,Intermediate,1,CHEMBL619292,BAO_0000219,,
5339,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,1,,,80641,9606.0,Intermediate,1,CHEMBL619293,BAO_0000219,,
5340,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),1,,,80641,9606.0,Intermediate,1,CHEMBL619294,BAO_0000219,,
5341,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),1,,,80641,9606.0,Intermediate,1,CHEMBL619295,BAO_0000219,,
5342,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),1,,,80641,9606.0,Intermediate,1,CHEMBL619296,BAO_0000219,,
5343,791T cell line,F,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,1,,,80641,9606.0,Intermediate,1,CHEMBL619297,BAO_0000219,,
5344,786-0,F,391.0,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,1,,,80640,9606.0,Intermediate,1,CHEMBL619298,BAO_0000219,,
5345,,F,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,0,,,22226,,Intermediate,1,CHEMBL619299,BAO_0000019,,
5346,RPMI-8226,F,741.0,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,1,,,80433,9606.0,Expert,1,CHEMBL619300,BAO_0000219,,
5347,RPMI-8226,F,741.0,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,1,,,80433,9606.0,Expert,1,CHEMBL619301,BAO_0000219,,
5348,RPMI-8226,F,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,1,,,80433,9606.0,Intermediate,1,CHEMBL619302,BAO_0000219,,
5349,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,,,80433,9606.0,Intermediate,1,CHEMBL619303,BAO_0000219,,
5350,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,,,80433,9606.0,Intermediate,1,CHEMBL619304,BAO_0000219,,
5351,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL857706,BAO_0000219,,
5352,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL619305,BAO_0000219,,
5353,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL619306,BAO_0000219,,
5354,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL619307,BAO_0000219,,
5355,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL619308,BAO_0000219,,
5356,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL619309,BAO_0000219,,
5357,RPMI-8226,F,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL619310,BAO_0000219,,
5358,A498,F,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,,,80021,9606.0,Intermediate,1,CHEMBL619311,BAO_0000219,,
5359,A498,F,624.0,,Compound was tested for the growth inhibition of A498 renal tumor cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL619312,BAO_0000219,,
5360,A498,F,624.0,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),1,,,80021,9606.0,Intermediate,1,CHEMBL619313,BAO_0000219,,
5361,A498,F,624.0,,In vitro inhibitory concentration against renal cancer cell line A498,1,,,80021,9606.0,Intermediate,1,CHEMBL619314,BAO_0000219,,
5362,A498,F,624.0,,Cytotoxicity against A 498 tumor cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL619959,BAO_0000219,,
5363,A498,F,624.0,,In vitro antitumor activity against A498 human cancer cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL619960,BAO_0000219,,
5364,A498,F,624.0,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),1,,,80021,9606.0,Intermediate,1,CHEMBL619961,BAO_0000219,,
5365,A498,F,624.0,,Inhibitory dose required against A498 human tumor cell lines,1,,,80021,9606.0,Intermediate,1,CHEMBL619962,BAO_0000219,,
5366,A498,F,624.0,,Anticancer activity against one renal cancer (A498 cell line),1,,,80021,9606.0,Intermediate,1,CHEMBL875586,BAO_0000219,,
5367,A498,F,624.0,,In vitro cytotoxicity against melanoma A498 cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL619963,BAO_0000219,,
5368,A498,F,624.0,,Compound was tested for growth inhibitory activity against A498 cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL619964,BAO_0000219,,
5369,A498,F,624.0,,Compound tested for growth inhibition of renal cancer cell line A498,1,,,80021,9606.0,Intermediate,1,CHEMBL620108,BAO_0000219,,
5370,A498,F,624.0,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL620109,BAO_0000219,,
5371,A498,F,624.0,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,1,,,80021,9606.0,Intermediate,1,CHEMBL620110,BAO_0000219,,
5372,A498,F,624.0,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,1,,,80021,9606.0,Intermediate,1,CHEMBL620111,BAO_0000219,,
5373,A498,F,624.0,,Tested for cytotoxicity against A498 cell lines in renal cancer,1,,,80021,9606.0,Intermediate,1,CHEMBL620112,BAO_0000219,,
5374,A498,F,624.0,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,1,,,80021,9606.0,Intermediate,1,CHEMBL620113,BAO_0000219,,
5375,A498,F,624.0,,Cytotoxic effect on renal cancer lines A498,1,,,80021,9606.0,Expert,1,CHEMBL620114,BAO_0000219,,
5376,A498,F,624.0,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,1,,,80021,9606.0,Intermediate,1,CHEMBL620115,BAO_0000219,,
5377,A498,F,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,,,80021,9606.0,Intermediate,1,CHEMBL620116,BAO_0000219,,
5378,A498,F,624.0,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL620117,BAO_0000219,,
5379,A498,F,624.0,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,1,,,80021,9606.0,Intermediate,1,CHEMBL620118,BAO_0000219,,
5380,A498,F,624.0,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,1,,,80021,9606.0,Intermediate,1,CHEMBL620119,BAO_0000219,,
5381,A498,F,624.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,1,,,80021,9606.0,Intermediate,1,CHEMBL620120,BAO_0000219,,
5382,A549,F,646.0,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL620121,BAO_0000219,,
5383,A549,F,646.0,,Antitumor activity against A549 human lung carcinoma cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620122,BAO_0000219,,
5384,A549,F,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,1,,,80682,9606.0,Intermediate,1,CHEMBL620123,BAO_0000219,,
5385,A549,F,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,1,,,80682,9606.0,Intermediate,1,CHEMBL620124,BAO_0000219,,
5386,A549,F,646.0,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",1,,,80682,9606.0,Intermediate,1,CHEMBL620125,BAO_0000219,,
5387,A549,F,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,1,,,80682,9606.0,Expert,1,CHEMBL620126,BAO_0000219,,
5388,A549,F,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,,80682,9606.0,Intermediate,1,CHEMBL883027,BAO_0000219,,
5389,A549,F,646.0,,In vitro cytotoxic activity against human lung A549 cell line,1,,,80682,9606.0,Expert,1,CHEMBL620127,BAO_0000219,,
5390,A549,F,646.0,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),1,,,80682,9606.0,Intermediate,1,CHEMBL620128,BAO_0000219,,
5391,A549,F,646.0,,In vitro cytotoxic activity against human lung A549 cell line),1,,,80682,9606.0,Intermediate,1,CHEMBL620129,BAO_0000219,,
5392,A549,F,646.0,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,1,,,80682,9606.0,Intermediate,1,CHEMBL620130,BAO_0000219,,
5393,A549,F,646.0,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,1,,,80682,9606.0,Expert,1,CHEMBL620131,BAO_0000219,,
5394,A549,F,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",1,,,80682,9606.0,Intermediate,1,CHEMBL620132,BAO_0000219,,
5395,A549,F,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",1,,,80682,9606.0,Intermediate,1,CHEMBL620133,BAO_0000219,,
5396,A549,F,646.0,,Inhibition of A549 human lung carcinoma cell proliferation,1,,,80682,9606.0,Expert,1,CHEMBL620134,BAO_0000219,,
5397,A549,F,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620135,BAO_0000219,,
5398,A549,F,646.0,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL620136,BAO_0000219,,
5399,A549,F,646.0,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620137,BAO_0000219,,
5400,A549,F,646.0,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620268,BAO_0000219,,
5401,A549,F,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,,80682,9606.0,Intermediate,1,CHEMBL620269,BAO_0000219,,
5402,A549,F,646.0,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620270,BAO_0000219,,
5403,A549,F,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL620271,BAO_0000219,,
5404,A549,F,646.0,,Inhibition of A549 cancer cell proliferation,1,,,80682,9606.0,Expert,1,CHEMBL620272,BAO_0000219,,
5405,A549,F,646.0,,Inhibition of A549 cancer cell proliferation (Not tested),1,,,80682,9606.0,Expert,1,CHEMBL620273,BAO_0000219,,
5406,A549,F,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL620274,BAO_0000219,,
5407,A549,F,646.0,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,1,,,80682,9606.0,Intermediate,1,CHEMBL620275,BAO_0000219,,
5408,A549,F,646.0,,Antiproliferative potency determined as inhibitory concentration against A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL620276,BAO_0000219,,
5409,A549,F,646.0,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,1,,,80682,9606.0,Intermediate,1,CHEMBL620277,BAO_0000219,,
5410,A549,F,646.0,,Cytotoxicity against Renal cell lines A549 was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL620278,BAO_0000219,,
5411,,A,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL620279,BAO_0000218,,
5412,,A,,,Area under curve was determined in dog after oral administration at 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL620280,BAO_0000218,,
5413,,A,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,,50588,9615.0,Intermediate,1,CHEMBL620281,BAO_0000218,,
5414,,A,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,,50588,9615.0,Intermediate,1,CHEMBL620282,BAO_0000218,,
5415,,A,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),1,,,50588,9615.0,Intermediate,1,CHEMBL621134,BAO_0000218,,
5416,,A,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),1,,,50588,9615.0,Intermediate,1,CHEMBL621135,BAO_0000218,,
5417,,A,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),1,,,50588,9615.0,Intermediate,1,CHEMBL621136,BAO_0000218,,
5418,,A,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),1,,,50588,9615.0,Intermediate,1,CHEMBL621137,BAO_0000218,,
5419,,A,,,Area under plasma concentration time curve in dog upon oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621138,BAO_0000218,1969.0,
5420,,A,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL875587,BAO_0000218,1969.0,
5421,,A,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,1,,,50588,9615.0,Intermediate,1,CHEMBL621139,BAO_0000218,,
5422,,A,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,1,,,50588,9615.0,Intermediate,1,CHEMBL621140,BAO_0000218,,
5423,,A,,,Area under the curve for the compound was obtained when tested in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621141,BAO_0000218,,
5424,,A,,,Area under the curve at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621142,BAO_0000218,,
5425,,A,,,Area under the curve at a dose of 1 mg/kg (oral),1,,,50588,9615.0,Intermediate,1,CHEMBL621143,BAO_0000218,,
5426,,A,,,Area under the curve at i.v. dose of 0.2 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621144,BAO_0000218,,
5427,,A,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621145,BAO_0000218,,
5428,,A,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621146,BAO_0000218,,
5429,,A,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,1,,,50588,9615.0,Intermediate,1,CHEMBL622567,BAO_0000218,,
5430,,A,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,1,,,50588,9615.0,Intermediate,1,CHEMBL622568,BAO_0000218,,
5431,,A,,,Compound was evaluated for area under the curve in dog blood.,1,,,50588,9615.0,Intermediate,1,CHEMBL622569,BAO_0000218,,
5432,,A,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622570,BAO_0000218,,
5433,,A,,,AUC in dog after oral dose (1 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL622571,BAO_0000218,1969.0,
5434,,A,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622572,BAO_0000218,,
5435,,A,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",1,,,50588,9615.0,Intermediate,1,CHEMBL622573,BAO_0000218,,
5436,,A,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL622574,BAO_0000218,,
5437,,A,,,Pharmacokinetic parameter AUC after oral administration to dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL622575,BAO_0000218,,
5438,,A,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,1,,,50588,9615.0,Intermediate,1,CHEMBL622576,BAO_0000218,,
5439,,A,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,1,,,50588,9615.0,Intermediate,1,CHEMBL622577,BAO_0000218,,
5440,,A,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,1,,,50588,9615.0,Intermediate,1,CHEMBL622578,BAO_0000218,,
5441,,A,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622579,BAO_0000218,,
5442,,A,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",1,,,50588,9615.0,Intermediate,1,CHEMBL622580,BAO_0000218,,
5443,,A,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",1,,,50588,9615.0,Intermediate,1,CHEMBL622581,BAO_0000218,,
5444,,A,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,50588,9615.0,Intermediate,1,CHEMBL622582,BAO_0000218,,
5445,,A,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,50588,9615.0,Intermediate,1,CHEMBL622583,BAO_0000218,,
5446,,A,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,,,50588,9615.0,Intermediate,1,CHEMBL622584,BAO_0000218,,
5447,,A,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,,,50588,9615.0,Intermediate,1,CHEMBL622585,BAO_0000218,,
5448,,A,,,Compound was evaluated for oral bioavailability in dog; 90-100,1,,,50588,9615.0,Intermediate,1,CHEMBL622586,BAO_0000218,,
5449,,A,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,1,,,50588,9615.0,Intermediate,1,CHEMBL623281,BAO_0000218,,
5450,,A,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL623282,BAO_0000218,,
5451,,A,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,1,,,50588,9615.0,Intermediate,1,CHEMBL623283,BAO_0000218,,
5452,,A,,,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623284,BAO_0000218,,
5453,,A,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL623285,BAO_0000218,,
5454,,A,,,Plasma protein binding towards dog plasma at 10 uM,1,,,50588,9615.0,Intermediate,1,CHEMBL623463,BAO_0000218,1969.0,
5455,,A,,,Plasma protein binding towards dog plasma at 100 uM,1,,,50588,9615.0,Intermediate,1,CHEMBL875952,BAO_0000218,1969.0,
5456,,A,,In vivo,Bioavailability in dog (dose 4 mg/kg p.o.),1,,,50588,9615.0,Intermediate,1,CHEMBL621705,BAO_0000218,,
5457,,A,,In vivo,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621706,BAO_0000218,,
5458,,A,,In vivo,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621707,BAO_0000218,,
5459,,A,,In vivo,Bioavailability in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621708,BAO_0000218,,
5460,,A,,In vivo,Bioavailability,1,,,50588,9615.0,Intermediate,1,CHEMBL621709,BAO_0000218,,
5461,,A,,In vivo,Oral bioavailability in dog (dose 10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621710,BAO_0000218,,
5462,,A,,In vivo,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621711,BAO_0000218,,
5463,,A,,In vivo,Bioavailability in dog (dose 10.0 mg/kg p.o.),1,,,50588,9615.0,Intermediate,1,CHEMBL621712,BAO_0000218,,
5464,,A,,In vivo,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621713,BAO_0000218,,
5465,,A,,In vivo,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621714,BAO_0000218,,
5466,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL621715,BAO_0000218,,
5467,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623717,BAO_0000218,2107.0,
5468,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623718,BAO_0000218,2107.0,
5469,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623719,BAO_0000218,2107.0,
5470,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623720,BAO_0000218,,
5471,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623721,BAO_0000218,,
5472,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623722,BAO_0000218,2385.0,
5473,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623723,BAO_0000218,2385.0,
5474,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL618543,BAO_0000218,2385.0,
5475,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL618544,BAO_0000218,2106.0,
5476,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL875155,BAO_0000218,2106.0,
5477,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL618545,BAO_0000218,,
5478,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL618546,BAO_0000218,,
5479,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623529,BAO_0000218,,
5480,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL623530,BAO_0000218,,
5481,,A,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,0,,,22224,10095.0,Autocuration,1,CHEMBL621764,BAO_0000218,,
5482,,A,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621765,BAO_0000019,,
5483,,A,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621766,BAO_0000019,2037.0,
5484,,A,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621767,BAO_0000019,1870.0,
5485,,A,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621768,BAO_0000019,,
5486,,A,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621769,BAO_0000019,2435.0,
5487,,A,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621770,BAO_0000019,,
5488,,A,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621771,BAO_0000019,2037.0,
5489,,A,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621772,BAO_0000019,1870.0,
5490,,A,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621773,BAO_0000019,,
5491,,A,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),0,,,22224,9527.0,Autocuration,1,CHEMBL621774,BAO_0000019,2435.0,
5492,,A,,,Compound was evaluated for oral bioavailability in rats,0,,,22224,9527.0,Autocuration,1,CHEMBL621775,BAO_0000218,,
5493,,A,,In vivo,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,0,,,22224,9527.0,Autocuration,1,CHEMBL621776,BAO_0000218,1969.0,
5494,,A,,,Half life period was evaluated in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL621777,BAO_0000019,,
5495,,A,,In vivo,Half-life in rhesus monkeys by intravenous administration of dose,0,,,22224,9527.0,Autocuration,1,CHEMBL875162,BAO_0000218,,
5496,,A,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL621778,BAO_0000218,1969.0,
5497,,A,,,AUC after intraperitoneal administration of 100 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621779,BAO_0000218,1969.0,
5498,,A,,,AUC value was determined after oral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL622479,BAO_0000218,1969.0,
5499,,A,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622480,BAO_0000218,,
5500,,A,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,,50594,10090.0,Intermediate,1,CHEMBL622481,BAO_0000218,,
5501,,A,,,Area under curve by ioral administration in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL622482,BAO_0000218,,
5502,,A,,,Area under curve by iv administration in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL622483,BAO_0000218,,
5503,,A,,,Area under curve at 0-8 hr in IRC mice after peroral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL622484,BAO_0000218,,
5504,,A,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622641,BAO_0000218,,
5505,,A,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622642,BAO_0000218,,
5506,,A,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622643,BAO_0000218,,
5507,,A,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622644,BAO_0000218,,
5508,RPMI-8226,F,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,,,80433,9606.0,Intermediate,1,CHEMBL622645,BAO_0000219,,
5509,RPMI-8226,F,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,,,80433,9606.0,Intermediate,1,CHEMBL622646,BAO_0000219,,
5510,RPMI-8226,F,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL621238,BAO_0000219,,
5511,RPMI-8226,F,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL621239,BAO_0000219,,
5512,RPMI-8226,F,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL621240,BAO_0000219,,
5513,RPMI-8226,F,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL621241,BAO_0000219,,
5514,RPMI-8226,F,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL621242,BAO_0000219,,
5515,RPMI-8226,F,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL620350,BAO_0000219,,
5516,RPMI-8226,F,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,,,80433,9606.0,Intermediate,1,CHEMBL620351,BAO_0000219,,
5517,RPMI-8226,F,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,,,80433,9606.0,Intermediate,1,CHEMBL620352,BAO_0000219,,
5518,RPMI-8226,F,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL620353,BAO_0000219,,
5519,RPMI-8226,F,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL620354,BAO_0000219,,
5520,RPMI-8226,F,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL620355,BAO_0000219,,
5521,RPMI-8226,F,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL620356,BAO_0000219,,
5522,RPMI-8226,F,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL620357,BAO_0000219,,
5523,RPMI-8226,F,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,,,80433,9606.0,Intermediate,1,CHEMBL620358,BAO_0000219,,
5524,RPMI-8226,F,741.0,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,1,,,80433,9606.0,Expert,1,CHEMBL620359,BAO_0000219,,
5525,RPMI-8226,F,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,1,,,80433,9606.0,Intermediate,1,CHEMBL620360,BAO_0000219,,
5526,RPMI-8226,F,741.0,,Cytotoxicity of compound against 8226/DOX1V cells,1,,,80433,9606.0,Intermediate,1,CHEMBL620361,BAO_0000219,,
5527,RPMI-8226,F,741.0,,Cytotoxicity of compound against 8226/S cells,1,,,80433,9606.0,Intermediate,1,CHEMBL620362,BAO_0000219,,
5528,RPMI-8226,F,741.0,,Inhibitory concentration against 8226 myeloma cancer cell line,1,,,80433,9606.0,Intermediate,1,CHEMBL620363,BAO_0000219,,
5529,RPMI-8226,F,741.0,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,1,,,80433,9606.0,Intermediate,1,CHEMBL620364,BAO_0000219,,
5530,833K,F,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,1,,,80647,9606.0,Intermediate,1,CHEMBL620365,BAO_0000219,,
5531,833K,F,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',1,,,80647,9606.0,Intermediate,1,CHEMBL620366,BAO_0000219,,
5532,833K,F,854.0,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,1,,,80647,9606.0,Expert,1,CHEMBL620367,BAO_0000219,,
5533,833K,F,854.0,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,1,,,80647,9606.0,Intermediate,1,CHEMBL620368,BAO_0000219,,
5534,,B,,,Inhibitory activity against caspase-1,0,,,22226,,Autocuration,1,CHEMBL620369,BAO_0000019,,
5535,,B,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,8,,,45,1351.0,Autocuration,1,CHEMBL620370,BAO_0000357,,
5536,8701-BC,F,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,1,,,80648,9606.0,Intermediate,1,CHEMBL620371,BAO_0000219,,
5537,8701-BC,F,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,1,,,80648,9606.0,Intermediate,1,CHEMBL620372,BAO_0000219,,
5538,,F,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,0,,,22226,,Intermediate,1,CHEMBL876492,BAO_0000019,,
5539,,F,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,0,,,22226,,Intermediate,1,CHEMBL620373,BAO_0000019,,
5540,,F,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,0,,,22226,,Intermediate,1,CHEMBL620374,BAO_0000019,,
5541,,B,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,0,,,22226,,Autocuration,1,CHEMBL620375,BAO_0000019,,
5542,,F,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,0,,,22226,1314.0,Autocuration,1,CHEMBL857902,BAO_0000019,,
5543,,F,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,0,,,22226,1314.0,Autocuration,1,CHEMBL620376,BAO_0000019,,
5544,,B,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,8,,,11922,,Autocuration,1,CHEMBL620377,BAO_0000357,,
5545,KB ,F,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,,,81115,9606.0,Intermediate,1,CHEMBL620378,BAO_0000219,,
5546,KB ,A,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,,,81115,9606.0,Intermediate,1,CHEMBL620379,BAO_0000219,,
5547,,F,,,In vitro cytotoxicity of compound was tested against 9KB cells.,0,,,22226,9606.0,Autocuration,1,CHEMBL620380,BAO_0000219,,
5548,9L,F,392.0,,Cytotoxic concentration against 9L cells was determined on day 3,1,,,80653,10116.0,Intermediate,1,CHEMBL884006,BAO_0000219,,
5549,9L,F,392.0,,Tested in vitro for anticancer activity against 9L cells,1,,,80653,10116.0,Expert,1,CHEMBL620381,BAO_0000219,,
5550,9L,F,392.0,,Tested in vitro for anticancer activity against 9L cells; Not determined,1,,,80653,10116.0,Expert,1,CHEMBL620382,BAO_0000219,,
5551,A549,F,646.0,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,1,,,80682,9606.0,Intermediate,1,CHEMBL620383,BAO_0000219,,
5552,A549,F,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,1,,,80682,9606.0,Intermediate,1,CHEMBL876493,BAO_0000219,,
5553,A549,F,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,1,,,80682,9606.0,Intermediate,1,CHEMBL620384,BAO_0000219,,
5554,A549,F,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,1,,,80682,9606.0,Intermediate,1,CHEMBL620385,BAO_0000219,,
5555,A549,F,646.0,,Cytotoxicity against human lung carcinoma A549 cell line,1,,,80682,9606.0,Expert,1,CHEMBL620386,BAO_0000219,,
5556,A549,F,646.0,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,9,,,25,9606.0,Expert,1,CHEMBL620387,BAO_0000219,,
5557,A549,F,646.0,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",9,,,25,9606.0,Expert,1,CHEMBL621404,BAO_0000219,,
5558,A549,F,646.0,,"In vitro growth inhibition of A549, lung carcinoma",1,,,80682,9606.0,Intermediate,1,CHEMBL621405,BAO_0000219,,
5559,A549,F,646.0,,"In vitro growth inhibition of A549, lung carcinoma.",1,,,80682,9606.0,Intermediate,1,CHEMBL621406,BAO_0000219,,
5560,A549,F,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL621407,BAO_0000219,,
5561,A549,F,646.0,,Cytotoxic activity against human lung cancer A549 cell line was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL621408,BAO_0000219,,
5562,A549,F,646.0,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,1,,,80682,9606.0,Expert,1,CHEMBL885345,BAO_0000219,,
5563,A549,F,646.0,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621409,BAO_0000219,,
5564,A549,F,646.0,,Cytotoxicity in A549 (human carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL876034,BAO_0000219,,
5565,A549,F,646.0,,Cytotoxicity on lung carcinoma (A-549) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621410,BAO_0000219,,
5566,A549,F,646.0,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,1,,,80682,9606.0,Expert,1,CHEMBL621411,BAO_0000219,,
5567,A549,F,646.0,,Effective dose of compound against replication of A549 cell line was evaluated,1,,,80682,9606.0,Intermediate,1,CHEMBL621412,BAO_0000219,,
5568,A549,F,646.0,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,1,,,80682,9606.0,Expert,1,CHEMBL621413,BAO_0000219,,
5569,A549,F,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),1,,,80682,9606.0,Intermediate,1,CHEMBL621414,BAO_0000219,,
5570,A549,F,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,1,,,80682,9606.0,Intermediate,1,CHEMBL621415,BAO_0000219,,
5571,A549,F,646.0,,The compound was evaluated for antiproliferative activity against A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621416,BAO_0000219,,
5572,A549,F,646.0,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,1,,,80682,9606.0,Intermediate,1,CHEMBL621417,BAO_0000219,,
5573,A549,F,646.0,,Concentration required for growth inhibition of human lung carcinoma cell line A549,1,,,80682,9606.0,Intermediate,1,CHEMBL621418,BAO_0000219,,
5574,A549,F,646.0,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621419,BAO_0000219,,
5575,A549,F,646.0,,Growth inhibition against A549 cell line was evaluated,1,,,80682,9606.0,Intermediate,1,CHEMBL621420,BAO_0000219,,
5576,A549,F,646.0,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL875823,BAO_0000219,,
5577,A549,F,646.0,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,1,,,80682,9606.0,Expert,1,CHEMBL621421,BAO_0000219,,
5578,A549,F,646.0,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,1,,,80682,9606.0,Intermediate,1,CHEMBL621422,BAO_0000219,,
5579,A549,F,646.0,,Chemosensitivity against DT-diaphorase rich A549 cell lines,1,,,80682,9606.0,Expert,1,CHEMBL884014,BAO_0000219,,
5580,A549,F,646.0,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,1,,,80682,9606.0,Intermediate,1,CHEMBL621423,BAO_0000219,,
5581,A549,F,646.0,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL621424,BAO_0000219,,
5582,A549,F,646.0,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,1,,,80682,9606.0,Intermediate,1,CHEMBL621425,BAO_0000219,,
5583,A549,F,646.0,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,1,,,80682,9606.0,Expert,1,CHEMBL621426,BAO_0000219,,
5584,A549,F,646.0,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,1,,,80682,9606.0,Intermediate,1,CHEMBL621427,BAO_0000219,,
5585,A549,F,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,,,80682,9606.0,Intermediate,1,CHEMBL621428,BAO_0000219,,
5586,A549,F,646.0,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,1,,,80682,9606.0,Expert,1,CHEMBL621429,BAO_0000219,,
5587,A549,F,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),1,,,80682,9606.0,Intermediate,1,CHEMBL621430,BAO_0000219,,
5588,A549,F,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,1,,,80682,9606.0,Intermediate,1,CHEMBL621431,BAO_0000219,,
5589,A549,F,646.0,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,1,,,80682,9606.0,Intermediate,1,CHEMBL621432,BAO_0000219,,
5590,A549,F,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,1,,,80682,9606.0,Expert,1,CHEMBL621433,BAO_0000219,,
5591,A549,F,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL875824,BAO_0000219,,
5592,A549,F,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,,,80682,9606.0,Intermediate,1,CHEMBL621434,BAO_0000219,,
5593,A549,F,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,1,,,80682,9606.0,Intermediate,1,CHEMBL621435,BAO_0000219,,
5594,A549,F,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,1,,,80682,9606.0,Intermediate,1,CHEMBL621436,BAO_0000219,,
5595,A549,F,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,1,,,80682,9606.0,Intermediate,1,CHEMBL621437,BAO_0000219,,
5596,A549,F,646.0,,Compound was tested for the growth inhibition of A549 lung tumor cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621438,BAO_0000219,,
5597,A549,F,646.0,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,1,,,80682,9606.0,Expert,1,CHEMBL621439,BAO_0000219,,
5598,A549,F,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,,,80682,9606.0,Intermediate,1,CHEMBL621440,BAO_0000219,,
5599,,A,,In vivo,Oral bioavailability in dog (conscious),1,,,50588,9615.0,Intermediate,1,CHEMBL621441,BAO_0000218,,
5600,,A,,In vivo,Compound was evaluated for the oral bioavailability after oral administration in dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL621442,BAO_0000218,,
5601,,A,,In vivo,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621443,BAO_0000218,,
5602,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621444,BAO_0000218,,
5603,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625133,BAO_0000218,,
5604,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625134,BAO_0000218,,
5605,,A,,In vivo,Oral bioavailability in dog (fasted),1,,,50588,9615.0,Intermediate,1,CHEMBL625135,BAO_0000218,,
5606,,A,,In vivo,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625136,BAO_0000218,,
5607,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625137,BAO_0000218,,
5608,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625138,BAO_0000218,,
5609,,A,,In vivo,Percent bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625139,BAO_0000218,,
5610,,A,,In vivo,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL872264,BAO_0000218,,
5611,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625140,BAO_0000218,,
5612,,A,,In vivo,The compound was evaluated for bioavailability in dogs; 34-44,1,,,50588,9615.0,Intermediate,1,CHEMBL624436,BAO_0000218,,
5613,,A,,In vivo,Bioavailability in dog (dose 4 mg/kg p.o.),1,,,50588,9615.0,Intermediate,1,CHEMBL624437,BAO_0000218,,
5614,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL872261,BAO_0000218,,
5615,,A,,,8 hour trough Blood level in dog was measured after administration of compound,1,,,50588,9615.0,Intermediate,1,CHEMBL624438,BAO_0000218,,
5616,,A,,In vivo,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,1,,,50588,9615.0,Intermediate,1,CHEMBL624439,BAO_0000218,1969.0,
5617,,A,,,C24 after oral administration at 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624440,BAO_0000218,,
5618,,A,,,Clearance after oral and iv dosing in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624441,BAO_0000218,,
5619,,A,,,Clearance of the drug was measured in the plasma of dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624442,BAO_0000218,1969.0,
5620,,A,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,1,,,50588,9615.0,Intermediate,1,CHEMBL624443,BAO_0000218,,
5621,,A,,In vivo,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624444,BAO_0000218,,
5622,,A,,In vivo,Clearance of compound was determined in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624445,BAO_0000218,,
5623,,A,,In vivo,Clearance on i.v. administration of 2 mg/kg was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624446,BAO_0000218,,
5624,,A,,In vivo,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624447,BAO_0000218,,
5625,,A,,In vivo,Plasma clearance in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624448,BAO_0000218,,
5626,,A,,In vivo,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624449,BAO_0000218,,
5627,,A,,In vivo,Plasma clearance in dog after administration of 0.25 mg/kg iv,1,,,50588,9615.0,Intermediate,1,CHEMBL624450,BAO_0000218,,
5628,,A,,In vivo,Plasma clearance in dog after administration of 1 mg/kg iv,1,,,50588,9615.0,Intermediate,1,CHEMBL875942,BAO_0000218,,
5629,,A,,In vivo,Plasma clearance in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624451,BAO_0000218,,
5630,,A,,In vivo,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624452,BAO_0000218,,
5631,,A,,In vivo,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,,,50588,9615.0,Intermediate,1,CHEMBL624453,BAO_0000218,,
5632,,A,,In vivo,Plasma clearance after 15 mg/kg iv dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624454,BAO_0000218,,
5633,,A,,In vivo,Plasma clearance after 30 mg/kg po dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624455,BAO_0000218,,
5634,,A,,In vivo,Plasma administration to dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624456,BAO_0000218,,
5635,,A,,In vivo,Plasma clearance was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624457,BAO_0000218,,
5636,,A,,In vivo,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624458,BAO_0000218,,
5637,,A,,In vivo,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624459,BAO_0000218,,
5638,,A,,In vitro,Intrinsic clearance in human liver microsomes,2,,,102164,9606.0,Intermediate,1,CHEMBL624460,BAO_0000251,2107.0,
5639,,A,,In vitro,Intrinsic clearance in human liver microsomes,2,,,102164,9606.0,Intermediate,1,CHEMBL624461,BAO_0000251,2107.0,
5640,,A,,In vivo,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,,50588,9615.0,Intermediate,1,CHEMBL875943,BAO_0000218,,
5641,,A,,In vivo,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,,50588,9615.0,Intermediate,1,CHEMBL624462,BAO_0000218,,
5642,,A,,In vivo,Clearance in dog (dose 1 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL624463,BAO_0000218,,
5643,,A,,In vivo,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624464,BAO_0000218,,
5644,,A,,In vivo,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL624465,BAO_0000218,,
5645,,A,,In vivo,Plasma clearance after peroral administration at 10 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624466,BAO_0000218,,
5646,,A,,In vivo,Plasma clearance after peroral administration at 5 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624467,BAO_0000218,,
5647,,A,,In vivo,Plasma clearance after peroral administration at 5 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624468,BAO_0000218,,
5648,,A,,In vivo,Plasma clearance was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624469,BAO_0000218,,
5649,,A,,In vivo,Plasma clearance was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624470,BAO_0000218,,
5650,,A,,In vivo,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,1,,,50588,9615.0,Intermediate,1,CHEMBL624471,BAO_0000218,,
5651,,A,,In vivo,Total clearance was determined after 0.1 mg/kg iv administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624472,BAO_0000218,,
5652,,A,,In vivo,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622775,BAO_0000218,,
5653,,A,,In vivo,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622776,BAO_0000218,,
5654,,A,,In vivo,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622777,BAO_0000218,,
5655,,A,,In vivo,Clearance after peroral administration of 0.2 mg/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622778,BAO_0000218,,
5656,,A,,In vivo,Clearance by intravenous administration of 1.2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622779,BAO_0000218,,
5657,,A,,In vivo,Clearance by iv administration in dogs at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622780,BAO_0000218,,
5658,,A,,In vivo,Clearance value was evaluated in dog plasma,1,,,50588,9615.0,Intermediate,1,CHEMBL622781,BAO_0000218,1969.0,
5659,,A,,In vivo,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622782,BAO_0000218,,
5660,,A,,In vivo,Compound was tested for plasma clearance in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622783,BAO_0000218,1969.0,
5661,,A,,In vivo,Pharmacokinetic property (Plasma clearance) was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622784,BAO_0000218,,
5662,,A,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622785,BAO_0000218,,
5663,,A,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622786,BAO_0000218,,
5664,,A,,,Area under curve value in mouse at a dose of 10 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622787,BAO_0000218,,
5665,,A,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,,50594,10090.0,Intermediate,1,CHEMBL875949,BAO_0000218,,
5666,,A,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622788,BAO_0000218,,
5667,,F,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622789,BAO_0000218,,
5668,,F,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622790,BAO_0000218,,
5669,,F,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622791,BAO_0000218,,
5670,,F,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622792,BAO_0000218,,
5671,,A,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622793,BAO_0000218,,
5672,,A,,,Area under curve was determined for the compound at 24 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622794,BAO_0000218,,
5673,,A,,,Area under curve was determined for the compound at 40 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622795,BAO_0000218,,
5674,,A,,,Area under curve was determined for the compound at 5 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL621803,BAO_0000218,,
5675,,A,,,Area under the curve for the compound is obtained at dose 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL621804,BAO_0000218,,
5676,,A,,,Area under the curve for the compound was obtained when tested in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL621805,BAO_0000218,,
5677,,A,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL621806,BAO_0000218,,
5678,,A,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL621807,BAO_0000218,,
5679,,A,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL621808,BAO_0000218,,
5680,,A,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621809,BAO_0000218,,
5681,,A,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,,,50594,10090.0,Intermediate,1,CHEMBL621810,BAO_0000218,,
5682,,A,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL875164,BAO_0000218,,
5683,,A,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621811,BAO_0000218,,
5684,,A,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",1,,,50594,10090.0,Intermediate,1,CHEMBL621812,BAO_0000218,,
5685,,A,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),1,,,50594,10090.0,Intermediate,1,CHEMBL621813,BAO_0000218,,
5686,,A,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),1,,,50594,10090.0,Intermediate,1,CHEMBL621814,BAO_0000218,,
5687,,A,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL621815,BAO_0000218,,
5688,,A,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL621816,BAO_0000218,,
5689,,A,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL621817,BAO_0000218,,
5690,,A,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL621818,BAO_0000218,,
5691,,A,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL621819,BAO_0000218,,
5692,,A,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621820,BAO_0000218,,
5693,,A,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL621821,BAO_0000218,,
5694,,A,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621822,BAO_0000218,,
5695,,A,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL619474,BAO_0000218,,
5696,,A,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,,,50594,10090.0,Intermediate,1,CHEMBL619475,BAO_0000218,,
5697,,A,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,,,50594,10090.0,Intermediate,1,CHEMBL619476,BAO_0000218,,
5698,,A,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",1,,,50594,10090.0,Intermediate,1,CHEMBL619477,BAO_0000218,,
5699,,A,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",1,,,50594,10090.0,Intermediate,1,CHEMBL619478,BAO_0000218,,
5700,,A,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",1,,,50594,10090.0,Intermediate,1,CHEMBL619479,BAO_0000218,,
5701,,A,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",1,,,50594,10090.0,Intermediate,1,CHEMBL619480,BAO_0000218,,
5702,,A,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,1,,,50594,10090.0,Intermediate,1,CHEMBL619481,BAO_0000218,,
5703,,A,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,1,,,50594,10090.0,Intermediate,1,CHEMBL619482,BAO_0000218,,
5704,,A,,,Area under the curve was evaluated in mice after intravenous administration,1,,,50594,10090.0,Intermediate,1,CHEMBL619483,BAO_0000218,,
5705,,A,,,Area under the curve was evaluated in mice after oral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL619484,BAO_0000218,,
5706,,A,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL619485,BAO_0000218,1969.0,
5707,,A,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL619486,BAO_0000218,1969.0,
5708,,A,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,,,50594,10090.0,Intermediate,1,CHEMBL619487,BAO_0000218,,
5709,,A,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL619488,BAO_0000218,,
5710,,A,,In vivo,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620106,BAO_0000218,178.0,
5711,9L,F,392.0,,The compound was tested in vitro for anticancer activity against 9L cells,1,,,80653,,Intermediate,1,CHEMBL620107,BAO_0000219,,
5712,,F,,,Anti proliferation activity determined; Weak effect,0,,,22226,10116.0,Autocuration,1,CHEMBL620283,BAO_0000019,,
5713,,F,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,0,,,22226,10116.0,Autocuration,1,CHEMBL875176,BAO_0000219,,
5714,,F,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,0,,,22226,10116.0,Autocuration,1,CHEMBL620284,BAO_0000219,,
5715,,F,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,0,,,22226,10116.0,Autocuration,1,CHEMBL623515,BAO_0000219,,
5716,,F,,,The cytotoxic activity was in vitro tested by 9PS assay method,0,,,22226,10090.0,Autocuration,1,CHEMBL623516,BAO_0000019,,
5717,,F,,,The cytotoxic activity was in vitro tested by 9PS assay method.,0,,,22226,10090.0,Autocuration,1,CHEMBL623517,BAO_0000019,,
5718,,A,,,Partition coefficient (logD6.5),0,,,22224,,Autocuration,1,CHEMBL857878,BAO_0000019,,
5719,A2780,F,478.0,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,1,,,81034,9606.0,Expert,1,CHEMBL623518,BAO_0000219,,
5720,A-375,F,455.0,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),1,,,80018,9606.0,Intermediate,1,CHEMBL624195,BAO_0000219,,
5721,A-431,F,500.0,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,1,,,80852,9606.0,Expert,1,CHEMBL624196,BAO_0000219,,
5722,A-431,F,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,9,9606.0,Expert,1,CHEMBL624197,BAO_0000219,,
5723,A498,F,624.0,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL624198,BAO_0000219,,
5724,A498,F,624.0,,in vitro cytotoxicity against A 498 cancer cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL621287,BAO_0000219,,
5725,A498,F,624.0,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,1,,,80021,9606.0,Intermediate,1,CHEMBL621288,BAO_0000219,,
5726,A498,F,624.0,,Cytotoxic activity against A 498 renal cancer cell lines.,1,,,80021,9606.0,Intermediate,1,CHEMBL876496,BAO_0000219,,
5727,A498,F,624.0,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,1,,,80021,9606.0,Intermediate,1,CHEMBL621289,BAO_0000219,,
5728,,F,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,0,,,22226,1280.0,Autocuration,1,CHEMBL621290,BAO_0000019,,
5729,,F,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,0,,,22226,1280.0,Autocuration,1,CHEMBL621291,BAO_0000019,,
5730,,F,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,0,,,22226,1280.0,Autocuration,1,CHEMBL621292,BAO_0000019,,
5731,,F,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,0,,,22226,1280.0,Autocuration,1,CHEMBL621293,BAO_0000019,,
5732,A549,F,646.0,,Inhibitory concentration required against A 549 lung cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621294,BAO_0000219,,
5733,A549,F,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,1,,,80682,9606.0,Intermediate,1,CHEMBL621295,BAO_0000219,,
5734,A549,F,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,1,,,80682,9606.0,Intermediate,1,CHEMBL884007,BAO_0000219,,
5735,A549,F,646.0,,In vitro cytotoxicity against lung cancer A 549 cell lines,1,,,80682,9606.0,Intermediate,1,CHEMBL621296,BAO_0000219,,
5736,A549,F,646.0,,Compound was tested for its cytotoxicity against A 549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621297,BAO_0000219,,
5737,A549,F,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",1,,,80682,9606.0,Expert,1,CHEMBL839828,BAO_0000219,,
5738,A549,F,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",1,,,80682,9606.0,Intermediate,1,CHEMBL620397,BAO_0000219,,
5739,A549,F,646.0,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,1,,,80682,9606.0,Expert,1,CHEMBL620398,BAO_0000219,,
5740,A549,F,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,,,80682,9606.0,Intermediate,1,CHEMBL620399,BAO_0000219,,
5741,A549,F,646.0,,In vitro inhibition of A549 (human lung cancer) cell growth.,1,,,80682,9606.0,Expert,1,CHEMBL620400,BAO_0000219,,
5742,A549,F,646.0,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,1,,,80682,9606.0,Intermediate,1,CHEMBL620401,BAO_0000219,,
5743,A549,F,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,,,80682,9606.0,Expert,1,CHEMBL620402,BAO_0000219,,
5744,A549,F,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),1,,,80682,9606.0,Expert,1,CHEMBL620403,BAO_0000219,,
5745,,F,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,0,,,22226,,Autocuration,1,CHEMBL620404,BAO_0000218,,
5746,,F,,In vivo,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,4,,,104694,,Autocuration,1,CHEMBL620405,BAO_0000218,,
5747,,F,,In vivo,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,4,,,104694,,Autocuration,1,CHEMBL620406,BAO_0000218,,
5748,,F,,In vivo,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,4,,,104694,,Autocuration,1,CHEMBL620407,BAO_0000218,,
5749,,F,,In vivo,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,4,,,104694,,Autocuration,1,CHEMBL620408,BAO_0000218,,
5750,,F,,In vivo,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,4,,,104694,,Autocuration,1,CHEMBL620409,BAO_0000218,,
5751,A498,F,624.0,,Inhibition of A-498 human Renal cell proliferation,1,,,80021,9606.0,Expert,1,CHEMBL620410,BAO_0000219,,
5752,,F,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",0,,,22226,10116.0,Autocuration,1,CHEMBL620411,BAO_0000019,,
5753,,F,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",0,,,22226,10116.0,Autocuration,1,CHEMBL620412,BAO_0000019,,
5754,,F,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",0,,,22226,10116.0,Autocuration,1,CHEMBL876596,BAO_0000019,,
5755,A 172,F,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,1,,,80012,9606.0,Expert,1,CHEMBL620413,BAO_0000219,,
5756,A 172,F,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,,80012,9606.0,Intermediate,1,CHEMBL620414,BAO_0000219,,
5757,A 172,F,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,,80012,9606.0,Intermediate,1,CHEMBL620415,BAO_0000219,,
5758,A549,F,646.0,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL620416,BAO_0000219,,
5759,A549,F,646.0,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,1,,,80682,9606.0,Intermediate,1,CHEMBL620417,BAO_0000219,,
5760,A549,F,646.0,,Cytotoxic activity evaluated against A549 tumor cells,1,,,80682,9606.0,Expert,1,CHEMBL620418,BAO_0000219,,
5761,A549,F,646.0,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620419,BAO_0000219,,
5762,A549,F,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,1,,,80682,9606.0,Intermediate,1,CHEMBL620420,BAO_0000219,,
5763,A549,F,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,1,,,80682,9606.0,Intermediate,1,CHEMBL620421,BAO_0000219,,
5764,A549,F,646.0,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,1,,,80682,9606.0,Intermediate,1,CHEMBL620422,BAO_0000219,,
5765,A549,F,646.0,,Cytotoxicity of compound against A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620423,BAO_0000219,,
5766,A549,F,646.0,,Cytotoxicity against human lung cell carcinoma A549 cell line,1,,,80682,9606.0,Expert,1,CHEMBL620424,BAO_0000219,,
5767,A549,F,646.0,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL620425,BAO_0000219,,
5768,A549,F,646.0,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,1,,,80682,9606.0,Intermediate,1,CHEMBL620426,BAO_0000219,,
5769,A549,F,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,1,,,80682,9606.0,Intermediate,1,CHEMBL620427,BAO_0000219,,
5770,A549,F,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,1,,,80682,9606.0,Intermediate,1,CHEMBL620428,BAO_0000219,,
5771,A549,F,646.0,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,1,,,80682,9606.0,Intermediate,1,CHEMBL620429,BAO_0000219,,
5772,A549,F,646.0,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,1,,,80682,9606.0,Expert,1,CHEMBL620430,BAO_0000219,,
5773,A549,F,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL839887,BAO_0000219,,
5774,A549,F,646.0,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,1,,,80682,9606.0,Intermediate,1,CHEMBL620431,BAO_0000219,,
5775,A549,F,646.0,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,1,,,80682,9606.0,Intermediate,1,CHEMBL884010,BAO_0000219,,
5776,A549,F,646.0,,In vitro cytotoxicity against A549 (human lung cancer),1,,,80682,9606.0,Intermediate,1,CHEMBL620538,BAO_0000219,,
5777,A549,F,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL620539,BAO_0000219,,
5778,A549,F,646.0,,In vivo antiproliferative activity against A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL623373,BAO_0000218,,
5779,A549,F,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549),1,,,80682,9606.0,Intermediate,1,CHEMBL623374,BAO_0000219,,
5780,A549,F,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,1,,,80682,9606.0,Intermediate,1,CHEMBL623375,BAO_0000219,,
5781,A549,F,646.0,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,1,,,80682,9606.0,Intermediate,1,CHEMBL623376,BAO_0000219,,
5782,A549,F,646.0,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),1,,,80682,9606.0,Intermediate,1,CHEMBL623377,BAO_0000219,,
5783,A549,F,646.0,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,,,80682,9606.0,Intermediate,1,CHEMBL623378,BAO_0000219,,
5784,A549,F,646.0,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,1,,,80682,9606.0,Intermediate,1,CHEMBL623379,BAO_0000219,,
5785,A549,F,646.0,,Inhibitory activity against A549 lung cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL623380,BAO_0000219,,
5786,A549,F,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL623381,BAO_0000219,,
5787,A549,F,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,1,,,80682,9606.0,Intermediate,1,CHEMBL623382,BAO_0000219,,
5788,A549,F,646.0,,Inhibitory concentration against A549 (lung cancer) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL623383,BAO_0000219,,
5789,A549,F,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL623384,BAO_0000219,,
5790,A549,F,646.0,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL623385,BAO_0000219,,
5791,A549,F,646.0,,Activity against A549 cancer cell line.,1,,,80682,9606.0,Expert,1,CHEMBL623386,BAO_0000219,,
5792,A549,F,646.0,,The compound was evaluated for cytotoxicity against A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL884105,BAO_0000219,,
5793,A549,F,646.0,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,1,,,80682,9606.0,Intermediate,1,CHEMBL623387,BAO_0000219,,
5794,A549,F,646.0,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621568,BAO_0000219,,
5795,A549,F,646.0,,Growth inhibitory activity was measured for human A549 tumor cell line.,1,,,80682,9606.0,Intermediate,1,CHEMBL621569,BAO_0000219,,
5796,A549,F,646.0,,Inhibitory activity against A549 lung cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621570,BAO_0000219,,
5797,A549,F,646.0,,Inhibitory activity against A549 cell line; inactive,1,,,80682,9606.0,Intermediate,1,CHEMBL621571,BAO_0000219,,
5798,A549,F,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,,,80682,9606.0,Expert,1,CHEMBL621572,BAO_0000219,,
5799,A549,F,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,,,80682,9606.0,Expert,1,CHEMBL621573,BAO_0000219,,
5800,A549,F,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,,,80682,9606.0,Intermediate,1,CHEMBL621574,BAO_0000219,,
5801,A549,F,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),1,,,80682,9606.0,Intermediate,1,CHEMBL621575,BAO_0000219,,
5802,A549,F,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),1,,,80682,9606.0,Intermediate,1,CHEMBL621576,BAO_0000219,,
5803,A549,F,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),1,,,80682,9606.0,Intermediate,1,CHEMBL621577,BAO_0000219,,
5804,A549,F,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),1,,,80682,9606.0,Intermediate,1,CHEMBL621578,BAO_0000219,,
5805,A549,F,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),1,,,80682,9606.0,Intermediate,1,CHEMBL621579,BAO_0000219,,
5806,A549,F,646.0,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,1,,,80682,9606.0,Intermediate,1,CHEMBL621580,BAO_0000219,,
5807,,A,,In vivo,Plasma clearance (in vivo) in mongrel dogs was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621581,BAO_0000218,,
5808,,A,,In vivo,Plasma clearance was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621582,BAO_0000218,,
5809,,A,,In vivo,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621583,BAO_0000218,,
5810,,A,,In vivo,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621584,BAO_0000218,,
5811,,A,,In vivo,Tested for plasma clearance in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621585,BAO_0000218,1969.0,
5812,,A,,In vivo,The compound was tested for clearance in dog plasma.,1,,,50588,9615.0,Intermediate,1,CHEMBL621586,BAO_0000218,,
5813,,A,,In vivo,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",1,,,50588,9615.0,Intermediate,1,CHEMBL875835,BAO_0000218,,
5814,,A,,In vivo,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621587,BAO_0000218,,
5815,,A,,In vivo,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621588,BAO_0000218,1969.0,
5816,,A,,In vitro,In vitro clearance in dog liver microsomes,1,,,50588,9615.0,Intermediate,1,CHEMBL621589,BAO_0000218,2107.0,
5817,,A,,In vivo,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621590,BAO_0000218,,
5818,,A,,In vivo,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621591,BAO_0000218,,
5819,,A,,In vivo,Plasma clearance in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621592,BAO_0000218,,
5820,,A,,In vivo,Clearance rate in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621593,BAO_0000218,,
5821,,A,,In vivo,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL621594,BAO_0000218,1969.0,
5822,,A,,In vivo,Clearance in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621595,BAO_0000218,,
5823,,A,,In vivo,Plasma clearance in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621596,BAO_0000218,,
5824,,A,,In vivo,Plasma clearance was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621597,BAO_0000218,,
5825,,A,,In vivo,Lower clearance in dog (i.v.) at 0.5 mpk,1,,,50588,9615.0,Intermediate,1,CHEMBL621598,BAO_0000218,,
5826,,A,,In vivo,Plasma clearance in Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621599,BAO_0000218,,
5827,,A,,In vivo,Plasma clearance (Clp) in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL875836,BAO_0000218,,
5828,,A,,In vivo,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621600,BAO_0000218,,
5829,,A,,In vivo,Plasma clearance (pharmacokinetic parameter) in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621601,BAO_0000218,,
5830,,A,,In vivo,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618474,BAO_0000218,,
5831,,A,,In vivo,Plasma clearance of compound was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618475,BAO_0000218,,
5832,,A,,In vivo,Plasma clearance after intravenous administration of 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624524,BAO_0000218,,
5833,,A,,In vivo,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624525,BAO_0000218,,
5834,,A,,In vivo,Plasma clearance in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624526,BAO_0000218,,
5835,,A,,In vivo,Plasma clearance was calculated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624527,BAO_0000218,,
5836,,A,,In vivo,Plasma clearance at the dose of 2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624528,BAO_0000218,,
5837,,A,,In vivo,Plasma clearance in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624529,BAO_0000218,,
5838,,A,,In vivo,Plasma clearance in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624530,BAO_0000218,,
5839,,A,,In vivo,Plasma clearance in dog; Unable to calculate,1,,,50588,9615.0,Intermediate,1,CHEMBL624531,BAO_0000218,,
5840,,A,,In vivo,Plasma clearance in rhesus monkey,1,,,50588,9615.0,Intermediate,1,CHEMBL624532,BAO_0000218,,
5841,,A,,In vivo,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,50588,9615.0,Intermediate,1,CHEMBL624533,BAO_0000218,,
5842,,A,,In vivo,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,50588,9615.0,Intermediate,1,CHEMBL624534,BAO_0000218,,
5843,,A,,In vivo,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,50588,9615.0,Intermediate,1,CHEMBL624535,BAO_0000218,,
5844,,A,,In vivo,Plasma clearance was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624536,BAO_0000218,,
5845,,A,,In vivo,Plasma clearance was evaluated in dog; Not tested,1,,,50588,9615.0,Intermediate,1,CHEMBL624537,BAO_0000218,,
5846,,A,,In vivo,Plasma clearance was evaluated in rhesus,1,,,50588,9615.0,Intermediate,1,CHEMBL624538,BAO_0000218,,
5847,,A,,In vivo,Plasma clearance was evaluated in rhesus; Not tested,1,,,50588,9615.0,Intermediate,1,CHEMBL624539,BAO_0000218,,
5848,,A,,In vivo,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,1,,,50588,9615.0,Intermediate,1,CHEMBL624540,BAO_0000218,,
5849,,A,,In vivo,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624541,BAO_0000218,,
5850,,A,,In vivo,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624542,BAO_0000218,,
5851,,A,,In vivo,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624543,BAO_0000218,,
5852,,A,,In vivo,Clearance value at a dose of 0.2 mg/kg i.v.,1,,,50588,9615.0,Intermediate,1,CHEMBL624544,BAO_0000218,,
5853,,A,,In vivo,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624545,BAO_0000218,1969.0,
5854,,A,,In vivo,Cmax after oral dose of compound at 3 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624546,BAO_0000218,,
5855,,A,,In vivo,Cmax after single intravenous bolus of 1 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL875957,BAO_0000218,,
5856,,A,,In vivo,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624547,BAO_0000218,,
5857,,A,,In vivo,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624548,BAO_0000218,,
5858,,A,,In vivo,Cmax in dog after administration of 1 mg/kg iv,1,,,50588,9615.0,Intermediate,1,CHEMBL624549,BAO_0000218,,
5859,,A,,In vivo,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624550,BAO_0000218,1969.0,
5860,,A,,In vivo,Cmax on p.o. administration of 10 mg/kg was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621613,BAO_0000218,,
5861,,A,,In vivo,Cmax was determine after peroral administration at 10 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621614,BAO_0000218,,
5862,,A,,In vivo,Cmax was determine after peroral administration at 5 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623431,BAO_0000218,,
5863,,A,,In vivo,Cmax was determine after peroral administration at 5 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623432,BAO_0000218,,
5864,,A,,In vivo,Cmax after 0.3 mg/kg po administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623433,BAO_0000218,,
5865,,A,,In vivo,Cmax after peroral administration in dogs at 2.4 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL623434,BAO_0000218,,
5866,,A,,In vivo,Cmax in dog after oral administration at 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL623435,BAO_0000218,,
5867,,A,,In vivo,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,1,,,50588,9615.0,Intermediate,1,CHEMBL623436,BAO_0000218,,
5868,,A,,In vivo,Cmax upon oral administration in male Beagle dog at 10 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL875958,BAO_0000218,,
5869,,A,,In vivo,Cmax value after 15 mg/kg iv dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL623437,BAO_0000218,,
5870,,A,,In vivo,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623438,BAO_0000218,178.0,
5871,,A,,In vivo,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623439,BAO_0000218,178.0,
5872,,A,,In vivo,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623440,BAO_0000218,10000001.0,
5873,,A,,In vivo,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623441,BAO_0000218,10000001.0,
5874,,A,,In vivo,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623442,BAO_0000218,10000001.0,
5875,,A,,In vivo,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623469,BAO_0000218,,
5876,,A,,In vivo,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623470,BAO_0000218,,
5877,,A,,In vivo,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623471,BAO_0000218,,
5878,,A,,In vivo,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623472,BAO_0000218,948.0,
5879,,A,,In vivo,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623473,BAO_0000218,948.0,
5880,,A,,In vivo,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623474,BAO_0000218,948.0,
5881,,A,,In vivo,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623475,BAO_0000218,2113.0,
5882,,A,,In vivo,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623476,BAO_0000218,2113.0,
5883,,A,,In vivo,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL623477,BAO_0000218,2113.0,
5884,,A,,In vivo,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL621896,BAO_0000218,160.0,
5885,,A,,In vivo,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL621897,BAO_0000218,160.0,
5886,,A,,In vivo,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL621898,BAO_0000218,160.0,
5887,,A,,In vivo,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL621899,BAO_0000218,2107.0,
5888,,A,,In vivo,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL621900,BAO_0000218,2107.0,
5889,,A,,In vivo,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL621901,BAO_0000218,2107.0,
5890,,A,,In vivo,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL621902,BAO_0000218,2048.0,
5891,,A,,In vivo,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL621903,BAO_0000218,2048.0,
5892,,A,,In vivo,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL622587,BAO_0000218,2048.0,
5893,,A,,In vivo,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620285,BAO_0000218,2385.0,
5894,,A,,In vivo,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL875285,BAO_0000218,2385.0,
5895,,A,,In vivo,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620286,BAO_0000218,2385.0,
5896,,A,,In vivo,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620287,BAO_0000218,,
5897,,A,,In vivo,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620288,BAO_0000218,,
5898,,A,,In vivo,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620289,BAO_0000218,,
5899,,A,,In vivo,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620290,BAO_0000218,160.0,
5900,,A,,In vivo,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620291,BAO_0000218,160.0,
5901,,A,,In vivo,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620292,BAO_0000218,160.0,
5902,,A,,In vivo,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620293,BAO_0000218,2106.0,
5903,,A,,In vivo,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL620294,BAO_0000218,2106.0,
5904,,A,,In vivo,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL618614,BAO_0000218,2106.0,
5905,,A,,In vivo,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL618615,BAO_0000218,945.0,
5906,,A,,In vivo,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL618616,BAO_0000218,945.0,
5907,A 172,F,622.0,,Cytotoxicity against A-172 human tumor cell lines,1,,,80012,9606.0,Expert,1,CHEMBL618617,BAO_0000219,,
5908,A 172,F,622.0,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,1,,,80012,9606.0,Intermediate,1,CHEMBL618618,BAO_0000219,,
5909,A204,F,623.0,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,1,,,80014,9606.0,Intermediate,1,CHEMBL618619,BAO_0000219,,
5910,A2780,F,478.0,,Tested for antiproliferative activity against A-2780 tumoral cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL618620,BAO_0000219,,
5911,A-375,F,455.0,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,1,,,80018,9606.0,Intermediate,1,CHEMBL618621,BAO_0000219,,
5912,A-375,F,455.0,,Tested in vitro against A-375 cell line human melanoma,1,,,80018,9606.0,Intermediate,1,CHEMBL618622,BAO_0000219,,
5913,A-427,F,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,1,,,80019,9606.0,Expert,1,CHEMBL618623,BAO_0000219,,
5914,A-427,F,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,,80019,9606.0,Intermediate,1,CHEMBL618624,BAO_0000219,,
5915,A-427,F,797.0,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,1,,,80019,9606.0,Expert,1,CHEMBL618625,BAO_0000219,,
5916,A-427,F,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,,,80019,9606.0,Intermediate,1,CHEMBL618626,BAO_0000219,,
5917,A-427,F,797.0,,Antitumor activity on A-427 lung carcinoma cell lines,1,,,80019,9606.0,Intermediate,1,CHEMBL618627,BAO_0000219,,
5918,A-427,F,797.0,,Cytotoxic activity against human A-427 lung tumor cell line,1,,,80019,9606.0,Intermediate,1,CHEMBL618628,BAO_0000219,,
5919,A-427,F,797.0,,In vitro antitumor effects against human A-427 cell lines.,1,,,80019,9606.0,Expert,1,CHEMBL618629,BAO_0000219,,
5920,A-427,F,797.0,,In vitro inhibition of A-427 (human lung cancer) cell growth.,1,,,80019,9606.0,Expert,1,CHEMBL618630,BAO_0000219,,
5921,A-427,F,797.0,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,1,,,80019,9606.0,Intermediate,1,CHEMBL618631,BAO_0000219,,
5922,A-427,F,797.0,,Cytotoxic activity of compound against A-427 lung human tumor cell line,1,,,80019,9606.0,Intermediate,1,CHEMBL618632,BAO_0000219,,
5923,A-431,F,500.0,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,1,,,80852,9606.0,Expert,1,CHEMBL618633,BAO_0000219,,
5924,A498,F,624.0,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL619315,BAO_0000219,,
5925,A498,F,624.0,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,1,,,80021,9606.0,Expert,1,CHEMBL619316,BAO_0000219,,
5926,A498,F,624.0,,Cytotoxicity against human kidney carcinoma A-498cell lines,1,,,80021,9606.0,Intermediate,1,CHEMBL619317,BAO_0000219,,
5927,A498,F,624.0,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,1,,,80021,9606.0,Intermediate,1,CHEMBL619318,BAO_0000219,,
5928,A498,F,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,1,,,80021,9606.0,Intermediate,1,CHEMBL619319,BAO_0000219,,
5929,A498,F,624.0,,Antitumor cytotoxic activity against A-498 cell line was determined,1,,,80021,9606.0,Intermediate,1,CHEMBL619739,BAO_0000219,,
5930,A498,F,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,1,,,80021,9606.0,Intermediate,1,CHEMBL619740,BAO_0000219,,
5931,A498,F,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,1,,,80021,9606.0,Intermediate,1,CHEMBL883158,BAO_0000219,,
5932,A498,F,624.0,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,1,,,80021,9606.0,Intermediate,1,CHEMBL884012,BAO_0000219,,
5933,A498,F,624.0,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,1,,,80021,9606.0,Intermediate,1,CHEMBL619741,BAO_0000219,,
5934,A498,F,624.0,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",1,,,80021,9606.0,Intermediate,1,CHEMBL619742,BAO_0000219,,
5935,A549,F,646.0,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL876610,BAO_0000219,,
5936,A549,F,646.0,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619743,BAO_0000219,,
5937,A549,F,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619744,BAO_0000219,,
5938,A549,F,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,1,,,80682,9606.0,Intermediate,1,CHEMBL619745,BAO_0000219,,
5939,A549,F,646.0,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL619746,BAO_0000219,,
5940,A549,F,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL619747,BAO_0000219,,
5941,A549,F,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,1,,,80682,9606.0,Intermediate,1,CHEMBL619748,BAO_0000219,,
5942,A549,F,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL619749,BAO_0000219,,
5943,A549,F,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,1,,,80682,9606.0,Intermediate,1,CHEMBL619750,BAO_0000219,,
5944,A549,F,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,1,,,80682,9606.0,Intermediate,1,CHEMBL624014,BAO_0000219,,
5945,A549,F,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,1,,,80682,9606.0,Intermediate,1,CHEMBL624015,BAO_0000219,,
5946,A549,F,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,1,,,80682,9606.0,Expert,1,CHEMBL885344,BAO_0000219,,
5947,A549,F,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,1,,,80682,9606.0,Intermediate,1,CHEMBL623224,BAO_0000219,,
5948,A549,F,646.0,,Cytotoxic activity against A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL623225,BAO_0000219,,
5949,A549,F,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,1,,,80682,9606.0,Intermediate,1,CHEMBL622698,BAO_0000219,,
5950,A549,F,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,1,,,80682,9606.0,Intermediate,1,CHEMBL622699,BAO_0000219,,
5951,A549,F,646.0,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",1,,,80682,9606.0,Expert,1,CHEMBL622700,BAO_0000219,,
5952,A549,F,646.0,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),1,,,80682,9606.0,Intermediate,1,CHEMBL622701,BAO_0000219,,
5953,A549,F,646.0,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),1,,,80682,9606.0,Intermediate,1,CHEMBL622702,BAO_0000219,,
5954,A549,F,646.0,,Cytotoxic activity against human lung carcinoma (A-549) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL622703,BAO_0000219,,
5955,A549,F,646.0,,Cytotoxic activity towards A-549 cells,1,,,80682,9606.0,Expert,1,CHEMBL622704,BAO_0000219,,
5956,A549,F,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",1,,,80682,9606.0,Intermediate,1,CHEMBL622705,BAO_0000219,,
5957,A549,F,646.0,,"In vitro percent inhibition of A549, lung carcinoma",1,,,80682,9606.0,Intermediate,1,CHEMBL622706,BAO_0000219,,
5958,A549,F,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",1,,,80682,9606.0,Intermediate,1,CHEMBL622707,BAO_0000219,,
5959,A549,F,646.0,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",1,,,80682,9606.0,Intermediate,1,CHEMBL622708,BAO_0000219,,
5960,A549,F,646.0,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,1,,,80682,9606.0,Intermediate,1,CHEMBL622709,BAO_0000219,,
5961,A549,F,646.0,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,1,,,80682,9606.0,Intermediate,1,CHEMBL622710,BAO_0000219,,
5962,A549,F,646.0,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,1,,,80682,9606.0,Intermediate,1,CHEMBL622711,BAO_0000219,,
5963,A549,F,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,,80682,9606.0,Intermediate,1,CHEMBL622712,BAO_0000218,,
5964,A549,F,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,,80682,9606.0,Intermediate,1,CHEMBL622713,BAO_0000218,,
5965,A549,F,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,,80682,9606.0,Intermediate,1,CHEMBL622714,BAO_0000218,,
5966,A549,F,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,,80682,9606.0,Intermediate,1,CHEMBL622715,BAO_0000218,,
5967,A549,F,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,,,80682,9606.0,Intermediate,1,CHEMBL622716,BAO_0000218,,
5968,A549,F,646.0,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",1,,,80682,9606.0,Intermediate,1,CHEMBL622717,BAO_0000219,,
5969,A549,F,646.0,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),1,,,80682,9606.0,Intermediate,1,CHEMBL622718,BAO_0000218,,
5970,A549,F,646.0,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,1,,,80682,9606.0,Expert,1,CHEMBL622719,BAO_0000219,,
5971,A549,F,646.0,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,,,80682,9606.0,Intermediate,1,CHEMBL622720,BAO_0000219,,
5972,A549,F,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,1,,,80682,9606.0,Intermediate,1,CHEMBL622721,BAO_0000219,,
5973,A549,F,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,,,80682,9606.0,Intermediate,1,CHEMBL622722,BAO_0000219,,
5974,A549,F,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,,,80682,9606.0,Intermediate,1,CHEMBL876030,BAO_0000219,,
5975,A549,F,646.0,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",1,,,80682,9606.0,Intermediate,1,CHEMBL620206,BAO_0000219,,
5976,A549,F,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL620207,BAO_0000219,,
5977,A549,F,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL620208,BAO_0000219,,
5978,A549,F,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL620209,BAO_0000219,,
5979,A549,F,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL620210,BAO_0000219,,
5980,A549,F,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL621639,BAO_0000219,,
5981,A549,F,646.0,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621640,BAO_0000219,,
5982,A549,F,646.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,,,80682,9606.0,Expert,1,CHEMBL621641,BAO_0000219,,
5983,A549,F,646.0,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,1,,,80682,9606.0,Expert,1,CHEMBL621642,BAO_0000219,,
5984,A549,F,646.0,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621643,BAO_0000219,,
5985,A549,F,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL621644,BAO_0000219,,
5986,A549,F,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,1,,,80682,9606.0,Intermediate,1,CHEMBL621645,BAO_0000219,,
5987,A549,F,646.0,,In vitro antiproliferative activity against A549 cell line,1,,,80682,10090.0,Intermediate,1,CHEMBL621646,BAO_0000219,,
5988,A549,F,646.0,,Synergism with indomethacin in A549 cells,1,,,80682,,Intermediate,1,CHEMBL621647,BAO_0000219,,
5989,A549,F,646.0,,Synergism with tolmetin in A549 cells,1,,,80682,,Intermediate,1,CHEMBL621648,BAO_0000219,,
5990,A549,F,646.0,,Synergism with sulindac in A549 cells,1,,,80682,,Intermediate,1,CHEMBL621649,BAO_0000219,,
5991,A549,F,646.0,,Antagonism of indomethacin in A549 cells,1,,,80682,,Intermediate,1,CHEMBL621650,BAO_0000219,,
5992,A549,F,646.0,,Antagonism of sulindac in A549 cells,1,,,80682,,Intermediate,1,CHEMBL621651,BAO_0000219,,
5993,A549,F,646.0,,Antagonism of tolmetin in A549 cells,1,,,80682,,Intermediate,1,CHEMBL621652,BAO_0000219,,
5994,A549,F,646.0,,Synergism with indomethacin in A549 cells,1,,,80682,,Intermediate,1,CHEMBL621653,BAO_0000219,,
5995,A549,F,646.0,,Synergism with sulindac in A549 cells,1,,,80682,,Intermediate,1,CHEMBL621654,BAO_0000219,,
5996,A549,F,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,1,,,80682,,Intermediate,1,CHEMBL621655,BAO_0000219,,
5997,,A,,In vivo,Cmax value after 30 mg/kg po dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621656,BAO_0000218,,
5998,,A,,In vivo,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621657,BAO_0000218,,
5999,,A,,In vivo,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621658,BAO_0000218,,
6000,,A,,In vivo,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621659,BAO_0000218,,
6001,,A,,In vivo,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621660,BAO_0000218,,
6002,,A,,In vivo,Cmax value after administration of 4 mg/Kg oral dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621661,BAO_0000218,,
6003,,A,,In vivo,Cmax value in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621662,BAO_0000218,,
6004,,A,,In vivo,Cmax value in dogs after oral administration at 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621663,BAO_0000218,,
6005,,A,,In vivo,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL621664,BAO_0000218,,
6006,,A,,In vivo,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621665,BAO_0000218,1969.0,
6007,,A,,In vivo,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621666,BAO_0000218,1969.0,
6008,,A,,In vivo,Concentration maxima after oral dosing in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621667,BAO_0000218,,
6009,,A,,In vivo,Concentration maxima after oral dosing in dogs; not available,1,,,50588,9615.0,Intermediate,1,CHEMBL876738,BAO_0000218,,
6010,,A,,In vivo,Concentration maxima after oral dosing in dogs; not available,1,,,50588,9615.0,Intermediate,1,CHEMBL621668,BAO_0000218,,
6011,,A,,In vivo,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,1,,,50588,9615.0,Intermediate,1,CHEMBL621669,BAO_0000218,,
6012,,A,,In vivo,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,1,,,50588,9615.0,Intermediate,1,CHEMBL621670,BAO_0000218,,
6013,,A,,In vivo,In vivo maximal concentration was calculated at 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621671,BAO_0000218,,
6014,,A,,In vivo,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,1,,,50588,9615.0,Intermediate,1,CHEMBL622360,BAO_0000218,,
6015,,A,,In vivo,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,1,,,50588,9615.0,Intermediate,1,CHEMBL622361,BAO_0000218,,
6016,,A,,In vivo,Cmax in dog plasma after oral dose (1 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL622362,BAO_0000218,1969.0,
6017,,A,,In vivo,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622363,BAO_0000218,1969.0,
6018,,A,,In vivo,Maximal plasma concentration at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622364,BAO_0000218,1969.0,
6019,,A,,In vivo,Maximal plasma concentration at a dose of 1 mg/kg (oral),1,,,50588,9615.0,Intermediate,1,CHEMBL622365,BAO_0000218,1969.0,
6020,,A,,In vivo,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,1,,,50588,9615.0,Intermediate,1,CHEMBL622533,BAO_0000218,1969.0,
6021,,A,,In vivo,Maximum concentration of compound in dog was evaluated.,1,,,50588,9615.0,Intermediate,1,CHEMBL622534,BAO_0000218,,
6022,,A,,In vivo,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622535,BAO_0000218,,
6023,,A,,In vivo,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,1,,,50588,9615.0,Intermediate,1,CHEMBL876739,BAO_0000218,,
6024,,A,,In vivo,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL622536,BAO_0000218,,
6025,,A,,In vivo,Maximum concentration obtained in dog plasma was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622537,BAO_0000218,1969.0,
6026,,A,,In vivo,Maximum concentration was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622538,BAO_0000218,,
6027,,A,,In vivo,Maximum concentration at the dose of 2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL627867,BAO_0000218,,
6028,,A,,In vivo,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,50588,9615.0,Intermediate,1,CHEMBL627868,BAO_0000218,,
6029,,A,,In vivo,Maximum concentration was evaluated in dog plasma,1,,,50588,9615.0,Intermediate,1,CHEMBL627869,BAO_0000218,1969.0,
6030,,A,,In vivo,Maximum concentration was evaluated after 75 min after administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL627870,BAO_0000218,,
6031,,A,,In vivo,Maximum plasma concentration determined in dog after oral administration of 17b,1,,,50588,9615.0,Intermediate,1,CHEMBL627871,BAO_0000218,1969.0,
6032,,A,,In vivo,Maximum plasma concentration determined in dog after oral administration of 2b,1,,,50588,9615.0,Intermediate,1,CHEMBL627872,BAO_0000218,1969.0,
6033,,A,,In vivo,Maximum plasma concentration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL627873,BAO_0000218,1969.0,
6034,,A,,In vivo,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL627874,BAO_0000218,1969.0,
6035,,A,,In vivo,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL627875,BAO_0000218,1969.0,
6036,,A,,In vivo,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL627876,BAO_0000218,1969.0,
6037,,A,,In vivo,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL627877,BAO_0000218,1969.0,
6038,,A,,In vivo,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,50588,9615.0,Intermediate,1,CHEMBL627878,BAO_0000218,1969.0,
6039,,A,,In vivo,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL627879,BAO_0000218,1969.0,
6040,,A,,In vivo,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,,50588,9615.0,Intermediate,1,CHEMBL875355,BAO_0000218,1969.0,
6041,,A,,In vivo,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,,50588,9615.0,Intermediate,1,CHEMBL627880,BAO_0000218,1969.0,
6042,,A,,In vivo,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,,,50588,9615.0,Intermediate,1,CHEMBL627881,BAO_0000218,1969.0,
6043,,A,,In vivo,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL627882,BAO_0000218,1969.0,
6044,,A,,In vivo,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,,,50588,9615.0,Intermediate,1,CHEMBL627883,BAO_0000218,1969.0,
6045,,A,,In vivo,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,1,,,50588,9615.0,Intermediate,1,CHEMBL628526,BAO_0000218,1969.0,
6046,,A,,In vivo,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,1,,,50588,9615.0,Intermediate,1,CHEMBL628527,BAO_0000218,1969.0,
6047,,A,,In vivo,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL628528,BAO_0000218,1969.0,
6048,,A,,In vivo,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL628529,BAO_0000218,1969.0,
6049,,A,,In vivo,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL628530,BAO_0000218,1969.0,
6050,,A,,In vivo,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625243,BAO_0000218,1969.0,
6051,,A,,In vivo,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,50588,9615.0,Expert,1,CHEMBL625244,BAO_0000218,1969.0,
6052,,A,,In vivo,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625245,BAO_0000218,,
6053,,A,,In vivo,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625246,BAO_0000218,,
6054,,A,,In vivo,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL625247,BAO_0000218,945.0,
6055,,A,,In vivo,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,,50594,10090.0,Intermediate,1,CHEMBL625248,BAO_0000218,1088.0,
6056,,A,,In vivo,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,1,,,50594,10090.0,Intermediate,1,CHEMBL625249,BAO_0000218,1088.0,
6057,,A,,In vivo,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,1,,,50594,10090.0,Intermediate,1,CHEMBL625250,BAO_0000218,1088.0,
6058,,A,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,1,,,50594,10090.0,Intermediate,1,CHEMBL625251,BAO_0000218,,
6059,,A,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,1,,,50594,10090.0,Intermediate,1,CHEMBL875356,BAO_0000218,,
6060,,A,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL625252,BAO_0000218,,
6061,,A,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL625253,BAO_0000218,178.0,
6062,,A,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL625254,BAO_0000218,,
6063,,A,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL625255,BAO_0000218,,
6064,,A,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL625256,BAO_0000218,,
6065,,A,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL625257,BAO_0000218,178.0,
6066,,A,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL625258,BAO_0000218,178.0,
6067,,A,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL625259,BAO_0000218,,
6068,,A,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,1,,,50594,10090.0,Intermediate,1,CHEMBL625260,BAO_0000218,,
6069,,A,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,,50594,10090.0,Intermediate,1,CHEMBL625261,BAO_0000218,,
6070,,A,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,,50594,10090.0,Intermediate,1,CHEMBL625262,BAO_0000218,,
6071,,A,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,,50594,10090.0,Intermediate,1,CHEMBL622639,BAO_0000218,,
6072,,A,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622640,BAO_0000218,,
6073,,A,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,1,,,50594,10090.0,Intermediate,1,CHEMBL622812,BAO_0000218,,
6074,,A,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622813,BAO_0000218,,
6075,,A,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL622814,BAO_0000218,,
6076,,A,,,Time at maximum activity in mice (Radiolabeled compound),1,,,50594,10090.0,Intermediate,1,CHEMBL622815,BAO_0000218,,
6077,,A,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL625342,BAO_0000218,,
6078,,A,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL625343,BAO_0000218,,
6079,,A,,,Binding towards mouse plasma protein at 10 uM,1,,,50594,10090.0,Intermediate,1,CHEMBL877591,BAO_0000218,,
6080,,A,,,Binding towards mouse plasma protein at 100 uM,1,,,50594,10090.0,Intermediate,1,CHEMBL625344,BAO_0000218,,
6081,,A,,In vivo,Bioavailability was evaluated in mice after intravenous administration,1,,,50594,10090.0,Intermediate,1,CHEMBL625345,BAO_0000218,,
6082,,A,,In vivo,Bioavailability was evaluated in mice after oral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL625346,BAO_0000218,,
6083,,A,,In vivo,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL625347,BAO_0000218,,
6084,,A,,In vivo,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL625348,BAO_0000218,,
6085,,A,,In vivo,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL625349,BAO_0000218,,
6086,,A,,In vivo,Oral bioavailability in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL625350,BAO_0000218,,
6087,,A,,In vivo,Oral bioavailability after intravenous administration in mice at 24 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL882952,BAO_0000218,,
6088,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL625351,BAO_0000218,955.0,
6089,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL625352,BAO_0000218,955.0,
6090,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL877592,BAO_0000218,955.0,
6091,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL625353,BAO_0000218,955.0,
6092,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL625354,BAO_0000218,955.0,
6093,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL626019,BAO_0000218,955.0,
6094,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL626020,BAO_0000218,948.0,
6095,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL626021,BAO_0000218,948.0,
6096,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL626022,BAO_0000218,948.0,
6097,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL626192,BAO_0000218,948.0,
6098,A549,F,646.0,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),1,,,80682,9606.0,Intermediate,1,CHEMBL626193,BAO_0000219,,
6099,A549,F,646.0,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,1,,,80682,9606.0,Expert,1,CHEMBL626194,BAO_0000219,,
6100,A549,F,646.0,,Cytotoxicity against human lung carcinoma A-549 cell lines,1,,,80682,9606.0,Intermediate,1,CHEMBL626195,BAO_0000219,,
6101,A549,F,646.0,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL626196,BAO_0000219,,
6102,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549,1,,,80682,9606.0,Intermediate,1,CHEMBL626197,BAO_0000219,,
6103,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,1,,,80682,9606.0,Intermediate,1,CHEMBL626198,BAO_0000219,,
6104,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,1,,,80682,9606.0,Intermediate,1,CHEMBL626199,BAO_0000219,,
6105,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,1,,,80682,9606.0,Intermediate,1,CHEMBL626200,BAO_0000219,,
6106,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,1,,,80682,9606.0,Intermediate,1,CHEMBL626201,BAO_0000219,,
6107,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,1,,,80682,9606.0,Intermediate,1,CHEMBL626202,BAO_0000219,,
6108,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,1,,,80682,9606.0,Intermediate,1,CHEMBL626203,BAO_0000219,,
6109,A549,F,646.0,,In vitro cytotoxicity against A-549 human lung cancer cells,1,,,80682,9606.0,Intermediate,1,CHEMBL626204,BAO_0000219,,
6110,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL624701,BAO_0000219,,
6111,A549,F,646.0,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,1,,,80682,9606.0,Intermediate,1,CHEMBL624702,BAO_0000219,,
6112,A549,F,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,,,80682,9606.0,Expert,1,CHEMBL624703,BAO_0000219,,
6113,A549,F,646.0,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,1,,,80682,9606.0,Intermediate,1,CHEMBL624704,BAO_0000219,,
6114,A549,F,646.0,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,1,,,80682,9606.0,Intermediate,1,CHEMBL624705,BAO_0000219,,
6115,A549,F,646.0,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,1,,,80682,9606.0,Expert,1,CHEMBL624706,BAO_0000219,,
6116,A549,F,646.0,,Antitumor cytotoxic activity against A-549 cell line was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL624707,BAO_0000219,,
6117,A549,F,646.0,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",1,,,80682,9606.0,Intermediate,1,CHEMBL624708,BAO_0000219,,
6118,A549,F,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL624709,BAO_0000219,,
6119,A549,F,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL884107,BAO_0000219,,
6120,A549,F,646.0,,Antitumoral activity was assayed against A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL624710,BAO_0000219,,
6121,A549,F,646.0,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,1,,,80682,9606.0,Intermediate,1,CHEMBL624711,BAO_0000219,,
6122,A549,F,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL624712,BAO_0000219,,
6123,A549,F,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL624713,BAO_0000219,,
6124,A549,F,646.0,,Compound was tested for inhibition of cell growth of A-549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL624714,BAO_0000219,,
6125,A549,F,646.0,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,1,,,80682,9606.0,Intermediate,1,CHEMBL624715,BAO_0000219,,
6126,A549,F,646.0,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL624716,BAO_0000219,,
6127,A549,F,646.0,,In vitro cytotoxicity against A549-human lung carcinoma cells.,1,,,80682,9606.0,Expert,1,CHEMBL619505,BAO_0000219,,
6128,A549,F,646.0,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,1,,,80682,9606.0,Expert,1,CHEMBL619506,BAO_0000219,,
6129,A549,F,646.0,,Cytotoxic activity against A-549 cell lines.,1,,,80682,9606.0,Intermediate,1,CHEMBL619507,BAO_0000219,,
6130,A549,F,646.0,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,1,,,80682,9606.0,Expert,1,CHEMBL619508,BAO_0000219,,
6131,A549,F,646.0,,Cytotoxicity against human A549 non small cell lung cell lines,1,,,80682,9606.0,Intermediate,1,CHEMBL619509,BAO_0000219,,
6132,A549,F,646.0,,Inhibition of cell growth in (A-549) lung cell line,1,,,80682,9606.0,Expert,1,CHEMBL619510,BAO_0000219,,
6133,A549,F,646.0,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619511,BAO_0000219,,
6134,A549,F,646.0,,In vitro antitumor activity against A-549 tumor cells.,1,,,80682,9606.0,Intermediate,1,CHEMBL619512,BAO_0000219,,
6135,A549,F,646.0,,In vitro antitumor effects against human A-549 cell lines.,1,,,80682,9606.0,Expert,1,CHEMBL619513,BAO_0000219,,
6136,A549,F,646.0,,In vitro cytotoxic activity of compound against A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619514,BAO_0000219,,
6137,A549,F,646.0,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619515,BAO_0000219,,
6138,A549,F,646.0,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,1,,,80682,9606.0,Intermediate,1,CHEMBL619516,BAO_0000219,,
6139,A549,F,646.0,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,1,,,80682,9606.0,Intermediate,1,CHEMBL884005,BAO_0000219,,
6140,A549,F,646.0,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,1,,,80682,9606.0,Expert,1,CHEMBL619517,BAO_0000219,,
6141,A549,F,646.0,,Inhibitory concentration of compound against A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619518,BAO_0000219,,
6142,A549,F,646.0,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619519,BAO_0000219,,
6143,A549,F,646.0,,cytotoxic activity against leukemia (A-549) cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL876489,BAO_0000219,,
6144,A549,F,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,,,80682,9606.0,Expert,1,CHEMBL619520,BAO_0000219,,
6145,A549,F,646.0,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619521,BAO_0000219,,
6146,A549,F,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),1,,,80682,9606.0,Intermediate,1,CHEMBL619522,BAO_0000219,,
6147,A549,F,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),1,,,80682,9606.0,Intermediate,1,CHEMBL619523,BAO_0000219,,
6148,A549,F,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),1,,,80682,9606.0,Intermediate,1,CHEMBL619524,BAO_0000219,,
6149,A549,F,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),1,,,80682,9606.0,Intermediate,1,CHEMBL619525,BAO_0000219,,
6150,A549,F,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,1,,,80682,,Intermediate,1,CHEMBL619526,BAO_0000219,,
6151,A549,F,646.0,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,1,,,80682,9606.0,Intermediate,1,CHEMBL619527,BAO_0000219,,
6152,A549,F,646.0,,Cytotoxicity against A549 cells; No cytotoxicity,1,,,80682,9606.0,Intermediate,1,CHEMBL619528,BAO_0000219,,
6153,A549,F,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines,1,,,80682,9606.0,Expert,1,CHEMBL619529,BAO_0000219,,
6154,A549,F,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,1,,,80682,9606.0,Expert,1,CHEMBL619530,BAO_0000219,,
6155,A549,F,646.0,,In vitro anticancer activity against human lung (A549) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL876490,BAO_0000219,,
6156,A549,F,646.0,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619531,BAO_0000219,,
6157,A549,F,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619532,BAO_0000219,,
6158,A549,F,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619533,BAO_0000219,,
6159,A549,F,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619534,BAO_0000219,,
6160,A549,F,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL620164,BAO_0000219,,
6161,A549,F,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL620165,BAO_0000219,,
6162,A549,F,646.0,,Inhibition of A549 human lung tumor cell proliferation,1,,,80682,9606.0,Expert,1,CHEMBL620166,BAO_0000219,,
6163,A549,F,646.0,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",1,,,80682,9606.0,Intermediate,1,CHEMBL620167,BAO_0000219,,
6164,A549,F,646.0,,In vitro cytotoxicity against human tumor cell line A549,1,,,80682,9606.0,Expert,1,CHEMBL620168,BAO_0000219,,
6165,A549,F,646.0,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,1,,,80682,9606.0,Intermediate,1,CHEMBL620338,BAO_0000219,,
6166,A549,F,646.0,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620339,BAO_0000219,,
6167,A549,F,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL620340,BAO_0000219,,
6168,A549,F,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL620341,BAO_0000219,,
6169,A549,F,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,1,,,80682,9606.0,Intermediate,1,CHEMBL876491,BAO_0000219,,
6170,A549,F,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,,,80682,9606.0,Intermediate,1,CHEMBL620342,BAO_0000219,,
6171,A549,F,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,,,80682,9606.0,Intermediate,1,CHEMBL620343,BAO_0000219,,
6172,A549,F,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,,,80682,9606.0,Intermediate,1,CHEMBL620344,BAO_0000219,,
6173,A549,F,646.0,,In vitro anticancer activity against human lung (A549) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620345,BAO_0000219,,
6174,A549,F,646.0,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL620346,BAO_0000219,,
6175,A549,F,646.0,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL620347,BAO_0000219,,
6176,A549,F,646.0,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL620348,BAO_0000219,,
6177,A549,F,646.0,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,1,,,80682,9606.0,Intermediate,1,CHEMBL620349,BAO_0000219,,
6178,A549,F,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,1,,,80682,9606.0,Intermediate,1,CHEMBL618667,BAO_0000219,,
6179,A549,F,646.0,,Percentage inhibition of human lung carcinoma (A549) cell lines,1,,,80682,9606.0,Expert,1,CHEMBL618668,BAO_0000219,,
6180,A549,F,646.0,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,1,,,80682,9606.0,Intermediate,1,CHEMBL876031,BAO_0000219,,
6181,A549,F,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",1,,,80682,9606.0,Intermediate,1,CHEMBL618759,BAO_0000219,,
6182,A549,F,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,,,80682,9606.0,Intermediate,1,CHEMBL618760,BAO_0000219,,
6183,A549,F,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,,,80682,9606.0,Intermediate,1,CHEMBL619000,BAO_0000219,,
6184,A549,F,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",1,,,80682,9606.0,Intermediate,1,CHEMBL619001,BAO_0000219,,
6185,A549,F,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",1,,,80682,9606.0,Intermediate,1,CHEMBL619002,BAO_0000219,,
6186,A549,F,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",1,,,80682,9606.0,Intermediate,1,CHEMBL619003,BAO_0000219,,
6187,A549,F,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",1,,,80682,9606.0,Intermediate,1,CHEMBL619597,BAO_0000219,,
6188,A549,F,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",1,,,80682,9606.0,Intermediate,1,CHEMBL619598,BAO_0000219,,
6189,A549,F,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619599,BAO_0000219,,
6190,A549,F,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619600,BAO_0000219,,
6191,A549,F,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,,,80682,9606.0,Intermediate,1,CHEMBL619601,BAO_0000219,,
6192,A549,F,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619602,BAO_0000219,,
6193,A549,F,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619603,BAO_0000219,,
6194,A549,F,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619604,BAO_0000219,,
6195,A549,F,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619605,BAO_0000219,,
6196,,A,,In vivo,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619606,BAO_0000218,,
6197,,A,,In vivo,Pharmacokinetic activity (Cmax) in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL876032,BAO_0000218,,
6198,,A,,In vivo,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL619607,BAO_0000218,,
6199,,A,,In vivo,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL619608,BAO_0000218,,
6200,,A,,In vivo,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL619609,BAO_0000218,,
6201,,A,,In vivo,Cmax in dog plasma after 30mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL619610,BAO_0000218,1969.0,
6202,,A,,In vivo,Tested for the peak blood level in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619611,BAO_0000218,178.0,
6203,,A,,In vivo,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",1,,,50588,9615.0,Intermediate,1,CHEMBL619612,BAO_0000218,,
6204,,A,,In vivo,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",1,,,50588,9615.0,Intermediate,1,CHEMBL619613,BAO_0000218,,
6205,,A,,In vivo,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL619614,BAO_0000218,178.0,
6206,,A,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619615,BAO_0000218,,
6207,,A,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,1,,,50588,9615.0,Intermediate,1,CHEMBL619616,BAO_0000218,,
6208,,A,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL619617,BAO_0000218,1969.0,
6209,,A,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,1,,,50588,9615.0,Intermediate,1,CHEMBL619618,BAO_0000218,,
6210,,A,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,1,,,50588,9615.0,Intermediate,1,CHEMBL876033,BAO_0000218,,
6211,,A,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,1,,,50588,9615.0,Intermediate,1,CHEMBL619619,BAO_0000218,,
6212,,A,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL619620,BAO_0000218,,
6213,,A,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL619621,BAO_0000218,1088.0,
6214,,A,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,1,,,50588,9615.0,Intermediate,1,CHEMBL619622,BAO_0000218,1088.0,
6215,,A,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,1,,,50588,9615.0,Intermediate,1,CHEMBL618874,BAO_0000218,1088.0,
6216,,A,,In vivo,Absolute bioavailability was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618875,BAO_0000218,,
6217,,A,,In vivo,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL618876,BAO_0000218,,
6218,,A,,In vivo,Bioavailability after peroral administration (1 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618877,BAO_0000218,,
6219,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618878,BAO_0000218,,
6220,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618879,BAO_0000218,,
6221,,A,,In vivo,Bioavailability after intravenous administration in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618880,BAO_0000218,,
6222,,A,,In vivo,Bioavailability after peroral administration in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618881,BAO_0000218,,
6223,,A,,In vivo,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL618882,BAO_0000218,,
6224,,A,,In vivo,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,1,,,50588,9615.0,Intermediate,1,CHEMBL624226,BAO_0000218,,
6225,,A,,In vivo,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624227,BAO_0000218,1969.0,
6226,,A,,In vivo,Bioavailability,1,,,50588,9615.0,Intermediate,1,CHEMBL624228,BAO_0000218,,
6227,,A,,In vivo,Bioavailability,1,,,50588,9615.0,Intermediate,1,CHEMBL624229,BAO_0000218,,
6228,,A,,In vivo,Bioavailability by intravenous administration of 1.2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624230,BAO_0000218,,
6229,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624231,BAO_0000218,,
6230,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624232,BAO_0000218,,
6231,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625127,BAO_0000218,,
6232,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625128,BAO_0000218,,
6233,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621675,BAO_0000218,,
6234,,A,,In vivo,Bioavailability in dog (p.o.) at 2.0 mpk,1,,,50588,9615.0,Intermediate,1,CHEMBL621676,BAO_0000218,,
6235,,A,,In vivo,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL621677,BAO_0000218,,
6236,,A,,In vivo,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621678,BAO_0000218,,
6237,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621679,BAO_0000218,,
6238,,A,,In vivo,Bioavailability was evaluated after oral administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621680,BAO_0000218,,
6239,,A,,In vivo,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621681,BAO_0000218,,
6240,,A,,In vivo,Bioavailability was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL876740,BAO_0000218,,
6241,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621682,BAO_0000218,,
6242,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621683,BAO_0000218,,
6243,,A,,In vivo,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,,,50588,9615.0,Intermediate,1,CHEMBL621684,BAO_0000218,,
6244,,A,,In vivo,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,,,50588,9615.0,Intermediate,1,CHEMBL621685,BAO_0000218,,
6245,,A,,In vivo,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621686,BAO_0000218,,
6246,,A,,In vivo,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621687,BAO_0000218,,
6247,,A,,In vivo,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621688,BAO_0000218,,
6248,,A,,In vivo,Bioavailability of compound in dog was determined after peroral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621689,BAO_0000218,,
6249,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621690,BAO_0000218,,
6250,,A,,In vivo,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621691,BAO_0000218,,
6251,,A,,In vivo,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL875941,BAO_0000218,,
6252,,A,,In vivo,Compound was evaluated for oral bioavailability in dogs; 37-38 %,1,,,50588,9615.0,Intermediate,1,CHEMBL621692,BAO_0000218,,
6253,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621693,BAO_0000218,,
6254,,A,,In vivo,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL621694,BAO_0000218,,
6255,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL621695,BAO_0000218,948.0,
6256,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL621696,BAO_0000218,948.0,
6257,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL621697,BAO_0000218,2113.0,
6258,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL621698,BAO_0000218,2113.0,
6259,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623420,BAO_0000218,2113.0,
6260,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623421,BAO_0000218,2113.0,
6261,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623422,BAO_0000218,2113.0,
6262,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623423,BAO_0000218,2113.0,
6263,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623424,BAO_0000218,2107.0,
6264,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623425,BAO_0000218,2107.0,
6265,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623426,BAO_0000218,2107.0,
6266,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623427,BAO_0000218,2107.0,
6267,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623428,BAO_0000218,2107.0,
6268,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL875947,BAO_0000218,2107.0,
6269,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623429,BAO_0000218,2048.0,
6270,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL623430,BAO_0000218,2048.0,
6271,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL622588,BAO_0000218,2048.0,
6272,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL622589,BAO_0000218,2048.0,
6273,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL622751,BAO_0000218,2048.0,
6274,,A,,In vivo,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,,50594,10090.0,Intermediate,1,CHEMBL622752,BAO_0000218,2048.0,
6275,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL622753,BAO_0000218,,
6276,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622647,BAO_0000218,,
6277,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL875163,BAO_0000218,,
6278,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622648,BAO_0000218,,
6279,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622649,BAO_0000218,,
6280,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL622650,BAO_0000218,955.0,
6281,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622651,BAO_0000218,955.0,
6282,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL622652,BAO_0000218,955.0,
6283,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622653,BAO_0000218,955.0,
6284,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622654,BAO_0000218,955.0,
6285,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL622655,BAO_0000218,948.0,
6286,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622656,BAO_0000218,948.0,
6287,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL622657,BAO_0000218,948.0,
6288,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622658,BAO_0000218,948.0,
6289,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622659,BAO_0000218,948.0,
6290,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL624630,BAO_0000218,2113.0,
6291,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624631,BAO_0000218,2113.0,
6292,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL624632,BAO_0000218,2113.0,
6293,A549,F,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,1,,,80682,9606.0,Intermediate,1,CHEMBL624633,BAO_0000219,,
6294,A549,F,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,1,,,80682,9606.0,Intermediate,1,CHEMBL624634,BAO_0000219,,
6295,A549,F,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),1,,,80682,9606.0,Intermediate,1,CHEMBL624635,BAO_0000219,,
6296,A549,F,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),1,,,80682,9606.0,Intermediate,1,CHEMBL624636,BAO_0000219,,
6297,A549,F,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL857055,BAO_0000219,,
6298,A549,F,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL624637,BAO_0000219,,
6299,A549,F,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL624638,BAO_0000219,,
6300,A549,F,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL874366,BAO_0000219,,
6301,A549,F,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL624639,BAO_0000219,,
6302,A549,F,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,1,,,80682,9606.0,Expert,1,CHEMBL624640,BAO_0000219,,
6303,A549,F,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,1,,,80682,9606.0,Intermediate,1,CHEMBL624641,BAO_0000219,,
6304,A549,F,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,1,,,80682,9606.0,Intermediate,1,CHEMBL624642,BAO_0000219,,
6305,A549,F,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,1,,,80682,9606.0,Intermediate,1,CHEMBL624643,BAO_0000219,,
6306,A549,F,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,1,,,80682,9606.0,Intermediate,1,CHEMBL624644,BAO_0000219,,
6307,A549,F,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,1,,,80682,9606.0,Intermediate,1,CHEMBL624645,BAO_0000219,,
6308,A549,F,646.0,,The compound was evaluated for its cytotoxic potency against A-549 cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619445,BAO_0000219,,
6309,A549,F,646.0,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,1,,,80682,9606.0,Expert,1,CHEMBL839886,BAO_0000219,,
6310,A549,F,646.0,,Cytotoxic activity of compound against A-549 tumor cell line.,1,,,80682,9606.0,Intermediate,1,CHEMBL619446,BAO_0000219,,
6311,A549,F,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,1,,,80682,9606.0,Intermediate,1,CHEMBL619447,BAO_0000219,,
6312,A549,F,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,1,,,80682,9606.0,Intermediate,1,CHEMBL619448,BAO_0000219,,
6313,A549,F,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,1,,,80682,9606.0,Intermediate,1,CHEMBL619449,BAO_0000219,,
6314,A549,F,646.0,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,1,,,80682,9606.0,Intermediate,1,CHEMBL619450,BAO_0000219,,
6315,A549,F,646.0,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),1,,,80682,9606.0,Intermediate,1,CHEMBL619451,BAO_0000219,,
6316,A549,F,646.0,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,1,,,80682,9606.0,Expert,1,CHEMBL619452,BAO_0000219,,
6317,A549,F,646.0,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619453,BAO_0000219,,
6318,A549,F,646.0,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,1,,,80682,9606.0,Intermediate,1,CHEMBL874367,BAO_0000219,,
6319,A549,F,646.0,,Cytotoxic concentration against A-549 tumor cells.,1,,,80682,9606.0,Intermediate,1,CHEMBL619454,BAO_0000219,,
6320,A549,F,646.0,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,1,,,80682,9606.0,Intermediate,1,CHEMBL619455,BAO_0000219,,
6321,A549,F,646.0,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",1,,,80682,9606.0,Intermediate,1,CHEMBL619456,BAO_0000219,,
6322,,F,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,1,,,50191,470.0,Expert,1,CHEMBL619457,BAO_0000218,,
6323,,F,,,Activity against Acinetobacter calcoaceticus (AC54),1,,,50192,471.0,Intermediate,1,CHEMBL619458,BAO_0000218,,
6324,,F,,,In vitro antifungal activity against Aspergillus flavus CM74,1,,,50274,5059.0,Expert,1,CHEMBL619459,BAO_0000218,,
6325,,F,,,In vitro antifungal activity against Aspergillus flavus CM74,1,,,50274,5059.0,Expert,1,CHEMBL619460,BAO_0000218,,
6326,,F,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,1,,,50416,746128.0,Intermediate,1,CHEMBL619461,BAO_0000218,,
6327,,F,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),1,,,50416,746128.0,Intermediate,1,CHEMBL619462,BAO_0000218,,
6328,,F,,,Antimicrobial activity against Aspergillus fumigatus (MIC),1,,,50416,746128.0,Intermediate,1,CHEMBL620388,BAO_0000218,,
6329,,F,,,Antimicrobial activity against Aspergillus fumigatus (MIC),1,,,50416,746128.0,Intermediate,1,CHEMBL620389,BAO_0000218,,
6330,,F,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),1,,,50416,746128.0,Intermediate,1,CHEMBL620390,BAO_0000218,,
6331,,F,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,,,50416,746128.0,Expert,1,CHEMBL620391,BAO_0000218,,
6332,,F,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,,,50416,746128.0,Expert,1,CHEMBL621073,BAO_0000218,,
6333,,F,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,1,,,50296,1655.0,Intermediate,1,CHEMBL621074,BAO_0000218,,
6334,,F,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,1,,,50366,1656.0,Intermediate,1,CHEMBL621075,BAO_0000218,,
6335,,F,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,,,50535,6277.0,Intermediate,1,CHEMBL619554,BAO_0000218,,
6336,,F,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,,,50535,6277.0,Intermediate,1,CHEMBL619555,BAO_0000218,,
6337,,F,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,1,,,50169,714.0,Intermediate,1,CHEMBL619556,BAO_0000218,,
6338,,F,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,1,,,50169,714.0,Intermediate,1,CHEMBL619557,BAO_0000218,,
6339,,F,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,1,,,50169,714.0,Intermediate,1,CHEMBL619558,BAO_0000218,,
6340,A549,F,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619559,BAO_0000219,,
6341,A549,F,646.0,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619560,BAO_0000219,,
6342,A549,F,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,,,80682,9606.0,Intermediate,1,CHEMBL619561,BAO_0000219,,
6343,A549,F,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,,,80682,9606.0,Intermediate,1,CHEMBL619562,BAO_0000219,,
6344,A549,F,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,,,80682,9606.0,Intermediate,1,CHEMBL619563,BAO_0000219,,
6345,A549,F,646.0,,GI values against A549 cells (lung cancer),1,,,80682,9606.0,Intermediate,1,CHEMBL857457,BAO_0000219,,
6346,A549,F,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619564,BAO_0000219,,
6347,A549,F,646.0,,Inhibitory activity against A549 human adenocarcinoma,1,,,80682,9606.0,Intermediate,1,CHEMBL619565,BAO_0000219,,
6348,A549,F,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,1,,,80682,9606.0,Intermediate,1,CHEMBL619566,BAO_0000218,,
6349,A549,F,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,1,,,80682,9606.0,Intermediate,1,CHEMBL619567,BAO_0000218,,
6350,A549,F,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619568,BAO_0000219,,
6351,A549,F,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,1,,,80682,9606.0,Intermediate,1,CHEMBL619569,BAO_0000219,,
6352,A549,F,646.0,,Cytotoxicity against human A549 lung cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619570,BAO_0000219,,
6353,A549,F,646.0,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,1,,,80682,9606.0,Intermediate,1,CHEMBL619571,BAO_0000218,,
6354,A549,F,646.0,,Growth inhibition of A549 (human lung carcinoma) cell line.,1,,,80682,9606.0,Expert,1,CHEMBL619572,BAO_0000219,,
6355,A549,F,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line.,1,,,80682,9606.0,Expert,1,CHEMBL619573,BAO_0000219,,
6356,A549,F,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,1,,,80682,9606.0,Intermediate,1,CHEMBL619574,BAO_0000219,,
6357,A549,F,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,1,,,80682,9606.0,Intermediate,1,CHEMBL619575,BAO_0000219,,
6358,A549,F,646.0,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,1,,,80682,9606.0,Expert,1,CHEMBL619576,BAO_0000219,,
6359,A549,F,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,1,,,80682,9606.0,Intermediate,1,CHEMBL619577,BAO_0000219,,
6360,A549,F,646.0,,In vitro inhibitory activity against A549 tumor cell culture,1,,,80682,9606.0,Intermediate,1,CHEMBL619578,BAO_0000219,,
6361,A549,F,646.0,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,1,,,80682,9606.0,Intermediate,1,CHEMBL884009,BAO_0000219,,
6362,A549,F,646.0,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),1,,,80682,9606.0,Intermediate,1,CHEMBL619579,BAO_0000219,,
6363,A549,F,646.0,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,1,,,80682,9606.0,Intermediate,1,CHEMBL619580,BAO_0000219,,
6364,A549,F,646.0,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619581,BAO_0000219,,
6365,A549,F,646.0,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,1,,,80682,9606.0,Intermediate,1,CHEMBL619582,BAO_0000219,,
6366,A549,F,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,1,,,80682,9606.0,Intermediate,1,CHEMBL619583,BAO_0000219,,
6367,A549,F,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,1,,,80682,9606.0,Intermediate,1,CHEMBL876502,BAO_0000219,,
6368,A549,F,646.0,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,1,,,80682,9606.0,Intermediate,1,CHEMBL619584,BAO_0000219,,
6369,A549,F,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,,,80682,9606.0,Intermediate,1,CHEMBL619585,BAO_0000219,,
6370,A549,F,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619586,BAO_0000219,,
6371,A549,F,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,,,80682,9606.0,Intermediate,1,CHEMBL619587,BAO_0000219,,
6372,A549,F,646.0,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,1,,,80682,9606.0,Intermediate,1,CHEMBL619588,BAO_0000219,,
6373,A549,F,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,1,,,80682,9606.0,Intermediate,1,CHEMBL619589,BAO_0000219,,
6374,A549,F,646.0,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL619590,BAO_0000219,,
6375,A549,F,646.0,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),1,,,80682,9606.0,Intermediate,1,CHEMBL619591,BAO_0000219,,
6376,A549,F,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,1,,,80682,9606.0,Intermediate,1,CHEMBL619592,BAO_0000219,,
6377,A549,F,646.0,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,1,,,80682,9606.0,Intermediate,1,CHEMBL619593,BAO_0000219,,
6378,A549,F,646.0,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620217,BAO_0000219,,
6379,A549,F,646.0,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,1,,,80682,9606.0,Intermediate,1,CHEMBL620218,BAO_0000219,,
6380,A549,F,646.0,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620219,BAO_0000219,,
6381,A549,F,646.0,,Antitumor activity against A549/ATCC cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL620220,BAO_0000219,,
6382,A549,F,646.0,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,1,,,80682,9606.0,Intermediate,1,CHEMBL625141,BAO_0000219,,
6383,A549,F,646.0,,In vitro cytotoxicity against A549/ATCC cell line.,1,,,80682,9606.0,Expert,1,CHEMBL625142,BAO_0000219,,
6384,A549,F,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,1,,,80682,9606.0,Intermediate,1,CHEMBL625143,BAO_0000219,,
6385,A549,F,646.0,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,1,,,80682,9606.0,Intermediate,1,CHEMBL625144,BAO_0000219,,
6386,A549,F,646.0,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,1,,,80682,9606.0,Intermediate,1,CHEMBL622474,BAO_0000219,,
6387,A549,F,646.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,1,,,80682,9606.0,Intermediate,1,CHEMBL884104,BAO_0000219,,
6388,,F,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,0,,,22226,9606.0,Autocuration,1,CHEMBL622475,BAO_0000219,,
6389,,A,,In vivo,Compound was tested for oral bioavailability in dogs,0,,,22224,9615.0,Intermediate,1,CHEMBL622476,BAO_0000218,,
6390,,A,,In vivo,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,1,,,50588,9615.0,Intermediate,1,CHEMBL875831,BAO_0000218,,
6391,,A,,In vivo,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,1,,,50588,9615.0,Intermediate,1,CHEMBL622477,BAO_0000218,,
6392,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622478,BAO_0000218,,
6393,,A,,In vivo,Compound was tested for the oral bioavailability in dog; No availability,1,,,50588,9615.0,Intermediate,1,CHEMBL623172,BAO_0000218,,
6394,,A,,In vivo,Oral bioavailability in dog (dose 5 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL623173,BAO_0000218,,
6395,,A,,In vivo,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL623174,BAO_0000218,,
6396,,A,,In vivo,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL623175,BAO_0000218,,
6397,,A,,In vivo,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL623340,BAO_0000218,,
6398,,A,,In vivo,Oral bioavailability in dog (dose 5 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL623341,BAO_0000218,,
6399,,A,,In vivo,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),1,,,50588,9615.0,Intermediate,1,CHEMBL623342,BAO_0000218,,
6400,,A,,In vivo,Oral bioavailability of active FTIs in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL623343,BAO_0000218,,
6401,,A,,In vivo,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL623344,BAO_0000218,,
6402,,A,,In vivo,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,50588,9615.0,Expert,1,CHEMBL623345,BAO_0000218,,
6403,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL875832,BAO_0000218,,
6404,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623346,BAO_0000218,,
6405,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623347,BAO_0000218,,
6406,,A,,In vivo,Oral bioavailability of compound was determined in dog; Not tested,1,,,50588,9615.0,Intermediate,1,CHEMBL623348,BAO_0000218,,
6407,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623349,BAO_0000218,,
6408,,A,,In vivo,Oral bioavailability (10 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623350,BAO_0000218,,
6409,,A,,In vivo,Oral bioavailability,1,,,50588,9615.0,Intermediate,1,CHEMBL623351,BAO_0000218,,
6410,,A,,In vivo,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),1,,,50588,9615.0,Intermediate,1,CHEMBL623352,BAO_0000218,,
6411,,A,,In vivo,Oral bioavailability administered in solution in rats,1,,,50588,9615.0,Intermediate,1,CHEMBL623353,BAO_0000218,,
6412,,A,,In vivo,Oral bioavailability after 30 mg/kg po dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL875833,BAO_0000218,,
6413,,A,,In vivo,Oral bioavailability at a dose of 1 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL623354,BAO_0000218,,
6414,,A,,In vivo,Oral bioavailability in dog (dose 1 mg/kg p.o.),1,,,50588,9615.0,Intermediate,1,CHEMBL623355,BAO_0000218,,
6415,,A,,In vivo,Oral bioavailability in Dog; ND = not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL623356,BAO_0000218,,
6416,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623357,BAO_0000218,,
6417,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623358,BAO_0000218,,
6418,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623359,BAO_0000218,,
6419,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623360,BAO_0000218,,
6420,,A,,In vivo,Oral bioavailability in dogs; No data,1,,,50588,9615.0,Intermediate,1,CHEMBL623361,BAO_0000218,,
6421,,A,,In vivo,Oral bioavailability measured in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL623362,BAO_0000218,,
6422,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623363,BAO_0000218,,
6423,,A,,In vivo,Oral bioavailability was calculated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623364,BAO_0000218,,
6424,,A,,In vivo,Oral bioavailability after 0.3 mg/kg po administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL875834,BAO_0000218,,
6425,,A,,In vivo,Oral bioavailability in dog (i.v. dosing),1,,,50588,9615.0,Intermediate,1,CHEMBL623365,BAO_0000218,,
6426,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623366,BAO_0000218,,
6427,,A,,In vivo,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,1,,,50588,9615.0,Intermediate,1,CHEMBL623367,BAO_0000218,,
6428,,A,,In vivo,Oral bioavailability in Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL623368,BAO_0000218,,
6429,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623369,BAO_0000218,,
6430,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623370,BAO_0000218,,
6431,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623371,BAO_0000218,,
6432,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623372,BAO_0000218,,
6433,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621351,BAO_0000218,,
6434,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621352,BAO_0000218,,
6435,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621353,BAO_0000218,,
6436,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621354,BAO_0000218,,
6437,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621355,BAO_0000218,,
6438,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621356,BAO_0000218,,
6439,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621357,BAO_0000218,,
6440,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621358,BAO_0000218,,
6441,,A,,In vivo,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),1,,,50588,9615.0,Intermediate,1,CHEMBL621359,BAO_0000218,,
6442,,A,,In vivo,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,,,50588,9615.0,Intermediate,1,CHEMBL621360,BAO_0000218,,
6443,,A,,In vivo,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,,,50588,9615.0,Intermediate,1,CHEMBL621361,BAO_0000218,,
6444,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621362,BAO_0000218,,
6445,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621363,BAO_0000218,,
6446,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621364,BAO_0000218,,
6447,,A,,In vivo,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL621166,BAO_0000218,,
6448,,A,,In vivo,Oral bioavailability in dog (dose 1 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL621167,BAO_0000218,,
6449,,A,,In vivo,Oral bioavailability (F) in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621168,BAO_0000218,,
6450,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621169,BAO_0000218,,
6451,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL875950,BAO_0000218,,
6452,,A,,In vivo,Oral bioavailability in dog (dose 10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621170,BAO_0000218,,
6453,,A,,In vivo,Oral bioavailability after peroral administration at 5 mpk in Dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621171,BAO_0000218,,
6454,,A,,In vivo,Oral bioavailability in dog (dose 5 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621172,BAO_0000218,,
6455,,A,,In vivo,Oral bioavailability in dog (dose 10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621173,BAO_0000218,,
6456,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621174,BAO_0000218,2113.0,
6457,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621175,BAO_0000218,2113.0,
6458,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL621176,BAO_0000218,2107.0,
6459,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621177,BAO_0000218,2107.0,
6460,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL621178,BAO_0000218,2107.0,
6461,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621179,BAO_0000218,2107.0,
6462,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621180,BAO_0000218,2107.0,
6463,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL875951,BAO_0000218,2048.0,
6464,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621181,BAO_0000218,2048.0,
6465,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL621182,BAO_0000218,2048.0,
6466,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621183,BAO_0000218,2048.0,
6467,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621184,BAO_0000218,2048.0,
6468,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL621185,BAO_0000218,,
6469,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621186,BAO_0000218,,
6470,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL621187,BAO_0000218,,
6471,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621188,BAO_0000218,,
6472,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621189,BAO_0000218,,
6473,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL621190,BAO_0000218,2106.0,
6474,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618520,BAO_0000218,2106.0,
6475,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL621739,BAO_0000218,2106.0,
6476,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621740,BAO_0000218,2106.0,
6477,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621741,BAO_0000218,2106.0,
6478,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL621742,BAO_0000218,,
6479,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621743,BAO_0000218,,
6480,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL621744,BAO_0000218,,
6481,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621745,BAO_0000218,,
6482,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621746,BAO_0000218,,
6483,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL621747,BAO_0000218,,
6484,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621748,BAO_0000218,,
6485,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL621749,BAO_0000218,,
6486,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621750,BAO_0000218,,
6487,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621751,BAO_0000218,,
6488,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL621752,BAO_0000218,948.0,
6489,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621753,BAO_0000218,948.0,
6490,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL875955,BAO_0000218,948.0,
6491,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621754,BAO_0000218,948.0,
6492,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621755,BAO_0000218,948.0,
6493,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL621756,BAO_0000218,2107.0,
6494,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624199,BAO_0000218,2107.0,
6495,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL624200,BAO_0000218,2107.0,
6496,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624375,BAO_0000218,2107.0,
6497,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624376,BAO_0000218,2107.0,
6498,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL624377,BAO_0000218,2048.0,
6499,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624378,BAO_0000218,2048.0,
6500,,F,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,,50067,107673.0,Intermediate,1,CHEMBL857901,BAO_0000218,,
6501,,F,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,,50067,107673.0,Intermediate,1,CHEMBL875274,BAO_0000218,,
6502,,F,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,,50067,107673.0,Intermediate,1,CHEMBL624379,BAO_0000218,,
6503,,F,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,,50067,107673.0,Intermediate,1,CHEMBL624380,BAO_0000218,,
6504,,F,,,Activity against Acinetobacter calcoaceticus (AC54),1,,,50192,471.0,Intermediate,1,CHEMBL624381,BAO_0000218,,
6505,,F,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,1,,,50714,28377.0,Intermediate,1,CHEMBL624382,BAO_0000218,,
6506,,F,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,1,,,50714,28377.0,Intermediate,1,CHEMBL624383,BAO_0000218,,
6507,,F,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,1,,,50296,1655.0,Intermediate,1,CHEMBL624384,BAO_0000218,,
6508,,F,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,1,,,50296,1655.0,Intermediate,1,CHEMBL624385,BAO_0000218,,
6509,,F,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,1,,,50296,1655.0,Intermediate,1,CHEMBL624386,BAO_0000218,,
6510,,F,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,1,,,50296,1655.0,Intermediate,1,CHEMBL624387,BAO_0000218,,
6511,,F,,,Plaque bactericidal index against Actinomyces naeslundii 631,1,,,50296,1655.0,Intermediate,1,CHEMBL624388,BAO_0000218,,
6512,,F,,,Plaque bactericidal index against Actinomyces naeslundii N/9,1,,,50296,1655.0,Intermediate,1,CHEMBL624389,BAO_0000218,,
6513,,F,,,Plaque bactericidal index against Actinomyces naeslundii B74,1,,,50296,1655.0,Intermediate,1,CHEMBL624390,BAO_0000218,,
6514,,F,,,Plaque bactericidal index against Actinomyces naeslundii N/3,1,,,50296,1655.0,Intermediate,1,CHEMBL875275,BAO_0000218,,
6515,,F,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,1,,,50056,85549.0,Intermediate,1,CHEMBL624391,BAO_0000218,,
6516,,F,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",1,,,50056,85549.0,Intermediate,1,CHEMBL623636,BAO_0000218,,
6517,,F,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623637,BAO_0000218,,
6518,,F,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623638,BAO_0000218,,
6519,,F,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623639,BAO_0000218,,
6520,,F,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623640,BAO_0000218,,
6521,,F,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623641,BAO_0000218,,
6522,,F,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,1,,,50532,6253.0,Intermediate,1,CHEMBL623642,BAO_0000218,,
6523,,F,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623643,BAO_0000218,,
6524,,F,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623644,BAO_0000218,,
6525,,F,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623645,BAO_0000218,,
6526,,F,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623646,BAO_0000218,,
6527,,F,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623647,BAO_0000218,,
6528,,F,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,1,,,50532,6253.0,Intermediate,1,CHEMBL623648,BAO_0000218,,
6529,,F,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,,,50366,1656.0,Intermediate,1,CHEMBL623649,BAO_0000218,,
6530,,F,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,,,50366,1656.0,Intermediate,1,CHEMBL623650,BAO_0000218,,
6531,,F,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,1,,,50366,1656.0,Intermediate,1,CHEMBL623651,BAO_0000218,,
6532,,F,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,1,,,50366,1656.0,Expert,1,CHEMBL623652,BAO_0000218,,
6533,,F,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,1,,,50366,1656.0,Intermediate,1,CHEMBL623653,BAO_0000218,,
6534,,F,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,1,,,50366,1656.0,Intermediate,1,CHEMBL623654,BAO_0000218,,
6535,,F,,,Plaque bactericidal index against Actinomyces viscosus 8A06,1,,,50366,1656.0,Intermediate,1,CHEMBL623655,BAO_0000218,,
6536,,F,,,Plaque bactericidal index against Actinomyces viscosus M-100,1,,,50366,1656.0,Intermediate,1,CHEMBL623656,BAO_0000218,,
6537,,F,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,1,,,50366,1656.0,Expert,1,CHEMBL623657,BAO_0000218,,
6538,,F,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,,,50366,1656.0,Intermediate,1,CHEMBL623658,BAO_0000218,,
6539,,F,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,,,50366,1656.0,Intermediate,1,CHEMBL623659,BAO_0000218,,
6540,,F,,,Plaque bactericidal index against Actinomyces viscosus 626,1,,,50366,1656.0,Intermediate,1,CHEMBL623660,BAO_0000218,,
6541,,F,,,Plaque bactericidal index against Actinomyces viscosus T14V,1,,,50366,1656.0,Intermediate,1,CHEMBL623661,BAO_0000218,,
6542,,F,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,1,,,50535,6277.0,Intermediate,1,CHEMBL875281,BAO_0000218,,
6543,,F,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,1,,,50535,6277.0,Intermediate,1,CHEMBL623662,BAO_0000218,,
6544,,F,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,1,,,50535,6277.0,Intermediate,1,CHEMBL623663,BAO_0000218,,
6545,,F,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,1,,,50535,6277.0,Intermediate,1,CHEMBL623664,BAO_0000218,,
6546,,F,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,1,,,50535,6277.0,Intermediate,1,CHEMBL623665,BAO_0000218,,
6547,A673,F,165.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,1,,,80023,9606.0,Intermediate,1,CHEMBL621856,BAO_0000219,,
6548,A704,F,645.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,1,,,80661,9606.0,Intermediate,1,CHEMBL620432,BAO_0000219,,
6549,,F,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,0,,,22226,10116.0,Autocuration,1,CHEMBL620433,BAO_0000219,,
6550,A9,F,625.0,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,,,80024,10090.0,Intermediate,1,CHEMBL620434,BAO_0000219,,
6551,A9,F,625.0,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,,,80024,10090.0,Intermediate,1,CHEMBL620435,BAO_0000219,,
6552,A9,F,625.0,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,1,,,80024,9606.0,Intermediate,1,CHEMBL620436,BAO_0000219,,
6553,A9,F,625.0,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,1,,,80024,9606.0,Intermediate,1,CHEMBL876597,BAO_0000219,,
6554,Human ovarian carcinoma cell line,F,874.0,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,1,,,81037,9606.0,Expert,1,CHEMBL620437,BAO_0000219,,
6555,A9,F,625.0,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",1,,,80024,10090.0,Expert,1,CHEMBL620438,BAO_0000219,,
6556,A9,F,625.0,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,1,,,80024,10090.0,Expert,1,CHEMBL620439,BAO_0000219,,
6557,A9,F,625.0,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,1,,,80024,10090.0,Expert,1,CHEMBL619657,BAO_0000219,,
6558,A9,F,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,1,,,80024,10090.0,Intermediate,1,CHEMBL619658,BAO_0000219,,
6559,A9,F,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,1,,,80024,10090.0,Intermediate,1,CHEMBL619659,BAO_0000219,,
6560,,F,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",8,,,10649,,Expert,1,CHEMBL619660,BAO_0000019,,
6561,A9,F,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,1,,,80024,10090.0,Intermediate,1,CHEMBL619661,BAO_0000219,,
6562,A9,F,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,1,,,80024,10090.0,Intermediate,1,CHEMBL619662,BAO_0000219,,
6563,AA6,F,975.0,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,1,,,80663,10029.0,Intermediate,1,CHEMBL619663,BAO_0000219,,
6564,,F,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,0,,,22226,9606.0,Autocuration,1,CHEMBL619664,BAO_0000219,,
6565,,F,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",0,,,22226,9606.0,Autocuration,1,CHEMBL619665,BAO_0000219,,
6566,AA5,F,974.0,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),1,,,80662,9606.0,Intermediate,1,CHEMBL883244,BAO_0000219,,
6567,AA5,F,974.0,,Cytotoxicity was measured against AA5/HIV-1(IIIB),1,,,80662,9606.0,Intermediate,1,CHEMBL884011,BAO_0000219,,
6568,AA5,F,974.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,1,,,80662,9606.0,Intermediate,1,CHEMBL619666,BAO_0000219,,
6569,U-937,F,379.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,1,,,80566,9606.0,Intermediate,1,CHEMBL619667,BAO_0000219,,
6570,UV4,F,274.0,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,1,,,80578,10029.0,Intermediate,1,CHEMBL619668,BAO_0000219,,
6571,CHO-AA8,F,185.0,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,,,80089,10029.0,Expert,1,CHEMBL619669,BAO_0000219,,
6572,CHO-AA8,F,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6,1,,,80089,10029.0,Intermediate,1,CHEMBL876608,BAO_0000219,,
6573,CHO-AA8,F,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6.,1,,,80089,10029.0,Intermediate,1,CHEMBL619670,BAO_0000219,,
6574,CHO-AA8,F,185.0,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,1,,,80089,10029.0,Intermediate,1,CHEMBL619671,BAO_0000219,,
6575,CHO-AA8,F,185.0,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,1,,,80089,10029.0,Intermediate,1,CHEMBL619672,BAO_0000219,,
6576,CHO-AA8,F,185.0,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,1,,,80089,10029.0,Intermediate,1,CHEMBL619673,BAO_0000219,,
6577,CHO-AA8,F,185.0,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",1,,,80089,10029.0,Intermediate,1,CHEMBL619674,BAO_0000219,,
6578,CHO-AA8,F,185.0,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",1,,,80089,10029.0,Intermediate,1,CHEMBL619675,BAO_0000219,,
6579,CHO-AA8,F,185.0,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,1,,,80089,10029.0,Intermediate,1,CHEMBL619676,BAO_0000219,,
6580,CHO-AA8,F,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,,,80089,10029.0,Intermediate,1,CHEMBL619677,BAO_0000219,,
6581,CHO-AA8,A,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,,,80089,10029.0,Intermediate,1,CHEMBL619678,BAO_0000219,,
6582,CHO-AA8,A,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,1,,,80089,10029.0,Intermediate,1,CHEMBL619679,BAO_0000219,,
6583,CHO-AA8,A,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,1,,,80089,10029.0,Expert,1,CHEMBL619680,BAO_0000219,,
6584,CHO-AA8,A,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,1,,,80089,10029.0,Intermediate,1,CHEMBL621457,BAO_0000219,,
6585,CHO-AA8,F,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,1,,,80089,10029.0,Expert,1,CHEMBL876609,BAO_0000219,,
6586,CHO-AA8,F,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,1,,,80089,10029.0,Intermediate,1,CHEMBL621458,BAO_0000219,,
6587,CHO-AA8,F,185.0,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,1,,,80089,36483.0,Expert,1,CHEMBL621459,BAO_0000219,,
6588,CHO-AA8,F,185.0,,Aerobic growth inhibition in Chinese hamster cell line AA8,1,,,80089,10029.0,Expert,1,CHEMBL621460,BAO_0000219,,
6589,CHO-AA8,F,185.0,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,1,,,80089,10029.0,Expert,1,CHEMBL621461,BAO_0000219,,
6590,CHO-AA8,F,185.0,,Inhibition of growth under aerobic conditions in AA8 cells,1,,,80089,10029.0,Expert,1,CHEMBL621462,BAO_0000219,,
6591,,A,,In vivo,Oral bioavailability in dog (dose 10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621463,BAO_0000218,,
6592,,A,,In vivo,Oral bioavailability in dog at 10 mg/kg of the compound,1,,,50588,9615.0,Intermediate,1,CHEMBL621464,BAO_0000218,,
6593,,A,,In vivo,Oral bioavailability in dog (dose 5 uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621465,BAO_0000218,,
6594,,A,,In vivo,Oral bioavailability in dog (dose 5 uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621466,BAO_0000218,,
6595,,A,,In vivo,Oral bioavailability in dog (mongrel),1,,,50588,9615.0,Intermediate,1,CHEMBL621467,BAO_0000218,,
6596,,A,,In vivo,Oral bioavailability in dog (dose 10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621468,BAO_0000218,,
6597,,F,,In vivo,Oral bioavailability in dog (dose 10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL876734,BAO_0000218,,
6598,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618476,BAO_0000218,,
6599,,A,,In vivo,Bioavailability in dog (dose 1 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL618477,BAO_0000218,,
6600,,A,,In vivo,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),1,,,50588,9615.0,Intermediate,1,CHEMBL618478,BAO_0000218,,
6601,,A,,In vivo,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618479,BAO_0000218,,
6602,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618480,BAO_0000218,,
6603,,A,,In vivo,Bioavailability in dog (dose 3-10 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL618481,BAO_0000218,,
6604,,A,,In vivo,The compound was tested for bioavailability of compound in plasma of dog; Complete,1,,,50588,9615.0,Intermediate,1,CHEMBL618482,BAO_0000218,1969.0,
6605,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618483,BAO_0000218,,
6606,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618484,BAO_0000218,,
6607,,A,,In vivo,Bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618485,BAO_0000218,,
6608,,A,,In vivo,oral bioavailability was measured in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618486,BAO_0000218,,
6609,,A,,,Compound was tested for plasma protein binding in dog; Not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL618487,BAO_0000218,,
6610,,A,,,Compound was tested for plasma protein binding of dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618488,BAO_0000218,,
6611,,A,,,Compound was tested for plasma protein binding of dog; Not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL876735,BAO_0000218,,
6612,,A,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,1,,,50588,9615.0,Intermediate,1,CHEMBL618489,BAO_0000218,,
6613,,A,,In vivo,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,1,,,50588,9615.0,Intermediate,1,CHEMBL618490,BAO_0000218,,
6614,,A,,,Half life was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL618491,BAO_0000218,,
6615,,A,,In vivo,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618492,BAO_0000218,,
6616,,A,,,Half life was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL873354,BAO_0000218,,
6617,,A,,,Half life was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL618493,BAO_0000218,,
6618,,A,,In vivo,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,,50588,9615.0,Intermediate,1,CHEMBL618494,BAO_0000218,,
6619,,A,,In vivo,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,,50588,9615.0,Intermediate,1,CHEMBL618495,BAO_0000218,948.0,
6620,,A,,In vivo,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,,50588,9615.0,Intermediate,1,CHEMBL618496,BAO_0000218,2113.0,
6621,,A,,In vivo,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,,50588,9615.0,Intermediate,1,CHEMBL618497,BAO_0000218,2107.0,
6622,,A,,In vivo,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,,50588,9615.0,Intermediate,1,CHEMBL618498,BAO_0000218,2048.0,
6623,,A,,In vivo,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,,50588,9615.0,Intermediate,1,CHEMBL618499,BAO_0000218,2106.0,
6624,,A,,,LogP in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL876736,BAO_0000218,,
6625,,A,,,Partition coefficient (logP),1,,,50588,9615.0,Intermediate,1,CHEMBL618500,BAO_0000218,,
6626,,A,,,Partition coefficient in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL857831,BAO_0000218,,
6627,,A,,In vivo,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618501,BAO_0000218,,
6628,,A,,In vivo,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL618502,BAO_0000218,,
6629,,A,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,1,,,50588,9615.0,Intermediate,1,CHEMBL618503,BAO_0000218,,
6630,,A,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),1,,,50588,9615.0,Intermediate,1,CHEMBL618504,BAO_0000218,,
6631,,A,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),1,,,50588,9615.0,Intermediate,1,CHEMBL618505,BAO_0000218,,
6632,,A,,,Metabolism of compound in dog S9 microsomes; Trace,1,,,50588,9615.0,Intermediate,1,CHEMBL618506,BAO_0000218,,
6633,,A,,,In vitro metabolic potential in dog liver microsomes,1,,,50588,9615.0,Intermediate,1,CHEMBL618507,BAO_0000218,2107.0,
6634,,A,,In vivo,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL876737,BAO_0000218,,
6635,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618508,BAO_0000218,,
6636,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618509,BAO_0000218,,
6637,,A,,In vivo,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,50588,9615.0,Intermediate,1,CHEMBL618510,BAO_0000218,,
6638,,A,,In vivo,The compound was tested for bioavailability in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618511,BAO_0000218,,
6639,,A,,In vivo,The compound was tested for oral bioavailability in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618512,BAO_0000218,,
6640,,A,,In vivo,Oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618513,BAO_0000218,,
6641,,A,,,Compound was tested for percent protein binding (PB) in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618514,BAO_0000218,,
6642,,A,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,1,,,50588,9615.0,Intermediate,1,CHEMBL620052,BAO_0000218,,
6643,,A,,In vivo,Compound was evaluated for plasma clearance.,1,,,50588,9615.0,Intermediate,1,CHEMBL620053,BAO_0000218,1969.0,
6644,,A,,In vivo,The compound was tested for plasma clearance in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL620054,BAO_0000218,1969.0,
6645,,A,,In vivo,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,1,,,50588,9615.0,Intermediate,1,CHEMBL620055,BAO_0000218,1969.0,
6646,,A,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL620056,BAO_0000218,,
6647,,A,,,In vitro relative rate of metabolism was determined in dog liver microsomes,1,,,50588,9615.0,Intermediate,1,CHEMBL620057,BAO_0000218,2107.0,
6648,,A,,In vivo,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618939,BAO_0000218,,
6649,,A,,In vivo,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,,,50588,9615.0,Intermediate,1,CHEMBL618940,BAO_0000218,,
6650,,A,,In vivo,Half life after intravenous administration in dogs at 1.2 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618941,BAO_0000218,,
6651,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL624473,BAO_0000218,2048.0,
6652,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624474,BAO_0000218,2048.0,
6653,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624475,BAO_0000218,2048.0,
6654,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,1,,,50594,10090.0,Intermediate,1,CHEMBL624476,BAO_0000218,,
6655,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623478,BAO_0000218,,
6656,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,1,,,50594,10090.0,Intermediate,1,CHEMBL623479,BAO_0000218,,
6657,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623480,BAO_0000218,,
6658,CCRF S-180,A,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623481,BAO_0000218,,
6659,,A,,,C2 in brain of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623482,BAO_0000218,955.0,
6660,,A,,,C2 in kidney of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623483,BAO_0000218,2113.0,
6661,,A,,,C2 in liver of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623484,BAO_0000218,2107.0,
6662,,A,,,C2 in lungs of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623485,BAO_0000218,2048.0,
6663,,A,,,C2 in spleen of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623486,BAO_0000218,2106.0,
6664,,A,,In vivo,Plasma clearance in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL623487,BAO_0000218,,
6665,,A,,In vivo,Clearance of compound after intravenous administration in mice at 24 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623488,BAO_0000218,,
6666,,A,,In vivo,Clearance from mouse blood following i.v. administration of 10 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623489,BAO_0000218,,
6667,,A,,In vivo,Clearance was evaluated in mice after intravenous administration,1,,,50594,10090.0,Intermediate,1,CHEMBL875157,BAO_0000218,,
6668,,A,,In vivo,Clearance was evaluated in mice after oral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL623490,BAO_0000218,,
6669,,A,,In vivo,Pharmacokinetic property (Plasma clearance) was measured in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL623491,BAO_0000218,,
6670,,A,,In vivo,Plasma clearance of compound was determined at 40 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623492,BAO_0000218,,
6671,,A,,In vivo,Plasma clearance of at 24 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623493,BAO_0000218,,
6672,,A,,In vivo,Plasma clearance at 24 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623494,BAO_0000218,,
6673,,A,,In vivo,Plasma clearance at 5 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623495,BAO_0000218,,
6674,,A,,In vivo,Plasma clearance in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623496,BAO_0000218,,
6675,,A,,In vivo,Plasma clearance value upon iv administration in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL623497,BAO_0000218,,
6676,,A,,In vivo,Total plasma clearance in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623498,BAO_0000218,1969.0,
6677,,A,,In vivo,Clearance in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL623499,BAO_0000218,,
6678,,A,,In vivo,Clearance value was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL623500,BAO_0000218,,
6679,,A,,In vivo,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL623501,BAO_0000218,,
6680,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Intermediate,1,CHEMBL875158,BAO_0000100,,
6681,,A,,In vivo,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623502,BAO_0000218,,
6682,,A,,In vivo,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623503,BAO_0000218,,
6683,,A,,In vivo,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,50594,10090.0,Intermediate,1,CHEMBL623504,BAO_0000218,,
6684,,A,,In vivo,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623505,BAO_0000218,,
6685,,A,,In vivo,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623506,BAO_0000218,,
6686,,A,,In vivo,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL623507,BAO_0000218,,
6687,,A,,In vivo,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,1,,,50594,10090.0,Intermediate,1,CHEMBL623508,BAO_0000218,,
6688,,A,,In vivo,Cmax after oral administration at 30 mg/kg in ICR mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL623509,BAO_0000218,,
6689,,A,,In vivo,Cmax after peroral administration in mice at 2.4 uM/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL875159,BAO_0000218,,
6690,,A,,In vivo,Cmax in brain of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623510,BAO_0000218,955.0,
6691,,A,,In vivo,Cmax in kidney of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623511,BAO_0000218,2113.0,
6692,,A,,In vivo,Cmax in liver of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623512,BAO_0000218,2107.0,
6693,,A,,In vivo,Cmax in lungs of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623513,BAO_0000218,2048.0,
6694,,F,,In vivo,Cmax in mice at 18 uM/kg i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL623514,BAO_0000218,,
6695,,F,,In vivo,Cmax in mice at 23 uM/kg i.v. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL622609,BAO_0000218,,
6696,,F,,In vivo,Cmax in mice at 24 uM/kg i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL622610,BAO_0000218,,
6697,,F,,In vivo,Cmax in mice at 25 uM/kg i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL621823,BAO_0000218,,
6698,,F,,In vivo,Cmax in mice at 26 uM/kg i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL621824,BAO_0000218,,
6699,,A,,In vivo,Cmax in spleen of mice at the oral dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL621825,BAO_0000218,2106.0,
6700,,A,,In vivo,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL621826,BAO_0000218,,
6701,,A,,In vivo,Cmax value at a dose of 10 mg/kg peroral administration in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL621827,BAO_0000218,,
6702,,A,,In vivo,Cmax value was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL621828,BAO_0000218,,
6703,,A,,In vivo,Cmax value in IRC mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621829,BAO_0000218,,
6704,,A,,In vivo,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621830,BAO_0000218,,
6705,,A,,In vivo,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621831,BAO_0000218,,
6706,,A,,In vivo,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621832,BAO_0000218,1969.0,
6707,,A,,In vivo,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",1,,,50594,10090.0,Intermediate,1,CHEMBL624579,BAO_0000218,1969.0,
6708,,A,,In vivo,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL624580,BAO_0000218,,
6709,,F,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,1,,,50535,6277.0,Intermediate,1,CHEMBL624581,BAO_0000218,,
6710,,F,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,1,,,50535,6277.0,Intermediate,1,CHEMBL624582,BAO_0000218,,
6711,,F,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,1,,,50535,6277.0,Intermediate,1,CHEMBL624583,BAO_0000218,,
6712,A-375,F,455.0,,Inhibitory activity against human tumor cell line A0375 melanoma.,1,,,80018,9606.0,Intermediate,1,CHEMBL624584,BAO_0000219,,
6713,,B,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,9,,,12512,10116.0,Expert,1,CHEMBL624585,BAO_0000249,,
6714,,F,,,Forskolin-induced cAMP production at human A1 adenosine receptor,9,,,114,9606.0,Expert,1,CHEMBL875165,BAO_0000019,,
6715,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,8,,,114,,Autocuration,1,CHEMBL619490,BAO_0000219,,
6716,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,8,,,114,,Autocuration,1,CHEMBL619491,BAO_0000219,,
6717,CHO,F,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,8,,,114,,Expert,1,CHEMBL619492,BAO_0000219,,
6718,CHO,F,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,8,,,114,,Expert,1,CHEMBL619493,BAO_0000219,,
6719,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,8,,,114,,Autocuration,1,CHEMBL619494,BAO_0000219,,
6720,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,8,,,114,,Autocuration,1,CHEMBL619495,BAO_0000219,,
6721,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,8,,,114,,Autocuration,1,CHEMBL619496,BAO_0000219,,
6722,CHO,F,449.0,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,9,,,114,9606.0,Expert,1,CHEMBL619497,BAO_0000219,,
6723,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,8,,,114,,Autocuration,1,CHEMBL619498,BAO_0000219,,
6724,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,8,,,114,,Autocuration,1,CHEMBL619499,BAO_0000219,,
6725,CHO,F,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,8,,,114,,Expert,1,CHEMBL619500,BAO_0000219,,
6726,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,8,,,114,,Autocuration,1,CHEMBL619501,BAO_0000219,,
6727,CHO,F,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,8,,,114,,Expert,1,CHEMBL619502,BAO_0000219,,
6728,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,8,,,114,,Autocuration,1,CHEMBL619503,BAO_0000219,,
6729,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,8,,,114,,Autocuration,1,CHEMBL619504,BAO_0000219,,
6730,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,8,,,114,,Autocuration,1,CHEMBL621298,BAO_0000219,,
6731,CHO,F,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,8,,,114,,Expert,1,CHEMBL621299,BAO_0000219,,
6732,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,8,,,114,,Autocuration,1,CHEMBL621300,BAO_0000219,,
6733,CHO,F,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,8,,,114,,Autocuration,1,CHEMBL621301,BAO_0000219,,
6734,CHO,F,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,8,,,114,,Expert,1,CHEMBL621302,BAO_0000219,,
6735,A10,F,164.0,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,1,,,80013,9986.0,Intermediate,1,CHEMBL621303,BAO_0000219,,
6736,A10,F,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,0,,,22226,10116.0,Autocuration,1,CHEMBL621304,BAO_0000219,,
6737,A10,F,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,0,,,22226,10116.0,Autocuration,1,CHEMBL621305,BAO_0000219,,
6738,A10,F,164.0,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,1,,,80013,10116.0,Intermediate,1,CHEMBL621306,BAO_0000219,,
6739,A10,F,164.0,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,1,,,80013,10116.0,Intermediate,1,CHEMBL618444,BAO_0000219,,
6740,A10,F,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,1,,,80013,10116.0,Intermediate,1,CHEMBL618445,BAO_0000219,,
6741,CHO-AA8,F,185.0,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,1,,,80089,10029.0,Intermediate,1,CHEMBL618446,BAO_0000219,,
6742,CHO-AA8,F,185.0,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,1,,,80089,10029.0,Intermediate,1,CHEMBL618447,BAO_0000219,,
6743,CHO-AA8,F,185.0,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,1,,,80089,10029.0,Intermediate,1,CHEMBL618448,BAO_0000219,,
6744,CHO-AA8,F,185.0,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,1,,,80089,10029.0,Intermediate,1,CHEMBL618449,BAO_0000219,,
6745,CHO-AA8,F,185.0,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,,,80089,10029.0,Intermediate,1,CHEMBL618637,BAO_0000219,,
6746,CHO-AA8,F,185.0,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",1,,,80089,10029.0,Intermediate,1,CHEMBL618638,BAO_0000219,,
6747,CHO-AA8,F,185.0,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),1,,,80089,10029.0,Intermediate,1,CHEMBL618639,BAO_0000219,,
6748,CHO-AA8,F,185.0,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",1,,,80089,10029.0,Expert,1,CHEMBL618640,BAO_0000219,,
6749,CHO-AA8,F,185.0,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,1,,,80089,10029.0,Expert,1,CHEMBL618641,BAO_0000219,,
6750,CHO-AA8,F,185.0,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,1,,,80089,10029.0,Intermediate,1,CHEMBL618642,BAO_0000219,,
6751,CHO-AA8,F,185.0,,Inhibitory activity against aerobic growth of AA8 cells.,1,,,80089,10029.0,Intermediate,1,CHEMBL618643,BAO_0000219,,
6752,CHO-AA8,A,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,,,80089,10029.0,Intermediate,1,CHEMBL884013,BAO_0000219,,
6753,CHO-AA8,F,185.0,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,,,80089,10029.0,Expert,1,CHEMBL622723,BAO_0000219,,
6754,CHO-AA8,F,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,,,80089,10029.0,Intermediate,1,CHEMBL622724,BAO_0000219,,
6755,CHO-AA8,F,185.0,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,1,,,80089,10029.0,Expert,1,CHEMBL622725,BAO_0000219,,
6756,CHO-AA8,F,185.0,,Cytotoxicity against AA8 cell line,1,,,80089,10029.0,Expert,1,CHEMBL622726,BAO_0000219,,
6757,CHO-AA8,F,185.0,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),1,,,80089,10029.0,Intermediate,1,CHEMBL622727,BAO_0000219,,
6758,CHO-AA8,A,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,,,80089,10029.0,Intermediate,1,CHEMBL622728,BAO_0000219,,
6759,CHO-AA8,F,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,,,80089,10029.0,Intermediate,1,CHEMBL622729,BAO_0000219,,
6760,CHO-AA8,A,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,,,80089,10029.0,Intermediate,1,CHEMBL622730,BAO_0000219,,
6761,CHO-AA8,F,185.0,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,1,,,80089,10029.0,Intermediate,1,CHEMBL622731,BAO_0000219,,
6762,CHO-AA8,F,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,,,80089,10029.0,Intermediate,1,CHEMBL622732,BAO_0000219,,
6763,CHO-AA8,F,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,,,80089,10029.0,Intermediate,1,CHEMBL622733,BAO_0000219,,
6764,,F,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),0,,,22224,10029.0,Autocuration,1,CHEMBL622734,BAO_0000218,,
6765,CHO-AA8,F,185.0,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,1,,,80089,10029.0,Expert,1,CHEMBL622735,BAO_0000219,,
6766,CHO-AA8,F,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,0,,,22224,10029.0,Autocuration,1,CHEMBL618746,BAO_0000219,,
6767,CHO-AA8,F,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,0,,,22224,10029.0,Autocuration,1,CHEMBL618747,BAO_0000219,,
6768,CHO-AA8,F,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,0,,,22224,10029.0,Autocuration,1,CHEMBL620540,BAO_0000219,,
6769,CHO-AA8,F,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,0,,,22224,10029.0,Autocuration,1,CHEMBL620541,BAO_0000219,,
6770,CHO-AA8,F,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,0,,,22224,10029.0,Autocuration,1,CHEMBL620542,BAO_0000219,,
6771,CHO-AA8,F,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,0,,,22224,10029.0,Autocuration,1,CHEMBL620543,BAO_0000219,,
6772,CHO-AA8,F,185.0,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,0,,,22224,10029.0,Autocuration,1,CHEMBL618832,BAO_0000219,,
6773,CHO-AA8,F,185.0,,Concentration required to reduce AA8 cell survival by 10%,1,,,80089,10029.0,Expert,1,CHEMBL618833,BAO_0000219,,
6774,CHO-AA8,F,185.0,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",0,,,22224,10029.0,Autocuration,1,CHEMBL618834,BAO_0000219,,
6775,CHO-AA8,F,185.0,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,0,,,22224,10029.0,Autocuration,1,CHEMBL618835,BAO_0000219,,
6776,CHO-AA8,F,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,0,,,22224,10029.0,Autocuration,1,CHEMBL618836,BAO_0000219,,
6777,CHO-AA8,F,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,0,,,22224,10029.0,Autocuration,1,CHEMBL618837,BAO_0000219,,
6778,CHO-AA8,F,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,0,,,22224,10029.0,Autocuration,1,CHEMBL618838,BAO_0000219,,
6779,CHO-AA8,F,185.0,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,0,,,22224,10029.0,Autocuration,1,CHEMBL618839,BAO_0000219,,
6780,CHO-AA8,F,185.0,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,0,,,22224,10029.0,Autocuration,1,CHEMBL618840,BAO_0000219,,
6781,,F,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",0,,,22224,10029.0,Autocuration,1,CHEMBL618841,BAO_0000019,,
6782,CHO-AA8,F,185.0,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,0,,,22224,10029.0,Autocuration,1,CHEMBL618842,BAO_0000219,,
6783,CHO-AA8,F,185.0,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,0,,,22224,10029.0,Autocuration,1,CHEMBL618843,BAO_0000219,,
6784,,A,,In vivo,Half life period after 15 mg/kg iv dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618844,BAO_0000218,,
6785,,A,,In vivo,Half life period after 30 mg/kg po dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618845,BAO_0000218,,
6786,,A,,In vivo,Half life was measured after oral 2b administration (tested in 6 dogs),1,,,50588,9615.0,Intermediate,1,CHEMBL618846,BAO_0000218,,
6787,,A,,In vivo,Half life was measured in dog after oral 17b administration,1,,,50588,9615.0,Intermediate,1,CHEMBL618847,BAO_0000218,,
6788,,A,,In vivo,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,1,,,50588,9615.0,Intermediate,1,CHEMBL618848,BAO_0000218,,
6789,,A,,In vivo,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,1,,,50588,9615.0,Intermediate,1,CHEMBL618849,BAO_0000218,,
6790,,A,,In vivo,Tmax value after 15 mg/kg iv dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618850,BAO_0000218,,
6791,,A,,In vivo,Tmax value after 30 mg/kg po dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618851,BAO_0000218,,
6792,,A,,In vivo,Compound was evaluated for its half life when administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL873815,BAO_0000218,,
6793,,A,,In vivo,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL618852,BAO_0000218,1969.0,
6794,,A,,,Elimination Half-life of compound was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618853,BAO_0000218,,
6795,,A,,In vivo,Half life of compound in dog following oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL618854,BAO_0000218,,
6796,,A,,,Half life of compound was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618855,BAO_0000218,,
6797,,A,,,Half life of compound was determined in dog blood,1,,,50588,9615.0,Intermediate,1,CHEMBL618856,BAO_0000218,178.0,
6798,,A,,In vivo,Half life after oral and iv dosing in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL875827,BAO_0000218,,
6799,,A,,,Half life in dogs in hours,1,,,50588,9615.0,Intermediate,1,CHEMBL618857,BAO_0000218,,
6800,,A,,In vivo,Half life on i.v. administration of 2 mg/kg was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618858,BAO_0000218,,
6801,,A,,In vivo,t1/2 in dog after oral dose (1 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL618859,BAO_0000218,,
6802,,A,,,Half life was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618860,BAO_0000218,,
6803,,A,,In vivo,Half life period of compound was determined after intravenous administration at 2 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618861,BAO_0000218,,
6804,,A,,In vivo,Half life period of compound was determined after peroral administration at 2 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622539,BAO_0000218,,
6805,,A,,In vivo,Half life period (10 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622540,BAO_0000218,,
6806,,A,,In vivo,Half life period (10 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL873803,BAO_0000218,,
6807,,A,,In vivo,Half life period by iv administration in dog at a dose of 0.3 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL873804,BAO_0000218,,
6808,,A,,In vivo,Half life period by po administration in dog at a dose of 0.3 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624311,BAO_0000218,,
6809,,A,,,Half life period in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624312,BAO_0000218,,
6810,,A,,In vivo,Half life period in dogs after oral administration at 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624313,BAO_0000218,,
6811,,A,,In vivo,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624314,BAO_0000218,,
6812,,A,,,Half-life of compound was determined in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624315,BAO_0000218,,
6813,,A,,,Half-life in dog plasma,1,,,50588,9615.0,Intermediate,1,CHEMBL624316,BAO_0000218,1969.0,
6814,,A,,,Half-life in mongrel dogs was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624317,BAO_0000218,,
6815,,A,,In vivo,Half-life in dog upon oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624318,BAO_0000218,,
6816,,A,,In vivo,Half-life in dog upon oral administration; Unable to calculate,1,,,50588,9615.0,Intermediate,1,CHEMBL624319,BAO_0000218,,
6817,,A,,,Half-life was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624496,BAO_0000218,,
6818,,A,,,Half-life was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624497,BAO_0000218,,
6819,,A,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624498,BAO_0000218,,
6820,,A,,In vivo,Oral half life was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624499,BAO_0000218,,
6821,,A,,In vivo,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,1,,,50588,9615.0,Intermediate,1,CHEMBL624500,BAO_0000218,1969.0,
6822,,A,,,Plasma half life was evaluated,1,,,50588,9615.0,Intermediate,1,CHEMBL624501,BAO_0000218,1969.0,
6823,,A,,,Plasma half life was evaluated in Dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623666,BAO_0000218,1969.0,
6824,,A,,,Plasma half life was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623667,BAO_0000218,1969.0,
6825,,A,,In vivo,T1/2 (Half-life) was after oral administration at 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL623668,BAO_0000218,,
6826,,A,,,Tested for the half life value in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623669,BAO_0000218,,
6827,,A,,In vivo,Maximum time at the dose of 2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623670,BAO_0000218,,
6828,,A,,In vivo,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,,50588,9615.0,Intermediate,1,CHEMBL623671,BAO_0000218,,
6829,,A,,In vivo,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,,50588,9615.0,Intermediate,1,CHEMBL875945,BAO_0000218,178.0,
6830,,A,,In vivo,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,,50588,9615.0,Intermediate,1,CHEMBL623672,BAO_0000218,178.0,
6831,,A,,In vivo,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL623673,BAO_0000218,,
6832,,A,,In vivo,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL623674,BAO_0000218,,
6833,,A,,In vivo,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,1,,,50588,9615.0,Intermediate,1,CHEMBL623675,BAO_0000218,,
6834,,A,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",1,,,50588,9615.0,Intermediate,1,CHEMBL872526,BAO_0000218,,
6835,,A,,In vivo,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",1,,,50588,9615.0,Intermediate,1,CHEMBL623676,BAO_0000218,,
6836,,A,,In vivo,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL623677,BAO_0000218,1969.0,
6837,,A,,In vivo,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,,,50588,9615.0,Intermediate,1,CHEMBL623678,BAO_0000218,1969.0,
6838,,A,,,Time taken for maximum plasma concentration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623679,BAO_0000218,1969.0,
6839,,A,,In vivo,Time to reach Cmax after oral administration to dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL623680,BAO_0000218,,
6840,,A,,In vivo,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,50588,9615.0,Intermediate,1,CHEMBL623681,BAO_0000218,1969.0,
6841,,A,,In vivo,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL623682,BAO_0000218,,
6842,,A,,In vivo,Tmax after peroral administration (1 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623683,BAO_0000218,,
6843,,A,,In vivo,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,50588,9615.0,Expert,1,CHEMBL623684,BAO_0000218,,
6844,,A,,In vivo,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL622745,BAO_0000218,,
6845,,A,,In vivo,Tmax after peroral administration in dogs at 2.4 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL622746,BAO_0000218,,
6846,,A,,In vivo,In vivo Cmax in mice at dose of 100 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622747,BAO_0000218,,
6847,,A,,In vivo,In vivo Cmax in mice at dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622748,BAO_0000218,,
6848,,A,,In vivo,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622749,BAO_0000218,,
6849,,A,,In vivo,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,,50594,10090.0,Intermediate,1,CHEMBL622750,BAO_0000218,1969.0,
6850,,A,,In vivo,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623411,BAO_0000218,1969.0,
6851,,A,,In vivo,Maximum concentration obtained in mouse plasma was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL875946,BAO_0000218,1969.0,
6852,,A,,In vivo,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623412,BAO_0000218,1969.0,
6853,,A,,In vivo,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,50594,10090.0,Intermediate,1,CHEMBL623413,BAO_0000218,1969.0,
6854,,A,,In vivo,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623414,BAO_0000218,1969.0,
6855,,A,,In vivo,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623415,BAO_0000218,1969.0,
6856,,A,,In vivo,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623416,BAO_0000218,1969.0,
6857,,A,,In vivo,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,1,,,50594,10090.0,Intermediate,1,CHEMBL623417,BAO_0000218,1969.0,
6858,,A,,In vivo,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,1,,,50594,10090.0,Intermediate,1,CHEMBL623418,BAO_0000218,1969.0,
6859,,A,,In vivo,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,1,,,50594,10090.0,Intermediate,1,CHEMBL623419,BAO_0000218,1969.0,
6860,,A,,In vivo,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622816,BAO_0000218,,
6861,,A,,In vivo,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623313,BAO_0000218,,
6862,,A,,In vivo,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623314,BAO_0000218,,
6863,,A,,In vivo,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL876788,BAO_0000218,,
6864,,A,,In vivo,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623315,BAO_0000218,,
6865,,A,,In vivo,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623316,BAO_0000218,,
6866,,A,,In vivo,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623317,BAO_0000218,,
6868,,A,,In vivo,Cmax in male mice after 2 mg/kg oral dose,1,,,50594,10090.0,Intermediate,1,CHEMBL623319,BAO_0000218,,
6869,,A,,In vivo,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,1,,,50594,10090.0,Intermediate,1,CHEMBL623320,BAO_0000218,,
6870,,A,,In vivo,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL623321,BAO_0000218,,
6871,,A,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL623322,BAO_0000218,,
6872,,A,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL623323,BAO_0000218,,
6873,,A,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL623324,BAO_0000218,,
6874,,A,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL623325,BAO_0000218,,
6875,,A,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL623326,BAO_0000218,,
6876,,A,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL623327,BAO_0000218,,
6877,,A,,,Maximum concentration in plasma upon oral administration in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL623328,BAO_0000218,1969.0,
6878,,A,,,Maximum plasma concentration was evaluated in mice after oral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL623329,BAO_0000218,1969.0,
6879,,A,,In vivo,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL623330,BAO_0000218,1969.0,
6880,,A,,,Dose at which the compound induced fecal excretion in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL876789,BAO_0000218,,
6893,A10,F,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,1,,,80013,10116.0,Expert,1,CHEMBL623333,BAO_0000219,,
6894,A10,F,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,1,,,80013,10116.0,Expert,1,CHEMBL623334,BAO_0000219,,
6895,A10,F,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,1,,,80013,10116.0,Expert,1,CHEMBL627536,BAO_0000219,,
6896,A10,F,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,1,,,80013,10116.0,Expert,1,CHEMBL627537,BAO_0000219,,
6897,A10,F,164.0,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),1,,,80013,10116.0,Intermediate,1,CHEMBL627538,BAO_0000219,,
6898,A121,F,393.0,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,1,,,80655,9606.0,Intermediate,1,CHEMBL884106,BAO_0000219,,
6899,A121,F,393.0,,Anticancer activity against human ovarian carcinoma A121 cells,1,,,80655,9606.0,Intermediate,1,CHEMBL625294,BAO_0000219,,
6900,A121,F,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,1,,,80655,9606.0,Intermediate,1,CHEMBL625295,BAO_0000219,,
6901,A121,F,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,1,,,80655,9606.0,Intermediate,1,CHEMBL625296,BAO_0000219,,
6902,A121,F,393.0,,Growth inhibition of human ovarian carcinoma (A121) cell line,1,,,80655,9606.0,Expert,1,CHEMBL625297,BAO_0000219,,
6903,A121,F,393.0,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,1,,,80655,9606.0,Expert,1,CHEMBL625298,BAO_0000219,,
6904,A121,F,393.0,,Cytotoxicity against human A121 ovarian cells,1,,,80655,9606.0,Intermediate,1,CHEMBL625960,BAO_0000219,,
6905,A121,F,393.0,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,1,,,80655,9606.0,Intermediate,1,CHEMBL625961,BAO_0000219,,
6906,A121,F,393.0,,In vitro cytotoxicity against human ovarian carcinoma A21,1,,,80655,9606.0,Intermediate,1,CHEMBL625962,BAO_0000219,,
6907,A121,F,393.0,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,1,,,80655,9606.0,Intermediate,1,CHEMBL624717,BAO_0000219,,
6908,A121,F,393.0,,Inhibitory activity of compound against human A121 ovarian cell line.,1,,,80655,9606.0,Intermediate,1,CHEMBL624718,BAO_0000219,,
6909,A121,F,393.0,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,1,,,80655,9606.0,Intermediate,1,CHEMBL624719,BAO_0000219,,
6910,A121,F,393.0,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,1,,,80655,9606.0,Intermediate,1,CHEMBL624720,BAO_0000219,,
6911,A 172,F,622.0,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,1,,,80012,9606.0,Intermediate,1,CHEMBL624721,BAO_0000219,,
6912,A 172,F,622.0,,In vitro cytotoxicity against A172 human tumor cell lines.,1,,,80012,9606.0,Expert,1,CHEMBL624722,BAO_0000219,,
6913,A 172,F,622.0,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,1,,,80012,9606.0,Intermediate,1,CHEMBL877597,BAO_0000219,,
6914,A 172,F,622.0,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,1,,,80012,9606.0,Intermediate,1,CHEMBL624723,BAO_0000219,,
6915,A 172,F,622.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,1,,,80012,9606.0,Intermediate,1,CHEMBL624724,BAO_0000219,,
6916,,B,,,Association constant against A2 adenosine receptor,4,,,104729,9615.0,Autocuration,1,CHEMBL624725,BAO_0000224,,
6917,A2,F,1085.0,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,1,,,80656,,Intermediate,1,CHEMBL624726,BAO_0000219,,
6918,,B,,,Ratio of Ki for adenosine A2 and A1 receptor binding,5,,,104713,10116.0,Autocuration,1,CHEMBL857535,BAO_0000224,,
6919,A204,F,623.0,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,1,,,80014,9606.0,Expert,1,CHEMBL624727,BAO_0000219,,
6920,A204,F,623.0,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,1,,,80014,9606.0,Expert,1,CHEMBL624728,BAO_0000219,,
6921,A2058,F,404.0,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,1,,,80015,9606.0,Intermediate,1,CHEMBL624729,BAO_0000219,,
6922,A253 cell line,F,973.0,,Growth inhibition against Human squamous cell line(A 253),1,,,80657,9606.0,Intermediate,1,CHEMBL624730,BAO_0000219,,
6923,A253 cell line,F,973.0,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,1,,,80657,9606.0,Intermediate,1,CHEMBL624731,BAO_0000219,,
6924,A253 cell line,F,973.0,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,1,,,80657,9606.0,Intermediate,1,CHEMBL624732,BAO_0000219,,
6925,A253 cell line,F,973.0,,Growth inhibition of A253 cell lines.,1,,,80657,9606.0,Intermediate,1,CHEMBL883245,BAO_0000219,,
6926,A253 cell line,F,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),1,,,80657,9606.0,Intermediate,1,CHEMBL624733,BAO_0000219,,
6927,A253 cell line,F,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,,,80657,9606.0,Intermediate,1,CHEMBL624734,BAO_0000219,,
6928,A253 cell line,F,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,,,80657,9606.0,Intermediate,1,CHEMBL624735,BAO_0000219,,
6929,A2780,F,478.0,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL621780,BAO_0000219,,
6930,A2780,F,478.0,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL877598,BAO_0000219,,
6931,A2780,F,478.0,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,1,,,81034,9606.0,Expert,1,CHEMBL621781,BAO_0000219,,
6932,A2780,F,478.0,,Cytotoxicity against human cancer cell lines A2780 (ovarian),1,,,81034,9606.0,Intermediate,1,CHEMBL621782,BAO_0000219,,
6933,A2780,F,478.0,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,1,,,81034,9606.0,Expert,1,CHEMBL621783,BAO_0000219,,
6934,A2780,F,478.0,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,1,,,81034,9606.0,Intermediate,1,CHEMBL621784,BAO_0000219,,
6935,A2780,F,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,,,81034,9606.0,Intermediate,1,CHEMBL621785,BAO_0000219,,
6936,A2780,F,478.0,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,1,,,81034,9606.0,Expert,1,CHEMBL621968,BAO_0000219,,
6937,A2780,F,478.0,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,1,,,81034,9606.0,Expert,1,CHEMBL621969,BAO_0000219,,
6938,A2780,F,478.0,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,1,,,81034,9606.0,Expert,1,CHEMBL621970,BAO_0000219,,
6939,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,1,,,81034,9606.0,Intermediate,1,CHEMBL621971,BAO_0000219,,
6940,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,1,,,81034,9606.0,Intermediate,1,CHEMBL621972,BAO_0000219,,
6941,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,1,,,81034,9606.0,Intermediate,1,CHEMBL884108,BAO_0000219,,
6942,,F,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,0,,,22224,10029.0,Autocuration,1,CHEMBL623826,BAO_0000019,,
6943,CHO-AA8,A,185.0,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,0,,,22224,10029.0,Autocuration,1,CHEMBL623827,BAO_0000219,,
6944,CHO-AA8,F,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,0,,,22224,10029.0,Autocuration,1,CHEMBL623828,BAO_0000219,,
6945,CHO-AA8,F,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,0,,,22224,10029.0,Autocuration,1,CHEMBL623829,BAO_0000219,,
6946,CHO-AA8,F,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),0,,,22224,10029.0,Autocuration,1,CHEMBL623830,BAO_0000219,,
6947,,F,,,Growth inhibition against CHO-derived cell line AA8,0,,,22224,10029.0,Autocuration,1,CHEMBL623831,BAO_0000019,,
6948,CHO-AA8,F,185.0,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],0,,,22224,10029.0,Autocuration,1,CHEMBL623832,BAO_0000219,,
6949,CHO-AA8,F,185.0,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,1,,,80089,36483.0,Expert,1,CHEMBL623833,BAO_0000219,,
6950,CHO-AA8,F,185.0,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,1,,,80089,10029.0,Expert,1,CHEMBL623834,BAO_0000219,,
6951,CHO-AA8,F,185.0,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,0,,,22224,10029.0,Autocuration,1,CHEMBL623835,BAO_0000219,,
6952,CHO-AA8,F,185.0,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,0,,,22224,10029.0,Autocuration,1,CHEMBL623836,BAO_0000219,,
6953,CHO-AA8,F,185.0,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,0,,,22224,10029.0,Autocuration,1,CHEMBL623837,BAO_0000219,,
6954,CHO-AA8,F,185.0,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,1,,,80089,10029.0,Expert,1,CHEMBL623838,BAO_0000219,,
6955,,F,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,8,,,12675,,Autocuration,1,CHEMBL623839,BAO_0000019,,
6956,,F,,,Number of binding sites (n) of isolated serum protein AAG,8,,,12675,,Autocuration,1,CHEMBL623840,BAO_0000019,,
6957,,B,,,Association constant for binding to AATT duplex,3,,,22222,,Intermediate,1,CHEMBL623841,BAO_0000225,,
6958,ABAE,F,416.0,,Inhibition of ABAE human fibroblast cell proliferation,1,,,100090,9606.0,Expert,1,CHEMBL623842,BAO_0000219,,
6959,AC755,F,1064.0,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",1,,,80668,10090.0,Intermediate,1,CHEMBL623843,BAO_0000218,,
6960,,F,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,9,,,102444,9986.0,Expert,1,CHEMBL618669,BAO_0000218,,
6961,,F,,In vivo,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,9,,,102444,9986.0,Expert,1,CHEMBL618670,BAO_0000218,,
6962,,B,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,8,,,69,,Autocuration,1,CHEMBL618671,BAO_0000357,,
6963,,B,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,8,,,69,,Autocuration,1,CHEMBL618672,BAO_0000357,,
6964,ACH-2 cell line,F,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,1,,,80669,9606.0,Intermediate,1,CHEMBL618673,BAO_0000219,,
6965,ACH-2 cell line,F,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),1,,,80669,9606.0,Intermediate,1,CHEMBL618674,BAO_0000219,,
6966,T cell line,F,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,0,,,22224,11676.0,Autocuration,1,CHEMBL618675,BAO_0000219,,
6967,T cell line,F,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),0,,,22224,11676.0,Autocuration,1,CHEMBL618676,BAO_0000219,,
6968,T cell line,F,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),0,,,22224,11676.0,Autocuration,1,CHEMBL618677,BAO_0000219,,
6969,ACHN,F,626.0,,Inhibition of growth of renal cancer ACHN cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL618678,BAO_0000219,,
6970,ACHN,F,626.0,,Inhibition of growth of ACHN renal cancer cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL618679,BAO_0000219,,
6971,ACHN,F,626.0,,Inhibitory concentration required against ACHN renal cancer cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL618680,BAO_0000219,,
6972,ACHN,F,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line,1,,,80025,9606.0,Expert,1,CHEMBL618681,BAO_0000219,,
6973,ACHN,F,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,1,,,80025,9606.0,Intermediate,1,CHEMBL618682,BAO_0000219,,
6974,ACHN,F,626.0,,Cytotoxic activity against ACHN Renal cancer cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL618683,BAO_0000219,,
6975,ACHN,F,626.0,,Cytotoxicity evaluation against ACHN renal cancer cells,1,,,80025,9606.0,Intermediate,1,CHEMBL618684,BAO_0000219,,
6976,ACHN,F,626.0,,In vitro antitumor activity against human renal ACHN cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL618685,BAO_0000219,,
6977,ACHN,F,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,,,80025,9606.0,Intermediate,1,CHEMBL876499,BAO_0000219,,
6978,ACHN,F,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,,,80025,9606.0,Intermediate,1,CHEMBL618686,BAO_0000219,,
6979,ACHN,F,626.0,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",1,,,80025,9606.0,Intermediate,1,CHEMBL618687,BAO_0000219,,
6980,ACHN,F,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,,,80025,9606.0,Intermediate,1,CHEMBL618688,BAO_0000219,,
6981,ACHN,F,626.0,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,,,80025,9606.0,Expert,1,CHEMBL618689,BAO_0000219,,
6982,ACHN,F,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,1,,,80025,9606.0,Intermediate,1,CHEMBL618690,BAO_0000219,,
6983,ACHN,F,626.0,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,1,,,80025,9606.0,Intermediate,1,CHEMBL618691,BAO_0000219,,
6984,ACHN,F,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,,,80025,9606.0,Intermediate,1,CHEMBL619373,BAO_0000219,,
6985,ACHN,F,626.0,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",1,,,80025,9606.0,Intermediate,1,CHEMBL884008,BAO_0000219,,
6986,ACHN,F,626.0,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,1,,,80025,9606.0,Intermediate,1,CHEMBL619374,BAO_0000219,,
6987,ACHN,F,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL619375,BAO_0000219,,
6988,ACHN,F,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,1,,,80025,9606.0,Intermediate,1,CHEMBL619376,BAO_0000219,,
6989,ACHN,F,626.0,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL619377,BAO_0000219,,
6990,ACHN,F,626.0,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL619378,BAO_0000219,,
6991,,A,,In vivo,Tmax value after administration of 4 mg/Kg oral dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL872527,BAO_0000218,,
6992,,A,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL876500,BAO_0000218,,
6993,,A,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,,50588,9615.0,Intermediate,1,CHEMBL619379,BAO_0000218,,
6994,,A,,In vivo,Volume distribution after 15 mg/kg iv dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL619538,BAO_0000218,,
6995,,A,,In vivo,Volume distribution after 30 mg/kg po dose in Dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL619539,BAO_0000218,,
6996,,A,,In vivo,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,1,,,50588,9615.0,Intermediate,1,CHEMBL619540,BAO_0000218,,
6997,,A,,In vivo,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL619541,BAO_0000218,,
6998,,A,,In vivo,Volume of distribution was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619542,BAO_0000218,,
6999,,A,,In vivo,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL619543,BAO_0000218,,
7000,,A,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,,50588,9615.0,Expert,1,CHEMBL619544,BAO_0000218,,
7001,,A,,In vivo,The compound was tested for volume of distribution in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619545,BAO_0000218,,
7002,,A,,In vivo,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,1,,,50588,9615.0,Intermediate,1,CHEMBL619546,BAO_0000218,,
7003,,A,,In vivo,Vd (1 mg/kg) was determined in dog (in vivo),1,,,50588,9615.0,Intermediate,1,CHEMBL619547,BAO_0000218,,
7004,,A,,In vivo,Vd in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619548,BAO_0000218,,
7005,,A,,In vivo,Volume distribution was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL619549,BAO_0000218,,
7006,,A,,In vivo,Volume of distribution in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619550,BAO_0000218,,
7007,,A,,In vivo,Volume of distribution by as 4 fold increase by iv administration in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL876501,BAO_0000218,,
7008,,A,,In vivo,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,,,50588,9615.0,Intermediate,1,CHEMBL619551,BAO_0000218,,
7009,,A,,In vivo,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,50588,9615.0,Intermediate,1,CHEMBL619552,BAO_0000218,,
7010,,A,,In vivo,Volume distribution at the dose of 2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619553,BAO_0000218,,
7011,,A,,In vivo,Steady state volume of distribution was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL618722,BAO_0000218,,
7012,,A,,In vivo,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,1,,,50588,9615.0,Intermediate,1,CHEMBL618723,BAO_0000218,,
7013,,A,,In vivo,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,,50588,9615.0,Intermediate,1,CHEMBL618724,BAO_0000218,,
7014,,A,,In vivo,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,,50588,9615.0,Intermediate,1,CHEMBL618725,BAO_0000218,,
7015,,A,,In vivo,Bioavailability in dog (dose 1 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL618726,BAO_0000218,,
7016,,A,,In vivo,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,,,50588,9615.0,Intermediate,1,CHEMBL618727,BAO_0000218,,
7017,,A,,In vivo,Pharmacokinetic property (vdss) was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624233,BAO_0000218,,
7018,,A,,In vivo,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624234,BAO_0000218,,
7019,,A,,In vivo,Vdss was determined after iv 0.1 mg/kg administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624235,BAO_0000218,,
7020,,A,,In vivo,Volume displacement was calculated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624236,BAO_0000218,,
7021,,A,,In vivo,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624237,BAO_0000218,,
7022,,A,,In vivo,Volume distribution constant was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624238,BAO_0000218,,
7023,,A,,In vivo,Volume distribution at a dose of 1 uM/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624239,BAO_0000218,,
7024,,A,,In vivo,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,,50588,9615.0,Intermediate,1,CHEMBL875829,BAO_0000218,,
7025,,A,,In vivo,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624240,BAO_0000218,,
7026,,A,,In vivo,Volume distribution (Vdss) was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624241,BAO_0000218,,
7027,,A,,In vivo,Volume distribution (Vdss) was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624242,BAO_0000218,,
7028,,A,,In vivo,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624243,BAO_0000218,,
7029,,A,,In vivo,Volume of distribution in steady state was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624244,BAO_0000218,,
7030,,A,,In vivo,Volume of distribution of compound was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624245,BAO_0000218,,
7031,,A,,In vivo,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624246,BAO_0000218,,
7032,,A,,In vivo,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,,,50588,9615.0,Intermediate,1,CHEMBL624247,BAO_0000218,,
7033,,A,,In vivo,Volume of distribution (Vdss) was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624248,BAO_0000218,,
7034,,A,,In vivo,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,50588,9615.0,Intermediate,1,CHEMBL624249,BAO_0000218,,
7035,,A,,In vivo,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,50588,9615.0,Intermediate,1,CHEMBL624250,BAO_0000218,,
7036,,A,,In vivo,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,50588,9615.0,Intermediate,1,CHEMBL624251,BAO_0000218,,
7037,,A,,,Maximum rate of depolarization of the upstroke of the action potential,1,,,50588,9615.0,Intermediate,1,CHEMBL624252,BAO_0000218,,
7038,,A,,In vivo,Steady state volume distribution in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624253,BAO_0000218,,
7039,,A,,In vivo,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,1,,,50588,9615.0,Intermediate,1,CHEMBL624950,BAO_0000218,,
7040,,A,,In vivo,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624951,BAO_0000218,,
7041,,A,,In vivo,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL875830,BAO_0000218,,
7042,,A,,In vivo,Volume distribution in dog after administration of 1 mg/kg iv,1,,,50588,9615.0,Intermediate,1,CHEMBL624952,BAO_0000218,,
7043,,A,,In vivo,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624953,BAO_0000218,,
7044,,A,,In vivo,Vss after intravenous administration (0.5 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624954,BAO_0000218,,
7045,,A,,In vivo,Vss on i.v. administration of 2 mg/kg was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624955,BAO_0000218,,
7046,,A,,,Vss was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624956,BAO_0000218,,
7047,,A,,,Vss in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625129,BAO_0000218,,
7048,,A,,In vivo,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625130,BAO_0000218,,
7049,,A,,In vivo,Volume distribution in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625131,BAO_0000218,,
7050,,A,,In vivo,Volume of distribution in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625132,BAO_0000218,,
7051,,A,,In vivo,Tested for the oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL872263,BAO_0000218,,
7060,,A,,In vivo,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL624336,BAO_0000218,,
7061,,A,,In vivo,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL624337,BAO_0000218,,
7062,,A,,In vivo,Bioavailability after peroral administration of 50 mg/kg of dose in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL624338,BAO_0000218,,
7063,,A,,In vivo,Bioavailability was measured in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL624339,BAO_0000218,,
7064,,A,,In vivo,Bioavailability in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL624340,BAO_0000218,,
7065,,A,,In vivo,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,50594,10090.0,Intermediate,1,CHEMBL624341,BAO_0000218,,
7066,,A,,In vivo,Bioavailability in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL624342,BAO_0000218,,
7067,,A,,In vivo,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL624343,BAO_0000218,,
7068,,A,,In vivo,Oral bioavailability in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL624344,BAO_0000218,,
7069,,A,,In vivo,Oral availability at 50 mg/kg po in male mice,1,,,50594,10090.0,Intermediate,1,CHEMBL624345,BAO_0000218,,
7070,,A,,In vivo,Oral bioavailability in mouse (dose 10 mg/kg),1,,,50594,10090.0,Intermediate,1,CHEMBL624346,BAO_0000218,,
7071,,A,,In vivo,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,1,,,50594,10090.0,Expert,1,CHEMBL624347,BAO_0000218,,
7072,,A,,In vivo,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",1,,,50594,10090.0,Intermediate,1,CHEMBL624348,BAO_0000218,,
7074,,A,,In vivo,Oral bioavailability in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL622754,BAO_0000218,,
7075,,A,,In vivo,Oral bioavailability in vivo in mice;ND=Not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL622755,BAO_0000218,,
7076,,A,,In vivo,Oral bioavailability in mouse at 10 mg/kg of the compound,1,,,50594,10090.0,Intermediate,1,CHEMBL622756,BAO_0000218,,
7077,,A,,In vivo,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),1,,,50594,10090.0,Intermediate,1,CHEMBL622757,BAO_0000218,,
7078,,A,,In vivo,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),1,,,50594,10090.0,Intermediate,1,CHEMBL622758,BAO_0000218,,
7079,,A,,In vivo,Tested for bioavailability of the compound,1,,,50594,10090.0,Intermediate,1,CHEMBL622759,BAO_0000218,,
7080,,A,,In vivo,Tested for half life at the dose of 10 mg/kg when administered intravenously,1,,,50594,10090.0,Intermediate,1,CHEMBL622760,BAO_0000218,,
7081,,A,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,1,,,50594,10090.0,Intermediate,1,CHEMBL622761,BAO_0000218,1969.0,
7082,,A,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,1,,,50594,10090.0,Intermediate,1,CHEMBL622762,BAO_0000218,1969.0,
7083,,A,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,1,,,50594,10090.0,Intermediate,1,CHEMBL622763,BAO_0000218,1969.0,
7084,,A,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,1,,,50594,10090.0,Intermediate,1,CHEMBL622764,BAO_0000218,1969.0,
7085,,A,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,1,,,50594,10090.0,Intermediate,1,CHEMBL622765,BAO_0000218,1969.0,
7086,,F,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622766,BAO_0000218,,
7087,,A,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622767,BAO_0000218,,
7088,,A,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,1,,,50594,10090.0,Intermediate,1,CHEMBL622768,BAO_0000218,,
7089,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL875948,BAO_0000218,178.0,
7090,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622769,BAO_0000218,178.0,
7091,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622770,BAO_0000218,178.0,
7092,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622771,BAO_0000218,178.0,
7093,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622772,BAO_0000218,178.0,
7094,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622773,BAO_0000218,178.0,
7095,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL622774,BAO_0000218,178.0,
7096,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621725,BAO_0000218,10000001.0,
7097,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621726,BAO_0000218,10000001.0,
7098,A2780,F,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,1,,,81034,9606.0,Intermediate,1,CHEMBL621727,BAO_0000219,,
7099,A2780,F,478.0,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,1,,,81034,9606.0,Expert,1,CHEMBL622413,BAO_0000219,,
7100,A2780,F,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL622414,BAO_0000219,,
7101,A2780,F,478.0,,Inhibition of A2780 cell clonogenic assay,1,,,81034,9606.0,Expert,1,CHEMBL622415,BAO_0000219,,
7102,A2780,F,478.0,,Cytotoxic effect on ovarian cancer cell line (A2780),1,,,81034,9606.0,Expert,1,CHEMBL884001,BAO_0000219,,
7103,A2780,F,478.0,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,1,,,81034,9606.0,Intermediate,1,CHEMBL622416,BAO_0000219,,
7104,A2780,F,478.0,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",1,,,81034,9606.0,Intermediate,1,CHEMBL622417,BAO_0000219,,
7105,A2780,F,478.0,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,1,,,81034,9606.0,Expert,1,CHEMBL622590,BAO_0000219,,
7106,A2780,F,478.0,,Antiproliferative activity against human A2780 cells,1,,,81034,9606.0,Expert,1,CHEMBL622591,BAO_0000219,,
7107,A2780,F,478.0,,Inhibition of human A2780 cell proliferation,1,,,81034,9606.0,Expert,1,CHEMBL622592,BAO_0000219,,
7108,A2780,F,478.0,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,1,,,81034,9606.0,Expert,1,CHEMBL622593,BAO_0000219,,
7109,A2780,F,478.0,,Inhibition of human A2780 cell proliferation (No data),1,,,81034,9606.0,Expert,1,CHEMBL622594,BAO_0000219,,
7110,A2780,F,478.0,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL622595,BAO_0000219,,
7111,A2780,F,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780,1,,,81034,9606.0,Intermediate,1,CHEMBL622596,BAO_0000219,,
7112,A2780,F,478.0,,Growth inhibition against A2780 wild-type ovarian cell lines,1,,,81034,9606.0,Expert,1,CHEMBL622597,BAO_0000219,,
7113,A2780,F,478.0,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,1,,,81034,9606.0,Intermediate,1,CHEMBL622598,BAO_0000219,,
7114,,F,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,5,,,104766,9606.0,Autocuration,1,CHEMBL622599,BAO_0000019,,
7115,A2780,F,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,,,81034,9606.0,Intermediate,1,CHEMBL622600,BAO_0000219,,
7116,A2780,F,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,,,81034,9606.0,Intermediate,1,CHEMBL622601,BAO_0000219,,
7117,A2780,F,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,,,81034,9606.0,Intermediate,1,CHEMBL622602,BAO_0000219,,
7118,A2780,F,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,,,81034,9606.0,Intermediate,1,CHEMBL622603,BAO_0000219,,
7119,A2780,F,478.0,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,,,81034,9606.0,Intermediate,1,CHEMBL622604,BAO_0000219,,
7120,A2780,F,478.0,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,,,81034,9606.0,Intermediate,1,CHEMBL622605,BAO_0000219,,
7121,A2780,F,478.0,,In vitro inhibition of human ovarian cell line A2780,1,,,81034,9606.0,Expert,1,CHEMBL622606,BAO_0000219,,
7122,A2780,F,478.0,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",1,,,81034,9606.0,Expert,1,CHEMBL619463,BAO_0000219,,
7123,A2780,F,478.0,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),1,,,81034,9606.0,Intermediate,1,CHEMBL619464,BAO_0000219,,
7124,A2780,F,478.0,,Concentration required to inhibit A2780-cell growth by 50%,1,,,81034,9606.0,Expert,1,CHEMBL619465,BAO_0000219,,
7125,A2780,F,478.0,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,1,,,81034,9606.0,Expert,1,CHEMBL619466,BAO_0000219,,
7126,A2780,F,478.0,,Cytotoxic effect on human ovarian (A2780) cancer cell line,1,,,81034,9606.0,Expert,1,CHEMBL619467,BAO_0000219,,
7127,A2780,F,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,1,,,81034,9606.0,Intermediate,1,CHEMBL619468,BAO_0000219,,
7128,A2780,F,478.0,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,1,,,81034,9606.0,Expert,1,CHEMBL619469,BAO_0000219,,
7129,A2780,F,478.0,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,,,81034,9606.0,Expert,1,CHEMBL619470,BAO_0000219,,
7130,A2780,F,478.0,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,,,81034,9606.0,Intermediate,1,CHEMBL619471,BAO_0000219,,
7131,A2780,F,478.0,,Cytotoxicity against human ovarian carcinoma A2780 cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL619472,BAO_0000219,,
7132,A2780,F,478.0,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",1,,,81034,9606.0,Intermediate,1,CHEMBL619473,BAO_0000219,,
7133,A2780,F,478.0,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",1,,,81034,9606.0,Intermediate,1,CHEMBL874368,BAO_0000219,,
7134,A2780,F,478.0,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",1,,,81034,9606.0,Intermediate,1,CHEMBL884003,BAO_0000219,,
7135,A2780,F,478.0,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",1,,,81034,9606.0,Intermediate,1,CHEMBL622690,BAO_0000219,,
7136,A2780,F,478.0,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,1,,,81034,9606.0,Intermediate,1,CHEMBL622691,BAO_0000219,,
7137,A2780,F,478.0,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,,,81034,9606.0,Intermediate,1,CHEMBL622692,BAO_0000219,,
7138,A2780,F,478.0,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,,,81034,9606.0,Intermediate,1,CHEMBL623406,BAO_0000219,,
7139,A2780,F,478.0,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",1,,,81034,9606.0,Intermediate,1,CHEMBL884004,BAO_0000219,,
7140,A2780,F,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,1,,,81034,9606.0,Intermediate,1,CHEMBL623407,BAO_0000219,,
7141,A2780,F,478.0,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL623408,BAO_0000219,,
7142,A2780,F,478.0,,In vitro antitumor activity against A2780 cell line.,1,,,81034,9606.0,Expert,1,CHEMBL623409,BAO_0000219,,
7143,A2780,F,478.0,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,1,,,81034,9606.0,Intermediate,1,CHEMBL623410,BAO_0000219,,
7144,A2780,F,478.0,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,1,,,81034,9606.0,Expert,1,CHEMBL623576,BAO_0000219,,
7145,ACHN,F,626.0,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,1,,,80025,9606.0,Intermediate,1,CHEMBL623577,BAO_0000219,,
7146,ACHN,F,626.0,,The IC50 value was measured on ACHN cell line in renal tumor type.,1,,,80025,9606.0,Intermediate,1,CHEMBL623578,BAO_0000219,,
7147,ACHN,F,626.0,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,1,,,80025,9606.0,Intermediate,1,CHEMBL623579,BAO_0000219,,
7148,ACHN,F,626.0,,In vitro lethal concentration against most sensitive ACHN cell line,1,,,80025,9606.0,Expert,1,CHEMBL623580,BAO_0000219,,
7149,ACHN,F,626.0,,Tested for cytotoxic activity against renal cancer ACHN cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL623581,BAO_0000219,,
7150,ACHN,F,626.0,,Compound tested for growth inhibition of renal cancer cell line ACHN,1,,,80025,9606.0,Intermediate,1,CHEMBL857456,BAO_0000219,,
7151,ACHN,F,626.0,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL623582,BAO_0000219,,
7152,ACHN,F,626.0,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,1,,,80025,9606.0,Intermediate,1,CHEMBL623583,BAO_0000219,,
7153,ACHN,F,626.0,,In vitro anticancer activity against ACHN renal cancer cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL623584,BAO_0000219,,
7154,ACHN,F,626.0,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,1,,,80025,9606.0,Intermediate,1,CHEMBL623585,BAO_0000219,,
7155,ACHN,F,626.0,,Percent selectivity was evaluated in renal ACHN cell lines,1,,,80025,9606.0,Intermediate,1,CHEMBL623586,BAO_0000219,,
7156,ACHN,F,626.0,,In vitro inhibitory activity against renal ACHN cancer cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL623587,BAO_0000219,,
7157,ACHN,F,626.0,,Tested for cytotoxicity against ACHN cell lines in renal cancer,1,,,80025,9606.0,Intermediate,1,CHEMBL875279,BAO_0000219,,
7158,ACHN,F,626.0,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL623588,BAO_0000219,,
7159,ACHN,F,626.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,,,80025,9606.0,Intermediate,1,CHEMBL623589,BAO_0000219,,
7160,ACHN,F,626.0,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,1,,,80025,9606.0,Intermediate,1,CHEMBL623590,BAO_0000219,,
7161,ACHN,F,626.0,,Cytotoxic effect on renal cancer line ACHN,1,,,80025,9606.0,Expert,1,CHEMBL623591,BAO_0000219,,
7162,ACHN,F,626.0,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL623592,BAO_0000219,,
7163,ACHN,F,626.0,,In vitro inhibition of Renal Cancer ACHN cell lines,1,,,80025,9606.0,Intermediate,1,CHEMBL623593,BAO_0000219,,
7164,ACHN,F,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells,1,,,80025,9606.0,Intermediate,1,CHEMBL623594,BAO_0000219,,
7165,ACHN,F,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells.,1,,,80025,9606.0,Expert,1,CHEMBL621833,BAO_0000219,,
7166,ACHN,F,626.0,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,1,,,80025,9606.0,Intermediate,1,CHEMBL621834,BAO_0000219,,
7167,ACHN,F,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,,,80025,9606.0,Intermediate,1,CHEMBL621835,BAO_0000219,,
7168,ACHN,F,626.0,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",1,,,80025,9606.0,Intermediate,1,CHEMBL621836,BAO_0000219,,
7169,ACHN,F,626.0,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,1,,,80025,9606.0,Intermediate,1,CHEMBL621837,BAO_0000219,,
7170,ACHN,F,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,,,80025,9606.0,Intermediate,1,CHEMBL875280,BAO_0000219,,
7171,ACHN,F,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,1,,,80025,9606.0,Intermediate,1,CHEMBL621838,BAO_0000219,,
7172,ACHN,F,626.0,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,1,,,80025,9606.0,Intermediate,1,CHEMBL621839,BAO_0000219,,
7173,,A,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL621840,BAO_0000019,,
7174,,F,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,8,,,10647,,Autocuration,1,CHEMBL621841,BAO_0000019,,
7175,HEL,F,468.0,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,1,,,50529,10358.0,Expert,1,CHEMBL622979,BAO_0000218,,
7176,,F,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,1,,,50529,10358.0,Intermediate,1,CHEMBL876595,BAO_0000218,,
7177,,B,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),8,,,12159,,Autocuration,1,CHEMBL620221,BAO_0000357,,
7178,,B,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),8,,,12159,,Autocuration,1,CHEMBL620222,BAO_0000357,,
7179,ADDP cell line,F,979.0,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,1,,,80670,9913.0,Intermediate,1,CHEMBL620506,BAO_0000219,,
7180,ADJ/PC6,F,980.0,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,1,,,80671,10090.0,Intermediate,1,CHEMBL620507,BAO_0000219,,
7181,ADJ/PC6,F,980.0,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,1,,,80671,10090.0,Intermediate,1,CHEMBL620508,BAO_0000219,,
7182,ADJ/PC6,F,980.0,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",1,,,80671,10090.0,Intermediate,1,CHEMBL620509,BAO_0000219,,
7183,ADJ/PC6,F,980.0,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,1,,,80671,10090.0,Intermediate,1,CHEMBL620510,BAO_0000219,,
7184,ADJ/PC6,A,980.0,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,1,,,80671,10090.0,Intermediate,1,CHEMBL620511,BAO_0000219,,
7185,ADJ/PC6,F,980.0,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,1,,,80671,10090.0,Intermediate,1,CHEMBL620512,BAO_0000219,,
7186,,F,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,0,,,22224,10090.0,Autocuration,1,CHEMBL620513,BAO_0000019,,
7187,,F,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,0,,,22224,10090.0,Autocuration,1,CHEMBL620514,BAO_0000019,,
7188,,F,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,0,,,22224,10090.0,Autocuration,1,CHEMBL620515,BAO_0000019,,
7189,,A,,In vivo,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),0,,,22224,1423.0,Autocuration,1,CHEMBL620516,BAO_0000218,,
7190,,A,,,AUC value in dog after IV administration at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL620517,BAO_0000218,1969.0,
7191,,A,,,AUC value in dog after oral administration at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL620518,BAO_0000218,1969.0,
7192,,A,,In vivo,Cmax value in dog after oral administration at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL620519,BAO_0000218,,
7193,,A,,In vivo,Bioavailability in dog after oral administration at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621386,BAO_0000218,,
7194,,A,,In vivo,Tmax value in dog after oral administration at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621387,BAO_0000218,,
7195,,A,,In vivo,Compound was evaluated for its clearance when administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621388,BAO_0000218,,
7196,,A,,In vivo,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621389,BAO_0000218,,
7197,,A,,In vivo,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621390,BAO_0000218,,
7198,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Intermediate,1,CHEMBL621391,BAO_0000100,,
7199,,A,,,Half life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621392,BAO_0000218,,
7200,,A,,,Time taken for EC90 was determined when tested in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621393,BAO_0000218,,
7201,,A,,,Half life (iv) was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621394,BAO_0000218,,
7202,,A,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,,,50588,9615.0,Intermediate,1,CHEMBL621395,BAO_0000218,2107.0,
7203,,A,,,Area under the curve was calculated in dog after iv administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621396,BAO_0000218,,
7204,,A,,,Area under the curve was calculated in dog after peroral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621397,BAO_0000218,,
7205,,A,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,1,,,50588,9615.0,Intermediate,1,CHEMBL621398,BAO_0000218,,
7206,,A,,,pKa was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618818,BAO_0000218,,
7207,,A,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,1,,,50588,9615.0,Intermediate,1,CHEMBL618819,BAO_0000218,,
7208,,A,,In vivo,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618820,BAO_0000218,,
7209,,A,,In vivo,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL873810,BAO_0000218,,
7210,,A,,In vivo,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,,,50588,9615.0,Intermediate,1,CHEMBL876606,BAO_0000218,,
7211,,A,,,Compound was evaluated for the half-life (t 1/2) in hours,1,,,50588,9615.0,Intermediate,1,CHEMBL618821,BAO_0000218,,
7212,,A,,In vivo,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,,50588,9615.0,Intermediate,1,CHEMBL618822,BAO_0000218,178.0,
7213,,A,,In vivo,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,,50588,9615.0,Intermediate,1,CHEMBL618823,BAO_0000218,178.0,
7214,,A,,In vivo,Half life after intravenous administration of 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618824,BAO_0000218,,
7215,,A,,,Half life was measured in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL618825,BAO_0000218,,
7216,,A,,In vivo,Half life period in dog after 5 mg/kg dose,1,,,50588,9615.0,Intermediate,1,CHEMBL618826,BAO_0000218,,
7217,,A,,,Half life period was evaluated in dog; 4-4.8,1,,,50588,9615.0,Intermediate,1,CHEMBL618827,BAO_0000218,,
7218,,A,,In vivo,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,,50588,9615.0,Intermediate,1,CHEMBL618828,BAO_0000218,,
7219,,A,,In vivo,Half-life was determined in dog after a3 mg/kg of iv dose,1,,,50588,9615.0,Intermediate,1,CHEMBL618829,BAO_0000218,,
7220,,A,,,Half-life was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL618830,BAO_0000218,,
7221,,A,,,Half life in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618831,BAO_0000218,,
7222,,A,,In vivo,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619489,BAO_0000218,1969.0,
7223,,A,,In vivo,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL619649,BAO_0000218,,
7224,,A,,In vivo,Compound was evaluated for the half life period after iv administration in Beagle dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL876607,BAO_0000218,,
7225,,A,,In vivo,Compound was evaluated for the half life period after oral administration in conscious dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL619650,BAO_0000218,,
7226,,A,,,Compound was tested for half life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619651,BAO_0000218,,
7227,,A,,,Compound was tested for its half life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619652,BAO_0000218,,
7228,,A,,In vivo,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619653,BAO_0000218,,
7229,,A,,,Half life of compound in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL619654,BAO_0000218,,
7230,,A,,In vivo,Half life (iv) was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL619655,BAO_0000218,,
7231,,A,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),1,,,50588,9615.0,Intermediate,1,CHEMBL619656,BAO_0000218,178.0,
7232,,A,,In vivo,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,,,50588,9615.0,Intermediate,1,CHEMBL873812,BAO_0000218,1969.0,
7233,,F,,In vivo,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621365,BAO_0000218,1969.0,
7234,,A,,,Half life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621366,BAO_0000218,,
7235,,A,,,Half life in dog plasma,1,,,50588,9615.0,Intermediate,1,CHEMBL621367,BAO_0000218,1969.0,
7236,,A,,In vivo,Half life in dog plasma after administration of 0.25 mg/kg iv,1,,,50588,9615.0,Intermediate,1,CHEMBL621368,BAO_0000218,1969.0,
7237,,A,,In vivo,Half life in dog plasma after administration of 1 mg/kg iv,1,,,50588,9615.0,Intermediate,1,CHEMBL621369,BAO_0000218,1969.0,
7238,,A,,In vivo,Half life in dog plasma was determined at dose 10 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621370,BAO_0000218,1969.0,
7239,,A,,,Half life in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621371,BAO_0000218,,
7240,,A,,In vivo,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621372,BAO_0000218,,
7241,,A,,,Half life upon exposure to human plasma,1,,,50588,9615.0,Intermediate,1,CHEMBL621373,BAO_0000218,1969.0,
7242,,A,,,Half life was calculated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621374,BAO_0000218,,
7243,,A,,,Half life was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621375,BAO_0000218,,
7244,,A,,,Half life was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621376,BAO_0000218,,
7245,,A,,In vivo,Half life by intravenous administration of 1.2 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL619624,BAO_0000218,,
7246,,A,,,Half life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL875840,BAO_0000218,,
7247,,A,,,Half life in dog after intra venous administration of the compound,1,,,50588,9615.0,Intermediate,1,CHEMBL619625,BAO_0000218,,
7248,,A,,,Half life in dog after intra venous administration of the compound; ND means Not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL619626,BAO_0000218,,
7249,,A,,In vivo,Half life in dog after po administration of the compound,1,,,50588,9615.0,Intermediate,1,CHEMBL619627,BAO_0000218,,
7250,,A,,In vivo,Half life in dog after po administration of the compound; ND means Not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL873817,BAO_0000218,,
7251,,A,,In vivo,Half life in dog at the single oral dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL619628,BAO_0000218,,
7252,,A,,,Half life in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL619629,BAO_0000218,,
7253,,A,,In vivo,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,1,,,50588,9615.0,Intermediate,1,CHEMBL619630,BAO_0000218,,
7254,,A,,,Half life in rat,1,,,50588,9615.0,Intermediate,1,CHEMBL619631,BAO_0000218,,
7255,,A,,In vivo,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,,50588,9615.0,Intermediate,1,CHEMBL619632,BAO_0000218,,
7256,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619633,BAO_0000218,10000001.0,
7257,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL875841,BAO_0000218,10000001.0,
7258,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619634,BAO_0000218,10000001.0,
7259,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619635,BAO_0000218,10000001.0,
7260,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619636,BAO_0000218,10000001.0,
7261,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619637,BAO_0000218,10000004.0,
7262,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619638,BAO_0000218,10000004.0,
7263,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619639,BAO_0000218,10000004.0,
7264,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619640,BAO_0000218,10000004.0,
7265,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619641,BAO_0000218,10000004.0,
7266,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619642,BAO_0000218,10000004.0,
7267,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619643,BAO_0000218,10000004.0,
7268,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL619644,BAO_0000218,948.0,
7269,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621112,BAO_0000218,948.0,
7270,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621113,BAO_0000218,948.0,
7271,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621114,BAO_0000218,948.0,
7272,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621115,BAO_0000218,948.0,
7273,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621116,BAO_0000218,948.0,
7274,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621117,BAO_0000218,948.0,
7275,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621118,BAO_0000218,2113.0,
7276,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621119,BAO_0000218,2113.0,
7277,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621120,BAO_0000218,2113.0,
7278,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621757,BAO_0000218,2113.0,
7279,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621758,BAO_0000218,2113.0,
7280,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621759,BAO_0000218,2113.0,
7281,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621760,BAO_0000218,2113.0,
7282,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621761,BAO_0000218,2107.0,
7283,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621762,BAO_0000218,2107.0,
7284,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL621763,BAO_0000218,2107.0,
7285,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624502,BAO_0000218,2107.0,
7286,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624503,BAO_0000218,2107.0,
7287,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624504,BAO_0000218,2107.0,
7288,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624505,BAO_0000218,2107.0,
7289,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624506,BAO_0000218,2048.0,
7290,A2780,F,478.0,,In vitro cytotoxicity against A2780 (human ovarian cancer),1,,,81034,9606.0,Intermediate,1,CHEMBL624507,BAO_0000219,,
7291,A2780,F,478.0,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,1,,,81034,9606.0,Intermediate,1,CHEMBL624508,BAO_0000219,,
7292,A2780,F,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,1,,,81034,9606.0,Intermediate,1,CHEMBL624509,BAO_0000219,,
7293,A2780,F,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,1,,,81034,9606.0,Intermediate,1,CHEMBL624510,BAO_0000219,,
7294,A2780,F,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,1,,,81034,9606.0,Expert,1,CHEMBL875956,BAO_0000219,,
7295,A2780,F,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,1,,,81034,9606.0,Expert,1,CHEMBL839885,BAO_0000219,,
7296,A2780,F,478.0,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,1,,,81034,9606.0,Expert,1,CHEMBL624511,BAO_0000219,,
7297,A2780,F,478.0,,In vitro cytotoxicity against A2780 cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL624512,BAO_0000219,,
7298,A2780,F,478.0,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,1,,,81034,9606.0,Intermediate,1,CHEMBL624513,BAO_0000219,,
7299,A2780,F,478.0,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL624514,BAO_0000219,,
7300,A2780,F,478.0,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,1,,,81034,9606.0,Intermediate,1,CHEMBL618547,BAO_0000218,,
7301,A2780,F,478.0,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",1,,,81034,9606.0,Intermediate,1,CHEMBL618548,BAO_0000219,,
7302,A2780,F,478.0,,Inhibition of tubulin polymerization in analogy of ca.,1,,,81034,9606.0,Intermediate,1,CHEMBL618549,BAO_0000219,,
7303,A2780,F,478.0,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,1,,,81034,9606.0,Intermediate,1,CHEMBL618550,BAO_0000219,,
7304,A2780,F,478.0,,Cytotoxic effect in ovarian cancer cell line (A2780),1,,,81034,9606.0,Expert,1,CHEMBL618551,BAO_0000219,,
7305,A2780,F,478.0,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,1,,,81034,9606.0,Intermediate,1,CHEMBL618552,BAO_0000219,,
7306,A2780,F,478.0,,Tested for the cytotoxicity in A2780 ovarian cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL618553,BAO_0000219,,
7307,A2780,F,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,,,81034,9606.0,Intermediate,1,CHEMBL618554,BAO_0000219,,
7308,A2780,F,478.0,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,1,,,81034,9606.0,Intermediate,1,CHEMBL618555,BAO_0000219,,
7309,A2780cisR,F,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,1,,,80017,,Intermediate,1,CHEMBL618556,BAO_0000219,,
7310,A2780cisR,F,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,,,80017,,Intermediate,1,CHEMBL618557,BAO_0000219,,
7311,A2780cisR,F,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,1,,,80017,,Intermediate,1,CHEMBL618558,BAO_0000219,,
7312,A2780cisR,F,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),1,,,80017,,Intermediate,1,CHEMBL618559,BAO_0000219,,
7313,A2780,F,478.0,,In vivo log of cells killed after administration of compound in A2780 cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL618560,BAO_0000218,,
7314,A2780,F,478.0,In vivo,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL618561,BAO_0000218,,
7315,A2780,F,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,1,,,81034,9606.0,Intermediate,1,CHEMBL618562,BAO_0000219,,
7316,A2780,F,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,1,,,81034,9606.0,Intermediate,1,CHEMBL618563,BAO_0000219,,
7317,A2780,F,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,1,,,81034,9606.0,Intermediate,1,CHEMBL618564,BAO_0000219,,
7318,A2780,F,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,1,,,81034,9606.0,Intermediate,1,CHEMBL618565,BAO_0000219,,
7319,A2780,F,478.0,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),1,,,81034,9606.0,Intermediate,1,CHEMBL618566,BAO_0000218,,
7320,A2780,F,478.0,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,1,,,81034,9606.0,Intermediate,1,CHEMBL618567,BAO_0000219,,
7321,A2780,F,478.0,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,1,,,81034,9606.0,Expert,1,CHEMBL618568,BAO_0000219,,
7322,A2780,F,478.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,,,81034,9606.0,Expert,1,CHEMBL618569,BAO_0000219,,
7323,A2780,F,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,1,,,81034,9606.0,Intermediate,1,CHEMBL621857,BAO_0000219,,
7324,A2780,F,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,1,,,81034,9606.0,Intermediate,1,CHEMBL621858,BAO_0000219,,
7325,A2780,F,478.0,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,1,,,81034,9606.0,Intermediate,1,CHEMBL621859,BAO_0000219,,
7326,A2780,F,478.0,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",1,,,81034,9606.0,Intermediate,1,CHEMBL621860,BAO_0000219,,
7327,A2780,F,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),1,,,81034,9606.0,Intermediate,1,CHEMBL621861,BAO_0000219,,
7328,A2780,F,478.0,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",1,,,81034,9606.0,Expert,1,CHEMBL621862,BAO_0000219,,
7329,A2780,F,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,,,81034,9606.0,Intermediate,1,CHEMBL621863,BAO_0000219,,
7330,A2780,F,478.0,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,,,81034,9606.0,Intermediate,1,CHEMBL621864,BAO_0000219,,
7331,A2780,F,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,,,81034,9606.0,Intermediate,1,CHEMBL621865,BAO_0000219,,
7332,A2780,F,478.0,,In vitro antiproliferative activity against A2780 cell line,1,,,81034,10090.0,Intermediate,1,CHEMBL621866,BAO_0000219,,
7333,A2780,F,478.0,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,1,,,81034,10090.0,Expert,1,CHEMBL621867,BAO_0000219,,
7334,A2780,F,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,1,,,81034,9606.0,Intermediate,1,CHEMBL621868,BAO_0000219,,
7335,A2780,F,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,1,,,81034,9606.0,Intermediate,1,CHEMBL875282,BAO_0000219,,
7336,,A,,,Vc value in dog after IV administration at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621869,BAO_0000218,,
7337,,A,,In vivo,Half life period in dog after IV administration at a dose of 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621870,BAO_0000218,,
7338,,A,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,0,,,22224,9527.0,Autocuration,1,CHEMBL621871,BAO_0000019,,
7339,,A,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL621243,BAO_0000218,1969.0,
7340,,A,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL621244,BAO_0000218,1969.0,
7341,,A,,In vivo,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,0,,,22224,9541.0,Autocuration,1,CHEMBL621245,BAO_0000218,,
7342,,A,,In vivo,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,0,,,22224,9541.0,Autocuration,1,CHEMBL621246,BAO_0000218,,
7343,,A,,In vivo,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,0,,,22224,9541.0,Autocuration,1,CHEMBL621247,BAO_0000218,,
7344,,A,,In vivo,Oral Bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL618386,BAO_0000218,,
7345,,A,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,0,,,22224,9527.0,Autocuration,1,CHEMBL618387,BAO_0000218,,
7346,,A,,,Area under curve value in monkey at a dose of 5 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL618388,BAO_0000218,,
7347,,A,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,0,,,22224,9527.0,Autocuration,1,CHEMBL618389,BAO_0000218,,
7348,,A,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL618574,BAO_0000019,,
7349,,A,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL618575,BAO_0000019,,
7350,,A,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,0,,,22224,9527.0,Autocuration,1,CHEMBL618576,BAO_0000019,,
7351,,A,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618577,BAO_0000218,,
7352,,A,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL876487,BAO_0000218,,
7353,,A,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL618578,BAO_0000218,,
7354,,A,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618579,BAO_0000218,,
7355,,A,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618580,BAO_0000019,,
7356,,A,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL618581,BAO_0000218,,
7357,,A,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,0,,,22224,9527.0,Autocuration,1,CHEMBL618582,BAO_0000218,,
7358,,A,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL618583,BAO_0000218,,
7359,,A,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL618584,BAO_0000218,,
7360,,A,,In vivo,Oral AUCN in monkey (dosed at 0.5 mpk iv ),0,,,22224,9527.0,Autocuration,1,CHEMBL618585,BAO_0000218,,
7361,,A,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),0,,,22224,9527.0,Autocuration,1,CHEMBL618586,BAO_0000218,,
7362,,A,,In vivo,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL618587,BAO_0000218,,
7363,,A,,In vivo,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,0,,,22224,9527.0,Autocuration,1,CHEMBL618588,BAO_0000218,,
7364,,A,,,Binding towards monkey plasma protein at 10 uM,0,,,22224,9527.0,Autocuration,1,CHEMBL618589,BAO_0000019,,
7365,,A,,,Binding towards monkey plasma protein at 100 uM,0,,,22224,9527.0,Autocuration,1,CHEMBL618590,BAO_0000019,,
7366,,A,,In vivo,Apparent bioavailability in squirrel monkey was determined,0,,,22224,9527.0,Autocuration,1,CHEMBL872262,BAO_0000218,,
7367,,A,,In vivo,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618591,BAO_0000218,,
7368,,A,,In vivo,Bioavailability in monkey (dose 2 mg/kg),0,,,22224,9443.0,Autocuration,1,CHEMBL618592,BAO_0000218,,
7369,,A,,In vivo,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL876488,BAO_0000218,,
7370,,A,,In vivo,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL618593,BAO_0000218,,
7371,,A,,In vivo,Bioavailability in monkey (i.d. dosing),0,,,22224,9443.0,Autocuration,1,CHEMBL618594,BAO_0000218,,
7372,,A,,In vivo,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,0,,,22224,9527.0,Autocuration,1,CHEMBL618595,BAO_0000218,,
7373,,A,,,Clearance of the drug was measured in cynomolgus,0,,,22224,9527.0,Autocuration,1,CHEMBL621469,BAO_0000019,,
7374,,A,,In vivo,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,0,,,22224,9527.0,Autocuration,1,CHEMBL621470,BAO_0000218,,
7375,,A,,In vivo,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL621471,BAO_0000218,,
7376,,A,,In vivo,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,0,,,22224,9544.0,Autocuration,1,CHEMBL621472,BAO_0000218,1969.0,
7377,,A,,In vivo,Plasma clearance in rhesus monkey was determined,0,,,22224,9527.0,Autocuration,1,CHEMBL621473,BAO_0000218,,
7378,,A,,In vivo,Plasma clearance in monkey after administration of 1 mg/kg iv,0,,,22224,9527.0,Autocuration,1,CHEMBL621474,BAO_0000218,,
7379,,A,,In vivo,Plasma clearance in cynomolgus monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL621475,BAO_0000218,,
7380,,A,,In vivo,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,0,,,22224,9527.0,Autocuration,1,CHEMBL621476,BAO_0000218,,
7381,,A,,In vivo,Plasma clearance after peroral administration at 10 mpk in Rhesus,0,,,22224,9527.0,Autocuration,1,CHEMBL624290,BAO_0000218,,
7382,,A,,In vivo,The total clearance was determined after intravenous administration in cynomolgus monkeys,0,,,22224,9527.0,Autocuration,1,CHEMBL624291,BAO_0000218,,
7383,,A,,In vivo,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL624292,BAO_0000218,,
7384,,A,,In vivo,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,0,,,22224,9527.0,Autocuration,1,CHEMBL624293,BAO_0000218,,
7385,,A,,In vivo,Tested for Clearance upon iv administration to african green monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL624294,BAO_0000218,,
7386,,A,,In vivo,Clearance in monkey,0,,,22224,9527.0,Autocuration,1,CHEMBL624295,BAO_0000218,,
7387,,A,,In vivo,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,50588,9615.0,Intermediate,1,CHEMBL624296,BAO_0000218,,
7388,,A,,In vivo,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,,50588,9615.0,Intermediate,1,CHEMBL624297,BAO_0000218,,
7389,,A,,In vivo,Half life was evaluated after intravenous administration to dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624298,BAO_0000218,,
7390,,A,,,Half life was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624299,BAO_0000218,,
7391,,A,,,Half life was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624300,BAO_0000218,,
7392,,A,,In vivo,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624301,BAO_0000218,,
7393,,A,,In vivo,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),1,,,50588,9615.0,Intermediate,1,CHEMBL624302,BAO_0000218,,
7394,,A,,In vivo,Half life period after intravenous administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL876026,BAO_0000218,,
7395,,A,,In vivo,Half life period after oral administration (2.5 mg/kg) in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624303,BAO_0000218,,
7396,,A,,,Half life period at a dose of 1 uM/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624304,BAO_0000218,,
7397,,A,,In vivo,Half life period was determine after peroral administration at 10 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624305,BAO_0000218,,
7398,,A,,In vivo,Half life period was determine after peroral administration at 5 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624306,BAO_0000218,,
7399,,A,,,Half life period was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624307,BAO_0000218,,
7400,,A,,,Half life period was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624308,BAO_0000218,,
7401,,A,,In vivo,Half life period by iv administration in dog at a dose of 6 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL624309,BAO_0000218,,
7402,,A,,,Half life period was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624310,BAO_0000218,,
7403,,A,,In vivo,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,,50588,9615.0,Intermediate,1,CHEMBL625003,BAO_0000218,,
7404,,A,,In vivo,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL625004,BAO_0000218,,
7405,,A,,In vivo,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625005,BAO_0000218,,
7406,,A,,In vivo,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL873813,BAO_0000218,,
7407,,A,,In vivo,Half-life after oral dose of compound at 3 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625006,BAO_0000218,,
7408,,A,,In vivo,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625007,BAO_0000218,,
7409,,A,,In vivo,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL876027,BAO_0000218,,
7410,,A,,In vivo,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625008,BAO_0000218,,
7411,,A,,In vivo,Half-life of compound in dog following p.o. administration of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625009,BAO_0000218,,
7412,,A,,,Half-life of compound in plasma of dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL625010,BAO_0000218,1969.0,
7413,,A,,,Half-life of compound was determined in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625011,BAO_0000218,,
7414,,A,,In vivo,Half-life after administration of 4 mg/Kg oral dose in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621553,BAO_0000218,,
7415,,A,,In vivo,Half-life after intravenous administration of 1 mg/kg/h in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621554,BAO_0000218,,
7416,,A,,,Half-life in Dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621555,BAO_0000218,,
7417,,A,,,Half-life in Dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621556,BAO_0000218,,
7418,,A,,,Half-life in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621557,BAO_0000218,,
7419,,A,,In vivo,Half-life in dog after oral administration at 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621558,BAO_0000218,,
7420,,A,,In vivo,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL621559,BAO_0000218,,
7421,,A,,,Half-life in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621560,BAO_0000218,,
7422,,A,,,Half-life in dogs; ND indicates not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL876028,BAO_0000218,,
7423,,A,,,Half-life in plasma of dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621561,BAO_0000218,1969.0,
7424,,A,,,Half-life in plasma of dog at dose of 3-10 mgkg,1,,,50588,9615.0,Intermediate,1,CHEMBL621562,BAO_0000218,1969.0,
7425,,A,,In vivo,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621563,BAO_0000218,,
7426,,A,,In vivo,Half-life was measured in dog after an iv dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621564,BAO_0000218,,
7427,,A,,In vivo,Half-life was measured in dogs after an oral dose of 10 uM/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621565,BAO_0000218,,
7428,,A,,In vivo,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621566,BAO_0000218,,
7429,,A,,In vivo,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL621567,BAO_0000218,,
7430,,A,,In vivo,Half-life of the compound after 0.3 mg/kg po administration in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622978,BAO_0000218,,
7431,,A,,In vivo,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL873814,BAO_0000218,,
7432,,A,,In vivo,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL623219,BAO_0000218,,
7433,,A,,In vivo,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,1,,,50588,9615.0,Intermediate,1,CHEMBL624477,BAO_0000218,,
7434,,A,,,t1/2 in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624478,BAO_0000218,,
7435,,A,,,Half-life period measured in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL624479,BAO_0000218,,
7436,,A,,In vivo,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624480,BAO_0000218,,
7437,,A,,In vivo,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL623595,BAO_0000218,,
7438,,A,,In vivo,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,50588,9615.0,Intermediate,1,CHEMBL623596,BAO_0000218,,
7439,,A,,In vitro,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1,,,50588,9615.0,Intermediate,1,CHEMBL623597,BAO_0000218,1969.0,
7440,,A,,In vivo,In vivo half life period was calculated at 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623598,BAO_0000218,,
7441,,A,,In vivo,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,1,,,50588,9615.0,Intermediate,1,CHEMBL623599,BAO_0000218,,
7442,,A,,In vivo,Longer half-life in dog (i.v.) at 0.5 mpk,1,,,50588,9615.0,Intermediate,1,CHEMBL623600,BAO_0000218,,
7443,,A,,In vivo,Oral bioavailability in dog (dose 5 uM/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL623601,BAO_0000218,,
7444,,A,,In vivo,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,,50588,9615.0,Intermediate,1,CHEMBL623602,BAO_0000218,,
7445,,A,,In vivo,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,,50588,9615.0,Intermediate,1,CHEMBL623603,BAO_0000218,,
7446,,A,,In vivo,Bioavailability in dog (dose 1 mg/kg i.v.),1,,,50588,9615.0,Intermediate,1,CHEMBL623604,BAO_0000218,,
7447,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623605,BAO_0000218,2048.0,
7448,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623606,BAO_0000218,2048.0,
7449,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623607,BAO_0000218,2048.0,
7450,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623608,BAO_0000218,2048.0,
7451,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623609,BAO_0000218,2048.0,
7452,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623610,BAO_0000218,2048.0,
7453,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623611,BAO_0000218,2385.0,
7454,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623612,BAO_0000218,2385.0,
7455,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623613,BAO_0000218,2385.0,
7456,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623614,BAO_0000218,2385.0,
7457,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623615,BAO_0000218,2385.0,
7458,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623616,BAO_0000218,2385.0,
7459,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623617,BAO_0000218,2385.0,
7460,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL875944,BAO_0000218,14.0,
7461,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623618,BAO_0000218,14.0,
7462,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623619,BAO_0000218,14.0,
7463,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623620,BAO_0000218,14.0,
7464,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623621,BAO_0000218,14.0,
7465,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623622,BAO_0000218,14.0,
7466,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623623,BAO_0000218,14.0,
7467,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL623624,BAO_0000218,2106.0,
7468,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618521,BAO_0000218,2106.0,
7469,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618522,BAO_0000218,2106.0,
7470,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618523,BAO_0000218,2106.0,
7471,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618524,BAO_0000218,2106.0,
7472,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL618525,BAO_0000218,2106.0,
7473,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624586,BAO_0000218,2106.0,
7474,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624587,BAO_0000218,945.0,
7475,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624588,BAO_0000218,945.0,
7476,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624589,BAO_0000218,945.0,
7477,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624590,BAO_0000218,945.0,
7478,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624591,BAO_0000218,945.0,
7479,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624592,BAO_0000218,945.0,
7480,,A,,In vivo,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,,50594,10090.0,Intermediate,1,CHEMBL624593,BAO_0000218,945.0,
7481,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624594,BAO_0000218,,
7482,,A,,In vivo,Tested for the bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624595,BAO_0000218,,
7483,,A,,In vivo,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL624596,BAO_0000218,,
7484,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624597,BAO_0000218,,
7485,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624598,BAO_0000218,,
7486,,A,,In vivo,Bioavailability in rat (dose 3-10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL624599,BAO_0000218,,
7487,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL875166,BAO_0000218,,
7488,,A,,In vivo,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,,50597,10116.0,Intermediate,1,CHEMBL624600,BAO_0000218,1969.0,
7489,,A,,In vivo,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,,,50597,10116.0,Intermediate,1,CHEMBL624601,BAO_0000218,1969.0,
7490,,A,,In vivo,Half life after oral administration was determined in rats at 6 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624602,BAO_0000218,,
7491,,A,,,Half life was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL624603,BAO_0000218,,
7492,,A,,In vivo,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624604,BAO_0000218,,
7493,,A,,In vivo,Plasma half life in rat at oral dose 2.8 mg/mk body weight,1,,,50597,10116.0,Intermediate,1,CHEMBL624605,BAO_0000218,1969.0,
7494,,A,,,Half life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624606,BAO_0000218,,
7495,,A,,In vivo,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624607,BAO_0000218,178.0,
7496,,A,,,Hill coefficient of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL624608,BAO_0000218,,
7497,,A,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624609,BAO_0000218,178.0,
7498,,A,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624610,BAO_0000218,178.0,
7499,,A,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624611,BAO_0000218,178.0,
7500,,A,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624612,BAO_0000218,178.0,
7501,,A,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,1,,,50597,10116.0,Intermediate,1,CHEMBL875167,BAO_0000218,178.0,
7502,,A,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624613,BAO_0000218,178.0,
7503,,A,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",1,,,50597,10116.0,Intermediate,1,CHEMBL624614,BAO_0000218,178.0,
7504,,A,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,,,50597,10116.0,Intermediate,1,CHEMBL624392,BAO_0000218,,
7505,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624393,BAO_0000218,955.0,
7506,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624394,BAO_0000218,955.0,
7507,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624395,BAO_0000218,955.0,
7508,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624396,BAO_0000218,955.0,
7509,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624397,BAO_0000218,955.0,
7510,,A,,In vivo,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624398,BAO_0000218,2046.0,
7511,,A,,In vivo,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624399,BAO_0000218,2046.0,
7512,,A,,In vivo,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624400,BAO_0000218,2046.0,
7513,,A,,In vivo,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624401,BAO_0000218,2046.0,
7514,,A,,In vivo,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624402,BAO_0000218,2046.0,
7515,,A,,In vivo,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL624403,BAO_0000218,178.0,
7516,,A,,In vivo,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL624404,BAO_0000218,178.0,
7517,,A,,In vivo,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL624405,BAO_0000218,178.0,
7518,,A,,In vivo,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL624406,BAO_0000218,10000001.0,
7519,,A,,In vivo,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL624407,BAO_0000218,10000001.0,
7520,,A,,In vivo,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL624408,BAO_0000218,10000001.0,
7521,,A,,In vivo,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618644,BAO_0000218,948.0,
7522,,A,,In vivo,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL618645,BAO_0000218,948.0,
7523,,A,,In vivo,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618646,BAO_0000218,948.0,
7524,,A,,In vivo,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618647,BAO_0000218,2113.0,
7525,,A,,In vivo,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL618648,BAO_0000218,2113.0,
7526,,A,,In vivo,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618649,BAO_0000218,2113.0,
7527,,A,,In vivo,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618650,BAO_0000218,2107.0,
7528,,A,,In vivo,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL618651,BAO_0000218,2107.0,
7529,,A,,In vivo,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL876497,BAO_0000218,2107.0,
7530,,A,,In vivo,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618652,BAO_0000218,2048.0,
7531,,A,,In vivo,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL618653,BAO_0000218,2048.0,
7532,,A,,In vivo,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618654,BAO_0000218,2048.0,
7533,,A,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL618655,BAO_0000218,,
7534,,A,,,Compound was tested for solubility in water,1,,,50597,10116.0,Intermediate,1,CHEMBL618656,BAO_0000218,,
7535,,P,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),0,,,22229,,Intermediate,1,CHEMBL618657,BAO_0000100,,
7536,,A,,,Solubility was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618658,BAO_0000218,,
7537,,A,,,solubility in water (ug/mL) at 37 degree C.,1,,,50597,10116.0,Intermediate,1,CHEMBL618659,BAO_0000218,,
7538,,A,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,1,,,50597,10116.0,Intermediate,1,CHEMBL618660,BAO_0000218,,
7539,,A,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,1,,,50597,10116.0,Intermediate,1,CHEMBL618661,BAO_0000218,,
7540,,A,,,Half life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL873807,BAO_0000218,,
7541,,A,,,Half life in Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618662,BAO_0000218,,
7542,,A,,In vivo,Half life period after 3 mg/kg iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618663,BAO_0000218,,
7543,,A,,In vivo,Half life period after 3 mg/kg iv administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618664,BAO_0000218,,
7544,,A,,In vivo,Half life period after 3 mg/kg iv administration in the rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618665,BAO_0000218,,
7545,,A,,,Half life period in female Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL876498,BAO_0000218,,
7546,,A,,,Half life period in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618666,BAO_0000218,,
7547,,A,,,Half-life in rats was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620440,BAO_0000218,,
7548,,A,,,Half-life in rats with metabolic oxidation,1,,,50597,10116.0,Intermediate,1,CHEMBL620441,BAO_0000218,,
7549,,A,,,Half-life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620442,BAO_0000218,,
7550,,A,,In vivo,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620443,BAO_0000218,,
7551,,A,,In vivo,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620444,BAO_0000218,,
7552,,A,,In vivo,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620445,BAO_0000218,,
7553,,A,,In vivo,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620446,BAO_0000218,,
7554,,A,,,Biological half-life measured in plasma of rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620447,BAO_0000218,1969.0,
7555,,A,,,Biological half-life measured in plasma of rat; 22-25,1,,,50597,10116.0,Intermediate,1,CHEMBL621129,BAO_0000218,1969.0,
7556,,A,,,Biological half-life measured in plasma of rat; 9-16,1,,,50597,10116.0,Intermediate,1,CHEMBL621130,BAO_0000218,1969.0,
7557,,A,,In vivo,Compound was evaluated for its half life when administered intravenously in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL873808,BAO_0000218,,
7558,,A,,In vivo,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,1,,,50597,10116.0,Intermediate,1,CHEMBL876598,BAO_0000218,,
7559,,A,,In vivo,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621131,BAO_0000218,,
7560,,A,,In vivo,Half life (T1/2) after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621132,BAO_0000218,,
7561,,A,,In vivo,Half life of compound after iv administration of 20 mg/kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621133,BAO_0000218,,
7562,,A,,In vivo,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL621312,BAO_0000218,,
7563,,A,,,Half life of compound was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621313,BAO_0000218,,
7564,,A,,,Half life of compound was determined in rat blood,1,,,50597,10116.0,Intermediate,1,CHEMBL621314,BAO_0000218,178.0,
7565,,A,,In vivo,Half life at 1 mg/kg was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621315,BAO_0000218,,
7566,,A,,In vivo,Half life at 10 mg/kg was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621316,BAO_0000218,,
7567,,A,,,Half life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621317,BAO_0000218,,
7568,,A,,,Half life in rats in hours,1,,,50597,10116.0,Intermediate,1,CHEMBL621318,BAO_0000218,,
7569,,A,,In vivo,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621319,BAO_0000218,,
7570,,A,,In vivo,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621377,BAO_0000218,,
7571,,A,,,Half life was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621378,BAO_0000218,,
7572,,A,,In vivo,Half life after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL876599,BAO_0000218,,
7573,,A,,In vivo,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621379,BAO_0000218,,
7574,,A,,,Half life in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL621380,BAO_0000218,1969.0,
7575,,A,,,Half life in rat plasma; Not detected,1,,,50597,10116.0,Intermediate,1,CHEMBL621381,BAO_0000218,1969.0,
7576,,A,,,Half life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618515,BAO_0000218,,
7577,,A,,In vivo,Half life period of compound was determined after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618516,BAO_0000218,,
7578,,A,,In vivo,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618517,BAO_0000218,,
7579,,A,,,Half life period in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618518,BAO_0000218,,
7580,,A,,In vivo,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618519,BAO_0000218,,
7581,,A,,In vivo,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618698,BAO_0000218,,
7582,,A,,In vivo,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,1,,,50597,10116.0,Intermediate,1,CHEMBL618862,BAO_0000218,,
7583,,A,,In vivo,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618863,BAO_0000218,,
7584,,A,,In vivo,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618864,BAO_0000218,,
7585,,A,,In vivo,Half life time in rat the dose of 2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618865,BAO_0000218,,
7586,,A,,In vivo,Half-life 24 hr after 10 mg/kg iv administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618866,BAO_0000218,,
7587,,A,,In vivo,Half-life 24 hr after 2 mg/kg iv administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618867,BAO_0000218,,
7588,,A,,,Half-life consistent with the observed metabolic steady state in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL875828,BAO_0000218,,
7589,,A,,In vivo,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618868,BAO_0000218,,
7590,,A,,,Half-life for oxidative metabolic stability was determined using male human,1,,,50597,10116.0,Intermediate,1,CHEMBL618869,BAO_0000218,,
7591,,A,,In vivo,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",1,,,50597,10116.0,Intermediate,1,CHEMBL618870,BAO_0000218,,
7592,,A,,,Half-life in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL618871,BAO_0000218,1969.0,
7593,,A,,,Half-life in rat plasma was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618872,BAO_0000218,1969.0,
7594,,A,,,Half-life in rats was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL873816,BAO_0000218,,
7595,,A,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,0,,,22224,,Autocuration,1,CHEMBL618873,BAO_0000218,,
7596,,A,,,Area under curve after oral dose of 0.1 mg//kg,0,,,22224,,Autocuration,1,CHEMBL621602,BAO_0000019,,
7597,,A,,,Area under curve after oral dose of 0.3 mg/kg,0,,,22224,,Autocuration,1,CHEMBL621603,BAO_0000218,,
7598,,A,,,Area under curve after oral dose of 1 mg/kg,0,,,22224,,Autocuration,1,CHEMBL621604,BAO_0000218,,
7599,,A,,,Area under curve after oral dose of 10 mg/kg,0,,,22224,,Autocuration,1,CHEMBL621605,BAO_0000218,,
7600,,A,,,Area under curve after oral dose of 23.4 mg/kg,0,,,22224,,Autocuration,1,CHEMBL621606,BAO_0000218,,
7601,,A,,,Area under curve after oral dose of 3 mg/kg,0,,,22224,,Autocuration,1,CHEMBL621607,BAO_0000218,,
7602,,A,,,Area under curve after oral dose of 3.87 mg/kg,0,,,22224,,Autocuration,1,CHEMBL621608,BAO_0000218,,
7603,,A,,,Area under curve was determined,0,,,22224,,Autocuration,1,CHEMBL621609,BAO_0000019,,
7604,,A,,,Area under curve at a dose of 10 mg/kg,0,,,22224,,Autocuration,1,CHEMBL621610,BAO_0000218,,
7605,,A,,,Area under curve was determined; ND=No data,1,,,50597,10116.0,Intermediate,1,CHEMBL621611,BAO_0000218,,
7606,,A,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL621612,BAO_0000218,,
7607,,A,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622308,BAO_0000218,,
7608,,A,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622309,BAO_0000218,,
7609,,A,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622310,BAO_0000218,,
7610,,A,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622311,BAO_0000218,,
7611,,A,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,1,,,50597,10116.0,Intermediate,1,CHEMBL622312,BAO_0000218,,
7612,,A,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622931,BAO_0000218,,
7613,,A,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,1,,,50597,10116.0,Intermediate,1,CHEMBL622932,BAO_0000218,,
7614,,A,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622736,BAO_0000218,1969.0,
7615,,A,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622737,BAO_0000218,1969.0,
7616,,A,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622738,BAO_0000218,1969.0,
7617,,A,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622739,BAO_0000218,1969.0,
7618,,A,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622740,BAO_0000218,1969.0,
7619,,A,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622741,BAO_0000218,1969.0,
7620,,A,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622742,BAO_0000218,1969.0,
7621,,A,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622743,BAO_0000218,1969.0,
7622,,A,,,AUC in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622744,BAO_0000218,1969.0,
7623,,A,,,Area under curve was measured from the graph obtained from concentration Vs time,0,,,22224,,Autocuration,1,CHEMBL624134,BAO_0000019,,
7624,,A,,,Area under curve value of compound per hour after oral administration,0,,,22224,,Autocuration,1,CHEMBL624135,BAO_0000019,,
7625,,A,,,Area under curve was determined after oral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624136,BAO_0000218,,
7626,,A,,,Area under curve was determined after oral administration in rats; No data,1,,,50597,10116.0,Intermediate,1,CHEMBL624137,BAO_0000218,,
7627,,A,,,Area under curve was determined after oral administration in rats;No data,1,,,50597,10116.0,Intermediate,1,CHEMBL624320,BAO_0000218,,
7628,,A,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624321,BAO_0000218,,
7629,,A,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624322,BAO_0000218,,
7630,,A,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624323,BAO_0000218,,
7631,,A,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624324,BAO_0000218,,
7632,,A,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624325,BAO_0000218,,
7633,,A,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624326,BAO_0000218,,
7634,,A,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624327,BAO_0000218,,
7635,,A,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624328,BAO_0000218,,
7636,,A,,,Area under curve was determined in Dogs after peroral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL627848,BAO_0000218,,
7637,,A,,,Area under curve was determined in Rats after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627849,BAO_0000218,,
7638,,A,,,Area under curve was determined in carotid blood of rat when administered intradermally,1,,,50597,10116.0,Intermediate,1,CHEMBL627850,BAO_0000218,,
7639,,A,,,Area under curve was determined in portal blood of rat when administered intradermally,1,,,50597,10116.0,Intermediate,1,CHEMBL627851,BAO_0000218,,
7640,,A,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627852,BAO_0000218,,
7641,,A,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627853,BAO_0000218,,
7642,,A,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,,,50594,10090.0,Intermediate,1,CHEMBL627854,BAO_0000218,,
7643,,A,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627855,BAO_0000218,,
7644,,A,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),1,,,50594,10090.0,Intermediate,1,CHEMBL627856,BAO_0000218,,
7645,,A,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL875339,BAO_0000218,,
7646,,A,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),1,,,50594,10090.0,Intermediate,1,CHEMBL627857,BAO_0000218,,
7647,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627858,BAO_0000218,2106.0,
7648,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627859,BAO_0000218,178.0,
7649,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627860,BAO_0000218,955.0,
7650,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627019,BAO_0000218,948.0,
7651,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627020,BAO_0000218,2107.0,
7652,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627021,BAO_0000218,2048.0,
7653,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627022,BAO_0000218,2385.0,
7654,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627023,BAO_0000218,,
7655,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627024,BAO_0000218,2106.0,
7656,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627025,BAO_0000218,2046.0,
7657,,A,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627026,BAO_0000218,2113.0,
7658,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627027,BAO_0000218,178.0,
7659,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627028,BAO_0000218,955.0,
7660,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627029,BAO_0000218,948.0,
7661,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627030,BAO_0000218,2113.0,
7662,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627031,BAO_0000218,2107.0,
7663,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627032,BAO_0000218,2048.0,
7664,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627033,BAO_0000218,2385.0,
7665,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627034,BAO_0000218,,
7666,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627035,BAO_0000218,2106.0,
7667,,A,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627036,BAO_0000218,2046.0,
7668,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL875340,BAO_0000218,178.0,
7669,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627037,BAO_0000218,948.0,
7670,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627038,BAO_0000218,2113.0,
7671,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627039,BAO_0000218,2107.0,
7672,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627040,BAO_0000218,2385.0,
7673,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624663,BAO_0000218,2106.0,
7674,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625963,BAO_0000218,2046.0,
7675,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL876799,BAO_0000218,955.0,
7676,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626133,BAO_0000218,2048.0,
7677,,A,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626134,BAO_0000218,,
7678,,A,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626135,BAO_0000218,,
7679,,A,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626136,BAO_0000218,,
7680,,A,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,1,,,50597,10116.0,Intermediate,1,CHEMBL626137,BAO_0000218,,
7681,,A,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626138,BAO_0000218,,
7682,,A,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626139,BAO_0000218,,
7683,,A,,In vivo,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626140,BAO_0000218,,
7684,,A,,In vivo,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626141,BAO_0000218,,
7685,,A,,,C24h in rat p.o. at 20 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL626142,BAO_0000218,,
7686,,A,,In vivo,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL627930,BAO_0000218,2385.0,
7687,,A,,In vivo,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL627931,BAO_0000218,2385.0,
7688,,A,,In vivo,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL627932,BAO_0000218,2385.0,
7689,,A,,In vivo,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL627933,BAO_0000218,2106.0,
7690,,A,,In vivo,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL627934,BAO_0000218,2106.0,
7691,,A,,In vivo,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL627935,BAO_0000218,2106.0,
7692,,A,,In vivo,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL627936,BAO_0000218,178.0,
7693,,A,,In vivo,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL627937,BAO_0000218,178.0,
7694,,A,,In vivo,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL627938,BAO_0000218,178.0,
7695,,A,,In vivo,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL627939,BAO_0000218,178.0,
7696,,A,,In vivo,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL627940,BAO_0000218,178.0,
7697,,A,,In vivo,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL627941,BAO_0000218,178.0,
7698,,A,,In vivo,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL876800,BAO_0000218,178.0,
7699,,A,,In vivo,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL627942,BAO_0000218,178.0,
7700,,A,,In vivo,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL627943,BAO_0000218,178.0,
7701,,A,,In vivo,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627944,BAO_0000218,178.0,
7702,,A,,In vivo,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL627945,BAO_0000218,178.0,
7703,,A,,In vivo,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL628584,BAO_0000218,178.0,
7704,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628585,BAO_0000218,178.0,
7705,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL628586,BAO_0000218,178.0,
7706,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628587,BAO_0000218,178.0,
7707,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL628588,BAO_0000218,178.0,
7708,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628589,BAO_0000218,178.0,
7709,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625304,BAO_0000218,178.0,
7710,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL625305,BAO_0000218,178.0,
7711,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL625306,BAO_0000218,178.0,
7712,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625307,BAO_0000218,178.0,
7713,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625308,BAO_0000218,178.0,
7714,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL627740,BAO_0000218,178.0,
7715,,A,,In vivo,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL627741,BAO_0000218,178.0,
7716,,A,,In vivo,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL627742,BAO_0000218,178.0,
7717,,A,,In vivo,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,1,,,50597,10116.0,Intermediate,1,CHEMBL627743,BAO_0000218,178.0,
7718,,A,,In vivo,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL627744,BAO_0000218,178.0,
7719,,A,,In vivo,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL627745,BAO_0000218,10000001.0,
7720,,A,,In vivo,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL627746,BAO_0000218,10000001.0,
7721,,A,,In vivo,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL627747,BAO_0000218,10000001.0,
7722,,A,,In vivo,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL876810,BAO_0000218,10000001.0,
7723,,A,,In vivo,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL627748,BAO_0000218,10000001.0,
7724,,A,,In vivo,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL627749,BAO_0000218,10000001.0,
7725,,A,,In vivo,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL627750,BAO_0000218,10000001.0,
7726,,A,,In vivo,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL618728,BAO_0000218,10000001.0,
7727,,A,,In vivo,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL618729,BAO_0000218,10000001.0,
7728,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL618730,BAO_0000218,10000001.0,
7729,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618731,BAO_0000218,10000001.0,
7730,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL618732,BAO_0000218,10000001.0,
7731,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618733,BAO_0000218,10000001.0,
7732,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL618734,BAO_0000218,10000001.0,
7733,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618735,BAO_0000218,10000001.0,
7734,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL876602,BAO_0000218,10000001.0,
7735,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618736,BAO_0000218,10000001.0,
7736,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL618737,BAO_0000218,10000001.0,
7737,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618738,BAO_0000218,10000001.0,
7738,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL618739,BAO_0000218,10000001.0,
7739,,A,,In vivo,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL618740,BAO_0000218,10000001.0,
7740,,A,,In vivo,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL618741,BAO_0000218,10000001.0,
7741,,A,,In vivo,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,1,,,50597,10116.0,Intermediate,1,CHEMBL618742,BAO_0000218,10000001.0,
7742,,A,,In vivo,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL618743,BAO_0000218,10000001.0,
7743,,A,,In vivo,Half-life from rat plasma at a single oral dose of 25 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618744,BAO_0000218,1969.0,
7744,,A,,,Half-life in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618745,BAO_0000218,,
7745,,A,,In vivo,Half-life in rat after peroral administration at 10 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL620479,BAO_0000218,,
7746,,A,,In vivo,Half-life in rat after peroral administration at 5 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL620480,BAO_0000218,,
7747,,A,,In vivo,Half-life in rat at a dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620481,BAO_0000218,,
7748,,A,,,Half-life was evaluated in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620482,BAO_0000218,,
7749,,A,,,Half-life was measured in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL876603,BAO_0000218,,
7750,,A,,In vivo,Half-life period for the compound was determined in rats at 50 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL620483,BAO_0000218,,
7751,,A,,In vivo,Half-life period in rats after intravenous administration at 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620484,BAO_0000218,,
7752,,A,,In vivo,Half-life period in rat at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620485,BAO_0000218,,
7753,,A,,In vivo,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL620486,BAO_0000218,,
7754,,A,,In vivo,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL620487,BAO_0000218,,
7755,,A,,In vivo,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL620488,BAO_0000218,,
7756,,A,,In vivo,Half-life time in rat the dose of 2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620489,BAO_0000218,,
7757,,A,,In vivo,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620490,BAO_0000218,,
7758,,A,,In vivo,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620491,BAO_0000218,,
7759,,A,,In vivo,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,,,50597,10116.0,Intermediate,1,CHEMBL876604,BAO_0000218,1969.0,
7760,,A,,In vivo,Oral half life was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620492,BAO_0000218,,
7761,,A,,In vivo,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",1,,,50597,10116.0,Intermediate,1,CHEMBL620493,BAO_0000218,,
7762,,A,,In vivo,Pharmacokinetic property (t1/2) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620494,BAO_0000218,,
7763,,A,,,Plasma elimination half-life was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620495,BAO_0000218,1969.0,
7764,,A,,In vivo,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,,,50597,10116.0,Intermediate,1,CHEMBL620496,BAO_0000218,1969.0,
7765,,A,,In vivo,Plasma half life was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620497,BAO_0000218,1969.0,
7766,,A,,,Plasma half-life was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620498,BAO_0000218,1969.0,
7767,,A,,In vivo,Plasma half-life following oral administration in Fisher rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620499,BAO_0000218,1969.0,
7768,,A,,,Plasma half-life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620500,BAO_0000218,1969.0,
7769,,A,,In vivo,Plasmatic Half-life after intravenous administration to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL873809,BAO_0000218,1969.0,
7770,,A,,In vivo,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620501,BAO_0000218,,
7771,,A,,In vivo,Terminal half life after intravenous administration (1 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620502,BAO_0000218,,
7772,,A,,In vivo,Terminal half life in Rat at a oral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620503,BAO_0000218,,
7773,,A,,In vivo,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL620504,BAO_0000218,,
7774,,A,,In vivo,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL876605,BAO_0000218,,
7775,,A,,In vivo,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620505,BAO_0000218,,
7776,,A,,In vivo,plasma half life was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL873811,BAO_0000218,1969.0,
7777,,A,,In vivo,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL624016,BAO_0000218,,
7778,,A,,,Half life of compound determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624017,BAO_0000218,,
7779,,A,,,Mean residence time determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624018,BAO_0000218,,
7780,,A,,,Plasma half life determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624019,BAO_0000218,,
7781,,A,,In vivo,Compound was evaluated for Tmax in brain after intravenous administration in male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624020,BAO_0000218,955.0,
7782,,A,,In vivo,Compound was evaluated for pharmacokinetic parameter maximum time period,1,,,50597,10116.0,Intermediate,1,CHEMBL624201,BAO_0000218,,
7783,,A,,In vivo,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL872528,BAO_0000218,,
7784,,A,,In vivo,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624202,BAO_0000218,,
7785,,A,,In vivo,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624203,BAO_0000218,,
7786,,A,,In vivo,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624350,BAO_0000218,,
7787,,A,,In vivo,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621320,BAO_0000218,,
7788,,A,,In vivo,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621321,BAO_0000218,,
7789,,A,,,Maximum time (Tmax) required to reach Cmax in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621322,BAO_0000218,,
7790,,A,,In vivo,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621323,BAO_0000218,,
7791,,A,,In vivo,Maximum time of clearance of compound in rats after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621324,BAO_0000218,,
7792,,A,,,Maximum time at the dose of 2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621325,BAO_0000218,,
7793,,A,,In vivo,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL875837,BAO_0000218,1969.0,
7794,,A,,In vivo,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621326,BAO_0000218,1969.0,
7795,,A,,In vivo,Tmax in Guinea pig (PO dose),1,,,50597,10116.0,Intermediate,1,CHEMBL621327,BAO_0000218,,
7796,,A,,In vivo,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",1,,,50597,10116.0,Intermediate,1,CHEMBL621328,BAO_0000218,,
7797,,A,,In vivo,Pharmacokinetic parameter (Tmax) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621329,BAO_0000218,,
7798,,A,,In vivo,Pharmacokinetic parameter (Tmax) was estimated,1,,,50597,10116.0,Intermediate,1,CHEMBL621330,BAO_0000218,,
7799,,A,,In vivo,Pharmacokinetic property (Tmax) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621331,BAO_0000218,,
7800,,A,,In vivo,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,,50597,10116.0,Intermediate,1,CHEMBL621332,BAO_0000218,,
7801,,A,,In vivo,T max in Rat at a oral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621333,BAO_0000218,,
7802,,A,,In vivo,T max was determined at 10 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621334,BAO_0000218,,
7803,,A,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),1,,,50594,10090.0,Intermediate,1,CHEMBL621335,BAO_0000218,,
7804,,A,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621336,BAO_0000218,,
7805,,A,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621337,BAO_0000218,,
7806,,A,,,Area under curve was measured after i.v. administration into Beagle dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL621338,BAO_0000218,,
7807,,A,,,Area under curve was measured after iv administration into Beagle dog,1,,,50588,9615.0,Intermediate,1,CHEMBL875838,BAO_0000218,,
7808,,A,,,Area under curve was measured after po administration into Beagle dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621339,BAO_0000218,,
7809,,A,,,Area under curve was measured after po administration into Beagle dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL621340,BAO_0000218,,
7810,,A,,,Area under curve was measured at peroral dose of 3 mg/kg,0,,,22224,,Autocuration,1,CHEMBL621341,BAO_0000218,,
7811,,A,,,Area under curve was measured by using concentration Vs time,0,,,22224,,Autocuration,1,CHEMBL621342,BAO_0000019,,
7812,,A,,,Area under curve was measured by using concentration Vs time; not tested,0,,,22224,,Autocuration,1,CHEMBL621343,BAO_0000019,,
7813,,A,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),1,,,50594,10090.0,Intermediate,1,CHEMBL621344,BAO_0000218,,
7814,,A,,,Area under curve(AUC) was measured in mice after oral administration.,1,,,50594,10090.0,Intermediate,1,CHEMBL621345,BAO_0000218,,
7815,,A,,,Area under curve(AUC) value of the compound,0,,,22224,,Autocuration,1,CHEMBL621346,BAO_0000019,,
7816,,A,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,0,,,22224,,Autocuration,1,CHEMBL621347,BAO_0000218,,
7817,,A,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621348,BAO_0000218,,
7818,,A,,,Area under curve(carotid artery) was determined by the availability in blood,0,,,22224,,Autocuration,1,CHEMBL621349,BAO_0000019,178.0,
7819,,A,,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,0,,,22224,,Autocuration,1,CHEMBL621350,BAO_0000019,178.0,
7820,,A,,,Area under curve(carotid artery) was determined by the availability in blood; No data,0,,,22224,,Autocuration,1,CHEMBL875839,BAO_0000019,178.0,
7821,,A,,,Area under curve(portal vein) was determined by the availability in blood,0,,,22224,,Autocuration,1,CHEMBL620211,BAO_0000019,178.0,
7822,,A,,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,0,,,22224,,Autocuration,1,CHEMBL620212,BAO_0000019,178.0,
7823,,A,,,Area under curve(portal vein) was determined by the availability in blood; No data,0,,,22224,,Autocuration,1,CHEMBL620213,BAO_0000019,178.0,
7824,,A,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,,,50797,9544.0,Intermediate,1,CHEMBL620214,BAO_0000218,1969.0,
7825,,A,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,,,50797,9544.0,Intermediate,1,CHEMBL620215,BAO_0000218,1969.0,
7826,,A,,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1,,,50797,9544.0,Intermediate,1,CHEMBL620216,BAO_0000218,1969.0,
7827,,A,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1,,,50588,9615.0,Intermediate,1,CHEMBL620888,BAO_0000218,1969.0,
7828,,A,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1,,,50588,9615.0,Intermediate,1,CHEMBL620889,BAO_0000218,1969.0,
7829,,A,,,Area under plasma concentration vs time curve observed in rats for 0-3 h,0,,,22224,,Autocuration,1,CHEMBL620890,BAO_0000019,1969.0,
7830,,A,,,Area under plasma time curve determined in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620891,BAO_0000218,1969.0,
7831,,A,,,Area under the MAP curve measured over 5 min.,0,,,22224,,Autocuration,1,CHEMBL620892,BAO_0000019,,
7832,,A,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621079,BAO_0000218,,
7833,,A,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621080,BAO_0000218,,
7834,,A,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL621081,BAO_0000218,,
7835,,A,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,1,,,100712,10026.0,Intermediate,1,CHEMBL621082,BAO_0000218,,
7836,,A,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL621083,BAO_0000218,,
7837,,A,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621084,BAO_0000218,,
7838,,A,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621085,BAO_0000218,,
7839,,A,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL621086,BAO_0000218,,
7840,,A,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL621087,BAO_0000218,,
7841,,A,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL622607,BAO_0000218,,
7842,,A,,,Serum AUC in marmosets (IV dose),1,,,50588,9615.0,Intermediate,1,CHEMBL622608,BAO_0000218,,
7843,,A,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,0,,,22224,,Autocuration,1,CHEMBL624481,BAO_0000019,,
7844,,A,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,0,,,22224,,Autocuration,1,CHEMBL624482,BAO_0000019,,
7845,,A,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,0,,,22224,,Autocuration,1,CHEMBL624483,BAO_0000019,,
7846,,A,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,0,,,22224,,Autocuration,1,CHEMBL624484,BAO_0000019,,
7847,,A,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,0,,,22224,,Autocuration,1,CHEMBL624485,BAO_0000019,,
7848,,A,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL624486,BAO_0000218,,
7849,,A,,,Area under the curve for the compound was calculated.,0,,,22224,,Autocuration,1,CHEMBL624487,BAO_0000019,,
7850,,A,,,Area under the curve in concentration/ time,0,,,22224,,Autocuration,1,CHEMBL624488,BAO_0000019,,
7851,,A,,,Area under the curve administered intraintestinal in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL624489,BAO_0000218,,
7852,,A,,,Area under the curve administered intravenously in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL625184,BAO_0000218,,
7853,,A,,,Area under the curve during intravenous administration,0,,,22224,,Autocuration,1,CHEMBL625185,BAO_0000019,,
7854,,A,,,Area under the curve during intravenous administration; Not determined,0,,,22224,,Autocuration,1,CHEMBL875954,BAO_0000019,,
7855,,A,,,Area under the curve during systemic administration,0,,,22224,,Autocuration,1,CHEMBL625186,BAO_0000019,,
7856,,A,,,Area under the curve during systemic administration; Not determined,0,,,22224,,Autocuration,1,CHEMBL625187,BAO_0000019,,
7857,,A,,,Area under the curve was calculated for the compound.,0,,,22224,,Autocuration,1,CHEMBL625188,BAO_0000019,,
7858,,A,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625189,BAO_0000218,,
7859,,A,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625190,BAO_0000218,,
7860,,A,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621733,BAO_0000218,,
7861,,A,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621734,BAO_0000218,,
7862,,A,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621735,BAO_0000218,,
7863,,A,,,Clearance of the drug was measured in the plasma of rat; No data,1,,,50597,10116.0,Intermediate,1,CHEMBL621736,BAO_0000218,1969.0,
7864,,A,,,The pharmacokinetic parameter plasma clearance in vivo in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621737,BAO_0000218,1969.0,
7865,,A,,,Plasma clearance at the dose of 2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621738,BAO_0000218,,
7866,,A,,In vivo,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622806,BAO_0000218,,
7867,,A,,In vivo,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623519,BAO_0000218,,
7868,,A,,In vivo,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623520,BAO_0000218,,
7869,,A,,In vivo,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623521,BAO_0000218,,
7870,,A,,In vivo,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623522,BAO_0000218,,
7871,,A,,In vivo,Clearance rate in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623523,BAO_0000218,,
7872,,A,,In vivo,Clearance rate in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623690,BAO_0000218,,
7873,,A,,In vivo,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623691,BAO_0000218,,
7874,,A,,In vivo,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623692,BAO_0000218,,
7875,,A,,In vivo,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623693,BAO_0000218,,
7876,,A,,In vivo,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623694,BAO_0000218,,
7877,,A,,In vivo,Clearance of compound after iv administration of 20 mg/kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623695,BAO_0000218,,
7878,,A,,In vivo,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623696,BAO_0000218,,
7879,,A,,In vivo,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623697,BAO_0000218,,
7880,,A,,In vivo,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,0,,,22224,9544.0,Intermediate,1,CHEMBL623698,BAO_0000218,1969.0,
7881,,A,,In vivo,Compound was tested for its plasma clearance rate in Sprague Dawley rats,0,,,22224,10116.0,Intermediate,1,CHEMBL623699,BAO_0000218,1969.0,
7882,,A,,In vivo,Mean (%CV) PK parameters for CL(mL/min/kg).,1,,,50597,10116.0,Intermediate,1,CHEMBL623700,BAO_0000218,,
7883,,A,,In vivo,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623701,BAO_0000218,,
7884,,A,,In vivo,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1,,,50597,10116.0,Intermediate,1,CHEMBL623702,BAO_0000218,1969.0,
7885,,A,,In vivo,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623703,BAO_0000218,,
7886,,A,,In vivo,Plasma clearance in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623704,BAO_0000218,,
7887,,A,,In vivo,Plasma clearance in rat after administration of 2 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL623705,BAO_0000218,,
7888,,A,,In vivo,Plasma clearance in rat after administration of 2 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL623706,BAO_0000218,,
7889,,A,,In vivo,Plasma clearance was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623707,BAO_0000218,,
7890,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623708,BAO_0000218,,
7891,,A,,In vivo,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623709,BAO_0000218,,
7892,,A,,In vivo,Plasma clearance in rat by iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623710,BAO_0000218,,
7893,,A,,In vivo,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623711,BAO_0000218,,
7894,,A,,In vivo,Plasma clearance in rat p.o.,1,,,50597,10116.0,Intermediate,1,CHEMBL623712,BAO_0000218,,
7895,,A,,In vivo,Plasma clearance in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623713,BAO_0000218,,
7896,,A,,In vivo,Plasma clearance was determined; ND denotes no data,1,,,50597,10116.0,Intermediate,1,CHEMBL623714,BAO_0000218,,
7897,,A,,In vivo,Plasma clearance was determined; ND denotes not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623715,BAO_0000218,,
7898,,A,,In vivo,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623716,BAO_0000218,,
7899,,A,,In vivo,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,,,50597,10116.0,Intermediate,1,CHEMBL622980,BAO_0000218,,
7900,,A,,In vivo,Plasma administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622981,BAO_0000218,,
7901,,A,,In vivo,Plasma clearance of the compound in female Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622982,BAO_0000218,,
7902,,A,,In vivo,Plasma clearance was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622983,BAO_0000218,,
7903,,A,,In vivo,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622984,BAO_0000218,,
7904,,A,,In vivo,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622985,BAO_0000218,,
7905,,A,,In vivo,plasma clearance was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623631,BAO_0000218,1969.0,
7906,,A,,In vivo,In vivo CL/F determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623632,BAO_0000218,,
7907,,A,,In vivo,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623633,BAO_0000218,1969.0,
7908,,A,,In vivo,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623634,BAO_0000218,1969.0,
7909,,A,,In vivo,Compound was tested for the lower blood clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623635,BAO_0000218,,
7910,,A,,In vivo,Evaluated for the low clearance in rat (in vivo),1,,,50597,10116.0,Intermediate,1,CHEMBL621195,BAO_0000218,,
7911,,A,,In vivo,Pharmacokinetic property (CLb)of the compound was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621196,BAO_0000218,,
7912,,A,,In vivo,Rapid clearance after intravenous administration in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL875287,BAO_0000218,,
7913,,A,,In vivo,Clearance measured in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621197,BAO_0000218,,
7914,,A,,In vivo,Compound was evaluated for plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621198,BAO_0000218,1969.0,
7915,,A,,In vivo,Low plasma clearance was calculated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621199,BAO_0000218,1969.0,
7916,,A,,In vivo,Pharmacokinetic property (Clp) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621200,BAO_0000218,,
7917,,A,,In vivo,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621201,BAO_0000218,,
7918,,A,,In vivo,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621202,BAO_0000218,,
7919,,A,,In vivo,Plasma clearance after IV dosing at 0.5 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621203,BAO_0000218,,
7920,,A,,In vivo,Plasma clearance after IV dosing at 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621204,BAO_0000218,,
7921,,A,,In vivo,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL621205,BAO_0000218,948.0,
7922,,A,,In vivo,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621206,BAO_0000218,948.0,
7923,,A,,In vivo,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL621207,BAO_0000218,948.0,
7924,,A,,In vivo,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL621208,BAO_0000218,948.0,
7925,,A,,In vivo,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL621209,BAO_0000218,948.0,
7926,,A,,In vivo,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL876484,BAO_0000218,948.0,
7927,,A,,In vivo,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621210,BAO_0000218,948.0,
7928,,A,,In vivo,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621211,BAO_0000218,948.0,
7929,,A,,In vivo,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL621212,BAO_0000218,948.0,
7930,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621213,BAO_0000218,948.0,
7931,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621214,BAO_0000218,948.0,
7932,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621215,BAO_0000218,948.0,
7933,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621216,BAO_0000218,948.0,
7934,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621217,BAO_0000218,948.0,
7935,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621218,BAO_0000218,948.0,
7936,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621219,BAO_0000218,948.0,
7937,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621220,BAO_0000218,948.0,
7938,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621221,BAO_0000218,948.0,
7939,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621222,BAO_0000218,948.0,
7940,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621223,BAO_0000218,948.0,
7941,,A,,In vivo,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL876485,BAO_0000218,948.0,
7942,,A,,In vivo,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621224,BAO_0000218,948.0,
7943,,A,,In vivo,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,1,,,50597,10116.0,Intermediate,1,CHEMBL621225,BAO_0000218,948.0,
7944,,A,,In vivo,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL621226,BAO_0000218,948.0,
7945,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621227,BAO_0000218,2113.0,
7946,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL621228,BAO_0000218,2113.0,
7947,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL621229,BAO_0000218,2113.0,
7948,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL621230,BAO_0000218,2113.0,
7949,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,,,50597,10116.0,Intermediate,1,CHEMBL621231,BAO_0000218,2113.0,
7950,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL621232,BAO_0000218,2113.0,
7951,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621233,BAO_0000218,2113.0,
7952,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621234,BAO_0000218,2113.0,
7953,,A,,In vivo,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,,,50597,10116.0,Intermediate,1,CHEMBL621235,BAO_0000218,2113.0,
7954,,A,,In vivo,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621236,BAO_0000218,2113.0,
7955,,A,,In vivo,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,1,,,50597,10116.0,Intermediate,1,CHEMBL621237,BAO_0000218,2113.0,
7956,,A,,In vivo,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL876486,BAO_0000218,2113.0,
7957,,A,,In vivo,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL622436,BAO_0000218,160.0,
7958,,A,,In vivo,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL622437,BAO_0000218,160.0,
7959,,A,,In vivo,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL622438,BAO_0000218,160.0,
7960,,A,,In vivo,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622439,BAO_0000218,2107.0,
7961,,A,,In vivo,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL622440,BAO_0000218,2107.0,
7962,,A,,In vivo,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL622441,BAO_0000218,2107.0,
7963,,A,,In vivo,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL622442,BAO_0000218,2107.0,
7964,,A,,In vivo,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL622443,BAO_0000218,2107.0,
7965,,A,,In vivo,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL622444,BAO_0000218,2107.0,
7966,,A,,In vivo,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL622445,BAO_0000218,2107.0,
7967,,A,,In vivo,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,,,50597,10116.0,Intermediate,1,CHEMBL622446,BAO_0000218,2107.0,
7968,,A,,In vivo,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL622447,BAO_0000218,2107.0,
7969,,A,,In vivo,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL622448,BAO_0000218,2107.0,
7970,,A,,In vivo,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,,,50597,10116.0,Intermediate,1,CHEMBL622449,BAO_0000218,2107.0,
7971,,A,,In vivo,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL622450,BAO_0000218,2107.0,
7972,,A,,In vivo,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL622451,BAO_0000218,2107.0,
7973,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622452,BAO_0000218,2107.0,
7974,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL622453,BAO_0000218,2107.0,
7975,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622454,BAO_0000218,2107.0,
7976,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL622455,BAO_0000218,2107.0,
7977,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL876024,BAO_0000218,2107.0,
7978,,A,,In vivo,T max was determined at 3 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622456,BAO_0000218,,
7979,,A,,In vivo,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622457,BAO_0000218,,
7980,,A,,In vivo,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622458,BAO_0000218,,
7981,,A,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622459,BAO_0000218,,
7982,,A,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL873343,BAO_0000218,,
7983,,A,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622460,BAO_0000218,,
7984,,A,,,Time for maximum plasma concentration determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622461,BAO_0000218,1969.0,
7985,,A,,In vivo,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622462,BAO_0000218,1969.0,
7986,,A,,In vivo,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622463,BAO_0000218,,
7987,,A,,In vivo,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622464,BAO_0000218,,
7988,,A,,In vivo,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622465,BAO_0000218,,
7989,,A,,In vivo,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622466,BAO_0000218,,
7990,,A,,In vivo,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622467,BAO_0000218,,
7991,,A,,,Time of maximum plasma concentration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622468,BAO_0000218,1969.0,
7992,,A,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL876025,BAO_0000218,1969.0,
7993,,A,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622469,BAO_0000218,1969.0,
7994,,A,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,,,50597,10116.0,Intermediate,1,CHEMBL622470,BAO_0000218,1969.0,
7995,,A,,In vivo,Time required to reach maximum concentration (Cmax) after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622471,BAO_0000218,,
7996,,A,,,Time required to reach maximum concentration in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL622472,BAO_0000218,1969.0,
7997,,A,,In vivo,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL622473,BAO_0000218,1969.0,
7998,,A,,In vivo,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624282,BAO_0000218,1969.0,
7999,,A,,In vivo,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624283,BAO_0000218,1969.0,
8000,,A,,In vivo,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624284,BAO_0000218,1969.0,
8001,,A,,In vivo,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624285,BAO_0000218,1969.0,
8002,,A,,In vivo,Time to reach Cmax after oral administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624286,BAO_0000218,,
8003,,A,,In vivo,Time to reach Cmax when a dose of 1 mg/kg is administered orally,1,,,50597,10116.0,Intermediate,1,CHEMBL624287,BAO_0000218,,
8004,,A,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,1,,,50597,10116.0,Intermediate,1,CHEMBL624288,BAO_0000218,,
8005,,A,,In vivo,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1,,,50597,10116.0,Intermediate,1,CHEMBL624289,BAO_0000218,1969.0,
8006,,A,,In vivo,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL873344,BAO_0000218,1969.0,
8007,,A,,In vivo,Tmax after peroral administration (10 mg/kg) was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL619623,BAO_0000218,,
8008,,A,,In vivo,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL621399,BAO_0000218,,
8009,,A,,In vivo,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621400,BAO_0000218,,
8010,,A,,In vivo,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",1,,,50597,10116.0,Intermediate,1,CHEMBL621401,BAO_0000218,,
8011,,A,,,Tmax was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621402,BAO_0000218,,
8012,,A,,,Tmax was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621403,BAO_0000218,,
8013,,A,,In vivo,Tmax after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621121,BAO_0000218,,
8014,,A,,In vivo,Tmax after peroral administration in rats at 2.4 uM/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL872525,BAO_0000218,,
8015,,A,,,Tmax in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621122,BAO_0000218,,
8016,,A,,In vivo,Tmax in rat at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621123,BAO_0000218,,
8017,,A,,In vivo,Tmax in rat by po administration at a dose of 40 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621124,BAO_0000218,,
8018,,A,,,Tmax in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621125,BAO_0000218,,
8019,,A,,In vivo,Tmax was measured in rats after peroral administration at 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621126,BAO_0000218,,
8020,,A,,In vivo,Tmax value after oral dose at a dose of 10 mg/kg in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL621127,BAO_0000218,,
8021,,A,,In vivo,Tmax value after administration of 20 mg/Kg oral dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621128,BAO_0000218,,
8022,,A,,In vivo,Tmax value at a dose of 10 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618263,BAO_0000218,,
8023,,A,,In vivo,Tmax value at a dose of 100 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618264,BAO_0000218,,
8024,,A,,In vivo,Tmax value at a dose of 50 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618265,BAO_0000218,,
8025,,A,,In vivo,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,,50597,10116.0,Intermediate,1,CHEMBL618266,BAO_0000218,1969.0,
8026,,A,,In vivo,time required to reach maximum concentration (Cmax) after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618267,BAO_0000218,,
8027,,A,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL618450,BAO_0000218,1088.0,
8028,,A,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL618451,BAO_0000218,1088.0,
8029,,A,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618452,BAO_0000218,,
8030,,A,,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1,,,50597,10116.0,Intermediate,1,CHEMBL618453,BAO_0000218,1088.0,
8031,,A,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1,,,50597,10116.0,Intermediate,1,CHEMBL618454,BAO_0000218,1088.0,
8032,,A,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL618455,BAO_0000218,1088.0,
8033,,A,,In vivo,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,1,,,50597,10116.0,Intermediate,1,CHEMBL618456,BAO_0000218,,
8034,,A,,In vivo,Compound distribution in rat tissues was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618457,BAO_0000218,,
8035,,A,,In vivo,Volume of distribution was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618458,BAO_0000218,,
8036,,A,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618459,BAO_0000218,,
8037,,A,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL876733,BAO_0000218,,
8038,,A,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL618460,BAO_0000218,,
8039,,A,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618461,BAO_0000218,,
8040,,A,,,Area under the curve was determined after oral administration (300 uM/Kg),0,,,22224,,Autocuration,1,CHEMBL618462,BAO_0000019,,
8041,,A,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618463,BAO_0000218,,
8042,,A,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618464,BAO_0000218,,
8043,,A,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618465,BAO_0000218,,
8044,,A,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618466,BAO_0000218,,
8045,,A,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618467,BAO_0000218,,
8046,,A,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618468,BAO_0000218,,
8047,,A,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618469,BAO_0000218,1969.0,
8048,,A,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL618470,BAO_0000218,1969.0,
8049,,A,,,Plasma drug AUC in rat (PO dose),0,,,22224,,Autocuration,1,CHEMBL618471,BAO_0000218,,
8050,,A,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,1,,,50594,10090.0,Intermediate,1,CHEMBL618472,BAO_0000218,,
8051,,A,,,Area under was determined at a dose of 30 mg/kg,0,,,22224,,Autocuration,1,CHEMBL618473,BAO_0000218,,
8052,,A,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,1,,,50506,9669.0,Intermediate,1,CHEMBL621699,BAO_0000218,,
8053,,A,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621700,BAO_0000218,,
8054,,A,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621701,BAO_0000218,,
8055,,A,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,1,,,50506,9669.0,Intermediate,1,CHEMBL621702,BAO_0000218,,
8056,,A,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621703,BAO_0000218,,
8057,,A,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,1,,,50588,9615.0,Intermediate,1,CHEMBL621704,BAO_0000218,,
8058,,A,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",1,,,50597,10116.0,Intermediate,1,CHEMBL624259,BAO_0000218,,
8059,,A,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",1,,,50597,10116.0,Intermediate,1,CHEMBL624260,BAO_0000218,,
8060,,A,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",1,,,50597,10116.0,Intermediate,1,CHEMBL624430,BAO_0000218,,
8061,,A,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",1,,,50597,10116.0,Intermediate,1,CHEMBL624431,BAO_0000218,,
8062,,A,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",1,,,50597,10116.0,Intermediate,1,CHEMBL624432,BAO_0000218,,
8063,,A,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",1,,,50597,10116.0,Intermediate,1,CHEMBL624433,BAO_0000218,,
8064,,A,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",1,,,50597,10116.0,Intermediate,1,CHEMBL624434,BAO_0000218,,
8065,,A,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",1,,,50597,10116.0,Intermediate,1,CHEMBL624435,BAO_0000218,,
8066,,A,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,1,,,50594,10090.0,Intermediate,1,CHEMBL618570,BAO_0000218,,
8067,,A,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,,50594,10090.0,Intermediate,1,CHEMBL618571,BAO_0000218,,
8068,,A,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,1,,,50594,10090.0,Intermediate,1,CHEMBL618572,BAO_0000218,,
8069,,A,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,,50594,10090.0,Intermediate,1,CHEMBL618573,BAO_0000218,,
8070,,A,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,1,,,50594,10090.0,Intermediate,1,CHEMBL619267,BAO_0000218,,
8071,,A,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,,50594,10090.0,Intermediate,1,CHEMBL619431,BAO_0000218,,
8072,,A,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,1,,,50594,10090.0,Intermediate,1,CHEMBL619432,BAO_0000218,,
8073,,A,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,,50594,10090.0,Intermediate,1,CHEMBL619433,BAO_0000218,,
8074,,A,,,AUC in mice after oral dose (50 mg/kg),0,,,22224,,Autocuration,1,CHEMBL619434,BAO_0000218,1969.0,
8075,,A,,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1,,,50594,10090.0,Intermediate,1,CHEMBL619435,BAO_0000218,1977.0,
8076,,A,,,AUC (0-4 hr) ug/ml/h,0,,,22224,,Autocuration,1,CHEMBL619436,BAO_0000019,1969.0,
8077,,A,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,1,,,50597,10116.0,Intermediate,1,CHEMBL619437,BAO_0000218,,
8078,,A,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,0,,,22224,,Autocuration,1,CHEMBL619438,BAO_0000218,,
8079,,A,,,Compound was evaluated for Area under curve in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL619439,BAO_0000218,,
8080,,A,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,,50597,10116.0,Intermediate,1,CHEMBL619440,BAO_0000218,,
8081,,F,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,0,,,22224,,Autocuration,1,CHEMBL619441,BAO_0000218,,
8082,,A,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,,,50597,10116.0,Intermediate,1,CHEMBL619442,BAO_0000218,,
8083,,A,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,0,,,22224,,Autocuration,1,CHEMBL875156,BAO_0000019,,
8084,,A,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,0,,,22224,,Autocuration,1,CHEMBL619443,BAO_0000019,,
8085,,A,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,0,,,22224,,Autocuration,1,CHEMBL619444,BAO_0000019,,
8086,,A,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,0,,,22224,,Autocuration,1,CHEMBL623464,BAO_0000019,,
8087,,A,,,Compound was evaluated for area under curve when administered through oral route in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL623465,BAO_0000218,,
8088,,A,,In vivo,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,1,,,50597,10116.0,Intermediate,1,CHEMBL623466,BAO_0000218,,
8089,,A,,In vivo,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,1,,,50597,10116.0,Intermediate,1,CHEMBL623467,BAO_0000218,,
8090,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623468,BAO_0000218,,
8091,,A,,In vivo,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622660,BAO_0000218,,
8092,,A,,In vivo,Plasma clearance rate in Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622661,BAO_0000218,,
8093,,F,,In vivo,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622662,BAO_0000218,,
8094,,A,,In vivo,Pharmacokinetic property (total body clearance) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622663,BAO_0000218,,
8095,,A,,In vivo,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL622664,BAO_0000218,,
8096,,A,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622665,BAO_0000218,,
8097,,A,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622666,BAO_0000218,,
8098,,A,,In vivo,Cl in rat i.v. at 2 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL621615,BAO_0000218,,
8099,,A,,In vivo,Clearance of compound after intravenous administration in rats at 24 uM/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621616,BAO_0000218,,
8100,,A,,In vivo,Clearance was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621617,BAO_0000218,,
8101,,A,,In vivo,Clearance by intravenous administration of 3.4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621618,BAO_0000218,,
8102,,A,,In vivo,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621619,BAO_0000218,,
8103,,A,,In vivo,Clearance rate after i.v. administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621620,BAO_0000218,,
8104,,A,,In vivo,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621786,BAO_0000218,,
8105,,A,,In vivo,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621787,BAO_0000218,,
8106,,A,,In vivo,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621788,BAO_0000218,,
8107,,A,,In vivo,Clearance (Cl) after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621789,BAO_0000218,,
8108,,A,,In vivo,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621790,BAO_0000218,,
8109,,A,,In vivo,Compound was tested for plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621791,BAO_0000218,1969.0,
8110,,A,,In vitro,In vitro microsome metabolism clearance in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621792,BAO_0000218,,
8111,,A,,In vitro,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,1,,,50597,10116.0,Intermediate,1,CHEMBL621793,BAO_0000218,,
8112,,A,,In vivo,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621794,BAO_0000218,,
8113,,A,,In vivo,In vivo plasma clearance was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621795,BAO_0000218,1969.0,
8114,,A,,In vivo,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621796,BAO_0000218,,
8115,Hepatocyte,A,401.0,In vivo,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL621797,BAO_0000218,2107.0,
8116,,A,,In vivo,Pharmacokinetic property (Plasma clearance) was measured in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621798,BAO_0000218,,
8117,,A,,In vivo,Pharmacokinetic property (clearance) in rat i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL621799,BAO_0000218,,
8118,,A,,In vivo,"Plasma Clearance was evaluated in rats, iv",1,,,50597,10116.0,Intermediate,1,CHEMBL621800,BAO_0000218,,
8119,,A,,In vivo,Plasma clearance (in vivo) in rats was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621801,BAO_0000218,,
8120,,A,,In vivo,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621802,BAO_0000218,,
8121,,A,,In vivo,Plasma clearance was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618596,BAO_0000218,,
8122,,A,,In vivo,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL618597,BAO_0000218,,
8123,,A,,In vivo,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL618598,BAO_0000218,,
8124,,A,,In vivo,Plasma clearance in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618599,BAO_0000218,,
8125,,A,,In vivo,Plasma clearance rate determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618600,BAO_0000218,,
8126,,A,,In vivo,Plasma clearance was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618601,BAO_0000218,,
8127,,A,,In vivo,Plasma clearance was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618602,BAO_0000218,,
8128,,A,,In vivo,Plasma clearance value in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618603,BAO_0000218,,
8129,,A,,Ex vivo,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,,,50597,10116.0,Intermediate,1,CHEMBL618604,BAO_0000218,2107.0,
8130,,A,,In vivo,Clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618605,BAO_0000218,,
8131,,A,,In vivo,Total body clearance in rat i.v. at 2 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL618606,BAO_0000218,,
8132,,A,,In vivo,Clearance of compound in rats after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618607,BAO_0000218,,
8133,,A,,In vivo,Clearance after iv administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618608,BAO_0000218,,
8134,,A,,In vivo,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618609,BAO_0000218,,
8135,,A,,In vivo,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618610,BAO_0000218,,
8136,,A,,In vivo,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618611,BAO_0000218,,
8137,,A,,In vivo,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618612,BAO_0000218,,
8138,,A,,In vivo,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618613,BAO_0000218,,
8139,,A,,In vivo,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621076,BAO_0000218,,
8140,,A,,In vivo,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621077,BAO_0000218,,
8141,,A,,In vivo,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",1,,,50597,10116.0,Intermediate,1,CHEMBL621078,BAO_0000218,,
8142,,A,,In vivo,Clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621251,BAO_0000218,,
8143,,A,,In vivo,Clearance in rat after oral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621252,BAO_0000218,,
8144,,A,,In vivo,Clearance in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL621253,BAO_0000218,,
8145,,A,,In vivo,Clearance rate following an oral dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621254,BAO_0000218,,
8146,,A,,In vivo,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL621255,BAO_0000218,,
8147,,A,,In vivo,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1,,,50597,10116.0,Intermediate,1,CHEMBL621256,BAO_0000218,1969.0,
8148,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621257,BAO_0000218,2107.0,
8149,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621258,BAO_0000218,2107.0,
8150,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621259,BAO_0000218,2107.0,
8151,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621260,BAO_0000218,2107.0,
8152,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL876494,BAO_0000218,2107.0,
8153,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621261,BAO_0000218,2107.0,
8154,,A,,In vivo,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621262,BAO_0000218,2107.0,
8155,,A,,In vivo,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621263,BAO_0000218,2107.0,
8156,,A,,In vivo,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,1,,,50597,10116.0,Intermediate,1,CHEMBL621264,BAO_0000218,2107.0,
8157,,A,,In vivo,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621265,BAO_0000218,2385.0,
8158,,A,,In vivo,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL621266,BAO_0000218,2385.0,
8159,,A,,In vivo,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621267,BAO_0000218,2385.0,
8160,,A,,In vivo,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621268,BAO_0000218,2385.0,
8161,,A,,In vivo,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621269,BAO_0000218,2385.0,
8162,,A,,In vivo,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621270,BAO_0000218,2385.0,
8163,,A,,In vivo,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621271,BAO_0000218,2385.0,
8164,,A,,In vivo,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621272,BAO_0000218,2385.0,
8165,,A,,In vivo,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621273,BAO_0000218,2385.0,
8166,,A,,In vivo,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621274,BAO_0000218,2385.0,
8167,,A,,In vivo,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL876495,BAO_0000218,2385.0,
8168,,A,,In vivo,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621275,BAO_0000218,2385.0,
8169,,A,,In vivo,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,1,,,50597,10116.0,Intermediate,1,CHEMBL621276,BAO_0000218,2385.0,
8170,,A,,In vivo,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL621277,BAO_0000218,2385.0,
8171,,A,,In vivo,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621278,BAO_0000218,160.0,
8172,,A,,In vivo,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621279,BAO_0000218,160.0,
8173,,A,,In vivo,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),1,,,50597,10116.0,Intermediate,1,CHEMBL621280,BAO_0000218,160.0,
8174,,A,,In vivo,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621281,BAO_0000218,2106.0,
8175,,A,,In vivo,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,1,,,50597,10116.0,Intermediate,1,CHEMBL621282,BAO_0000218,2106.0,
8176,,A,,In vivo,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,,,50597,10116.0,Intermediate,1,CHEMBL621283,BAO_0000218,2106.0,
8177,,A,,In vivo,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,1,,,50597,10116.0,Intermediate,1,CHEMBL621284,BAO_0000218,2106.0,
8178,,A,,In vivo,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621285,BAO_0000218,2106.0,
8179,,A,,In vivo,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621286,BAO_0000218,2106.0,
8180,,A,,In vivo,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623220,BAO_0000218,2106.0,
8181,,A,,In vivo,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,1,,,50597,10116.0,Intermediate,1,CHEMBL623221,BAO_0000218,2106.0,
8182,,A,,In vivo,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,1,,,50597,10116.0,Intermediate,1,CHEMBL876029,BAO_0000218,2106.0,
8183,,A,,In vivo,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623222,BAO_0000218,945.0,
8184,,A,,In vivo,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623223,BAO_0000218,945.0,
8185,,A,,In vivo,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,1,,,50597,10116.0,Intermediate,1,CHEMBL621445,BAO_0000218,945.0,
8186,,A,,In vivo,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621446,BAO_0000218,178.0,
8187,,A,,In vivo,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621447,BAO_0000218,178.0,
8188,,A,,In vivo,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619681,BAO_0000218,178.0,
8189,,A,,In vivo,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619682,BAO_0000218,178.0,
8190,,A,,In vivo,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619683,BAO_0000218,178.0,
8191,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619684,BAO_0000218,955.0,
8192,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619685,BAO_0000218,955.0,
8193,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619686,BAO_0000218,955.0,
8194,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619687,BAO_0000218,955.0,
8195,,A,,In vivo,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619688,BAO_0000218,955.0,
8196,,A,,In vivo,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619689,BAO_0000218,948.0,
8197,,A,,In vivo,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619690,BAO_0000218,948.0,
8198,,A,,In vivo,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619691,BAO_0000218,948.0,
8199,,A,,In vivo,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL619692,BAO_0000218,,
8200,,A,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL619693,BAO_0000218,,
8201,,A,,In vivo,Vc value after IV dose at a dose of 5 mg/kg in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL619694,BAO_0000218,,
8202,,A,,In vivo,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL619695,BAO_0000218,,
8203,,A,,In vivo,Compound was evaluated for pharmacokinetic parameter volume of distribution,1,,,50597,10116.0,Intermediate,1,CHEMBL619696,BAO_0000218,,
8204,,A,,In vivo,Compound was evaluated for volume of distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL619697,BAO_0000218,,
8205,,A,,In vivo,Steady state volume distribution was determined; steady state(ss),1,,,50597,10116.0,Intermediate,1,CHEMBL619698,BAO_0000218,,
8206,,A,,In vivo,Steady state volume of distribution after iv administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL619699,BAO_0000218,,
8207,,A,,In vivo,Steady state volume of distribution dosing at 3 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL619700,BAO_0000218,,
8208,,A,,In vivo,The compound was evaluated for volume of distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL619701,BAO_0000218,,
8209,,A,,In vivo,The compound was tested for volume of distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL619702,BAO_0000218,,
8210,,A,,In vivo,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,1,,,50597,10116.0,Intermediate,1,CHEMBL620335,BAO_0000218,,
8211,,A,,In vivo,Volume distribution (VD) after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620336,BAO_0000218,,
8212,,A,,In vivo,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620337,BAO_0000218,,
8213,,A,,In vivo,Volume distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620520,BAO_0000218,,
8214,,A,,In vivo,Volume distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620521,BAO_0000218,,
8215,,A,,In vivo,Volume distribution in rat after peroral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL875825,BAO_0000218,,
8216,,A,,In vivo,Volume distribution in rat after peroral administration at 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620522,BAO_0000218,,
8217,,A,,In vivo,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620523,BAO_0000218,,
8218,,A,,In vivo,Volume of distribution in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL620524,BAO_0000218,,
8219,,A,,In vivo,Volume of distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620525,BAO_0000218,,
8220,,A,,In vivo,Volume of distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620526,BAO_0000218,,
8221,,A,,In vivo,Volume of distribution in rat by iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL620527,BAO_0000218,,
8222,,A,,In vivo,Volume of distribution in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620528,BAO_0000218,,
8223,,A,,In vivo,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,,,50597,10116.0,Intermediate,1,CHEMBL620529,BAO_0000218,,
8224,,A,,,Volume distribution at the dose of 2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620530,BAO_0000218,,
8225,,A,,In vivo,Steady state volume of distribution was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620531,BAO_0000218,,
8226,,A,,In vivo,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,0,,,22224,9544.0,Intermediate,1,CHEMBL620532,BAO_0000218,,
8227,,A,,In vivo,Compound was tested for its plasma volume distribution in Sprague Dawley rats,0,,,22224,10116.0,Intermediate,1,CHEMBL620533,BAO_0000218,,
8228,,A,,In vivo,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,0,,,22224,10116.0,Intermediate,1,CHEMBL620534,BAO_0000218,,
8229,,A,,In vivo,Mean (%CV) PK parameters for Vdss(mL/kg).,1,,,50597,10116.0,Intermediate,1,CHEMBL620535,BAO_0000218,,
8230,,A,,In vivo,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL875826,BAO_0000218,,
8231,,A,,In vivo,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620536,BAO_0000218,,
8232,,A,,In vivo,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620537,BAO_0000218,,
8233,,A,,In vivo,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618526,BAO_0000218,,
8234,,A,,In vivo,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618527,BAO_0000218,,
8235,,A,,In vivo,Pharmacokinetic property (Vdss) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618528,BAO_0000218,,
8236,,A,,In vivo,Pharmacokinetic property (vdss) was measured in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618529,BAO_0000218,,
8237,,A,,In vivo,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618530,BAO_0000218,,
8238,,A,,In vivo,Volume of distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618531,BAO_0000218,,
8239,,A,,In vivo,The pharmacokinetic parameter volume of distribution in vivo in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618532,BAO_0000218,,
8240,,F,,In vivo,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618533,BAO_0000218,,
8241,,A,,In vivo,Vdss in rat i.v. at 2 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL618534,BAO_0000218,,
8242,,A,,In vivo,Volume distribution after intravenous administration (1 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618535,BAO_0000218,,
8243,,A,,In vivo,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618536,BAO_0000218,,
8244,,A,,In vivo,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618537,BAO_0000218,,
8245,,A,,In vivo,Volume distribution at a dose of 10 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618538,BAO_0000218,,
8246,,A,,In vivo,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618539,BAO_0000218,,
8247,,A,,In vivo,Volume distribution was calculated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618540,BAO_0000218,,
8248,,A,,In vivo,Volume distribution was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618541,BAO_0000218,,
8249,,A,,In vivo,Volume of distribution after intravenous administration was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618542,BAO_0000218,,
8250,,A,,In vivo,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622544,BAO_0000218,,
8251,,A,,In vivo,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",1,,,50597,10116.0,Intermediate,1,CHEMBL622545,BAO_0000218,,
8252,,A,,In vivo,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,,50597,10116.0,Intermediate,1,CHEMBL622546,BAO_0000218,,
8253,,A,,In vivo,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622547,BAO_0000218,,
8254,,A,,In vivo,Volume of distribution in steady state was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622548,BAO_0000218,,
8255,,A,,In vivo,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622549,BAO_0000218,,
8256,,A,,In vivo,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622550,BAO_0000218,,
8257,,A,,,Compound was evaluated for area under curve when administered through oral route to mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL622551,BAO_0000218,,
8258,,A,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,,50597,10116.0,Intermediate,1,CHEMBL622552,BAO_0000218,,
8259,,A,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,,,50597,10116.0,Intermediate,1,CHEMBL622553,BAO_0000218,,
8260,,F,,In vivo,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,0,,,22224,,Autocuration,1,CHEMBL622554,BAO_0000218,,
8261,,A,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL622555,BAO_0000218,,
8262,,A,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622556,BAO_0000218,,
8263,,A,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622557,BAO_0000218,,
8264,,A,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622558,BAO_0000218,178.0,
8265,,A,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL622559,BAO_0000218,178.0,
8266,,A,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,1,,,50588,9615.0,Intermediate,1,CHEMBL622560,BAO_0000218,,
8267,,A,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622561,BAO_0000218,,
8268,,A,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,1,,,50597,10116.0,Intermediate,1,CHEMBL622562,BAO_0000218,,
8269,,A,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622563,BAO_0000218,,
8270,,A,,,Concentration of compound in Central nervous system,0,,,22224,,Autocuration,1,CHEMBL622564,BAO_0000019,,
8271,,A,,,Concentration of compound in Central nervous system; Not detectable,0,,,22224,,Autocuration,1,CHEMBL622565,BAO_0000019,,
8272,,A,,,"Concentration of diester in the blood, following oral administration in mice",1,,,50594,10090.0,Intermediate,1,CHEMBL622566,BAO_0000218,,
8273,,A,,,"Concentration of monoester in the blood, following oral administration in mice",1,,,50594,10090.0,Intermediate,1,CHEMBL624515,BAO_0000218,,
8274,,A,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL624516,BAO_0000218,,
8275,,A,,,Evaluated for Pharmacokinetic property: Area under the curve,0,,,22224,,Autocuration,1,CHEMBL624517,BAO_0000019,,
8276,,A,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,1,,,50594,10090.0,Intermediate,1,CHEMBL624518,BAO_0000218,,
8277,,A,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,1,,,100710,9541.0,Intermediate,1,CHEMBL624519,BAO_0000218,,
8278,,A,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,1,,,100710,9541.0,Intermediate,1,CHEMBL624520,BAO_0000218,,
8279,,A,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,1,,,100710,9541.0,Intermediate,1,CHEMBL624521,BAO_0000218,,
8280,,A,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,1,,,100710,9541.0,Intermediate,1,CHEMBL624522,BAO_0000218,,
8281,,A,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,1,,,100710,9541.0,Intermediate,1,CHEMBL624523,BAO_0000218,,
8282,,A,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,,100710,9541.0,Intermediate,1,CHEMBL624409,BAO_0000218,,
8283,,A,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",1,,,100710,9541.0,Intermediate,1,CHEMBL624410,BAO_0000218,,
8284,,A,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,,100710,9541.0,Intermediate,1,CHEMBL624411,BAO_0000218,,
8285,,A,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",1,,,100710,9541.0,Intermediate,1,CHEMBL623531,BAO_0000218,,
8286,,A,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",1,,,100710,9541.0,Intermediate,1,CHEMBL623532,BAO_0000218,,
8287,,A,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",1,,,100710,9541.0,Intermediate,1,CHEMBL623533,BAO_0000218,,
8288,,A,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,,100710,9541.0,Intermediate,1,CHEMBL623534,BAO_0000218,,
8289,,A,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,1,,,50594,10090.0,Intermediate,1,CHEMBL623535,BAO_0000218,,
8290,,A,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,1,,,50594,10090.0,Intermediate,1,CHEMBL623536,BAO_0000218,,
8291,,A,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,1,,,50594,10090.0,Intermediate,1,CHEMBL623537,BAO_0000218,,
8292,,A,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,1,,,50594,10090.0,Intermediate,1,CHEMBL623538,BAO_0000218,,
8293,,A,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,1,,,50594,10090.0,Intermediate,1,CHEMBL623539,BAO_0000218,,
8294,,A,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,1,,,50594,10090.0,Intermediate,1,CHEMBL623540,BAO_0000218,,
8295,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",1,,,50594,10090.0,Intermediate,1,CHEMBL623541,BAO_0000218,,
8296,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",1,,,50594,10090.0,Intermediate,1,CHEMBL623542,BAO_0000218,,
8297,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",1,,,50594,10090.0,Intermediate,1,CHEMBL623543,BAO_0000218,,
8298,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",1,,,50594,10090.0,Intermediate,1,CHEMBL623544,BAO_0000218,,
8299,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",1,,,50594,10090.0,Intermediate,1,CHEMBL623545,BAO_0000218,,
8300,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",1,,,50594,10090.0,Intermediate,1,CHEMBL623546,BAO_0000218,,
8301,,A,,In vivo,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623547,BAO_0000218,1969.0,
8302,,A,,In vivo,High i.v. clearance in Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623548,BAO_0000218,,
8303,,A,,In vitro,In vitro clearance in rat liver microsomes,1,,,50597,10116.0,Intermediate,1,CHEMBL623549,BAO_0000218,2107.0,
8304,,A,,In vitro,Intrinsic clearance in rat liver microsomes was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623550,BAO_0000218,2107.0,
8305,Hepatocyte,A,401.0,In vitro,Intrinsic clearance in rat hepatocytes was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL875276,BAO_0000218,2107.0,
8306,,A,,In vivo,Plasma Clearance was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621872,BAO_0000218,,
8307,,A,,In vivo,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621873,BAO_0000218,,
8308,,A,,In vivo,Plasma clearance in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL621874,BAO_0000218,,
8309,,A,,In vivo,Plasma clearance in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621875,BAO_0000218,,
8310,,A,,In vivo,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621876,BAO_0000218,,
8311,,A,,In vivo,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621877,BAO_0000218,,
8312,,A,,In vivo,Plasma clearance was measured in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621878,BAO_0000218,,
8313,,A,,In vivo,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621879,BAO_0000218,,
8314,,A,,In vivo,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1,,,50597,10116.0,Intermediate,1,CHEMBL621880,BAO_0000218,1969.0,
8315,,A,,In vivo,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621881,BAO_0000218,,
8316,,A,,In vivo,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621882,BAO_0000218,,
8317,,A,,In vivo,Total clearance at 1 mg/kg was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL875283,BAO_0000218,,
8318,,A,,In vivo,Total clearance at 10 mg/kg was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621883,BAO_0000218,,
8319,,A,,In vivo,Clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621884,BAO_0000218,,
8320,,A,,In vivo,Plasma clearance rate determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621885,BAO_0000218,,
8321,,A,,In vivo,Clearance of compound in rat was evaluated,1,,,50597,10116.0,Intermediate,1,CHEMBL621886,BAO_0000218,,
8322,,A,,In vivo,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL621887,BAO_0000218,1969.0,
8323,,A,,In vivo,Pharmacokinetic property (blood clearance) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621888,BAO_0000218,,
8324,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621889,BAO_0000218,,
8325,,A,,In vivo,Plasma clearance in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621890,BAO_0000218,,
8326,,A,,In vitro,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,1,,,50597,10116.0,Intermediate,1,CHEMBL621891,BAO_0000218,2107.0,
8327,,A,,In vivo,Clearance in Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621892,BAO_0000218,,
8328,,A,,In vivo,Clearance rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621893,BAO_0000218,,
8329,,A,,In vivo,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),1,,,50597,10116.0,Intermediate,1,CHEMBL621894,BAO_0000218,,
8330,,A,,In vivo,Clearance rat; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621895,BAO_0000218,,
8331,,A,,In vivo,Clearance rate was determined in rat at a dose of 1 mpk i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL875284,BAO_0000218,,
8332,,A,,In vivo,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618699,BAO_0000218,,
8333,,A,,In vivo,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618700,BAO_0000218,,
8334,,A,,In vivo,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618701,BAO_0000218,,
8335,,A,,In vivo,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,,,50597,10116.0,Intermediate,1,CHEMBL876600,BAO_0000218,1969.0,
8336,,A,,In vivo,Clearance of compound in rat after 1 mg/kg i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618702,BAO_0000218,,
8337,,A,,In vivo,Compound was evaluated for Hepatic clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618703,BAO_0000218,,
8338,,A,,In vivo,In vivo clearance after 5 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL618704,BAO_0000218,,
8339,,A,,In vivo,Compound was tested for plasma clearance in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618705,BAO_0000218,1969.0,
8340,,A,,In vivo,Hepatic clearance after intravenous administration was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618706,BAO_0000218,,
8341,,A,,In vivo,Lower clearance in rat (i.v.) at 0.5 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL618707,BAO_0000218,,
8342,,A,,In vivo,Pharmacokinetic parameter expressed as plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618708,BAO_0000218,1969.0,
8343,,A,,In vivo,Pharmacokinetic property (Clp) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618709,BAO_0000218,,
8344,,A,,In vivo,Plasma clearance in Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618710,BAO_0000218,,
8345,,A,,In vivo,Plasma clearance (Clp) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618711,BAO_0000218,,
8346,,A,,In vivo,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618712,BAO_0000218,,
8347,,A,,In vivo,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL618713,BAO_0000218,,
8348,,A,,In vivo,Plasma clearance after intravenous administration of 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618714,BAO_0000218,,
8349,,A,,In vivo,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618715,BAO_0000218,,
8350,,A,,In vivo,Plasma clearance in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618716,BAO_0000218,,
8351,,A,,In vivo,Plasma clearance measured in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL876601,BAO_0000218,,
8352,,A,,In vivo,Plasma clearance was calculated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618717,BAO_0000218,,
8353,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618718,BAO_0000218,,
8354,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618719,BAO_0000218,,
8355,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618720,BAO_0000218,,
8356,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618721,BAO_0000218,,
8357,,A,,In vivo,Plasma clearance in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621477,BAO_0000218,,
8358,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621478,BAO_0000218,,
8359,,A,,In vivo,Plasma clearance was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621479,BAO_0000218,,
8360,,A,,In vivo,Plasma clearance was evaluated in rat; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL621480,BAO_0000218,,
8361,,A,,In vivo,Plasma clearance rate was determined for the compound in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621481,BAO_0000218,,
8362,,A,,In vivo,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",1,,,50597,10116.0,Intermediate,1,CHEMBL621482,BAO_0000218,,
8363,,A,,In vivo,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,,50597,10116.0,Intermediate,1,CHEMBL621483,BAO_0000218,,
8364,,A,,In vivo,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL621484,BAO_0000218,,
8365,,A,,In vivo,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621485,BAO_0000218,948.0,
8366,,A,,In vivo,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621486,BAO_0000218,948.0,
8367,,A,,In vivo,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621487,BAO_0000218,160.0,
8368,,A,,In vivo,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621488,BAO_0000218,160.0,
8369,,A,,In vivo,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621489,BAO_0000218,160.0,
8370,,A,,In vivo,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621490,BAO_0000218,160.0,
8371,,A,,In vivo,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621491,BAO_0000218,160.0,
8372,,A,,In vivo,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621492,BAO_0000218,2113.0,
8373,,A,,In vivo,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621493,BAO_0000218,2113.0,
8374,,A,,In vivo,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621494,BAO_0000218,2113.0,
8375,,A,,In vivo,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621495,BAO_0000218,2113.0,
8376,,A,,In vivo,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621496,BAO_0000218,2113.0,
8377,,A,,In vivo,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621497,BAO_0000218,2107.0,
8378,,A,,In vivo,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621498,BAO_0000218,2107.0,
8379,,A,,In vivo,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL621499,BAO_0000218,2107.0,
8380,,A,,In vivo,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL618634,BAO_0000218,2107.0,
8381,,A,,In vivo,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL618635,BAO_0000218,2107.0,
8382,,A,,In vivo,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL618636,BAO_0000218,2048.0,
8383,,A,,In vivo,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619737,BAO_0000218,2048.0,
8384,,A,,In vivo,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL619738,BAO_0000218,2048.0,
8385,,A,,In vivo,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL624329,BAO_0000218,2048.0,
8386,,A,,In vivo,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL624330,BAO_0000218,2048.0,
8387,,A,,In vivo,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL624331,BAO_0000218,2385.0,
8388,,A,,In vivo,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL624332,BAO_0000218,2385.0,
8389,,A,,In vivo,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL624333,BAO_0000218,2385.0,
8390,,A,,In vivo,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL624334,BAO_0000218,2385.0,
8391,,A,,In vivo,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL624335,BAO_0000218,2385.0,
8392,,A,,In vivo,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620016,BAO_0000218,2106.0,
8393,,A,,In vivo,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620169,BAO_0000218,2106.0,
8394,,A,,In vivo,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620170,BAO_0000218,2106.0,
8395,,A,,In vivo,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620171,BAO_0000218,2106.0,
8396,,A,,In vivo,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620172,BAO_0000218,2106.0,
8397,,A,,In vivo,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620173,BAO_0000218,945.0,
8398,,A,,In vivo,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620174,BAO_0000218,945.0,
8399,,A,,In vivo,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620175,BAO_0000218,945.0,
8400,,A,,In vivo,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620176,BAO_0000218,945.0,
8401,,A,,In vivo,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620177,BAO_0000218,945.0,
8402,,A,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620178,BAO_0000218,2037.0,
8403,,A,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620179,BAO_0000218,2037.0,
8404,,A,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620180,BAO_0000218,,
8405,,A,,In vivo,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL620181,BAO_0000218,,
8406,,A,,In vivo,Volume of distribution of compound in rats after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL620182,BAO_0000218,,
8407,,A,,In vivo,Volume of distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620183,BAO_0000218,,
8408,,A,,In vivo,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL620184,BAO_0000218,,
8409,,A,,In vivo,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620185,BAO_0000218,,
8410,,A,,In vivo,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620186,BAO_0000218,,
8411,,A,,In vivo,Volume of distribution was determined in Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620187,BAO_0000218,,
8412,,A,,In vivo,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620188,BAO_0000218,,
8413,,A,,In vivo,Volume of distribution was reported in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620189,BAO_0000218,,
8414,,A,,In vivo,Volumes of distribution in rat after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL620190,BAO_0000218,,
8415,,A,,In vivo,Volumes of distribution in rat after po administration,1,,,50597,10116.0,Intermediate,1,CHEMBL620191,BAO_0000218,,
8416,,A,,In vivo,Volumes of distribution in rat after po administration; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620192,BAO_0000218,,
8417,,A,,In vivo,Pharmacokinetic property (Volume) in rat i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL620193,BAO_0000218,,
8418,,A,,In vivo,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,1,,,50597,10116.0,Intermediate,1,CHEMBL620194,BAO_0000218,,
8419,,A,,In vivo,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",1,,,50597,10116.0,Intermediate,1,CHEMBL876730,BAO_0000218,,
8420,,A,,In vivo,Volume distribution in rat after oral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620195,BAO_0000218,,
8421,,A,,In vivo,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620196,BAO_0000218,,
8422,,A,,In vivo,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620197,BAO_0000218,,
8423,,A,,In vivo,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL620198,BAO_0000218,,
8424,,A,,In vivo,Volume of distribution in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620199,BAO_0000218,,
8425,,A,,In vivo,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620200,BAO_0000218,,
8426,,A,,In vivo,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620201,BAO_0000218,,
8427,,A,,In vivo,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620202,BAO_0000218,,
8428,,A,,In vivo,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620203,BAO_0000218,,
8429,,A,,In vivo,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,1,,,50597,10116.0,Intermediate,1,CHEMBL620204,BAO_0000218,,
8430,,A,,In vivo,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620205,BAO_0000218,,
8431,,A,,In vivo,Pharmacokinetic parameter (Vss) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624664,BAO_0000218,,
8432,,A,,In vivo,Pharmacokinetic property (Volume) in rat i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL624665,BAO_0000218,,
8433,,A,,,Pharmacokinetic property (Vss) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624666,BAO_0000218,,
8434,,A,,In vivo,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624667,BAO_0000218,,
8435,,A,,In vivo,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624668,BAO_0000218,,
8436,,A,,In vivo,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624669,BAO_0000218,,
8437,,A,,In vivo,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624670,BAO_0000218,,
8438,,A,,In vivo,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624671,BAO_0000218,,
8439,,A,,In vivo,Steady state volume distribution in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624672,BAO_0000218,,
8440,,A,,In vivo,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1,,,50597,10116.0,Intermediate,1,CHEMBL624673,BAO_0000218,1969.0,
8441,,A,,In vivo,Steady state volume of distribution determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624674,BAO_0000218,,
8442,,A,,In vivo,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624675,BAO_0000218,,
8443,,A,,In vivo,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621728,BAO_0000218,,
8444,,A,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621729,BAO_0000218,,
8445,,A,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,1,,,50597,10116.0,Intermediate,1,CHEMBL621730,BAO_0000218,,
8446,,A,,In vivo,Volume distribution in rat after administration of 2 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL621731,BAO_0000218,,
8447,,A,,In vivo,Volume distribution in rat after administration of 2 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL621732,BAO_0000218,,
8448,,A,,In vivo,Volume in steady state distribution value was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621908,BAO_0000218,,
8449,,A,,In vivo,Volume in steady state distribution value was determined; ND denotes no data,1,,,50597,10116.0,Intermediate,1,CHEMBL875347,BAO_0000218,,
8450,,A,,In vivo,Volume in steady state distribution value was determined; ND denotes not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621909,BAO_0000218,,
8451,,A,,In vivo,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621910,BAO_0000218,,
8452,,A,,In vivo,Volume of distribution at steady state was evaluated in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621911,BAO_0000218,,
8453,,A,,In vivo,Volume of distribution at steady state was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621912,BAO_0000218,,
8454,,A,,In vivo,Volume of distribution in steady state was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621913,BAO_0000218,,
8455,,A,,In vivo,Volume of distribution in steady state was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621914,BAO_0000218,,
8456,,A,,In vivo,Volume of distribution after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621915,BAO_0000218,,
8457,,A,,In vivo,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621916,BAO_0000218,,
8458,,A,,In vivo,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL621917,BAO_0000218,2107.0,
8459,,A,,In vivo,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL621918,BAO_0000218,2107.0,
8460,,A,,In vivo,Biodistribution of compound (oxidized form) in spleen tissue,1,,,50594,10090.0,Intermediate,1,CHEMBL621919,BAO_0000218,2106.0,
8461,,A,,In vivo,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL621920,BAO_0000218,2106.0,
8462,,A,,In vivo,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL621921,BAO_0000218,2106.0,
8463,,A,,In vivo,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622401,BAO_0000218,2106.0,
8464,,A,,In vivo,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,,50594,10090.0,Intermediate,1,CHEMBL875348,BAO_0000218,2106.0,
8465,,A,,In vivo,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,,50594,10090.0,Intermediate,1,CHEMBL622402,BAO_0000218,2106.0,
8466,,A,,In vivo,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,1,,,50594,10090.0,Intermediate,1,CHEMBL622403,BAO_0000218,178.0,
8467,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622404,BAO_0000218,178.0,
8468,,A,,In vivo,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,1,,,50594,10090.0,Intermediate,1,CHEMBL622405,BAO_0000218,955.0,
8469,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622406,BAO_0000218,955.0,
8470,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622407,BAO_0000218,955.0,
8471,,A,,In vivo,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,1,,,50594,10090.0,Intermediate,1,CHEMBL622408,BAO_0000218,948.0,
8472,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622409,BAO_0000218,948.0,
8473,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL622410,BAO_0000218,948.0,
8474,,A,,In vivo,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,1,,,50594,10090.0,Intermediate,1,CHEMBL622411,BAO_0000218,2113.0,
8475,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL627864,BAO_0000218,2113.0,
8476,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL627865,BAO_0000218,2113.0,
8477,,A,,In vivo,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,1,,,50594,10090.0,Intermediate,1,CHEMBL627866,BAO_0000218,2107.0,
8478,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL627751,BAO_0000218,2107.0,
8479,,A,,In vivo,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,1,,,50594,10090.0,Intermediate,1,CHEMBL627752,BAO_0000218,2106.0,
8480,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL627753,BAO_0000218,2106.0,
8481,,A,,In vivo,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,,50594,10090.0,Intermediate,1,CHEMBL627754,BAO_0000218,2106.0,
8482,,A,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,1,,,50594,10090.0,Intermediate,1,CHEMBL627755,BAO_0000218,,
8483,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627756,BAO_0000218,955.0,
8484,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627757,BAO_0000218,955.0,
8485,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627758,BAO_0000218,955.0,
8486,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627759,BAO_0000218,955.0,
8487,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627760,BAO_0000218,955.0,
8488,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627761,BAO_0000218,955.0,
8489,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL876811,BAO_0000218,948.0,
8490,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627762,BAO_0000218,948.0,
8491,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627763,BAO_0000218,948.0,
8492,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627764,BAO_0000218,948.0,
8493,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627765,BAO_0000218,948.0,
8494,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627766,BAO_0000218,948.0,
8495,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627767,BAO_0000218,2113.0,
8496,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627768,BAO_0000218,2113.0,
8497,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL628422,BAO_0000218,2113.0,
8498,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL628423,BAO_0000218,2113.0,
8499,,A,,In vivo,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628424,BAO_0000218,,
8500,,A,,In vivo,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628425,BAO_0000218,,
8501,,A,,In vivo,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,1,,,50597,10116.0,Intermediate,1,CHEMBL628426,BAO_0000218,,
8502,,A,,In vivo,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,50597,10116.0,Intermediate,1,CHEMBL628427,BAO_0000218,,
8503,,A,,In vivo,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626938,BAO_0000218,,
8504,,A,,In vivo,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626939,BAO_0000218,,
8505,,A,,In vivo,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626940,BAO_0000218,,
8506,,A,,In vivo,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626941,BAO_0000218,,
8507,,A,,In vivo,Plasma clearance was reported in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626942,BAO_0000218,,
8508,,A,,In vivo,Plasma clearance after intravenous administration (1 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL876812,BAO_0000218,,
8509,,A,,In vivo,Plasma clearance of compound in rats was evaluated,1,,,50597,10116.0,Intermediate,1,CHEMBL626943,BAO_0000218,,
8510,,A,,In vivo,Plasma clearance of compound in rats was evaluated; ND indicates not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626944,BAO_0000218,,
8511,,A,,In vivo,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626945,BAO_0000218,,
8512,,A,,In vivo,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626946,BAO_0000218,,
8513,,A,,In vivo,Plasma clearance rate in Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626856,BAO_0000218,,
8514,,A,,In vivo,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL626857,BAO_0000218,,
8515,,A,,In vivo,The compound was evaluated for plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626858,BAO_0000218,1969.0,
8516,,A,,In vivo,Total plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627018,BAO_0000218,1969.0,
8517,,A,,In vivo,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL625331,BAO_0000218,178.0,
8518,,A,,In vivo,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625332,BAO_0000218,178.0,
8519,,A,,In vivo,C max was determined at 10 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL877590,BAO_0000218,,
8520,,A,,In vivo,C max was determined at 3 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625333,BAO_0000218,,
8521,,A,,In vivo,Cmax after repeated oral dose of compound at 1 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625334,BAO_0000218,,
8522,,A,,In vivo,Cmax after single intravenous bolus of 1 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625335,BAO_0000218,,
8523,,A,,In vivo,Cmax of compound at 5 mg/kg after po administration was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625336,BAO_0000218,,
8524,,A,,In vivo,Cmax 24 hr after 10 mg/kg oral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625337,BAO_0000218,,
8525,,A,,In vivo,Cmax 24 hr after 2 mg/kg oral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625338,BAO_0000218,,
8526,,A,,In vivo,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625339,BAO_0000218,1969.0,
8527,,A,,In vivo,Cmax in rat after administration of 2 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL625340,BAO_0000218,,
8528,,A,,In vivo,Cmax in rat after administration of 2 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL625341,BAO_0000218,,
8529,,A,,In vivo,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622687,BAO_0000218,,
8530,,A,,In vivo,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622688,BAO_0000218,1969.0,
8531,,A,,In vivo,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622689,BAO_0000218,178.0,
8532,,A,,In vivo,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620295,BAO_0000218,178.0,
8533,,A,,In vivo,Cmax after 10 mg/kg oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620296,BAO_0000218,,
8534,,A,,In vivo,Cmax after IV dosing at 0.5 mg/kg in rat; no data,1,,,50597,10116.0,Intermediate,1,CHEMBL620297,BAO_0000218,,
8535,,A,,In vivo,Cmax after IV dosing at 1 mg/kg in rat; no data,1,,,50597,10116.0,Intermediate,1,CHEMBL620298,BAO_0000218,,
8536,,A,,In vivo,Cmax after oral administration at 20 mpk in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620299,BAO_0000218,,
8537,,A,,In vivo,Cmax after oral administration at 20 mpk in rats; Not performed.,1,,,50597,10116.0,Intermediate,1,CHEMBL620300,BAO_0000218,,
8538,,A,,In vivo,Cmax after oral administration at 20 mpk in rats d; Not performed.,1,,,50597,10116.0,Intermediate,1,CHEMBL620301,BAO_0000218,,
8539,,A,,In vivo,Cmax after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620302,BAO_0000218,,
8540,,A,,In vivo,Cmax after oral administration at a dose of 2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620303,BAO_0000218,,
8541,,A,,In vivo,Cmax after oral administration at a dose of 4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620304,BAO_0000218,,
8542,,A,,In vivo,Cmax in rats after 20 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL620305,BAO_0000218,,
8543,,A,,In vivo,Cmax after peroral administration in rats at 2.4 uM/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620306,BAO_0000218,,
8544,,A,,In vivo,Cmax at the dose of 2 mg/Kg administered perorally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620307,BAO_0000218,,
8545,,A,,In vivo,Cmax at the dose of 5 mg/Kg administered perorally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620308,BAO_0000218,,
8546,,A,,In vivo,Cmax by administering at 20 mg/kg p.o. in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620309,BAO_0000218,,
8547,,A,,In vivo,Cmax in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620310,BAO_0000218,,
8548,,A,,In vivo,Cmax in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620311,BAO_0000218,,
8549,,A,,In vivo,Cmax in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620312,BAO_0000218,,
8550,,A,,In vivo,Cmax in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620313,BAO_0000218,,
8551,,A,,In vivo,Cmax in rat at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620314,BAO_0000218,,
8552,,A,,In vivo,Cmax in rat at the dose of 1 mg/kg i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL620315,BAO_0000218,,
8553,,A,,In vivo,Cmax in rat by po administration at a dose of 40 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620316,BAO_0000218,,
8554,,A,,In vivo,Cmax in rat p.o. at 20 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL620317,BAO_0000218,,
8555,,A,,In vivo,Cmax in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620318,BAO_0000218,,
8556,,A,,In vivo,Cmax in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL620319,BAO_0000218,,
8557,,A,,In vivo,Cmax was evaluated after 20 uM/kg of peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL620320,BAO_0000218,,
8558,,A,,In vivo,Cmax was measured in rats after peroral administration at 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620321,BAO_0000218,,
8559,,A,,In vivo,Cmax value after oral dose at a dose of 10 mg/kg in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL620322,BAO_0000218,,
8560,,A,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620323,BAO_0000218,,
8561,,A,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620324,BAO_0000218,1870.0,
8562,,A,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620325,BAO_0000218,1870.0,
8563,,A,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620326,BAO_0000218,10000000.0,
8564,,A,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620327,BAO_0000218,10000000.0,
8565,,A,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620328,BAO_0000218,,
8566,,A,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620329,BAO_0000218,,
8567,,A,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620330,BAO_0000218,1891.0,
8568,,A,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL875286,BAO_0000218,1891.0,
8569,,A,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620331,BAO_0000218,,
8570,,A,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620332,BAO_0000218,,
8571,,A,,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620333,BAO_0000218,2435.0,
8572,,A,,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL620334,BAO_0000218,2435.0,
8573,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621015,BAO_0000218,178.0,
8574,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621016,BAO_0000218,178.0,
8575,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621191,BAO_0000218,178.0,
8576,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621192,BAO_0000218,178.0,
8577,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621193,BAO_0000218,178.0,
8578,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621194,BAO_0000218,178.0,
8579,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624204,BAO_0000218,178.0,
8580,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624205,BAO_0000218,178.0,
8581,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624206,BAO_0000218,178.0,
8582,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624207,BAO_0000218,178.0,
8583,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624208,BAO_0000218,178.0,
8584,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624209,BAO_0000218,178.0,
8585,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624210,BAO_0000218,178.0,
8586,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624211,BAO_0000218,178.0,
8587,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624212,BAO_0000218,178.0,
8588,,A,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624213,BAO_0000218,178.0,
8589,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL876611,BAO_0000218,178.0,
8590,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624214,BAO_0000218,178.0,
8591,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624215,BAO_0000218,178.0,
8592,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624216,BAO_0000218,178.0,
8593,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624217,BAO_0000218,178.0,
8594,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624218,BAO_0000218,178.0,
8595,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624219,BAO_0000218,178.0,
8596,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624220,BAO_0000218,178.0,
8597,,A,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624221,BAO_0000218,178.0,
8598,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624222,BAO_0000218,,
8599,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624223,BAO_0000218,,
8600,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624224,BAO_0000218,,
8601,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624225,BAO_0000218,,
8602,,A,,In vivo,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622420,BAO_0000218,,
8603,,A,,In vivo,Volume of steady state distribution after i.v. administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622421,BAO_0000218,,
8604,,A,,In vivo,Vss after intravenous administration (5.0 mg/kg) was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622422,BAO_0000218,,
8605,,A,,In vivo,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622423,BAO_0000218,,
8606,,A,,In vivo,Vss was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622424,BAO_0000218,,
8607,,A,,In vivo,Vss in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622425,BAO_0000218,,
8608,,A,,In vivo,Vss was evaluated after 10 uM/kg of intra arterial administration,1,,,50597,10116.0,Intermediate,1,CHEMBL876612,BAO_0000218,,
8609,,A,,In vivo,volume of distribution at steady state was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622426,BAO_0000218,,
8610,,A,,In vivo,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622427,BAO_0000218,,
8611,,A,,In vivo,Pharmacokinetic (PK) parameter Vz in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622428,BAO_0000218,,
8612,,A,,In vivo,Volume distribution in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622429,BAO_0000218,,
8613,,A,,In vivo,Volume of distribution in rat; No data,1,,,50597,10116.0,Intermediate,1,CHEMBL622430,BAO_0000218,,
8614,,A,,In vivo,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622431,BAO_0000218,,
8615,,A,,,% absorption predicted from in vitro rat ileum transport studies,1,,,50597,10116.0,Intermediate,1,CHEMBL622432,BAO_0000218,2116.0,
8616,,A,,In vivo,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622433,BAO_0000218,,
8617,,A,,In vivo,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622434,BAO_0000218,,
8618,,A,,In vivo,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622435,BAO_0000218,,
8619,,A,,In vivo,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL618748,BAO_0000218,,
8620,,A,,In vivo,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618749,BAO_0000218,,
8621,,A,,In vivo,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618750,BAO_0000218,,
8622,,A,,In vivo,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618751,BAO_0000218,,
8623,,A,,In vivo,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618752,BAO_0000218,,
8624,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618753,BAO_0000218,,
8625,,A,,In vivo,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1,,,50597,10116.0,Intermediate,1,CHEMBL618754,BAO_0000218,1969.0,
8626,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618755,BAO_0000218,,
8627,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618756,BAO_0000218,,
8628,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618757,BAO_0000218,,
8629,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618758,BAO_0000218,,
8630,,A,,In vivo,Oral bioavailability in rat (dose 30 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL621088,BAO_0000218,,
8631,,A,,,Pharmacokinetic property (cLogP) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621089,BAO_0000218,,
8632,,F,,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,1,,,50597,10116.0,Intermediate,1,CHEMBL621090,BAO_0000218,178.0,
8633,,F,,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,1,,,50597,10116.0,Intermediate,1,CHEMBL621091,BAO_0000218,178.0,
8634,,A,,In vivo,Clearance in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL876731,BAO_0000218,,
8635,,A,,In vivo,Compound was evaluated for its clearance when administered intravenously in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621092,BAO_0000218,,
8636,,A,,In vivo,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621093,BAO_0000218,,
8637,,A,,,Blood: Brain distribution ratio is determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621094,BAO_0000218,,
8638,,A,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,1,,,50597,10116.0,Intermediate,1,CHEMBL621095,BAO_0000218,,
8639,,A,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,1,,,50597,10116.0,Intermediate,1,CHEMBL621096,BAO_0000218,,
8640,,A,,In vivo,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL621097,BAO_0000218,2113.0,
8641,,F,,,Percent dose excreted in 0-48 hours administered ip to male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621098,BAO_0000218,,
8642,,A,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621099,BAO_0000218,2037.0,
8643,,A,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621100,BAO_0000218,2037.0,
8644,,A,,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621101,BAO_0000218,2037.0,
8645,,A,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621102,BAO_0000218,2037.0,
8646,,A,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL876732,BAO_0000218,2037.0,
8647,,A,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621103,BAO_0000218,,
8648,,A,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621104,BAO_0000218,,
8649,,A,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621105,BAO_0000218,,
8650,,A,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621106,BAO_0000218,,
8651,,A,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621107,BAO_0000218,,
8652,,A,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621108,BAO_0000218,,
8653,,A,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621109,BAO_0000218,,
8654,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL621110,BAO_0000218,2113.0,
8655,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL621111,BAO_0000218,2113.0,
8656,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL622541,BAO_0000218,2107.0,
8657,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL622542,BAO_0000218,2107.0,
8658,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL622543,BAO_0000218,2107.0,
8659,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624412,BAO_0000218,2107.0,
8660,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624413,BAO_0000218,2107.0,
8661,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624414,BAO_0000218,2107.0,
8662,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624415,BAO_0000218,2048.0,
8663,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624416,BAO_0000218,2048.0,
8664,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624417,BAO_0000218,2048.0,
8665,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624418,BAO_0000218,2048.0,
8666,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624419,BAO_0000218,2048.0,
8667,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624420,BAO_0000218,2048.0,
8668,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624421,BAO_0000218,2385.0,
8669,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624422,BAO_0000218,2385.0,
8670,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL624423,BAO_0000218,2385.0,
8671,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL625123,BAO_0000218,2385.0,
8672,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL625124,BAO_0000218,2385.0,
8673,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL625125,BAO_0000218,2385.0,
8674,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL625126,BAO_0000218,14.0,
8675,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626947,BAO_0000218,14.0,
8676,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626948,BAO_0000218,14.0,
8677,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626949,BAO_0000218,14.0,
8678,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626950,BAO_0000218,14.0,
8679,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626951,BAO_0000218,14.0,
8680,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626952,BAO_0000218,2106.0,
8681,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626953,BAO_0000218,2106.0,
8682,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626954,BAO_0000218,2106.0,
8683,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626955,BAO_0000218,2106.0,
8684,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626956,BAO_0000218,2106.0,
8685,,A,,In vivo,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626957,BAO_0000218,2106.0,
8686,,A,,In vivo,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626958,BAO_0000218,178.0,
8687,,A,,In vivo,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626959,BAO_0000218,178.0,
8688,,A,,In vivo,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626960,BAO_0000218,178.0,
8689,,A,,In vivo,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL626961,BAO_0000218,178.0,
8690,,A,,In vivo,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627589,BAO_0000218,178.0,
8691,,A,,In vivo,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),1,,,50594,10090.0,Intermediate,1,CHEMBL627590,BAO_0000218,178.0,
8692,,A,,,Time taken for EC90 was determined when tested in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL627591,BAO_0000218,,
8693,,A,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627592,BAO_0000218,,
8694,,A,,In vivo,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,,,50594,10090.0,Intermediate,1,CHEMBL627593,BAO_0000218,,
8695,,A,,,Half life in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL627594,BAO_0000218,,
8696,,A,,In vivo,Half life period in mouse after 10 mg/Kg dose,1,,,50594,10090.0,Intermediate,1,CHEMBL876813,BAO_0000218,,
8697,,A,,In vivo,Half life period in mouse after 10 mg/kg dose,1,,,50594,10090.0,Intermediate,1,CHEMBL627595,BAO_0000218,,
8698,,A,,In vivo,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,,50594,10090.0,Intermediate,1,CHEMBL627596,BAO_0000218,,
8699,,A,,In vivo,Cmax value at 5 mg/kg po was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627597,BAO_0000218,,
8700,,A,,In vivo,Cmax value evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627598,BAO_0000218,,
8701,,A,,In vivo,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,1,,,50597,10116.0,Intermediate,1,CHEMBL627599,BAO_0000218,955.0,
8702,,A,,In vivo,Cmax value after administration of 20 mg/Kg oral dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627600,BAO_0000218,,
8703,,A,,In vivo,Cmax value at 1 mg/kg po in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627601,BAO_0000218,,
8704,,A,,In vivo,Cmax value at 5 mg/kg po in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627776,BAO_0000218,,
8705,,A,,In vivo,Cmax value at a dose of 10 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627777,BAO_0000218,,
8706,,A,,In vivo,Cmax value at a dose of 100 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627778,BAO_0000218,,
8707,,A,,In vivo,Cmax value at a dose of 50 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627779,BAO_0000218,,
8708,,A,,In vivo,Cmax value in rats at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL876814,BAO_0000218,,
8709,,A,,In vivo,Cmax value was evaluated in rats at a dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627780,BAO_0000218,,
8710,,A,,In vivo,Cmax value was determined after peroral administration of 20 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627781,BAO_0000218,,
8711,,A,,In vivo,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,,,50597,10116.0,Intermediate,1,CHEMBL627782,BAO_0000218,,
8712,,A,,In vivo,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627783,BAO_0000218,1969.0,
8713,,A,,In vivo,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627784,BAO_0000218,1969.0,
8714,,A,,In vivo,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627785,BAO_0000218,,
8715,,A,,In vivo,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627786,BAO_0000218,,
8716,,A,,In vivo,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL627787,BAO_0000218,1969.0,
8717,,A,,In vivo,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL627788,BAO_0000218,1969.0,
8718,,A,,In vivo,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL626579,BAO_0000218,1969.0,
8719,,A,,In vivo,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL626580,BAO_0000218,1969.0,
8720,,A,,In vivo,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL876815,BAO_0000218,,
8721,,A,,In vivo,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL626581,BAO_0000218,1969.0,
8722,,A,,In vivo,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL626582,BAO_0000218,1969.0,
8723,,A,,In vivo,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626583,BAO_0000218,,
8724,,A,,In vivo,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626205,BAO_0000218,,
8725,,A,,In vivo,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626206,BAO_0000218,,
8726,,A,,In vivo,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626207,BAO_0000218,,
8727,,A,,In vivo,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623882,BAO_0000218,,
8728,,A,,In vivo,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,1,,,50597,10116.0,Intermediate,1,CHEMBL623883,BAO_0000218,,
8729,,A,,In vivo,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL623884,BAO_0000218,,
8730,,A,,In vivo,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,,,50597,10116.0,Intermediate,1,CHEMBL623885,BAO_0000218,1969.0,
8731,,A,,In vivo,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623886,BAO_0000218,1969.0,
8732,,A,,In vivo,Maximal concentration in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623887,BAO_0000218,,
8733,,A,,In vivo,Maximal concentration after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623888,BAO_0000218,,
8734,,A,,In vivo,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623889,BAO_0000218,1969.0,
8735,,A,,In vivo,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623890,BAO_0000218,1969.0,
8736,,A,,In vivo,Cmax in rat plasma after oral dose (50 mg/Kg),1,,,50597,10116.0,Intermediate,1,CHEMBL623891,BAO_0000218,1969.0,
8737,,A,,In vivo,Maximal plasma concentration was determined.,1,,,50597,10116.0,Intermediate,1,CHEMBL623892,BAO_0000218,1969.0,
8738,,A,,In vivo,Maximal plasma drug concentration was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623893,BAO_0000218,1969.0,
8739,,A,,In vivo,Maximal concentration in rats after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL877616,BAO_0000218,,
8740,,A,,In vivo,Maximum concentration in rat after 2 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623894,BAO_0000218,,
8741,,A,,In vivo,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1,,,50597,10116.0,Intermediate,1,CHEMBL623895,BAO_0000218,1969.0,
8742,,A,,In vivo,Maximum concentration of compound in rat was evaluated.,1,,,50597,10116.0,Intermediate,1,CHEMBL623896,BAO_0000218,,
8743,,A,,In vivo,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623897,BAO_0000218,,
8744,,A,,In vivo,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623898,BAO_0000218,,
8745,,A,,In vivo,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623899,BAO_0000218,,
8746,,A,,In vivo,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623900,BAO_0000218,,
8747,,A,,In vivo,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623901,BAO_0000218,,
8748,,A,,In vivo,Maximum concentration was evaluated in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623902,BAO_0000218,,
8749,,A,,In vivo,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623903,BAO_0000218,1359.0,
8750,,A,,In vivo,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623904,BAO_0000218,1969.0,
8751,,A,,In vivo,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,,,50597,10116.0,Intermediate,1,CHEMBL877617,BAO_0000218,1969.0,
8752,,A,,In vivo,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623905,BAO_0000218,,
8753,,A,,In vivo,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623906,BAO_0000218,,
8754,,A,,In vivo,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,,50597,10116.0,Intermediate,1,CHEMBL623907,BAO_0000218,1969.0,
8755,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623908,BAO_0000218,,
8756,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623909,BAO_0000218,,
8757,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623910,BAO_0000218,,
8758,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623911,BAO_0000218,,
8759,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623912,BAO_0000218,,
8760,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624616,BAO_0000218,,
8761,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624617,BAO_0000218,,
8762,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624618,BAO_0000218,,
8763,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624619,BAO_0000218,,
8764,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624794,BAO_0000218,,
8765,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624795,BAO_0000218,,
8766,,A,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623921,BAO_0000218,,
8767,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623922,BAO_0000218,,
8768,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623923,BAO_0000218,,
8769,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623924,BAO_0000218,,
8770,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623925,BAO_0000218,,
8771,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623926,BAO_0000218,,
8772,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623927,BAO_0000218,,
8773,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623928,BAO_0000218,,
8774,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623929,BAO_0000218,,
8775,,A,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623930,BAO_0000218,,
8776,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623931,BAO_0000218,955.0,
8777,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622165,BAO_0000218,955.0,
8778,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621249,BAO_0000218,955.0,
8779,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621250,BAO_0000218,955.0,
8780,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621448,BAO_0000218,955.0,
8781,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621449,BAO_0000218,955.0,
8782,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621450,BAO_0000218,955.0,
8783,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621451,BAO_0000218,955.0,
8784,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621452,BAO_0000218,955.0,
8785,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621453,BAO_0000218,955.0,
8786,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621454,BAO_0000218,955.0,
8787,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621455,BAO_0000218,955.0,
8788,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621456,BAO_0000218,955.0,
8789,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625145,BAO_0000218,955.0,
8790,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL875847,BAO_0000218,955.0,
8791,,A,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625146,BAO_0000218,955.0,
8792,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625147,BAO_0000218,955.0,
8793,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625148,BAO_0000218,955.0,
8794,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625149,BAO_0000218,955.0,
8795,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625150,BAO_0000218,955.0,
8796,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625151,BAO_0000218,955.0,
8797,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625152,BAO_0000218,955.0,
8798,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625153,BAO_0000218,955.0,
8799,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625154,BAO_0000218,955.0,
8800,,A,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625155,BAO_0000218,955.0,
8801,,A,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625156,BAO_0000218,,
8802,,A,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624354,BAO_0000218,,
8803,,A,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624355,BAO_0000218,10000000.0,
8804,,A,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624356,BAO_0000218,10000000.0,
8805,,A,,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624357,BAO_0000218,10000000.0,
8806,,A,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624358,BAO_0000218,10000000.0,
8807,,A,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624359,BAO_0000218,2435.0,
8808,,A,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624360,BAO_0000218,2435.0,
8809,,A,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624361,BAO_0000218,2435.0,
8810,,A,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624362,BAO_0000218,2435.0,
8811,,A,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624363,BAO_0000218,2435.0,
8812,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624364,BAO_0000218,178.0,
8813,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624365,BAO_0000218,178.0,
8814,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624366,BAO_0000218,178.0,
8815,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624367,BAO_0000218,178.0,
8816,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624368,BAO_0000218,955.0,
8817,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624369,BAO_0000218,955.0,
8818,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL624370,BAO_0000218,955.0,
8819,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625069,BAO_0000218,955.0,
8820,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625070,BAO_0000218,955.0,
8821,,A,,In vivo,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626051,BAO_0000218,948.0,
8822,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626052,BAO_0000218,948.0,
8823,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626053,BAO_0000218,948.0,
8824,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626054,BAO_0000218,948.0,
8825,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626055,BAO_0000218,948.0,
8826,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626056,BAO_0000218,2113.0,
8827,,A,,In vivo,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626057,BAO_0000218,2113.0,
8828,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625193,BAO_0000218,2113.0,
8829,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625194,BAO_0000218,2113.0,
8830,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625195,BAO_0000218,2107.0,
8831,,A,,In vivo,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625196,BAO_0000218,2107.0,
8832,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625197,BAO_0000218,2107.0,
8833,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625198,BAO_0000218,2107.0,
8834,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL627929,BAO_0000218,2107.0,
8835,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL627074,BAO_0000218,2048.0,
8836,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL627075,BAO_0000218,2048.0,
8837,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL627076,BAO_0000218,2048.0,
8838,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL627077,BAO_0000218,2048.0,
8839,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL627078,BAO_0000218,2048.0,
8840,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL627079,BAO_0000218,2385.0,
8841,,A,,In vivo,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL873824,BAO_0000218,,
8842,,A,,In vivo,Half life in mouse plasma was determined at dose 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627080,BAO_0000218,1969.0,
8843,,A,,,Half life was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL627081,BAO_0000218,,
8844,,A,,In vivo,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL627082,BAO_0000218,,
8845,,A,,In vivo,Half-life in male mice after 1 mg/kg intravenous dose,1,,,50594,10090.0,Intermediate,1,CHEMBL627083,BAO_0000218,,
8847,,A,,,Half life in mice plasma,1,,,50594,10090.0,Intermediate,1,CHEMBL627085,BAO_0000218,1969.0,
8848,,A,,,Half life in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL627086,BAO_0000218,,
8849,,A,,In vivo,Half life in mouse plasma at dose 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627087,BAO_0000218,1969.0,
8850,,A,,In vivo,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL627088,BAO_0000218,,
8851,,A,,In vivo,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL627089,BAO_0000218,,
8852,,A,,In vivo,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL627090,BAO_0000218,,
8853,,A,,In vivo,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,,50594,10090.0,Intermediate,1,CHEMBL627091,BAO_0000218,,
8854,,A,,In vivo,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",1,,,50594,10090.0,Intermediate,1,CHEMBL627092,BAO_0000218,,
8855,,A,,In vivo,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",1,,,50594,10090.0,Intermediate,1,CHEMBL876785,BAO_0000218,,
8856,,A,,In vivo,Half-life by iv administration in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL627093,BAO_0000218,,
8857,,A,,In vivo,Half-life by oral administration in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL627094,BAO_0000218,,
8858,,A,,,Half-life in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL627095,BAO_0000218,,
8859,,A,,,Half-life using mouse brain homogenate,1,,,50594,10090.0,Intermediate,1,CHEMBL627096,BAO_0000218,955.0,
8860,,A,,,Half-life was measured in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL627097,BAO_0000218,,
8861,,A,,In vivo,Half-life was measured in mouse after an iv dose of 1 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627098,BAO_0000218,,
8862,,A,,,Half-life period was determined in mouse blood,1,,,50594,10090.0,Intermediate,1,CHEMBL627099,BAO_0000218,178.0,
8863,,A,,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",1,,,50594,10090.0,Intermediate,1,CHEMBL627100,BAO_0000218,955.0,
8864,,A,,,Plasma half life in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL627101,BAO_0000218,1969.0,
8865,,A,,,Stability of the peptide in the presence of mouse serum,1,,,50594,10090.0,Intermediate,1,CHEMBL627102,BAO_0000218,,
8866,,A,,,Terminal half life of compound was determined in mouse,1,,,50594,10090.0,Intermediate,1,CHEMBL627103,BAO_0000218,,
8867,,A,,In vivo,Terminal half life was evaluated in mice after intravenous administration,1,,,50594,10090.0,Intermediate,1,CHEMBL627104,BAO_0000218,,
8868,,A,,In vivo,Terminal half life was evaluated in mice after oral administration,1,,,50594,10090.0,Intermediate,1,CHEMBL627105,BAO_0000218,,
8869,,A,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,1,,,50594,10090.0,Intermediate,1,CHEMBL876786,BAO_0000218,,
8870,,A,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,1,,,50594,10090.0,Intermediate,1,CHEMBL873825,BAO_0000218,,
8871,,A,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,1,,,50594,10090.0,Intermediate,1,CHEMBL627106,BAO_0000218,,
8872,,A,,In vivo,half life period is evaluated by administering intravenously at 25 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL626336,BAO_0000218,,
8873,,A,,In vivo,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",1,,,50594,10090.0,Intermediate,1,CHEMBL877462,BAO_0000218,,
8874,,A,,In vivo,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",1,,,50594,10090.0,Intermediate,1,CHEMBL626337,BAO_0000218,,
8875,,A,,,Half life after intraperitoneal administration of 100 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL626338,BAO_0000218,,
8876,,A,,In vivo,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL626339,BAO_0000218,,
8877,,A,,In vivo,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL626340,BAO_0000218,,
8878,,A,,In vivo,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL625377,BAO_0000218,,
8879,,A,,In vivo,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL625378,BAO_0000218,,
8880,,A,,In vivo,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,1,,,50594,10090.0,Intermediate,1,CHEMBL625379,BAO_0000218,,
8881,,A,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),0,,,22224,9823.0,Autocuration,1,CHEMBL625380,BAO_0000251,,
8882,,A,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),0,,,22224,9823.0,Autocuration,1,CHEMBL625381,BAO_0000251,,
8883,,A,,,Stability to porcine renal DHP-I,0,,,22224,9823.0,Autocuration,1,CHEMBL625382,BAO_0000019,,
8884,,A,,In vivo,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,0,,,22224,9823.0,Autocuration,1,CHEMBL873828,BAO_0000218,,
8885,,A,,In vivo,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,0,,,22224,9823.0,Autocuration,1,CHEMBL625383,BAO_0000218,,
8886,,A,,,Half-life of the parent prodrug in porcine esterase solution,0,,,22224,9823.0,Autocuration,1,CHEMBL625384,BAO_0000019,,
8887,,A,,,"First order rate constant, k was determined in in pig liver Esterase",0,,,22224,9823.0,Autocuration,1,CHEMBL625385,BAO_0000019,,
8888,,A,,,Half life of the in pig liver Esterase,0,,,22224,9823.0,Autocuration,1,CHEMBL625386,BAO_0000221,2107.0,
8889,,A,,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,0,,,22224,9823.0,Autocuration,1,CHEMBL623571,BAO_0000221,2107.0,
8890,,A,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,0,,,22224,9823.0,Autocuration,1,CHEMBL623572,BAO_0000221,2107.0,
8891,,A,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,0,,,22224,9823.0,Autocuration,1,CHEMBL623573,BAO_0000221,2107.0,
8892,,A,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,0,,,22224,9823.0,Autocuration,1,CHEMBL623574,BAO_0000221,2107.0,
8893,,A,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,0,,,22224,9823.0,Autocuration,1,CHEMBL623575,BAO_0000221,2107.0,
8894,,A,,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,0,,,22224,9823.0,Autocuration,1,CHEMBL623749,BAO_0000221,2107.0,
8895,,A,,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,0,,,22224,9823.0,Autocuration,1,CHEMBL623750,BAO_0000221,2107.0,
8896,,A,,In vitro,Half-life in vitro in pig liver,0,,,22224,9823.0,Autocuration,1,CHEMBL623751,BAO_0000221,2107.0,
8897,,A,,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,0,,,22224,9823.0,Autocuration,1,CHEMBL623752,BAO_0000221,2107.0,
8898,,A,,In vivo,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,,,50597,10116.0,Intermediate,1,CHEMBL623753,BAO_0000218,1969.0,
8899,,A,,In vivo,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL623754,BAO_0000218,1969.0,
8900,,A,,In vivo,Maximum concentration in rat plasma was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623755,BAO_0000218,1969.0,
8901,,A,,In vivo,Maximum concentration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623756,BAO_0000218,,
8902,,A,,In vivo,Maximum concentration in rats at 1-2 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL623757,BAO_0000218,,
8903,,A,,In vivo,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,1,,,50597,10116.0,Intermediate,1,CHEMBL623758,BAO_0000218,,
8904,,A,,In vivo,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623759,BAO_0000218,955.0,
8905,,A,,In vivo,Maximum concentration at the dose of 2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623760,BAO_0000218,,
8906,,A,,In vivo,Maximum concentration was evaluated in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623761,BAO_0000218,,
8907,,A,,In vivo,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623762,BAO_0000218,1969.0,
8908,,A,,In vivo,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL877594,BAO_0000218,1969.0,
8909,,A,,In vivo,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623763,BAO_0000218,1969.0,
8910,,A,,In vivo,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623764,BAO_0000218,1969.0,
8911,,A,,In vivo,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623765,BAO_0000218,1969.0,
8912,,A,,In vivo,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623766,BAO_0000218,178.0,
8913,,A,,In vivo,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623767,BAO_0000218,178.0,
8914,,A,,In vivo,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623768,BAO_0000218,178.0,
8915,,A,,In vivo,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623769,BAO_0000218,1969.0,
8916,,A,,In vivo,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623770,BAO_0000218,1969.0,
8917,,A,,In vivo,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623771,BAO_0000218,1969.0,
8918,,A,,In vivo,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623772,BAO_0000218,1969.0,
8919,,A,,In vivo,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623773,BAO_0000218,1969.0,
8920,,A,,In vivo,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623774,BAO_0000218,1969.0,
8921,,A,,In vivo,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623775,BAO_0000218,1969.0,
8922,,A,,In vivo,Cmax in rat (PO dose),1,,,50597,10116.0,Intermediate,1,CHEMBL623776,BAO_0000218,,
8923,,A,,In vivo,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622191,BAO_0000218,1969.0,
8924,,A,,In vivo,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622192,BAO_0000218,1969.0,
8925,,A,,In vivo,Maximum plasma concentration determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622193,BAO_0000218,1969.0,
8926,,A,,In vivo,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622194,BAO_0000218,1969.0,
8927,,A,,In vivo,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622195,BAO_0000218,1969.0,
8928,,A,,In vivo,Maximum plasma concentration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622196,BAO_0000218,1969.0,
8929,,A,,In vivo,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622197,BAO_0000218,1969.0,
8930,,A,,In vivo,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622198,BAO_0000218,1969.0,
8931,,A,,In vivo,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622199,BAO_0000218,1969.0,
8932,,A,,In vivo,Maximum plasma concentration of compound was measured in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622200,BAO_0000218,1969.0,
8933,,A,,In vivo,Maximum plasma concentration after 20 mg/kg oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622201,BAO_0000218,1969.0,
8934,,A,,In vivo,Maximum plasma concentration after oral administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623990,BAO_0000218,1969.0,
8935,,A,,In vivo,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,50597,10116.0,Intermediate,1,CHEMBL623991,BAO_0000218,1969.0,
8936,,A,,In vivo,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1,,,50597,10116.0,Intermediate,1,CHEMBL623992,BAO_0000218,1969.0,
8937,,A,,In vivo,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,50597,10116.0,Intermediate,1,CHEMBL623993,BAO_0000218,1969.0,
8938,,A,,In vivo,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1,,,50597,10116.0,Intermediate,1,CHEMBL623994,BAO_0000218,1969.0,
8939,,F,,In vivo,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623995,BAO_0000218,1969.0,
8940,,F,,In vivo,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623996,BAO_0000218,1969.0,
8941,,F,,In vivo,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623997,BAO_0000218,1969.0,
8942,,A,,In vivo,Maximum plasma concentration dosed orally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623998,BAO_0000218,1969.0,
8943,,A,,In vivo,Maximum plasma concentration dosed orally in rats after 6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL623999,BAO_0000218,1969.0,
8944,,A,,In vivo,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1,,,50597,10116.0,Intermediate,1,CHEMBL624000,BAO_0000218,1969.0,
8945,,A,,In vivo,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624001,BAO_0000218,1969.0,
8946,,A,,In vivo,Maximum plasma concentration in rat after po administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624002,BAO_0000218,1969.0,
8947,,A,,In vivo,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL624003,BAO_0000218,1969.0,
8948,,A,,In vivo,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL624004,BAO_0000218,1969.0,
8949,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624005,BAO_0000218,948.0,
8950,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624006,BAO_0000218,948.0,
8951,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624007,BAO_0000218,948.0,
8952,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624008,BAO_0000218,948.0,
8953,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624009,BAO_0000218,948.0,
8954,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL874387,BAO_0000218,948.0,
8955,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624010,BAO_0000218,948.0,
8956,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624011,BAO_0000218,948.0,
8957,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624012,BAO_0000218,948.0,
8958,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624013,BAO_0000218,948.0,
8959,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624736,BAO_0000218,948.0,
8960,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624737,BAO_0000218,948.0,
8961,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624738,BAO_0000218,948.0,
8962,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624739,BAO_0000218,948.0,
8963,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624740,BAO_0000218,948.0,
8964,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624896,BAO_0000218,948.0,
8965,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624897,BAO_0000218,948.0,
8966,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624108,BAO_0000218,948.0,
8967,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624109,BAO_0000218,948.0,
8968,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624110,BAO_0000218,948.0,
8969,,A,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624111,BAO_0000218,948.0,
8970,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624112,BAO_0000218,948.0,
8971,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL624113,BAO_0000218,948.0,
8972,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619709,BAO_0000218,948.0,
8973,,A,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619710,BAO_0000218,948.0,
8974,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619711,BAO_0000218,2113.0,
8975,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619712,BAO_0000218,2113.0,
8976,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619713,BAO_0000218,2113.0,
8977,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619714,BAO_0000218,2113.0,
8978,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619715,BAO_0000218,2113.0,
8979,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619716,BAO_0000218,2113.0,
8980,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619717,BAO_0000218,2113.0,
8981,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619718,BAO_0000218,2113.0,
8982,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619719,BAO_0000218,2113.0,
8983,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL875329,BAO_0000218,2113.0,
8984,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619720,BAO_0000218,2113.0,
8985,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619721,BAO_0000218,2113.0,
8986,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619722,BAO_0000218,2113.0,
8987,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619723,BAO_0000218,2113.0,
8988,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619724,BAO_0000218,2113.0,
8989,,A,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL619725,BAO_0000218,2113.0,
8990,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL619726,BAO_0000218,2113.0,
8991,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL619727,BAO_0000218,2113.0,
8992,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL619728,BAO_0000218,2113.0,
8993,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL619729,BAO_0000218,2113.0,
8994,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL619730,BAO_0000218,2385.0,
8995,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL619731,BAO_0000218,2385.0,
8996,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL619732,BAO_0000218,2385.0,
8997,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL619733,BAO_0000218,2385.0,
8998,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL619734,BAO_0000218,2385.0,
8999,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL619735,BAO_0000218,14.0,
9000,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL875330,BAO_0000218,14.0,
9001,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL628465,BAO_0000218,14.0,
9002,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL628466,BAO_0000218,14.0,
9003,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL628467,BAO_0000218,14.0,
9004,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL628468,BAO_0000218,2106.0,
9005,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL628469,BAO_0000218,2106.0,
9006,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL628470,BAO_0000218,2106.0,
9007,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL628471,BAO_0000218,2106.0,
9008,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL628472,BAO_0000218,2106.0,
9009,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625191,BAO_0000218,2046.0,
9010,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL625192,BAO_0000218,2046.0,
9011,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL875337,BAO_0000218,2046.0,
9012,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626341,BAO_0000218,2046.0,
9013,,A,,In vivo,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL626342,BAO_0000218,2046.0,
9014,,A,,In vivo,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,,50597,10116.0,Intermediate,1,CHEMBL621943,BAO_0000218,2107.0,
9015,,A,,,Half life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621944,BAO_0000218,,
9016,,A,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,1,,,50597,10116.0,Intermediate,1,CHEMBL621945,BAO_0000218,,
9017,,A,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),1,,,50597,10116.0,Intermediate,1,CHEMBL621946,BAO_0000218,,
9018,,A,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621947,BAO_0000218,,
9019,,A,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),1,,,50597,10116.0,Intermediate,1,CHEMBL621948,BAO_0000218,,
9020,,A,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621949,BAO_0000218,,
9021,,A,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),1,,,50597,10116.0,Intermediate,1,CHEMBL621950,BAO_0000218,,
9022,,A,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621951,BAO_0000218,,
9023,,A,,In vivo,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL621952,BAO_0000218,178.0,
9024,,A,,,Stability (%) in rat liver microsomes,1,,,50597,10116.0,Intermediate,1,CHEMBL621953,BAO_0000218,2107.0,
9025,,A,,,Area under curve was calculated after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621954,BAO_0000218,,
9026,,A,,,Area under the curve was calculated after iv administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621955,BAO_0000218,,
9027,,A,,,Area under the curve was calculated in rat after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621956,BAO_0000218,,
9028,,A,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621957,BAO_0000218,,
9029,,A,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621958,BAO_0000218,,
9030,,A,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621959,BAO_0000218,,
9031,,A,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL621960,BAO_0000218,,
9032,,A,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL621961,BAO_0000218,,
9033,,A,,,p value of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL621962,BAO_0000218,,
9034,,F,,,p value of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL876787,BAO_0000218,,
9035,,A,,,p value of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL621963,BAO_0000218,,
9036,,A,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,,50597,10116.0,Intermediate,1,CHEMBL622637,BAO_0000218,945.0,
9037,,A,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,,50597,10116.0,Intermediate,1,CHEMBL622638,BAO_0000218,945.0,
9038,,A,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,,50597,10116.0,Intermediate,1,CHEMBL626561,BAO_0000218,945.0,
9039,,F,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),0,,,22224,9986.0,Autocuration,1,CHEMBL626562,BAO_0000019,,
9040,,A,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),0,,,22224,9986.0,Autocuration,1,CHEMBL626563,BAO_0000218,,
9041,,A,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),0,,,22224,9986.0,Autocuration,1,CHEMBL626564,BAO_0000218,,
9042,,A,,In vivo,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,0,,,22224,9986.0,Autocuration,1,CHEMBL626565,BAO_0000218,,
9043,,A,,In vivo,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,0,,,22224,9986.0,Autocuration,1,CHEMBL626566,BAO_0000218,,
9044,,A,,In vivo,Clearance rate in rabbits,0,,,22224,9986.0,Autocuration,1,CHEMBL626567,BAO_0000218,,
9045,,A,,In vivo,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,0,,,22224,9986.0,Autocuration,1,CHEMBL626568,BAO_0000218,,
9046,,A,,In vivo,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL626569,BAO_0000218,,
9047,,A,,In vivo,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL626570,BAO_0000218,,
9048,,A,,In vivo,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL626571,BAO_0000218,,
9049,,A,,In vivo,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL626572,BAO_0000218,,
9050,,A,,In vivo,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,0,,,22224,9986.0,Autocuration,1,CHEMBL626573,BAO_0000218,1969.0,
9051,,A,,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,0,,,22224,9986.0,Autocuration,1,CHEMBL626574,BAO_0000251,2107.0,
9052,,A,,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,0,,,22224,9986.0,Autocuration,1,CHEMBL626575,BAO_0000251,2107.0,
9053,,A,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,0,,,22224,9986.0,Autocuration,1,CHEMBL626576,BAO_0000218,,
9054,,A,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,0,,,22224,9986.0,Autocuration,1,CHEMBL626577,BAO_0000218,,
9055,,A,,In vivo,The compound was tested for its bioavailability in rabbit (by oral dosage).,0,,,22224,9986.0,Autocuration,1,CHEMBL626578,BAO_0000218,,
9056,,A,,In vivo,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL625263,BAO_0000218,,
9057,,A,,In vivo,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL625264,BAO_0000218,,
9058,,A,,In vivo,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL625265,BAO_0000218,,
9059,,A,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),0,,,22224,9986.0,Autocuration,1,CHEMBL625266,BAO_0000251,,
9060,,A,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),0,,,22224,9986.0,Autocuration,1,CHEMBL876796,BAO_0000251,,
9061,,A,,In vivo,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL625267,BAO_0000218,,
9062,,A,,In vivo,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL625268,BAO_0000218,1969.0,
9063,,A,,In vivo,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL625269,BAO_0000218,1969.0,
9064,,A,,In vivo,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL624689,BAO_0000218,1969.0,
9065,,A,,In vivo,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL624690,BAO_0000218,,
9066,,A,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),0,,,22224,9986.0,Autocuration,1,CHEMBL624691,BAO_0000218,1088.0,
9067,,A,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),0,,,22224,9986.0,Autocuration,1,CHEMBL624692,BAO_0000218,1088.0,
9068,,A,,In vivo,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,0,,,22224,9986.0,Autocuration,1,CHEMBL624693,BAO_0000218,,
9069,,A,,In vivo,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,0,,,22224,9986.0,Autocuration,1,CHEMBL624694,BAO_0000218,,
9070,,A,,In vitro,In vitro Biological half-life in crude homogenate of rabbit renal cortex,0,,,22224,9986.0,Autocuration,1,CHEMBL877596,BAO_0000221,,
9071,,A,,,Time within which only 10% of the drug was degraded,0,,,22224,9986.0,Autocuration,1,CHEMBL624695,BAO_0000019,,
9072,,A,,,Half life period in rabbit liver homogenate,0,,,22224,9986.0,Autocuration,1,CHEMBL624696,BAO_0000221,2107.0,
9073,,A,,,Half life value in rabbits,0,,,22224,9986.0,Autocuration,1,CHEMBL624697,BAO_0000019,,
9074,,A,,In vivo,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,0,,,22224,9986.0,Autocuration,1,CHEMBL624698,BAO_0000218,178.0,
9075,,A,,In vivo,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,0,,,22224,9986.0,Autocuration,1,CHEMBL624699,BAO_0000218,178.0,
9076,,A,,In vivo,Half-life period in rabbits following intravenous administration at 2 mg/kg,0,,,22224,9986.0,Autocuration,1,CHEMBL624700,BAO_0000218,,
9077,,A,,,AUC 0-8 hr value in rats at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622903,BAO_0000218,1969.0,
9078,,A,,,AUC after administration at 2000 mg/kg/day in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622904,BAO_0000218,1969.0,
9079,,A,,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL622905,BAO_0000218,1969.0,
9080,,A,,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622906,BAO_0000218,1969.0,
9081,,A,,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622907,BAO_0000218,1969.0,
9082,,A,,,AUC in rat after oral administration at 10.5 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622908,BAO_0000218,1969.0,
9083,,A,,,AUC in rat after oral administration at 11.2 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622909,BAO_0000218,1969.0,
9084,,A,,,AUC in rat after oral administration at 9.7 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622910,BAO_0000218,1969.0,
9085,,A,,,AUC in rat brain after oral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622911,BAO_0000218,955.0,
9086,,A,,,AUC in rat p.o.,1,,,50597,10116.0,Intermediate,1,CHEMBL622912,BAO_0000218,1969.0,
9087,,A,,,AUC in rat p.o. at 20 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL622913,BAO_0000218,1969.0,
9088,,A,,,AUC in rat plasma after oral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622914,BAO_0000218,1969.0,
9089,,A,,,AUC in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622915,BAO_0000218,1969.0,
9090,,A,,,AUC value after IV dose at a dose of 5 mg/kg in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL622916,BAO_0000218,1969.0,
9091,,A,,,AUC value after oral dose at a dose of 10 mg/kg in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL622917,BAO_0000218,1969.0,
9092,,A,,In vivo,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,,,50597,10116.0,Intermediate,1,CHEMBL622918,BAO_0000218,1969.0,
9093,,A,,In vivo,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1,,,50597,10116.0,Intermediate,1,CHEMBL622919,BAO_0000218,1969.0,
9094,,A,,In vivo,Maximum plasma concentration was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622920,BAO_0000218,1969.0,
9095,,A,,In vivo,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622921,BAO_0000218,1969.0,
9096,,A,,In vivo,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622922,BAO_0000218,1969.0,
9097,,A,,In vivo,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622923,BAO_0000218,1969.0,
9098,,A,,In vivo,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL877604,BAO_0000218,1969.0,
9099,,A,,In vivo,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622924,BAO_0000218,1969.0,
9100,,A,,In vivo,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622925,BAO_0000218,1969.0,
9101,,A,,In vivo,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1,,,50597,10116.0,Intermediate,1,CHEMBL622926,BAO_0000218,1969.0,
9102,,A,,In vivo,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623625,BAO_0000218,1969.0,
9103,,A,,In vivo,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL623626,BAO_0000218,1969.0,
9104,,A,,In vivo,Maximum plasma drug concentration was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623627,BAO_0000218,1969.0,
9105,,A,,In vivo,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623628,BAO_0000218,,
9106,,A,,In vivo,Mean peak plasma concentration was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623629,BAO_0000218,1969.0,
9107,,A,,In vivo,Mean peak plasma concentration was observed after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623630,BAO_0000218,1969.0,
9108,,A,,In vivo,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623804,BAO_0000218,,
9109,,A,,In vivo,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623805,BAO_0000218,,
9110,,A,,In vivo,Peak oral plasma concentration was determined in rats by oral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623806,BAO_0000218,1969.0,
9111,,A,,In vivo,Peak plasma concentration (Cmax) was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623807,BAO_0000218,1969.0,
9112,,A,,In vivo,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623808,BAO_0000218,1969.0,
9113,,A,,In vivo,Peak plasma concentration (Cmax) in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623809,BAO_0000218,1969.0,
9114,,A,,In vivo,Peak plasma concentration at 1 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623810,BAO_0000218,1969.0,
9115,,A,,In vivo,Peak plasma concentration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623811,BAO_0000218,1969.0,
9116,,A,,In vivo,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1,,,50597,10116.0,Intermediate,1,CHEMBL623812,BAO_0000218,1969.0,
9117,,A,,In vivo,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL877605,BAO_0000218,,
9118,,A,,In vivo,Pharmacokinetic property (Cmax) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623813,BAO_0000218,,
9119,,A,,In vivo,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,,50597,10116.0,Intermediate,1,CHEMBL623814,BAO_0000218,,
9120,,A,,In vivo,Cmax in rat after 3mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL623815,BAO_0000218,,
9121,,A,,In vivo,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL623816,BAO_0000218,,
9122,,A,,In vivo,Cmax in rats after 20 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL623145,BAO_0000218,,
9123,,A,,In vivo,Cmax in rat plasma after 30mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL623146,BAO_0000218,1969.0,
9124,,A,,In vivo,Plasma concentration after oral administration of 100 mg/kg to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623147,BAO_0000218,1969.0,
9125,,A,,In vivo,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623042,BAO_0000218,955.0,
9126,,A,,In vivo,Tested for the Cmax in rat at 10 mg/kg per orally,1,,,50597,10116.0,Intermediate,1,CHEMBL623043,BAO_0000218,,
9127,,A,,In vivo,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL623044,BAO_0000218,,
9128,,A,,In vivo,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL623045,BAO_0000218,,
9129,,A,,In vivo,Bioavailability as oral Cmax in rats at 30 mins,1,,,50597,10116.0,Intermediate,1,CHEMBL623046,BAO_0000218,,
9130,,A,,In vivo,Bioavailability as oral Cmax in rats at 6hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623226,BAO_0000218,,
9131,,A,,In vivo,The maximum concentration of compound was measured at the dose of 100 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623227,BAO_0000218,,
9132,,A,,In vivo,The maximum concentration of compound was measured at the dose of 300 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623228,BAO_0000218,,
9133,,A,,In vivo,The maximum concentration of compound was measured at the dose of 30 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623229,BAO_0000218,,
9134,,A,,In vivo,The maximum plasma levels for the compounds were determined by LC-MS.,1,,,50597,10116.0,Intermediate,1,CHEMBL623230,BAO_0000218,1969.0,
9135,,A,,In vivo,mean peak plasma concentration was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623231,BAO_0000218,1969.0,
9136,,A,,In vivo,mean peak plasma concentration was observed after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623232,BAO_0000218,1969.0,
9137,,A,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623233,BAO_0000218,,
9138,,A,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623234,BAO_0000218,,
9139,,A,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623235,BAO_0000218,,
9140,,A,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623236,BAO_0000218,,
9141,,A,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623237,BAO_0000218,,
9142,,A,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623238,BAO_0000218,,
9143,,A,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623239,BAO_0000218,,
9144,,A,,In vivo,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,0,,,22224,10116.0,Intermediate,1,CHEMBL623240,BAO_0000218,1969.0,
9145,,A,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1,,,50597,10116.0,Intermediate,1,CHEMBL623241,BAO_0000218,1898.0,
9146,,A,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1,,,50597,10116.0,Intermediate,1,CHEMBL623242,BAO_0000218,1898.0,
9147,,A,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",1,,,50597,10116.0,Intermediate,1,CHEMBL874394,BAO_0000218,,
9148,,A,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",1,,,50597,10116.0,Intermediate,1,CHEMBL623243,BAO_0000218,,
9149,,A,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623244,BAO_0000218,,
9150,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623245,BAO_0000218,2113.0,
9151,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623246,BAO_0000218,2113.0,
9152,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623247,BAO_0000218,2113.0,
9153,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623248,BAO_0000218,2113.0,
9154,,A,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623249,BAO_0000218,2113.0,
9155,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625072,BAO_0000218,2107.0,
9156,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625073,BAO_0000218,2107.0,
9157,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625074,BAO_0000218,2107.0,
9158,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625075,BAO_0000218,2107.0,
9159,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625076,BAO_0000218,2107.0,
9160,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625077,BAO_0000218,2107.0,
9161,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625078,BAO_0000218,2107.0,
9162,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL874395,BAO_0000218,2107.0,
9163,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625079,BAO_0000218,2107.0,
9164,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625080,BAO_0000218,2107.0,
9165,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625081,BAO_0000218,2107.0,
9166,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625082,BAO_0000218,2107.0,
9167,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625083,BAO_0000218,2107.0,
9168,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625084,BAO_0000218,2107.0,
9169,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625085,BAO_0000218,2107.0,
9170,,A,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625086,BAO_0000218,2107.0,
9171,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625087,BAO_0000218,2107.0,
9172,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625088,BAO_0000218,2107.0,
9173,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622205,BAO_0000218,2107.0,
9174,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622206,BAO_0000218,2107.0,
9175,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622207,BAO_0000218,2107.0,
9176,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622366,BAO_0000218,2107.0,
9177,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622367,BAO_0000218,2107.0,
9178,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL875331,BAO_0000218,2107.0,
9179,,A,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622368,BAO_0000218,2107.0,
9180,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622369,BAO_0000218,2048.0,
9181,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622370,BAO_0000218,2048.0,
9182,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622371,BAO_0000218,2048.0,
9183,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622372,BAO_0000218,2048.0,
9184,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622373,BAO_0000218,2048.0,
9185,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622374,BAO_0000218,2048.0,
9186,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622375,BAO_0000218,2048.0,
9187,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622376,BAO_0000218,2048.0,
9188,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622377,BAO_0000218,2048.0,
9189,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622378,BAO_0000218,2048.0,
9190,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622379,BAO_0000218,2048.0,
9191,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622380,BAO_0000218,2048.0,
9192,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622381,BAO_0000218,2048.0,
9193,,A,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622382,BAO_0000218,2048.0,
9194,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622383,BAO_0000218,2048.0,
9195,,A,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,,50597,10116.0,Intermediate,1,CHEMBL875332,BAO_0000218,945.0,
9196,,A,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,,50597,10116.0,Intermediate,1,CHEMBL622384,BAO_0000218,945.0,
9197,,A,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,,50597,10116.0,Intermediate,1,CHEMBL622385,BAO_0000218,945.0,
9198,,A,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,,50597,10116.0,Intermediate,1,CHEMBL622386,BAO_0000218,945.0,
9199,,A,,,The compound was tested for the plasma binding in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622387,BAO_0000218,,
9200,,A,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",1,,,50597,10116.0,Intermediate,1,CHEMBL622388,BAO_0000218,,
9201,,A,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",1,,,50597,10116.0,Intermediate,1,CHEMBL622389,BAO_0000218,,
9202,,A,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",1,,,50597,10116.0,Intermediate,1,CHEMBL622390,BAO_0000218,,
9203,,A,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622391,BAO_0000218,,
9204,,A,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622392,BAO_0000218,,
9205,,A,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622393,BAO_0000218,,
9206,,A,,,Plasma level at 2 hr after administration of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL622394,BAO_0000218,,
9207,,A,,,plasma level at 2 hr after administration of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL622395,BAO_0000218,,
9208,,A,,,Stability in rat serum measured as % recovery at 1 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622396,BAO_0000218,1977.0,
9209,,A,,,Stability in rat serum measured as % recovery at 10 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624894,BAO_0000218,1977.0,
9210,,A,,,Stability in rat serum measured as % recovery at 10 mins,1,,,50597,10116.0,Intermediate,1,CHEMBL624895,BAO_0000218,1977.0,
9211,,A,,,Stability in rat serum measured as % recovery at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL624058,BAO_0000218,1977.0,
9212,,A,,,Stability in rat serum measured as % recovery at 3 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624059,BAO_0000218,1977.0,
9213,,A,,,Stability in rat serum measured as % recovery at 3 mins,1,,,50597,10116.0,Intermediate,1,CHEMBL624060,BAO_0000218,1977.0,
9214,,A,,,Stability in rat serum measured as % recovery at 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL624061,BAO_0000218,1977.0,
9215,,A,,,Stability in rat serum measured as % recovery at 5 mins,1,,,50597,10116.0,Intermediate,1,CHEMBL624062,BAO_0000218,1977.0,
9216,,A,,In vivo,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624063,BAO_0000218,,
9217,,A,,In vivo,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624064,BAO_0000218,,
9218,,A,,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL624065,BAO_0000218,1969.0,
9219,,A,,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1,,,50597,10116.0,Intermediate,1,CHEMBL624066,BAO_0000218,1969.0,
9220,,A,,In vivo,Half life tested in mature male rat at a dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL877490,BAO_0000218,,
9221,,A,,In vivo,Half life after intravenous administration of 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL874442,BAO_0000218,,
9222,,A,,In vivo,Half life period after administration (30 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626890,BAO_0000218,,
9223,,A,,In vivo,Half life period in rat after 5 mg/Kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626891,BAO_0000218,,
9224,,A,,In vivo,Half life period in rat after 5 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626892,BAO_0000218,,
9225,,A,,,Half life period was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626893,BAO_0000218,,
9226,,A,,,Half life period was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626894,BAO_0000218,,
9227,,A,,,Half life period was evaluated in rat; 0.5-1.0,1,,,50597,10116.0,Intermediate,1,CHEMBL626895,BAO_0000218,,
9228,,A,,,Half life period was evaluated in rat; 5.9-7.5,1,,,50597,10116.0,Intermediate,1,CHEMBL626896,BAO_0000218,,
9229,,A,,,Half-life in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL626897,BAO_0000218,1969.0,
9230,,A,,,Half-life time in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626898,BAO_0000218,,
9231,,A,,In vivo,Terminal half-life after iv administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626899,BAO_0000218,,
9232,,A,,In vivo,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626900,BAO_0000218,,
9233,,A,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626901,BAO_0000218,,
9234,,A,,In vivo,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),1,,,50597,10116.0,Intermediate,1,CHEMBL626902,BAO_0000218,,
9235,,A,,In vivo,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),1,,,50597,10116.0,Intermediate,1,CHEMBL626903,BAO_0000218,,
9236,,A,,In vivo,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL874443,BAO_0000218,,
9237,,A,,In vivo,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626904,BAO_0000218,,
9238,,A,,,Half life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626905,BAO_0000218,,
9239,,A,,In vivo,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL873830,BAO_0000218,1969.0,
9240,,A,,In vivo,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626906,BAO_0000218,,
9241,,A,,In vivo,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,,50597,10116.0,Intermediate,1,CHEMBL631076,BAO_0000218,1969.0,
9242,,A,,,Biological half-life was measured in plasma of rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631077,BAO_0000218,1969.0,
9243,,A,,In vivo,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631078,BAO_0000218,,
9244,,A,,In vivo,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL631079,BAO_0000218,,
9245,,A,,In vivo,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631080,BAO_0000218,,
9246,,A,,In vivo,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631081,BAO_0000218,,
9247,,A,,In vivo,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631239,BAO_0000218,,
9248,,A,,,Compound was evaluated for plasma half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631240,BAO_0000218,1969.0,
9249,,A,,,AUC value at a dose of 5 mg/kg (p.o.) in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631241,BAO_0000218,1969.0,
9250,,A,,,AUC value after administration of 20 mg/Kg oral dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631242,BAO_0000218,1969.0,
9251,,A,,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631243,BAO_0000218,1969.0,
9252,,A,,,AUC0-96 after administration at 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL874444,BAO_0000218,1969.0,
9253,,A,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631244,BAO_0000218,1969.0,
9254,,A,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",1,,,50597,10116.0,Intermediate,1,CHEMBL631245,BAO_0000218,,
9255,,A,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627162,BAO_0000218,,
9256,,A,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627163,BAO_0000218,,
9257,,A,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627164,BAO_0000218,,
9258,,A,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,1,,,50597,10116.0,Intermediate,1,CHEMBL627165,BAO_0000218,2113.0,
9259,,A,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,1,,,50597,10116.0,Intermediate,1,CHEMBL627166,BAO_0000218,,
9260,,A,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,1,,,50597,10116.0,Intermediate,1,CHEMBL627167,BAO_0000218,,
9261,,A,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627822,BAO_0000218,,
9262,,A,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627823,BAO_0000218,,
9263,,A,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627824,BAO_0000218,,
9264,,A,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627825,BAO_0000218,,
9265,,A,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627826,BAO_0000218,,
9266,,A,,,Area under curve (Pharmacokinetic property) was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627827,BAO_0000218,,
9267,,A,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627828,BAO_0000218,,
9268,,A,,,Area under curve after intravenous administration (1 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627829,BAO_0000218,,
9269,,A,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627830,BAO_0000218,,
9270,,A,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627831,BAO_0000218,,
9271,,A,,,Area under curve in male SD rats was observed after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627832,BAO_0000218,,
9272,,A,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627833,BAO_0000218,,
9273,,A,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL627834,BAO_0000218,,
9274,,A,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL628004,BAO_0000218,,
9275,,A,,,Area under curve at 5 mg/kg po was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628005,BAO_0000218,,
9276,,A,,,Area under curve in Rat at a oral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628006,BAO_0000218,,
9277,,A,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,,50597,10116.0,Intermediate,1,CHEMBL628007,BAO_0000218,,
9278,,A,,,Area under curve was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625676,BAO_0000218,,
9279,,A,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL631309,BAO_0000218,,
9280,,A,,,Area under curve after intravenous administration at 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631310,BAO_0000218,,
9281,,A,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,1,,,50597,10116.0,Intermediate,1,CHEMBL631311,BAO_0000218,,
9282,,A,,,Area under curve at 4 hr in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631312,BAO_0000218,,
9283,,A,,,Area under curve at a dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631313,BAO_0000218,,
9284,,A,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631314,BAO_0000218,,
9285,,A,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631315,BAO_0000218,,
9286,,A,,,Area under curve for a 2-mpk po dose in SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631316,BAO_0000218,,
9287,,A,,,Area under curve in SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631317,BAO_0000218,,
9288,,A,,,Area under curve in rat after oral administration at 13 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL874471,BAO_0000218,,
9289,,A,,,Area under curve in rat by po administration at 0-24 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL631318,BAO_0000218,,
9290,,A,,,Area under curve in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL631319,BAO_0000218,1969.0,
9291,,A,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631320,BAO_0000218,,
9292,,A,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631321,BAO_0000218,,
9293,,A,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,1,,,50597,10116.0,Intermediate,1,CHEMBL631322,BAO_0000218,,
9294,,A,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631323,BAO_0000218,,
9295,,A,,,Area under curve value in rat at a dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631324,BAO_0000218,,
9296,,A,,,Area under curve was determined after oral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631325,BAO_0000218,,
9297,,A,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631326,BAO_0000218,,
9298,,A,,,Area under curve was determined after peroral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631327,BAO_0000218,,
9299,,A,,,Area under curve was determined at a dose 30 mpk administered orally.,1,,,50597,10116.0,Intermediate,1,CHEMBL631328,BAO_0000218,,
9300,,A,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631329,BAO_0000218,,
9301,,A,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627217,BAO_0000218,,
9302,,A,,,Area under curve was determined in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626352,BAO_0000218,,
9303,,A,,,Area under curve was determined in rat after PO administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626353,BAO_0000218,,
9304,,A,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626354,BAO_0000218,,
9305,,A,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626355,BAO_0000218,,
9306,,A,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626356,BAO_0000218,,
9307,,A,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,1,,,50597,10116.0,Intermediate,1,CHEMBL626357,BAO_0000218,,
9308,,A,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626358,BAO_0000218,,
9309,,A,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626359,BAO_0000218,,
9310,,A,,,Peak plasma concentration in rat at a dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626360,BAO_0000218,1969.0,
9311,,A,,,Plasma concentration at 2 hr in rats was evaluated.,1,,,50597,10116.0,Intermediate,1,CHEMBL626361,BAO_0000218,,
9312,,A,,,Plasma concentration at 2 hr in rats was evaluated; Not available,1,,,50597,10116.0,Intermediate,1,CHEMBL626362,BAO_0000218,,
9313,,A,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626363,BAO_0000218,,
9314,,A,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626970,BAO_0000218,,
9315,,A,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626971,BAO_0000218,,
9316,,A,,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626972,BAO_0000218,1969.0,
9317,,A,,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626973,BAO_0000218,1969.0,
9318,,A,,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626974,BAO_0000218,1969.0,
9319,,A,,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL874592,BAO_0000218,1969.0,
9320,,A,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,1,,,50597,10116.0,Intermediate,1,CHEMBL626975,BAO_0000218,,
9321,,A,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626976,BAO_0000218,,
9322,,A,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626977,BAO_0000218,,
9323,,A,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL626978,BAO_0000218,,
9324,,A,,,PK study was carried to determine the relative absorption ranking in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL626979,BAO_0000218,,
9325,,A,,In vivo,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626980,BAO_0000218,1969.0,
9326,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL626981,BAO_0000218,178.0,
9327,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL626982,BAO_0000218,178.0,
9328,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL626983,BAO_0000218,178.0,
9329,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622522,BAO_0000218,178.0,
9330,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622523,BAO_0000218,178.0,
9331,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622524,BAO_0000218,178.0,
9332,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622525,BAO_0000218,955.0,
9333,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622526,BAO_0000218,955.0,
9334,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL619849,BAO_0000218,955.0,
9335,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL619850,BAO_0000218,955.0,
9336,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL623864,BAO_0000218,955.0,
9337,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL623865,BAO_0000218,955.0,
9338,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL623866,BAO_0000218,948.0,
9339,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL623867,BAO_0000218,948.0,
9340,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL877615,BAO_0000218,948.0,
9341,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL623868,BAO_0000218,948.0,
9342,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL623869,BAO_0000218,948.0,
9343,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL623870,BAO_0000218,948.0,
9344,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623871,BAO_0000218,2048.0,
9345,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623872,BAO_0000218,2048.0,
9346,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622129,BAO_0000218,2048.0,
9347,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622130,BAO_0000218,2048.0,
9348,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622131,BAO_0000218,2048.0,
9349,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622132,BAO_0000218,2048.0,
9350,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622133,BAO_0000218,2048.0,
9351,,A,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622134,BAO_0000218,2048.0,
9352,,A,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622135,BAO_0000218,2048.0,
9353,,A,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622136,BAO_0000218,2048.0,
9354,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622137,BAO_0000218,2385.0,
9355,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622138,BAO_0000218,2385.0,
9356,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623017,BAO_0000218,2385.0,
9357,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623018,BAO_0000218,2385.0,
9358,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623019,BAO_0000218,2385.0,
9359,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623020,BAO_0000218,2385.0,
9360,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623021,BAO_0000218,2385.0,
9361,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623022,BAO_0000218,2385.0,
9362,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623023,BAO_0000218,2385.0,
9363,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623024,BAO_0000218,2385.0,
9364,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623025,BAO_0000218,2385.0,
9365,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL620545,BAO_0000218,2385.0,
9366,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL620546,BAO_0000218,2385.0,
9367,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL620547,BAO_0000218,2385.0,
9368,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL620548,BAO_0000218,2385.0,
9369,,A,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL620549,BAO_0000218,2385.0,
9370,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL620550,BAO_0000218,2385.0,
9371,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL620551,BAO_0000218,2385.0,
9372,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL620552,BAO_0000218,2385.0,
9373,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL620553,BAO_0000218,2385.0,
9374,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL620554,BAO_0000218,2385.0,
9375,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL875845,BAO_0000218,2385.0,
9376,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL620555,BAO_0000218,2385.0,
9377,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL620556,BAO_0000218,2385.0,
9378,,A,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL620557,BAO_0000218,2385.0,
9379,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL620558,BAO_0000218,,
9380,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL620559,BAO_0000218,,
9381,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622939,BAO_0000218,,
9382,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622940,BAO_0000218,,
9383,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622941,BAO_0000218,,
9384,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622942,BAO_0000218,,
9385,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622943,BAO_0000218,,
9386,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622944,BAO_0000218,,
9387,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622945,BAO_0000218,,
9388,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622946,BAO_0000218,,
9389,,A,,,Compound was evaluated for terminal half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622947,BAO_0000218,,
9390,,A,,In vivo,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1,,,50597,10116.0,Intermediate,1,CHEMBL622948,BAO_0000218,1969.0,
9391,,A,,In vivo,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1,,,50597,10116.0,Intermediate,1,CHEMBL622949,BAO_0000218,1969.0,
9392,,A,,,Compound was tested for its half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622950,BAO_0000218,,
9393,,A,,In vivo,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,0,,,22224,9544.0,Intermediate,1,CHEMBL622951,BAO_0000218,1969.0,
9394,,A,,,Compound was tested for its plasma half life in Sprague Dawley rats,0,,,22224,10116.0,Intermediate,1,CHEMBL622952,BAO_0000366,1969.0,
9395,,A,,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,0,,,22224,10116.0,Intermediate,1,CHEMBL622953,BAO_0000366,1969.0,
9396,,A,,,Compound was tested for plasma half-life period in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL873818,BAO_0000218,1969.0,
9397,,A,,In vivo,Elimination half life after i.v. administration of compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622954,BAO_0000218,,
9398,,A,,In vivo,Elimination half-life after IV dosing at 0.5 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622955,BAO_0000218,,
9399,,A,,In vivo,Elimination half-life after IV dosing at 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL875229,BAO_0000218,,
9400,,A,,In vivo,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622956,BAO_0000218,,
9401,,A,,In vivo,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622957,BAO_0000218,,
9402,,A,,In vivo,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622958,BAO_0000218,955.0,
9403,,A,,In vivo,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL622959,BAO_0000218,1969.0,
9404,,A,,In vivo,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,,,50597,10116.0,Intermediate,1,CHEMBL622960,BAO_0000218,955.0,
9405,,A,,In vivo,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL622961,BAO_0000218,1969.0,
9406,,A,,In vivo,Evaluated for the half life in rat (in vivo),1,,,50597,10116.0,Intermediate,1,CHEMBL622962,BAO_0000218,,
9407,,A,,,Hafl life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622963,BAO_0000218,,
9408,,A,,,Hafl life rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622964,BAO_0000218,,
9409,,A,,,Hafl life rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622965,BAO_0000218,,
9410,,A,,,Hafl life rat; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622966,BAO_0000218,,
9411,,A,,,Hafl life rat; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622967,BAO_0000218,,
9412,,A,,In vivo,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622968,BAO_0000218,2113.0,
9413,,A,,In vivo,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622969,BAO_0000218,2107.0,
9414,,A,,In vivo,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL875327,BAO_0000218,2048.0,
9415,,A,,In vivo,Half life in rat after 1 mg/kg i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL628638,BAO_0000218,,
9416,,A,,In vivo,Half life in rat after 2 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL628639,BAO_0000218,,
9417,,A,,In vivo,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625840,BAO_0000218,,
9418,,A,,In vivo,Half life of 10 mg/kg oral dose determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625841,BAO_0000218,,
9419,,A,,In vivo,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625842,BAO_0000218,,
9420,,A,,In vivo,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625843,BAO_0000218,,
9421,,A,,In vivo,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625844,BAO_0000218,,
9422,,A,,In vivo,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL873822,BAO_0000218,,
9423,,A,,In vivo,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625845,BAO_0000218,,
9424,,A,,In vivo,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627059,BAO_0000218,,
9425,,A,,In vivo,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627060,BAO_0000218,,
9426,,A,,In vivo,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627061,BAO_0000218,,
9427,,A,,In vivo,Half life of compound at 5 mg/kg after po administration was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627709,BAO_0000218,,
9428,,A,,In vivo,Half life of compound determined after intravenous administration to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627710,BAO_0000218,,
9429,,A,,,Half life of compound was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627711,BAO_0000218,,
9430,,A,,In vivo,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627712,BAO_0000218,1969.0,
9431,,A,,In vivo,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627713,BAO_0000218,,
9432,,A,,In vivo,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627714,BAO_0000218,,
9433,,A,,In vivo,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,0,,,22224,9541.0,Intermediate,1,CHEMBL627889,BAO_0000218,,
9434,,A,,In vivo,Half life determined in rat by intravenous administration,0,,,22224,10116.0,Intermediate,1,CHEMBL627890,BAO_0000218,,
9435,,A,,In vivo,Half life determined in rats after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627891,BAO_0000218,,
9436,,A,,In vivo,Half life in rat plasma after administration of 2 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL627892,BAO_0000218,1969.0,
9437,,A,,In vivo,Half life in rat plasma after administration of 2 mg/kg iv,1,,,50597,10116.0,Intermediate,1,CHEMBL627893,BAO_0000218,1969.0,
9438,,A,,,Half life in rat plasma was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627894,BAO_0000218,1969.0,
9439,,A,,,Half life in rat plasma was determined; NA means not applicable,1,,,50597,10116.0,Intermediate,1,CHEMBL627895,BAO_0000218,1969.0,
9440,,A,,,Half life in rat was tested,1,,,50597,10116.0,Intermediate,1,CHEMBL627896,BAO_0000218,,
9441,,A,,,Half life measured in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL627897,BAO_0000218,1969.0,
9442,,A,,,Half life recorded in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627898,BAO_0000218,,
9443,,A,,,Half life was calculated,1,,,50597,10116.0,Intermediate,1,CHEMBL627899,BAO_0000218,,
9444,,A,,,Half life was calculated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL873823,BAO_0000218,,
9445,,A,,,Half life was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627900,BAO_0000218,,
9446,,A,,In vivo,Half life after 10 mg/kg oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627901,BAO_0000218,,
9447,,A,,In vivo,Half life after administering orally a dose of 10 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627902,BAO_0000218,,
9448,,A,,In vivo,Half life after administering orally a dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627903,BAO_0000218,,
9449,,A,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627904,BAO_0000218,,
9450,,A,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL627905,BAO_0000218,,
9451,,A,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627906,BAO_0000218,,
9452,,A,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627907,BAO_0000218,,
9453,,A,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL876783,BAO_0000218,,
9454,,A,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627908,BAO_0000218,,
9455,,A,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627909,BAO_0000218,,
9456,,A,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627910,BAO_0000218,,
9457,,A,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),1,,,50597,10116.0,Intermediate,1,CHEMBL627911,BAO_0000218,,
9458,,A,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),1,,,50597,10116.0,Intermediate,1,CHEMBL627912,BAO_0000218,,
9459,,A,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),1,,,50597,10116.0,Intermediate,1,CHEMBL627913,BAO_0000218,,
9460,,A,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),1,,,50597,10116.0,Intermediate,1,CHEMBL627914,BAO_0000218,,
9461,,A,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627915,BAO_0000218,,
9462,,A,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627916,BAO_0000218,,
9463,,A,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627917,BAO_0000218,,
9464,,A,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627918,BAO_0000218,,
9465,,A,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627919,BAO_0000218,,
9466,,A,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627920,BAO_0000218,,
9467,,A,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627921,BAO_0000218,,
9468,,A,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627922,BAO_0000218,,
9469,,A,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL876784,BAO_0000218,,
9470,,A,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627923,BAO_0000218,,
9471,,A,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626208,BAO_0000218,,
9472,,A,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626209,BAO_0000218,,
9473,,A,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626210,BAO_0000218,,
9474,,A,,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627994,BAO_0000218,1969.0,
9475,,A,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627995,BAO_0000218,,
9476,,A,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627996,BAO_0000218,,
9477,,A,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,1,,,50597,10116.0,Intermediate,1,CHEMBL627997,BAO_0000218,,
9478,,A,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627998,BAO_0000218,,
9479,,A,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628640,BAO_0000218,,
9480,,A,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628641,BAO_0000218,,
9481,,A,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628642,BAO_0000218,,
9482,,A,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,,,50597,10116.0,Intermediate,1,CHEMBL628643,BAO_0000218,,
9483,,A,,,Compound was tested for area under curve in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628644,BAO_0000218,,
9484,,A,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL628645,BAO_0000218,,
9485,,A,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628646,BAO_0000218,,
9486,,A,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL628647,BAO_0000218,,
9487,,A,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL628648,BAO_0000218,,
9488,,A,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL625358,BAO_0000218,,
9489,,A,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,,,50597,10116.0,Intermediate,1,CHEMBL625359,BAO_0000218,,
9490,,A,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL625360,BAO_0000218,,
9491,,A,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL625361,BAO_0000218,,
9492,,A,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL625362,BAO_0000218,,
9493,,A,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625363,BAO_0000218,,
9494,,A,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625364,BAO_0000218,,
9495,,A,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625365,BAO_0000218,,
9496,,A,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625366,BAO_0000218,,
9497,,A,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625367,BAO_0000218,,
9498,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625368,BAO_0000218,2113.0,
9499,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625369,BAO_0000218,2113.0,
9500,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625370,BAO_0000218,2113.0,
9501,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625371,BAO_0000218,2113.0,
9502,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625372,BAO_0000218,2113.0,
9503,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625373,BAO_0000218,2113.0,
9504,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625374,BAO_0000218,2107.0,
9505,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL877593,BAO_0000218,2107.0,
9506,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625375,BAO_0000218,2107.0,
9507,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL625376,BAO_0000218,2107.0,
9508,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL621973,BAO_0000218,2107.0,
9509,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL621974,BAO_0000218,2107.0,
9510,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL621975,BAO_0000218,2048.0,
9511,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622166,BAO_0000218,2048.0,
9512,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622167,BAO_0000218,2048.0,
9513,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622168,BAO_0000218,2048.0,
9514,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622169,BAO_0000218,2048.0,
9515,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622170,BAO_0000218,2048.0,
9516,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622171,BAO_0000218,2046.0,
9517,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622172,BAO_0000218,2046.0,
9518,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622173,BAO_0000218,2046.0,
9519,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622174,BAO_0000218,2046.0,
9520,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622175,BAO_0000218,2046.0,
9521,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622176,BAO_0000218,2046.0,
9522,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622177,BAO_0000218,2046.0,
9523,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622178,BAO_0000218,2046.0,
9524,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622179,BAO_0000218,2046.0,
9525,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622180,BAO_0000218,2046.0,
9526,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622181,BAO_0000218,,
9527,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622182,BAO_0000218,,
9528,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622183,BAO_0000218,,
9529,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622184,BAO_0000218,,
9530,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622185,BAO_0000218,,
9531,,A,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622186,BAO_0000218,,
9532,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622187,BAO_0000218,,
9533,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625002,BAO_0000218,,
9534,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622090,BAO_0000218,,
9535,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622091,BAO_0000218,,
9536,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622092,BAO_0000218,,
9537,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622093,BAO_0000218,,
9538,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622094,BAO_0000218,,
9539,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622095,BAO_0000218,,
9540,,A,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622264,BAO_0000218,,
9541,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622265,BAO_0000218,2106.0,
9542,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622266,BAO_0000218,2106.0,
9543,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622267,BAO_0000218,2106.0,
9544,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622268,BAO_0000218,2106.0,
9545,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622269,BAO_0000218,2106.0,
9546,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL625071,BAO_0000218,2106.0,
9547,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621621,BAO_0000218,2106.0,
9548,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621622,BAO_0000218,2106.0,
9549,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621623,BAO_0000218,2106.0,
9550,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621624,BAO_0000218,2106.0,
9551,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621625,BAO_0000218,2106.0,
9552,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621626,BAO_0000218,2106.0,
9553,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621627,BAO_0000218,2106.0,
9554,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621628,BAO_0000218,2106.0,
9555,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL875328,BAO_0000218,2106.0,
9556,,A,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL621629,BAO_0000218,2106.0,
9557,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621630,BAO_0000218,2106.0,
9558,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621631,BAO_0000218,2106.0,
9559,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621632,BAO_0000218,2106.0,
9560,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621633,BAO_0000218,2106.0,
9561,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621634,BAO_0000218,2106.0,
9562,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621635,BAO_0000218,2106.0,
9563,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621636,BAO_0000218,2106.0,
9564,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621637,BAO_0000218,2106.0,
9565,,A,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL621638,BAO_0000218,2106.0,
9566,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL618883,BAO_0000218,,
9567,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL618884,BAO_0000218,,
9568,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL628627,BAO_0000218,,
9569,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL628628,BAO_0000218,,
9570,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL628629,BAO_0000218,,
9571,,A,,In vivo,Half life after administering orally a dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628630,BAO_0000218,,
9572,,A,,In vivo,Half life after administering orally a dose of 3 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628631,BAO_0000218,,
9573,,A,,In vivo,Half life after administering intravenously a dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628632,BAO_0000218,,
9574,,A,,In vivo,Half life after oral dosing in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628633,BAO_0000218,,
9575,,A,,In vivo,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628634,BAO_0000218,,
9576,,A,,In vivo,Half life by intravenous administration of 3.4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627789,BAO_0000218,,
9577,,A,,,Half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627790,BAO_0000218,,
9578,,A,,,Half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627791,BAO_0000218,,
9579,,A,,,Half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627792,BAO_0000218,,
9580,,A,,In vivo,Half life in rat after intravenous administration of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627793,BAO_0000218,,
9581,,A,,In vivo,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1,,,50597,10116.0,Intermediate,1,CHEMBL627794,BAO_0000218,1969.0,
9582,,A,,In vivo,Half life in rat after po administration of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627795,BAO_0000218,,
9583,,A,,In vivo,Half life in rat after po administration of the compound; ND means Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627796,BAO_0000218,,
9584,,A,,In vivo,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1,,,50597,10116.0,Intermediate,1,CHEMBL875335,BAO_0000218,1969.0,
9585,,A,,In vivo,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1,,,50597,10116.0,Intermediate,1,CHEMBL627797,BAO_0000218,1969.0,
9586,,A,,In vivo,Half life in rat i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL627798,BAO_0000218,,
9587,,A,,In vivo,Half life in rat i.v. at 2 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL627799,BAO_0000218,,
9588,,A,,,Half life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627800,BAO_0000218,,
9589,,A,,In vivo,Half life in rats after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627801,BAO_0000218,,
9590,,A,,In vivo,Half life in rats at the dose of 1.0 mpk by i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627802,BAO_0000218,,
9591,,A,,,Half life in rat,1,,,50597,10116.0,Expert,1,CHEMBL627803,BAO_0000218,,
9592,,A,,In vivo,Half life was evaluated after intravenous administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL873820,BAO_0000218,,
9593,,A,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),1,,,50597,10116.0,Intermediate,1,CHEMBL627804,BAO_0000218,,
9594,,A,,,Half life was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627805,BAO_0000218,,
9595,,A,,,Half life was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627806,BAO_0000218,,
9596,,A,,,Half life was evaluated in rat; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL627107,BAO_0000218,,
9597,,A,,In vivo,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627108,BAO_0000218,,
9598,,A,,In vivo,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627109,BAO_0000218,,
9599,,A,,In vivo,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627110,BAO_0000218,178.0,
9600,,A,,In vivo,Half life was measured in monkey at dose of 10 mg/kg by po administration,0,,,22224,9443.0,Intermediate,1,CHEMBL627111,BAO_0000218,,
9601,,A,,In vivo,Half life was measured in monkey at dose of 10 mg/kg by po administration,0,,,22224,9443.0,Intermediate,1,CHEMBL627112,BAO_0000218,,
9602,,A,,In vivo,Half life was measured in rat at dose of 30 mg/kg by iv administration,0,,,22224,10116.0,Intermediate,1,CHEMBL627113,BAO_0000218,,
9603,,A,,In vivo,Half life was measured in rat at dose of 30 mg/kg by po administration,0,,,22224,10116.0,Intermediate,1,CHEMBL627114,BAO_0000218,,
9604,,A,,,Half life (t1/2) was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627115,BAO_0000218,,
9605,,A,,,Half life period at a dose of 10 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627116,BAO_0000218,,
9606,,A,,In vivo,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627117,BAO_0000218,,
9607,,A,,,Half life period was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627118,BAO_0000218,,
9608,,A,,In vivo,Half life period after intravenous administration at 20 mpk in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627119,BAO_0000218,,
9609,,A,,In vivo,Half life period after intravenous administration at 20 mpk in rats; Not performed.,1,,,50597,10116.0,Intermediate,1,CHEMBL627120,BAO_0000218,,
9610,,A,,In vivo,Half life period after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626922,BAO_0000218,,
9611,,A,,In vivo,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626923,BAO_0000218,,
9612,,A,,In vivo,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626924,BAO_0000218,,
9613,,A,,,Half life period in 80% rat plasma at 37 degree Centigrade,1,,,50597,10116.0,Intermediate,1,CHEMBL626925,BAO_0000218,1969.0,
9614,,A,,,Half life period in SD rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626926,BAO_0000218,,
9615,,A,,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1,,,50597,10116.0,Intermediate,1,CHEMBL626927,BAO_0000218,1969.0,
9616,,A,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1,,,50597,10116.0,Intermediate,1,CHEMBL626928,BAO_0000218,1969.0,
9617,,A,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,,,50597,10116.0,Intermediate,1,CHEMBL626929,BAO_0000218,1969.0,
9618,,A,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,,,50597,10116.0,Intermediate,1,CHEMBL626930,BAO_0000218,1969.0,
9619,,A,,,Half life period in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626931,BAO_0000218,,
9620,,A,,,Half life period in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626932,BAO_0000218,,
9621,,A,,,Half life period in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626933,BAO_0000218,,
9622,,A,,In vivo,Half life period in rat after oral administration at 10.5 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL873826,BAO_0000218,,
9623,,A,,In vivo,Half life period in rat after oral administration at 11.2 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626934,BAO_0000218,,
9624,,A,,In vivo,Half life period in rat after oral administration at 13 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626935,BAO_0000218,,
9625,,A,,In vivo,Half life period in rat after oral administration at 9.7 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626936,BAO_0000218,,
9626,,A,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626937,BAO_0000218,,
9627,,A,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625906,BAO_0000218,,
9628,,A,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625907,BAO_0000218,,
9629,,A,,,PK study was carried to determine AUC (area under curve) value in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625908,BAO_0000218,,
9630,,A,,,Pharmacokinetic parameter AUC after intravenous administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625909,BAO_0000218,,
9631,,A,,,Pharmacokinetic parameter AUC after oral administration to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625910,BAO_0000218,,
9632,,A,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625911,BAO_0000218,,
9633,,A,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625912,BAO_0000218,,
9634,,A,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626538,BAO_0000218,,
9635,,A,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,1,,,50597,10116.0,Intermediate,1,CHEMBL876794,BAO_0000218,,
9636,,A,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,1,,,50597,10116.0,Intermediate,1,CHEMBL626539,BAO_0000218,,
9637,,A,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626540,BAO_0000218,,
9638,,A,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626541,BAO_0000218,,
9639,,A,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626542,BAO_0000218,,
9640,,A,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626543,BAO_0000218,,
9641,,A,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626544,BAO_0000218,,
9642,,A,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626545,BAO_0000218,,
9643,,A,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626546,BAO_0000218,,
9644,,A,,,Pharmacokinetic parameter area under curve was reported,1,,,50597,10116.0,Intermediate,1,CHEMBL626547,BAO_0000218,,
9645,,A,,,Pharmacokinetic property (AUC) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626548,BAO_0000218,,
9646,,A,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,,50597,10116.0,Intermediate,1,CHEMBL626549,BAO_0000218,,
9647,,A,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,1,,,50597,10116.0,Intermediate,1,CHEMBL626550,BAO_0000218,,
9648,,A,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL626551,BAO_0000218,,
9649,,A,,,Pharmacokinetic property was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623777,BAO_0000218,,
9650,,A,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623778,BAO_0000218,,
9651,,A,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL623779,BAO_0000218,,
9652,,A,,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623780,BAO_0000218,1969.0,
9653,,A,,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622015,BAO_0000218,1969.0,
9654,,A,,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622016,BAO_0000218,1969.0,
9655,,A,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",1,,,50597,10116.0,Intermediate,1,CHEMBL622017,BAO_0000218,,
9656,,A,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",1,,,50597,10116.0,Intermediate,1,CHEMBL622018,BAO_0000218,,
9657,,A,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",1,,,50597,10116.0,Intermediate,1,CHEMBL622019,BAO_0000218,,
9658,,A,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",1,,,50597,10116.0,Intermediate,1,CHEMBL622020,BAO_0000218,,
9659,,A,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,1,,,50597,10116.0,Intermediate,1,CHEMBL622021,BAO_0000218,,
9660,,A,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,1,,,50597,10116.0,Intermediate,1,CHEMBL622022,BAO_0000218,,
9661,,A,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622023,BAO_0000218,,
9662,,A,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622024,BAO_0000218,,
9663,,A,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),1,,,50597,10116.0,Intermediate,1,CHEMBL622693,BAO_0000218,,
9664,,A,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),1,,,50597,10116.0,Intermediate,1,CHEMBL622694,BAO_0000218,,
9665,,A,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622695,BAO_0000218,,
9666,,A,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622696,BAO_0000218,,
9667,,A,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622697,BAO_0000218,,
9668,,A,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",1,,,50597,10116.0,Intermediate,1,CHEMBL622874,BAO_0000218,,
9669,,A,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",1,,,50597,10116.0,Intermediate,1,CHEMBL622875,BAO_0000218,,
9670,,A,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,,,50597,10116.0,Intermediate,1,CHEMBL622876,BAO_0000218,,
9671,,A,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622877,BAO_0000218,,
9672,,A,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622878,BAO_0000218,,
9673,,A,,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622879,BAO_0000218,1969.0,
9674,,A,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,1,,,50597,10116.0,Intermediate,1,CHEMBL877602,BAO_0000218,,
9675,,A,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622880,BAO_0000218,,
9676,,A,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622881,BAO_0000218,,
9677,,A,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622882,BAO_0000218,,
9678,,A,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL622883,BAO_0000218,,
9679,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622884,BAO_0000218,2046.0,
9680,,A,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL622885,BAO_0000218,2046.0,
9681,,A,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,,,50597,10116.0,Intermediate,1,CHEMBL622886,BAO_0000218,,
9682,,A,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622887,BAO_0000218,,
9683,,A,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622888,BAO_0000218,1088.0,
9684,,A,,In vivo,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622889,BAO_0000218,178.0,
9685,,A,,In vivo,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622890,BAO_0000218,178.0,
9686,,A,,In vivo,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622891,BAO_0000218,178.0,
9687,,A,,In vivo,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL877603,BAO_0000218,178.0,
9688,,A,,In vivo,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622892,BAO_0000218,955.0,
9689,,A,,In vivo,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622893,BAO_0000218,955.0,
9690,,A,,In vivo,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622894,BAO_0000218,955.0,
9691,,A,,In vivo,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622895,BAO_0000218,955.0,
9692,,A,,In vivo,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL622896,BAO_0000218,955.0,
9693,,A,,In vivo,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622897,BAO_0000218,948.0,
9694,,A,,In vivo,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622898,BAO_0000218,948.0,
9695,,A,,In vivo,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622899,BAO_0000218,948.0,
9696,,A,,In vivo,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622900,BAO_0000218,2113.0,
9697,,A,,In vivo,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624114,BAO_0000218,2113.0,
9698,,A,,In vivo,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624115,BAO_0000218,2113.0,
9699,,A,,In vivo,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624116,BAO_0000218,2113.0,
9700,,A,,In vivo,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624117,BAO_0000218,2107.0,
9701,,A,,In vivo,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624118,BAO_0000218,2107.0,
9702,,A,,In vivo,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624119,BAO_0000218,2107.0,
9703,,A,,In vivo,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624120,BAO_0000218,2107.0,
9704,,A,,In vivo,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624121,BAO_0000218,2048.0,
9705,,A,,In vivo,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624122,BAO_0000218,2048.0,
9706,,A,,In vivo,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624123,BAO_0000218,2048.0,
9707,,A,,In vivo,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624124,BAO_0000218,2048.0,
9708,,A,,In vivo,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624125,BAO_0000218,2385.0,
9709,,A,,In vivo,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624126,BAO_0000218,2385.0,
9710,,A,,In vivo,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624127,BAO_0000218,2385.0,
9711,,A,,In vivo,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624128,BAO_0000218,2385.0,
9712,,A,,In vivo,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624129,BAO_0000218,14.0,
9713,,A,,In vivo,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL624130,BAO_0000218,14.0,
9714,,A,,In vivo,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622340,BAO_0000218,14.0,
9715,,A,,In vivo,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622341,BAO_0000218,14.0,
9716,,A,,In vivo,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622342,BAO_0000218,160.0,
9717,,A,,In vivo,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622343,BAO_0000218,160.0,
9718,,A,,In vivo,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622344,BAO_0000218,160.0,
9719,,A,,In vivo,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622345,BAO_0000218,160.0,
9720,,A,,In vivo,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622346,BAO_0000218,2106.0,
9721,,A,,In vivo,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622347,BAO_0000218,2106.0,
9722,,A,,In vivo,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622348,BAO_0000218,2106.0,
9723,,A,,In vivo,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622349,BAO_0000218,2106.0,
9724,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622350,BAO_0000218,,
9725,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622351,BAO_0000218,,
9726,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622352,BAO_0000218,,
9727,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622353,BAO_0000218,,
9728,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622354,BAO_0000218,,
9729,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622355,BAO_0000218,,
9730,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622356,BAO_0000218,,
9731,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622357,BAO_0000218,,
9732,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622358,BAO_0000218,,
9733,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL622359,BAO_0000218,,
9734,,A,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL874393,BAO_0000218,,
9735,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622872,BAO_0000218,,
9736,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622873,BAO_0000218,,
9737,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623047,BAO_0000218,,
9738,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623048,BAO_0000218,,
9739,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623049,BAO_0000218,,
9740,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623050,BAO_0000218,,
9741,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623051,BAO_0000218,,
9742,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623052,BAO_0000218,,
9743,,A,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626343,BAO_0000218,,
9744,,A,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL626344,BAO_0000218,,
9745,,A,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL626345,BAO_0000218,,
9746,,A,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL626346,BAO_0000218,,
9747,,A,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626347,BAO_0000218,,
9748,,A,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626348,BAO_0000218,,
9749,,A,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626349,BAO_0000218,,
9750,,F,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626350,BAO_0000218,,
9751,,A,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626351,BAO_0000218,,
9752,,A,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627650,BAO_0000218,,
9753,,F,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627651,BAO_0000218,,
9754,,A,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627652,BAO_0000218,,
9755,,A,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627653,BAO_0000218,,
9756,,A,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627654,BAO_0000218,,
9757,,A,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627835,BAO_0000218,,
9758,,A,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627836,BAO_0000218,,
9759,,A,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627837,BAO_0000218,,
9760,,A,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627838,BAO_0000218,,
9761,,A,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL875338,BAO_0000218,,
9762,,A,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627839,BAO_0000218,,
9763,,A,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627840,BAO_0000218,,
9764,,A,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627841,BAO_0000218,,
9765,,A,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627842,BAO_0000218,,
9766,,A,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627843,BAO_0000218,,
9767,,A,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627844,BAO_0000218,,
9768,,A,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL627845,BAO_0000218,,
9769,,A,,In vivo,Half life period in rat by iv administration at a dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627846,BAO_0000218,,
9770,,A,,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1,,,50597,10116.0,Intermediate,1,CHEMBL627847,BAO_0000218,1969.0,
9771,,A,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1,,,50597,10116.0,Intermediate,1,CHEMBL873821,BAO_0000218,1969.0,
9772,,A,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,,,50597,10116.0,Intermediate,1,CHEMBL626079,BAO_0000218,1969.0,
9773,,A,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,,,50597,10116.0,Intermediate,1,CHEMBL626080,BAO_0000218,1969.0,
9774,,A,,,Half life period was evaluated in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL626081,BAO_0000218,1969.0,
9775,,A,,,Half life period was evaluated in rat plasma; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL875344,BAO_0000218,1969.0,
9776,,A,,,Half life period was evaluated in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626082,BAO_0000218,,
9777,,A,,In vivo,"Half life period was evaluated in rats, iv",1,,,50597,10116.0,Intermediate,1,CHEMBL626250,BAO_0000218,,
9778,,A,,In vivo,Half life period after intravenous administration at 5 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626251,BAO_0000218,,
9779,,A,,In vivo,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626252,BAO_0000218,,
9780,,A,,In vivo,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626253,BAO_0000218,,
9781,,A,,,Half life stability of compound was evaluated in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL626254,BAO_0000218,1969.0,
9782,,A,,In vivo,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626255,BAO_0000218,,
9783,,A,,In vivo,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626256,BAO_0000218,,
9784,,A,,In vivo,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626257,BAO_0000218,,
9785,,A,,In vivo,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,1,,,50597,10116.0,Intermediate,1,CHEMBL626258,BAO_0000218,,
9786,,A,,In vivo,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL626259,BAO_0000218,,
9787,,A,,In vivo,Half in rat i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL626260,BAO_0000218,,
9788,,A,,In vivo,Half period in rat after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL875345,BAO_0000218,,
9789,,A,,In vivo,Half-life after repeated oral dose of compound at 1 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626261,BAO_0000218,,
9790,,A,,In vitro,Half-life measured in in vitro Cathepsin B assay in rat liver,1,,,50597,10116.0,Intermediate,1,CHEMBL626262,BAO_0000218,2107.0,
9791,,A,,,Half-life of compound was determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626263,BAO_0000218,,
9792,,A,,In vivo,Half-life at 10 mg/kg in rat upon intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625270,BAO_0000218,,
9793,,A,,,Half-life determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625271,BAO_0000218,,
9794,,A,,,Half-life determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625272,BAO_0000218,,
9795,,A,,In vivo,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625273,BAO_0000218,955.0,
9796,,A,,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1,,,50597,10116.0,Intermediate,1,CHEMBL625274,BAO_0000218,1969.0,
9797,,A,,In vivo,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625275,BAO_0000218,,
9798,,A,,In vivo,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625276,BAO_0000218,1969.0,
9799,,A,,,Half-life in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL625277,BAO_0000218,1969.0,
9800,,A,,,Half-life in rat plasma was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625278,BAO_0000218,1969.0,
9801,,A,,,Half-life in rat plasma; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL625279,BAO_0000218,1969.0,
9802,,A,,,Half-life in rat serum,1,,,50597,10116.0,Intermediate,1,CHEMBL625280,BAO_0000218,1977.0,
9803,,A,,,Half-life in rat serum; na is not available,1,,,50597,10116.0,Intermediate,1,CHEMBL876797,BAO_0000218,1977.0,
9804,,A,,,Half-life was calculated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625281,BAO_0000218,,
9805,,A,,,Half-life was calculated in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL873827,BAO_0000218,1969.0,
9806,,A,,,Half-life was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625282,BAO_0000218,,
9807,,A,,,Half-life was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625283,BAO_0000218,,
9808,,A,,In vivo,Half-life after administration of 20 mg/Kg oral dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625284,BAO_0000218,,
9809,,A,,In vivo,Half-life after administration of 3.2 mg/kg intravenously in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625285,BAO_0000218,,
9810,,A,,In vivo,Half-life after intravenous administration in female rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625286,BAO_0000218,,
9811,,A,,In vivo,Half-life after intravenous administration in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625287,BAO_0000218,,
9812,,A,,In vivo,Half-life after intravenous dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625288,BAO_0000218,,
9813,,A,,,Half-life in a rat liver homogenate preparation,1,,,50597,10116.0,Intermediate,1,CHEMBL625289,BAO_0000218,2107.0,
9814,,A,,,Half-life in plasma of rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625290,BAO_0000218,1969.0,
9815,,A,,,Half-life in plasma of rat at dose of 3-10 mgkg,1,,,50597,10116.0,Intermediate,1,CHEMBL876798,BAO_0000218,1969.0,
9816,,A,,,Half-life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625291,BAO_0000218,,
9817,,A,,,Half-life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625292,BAO_0000218,,
9818,,A,,,Half-life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625293,BAO_0000218,,
9819,,A,,,Half-life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622832,BAO_0000218,,
9820,,A,,,Half-life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622833,BAO_0000218,,
9821,,A,,,Half-life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622834,BAO_0000218,,
9822,,A,,In vivo,Half-life in rat after oral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622835,BAO_0000218,,
9823,,A,,In vivo,Half-life in rat after po administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622836,BAO_0000218,,
9824,,A,,In vivo,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622837,BAO_0000218,,
9825,,A,,In vivo,Half-life in rat at 3 mg/kg dose administered intravenously,1,,,50597,10116.0,Intermediate,1,CHEMBL622838,BAO_0000218,,
9826,,A,,,Half-life in rat brain homogenate,1,,,50597,10116.0,Intermediate,1,CHEMBL622839,BAO_0000218,955.0,
9827,,A,,,Half-life in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL622840,BAO_0000218,1969.0,
9828,,A,,,Half-life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622841,BAO_0000218,,
9829,,A,,,Half-life in Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622842,BAO_0000218,,
9830,,A,,In vitro,Half-life in vitro in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL622843,BAO_0000218,1969.0,
9831,,A,,In vitro,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622844,BAO_0000218,1969.0,
9832,,A,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",1,,,50597,10116.0,Intermediate,1,CHEMBL622845,BAO_0000218,,
9833,,A,,,The area under the curve of compound was measured at the dose of 100 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622846,BAO_0000218,,
9834,,A,,,The area under the curve of compound was measured at the dose of 300 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622847,BAO_0000218,,
9835,,A,,,The area under the curve of compound was measured at the dose of 30 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622848,BAO_0000218,,
9836,,A,,In vivo,Bioavailability as oral AUC in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622849,BAO_0000218,,
9837,,A,,,The plasma concentration versus time curve (AUC) was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622850,BAO_0000218,1969.0,
9838,,A,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL876807,BAO_0000218,,
9839,,A,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622851,BAO_0000218,,
9840,,A,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622852,BAO_0000218,,
9841,,A,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622853,BAO_0000218,,
9842,,A,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL622854,BAO_0000218,,
9843,,A,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622855,BAO_0000218,,
9844,,A,,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1,,,50597,10116.0,Intermediate,1,CHEMBL622856,BAO_0000218,1969.0,
9845,,A,,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1,,,50597,10116.0,Intermediate,1,CHEMBL622857,BAO_0000218,1969.0,
9846,,A,,,AUC in rat after po administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622858,BAO_0000218,1969.0,
9847,,A,,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622859,BAO_0000218,1969.0,
9848,,A,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622860,BAO_0000218,,
9849,,A,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622861,BAO_0000218,,
9850,,A,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622862,BAO_0000218,,
9851,,A,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622863,BAO_0000218,,
9852,,A,,,Area under curve value 6 hr after po administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623817,BAO_0000218,,
9853,,A,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,50597,10116.0,Intermediate,1,CHEMBL623818,BAO_0000218,,
9854,,A,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",1,,,50597,10116.0,Intermediate,1,CHEMBL623819,BAO_0000218,,
9855,,A,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,50597,10116.0,Intermediate,1,CHEMBL623820,BAO_0000218,,
9856,,A,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,1,,,50597,10116.0,Intermediate,1,CHEMBL623821,BAO_0000218,,
9857,,A,,,AUC normalized for dose (AUCN) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623822,BAO_0000218,1969.0,
9858,,A,,,Area under curve in rat after p.o. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623823,BAO_0000218,,
9859,,A,,,Area under curve in rat after p.o. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623824,BAO_0000218,,
9860,,A,,,Area under curve in rat after p.o. administration; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623825,BAO_0000218,,
9861,,A,,,Area under curve in rat after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622070,BAO_0000218,,
9862,,A,,,Area under curve (carotid artery) value of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL622071,BAO_0000218,,
9863,,A,,,Bioavailability expressed as the area under curve of rat carotid artery,1,,,50597,10116.0,Intermediate,1,CHEMBL622072,BAO_0000218,,
9864,,A,,,Area under curve in male SD rats was observed after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622073,BAO_0000218,,
9865,,A,,,Area under curve of the compound was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622074,BAO_0000218,,
9866,,A,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,1,,,50597,10116.0,Intermediate,1,CHEMBL622075,BAO_0000218,,
9867,,A,,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622076,BAO_0000218,1969.0,
9868,,A,,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622077,BAO_0000218,1969.0,
9869,,A,,,Area under curve (portal vein) value of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL622078,BAO_0000218,,
9870,,A,,,Bioavailability expressed as the area under curve of rat portal vein,1,,,50597,10116.0,Intermediate,1,CHEMBL622079,BAO_0000218,,
9871,,A,,,Area Under plasma concentration time curve in rat upon peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622080,BAO_0000218,1969.0,
9872,,A,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL877612,BAO_0000218,,
9873,,A,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622081,BAO_0000218,,
9874,,A,,,Compound was evaluated for oral bioavailability in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622082,BAO_0000218,,
9875,,A,,,Compound was evaluated for oral bioavailability in rats after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622083,BAO_0000218,,
9876,,A,,,Compound was evaluated for oral bioavailability in rats; 30-80,1,,,50597,10116.0,Intermediate,1,CHEMBL622084,BAO_0000218,,
9877,,A,,,Compound was evaluated for oral bioavailability in rats; 50-60,1,,,50597,10116.0,Intermediate,1,CHEMBL622085,BAO_0000218,,
9878,,A,,,Compound was evaluated for oral bioavailability in rats; no data,1,,,50597,10116.0,Intermediate,1,CHEMBL622086,BAO_0000218,,
9879,,A,,,Compound was evaluated for oral bioavailability in rats; peptide,1,,,50597,10116.0,Intermediate,1,CHEMBL622087,BAO_0000218,,
9880,,A,,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",1,,,50597,10116.0,Intermediate,1,CHEMBL622088,BAO_0000218,178.0,
9881,,A,,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",1,,,50597,10116.0,Intermediate,1,CHEMBL622089,BAO_0000218,178.0,
9882,,A,,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",1,,,50597,10116.0,Intermediate,1,CHEMBL623685,BAO_0000218,178.0,
9883,,A,,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",1,,,50597,10116.0,Intermediate,1,CHEMBL623686,BAO_0000218,178.0,
9884,,A,,In vivo,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL623687,BAO_0000218,945.0,
9885,,A,,In vivo,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL623688,BAO_0000218,945.0,
9886,,A,,In vivo,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL623689,BAO_0000218,945.0,
9887,,A,,In vivo,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622485,BAO_0000218,945.0,
9888,,A,,In vivo,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622486,BAO_0000218,2046.0,
9889,,A,,In vivo,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL877613,BAO_0000218,2046.0,
9890,,A,,In vivo,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622487,BAO_0000218,2046.0,
9891,,A,,In vivo,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622488,BAO_0000218,2046.0,
9892,,A,,In vivo,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622489,BAO_0000218,948.0,
9893,,A,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,,,50597,10116.0,Intermediate,1,CHEMBL622490,BAO_0000218,1088.0,
9894,,A,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,,,50597,10116.0,Intermediate,1,CHEMBL622491,BAO_0000218,1088.0,
9895,,A,,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,1,,,50597,10116.0,Intermediate,1,CHEMBL622492,BAO_0000218,2107.0,
9896,,A,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,,,50597,10116.0,Intermediate,1,CHEMBL622493,BAO_0000218,1088.0,
9897,,A,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,,,50597,10116.0,Intermediate,1,CHEMBL622494,BAO_0000218,1088.0,
9898,,A,,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,,50597,10116.0,Intermediate,1,CHEMBL622495,BAO_0000218,2385.0,
9899,,A,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,1,,,50597,10116.0,Intermediate,1,CHEMBL622496,BAO_0000218,,
9900,,A,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,,,50597,10116.0,Intermediate,1,CHEMBL622497,BAO_0000218,1088.0,
9901,,A,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622498,BAO_0000218,,
9902,,A,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624918,BAO_0000218,1088.0,
9903,,A,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1,,,50597,10116.0,Intermediate,1,CHEMBL624919,BAO_0000218,1088.0,
9904,,A,,In vivo,Biodistribution of compound in rat blood after 5 min of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624920,BAO_0000218,178.0,
9905,,A,,In vivo,Biodistribution of compound in rat blood after 5 min of administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL624921,BAO_0000218,178.0,
9906,,A,,In vivo,Biodistribution of compound in rat brain after 5 min of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624922,BAO_0000218,955.0,
9907,,A,,In vivo,Biodistribution of compound in rat heart after 5 min of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624923,BAO_0000218,948.0,
9908,,A,,In vivo,Biodistribution of compound in rat heart after 5 min of administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL624924,BAO_0000218,948.0,
9909,,A,,In vivo,Biodistribution of compound in rat kidney after 5 min of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624925,BAO_0000218,2113.0,
9910,,A,,In vivo,Biodistribution of compound in rat kidney after 5 min of administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL624926,BAO_0000218,2113.0,
9911,,A,,In vivo,Biodistribution of compound in rat liver after 5 min of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624927,BAO_0000218,2107.0,
9912,,A,,In vivo,Biodistribution of compound in rat liver after 5 min of administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL874402,BAO_0000218,2107.0,
9913,,A,,In vivo,Biodistribution of compound in rat lung after 5 min of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624928,BAO_0000218,2048.0,
9914,,A,,In vivo,Biodistribution of compound in rat lung after 5 min of administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL624929,BAO_0000218,2048.0,
9915,,A,,In vivo,Biodistribution of compound in rat muscle after 5 min of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624930,BAO_0000218,2385.0,
9916,,A,,In vivo,Biodistribution of compound in rat muscle after 5 min of administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL624931,BAO_0000218,2385.0,
9917,,A,,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624932,BAO_0000218,948.0,
9918,,A,,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624933,BAO_0000218,948.0,
9919,,A,,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624934,BAO_0000218,2107.0,
9920,,A,,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624935,BAO_0000218,2107.0,
9921,,A,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624936,BAO_0000218,,
9922,,A,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624937,BAO_0000218,,
9923,,A,,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624938,BAO_0000218,2106.0,
9924,,A,,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624939,BAO_0000218,2106.0,
9925,,A,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL624940,BAO_0000218,,
9926,,A,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,,50597,10116.0,Intermediate,1,CHEMBL874403,BAO_0000218,,
9927,,A,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,1,,,50597,10116.0,Intermediate,1,CHEMBL624941,BAO_0000218,,
9928,,A,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624942,BAO_0000218,1088.0,
9929,,A,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL624943,BAO_0000218,1088.0,
9930,,A,,In vivo,% Bioavailability after 1 day of the drug administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624944,BAO_0000218,,
9931,,A,,In vivo,% Bioavailability after 4 day of the drug administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624945,BAO_0000218,,
9932,,A,,In vivo,Absolute bioavailability was evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624946,BAO_0000218,,
9933,,A,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624947,BAO_0000218,,
9934,,A,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624948,BAO_0000218,,
9935,,A,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624949,BAO_0000218,,
9936,,A,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622025,BAO_0000218,2113.0,
9937,,A,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622026,BAO_0000218,2113.0,
9938,,A,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622027,BAO_0000218,2113.0,
9939,,A,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622028,BAO_0000218,2113.0,
9940,,A,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622029,BAO_0000218,2107.0,
9941,,A,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622208,BAO_0000218,2107.0,
9942,,A,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622209,BAO_0000218,2107.0,
9943,,A,,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622210,BAO_0000218,2107.0,
9944,,A,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622211,BAO_0000218,,
9945,,A,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622212,BAO_0000218,,
9946,,A,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL622213,BAO_0000218,,
9947,,A,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL874404,BAO_0000218,,
9948,,A,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL620452,BAO_0000218,2385.0,
9949,,A,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL620453,BAO_0000218,2385.0,
9950,,A,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL620454,BAO_0000218,2385.0,
9951,,A,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624067,BAO_0000218,2385.0,
9952,,A,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624068,BAO_0000218,,
9953,,A,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624069,BAO_0000218,992.0,
9954,,A,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624070,BAO_0000218,992.0,
9955,,A,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624071,BAO_0000218,992.0,
9956,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624072,BAO_0000218,995.0,
9957,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624073,BAO_0000218,995.0,
9958,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624788,BAO_0000218,995.0,
9959,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624789,BAO_0000218,995.0,
9960,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624790,BAO_0000218,,
9961,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624791,BAO_0000218,,
9962,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624792,BAO_0000218,,
9963,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624793,BAO_0000218,,
9964,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL877491,BAO_0000218,2385.0,
9965,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624957,BAO_0000218,2385.0,
9966,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624958,BAO_0000218,2385.0,
9967,,A,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,1,,,50597,10116.0,Intermediate,1,CHEMBL624959,BAO_0000218,2385.0,
9968,,A,,,Dissociation constant was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL624960,BAO_0000218,,
9969,,A,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",1,,,50597,10116.0,Intermediate,1,CHEMBL624961,BAO_0000218,,
9970,,A,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL624962,BAO_0000218,,
9971,,A,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL624963,BAO_0000218,,
9972,,A,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,1,,,50597,10116.0,Intermediate,1,CHEMBL624964,BAO_0000218,,
9973,,A,,,LogP value was evaluated in the in situ rat gut perfusion assay,1,,,50597,10116.0,Intermediate,1,CHEMBL624965,BAO_0000218,,
9974,,A,,In vivo,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624966,BAO_0000218,,
9975,,A,,In vivo,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624967,BAO_0000218,,
9976,,A,,In vivo,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624968,BAO_0000218,,
9977,,A,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624969,BAO_0000218,,
9978,,F,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,1,,,50597,10116.0,Expert,1,CHEMBL624970,BAO_0000218,,
9979,,A,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624971,BAO_0000218,,
9980,,A,,In vivo,Half-life was evaluated after 20 uM/kg of peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624972,BAO_0000218,,
9981,,A,,In vivo,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624973,BAO_0000218,,
9982,,A,,,Half-life was evaluated in plasma of rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624974,BAO_0000218,1969.0,
9983,,A,,In vivo,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624975,BAO_0000218,,
9984,,A,,In vivo,Half-life was evaluated in rats at an oral dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL877492,BAO_0000218,,
9985,,A,,In vivo,Half-life was measured in rat after an iv dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624976,BAO_0000218,,
9986,,A,,In vivo,Half-life period of compound in rats after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624977,BAO_0000218,,
9987,,A,,,Half-life period of compound was measured in rat plasma.,1,,,50597,10116.0,Intermediate,1,CHEMBL626848,BAO_0000218,1969.0,
9988,,A,,,Half-life period of compound was measured in rat plasma; ND is not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626849,BAO_0000218,1969.0,
9989,,A,,,Half-life period of compound was measured in rat plasma; not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626850,BAO_0000218,1969.0,
9990,,A,,In vivo,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626851,BAO_0000218,,
9991,,A,,In vivo,Half-life period in rat by iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626852,BAO_0000218,,
9992,,A,,In vivo,Half-life period in rats following intravenous administration at 2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626853,BAO_0000218,,
9993,,A,,In vivo,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626854,BAO_0000218,,
9994,,A,,,Half-life period was determined for the compound in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627486,BAO_0000218,,
9995,,A,,In vivo,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",1,,,50597,10116.0,Intermediate,1,CHEMBL627487,BAO_0000218,,
9996,,A,,In vivo,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",1,,,50597,10116.0,Intermediate,1,CHEMBL627488,BAO_0000218,,
9997,,A,,In vivo,Half-life value after IV dose at a dose of 5 mg/kg in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL627489,BAO_0000218,,
9998,,A,,In vivo,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627490,BAO_0000218,,
9999,,A,,In vivo,Half-life was determined in rat after intravenous administration (0.5 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL873829,BAO_0000218,,
10000,,A,,In vivo,Half-life was determined in rat at a dose of 1 mpk i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL627655,BAO_0000218,,
10001,,A,,In vivo,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625994,BAO_0000218,,
10002,,A,,In vivo,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625995,BAO_0000218,,
10003,,A,,,Half-life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625996,BAO_0000218,,
10004,,A,,In vitro,In vitro half life in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL625850,BAO_0000218,1969.0,
10005,,A,,In vitro,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1,,,50597,10116.0,Intermediate,1,CHEMBL625851,BAO_0000218,1969.0,
10006,,A,,In vitro,In vitro half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625852,BAO_0000218,,
10007,,A,,In vivo,In vivo half life period after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625853,BAO_0000218,,
10008,,A,,In vivo,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625854,BAO_0000218,,
10009,,A,,In vivo,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL874450,BAO_0000218,,
10010,,A,,In vivo,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625855,BAO_0000218,,
10011,,A,,In vivo,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625856,BAO_0000218,,
10012,,A,,In vivo,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625857,BAO_0000218,,
10013,,A,,In vivo,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL873831,BAO_0000218,,
10014,,A,,In vivo,Longer half-life in rat (i.v.) at 0.5 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL625858,BAO_0000218,,
10015,,A,,In vivo,Longer half-life in rat (p.o.) at 2.0 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL625859,BAO_0000218,,
10016,,A,,,Pharmacokinetic property (half life) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625860,BAO_0000218,,
10017,,A,,In vivo,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625861,BAO_0000218,,
10018,,A,,In vivo,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625862,BAO_0000218,,
10019,,A,,In vivo,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625863,BAO_0000218,,
10020,,A,,In vivo,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625864,BAO_0000218,,
10021,,A,,In vivo,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625865,BAO_0000218,,
10022,,A,,In vivo,Pharmacokinetic half time was determined intravenously in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL625866,BAO_0000218,,
10023,,A,,In vivo,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1,,,50597,10116.0,Intermediate,1,CHEMBL625867,BAO_0000218,1969.0,
10024,,A,,,Plasma half life of hydrolysis of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL625868,BAO_0000218,1969.0,
10025,,A,,In vivo,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625869,BAO_0000218,1969.0,
10026,,A,,,Plasma half life period was calculated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL874451,BAO_0000218,1969.0,
10027,,A,,,Plasma half-life in Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625870,BAO_0000218,1969.0,
10028,,A,,,Plasma half-life in Sprague-Dawley rats; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625871,BAO_0000218,1969.0,
10029,,A,,,Plasma half-life in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625872,BAO_0000218,1969.0,
10030,,A,,,Plasma half-life in rats; <MQL,1,,,50597,10116.0,Intermediate,1,CHEMBL625873,BAO_0000218,1969.0,
10031,,A,,,Plasma half-life period (0-8 h) was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625874,BAO_0000218,1969.0,
10032,,A,,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625875,BAO_0000218,1969.0,
10033,,A,,In vivo,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625876,BAO_0000218,1969.0,
10034,,A,,In vivo,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631258,BAO_0000218,1969.0,
10035,,A,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL631259,BAO_0000218,1969.0,
10036,,A,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL631260,BAO_0000218,1969.0,
10037,,A,,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",1,,,50597,10116.0,Intermediate,1,CHEMBL631261,BAO_0000218,178.0,
10038,,A,,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",1,,,50597,10116.0,Intermediate,1,CHEMBL631262,BAO_0000218,178.0,
10039,,A,,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",1,,,50597,10116.0,Intermediate,1,CHEMBL631263,BAO_0000218,178.0,
10040,,A,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",1,,,50597,10116.0,Intermediate,1,CHEMBL631264,BAO_0000218,,
10041,,A,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",1,,,50597,10116.0,Intermediate,1,CHEMBL631265,BAO_0000218,,
10042,,A,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",1,,,50597,10116.0,Intermediate,1,CHEMBL631266,BAO_0000218,,
10043,,A,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",1,,,50597,10116.0,Intermediate,1,CHEMBL631267,BAO_0000218,,
10044,,A,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",1,,,50597,10116.0,Intermediate,1,CHEMBL631268,BAO_0000218,,
10045,,A,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",1,,,50597,10116.0,Intermediate,1,CHEMBL631269,BAO_0000218,,
10046,,A,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",1,,,50597,10116.0,Intermediate,1,CHEMBL631270,BAO_0000218,,
10047,,A,,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,,,50597,10116.0,Intermediate,1,CHEMBL631271,BAO_0000218,948.0,
10048,,A,,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",1,,,50597,10116.0,Intermediate,1,CHEMBL631272,BAO_0000218,948.0,
10049,,A,,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",1,,,50597,10116.0,Intermediate,1,CHEMBL631273,BAO_0000218,948.0,
10050,,A,,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",1,,,50597,10116.0,Intermediate,1,CHEMBL631274,BAO_0000218,948.0,
10051,,A,,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",1,,,50597,10116.0,Intermediate,1,CHEMBL631275,BAO_0000218,948.0,
10052,,A,,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",1,,,50597,10116.0,Intermediate,1,CHEMBL626984,BAO_0000218,948.0,
10053,,A,,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",1,,,50597,10116.0,Intermediate,1,CHEMBL626985,BAO_0000218,948.0,
10054,,A,,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,,,50597,10116.0,Intermediate,1,CHEMBL626986,BAO_0000218,2107.0,
10055,,A,,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",1,,,50597,10116.0,Intermediate,1,CHEMBL626987,BAO_0000218,2107.0,
10056,,A,,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",1,,,50597,10116.0,Intermediate,1,CHEMBL626988,BAO_0000218,2107.0,
10057,,A,,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",1,,,50597,10116.0,Intermediate,1,CHEMBL626989,BAO_0000218,2107.0,
10058,,A,,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",1,,,50597,10116.0,Intermediate,1,CHEMBL626990,BAO_0000218,2107.0,
10059,,A,,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",1,,,50597,10116.0,Intermediate,1,CHEMBL626991,BAO_0000218,2107.0,
10060,,A,,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",1,,,50597,10116.0,Intermediate,1,CHEMBL626992,BAO_0000218,2107.0,
10061,,A,,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",1,,,50597,10116.0,Intermediate,1,CHEMBL626993,BAO_0000218,2048.0,
10062,,A,,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",1,,,50597,10116.0,Intermediate,1,CHEMBL874593,BAO_0000218,2048.0,
10063,,A,,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",1,,,50597,10116.0,Intermediate,1,CHEMBL626994,BAO_0000218,2048.0,
10064,,A,,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",1,,,50597,10116.0,Intermediate,1,CHEMBL626995,BAO_0000218,2048.0,
10065,,A,,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",1,,,50597,10116.0,Intermediate,1,CHEMBL626190,BAO_0000218,2048.0,
10066,,A,,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",1,,,50597,10116.0,Intermediate,1,CHEMBL626191,BAO_0000218,2048.0,
10067,,A,,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",1,,,50597,10116.0,Intermediate,1,CHEMBL626364,BAO_0000218,2048.0,
10068,,A,,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",1,,,50597,10116.0,Intermediate,1,CHEMBL626365,BAO_0000218,2046.0,
10069,,A,,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",1,,,50597,10116.0,Intermediate,1,CHEMBL626366,BAO_0000218,2046.0,
10070,,A,,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",1,,,50597,10116.0,Intermediate,1,CHEMBL626367,BAO_0000218,2046.0,
10071,,A,,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",1,,,50597,10116.0,Intermediate,1,CHEMBL626368,BAO_0000218,2046.0,
10072,,A,,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",1,,,50597,10116.0,Intermediate,1,CHEMBL626369,BAO_0000218,2046.0,
10073,,A,,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",1,,,50597,10116.0,Intermediate,1,CHEMBL626370,BAO_0000218,2046.0,
10074,,A,,In vivo,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",1,,,50597,10116.0,Intermediate,1,CHEMBL626371,BAO_0000218,,
10075,,A,,In vivo,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",1,,,50597,10116.0,Intermediate,1,CHEMBL626372,BAO_0000218,,
10076,,A,,In vivo,Bioavailability after a dose of 10 mg/kg p.o.,1,,,50597,10116.0,Intermediate,1,CHEMBL626373,BAO_0000218,,
10077,,A,,In vivo,Bioavailability after peroral administration (10 mg/kg) was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626374,BAO_0000218,,
10078,,A,,In vivo,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,1,,,50597,10116.0,Intermediate,1,CHEMBL626375,BAO_0000218,,
10079,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL626376,BAO_0000218,,
10080,,A,,In vivo,Bioavailability in rat po was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626377,BAO_0000218,,
10081,,A,,In vivo,Bioavailability of compound at 10 mg/kg in rat after oral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626378,BAO_0000218,,
10082,,A,,In vivo,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626379,BAO_0000218,,
10083,,A,,In vivo,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL626380,BAO_0000218,,
10084,,A,,In vivo,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL626381,BAO_0000218,,
10085,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626382,BAO_0000218,,
10086,,A,,In vivo,Bioavailability in rat (Sprague-Dawley) (female),1,,,50597,10116.0,Intermediate,1,CHEMBL626383,BAO_0000218,,
10087,,A,,In vivo,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL874652,BAO_0000218,,
10088,,A,,In vivo,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL626384,BAO_0000218,,
10089,,A,,In vivo,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL626385,BAO_0000218,,
10090,,A,,In vivo,Bioavailability in rat at an oral dose of 2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626386,BAO_0000218,,
10091,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626387,BAO_0000218,,
10092,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626388,BAO_0000218,,
10093,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626389,BAO_0000218,,
10094,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626390,BAO_0000218,,
10095,,A,,In vivo,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,1,,,50597,10116.0,Intermediate,1,CHEMBL626391,BAO_0000218,,
10096,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626392,BAO_0000218,,
10097,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626393,BAO_0000218,,
10098,,A,,In vivo,Bioavailability was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623026,BAO_0000218,,
10099,,A,,In vivo,Bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL623027,BAO_0000218,,
10100,,A,,In vivo,Bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL623028,BAO_0000218,,
10101,,A,,In vivo,Bioavailability in rat after 1 day dosing,1,,,50597,10116.0,Intermediate,1,CHEMBL623029,BAO_0000218,,
10102,,A,,In vivo,Bioavailability in rat after 4 day dosing,1,,,50597,10116.0,Intermediate,1,CHEMBL623030,BAO_0000218,,
10103,,A,,In vivo,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,1,,,50597,10116.0,Intermediate,1,CHEMBL623031,BAO_0000218,,
10104,,A,,In vivo,Bioavailability after IV dosing at 1 mg/kg in rat; no data,1,,,50597,10116.0,Intermediate,1,CHEMBL623032,BAO_0000218,,
10105,,A,,In vivo,Bioavailability after oral administration at a dose of 2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623033,BAO_0000218,,
10106,,A,,In vivo,Bioavailability after oral administration at a dose of 4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623034,BAO_0000218,,
10107,,A,,In vivo,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623035,BAO_0000218,,
10108,,A,,In vivo,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623036,BAO_0000218,,
10109,,A,,In vivo,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL623037,BAO_0000218,,
10110,,A,,In vivo,Bioavailability by intravenous administration of 3.4 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623038,BAO_0000218,,
10111,,A,,In vivo,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL874385,BAO_0000218,1969.0,
10112,,A,,In vivo,Bioavailability in rat (Fisher) (fasted),1,,,50597,10116.0,Intermediate,1,CHEMBL623039,BAO_0000218,,
10113,,A,,In vivo,Bioavailability in monkey after po administration of 10 mg/kg dose,0,,,22224,9443.0,Intermediate,1,CHEMBL623040,BAO_0000218,,
10114,,A,,In vivo,Oral bioavailability in monkey (dose 10 mg/kg),0,,,22224,9443.0,Intermediate,1,CHEMBL623041,BAO_0000218,,
10115,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623741,BAO_0000218,,
10116,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623742,BAO_0000218,,
10117,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623743,BAO_0000218,,
10118,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623744,BAO_0000218,,
10119,,A,,In vivo,Bioavailability in rat (dose 2.0 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL623745,BAO_0000218,,
10120,,A,,In vivo,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL623746,BAO_0000218,,
10121,,A,,In vivo,Oral bioavailability in rat (dose 5 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL623747,BAO_0000218,,
10122,,A,,In vivo,Bioavailability in rat after po administration of 30 mg/kg dose,0,,,22224,10116.0,Intermediate,1,CHEMBL623748,BAO_0000218,,
10123,,A,,In vivo,Bioavailability in rat after po administration of 30 mg/kg dose,0,,,22224,10116.0,Intermediate,1,CHEMBL623916,BAO_0000218,,
10124,,A,,In vivo,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623917,BAO_0000218,,
10125,,A,,In vivo,Bioavailability in rat (dose 2 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL623918,BAO_0000218,,
10126,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL874386,BAO_0000218,,
10127,,A,,In vivo,Bioavailability in rat; Only traces detected in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL623919,BAO_0000218,1969.0,
10128,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623920,BAO_0000218,,
10129,,A,,In vivo,Bioavailability upon oral administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL623148,BAO_0000218,,
10130,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL623149,BAO_0000218,,
10131,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623150,BAO_0000218,,
10132,,A,,In vivo,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",1,,,50597,10116.0,Intermediate,1,CHEMBL623151,BAO_0000218,,
10133,,A,,In vivo,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",1,,,50597,10116.0,Intermediate,1,CHEMBL623152,BAO_0000218,,
10134,,F,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,1,,,50597,10116.0,Expert,1,CHEMBL623153,BAO_0000218,,
10135,,F,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,1,,,50597,10116.0,Expert,1,CHEMBL623154,BAO_0000218,,
10136,,A,,,In vitro and metabolic stability was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623155,BAO_0000218,,
10137,,A,,,In vitro metabolic stability in rat hepatocytes,1,,,50597,10116.0,Intermediate,1,CHEMBL623156,BAO_0000218,,
10138,,A,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,1,,,50597,10116.0,Intermediate,1,CHEMBL623157,BAO_0000218,,
10139,Hepatocyte,A,401.0,In vitro,Metabolic rate for compound was observed in rat hepatocytes,1,,,50597,10116.0,Intermediate,1,CHEMBL623158,BAO_0000218,2107.0,
10140,,A,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,1,,,50597,10116.0,Intermediate,1,CHEMBL623159,BAO_0000218,,
10141,,A,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),1,,,50597,10116.0,Intermediate,1,CHEMBL874390,BAO_0000218,,
10142,,A,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),1,,,50597,10116.0,Intermediate,1,CHEMBL623160,BAO_0000218,,
10143,,A,,,Metabolism of compound in rat S9 microsomes; Trace,1,,,50597,10116.0,Intermediate,1,CHEMBL623161,BAO_0000218,,
10144,,A,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,1,,,50597,10116.0,Intermediate,1,CHEMBL623162,BAO_0000218,,
10145,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,1,,,50597,10116.0,Intermediate,1,CHEMBL623163,BAO_0000218,,
10146,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,1,,,50597,10116.0,Intermediate,1,CHEMBL623164,BAO_0000218,,
10147,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,1,,,50597,10116.0,Intermediate,1,CHEMBL623165,BAO_0000218,,
10148,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,1,,,50597,10116.0,Intermediate,1,CHEMBL623166,BAO_0000218,,
10149,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,1,,,50597,10116.0,Intermediate,1,CHEMBL624983,BAO_0000218,,
10150,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,1,,,50597,10116.0,Intermediate,1,CHEMBL624984,BAO_0000218,,
10151,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,1,,,50597,10116.0,Intermediate,1,CHEMBL624985,BAO_0000218,,
10152,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,1,,,50597,10116.0,Intermediate,1,CHEMBL622970,BAO_0000218,,
10153,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL622971,BAO_0000218,,
10154,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL622972,BAO_0000218,,
10155,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL622973,BAO_0000218,,
10156,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL622974,BAO_0000218,,
10157,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL622975,BAO_0000218,,
10158,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL622976,BAO_0000218,,
10159,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,1,,,50597,10116.0,Intermediate,1,CHEMBL622977,BAO_0000218,,
10160,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,,,50597,10116.0,Intermediate,1,CHEMBL624351,BAO_0000218,,
10161,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,1,,,50597,10116.0,Intermediate,1,CHEMBL624352,BAO_0000218,,
10162,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,,,50597,10116.0,Intermediate,1,CHEMBL624353,BAO_0000218,,
10163,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,1,,,50597,10116.0,Intermediate,1,CHEMBL622397,BAO_0000218,,
10164,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,1,,,50597,10116.0,Intermediate,1,CHEMBL622398,BAO_0000218,,
10165,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,1,,,50597,10116.0,Intermediate,1,CHEMBL622399,BAO_0000218,,
10166,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,,,50597,10116.0,Intermediate,1,CHEMBL622400,BAO_0000218,,
10167,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,,,50597,10116.0,Intermediate,1,CHEMBL628428,BAO_0000218,,
10168,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,1,,,50597,10116.0,Intermediate,1,CHEMBL628590,BAO_0000218,,
10169,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL628591,BAO_0000218,,
10170,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL628592,BAO_0000218,,
10171,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL628593,BAO_0000218,,
10172,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL875333,BAO_0000218,,
10173,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL628594,BAO_0000218,,
10174,,A,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL628595,BAO_0000218,1969.0,
10175,,A,,,Stability in rat plasma was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL628596,BAO_0000218,1969.0,
10176,,A,,,Stability in rat plasma was determined; ND= no data,1,,,50597,10116.0,Intermediate,1,CHEMBL628597,BAO_0000218,1969.0,
10177,,A,,,Tested for plasma half life period in rat (0-8 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL628598,BAO_0000218,1969.0,
10178,,A,,,Tested for plasma half life period in rat (0-8 hr); Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL628599,BAO_0000218,1969.0,
10179,,A,,In vivo,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628600,BAO_0000218,,
10180,,A,,In vivo,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628601,BAO_0000218,,
10181,,A,,,Tested for the half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628602,BAO_0000218,,
10182,,A,,In vitro,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,1,,,50597,10116.0,Intermediate,1,CHEMBL628603,BAO_0000218,,
10183,,A,,In vitro,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL628604,BAO_0000218,,
10184,,A,,In vitro,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,1,,,50597,10116.0,Intermediate,1,CHEMBL628605,BAO_0000218,,
10185,,A,,In vitro,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL628606,BAO_0000218,,
10186,,A,,In vitro,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,1,,,50597,10116.0,Intermediate,1,CHEMBL628607,BAO_0000218,,
10187,,A,,,The biological half life the compound was measured at the dose of 100 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628608,BAO_0000218,,
10188,,A,,,The biological half life the compound was measured at the dose of 30 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628609,BAO_0000218,,
10189,,A,,,The compound was evaluated for plasma half life period in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628610,BAO_0000218,1969.0,
10190,,A,,In vivo,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL873819,BAO_0000218,,
10191,,A,,In vivo,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL628611,BAO_0000218,,
10192,,A,,In vivo,The pharmacokinetic parameter half-life period in vivo in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628612,BAO_0000218,,
10193,,A,,In vivo,"The pharmacokinetic property, Half-life was determined",1,,,50597,10116.0,Intermediate,1,CHEMBL628613,BAO_0000218,,
10194,,A,,In vivo,"The pharmacokinetic property, Half-life in rat in vivo",1,,,50597,10116.0,Intermediate,1,CHEMBL628614,BAO_0000218,,
10195,,A,,In vivo,"The pharmacokinetic property, Half-life was determined; ND denotes no data",1,,,50597,10116.0,Intermediate,1,CHEMBL628615,BAO_0000218,,
10196,,A,,In vivo,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",1,,,50597,10116.0,Intermediate,1,CHEMBL628616,BAO_0000218,,
10197,,A,,,The plasma half life period in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627924,BAO_0000218,1969.0,
10198,,A,,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,1,,,50597,10116.0,Intermediate,1,CHEMBL627925,BAO_0000218,2107.0,
10199,,A,,In vivo,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627926,BAO_0000218,,
10200,,A,,,t1/2 (apparent elimination)of the compound was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL627927,BAO_0000218,,
10201,,A,,,t1/2 value in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627928,BAO_0000218,,
10202,,A,,,Half life in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627539,BAO_0000218,,
10203,,A,,In vivo,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,,,50597,10116.0,Intermediate,1,CHEMBL876790,BAO_0000218,1969.0,
10204,,A,,In vivo,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,1,,,50597,10116.0,Intermediate,1,CHEMBL858186,BAO_0000218,,
10205,,A,,,Half-life period in fasted rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627540,BAO_0000218,,
10206,,A,,In vivo,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627541,BAO_0000218,,
10207,,A,,In vivo,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627715,BAO_0000218,,
10208,,A,,In vivo,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627716,BAO_0000218,,
10209,,A,,,Maximum time required to achieve Cmax was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627717,BAO_0000218,,
10210,,A,,In vivo,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,50597,10116.0,Intermediate,1,CHEMBL627718,BAO_0000218,,
10211,,A,,In vivo,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,,50597,10116.0,Intermediate,1,CHEMBL627719,BAO_0000218,,
10212,,A,,In vivo,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,1,,,50597,10116.0,Intermediate,1,CHEMBL627720,BAO_0000218,,
10213,,A,,In vivo,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627721,BAO_0000218,,
10214,,A,,In vivo,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,1,,,50597,10116.0,Intermediate,1,CHEMBL627722,BAO_0000218,,
10215,,A,,In vivo,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627723,BAO_0000218,,
10216,,A,,In vivo,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626058,BAO_0000218,,
10217,,A,,In vivo,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626059,BAO_0000218,,
10218,,A,,In vivo,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626060,BAO_0000218,,
10219,,A,,In vivo,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626061,BAO_0000218,1969.0,
10220,,A,,In vivo,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL876791,BAO_0000218,,
10221,,A,,In vivo,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626062,BAO_0000218,,
10222,,A,,In vivo,Tmax at the dose of 2 mg/Kg administered perorally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626063,BAO_0000218,,
10223,,A,,In vivo,Tmax at the dose of 5 mg/Kg administered perorally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626064,BAO_0000218,,
10224,,A,,In vivo,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626065,BAO_0000218,1969.0,
10225,,A,,In vivo,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626066,BAO_0000218,1969.0,
10226,,A,,In vivo,tmax upon peroral administration of 10.0 mg/Kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626067,BAO_0000218,,
10227,,F,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,1,,,50597,10116.0,Intermediate,1,CHEMBL626068,BAO_0000218,,
10228,,F,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,1,,,50597,10116.0,Intermediate,1,CHEMBL626069,BAO_0000218,,
10229,,F,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,1,,,50597,10116.0,Intermediate,1,CHEMBL626070,BAO_0000218,,
10230,,F,,,Percent total excretion of N-methoxyacetaminophen glucuronide,1,,,50597,10116.0,Intermediate,1,CHEMBL626071,BAO_0000218,,
10231,,F,,,Percent total excretion of N-methoxyacetaminophen sulfate,1,,,50597,10116.0,Intermediate,1,CHEMBL626072,BAO_0000218,,
10232,,F,,,Percent total excretion of acetaminophen,1,,,50597,10116.0,Intermediate,1,CHEMBL626073,BAO_0000218,,
10233,,A,,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",1,,,50597,10116.0,Intermediate,1,CHEMBL626741,BAO_0000218,2046.0,
10234,,A,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",1,,,50597,10116.0,Intermediate,1,CHEMBL626742,BAO_0000218,,
10235,,A,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626743,BAO_0000218,,
10236,,A,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,,,50597,10116.0,Intermediate,1,CHEMBL876792,BAO_0000218,,
10237,,A,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626744,BAO_0000218,,
10238,,A,,,Compound was tested for antidiuretic activity in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626745,BAO_0000218,,
10239,,A,,In vivo,AUC in rat after 3mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626746,BAO_0000218,1969.0,
10240,,A,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626747,BAO_0000218,,
10241,,A,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626748,BAO_0000218,,
10242,,A,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626749,BAO_0000218,,
10243,,A,,,Oral Bioavailability was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626750,BAO_0000218,,
10244,,A,,,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626751,BAO_0000218,,
10245,,A,,,Oral bioavailability in rat; Not performed.,1,,,50597,10116.0,Intermediate,1,CHEMBL626913,BAO_0000218,,
10246,,A,,,Bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL626914,BAO_0000218,,
10247,,A,,,Bioavailability was determined; ND denotes no data,1,,,50597,10116.0,Intermediate,1,CHEMBL626915,BAO_0000218,,
10248,,A,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626916,BAO_0000218,,
10249,,A,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626917,BAO_0000218,,
10250,,A,,,Binding towards rat plasma protein at 10 uM,1,,,50597,10116.0,Intermediate,1,CHEMBL626918,BAO_0000218,,
10251,,A,,,Binding towards rat plasma protein at 100 uM,1,,,50597,10116.0,Intermediate,1,CHEMBL626919,BAO_0000218,,
10252,,A,,In vivo,Bioavailability in rat (dose 20 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL626920,BAO_0000218,,
10253,,A,,In vivo,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621976,BAO_0000218,,
10254,,A,,In vivo,Bioavailability in rat after 5 mg/kg oral gavage,1,,,50597,10116.0,Intermediate,1,CHEMBL877599,BAO_0000218,,
10255,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621977,BAO_0000218,,
10256,,A,,In vivo,Bioavailability in rat (dose 1 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL621978,BAO_0000218,,
10257,,A,,In vivo,Bioavailability in rat (dose 3 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL621979,BAO_0000218,,
10258,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621980,BAO_0000218,,
10259,,A,,In vivo,Bioavailability of the compound in rats after administration of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621981,BAO_0000218,,
10260,,A,,In vivo,Bioavailability after administration of 10 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621982,BAO_0000218,,
10261,,A,,In vivo,Bioavailability after administration of 2 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL882953,BAO_0000218,,
10262,,A,,In vivo,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621983,BAO_0000218,,
10263,,A,,In vivo,Bioavailability in dogs was determined; high,1,,,50597,10116.0,Intermediate,1,CHEMBL621984,BAO_0000218,,
10264,,A,,In vivo,Bioavailability in monkey after intravenous administration at 1 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL621985,BAO_0000218,,
10265,,A,,In vivo,Bioavailability in monkey after peroral administration at 10 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL621986,BAO_0000218,,
10266,,A,,In vivo,Bioavailability in rat after intravenous administration at 1 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL621987,BAO_0000218,,
10267,,F,,In vivo,Bioavailability in rat after intravenous administration at 2 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL877600,BAO_0000218,,
10268,,A,,In vivo,Bioavailability in rat after peroral administration at 30 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL621988,BAO_0000218,,
10269,,F,,In vivo,Bioavailability in rat after peroral administration at at 100 mpk,1,,,50597,10116.0,Intermediate,1,CHEMBL621989,BAO_0000218,,
10270,,A,,In vivo,Bioavailability in rats was evaluated,1,,,50597,10116.0,Intermediate,1,CHEMBL621990,BAO_0000218,,
10271,,A,,In vivo,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621991,BAO_0000218,,
10272,,A,,In vivo,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621992,BAO_0000218,,
10273,,A,,In vivo,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621993,BAO_0000218,,
10274,,A,,In vivo,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL621994,BAO_0000218,,
10275,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621995,BAO_0000218,,
10276,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621996,BAO_0000218,,
10277,,A,,In vivo,Oral bioavailability in rat (dose 10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL621997,BAO_0000218,,
10278,,A,,In vivo,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL621998,BAO_0000218,,
10279,,A,,In vivo,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621999,BAO_0000218,,
10280,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622000,BAO_0000218,,
10281,,A,,In vivo,Bioavailability was measured in rat after oral administration; 2-4,1,,,50597,10116.0,Intermediate,1,CHEMBL622001,BAO_0000218,,
10282,,A,,In vivo,Bioavailability was measured in rat after oral administration; 3-7,1,,,50597,10116.0,Intermediate,1,CHEMBL622002,BAO_0000218,,
10283,,A,,In vivo,Bioavailability in rat (intraduodenal administration),1,,,50597,10116.0,Intermediate,1,CHEMBL622003,BAO_0000218,,
10284,,A,,In vivo,Bioavailability in rat (intraduodenal administration),1,,,50597,10116.0,Intermediate,1,CHEMBL877601,BAO_0000218,,
10285,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624871,BAO_0000218,,
10286,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622004,BAO_0000218,,
10287,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL882954,BAO_0000218,,
10288,,A,,In vivo,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,1,,,50597,10116.0,Intermediate,1,CHEMBL622005,BAO_0000218,,
10289,,A,,In vivo,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622006,BAO_0000218,,
10290,,A,,In vivo,Bioavailability was measured in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622007,BAO_0000218,,
10291,,A,,In vivo,Bioavailability was reported,1,,,50597,10116.0,Intermediate,1,CHEMBL622008,BAO_0000218,,
10292,,A,,In vivo,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL622009,BAO_0000218,,
10293,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622010,BAO_0000218,,
10294,,A,,In vivo,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622011,BAO_0000218,,
10295,,A,,In vivo,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL622012,BAO_0000218,,
10296,,A,,In vivo,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),1,,,50597,10116.0,Intermediate,1,CHEMBL622013,BAO_0000218,,
10297,,A,,In vivo,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622014,BAO_0000218,,
10298,,A,,In vivo,Bioavailability was determined at 3 mg/kg po dose in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624749,BAO_0000218,,
10299,,A,,In vivo,Oral bioavailability in rat (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL624750,BAO_0000218,,
10300,,A,,In vivo,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL624751,BAO_0000218,,
10301,,A,,In vivo,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,,50597,10116.0,Intermediate,1,CHEMBL624752,BAO_0000218,,
10302,,A,,In vivo,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,,,50597,10116.0,Intermediate,1,CHEMBL624753,BAO_0000218,,
10303,,A,,In vivo,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624754,BAO_0000218,,
10304,,A,,In vivo,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,,,50597,10116.0,Intermediate,1,CHEMBL624755,BAO_0000218,,
10305,,A,,In vivo,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624756,BAO_0000218,,
10306,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624757,BAO_0000218,,
10307,,A,,In vivo,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,,,50597,10116.0,Intermediate,1,CHEMBL624758,BAO_0000218,,
10308,,A,,In vivo,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622270,BAO_0000218,,
10309,,A,,In vivo,Bioavailability in rat (Sprague-Dawley),1,,,50597,10116.0,Intermediate,1,CHEMBL622271,BAO_0000218,,
10310,,A,,In vivo,Bioavailability in rat at the dose of 2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622272,BAO_0000218,,
10311,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622273,BAO_0000218,,
10312,,A,,In vivo,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622274,BAO_0000218,,
10313,,A,,In vivo,Bioavailability value of compound in rats was determined after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622275,BAO_0000218,,
10314,,A,,In vivo,Oral bioavailability in rat (dose 20 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622276,BAO_0000218,,
10315,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622277,BAO_0000218,,
10316,,A,,In vivo,Oral bioavailability in rat (dose 5 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622278,BAO_0000218,,
10317,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622279,BAO_0000218,,
10318,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622280,BAO_0000218,,
10319,,A,,In vivo,Compound was evaluated for oral bioavailability in rats; 15-27 %,1,,,50597,10116.0,Intermediate,1,CHEMBL624083,BAO_0000218,,
10320,,A,,In vivo,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,1,,,50597,10116.0,Intermediate,1,CHEMBL624084,BAO_0000218,,
10321,,A,,In vivo,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),1,,,50597,10116.0,Intermediate,1,CHEMBL624085,BAO_0000218,,
10322,,A,,In vivo,Compound was tested for bioavailability in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624086,BAO_0000218,,
10323,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624087,BAO_0000218,,
10324,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624088,BAO_0000218,,
10325,,A,,In vivo,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,0,,,22224,9544.0,Intermediate,1,CHEMBL624089,BAO_0000218,,
10326,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),0,,,22224,10116.0,Intermediate,1,CHEMBL624090,BAO_0000218,,
10327,,A,,In vivo,Evaluated for the bioavailability in rat (in vivo),1,,,50597,10116.0,Intermediate,1,CHEMBL624091,BAO_0000218,,
10328,,A,,In vivo,F value of compound in rats was determined after peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624092,BAO_0000218,,
10329,,A,,In vivo,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624093,BAO_0000218,,
10330,,A,,In vivo,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624094,BAO_0000218,,
10331,,A,,In vivo,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624095,BAO_0000218,,
10332,,A,,In vivo,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624096,BAO_0000218,,
10333,,A,,In vivo,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",1,,,50597,10116.0,Intermediate,1,CHEMBL624097,BAO_0000218,,
10334,,A,,In vivo,Maximum fall in carotid flow in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624098,BAO_0000218,,
10335,,A,,In vivo,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL874392,BAO_0000218,,
10336,,A,,In vivo,Oral bioavailability in rat (dose 5 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL624099,BAO_0000218,,
10337,,A,,In vivo,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624100,BAO_0000218,,
10338,,A,,In vivo,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624101,BAO_0000218,,
10339,,A,,In vivo,Oral bioavailability in rat (male Wistar),1,,,50597,10116.0,Intermediate,1,CHEMBL624102,BAO_0000218,,
10340,,A,,In vivo,Oral bioavailability after administration (30 mg/kg) in rat; good,1,,,50597,10116.0,Intermediate,1,CHEMBL624103,BAO_0000218,,
10341,,A,,In vivo,Oral bioavailability at the dose of 2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624104,BAO_0000218,,
10342,,A,,In vivo,Oral bioavailability determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624105,BAO_0000218,,
10343,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL624106,BAO_0000218,,
10344,,A,,In vivo,Oral bioavailability in rat (dose single 10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL624107,BAO_0000218,,
10345,,A,,In vivo,Oral bioavailability in rat (dose single 10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL623943,BAO_0000218,,
10346,,A,,In vivo,Oral bioavailability in rat (dose 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623944,BAO_0000218,,
10347,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL623945,BAO_0000218,,
10348,,A,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,1,,,50597,10116.0,Intermediate,1,CHEMBL623946,BAO_0000218,,
10349,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,1,,,50597,10116.0,Intermediate,1,CHEMBL623947,BAO_0000218,,
10350,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,1,,,50597,10116.0,Intermediate,1,CHEMBL623948,BAO_0000218,,
10351,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,1,,,50597,10116.0,Intermediate,1,CHEMBL623949,BAO_0000218,,
10352,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,1,,,50597,10116.0,Intermediate,1,CHEMBL623950,BAO_0000218,,
10353,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,1,,,50597,10116.0,Intermediate,1,CHEMBL874398,BAO_0000218,,
10354,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,1,,,50597,10116.0,Intermediate,1,CHEMBL623951,BAO_0000218,,
10355,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,1,,,50597,10116.0,Intermediate,1,CHEMBL623952,BAO_0000218,,
10356,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,1,,,50597,10116.0,Intermediate,1,CHEMBL623953,BAO_0000218,,
10357,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL623954,BAO_0000218,,
10358,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL623955,BAO_0000218,,
10359,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL623956,BAO_0000218,,
10360,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL627807,BAO_0000218,,
10361,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL627808,BAO_0000218,,
10362,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL627809,BAO_0000218,,
10363,,A,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,1,,,50597,10116.0,Intermediate,1,CHEMBL627810,BAO_0000218,,
10364,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",1,,,50597,10116.0,Intermediate,1,CHEMBL627811,BAO_0000218,,
10365,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",1,,,50597,10116.0,Intermediate,1,CHEMBL627812,BAO_0000218,,
10366,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",1,,,50597,10116.0,Intermediate,1,CHEMBL627813,BAO_0000218,,
10367,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",1,,,50597,10116.0,Intermediate,1,CHEMBL627814,BAO_0000218,,
10368,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",1,,,50597,10116.0,Intermediate,1,CHEMBL875336,BAO_0000218,,
10369,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",1,,,50597,10116.0,Intermediate,1,CHEMBL627815,BAO_0000218,,
10370,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",1,,,50597,10116.0,Intermediate,1,CHEMBL627816,BAO_0000218,,
10371,,A,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",1,,,50597,10116.0,Intermediate,1,CHEMBL627817,BAO_0000218,,
10372,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",1,,,50597,10116.0,Intermediate,1,CHEMBL627818,BAO_0000218,,
10373,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",1,,,50597,10116.0,Intermediate,1,CHEMBL627819,BAO_0000218,,
10374,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",1,,,50597,10116.0,Intermediate,1,CHEMBL627820,BAO_0000218,,
10375,,A,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",1,,,50597,10116.0,Intermediate,1,CHEMBL627821,BAO_0000218,,
10376,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,,,50597,10116.0,Intermediate,1,CHEMBL628464,BAO_0000218,,
10377,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,1,,,50597,10116.0,Intermediate,1,CHEMBL626239,BAO_0000218,,
10378,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,1,,,50597,10116.0,Intermediate,1,CHEMBL626240,BAO_0000218,,
10379,,A,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,1,,,50597,10116.0,Intermediate,1,CHEMBL626241,BAO_0000218,,
10380,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,1,,,50597,10116.0,Intermediate,1,CHEMBL626242,BAO_0000218,,
10381,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,1,,,50597,10116.0,Intermediate,1,CHEMBL626243,BAO_0000218,,
10382,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,,,50597,10116.0,Intermediate,1,CHEMBL626244,BAO_0000218,,
10383,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL626907,BAO_0000218,,
10384,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL626908,BAO_0000218,,
10385,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL626909,BAO_0000218,,
10386,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,,,50597,10116.0,Intermediate,1,CHEMBL626910,BAO_0000218,,
10387,,F,,,Percent total excretion of acetaminophen cysteine conjugate,1,,,50597,10116.0,Intermediate,1,CHEMBL875342,BAO_0000218,,
10388,,F,,,Percent total excretion of acetaminophen glucuronide,1,,,50597,10116.0,Intermediate,1,CHEMBL626911,BAO_0000218,,
10389,,F,,,Percent total excretion of acetaminophen sulfate,1,,,50597,10116.0,Intermediate,1,CHEMBL626912,BAO_0000218,,
10390,,F,,,Percent total excretion of acetaminophen-mercapturic acid,1,,,50597,10116.0,Intermediate,1,CHEMBL627065,BAO_0000218,,
10391,,A,,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1,,,50597,10116.0,Intermediate,1,CHEMBL627066,BAO_0000218,1088.0,
10392,,A,,In vivo,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627067,BAO_0000218,,
10393,,A,,In vivo,Biodistribution of compound in rat muscle after 5 min of administration,0,,,22224,8656.0,Autocuration,1,CHEMBL627068,BAO_0000218,2385.0,
10394,,A,,In vivo,Biodistribution of compound in rat muscle after 5 min of administration.,0,,,22224,8656.0,Autocuration,1,CHEMBL627069,BAO_0000218,2385.0,
10395,,A,,In vivo,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),0,,,22224,9940.0,Autocuration,1,CHEMBL627070,BAO_0000218,,
10396,,A,,In vivo,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),0,,,22224,9940.0,Autocuration,1,CHEMBL627071,BAO_0000218,,
10397,,A,,In vivo,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),0,,,22224,9940.0,Autocuration,1,CHEMBL627072,BAO_0000218,,
10398,,A,,In vivo,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),0,,,22224,9940.0,Autocuration,1,CHEMBL627073,BAO_0000218,,
10399,,A,,In vivo,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),0,,,22224,9940.0,Autocuration,1,CHEMBL625387,BAO_0000218,,
10400,,A,,In vivo,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),0,,,22224,9940.0,Autocuration,1,CHEMBL625388,BAO_0000218,,
10401,,A,,In vivo,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),0,,,22224,9940.0,Autocuration,1,CHEMBL625389,BAO_0000218,1969.0,
10402,,A,,In vivo,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),0,,,22224,9940.0,Autocuration,1,CHEMBL875343,BAO_0000218,1969.0,
10403,,A,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),1,,,50497,8570.0,Intermediate,1,CHEMBL876795,BAO_0000218,,
10404,,A,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,1,,,50497,8570.0,Intermediate,1,CHEMBL626552,BAO_0000218,,
10405,,A,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,1,,,50497,8570.0,Intermediate,1,CHEMBL626553,BAO_0000218,,
10406,,A,,,The human biological plasma half life of the compound,0,,,22224,9606.0,Autocuration,1,CHEMBL626554,BAO_0000366,1969.0,
10407,,A,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626555,BAO_0000218,1088.0,
10408,,A,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626556,BAO_0000218,,
10409,,A,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626557,BAO_0000218,,
10410,,A,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626558,BAO_0000218,,
10411,,A,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626559,BAO_0000218,,
10412,,A,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626560,BAO_0000218,,
10413,,A,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL876803,BAO_0000218,,
10414,,A,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627964,BAO_0000218,,
10415,,A,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627965,BAO_0000218,,
10416,,A,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627966,BAO_0000218,,
10417,,A,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627967,BAO_0000218,,
10418,,A,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627968,BAO_0000218,,
10419,,A,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627969,BAO_0000218,,
10420,,A,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627970,BAO_0000218,,
10421,,A,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627971,BAO_0000218,178.0,
10422,,A,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627972,BAO_0000218,178.0,
10423,,B,,,Dissociation constant against binding to human cyclophilin A,9,,,180,9606.0,Expert,1,CHEMBL856029,BAO_0000357,,
10424,,B,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,8,,,11591,9913.0,Expert,1,CHEMBL627973,BAO_0000019,,
10425,,A,,,-Log C was determined by performing the electroshock minimum test,0,,,22224,,Autocuration,1,CHEMBL627974,BAO_0000019,,
10426,,A,,,-Log C was determined by performing the foot shock test,0,,,22224,,Autocuration,1,CHEMBL627975,BAO_0000019,,
10427,,A,,,-Log C was determined by performing the incl screen test,0,,,22224,,Autocuration,1,CHEMBL627976,BAO_0000019,,
10428,,A,,,-Log C was determined by performing the maximum electroshock test,0,,,22224,,Autocuration,1,CHEMBL627977,BAO_0000019,,
10429,,A,,,-Log C was determined by performing the pentylenetetrazole test,0,,,22224,,Autocuration,1,CHEMBL627978,BAO_0000019,,
10430,,A,,,Tested for experimental arotinoid inhibitory dose,0,,,22224,,Autocuration,1,CHEMBL627979,BAO_0000019,,
10431,,A,,,Negative log transformed activity,0,,,22224,,Autocuration,1,CHEMBL876804,BAO_0000019,,
10432,,A,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",0,,,22224,,Autocuration,1,CHEMBL627980,BAO_0000019,,
10433,,A,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,1,,,50512,10141.0,Intermediate,1,CHEMBL627981,BAO_0000218,,
10434,,A,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,1,,,50512,10141.0,Intermediate,1,CHEMBL627982,BAO_0000218,,
10435,,A,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,1,,,50512,10141.0,Intermediate,1,CHEMBL627983,BAO_0000218,,
10436,,A,,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,1,,,50512,10141.0,Intermediate,1,CHEMBL627984,BAO_0000218,2116.0,
10437,,P,,,Solubility in water was determined; values expressed as -log,0,,,22229,,Autocuration,1,CHEMBL627985,BAO_0000100,,
10438,,A,,,Ratio of Kcat to that of Km was determined,0,,,22224,,Autocuration,1,CHEMBL627986,BAO_0000019,,
10439,,A,,,Observed first order rate constant,0,,,22224,,Autocuration,1,CHEMBL627987,BAO_0000019,,
10440,,A,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,0,,,22224,,Autocuration,1,CHEMBL627988,BAO_0000019,,
10441,,A,,In vivo,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627989,BAO_0000218,,
10442,,A,,In vivo,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627990,BAO_0000218,,
10443,,A,,In vivo,Oral Bioavailability after administration of 10 mg/kg in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL876805,BAO_0000218,,
10444,,A,,In vivo,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL627991,BAO_0000218,,
10445,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627992,BAO_0000218,,
10446,,A,,In vivo,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627993,BAO_0000218,,
10447,,A,,In vivo,Oral bioavailability at 1 mg/kg was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622817,BAO_0000218,,
10448,,A,,In vivo,Oral bioavailability at 10 mg/kg was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622818,BAO_0000218,,
10449,,A,,In vivo,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",1,,,50597,10116.0,Intermediate,1,CHEMBL622819,BAO_0000218,,
10450,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL872267,BAO_0000218,,
10451,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622820,BAO_0000218,,
10452,,A,,In vivo,Oral bioavailability after intravenous administration in rats at 24 uM/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622821,BAO_0000218,,
10453,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622822,BAO_0000218,,
10454,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622823,BAO_0000218,,
10455,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622824,BAO_0000218,,
10456,,A,,In vivo,Oral bioavailability in rat at a dose of 3 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622825,BAO_0000218,,
10457,,A,,In vivo,Oral bioavailability in rat after oral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622901,BAO_0000218,,
10458,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622902,BAO_0000218,,
10459,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621844,BAO_0000218,,
10460,,A,,In vivo,Oral bioavailability in Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL621845,BAO_0000218,,
10461,,A,,In vivo,Oral bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL621846,BAO_0000218,,
10462,,A,,In vivo,Oral bioavailability in rat (dose 30 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL621847,BAO_0000218,,
10463,,A,,In vivo,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,,,50597,10116.0,Intermediate,1,CHEMBL877609,BAO_0000218,,
10464,,A,,In vivo,Bioavailability in rat (dose 3 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL621848,BAO_0000218,,
10465,,A,,In vivo,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,,,50597,10116.0,Intermediate,1,CHEMBL621849,BAO_0000218,,
10466,,A,,In vivo,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL622030,BAO_0000218,,
10467,,A,,In vivo,Percent oral bioavailability determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622031,BAO_0000218,,
10468,,A,,In vivo,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622032,BAO_0000218,,
10469,,A,,In vivo,The compound was evaluated for bioavailability in rats; 32-51,1,,,50597,10116.0,Intermediate,1,CHEMBL622033,BAO_0000218,,
10470,,A,,In vivo,Bioavailability in rat (dose 20 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL622034,BAO_0000218,,
10471,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622035,BAO_0000218,,
10472,,A,,In vivo,Bioavailability percent in rat at the dose of 2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL882966,BAO_0000218,,
10473,,A,,In vivo,Bioavailability was evaluated after 20 uM/kg of peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622036,BAO_0000218,,
10474,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622037,BAO_0000218,,
10475,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622038,BAO_0000218,,
10476,,A,,In vivo,Bioavailability in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622039,BAO_0000218,,
10477,,A,,In vivo,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622040,BAO_0000218,178.0,
10478,,A,,In vivo,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622041,BAO_0000218,178.0,
10479,,A,,In vivo,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622042,BAO_0000218,178.0,
10480,,A,,In vivo,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622043,BAO_0000218,178.0,
10481,,A,,In vivo,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622044,BAO_0000218,178.0,
10482,,A,,In vivo,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622045,BAO_0000218,10000001.0,
10483,,A,,In vivo,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622046,BAO_0000218,10000001.0,
10484,,A,,In vivo,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622047,BAO_0000218,10000001.0,
10485,,A,,In vivo,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL877610,BAO_0000218,10000001.0,
10486,,A,,In vivo,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622048,BAO_0000218,955.0,
10487,,A,,In vivo,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622049,BAO_0000218,955.0,
10488,,A,,In vivo,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622050,BAO_0000218,955.0,
10489,,A,,In vivo,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622051,BAO_0000218,955.0,
10490,,A,,In vivo,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622052,BAO_0000218,,
10491,,A,,In vivo,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622053,BAO_0000218,,
10492,,A,,In vivo,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622054,BAO_0000218,,
10493,,A,,In vivo,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622055,BAO_0000218,,
10494,,A,,In vivo,Oral bioavailability in rats was determined; High,1,,,50597,10116.0,Intermediate,1,CHEMBL622056,BAO_0000218,,
10495,,A,,In vivo,Oral bioavailability in the rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622057,BAO_0000218,,
10496,,A,,In vivo,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628008,BAO_0000218,,
10497,,A,,In vivo,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL622058,BAO_0000218,,
10498,,A,,In vivo,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622059,BAO_0000218,,
10499,,A,,In vivo,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622060,BAO_0000218,,
10500,,A,,In vivo,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622061,BAO_0000218,,
10501,,A,,In vivo,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622062,BAO_0000218,,
10502,,A,,In vivo,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622063,BAO_0000218,,
10503,,A,,In vivo,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL877611,BAO_0000218,,
10504,,A,,In vivo,Oral bioavailability of compound in Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622064,BAO_0000218,,
10505,,A,,In vivo,Oral bioavailability of compound in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622065,BAO_0000218,,
10506,,A,,In vivo,Oral bioavailability in rat (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622066,BAO_0000218,,
10507,,A,,In vivo,Oral bioavailability of compound in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622067,BAO_0000218,,
10508,,A,,In vivo,Oral bioavailability of compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622068,BAO_0000218,,
10509,,A,,In vivo,Oral bioavailability of compound was determined in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622069,BAO_0000218,,
10510,,A,,In vivo,Oral bioavailability at a dose of 30 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624796,BAO_0000218,,
10511,,A,,In vivo,Oral bioavailability in rat (dose 10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL624797,BAO_0000218,,
10512,,A,,In vivo,Oral bioavailability in rat (dose 10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL623053,BAO_0000218,,
10513,,A,,In vivo,Oral bioavailability evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623054,BAO_0000218,,
10514,,A,,In vivo,Oral bioavailability in fasted rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623055,BAO_0000218,,
10515,,A,,In vivo,Oral bioavailability in fed rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623056,BAO_0000218,,
10516,,A,,In vivo,Oral bioavailability in rat (mature male) (dose 30 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL623057,BAO_0000218,,
10517,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623058,BAO_0000218,,
10518,,A,,In vivo,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL623059,BAO_0000218,,
10519,,A,,In vivo,Oral bioavailability in rat after administration of 10 mg/kg po,1,,,50597,10116.0,Intermediate,1,CHEMBL623060,BAO_0000218,,
10520,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623061,BAO_0000218,,
10521,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623062,BAO_0000218,,
10522,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623063,BAO_0000218,,
10523,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623064,BAO_0000218,,
10524,,A,,In vivo,Oral bioavailability in ratrs,1,,,50597,10116.0,Intermediate,1,CHEMBL623065,BAO_0000218,,
10525,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623066,BAO_0000218,,
10526,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623067,BAO_0000218,,
10527,,A,,In vivo,Oral bioavailability in rats was determined; High,1,,,50597,10116.0,Intermediate,1,CHEMBL623068,BAO_0000218,,
10528,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623069,BAO_0000218,,
10529,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623070,BAO_0000218,,
10530,,A,,In vivo,Oral bioavailability was calculated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623071,BAO_0000218,,
10531,,A,,In vivo,Oral bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL623072,BAO_0000218,,
10532,,A,,In vivo,Oral bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL623073,BAO_0000218,,
10533,,A,,In vivo,Oral bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL623074,BAO_0000218,,
10534,,A,,In vivo,Oral bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL623075,BAO_0000218,,
10535,,A,,In vivo,Oral bioavailability after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623076,BAO_0000218,,
10536,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL623077,BAO_0000218,,
10537,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley),1,,,50597,10116.0,Intermediate,1,CHEMBL623078,BAO_0000218,,
10538,,A,,In vivo,Oral bioavailability in Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623079,BAO_0000218,,
10539,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL623080,BAO_0000218,,
10540,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL623081,BAO_0000218,,
10541,,A,,In vivo,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623082,BAO_0000218,,
10542,,A,,In vivo,Oral bioavailability in fasted rat,1,,,50597,10116.0,Intermediate,1,CHEMBL874400,BAO_0000218,,
10543,,A,,In vivo,Oral bioavailability in fed rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623083,BAO_0000218,,
10544,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623084,BAO_0000218,,
10545,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623085,BAO_0000218,,
10546,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623086,BAO_0000218,,
10547,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623087,BAO_0000218,,
10548,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623088,BAO_0000218,,
10549,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623089,BAO_0000218,,
10550,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623090,BAO_0000218,,
10551,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623091,BAO_0000218,,
10552,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623092,BAO_0000218,,
10553,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623093,BAO_0000218,,
10554,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL874401,BAO_0000218,,
10555,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623094,BAO_0000218,,
10556,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623095,BAO_0000218,,
10557,,A,,In vivo,Oral bioavailability in rat after peroral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623096,BAO_0000218,,
10558,,A,,In vivo,Oral bioavailability in rat after peroral administration at 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624913,BAO_0000218,,
10559,,A,,In vivo,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL624914,BAO_0000218,,
10560,,A,,In vivo,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624915,BAO_0000218,,
10561,,A,,In vivo,Oral bioavailability in rat; Not measured,1,,,50597,10116.0,Intermediate,1,CHEMBL624916,BAO_0000218,,
10562,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624917,BAO_0000218,,
10563,,A,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,1,,,50597,10116.0,Intermediate,1,CHEMBL625157,BAO_0000218,,
10564,,A,,,In vitro metabolic potential in rat liver microsomes,1,,,50597,10116.0,Intermediate,1,CHEMBL625158,BAO_0000218,2107.0,
10565,,A,,In vivo,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",1,,,50597,10116.0,Intermediate,1,CHEMBL625159,BAO_0000218,,
10566,,A,,In vivo,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",1,,,50597,10116.0,Intermediate,1,CHEMBL625160,BAO_0000218,,
10567,,A,,In vivo,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625161,BAO_0000218,,
10568,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625162,BAO_0000218,,
10569,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625163,BAO_0000218,,
10570,,A,,In vivo,Oral bioavailability in rats at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625164,BAO_0000218,,
10571,,A,,In vivo,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625165,BAO_0000218,,
10572,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625166,BAO_0000218,,
10573,,A,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,1,,,50597,10116.0,Intermediate,1,CHEMBL625167,BAO_0000218,,
10574,,A,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL625168,BAO_0000218,,
10575,,A,,In vivo,Plasma clearance of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL625169,BAO_0000218,,
10576,,A,,In vivo,Plasma clearance at 10 mg/kg in rat upon intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626264,BAO_0000218,,
10577,,A,,In vivo,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626265,BAO_0000218,,
10578,,A,,In vivo,The compound was tested for plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626266,BAO_0000218,1969.0,
10579,,A,,In vivo,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1,,,50597,10116.0,Intermediate,1,CHEMBL626267,BAO_0000218,1969.0,
10580,,A,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626268,BAO_0000218,,
10581,,A,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,1,,,50597,10116.0,Intermediate,1,CHEMBL626269,BAO_0000218,,
10582,,A,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,1,,,50597,10116.0,Intermediate,1,CHEMBL626270,BAO_0000218,,
10583,,A,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626271,BAO_0000218,,
10584,,A,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",1,,,50597,10116.0,Intermediate,1,CHEMBL626272,BAO_0000218,,
10585,,A,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,,,50597,10116.0,Intermediate,1,CHEMBL626273,BAO_0000218,,
10586,,A,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,,,50597,10116.0,Intermediate,1,CHEMBL875346,BAO_0000218,,
10587,,A,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",1,,,50597,10116.0,Intermediate,1,CHEMBL626274,BAO_0000218,,
10588,,A,,,Compound was tested for protein binding in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL626275,BAO_0000218,,
10589,,A,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,1,,,50597,10116.0,Intermediate,1,CHEMBL624646,BAO_0000218,,
10590,,A,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624647,BAO_0000218,,
10591,,A,,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,1,,,50597,10116.0,Intermediate,1,CHEMBL624648,BAO_0000218,2107.0,
10592,,A,,,Area under curve ratio was determined (po/iv) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624649,BAO_0000218,,
10593,,A,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624650,BAO_0000218,,
10594,,A,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624651,BAO_0000218,,
10595,,A,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624652,BAO_0000218,,
10596,,A,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624653,BAO_0000218,,
10597,,A,,,Ratio of AUCbrain to AUCplasma,1,,,50597,10116.0,Intermediate,1,CHEMBL624654,BAO_0000218,,
10598,,A,,,Ratio of brain to plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL624655,BAO_0000218,,
10599,,A,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,1,,,50597,10116.0,Intermediate,1,CHEMBL624656,BAO_0000218,,
10600,,A,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,,,50597,10116.0,Intermediate,1,CHEMBL624657,BAO_0000218,,
10601,,A,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,,,50597,10116.0,Intermediate,1,CHEMBL624658,BAO_0000218,,
10602,,A,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,1,,,50597,10116.0,Intermediate,1,CHEMBL624659,BAO_0000218,,
10603,,A,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,1,,,50597,10116.0,Intermediate,1,CHEMBL624660,BAO_0000218,,
10604,,A,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,1,,,50597,10116.0,Intermediate,1,CHEMBL624661,BAO_0000218,,
10605,,A,,,Steady state brain :blood ratio was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL624662,BAO_0000218,,
10606,,A,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625199,BAO_0000218,,
10607,,A,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625200,BAO_0000218,,
10608,,A,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625201,BAO_0000218,,
10609,,A,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625202,BAO_0000218,,
10610,,A,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625203,BAO_0000218,,
10611,,A,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,1,,,50597,10116.0,Intermediate,1,CHEMBL625204,BAO_0000218,,
10612,,A,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,1,,,50597,10116.0,Intermediate,1,CHEMBL625205,BAO_0000218,,
10613,,A,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625206,BAO_0000218,,
10614,,A,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",0,,,22224,,Autocuration,1,CHEMBL625207,BAO_0000019,,
10615,,A,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,0,,,22224,,Autocuration,1,CHEMBL625208,BAO_0000019,,
10616,Caco-2,A,495.0,,In vivo absorption in Caco-2 cell line monolayers was determined,1,,,50587,9606.0,Intermediate,1,CHEMBL625209,BAO_0000218,,
10617,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625210,BAO_0000100,,
10618,,A,,,Area under curve was determine after peroral administration at 10 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625211,BAO_0000218,,
10619,,A,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,,,50797,9544.0,Intermediate,1,CHEMBL625212,BAO_0000218,,
10620,,A,,,Area under curve was determine after peroral administration at 160 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625213,BAO_0000218,,
10621,,A,,,Area under curve was determine after peroral administration at 20 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625214,BAO_0000218,,
10622,,A,,,Area under curve was determine after peroral administration at 50 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL874542,BAO_0000218,,
10623,,P,,,Calculated partition coefficient (clogP) (AlogP),0,,,22229,,Autocuration,1,CHEMBL625215,BAO_0000100,,
10624,,A,,,Activated partial thromboplastin time measured,0,,,22224,,Autocuration,1,CHEMBL625216,BAO_0000019,,
10625,,P,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),0,,,22224,,Autocuration,1,CHEMBL625217,BAO_0000100,,
10626,,P,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),0,,,22224,,Autocuration,1,CHEMBL625218,BAO_0000100,,
10627,,A,,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622864,BAO_0000218,1969.0,
10628,,A,,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL622865,BAO_0000218,1969.0,
10629,,A,,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL622866,BAO_0000218,1969.0,
10630,,A,,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622867,BAO_0000218,1969.0,
10631,,A,,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1,,,50512,10141.0,Intermediate,1,CHEMBL876808,BAO_0000218,1969.0,
10632,,A,,,AUC in brain,0,,,22224,,Autocuration,1,CHEMBL627725,BAO_0000019,955.0,
10633,,A,,,AUC in serum,0,,,22224,,Autocuration,1,CHEMBL627726,BAO_0000019,1977.0,
10634,,A,,,AUC was determined,0,,,22224,,Autocuration,1,CHEMBL627727,BAO_0000019,1969.0,
10635,,A,,,AUC of the compound.,0,,,22224,,Autocuration,1,CHEMBL627728,BAO_0000019,1969.0,
10636,,A,,,AUC value (0-4 hr),0,,,22224,,Autocuration,1,CHEMBL627729,BAO_0000019,1969.0,
10637,,A,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",0,,,22224,,Autocuration,1,CHEMBL627730,BAO_0000019,1969.0,
10638,,A,,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,0,,,22224,,Autocuration,1,CHEMBL627731,BAO_0000019,1969.0,
10639,,A,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",0,,,22224,,Autocuration,1,CHEMBL627732,BAO_0000019,1969.0,
10640,,A,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",0,,,22224,,Autocuration,1,CHEMBL627733,BAO_0000019,1969.0,
10641,,A,,,AUC(area under curve) was determined after intravenous administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627734,BAO_0000218,1969.0,
10642,,A,,,AUC(area under curve) was determined after oral administration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627735,BAO_0000218,1969.0,
10643,,A,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1,,,50512,10141.0,Intermediate,1,CHEMBL627736,BAO_0000218,1969.0,
10644,,A,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL876809,BAO_0000218,1969.0,
10645,,A,,,Area Under Curve after oral dosing of 100 uM/Kg,0,,,22224,,Autocuration,1,CHEMBL627737,BAO_0000019,,
10646,,A,,,Area Under Curve after oral dosing of 30 uM/Kg,0,,,22224,,Autocuration,1,CHEMBL627738,BAO_0000019,,
10647,,A,,,Area Under Curve was measured by ploting the graph between concentration verses time,0,,,22224,,Autocuration,1,CHEMBL627739,BAO_0000019,,
10648,,A,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,1,,,50588,9615.0,Intermediate,1,CHEMBL626143,BAO_0000218,,
10649,,A,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,0,,,22224,314293.0,Autocuration,1,CHEMBL626144,BAO_0000218,,
10650,,A,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,1,,,50592,9986.0,Intermediate,1,CHEMBL626145,BAO_0000218,,
10651,,A,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,1,,,50597,10116.0,Intermediate,1,CHEMBL626146,BAO_0000218,,
10652,,A,,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,1,,,50597,10116.0,Intermediate,1,CHEMBL626147,BAO_0000218,178.0,
10653,,A,,,Area under curve (AUC) was determined,0,,,22224,,Autocuration,1,CHEMBL626148,BAO_0000019,,
10654,,A,,,Area under curve (AUC) following ip administration at 1 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626149,BAO_0000218,,
10655,,A,,,Area under curve (AUC) was determined; ND is Not determined,0,,,22224,,Autocuration,1,CHEMBL626150,BAO_0000019,,
10656,,A,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,1,,,50588,9615.0,Intermediate,1,CHEMBL626151,BAO_0000218,,
10657,,A,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,1,,,50588,9615.0,Intermediate,1,CHEMBL626152,BAO_0000218,,
10658,,A,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,1,,,50588,9615.0,Intermediate,1,CHEMBL626153,BAO_0000218,,
10659,,A,,,Area under curve (AUR) was determined,0,,,22224,,Autocuration,1,CHEMBL626154,BAO_0000019,,
10660,,A,,,Area under curve at 1 uM/dg administered intravenously,0,,,22224,,Autocuration,1,CHEMBL626155,BAO_0000019,,
10661,,A,,,Area under curve at 10 uM/dg administered perorally,0,,,22224,,Autocuration,1,CHEMBL626156,BAO_0000019,,
10662,,A,,,Area under curve at 2 uM/dg administered intravenously,0,,,22224,,Autocuration,1,CHEMBL626157,BAO_0000019,,
10663,,A,,,Area under curve at 20 uM/dg administered perorally,0,,,22224,,Autocuration,1,CHEMBL626158,BAO_0000019,,
10664,,A,,,Area under curve at a peroral dose of 3 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626159,BAO_0000218,,
10665,,A,,,Area under curve at a peroral dose of 3 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626160,BAO_0000218,,
10666,,A,,,Area under curve at an iv dose of 1 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626161,BAO_0000218,,
10667,,A,,,Area under curve at an iv dose of 1 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626162,BAO_0000218,,
10668,,A,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,0,,,22224,,Autocuration,1,CHEMBL626163,BAO_0000019,,
10669,,A,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,0,,,22224,,Autocuration,1,CHEMBL626164,BAO_0000019,,
10670,,A,,,Area under curve measured as conc vs time after intravenous administration to mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL626165,BAO_0000218,,
10671,,A,,,Area under curve measured as conc vs time after peroral administration to mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL626166,BAO_0000218,,
10672,,A,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626167,BAO_0000218,,
10673,,A,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626168,BAO_0000218,,
10674,,A,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL877463,BAO_0000218,,
10675,,A,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626169,BAO_0000218,,
10676,,A,,In vivo,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626170,BAO_0000218,948.0,
10677,,A,,In vivo,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626171,BAO_0000218,948.0,
10678,,A,,In vivo,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626172,BAO_0000218,948.0,
10679,,A,,In vivo,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626173,BAO_0000218,948.0,
10680,,A,,In vivo,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626174,BAO_0000218,2113.0,
10681,,A,,In vivo,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626175,BAO_0000218,2113.0,
10682,,A,,In vivo,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626176,BAO_0000218,2113.0,
10683,,A,,In vivo,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL626177,BAO_0000218,2113.0,
10684,,A,,In vivo,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622499,BAO_0000218,2113.0,
10685,,A,,In vivo,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622500,BAO_0000218,2107.0,
10686,,A,,In vivo,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622501,BAO_0000218,2107.0,
10687,,A,,In vivo,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622502,BAO_0000218,2107.0,
10688,,A,,In vivo,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622503,BAO_0000218,2107.0,
10689,,A,,In vivo,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL877614,BAO_0000218,2107.0,
10690,,A,,In vivo,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624839,BAO_0000218,2048.0,
10691,,A,,In vivo,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624840,BAO_0000218,2048.0,
10692,,A,,In vivo,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624841,BAO_0000218,2048.0,
10693,,A,,In vivo,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624842,BAO_0000218,2048.0,
10694,,A,,In vivo,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624843,BAO_0000218,2385.0,
10695,,A,,In vivo,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624844,BAO_0000218,2385.0,
10696,,A,,In vivo,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624845,BAO_0000218,2385.0,
10697,,A,,In vivo,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,1,,,50597,10116.0,Intermediate,1,CHEMBL621904,BAO_0000218,2385.0,
10698,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621905,BAO_0000218,178.0,
10699,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL874382,BAO_0000218,178.0,
10700,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621906,BAO_0000218,178.0,
10701,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621907,BAO_0000218,955.0,
10702,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622096,BAO_0000218,955.0,
10703,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622097,BAO_0000218,955.0,
10704,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622098,BAO_0000218,948.0,
10705,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622099,BAO_0000218,948.0,
10706,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622100,BAO_0000218,948.0,
10707,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622101,BAO_0000218,2113.0,
10708,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622102,BAO_0000218,2113.0,
10709,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622103,BAO_0000218,2113.0,
10710,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622104,BAO_0000218,2107.0,
10711,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622105,BAO_0000218,2107.0,
10712,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622106,BAO_0000218,2107.0,
10713,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622107,BAO_0000218,2048.0,
10714,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622108,BAO_0000218,2048.0,
10715,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622109,BAO_0000218,2048.0,
10716,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622110,BAO_0000218,2385.0,
10717,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622111,BAO_0000218,2385.0,
10718,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL874383,BAO_0000218,2385.0,
10719,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622112,BAO_0000218,14.0,
10720,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622113,BAO_0000218,14.0,
10721,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622114,BAO_0000218,14.0,
10722,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622115,BAO_0000218,2106.0,
10723,,A,,In vivo,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622116,BAO_0000218,2106.0,
10724,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622117,BAO_0000218,,
10725,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622118,BAO_0000218,,
10726,,A,,In vivo,Oral bioavailability in rats at 6 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622119,BAO_0000218,,
10727,,A,,In vivo,Oral bioavailability in rat (dose 6 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL622120,BAO_0000218,,
10728,,A,,In vivo,Oral bioavailability in rats at 6 mg/kg dose; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL622121,BAO_0000218,,
10729,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622122,BAO_0000218,,
10730,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622123,BAO_0000218,,
10731,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622124,BAO_0000218,,
10732,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622125,BAO_0000218,,
10733,,A,,In vivo,Oral bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL622126,BAO_0000218,,
10734,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL620455,BAO_0000218,,
10735,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620456,BAO_0000218,,
10736,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620457,BAO_0000218,,
10737,,A,,In vivo,Oral bioavailability was evaluated; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL620458,BAO_0000218,,
10738,,A,,In vivo,Oral bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL620459,BAO_0000218,,
10739,,A,,In vivo,Oral bioavailability in rat by oral dosing,1,,,50597,10116.0,Intermediate,1,CHEMBL620460,BAO_0000218,,
10740,,A,,In vivo,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL620461,BAO_0000218,,
10741,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley),1,,,50597,10116.0,Intermediate,1,CHEMBL620462,BAO_0000218,,
10742,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL620463,BAO_0000218,,
10743,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL620464,BAO_0000218,,
10744,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL620465,BAO_0000218,,
10745,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL620466,BAO_0000218,,
10746,,A,,In vivo,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620467,BAO_0000218,,
10747,,A,,In vivo,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL620468,BAO_0000218,,
10748,,A,,In vivo,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,1,,,50597,10116.0,Intermediate,1,CHEMBL620469,BAO_0000218,,
10749,,A,,In vivo,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,1,,,50597,10116.0,Intermediate,1,CHEMBL620470,BAO_0000218,,
10750,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620471,BAO_0000218,,
10751,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620472,BAO_0000218,,
10752,,A,,In vivo,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620473,BAO_0000218,,
10753,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620474,BAO_0000218,,
10754,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL620475,BAO_0000218,,
10755,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620476,BAO_0000218,,
10756,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL620477,BAO_0000218,,
10757,,A,,In vivo,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL620478,BAO_0000218,,
10758,,A,,In vivo,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL618768,BAO_0000218,,
10759,,A,,In vivo,Oral bioavailability in rat after oral administration at 13 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL618769,BAO_0000218,,
10760,,A,,In vivo,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL618770,BAO_0000218,,
10761,,A,,In vivo,Oral bioavailability (dose 20 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL618771,BAO_0000218,,
10762,,A,,In vivo,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618772,BAO_0000218,,
10763,,A,,In vivo,Oral bioavailability in rat at 10 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL618773,BAO_0000218,,
10764,,A,,In vivo,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,,,50597,10116.0,Intermediate,1,CHEMBL875842,BAO_0000218,,
10765,,A,,In vivo,Bioavailability in rat (dose 3 mg/kg i.v.),1,,,50597,10116.0,Intermediate,1,CHEMBL618774,BAO_0000218,,
10766,,A,,In vivo,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,,,50597,10116.0,Intermediate,1,CHEMBL618775,BAO_0000218,,
10767,,A,,In vivo,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL618776,BAO_0000218,,
10768,,A,,In vivo,Percent bioavailability (F) in rats after iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL618777,BAO_0000218,,
10769,,A,,In vivo,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL618778,BAO_0000218,,
10770,,A,,In vivo,Bioavailability in rat (dose 5 uM/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL618779,BAO_0000218,,
10771,,A,,In vivo,Oral bioavailability,1,,,50597,10116.0,Intermediate,1,CHEMBL618780,BAO_0000218,,
10772,,A,,In vivo,Bioavailability in rat (dose 2 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL618781,BAO_0000218,,
10773,,A,,In vivo,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL618782,BAO_0000218,,
10774,,A,,In vivo,Oral bioavailability in rat (dose 20 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL618783,BAO_0000218,,
10775,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618784,BAO_0000218,,
10776,,A,,In vivo,Percent oral bioavailability evaluated in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618785,BAO_0000218,,
10777,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618786,BAO_0000218,,
10778,,A,,In vivo,Percent oral bioavailability in rat; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL618787,BAO_0000218,,
10779,,A,,In vivo,Oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618788,BAO_0000218,,
10780,,A,,In vivo,Bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL618789,BAO_0000218,,
10781,,A,,In vivo,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),1,,,50597,10116.0,Intermediate,1,CHEMBL618790,BAO_0000218,,
10782,,A,,In vivo,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),1,,,50597,10116.0,Intermediate,1,CHEMBL618791,BAO_0000218,,
10783,,A,,In vivo,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL875843,BAO_0000218,,
10784,,A,,In vivo,Oral bioavailability in rat (dose 20 mg/kg p.o.),1,,,50597,10116.0,Intermediate,1,CHEMBL618792,BAO_0000218,,
10785,,A,,In vivo,Cmax at a dose of 30 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623395,BAO_0000218,,
10786,,A,,In vivo,Cmax in monkeys at a dose of 1 mg/kg,0,,,22224,314293.0,Autocuration,1,CHEMBL623396,BAO_0000218,,
10787,,A,,In vivo,Cmax in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623397,BAO_0000218,,
10788,,A,,In vivo,Cmax in rats at a dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623398,BAO_0000218,,
10789,,A,,In vivo,Cmax was measured in mice after an oral dose of 50 mg/kg.,1,,,50594,10090.0,Intermediate,1,CHEMBL623399,BAO_0000218,,
10790,,A,,In vivo,"Cmax value at a dose of 12.7 uM/kg, po",0,,,22224,,Autocuration,1,CHEMBL623400,BAO_0000218,,
10791,,A,,In vivo,"Cmax value at a dose of 6.3 uM/kg, iv",0,,,22224,,Autocuration,1,CHEMBL623401,BAO_0000218,,
10792,,A,,In vivo,"Cmax value at a dose of 7.1 uM/kg, iv",0,,,22224,,Autocuration,1,CHEMBL623402,BAO_0000218,,
10793,,A,,In vivo,Cmax value of compound was determined after 1 hr,0,,,22224,,Autocuration,1,CHEMBL623403,BAO_0000218,,
10794,,A,,In vivo,Cmax value of the compound,0,,,22224,,Autocuration,1,CHEMBL623404,BAO_0000218,,
10795,,A,,In vivo,Cmax value administered intraintestinal in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL625997,BAO_0000218,,
10796,,A,,In vivo,Cmax value administered perorally was determined in rat; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL625998,BAO_0000218,,
10797,,A,,In vivo,Cmax value at the dose of 2.3 mg/kg,0,,,22224,,Autocuration,1,CHEMBL625999,BAO_0000218,,
10798,,A,,In vivo,Cmax value at the dose of 5 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626000,BAO_0000218,,
10799,,A,,In vivo,Cmax value in the period of 8 hr after dosing. ,0,,,22224,,Autocuration,1,CHEMBL626001,BAO_0000218,,
10800,,A,,In vivo,Cmax value at a oral dose of 20 mg/kg; Not tested,0,,,22224,,Autocuration,1,CHEMBL626002,BAO_0000218,,
10801,,A,,In vivo,Cmax value at a oral dose of 20 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626003,BAO_0000218,,
10802,,A,,In vivo,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,,,50597,10116.0,Intermediate,1,CHEMBL626004,BAO_0000218,,
10803,,A,,In vivo,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,1,,,50512,10141.0,Intermediate,1,CHEMBL626005,BAO_0000218,,
10804,,A,,In vivo,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL626006,BAO_0000218,,
10805,,A,,In vivo,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1,,,50597,10116.0,Intermediate,1,CHEMBL626007,BAO_0000218,1969.0,
10806,,A,,In vivo,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL626008,BAO_0000218,1969.0,
10807,,A,,In vivo,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,1,,,50588,9615.0,Intermediate,1,CHEMBL626009,BAO_0000218,2107.0,
10808,,A,,In vivo,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,1,,,50588,9615.0,Intermediate,1,CHEMBL626010,BAO_0000218,,
10809,,A,,In vivo,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL626011,BAO_0000218,178.0,
10810,,A,,In vivo,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL626012,BAO_0000218,178.0,
10811,,A,,In vivo,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL626013,BAO_0000218,178.0,
10812,,A,,In vivo,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL626014,BAO_0000218,178.0,
10813,,A,,In vivo,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL877496,BAO_0000218,178.0,
10814,,F,,In vivo,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626015,BAO_0000218,,
10815,,F,,In vivo,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626016,BAO_0000218,,
10816,,F,,In vivo,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626017,BAO_0000218,,
10817,,A,,In vivo,Bioavailability as maximal plasma concentration in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626018,BAO_0000218,1969.0,
10818,,A,,In vivo,Bioavailability as maximal plasma concentration in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626692,BAO_0000218,1969.0,
10819,,A,,In vivo,Bioavailability as maximal plasma concentration in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626693,BAO_0000218,1969.0,
10820,,A,,In vivo,Bioavailability as maximal plasma concentration in rats,0,,,22224,10116.0,Autocuration,1,CHEMBL626694,BAO_0000218,1969.0,
10821,,A,,In vivo,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,,50588,9615.0,Intermediate,1,CHEMBL626695,BAO_0000218,178.0,
10822,,A,,In vivo,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,,50588,9615.0,Intermediate,1,CHEMBL626696,BAO_0000218,178.0,
10823,,A,,In vivo,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,,50588,9615.0,Intermediate,1,CHEMBL626697,BAO_0000218,178.0,
10824,,A,,In vivo,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,1,,,50588,9615.0,Intermediate,1,CHEMBL626859,BAO_0000218,178.0,
10825,,A,,In vivo,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,,50588,9615.0,Intermediate,1,CHEMBL626860,BAO_0000218,178.0,
10826,,A,,In vivo,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,,50588,9615.0,Intermediate,1,CHEMBL626861,BAO_0000218,178.0,
10827,,A,,In vivo,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626296,BAO_0000218,,
10828,,A,,In vivo,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626297,BAO_0000218,,
10829,,A,,In vivo,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,0,,,22224,,Autocuration,1,CHEMBL626298,BAO_0000218,1969.0,
10830,,A,,In vivo,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1,,,50597,10116.0,Intermediate,1,CHEMBL626299,BAO_0000218,1969.0,
10831,,A,,In vivo,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL626300,BAO_0000218,1969.0,
10832,,A,,In vivo,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL626301,BAO_0000218,1969.0,
10833,,A,,In vivo,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL626962,BAO_0000218,1969.0,
10834,,A,,In vivo,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL626963,BAO_0000218,1969.0,
10835,,A,,In vivo,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL626964,BAO_0000218,1969.0,
10836,,A,,In vivo,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1,,,100710,9541.0,Intermediate,1,CHEMBL626965,BAO_0000218,1969.0,
10837,,A,,In vivo,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,,50594,10090.0,Intermediate,1,CHEMBL626966,BAO_0000218,1969.0,
10838,,A,,In vivo,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,,50594,10090.0,Intermediate,1,CHEMBL626967,BAO_0000218,1969.0,
10839,,A,,In vivo,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1,,,100710,9541.0,Intermediate,1,CHEMBL626968,BAO_0000218,1969.0,
10840,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,1,,,50597,10116.0,Intermediate,1,CHEMBL626969,BAO_0000218,948.0,
10841,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,1,,,50597,10116.0,Intermediate,1,CHEMBL627126,BAO_0000218,948.0,
10842,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,1,,,50597,10116.0,Intermediate,1,CHEMBL631276,BAO_0000218,948.0,
10843,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,1,,,50597,10116.0,Intermediate,1,CHEMBL631277,BAO_0000218,948.0,
10844,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,1,,,50597,10116.0,Intermediate,1,CHEMBL631278,BAO_0000218,948.0,
10845,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,1,,,50597,10116.0,Intermediate,1,CHEMBL874457,BAO_0000218,948.0,
10846,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,1,,,50597,10116.0,Intermediate,1,CHEMBL631279,BAO_0000218,948.0,
10847,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,1,,,50597,10116.0,Intermediate,1,CHEMBL631280,BAO_0000218,948.0,
10848,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,1,,,50597,10116.0,Intermediate,1,CHEMBL631281,BAO_0000218,948.0,
10849,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,1,,,50597,10116.0,Intermediate,1,CHEMBL631968,BAO_0000218,948.0,
10850,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,1,,,50597,10116.0,Intermediate,1,CHEMBL631969,BAO_0000218,948.0,
10851,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,1,,,50597,10116.0,Intermediate,1,CHEMBL631970,BAO_0000218,948.0,
10852,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,1,,,50597,10116.0,Intermediate,1,CHEMBL631971,BAO_0000218,948.0,
10853,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,1,,,50597,10116.0,Intermediate,1,CHEMBL631972,BAO_0000218,948.0,
10854,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,1,,,50597,10116.0,Intermediate,1,CHEMBL630435,BAO_0000218,948.0,
10855,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,1,,,50597,10116.0,Intermediate,1,CHEMBL630436,BAO_0000218,948.0,
10856,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,1,,,50597,10116.0,Intermediate,1,CHEMBL630437,BAO_0000218,948.0,
10857,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,1,,,50597,10116.0,Intermediate,1,CHEMBL630438,BAO_0000218,948.0,
10858,,A,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,1,,,50597,10116.0,Intermediate,1,CHEMBL630439,BAO_0000218,948.0,
10859,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,1,,,50597,10116.0,Intermediate,1,CHEMBL630440,BAO_0000218,2113.0,
10860,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,1,,,50597,10116.0,Intermediate,1,CHEMBL630441,BAO_0000218,2113.0,
10861,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,1,,,50597,10116.0,Intermediate,1,CHEMBL630442,BAO_0000218,2113.0,
10862,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,1,,,50597,10116.0,Intermediate,1,CHEMBL625234,BAO_0000218,2113.0,
10863,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,1,,,50597,10116.0,Intermediate,1,CHEMBL625235,BAO_0000218,2113.0,
10864,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,1,,,50597,10116.0,Intermediate,1,CHEMBL625236,BAO_0000218,2113.0,
10865,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,1,,,50597,10116.0,Intermediate,1,CHEMBL625237,BAO_0000218,2113.0,
10866,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,1,,,50597,10116.0,Intermediate,1,CHEMBL626125,BAO_0000218,2113.0,
10867,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,1,,,50597,10116.0,Intermediate,1,CHEMBL626126,BAO_0000218,2113.0,
10868,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,1,,,50597,10116.0,Intermediate,1,CHEMBL626127,BAO_0000218,2113.0,
10869,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,1,,,50597,10116.0,Intermediate,1,CHEMBL626128,BAO_0000218,2113.0,
10870,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,1,,,50597,10116.0,Intermediate,1,CHEMBL626129,BAO_0000218,2113.0,
10871,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,1,,,50597,10116.0,Intermediate,1,CHEMBL626130,BAO_0000218,2113.0,
10872,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,1,,,50597,10116.0,Intermediate,1,CHEMBL626131,BAO_0000218,2113.0,
10873,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,1,,,50597,10116.0,Intermediate,1,CHEMBL626132,BAO_0000218,2113.0,
10874,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,1,,,50597,10116.0,Intermediate,1,CHEMBL626752,BAO_0000218,2113.0,
10875,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,1,,,50597,10116.0,Intermediate,1,CHEMBL626753,BAO_0000218,2113.0,
10876,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,1,,,50597,10116.0,Intermediate,1,CHEMBL626754,BAO_0000218,2113.0,
10877,,A,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,1,,,50597,10116.0,Intermediate,1,CHEMBL626755,BAO_0000218,2113.0,
10878,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,1,,,50597,10116.0,Intermediate,1,CHEMBL626756,BAO_0000218,2107.0,
10879,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,1,,,50597,10116.0,Intermediate,1,CHEMBL626757,BAO_0000218,2107.0,
10880,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,1,,,50597,10116.0,Intermediate,1,CHEMBL626758,BAO_0000218,2107.0,
10881,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,1,,,50597,10116.0,Intermediate,1,CHEMBL626759,BAO_0000218,2107.0,
10882,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,1,,,50597,10116.0,Intermediate,1,CHEMBL626760,BAO_0000218,2107.0,
10883,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL626394,BAO_0000218,,
10884,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL626395,BAO_0000218,,
10885,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL626396,BAO_0000218,,
10886,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL626397,BAO_0000218,,
10887,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,,,50588,9615.0,Intermediate,1,CHEMBL626398,BAO_0000218,,
10888,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL626399,BAO_0000218,,
10889,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL874653,BAO_0000218,,
10890,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL626400,BAO_0000218,,
10891,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL626401,BAO_0000218,,
10892,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL626402,BAO_0000218,,
10893,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL626403,BAO_0000218,,
10894,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL626404,BAO_0000218,,
10895,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL626405,BAO_0000218,,
10896,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625529,BAO_0000218,,
10897,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625530,BAO_0000218,,
10898,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625531,BAO_0000218,,
10899,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL625532,BAO_0000218,,
10900,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625533,BAO_0000218,,
10901,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL875474,BAO_0000218,,
10902,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625534,BAO_0000218,,
10903,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625535,BAO_0000218,,
10904,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625536,BAO_0000218,,
10905,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL625537,BAO_0000218,,
10906,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625538,BAO_0000218,,
10907,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625539,BAO_0000218,,
10908,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625540,BAO_0000218,,
10909,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625541,BAO_0000218,,
10910,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625542,BAO_0000218,,
10911,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL625543,BAO_0000218,,
10912,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL625544,BAO_0000218,,
10913,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL625545,BAO_0000218,,
10914,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625546,BAO_0000218,,
10915,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL625547,BAO_0000218,,
10916,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625548,BAO_0000218,,
10917,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625549,BAO_0000218,,
10918,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625550,BAO_0000218,,
10919,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625551,BAO_0000218,,
10920,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL875475,BAO_0000218,,
10921,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625552,BAO_0000218,,
10922,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625553,BAO_0000218,,
10923,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625554,BAO_0000218,,
10924,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,,,50588,9615.0,Intermediate,1,CHEMBL625555,BAO_0000218,,
10925,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL625556,BAO_0000218,,
10926,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624986,BAO_0000218,,
10927,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624987,BAO_0000218,,
10928,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624988,BAO_0000218,,
10929,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1,,,50588,9615.0,Intermediate,1,CHEMBL624989,BAO_0000218,1637.0,
10930,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1,,,50588,9615.0,Intermediate,1,CHEMBL624990,BAO_0000218,1637.0,
10931,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1,,,50588,9615.0,Intermediate,1,CHEMBL874391,BAO_0000218,1637.0,
10932,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1,,,50588,9615.0,Intermediate,1,CHEMBL624991,BAO_0000218,1637.0,
10933,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1,,,50588,9615.0,Intermediate,1,CHEMBL624992,BAO_0000218,1637.0,
10934,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1,,,50588,9615.0,Intermediate,1,CHEMBL624993,BAO_0000218,1637.0,
10935,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1,,,50588,9615.0,Intermediate,1,CHEMBL624994,BAO_0000218,1637.0,
10936,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1,,,50588,9615.0,Intermediate,1,CHEMBL624995,BAO_0000218,1637.0,
10937,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1,,,50588,9615.0,Intermediate,1,CHEMBL624996,BAO_0000218,1637.0,
10938,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1,,,50588,9615.0,Intermediate,1,CHEMBL624997,BAO_0000218,1637.0,
10939,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1,,,50588,9615.0,Intermediate,1,CHEMBL624998,BAO_0000218,1637.0,
10940,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1,,,50588,9615.0,Intermediate,1,CHEMBL624999,BAO_0000218,1637.0,
10941,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1,,,50588,9615.0,Intermediate,1,CHEMBL882955,BAO_0000218,1637.0,
10942,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1,,,50588,9615.0,Intermediate,1,CHEMBL625000,BAO_0000218,1637.0,
10943,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1,,,50588,9615.0,Intermediate,1,CHEMBL625001,BAO_0000218,1637.0,
10944,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1,,,50588,9615.0,Intermediate,1,CHEMBL625089,BAO_0000218,1637.0,
10945,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1,,,50588,9615.0,Intermediate,1,CHEMBL625090,BAO_0000218,1637.0,
10946,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1,,,50588,9615.0,Intermediate,1,CHEMBL625091,BAO_0000218,1637.0,
10947,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1,,,50588,9615.0,Intermediate,1,CHEMBL625092,BAO_0000218,1637.0,
10948,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1,,,50588,9615.0,Intermediate,1,CHEMBL625093,BAO_0000218,1637.0,
10949,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1,,,50588,9615.0,Intermediate,1,CHEMBL625094,BAO_0000218,1637.0,
10950,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1,,,50588,9615.0,Intermediate,1,CHEMBL625095,BAO_0000218,1637.0,
10951,,A,,In vivo,Compound was evaluated for its bioavailability in the dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625096,BAO_0000218,,
10952,,A,,In vivo,Compound was evaluated for its bioavailability in the rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625097,BAO_0000218,,
10953,,A,,In vivo,Compound was evaluated for oral bioavailability,0,,,22224,,Autocuration,1,CHEMBL882956,BAO_0000218,,
10954,,A,,In vivo,Compound was evaluated for percentage of Oral bioavailability in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625098,BAO_0000218,,
10955,,A,,In vivo,Bioavailability in guinea pig,0,,,22224,10141.0,Autocuration,1,CHEMBL625099,BAO_0000218,,
10956,,A,,In vivo,Compound was evaluated for the oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625100,BAO_0000218,,
10957,,A,,In vivo,Compound was evaluated for the oral bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625101,BAO_0000218,,
10958,,A,,In vivo,Compound was evaluated for the oral bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL874396,BAO_0000218,,
10959,,F,,In vivo,Bioavailability in dog (dosed i.v.),0,,,22224,9615.0,Autocuration,1,CHEMBL625102,BAO_0000218,,
10960,,A,,In vivo,Compound was tested for in vivo bioavailability in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625103,BAO_0000218,,
10961,,A,,In vivo,Compound was tested for in vivo bioavailability in hamsters,1,,,100712,10026.0,Intermediate,1,CHEMBL625104,BAO_0000218,,
10962,,A,,In vivo,Compound was tested for in vivo bioavailability in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL625105,BAO_0000218,,
10963,,A,,In vivo,Compound was tested for in vivo bioavailability in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625106,BAO_0000218,,
10964,,A,,In vivo,Oral bioavailability in mouse,0,,,22224,10090.0,Autocuration,1,CHEMBL625107,BAO_0000218,,
10965,,A,,In vivo,Compound was tested for percent of oral bioavailability in mice; 56-74,1,,,50594,10090.0,Intermediate,1,CHEMBL625108,BAO_0000218,,
10966,,A,,In vivo,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),0,,,22224,10090.0,Autocuration,1,CHEMBL625109,BAO_0000218,,
10967,,A,,In vivo,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),0,,,22224,9541.0,Autocuration,1,CHEMBL625110,BAO_0000218,,
10968,,A,,In vivo,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),0,,,22224,9541.0,Autocuration,1,CHEMBL625111,BAO_0000218,,
10969,,A,,In vivo,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),1,,,50594,10090.0,Intermediate,1,CHEMBL625112,BAO_0000218,,
10970,,A,,In vivo,Oral bioavailability in nude mice,1,,,50594,10090.0,Intermediate,1,CHEMBL875334,BAO_0000218,,
10971,,A,,In vivo,Bioavailability in monkey (i.d. dosing),0,,,22224,9443.0,Autocuration,1,CHEMBL628617,BAO_0000218,,
10972,,A,,In vivo,Bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL628618,BAO_0000218,,
10973,,A,,In vivo,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,0,,,22224,,Autocuration,1,CHEMBL628619,BAO_0000218,,
10974,,A,,In vivo,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,0,,,22224,,Autocuration,1,CHEMBL628620,BAO_0000218,,
10975,,A,,In vivo,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,,100710,9541.0,Intermediate,1,CHEMBL628621,BAO_0000218,,
10976,,A,,In vivo,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,,100710,9541.0,Intermediate,1,CHEMBL628622,BAO_0000218,,
10977,,A,,In vivo,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,,100710,9541.0,Intermediate,1,CHEMBL628623,BAO_0000218,,
10978,,A,,In vivo,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1,,,100710,9541.0,Intermediate,1,CHEMBL628624,BAO_0000218,1969.0,
10979,,A,,In vivo,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,,50594,10090.0,Intermediate,1,CHEMBL628625,BAO_0000218,1969.0,
10980,,A,,In vivo,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1,,,100710,9541.0,Intermediate,1,CHEMBL628626,BAO_0000218,1969.0,
10981,,A,,In vivo,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,,50594,10090.0,Intermediate,1,CHEMBL627041,BAO_0000218,1969.0,
10982,,A,,In vivo,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,,50594,10090.0,Intermediate,1,CHEMBL627042,BAO_0000218,1969.0,
10983,,A,,In vivo,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,,50594,10090.0,Intermediate,1,CHEMBL627043,BAO_0000218,1969.0,
10984,,A,,In vivo,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,0,,,22224,,Autocuration,1,CHEMBL627044,BAO_0000218,1969.0,
10985,,A,,In vivo,Cmax in mouse plasma,1,,,50594,10090.0,Intermediate,1,CHEMBL627045,BAO_0000218,1969.0,
10986,,A,,In vivo,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,0,,,22224,,Autocuration,1,CHEMBL627046,BAO_0000218,1969.0,
10987,,A,,In vivo,Maximal plasma concentration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627047,BAO_0000218,1969.0,
10988,,A,,In vivo,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627048,BAO_0000218,1969.0,
10989,,A,,In vivo,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627049,BAO_0000218,,
10990,,A,,In vivo,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627050,BAO_0000218,,
10991,,A,,In vivo,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627051,BAO_0000218,,
10992,,A,,In vivo,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627052,BAO_0000218,,
10993,,A,,In vivo,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627053,BAO_0000218,,
10994,,A,,In vivo,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627054,BAO_0000218,,
10995,,A,,In vivo,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627055,BAO_0000218,,
10996,,A,,In vivo,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627056,BAO_0000218,,
10997,,A,,In vivo,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,,,50594,10090.0,Intermediate,1,CHEMBL627057,BAO_0000218,,
10998,,A,,In vivo,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL627058,BAO_0000218,,
10999,,A,,In vivo,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL626211,BAO_0000218,,
11000,,A,,In vivo,Maximum Concentration of the compound.,0,,,22224,,Autocuration,1,CHEMBL626212,BAO_0000218,,
11001,,A,,In vivo,Maximum Concentration was measured after iv administration into Beagle dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626213,BAO_0000218,,
11002,,A,,In vivo,Maximum Concentration was measured after iv administration into Beagle dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL626214,BAO_0000218,,
11003,,A,,In vivo,Maximum Concentration was measured after po administration into Beagle dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626215,BAO_0000218,,
11004,,A,,In vivo,Maximum Concentration was measured after po administration into Beagle dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL626216,BAO_0000218,,
11005,,A,,In vivo,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,0,,,22224,,Autocuration,1,CHEMBL626217,BAO_0000218,178.0,
11006,,A,,In vivo,Maximum blood level reached after an iv dose of 12.2 uM/kg,0,,,22224,,Autocuration,1,CHEMBL626218,BAO_0000218,178.0,
11007,,A,,In vivo,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,0,,,22224,,Autocuration,1,CHEMBL626219,BAO_0000218,178.0,
11008,,A,,In vivo,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,0,,,22224,,Autocuration,1,CHEMBL626220,BAO_0000218,178.0,
11009,,A,,In vivo,Maximum blood level reached after an oral dose of 5.0 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626221,BAO_0000218,178.0,
11010,,A,,In vivo,Maximum blood level reached at dose of 10.6 uM/kg orally,0,,,22224,,Autocuration,1,CHEMBL626222,BAO_0000218,178.0,
11011,,A,,In vivo,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,1,,,50512,10141.0,Intermediate,1,CHEMBL626223,BAO_0000218,,
11012,,A,,In vivo,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,1,,,50512,10141.0,Intermediate,1,CHEMBL626224,BAO_0000218,,
11013,,A,,In vivo,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626225,BAO_0000218,955.0,
11014,,A,,In vivo,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626226,BAO_0000218,955.0,
11015,,A,,In vivo,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626227,BAO_0000218,955.0,
11016,,A,,In vivo,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626228,BAO_0000218,955.0,
11017,,A,,In vivo,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626229,BAO_0000218,,
11018,,A,,In vivo,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626921,BAO_0000218,,
11019,,A,,In vivo,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL876793,BAO_0000218,,
11020,,A,,In vivo,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625309,BAO_0000218,,
11021,,A,,In vivo,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,,,50278,1423.0,Intermediate,1,CHEMBL625310,BAO_0000218,,
11022,,A,,In vivo,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,0,,,22224,314293.0,Autocuration,1,CHEMBL625311,BAO_0000218,,
11023,,A,,In vivo,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625312,BAO_0000218,,
11024,,A,,In vivo,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,0,,,22224,,Autocuration,1,CHEMBL625313,BAO_0000218,,
11025,,A,,In vivo,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL625314,BAO_0000218,,
11026,,A,,In vivo,Maximum concentration in male rats after iv administration of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625315,BAO_0000218,,
11027,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,1,,,50597,10116.0,Intermediate,1,CHEMBL625316,BAO_0000218,2107.0,
11028,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,1,,,50597,10116.0,Intermediate,1,CHEMBL625317,BAO_0000218,2107.0,
11029,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,1,,,50597,10116.0,Intermediate,1,CHEMBL625318,BAO_0000218,2107.0,
11030,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,1,,,50597,10116.0,Intermediate,1,CHEMBL625319,BAO_0000218,2107.0,
11031,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,1,,,50597,10116.0,Intermediate,1,CHEMBL625320,BAO_0000218,2107.0,
11032,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,1,,,50597,10116.0,Intermediate,1,CHEMBL625321,BAO_0000218,2107.0,
11033,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,1,,,50597,10116.0,Intermediate,1,CHEMBL625322,BAO_0000218,2107.0,
11034,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,1,,,50597,10116.0,Intermediate,1,CHEMBL876801,BAO_0000218,2107.0,
11035,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,1,,,50597,10116.0,Intermediate,1,CHEMBL625323,BAO_0000218,2107.0,
11036,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,1,,,50597,10116.0,Intermediate,1,CHEMBL625324,BAO_0000218,2107.0,
11037,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,1,,,50597,10116.0,Intermediate,1,CHEMBL625325,BAO_0000218,2107.0,
11038,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,1,,,50597,10116.0,Intermediate,1,CHEMBL625326,BAO_0000218,2107.0,
11039,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,1,,,50597,10116.0,Intermediate,1,CHEMBL625327,BAO_0000218,2107.0,
11040,,A,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,1,,,50597,10116.0,Intermediate,1,CHEMBL625328,BAO_0000218,2107.0,
11041,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,1,,,50597,10116.0,Intermediate,1,CHEMBL625329,BAO_0000218,2048.0,
11042,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,1,,,50597,10116.0,Intermediate,1,CHEMBL625330,BAO_0000218,2048.0,
11043,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,1,,,50597,10116.0,Intermediate,1,CHEMBL627774,BAO_0000218,2048.0,
11044,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,1,,,50597,10116.0,Intermediate,1,CHEMBL627775,BAO_0000218,2048.0,
11045,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,1,,,50597,10116.0,Intermediate,1,CHEMBL627949,BAO_0000218,2048.0,
11046,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,1,,,50597,10116.0,Intermediate,1,CHEMBL627950,BAO_0000218,2048.0,
11047,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,1,,,50597,10116.0,Intermediate,1,CHEMBL627951,BAO_0000218,2048.0,
11048,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,1,,,50597,10116.0,Intermediate,1,CHEMBL627952,BAO_0000218,2048.0,
11049,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,1,,,50597,10116.0,Intermediate,1,CHEMBL627953,BAO_0000218,2048.0,
11050,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,1,,,50597,10116.0,Intermediate,1,CHEMBL627954,BAO_0000218,2048.0,
11051,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,1,,,50597,10116.0,Intermediate,1,CHEMBL627955,BAO_0000218,2048.0,
11052,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,1,,,50597,10116.0,Intermediate,1,CHEMBL627956,BAO_0000218,2048.0,
11053,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,1,,,50597,10116.0,Intermediate,1,CHEMBL876802,BAO_0000218,2048.0,
11054,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,1,,,50597,10116.0,Intermediate,1,CHEMBL627957,BAO_0000218,2048.0,
11055,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,1,,,50597,10116.0,Intermediate,1,CHEMBL627958,BAO_0000218,2048.0,
11056,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,1,,,50597,10116.0,Intermediate,1,CHEMBL627959,BAO_0000218,2048.0,
11057,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,1,,,50597,10116.0,Intermediate,1,CHEMBL627960,BAO_0000218,2048.0,
11058,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,1,,,50597,10116.0,Intermediate,1,CHEMBL627961,BAO_0000218,2048.0,
11059,,A,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,1,,,50597,10116.0,Intermediate,1,CHEMBL627962,BAO_0000218,2048.0,
11060,,A,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL627963,BAO_0000218,,
11061,,A,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL624759,BAO_0000218,,
11062,,A,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL624760,BAO_0000218,,
11063,,A,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL624761,BAO_0000218,,
11064,,A,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL877607,BAO_0000218,,
11065,,A,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL624762,BAO_0000218,2107.0,
11066,,A,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL624763,BAO_0000218,2107.0,
11067,,A,,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL624764,BAO_0000218,2107.0,
11068,,A,,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL624765,BAO_0000218,2107.0,
11069,,A,,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL624766,BAO_0000218,2107.0,
11070,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624767,BAO_0000218,,
11071,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624768,BAO_0000218,,
11072,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624769,BAO_0000218,,
11073,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624770,BAO_0000218,,
11074,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,,,50588,9615.0,Intermediate,1,CHEMBL624771,BAO_0000218,,
11075,,A,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624772,BAO_0000218,,
11076,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624773,BAO_0000218,,
11077,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624774,BAO_0000218,,
11078,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624775,BAO_0000218,,
11079,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624776,BAO_0000218,,
11080,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL624777,BAO_0000218,,
11081,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624778,BAO_0000218,,
11082,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624779,BAO_0000218,,
11083,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624780,BAO_0000218,,
11084,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL624781,BAO_0000218,,
11085,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL877608,BAO_0000218,,
11086,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624782,BAO_0000218,,
11087,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624783,BAO_0000218,,
11088,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624784,BAO_0000218,,
11089,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624785,BAO_0000218,,
11090,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL624786,BAO_0000218,,
11091,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL624787,BAO_0000218,,
11092,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL628676,BAO_0000218,,
11093,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL621842,BAO_0000218,,
11094,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL621843,BAO_0000218,,
11095,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL623873,BAO_0000218,,
11096,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL623874,BAO_0000218,,
11097,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL623875,BAO_0000218,,
11098,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL623876,BAO_0000218,,
11099,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL623877,BAO_0000218,,
11100,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623878,BAO_0000218,,
11101,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL623879,BAO_0000218,,
11102,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623880,BAO_0000218,,
11103,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623881,BAO_0000218,,
11104,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623957,BAO_0000218,,
11105,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623958,BAO_0000218,,
11106,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623959,BAO_0000218,,
11107,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623960,BAO_0000218,,
11108,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623961,BAO_0000218,,
11109,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL623962,BAO_0000218,,
11110,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,,,50588,9615.0,Intermediate,1,CHEMBL624676,BAO_0000218,,
11111,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624677,BAO_0000218,,
11112,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624678,BAO_0000218,,
11113,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624679,BAO_0000218,,
11114,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624680,BAO_0000218,,
11115,,A,,In vivo,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,0,,,22224,,Autocuration,1,CHEMBL624849,BAO_0000218,,
11116,,A,,In vivo,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,0,,,22224,,Autocuration,1,CHEMBL624850,BAO_0000218,,
11117,,A,,In vivo,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,0,,,22224,,Autocuration,1,CHEMBL874399,BAO_0000218,,
11118,,A,,In vivo,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,0,,,22224,,Autocuration,1,CHEMBL624851,BAO_0000218,,
11119,,A,,In vivo,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,0,,,22224,,Autocuration,1,CHEMBL624852,BAO_0000218,,
11120,,A,,In vivo,Oral bioavailability in rat (dose 10 mg/kg),0,,,22224,10116.0,Autocuration,1,CHEMBL624853,BAO_0000218,,
11121,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley),0,,,22224,10116.0,Autocuration,1,CHEMBL624854,BAO_0000218,,
11122,,A,,In vivo,Oral bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL624855,BAO_0000218,,
11123,,A,,In vivo,Oral bioavailability in rats was determined in vivo,0,,,22224,10116.0,Autocuration,1,CHEMBL624856,BAO_0000218,,
11124,,A,,In vivo,Oral bioavailability in dog,0,,,22224,9615.0,Autocuration,1,CHEMBL882957,BAO_0000218,,
11125,,A,,In vivo,Oral bioavailability of compound in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL624857,BAO_0000218,,
11126,,A,,In vivo,Oral bioavailability of compound in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622202,BAO_0000218,,
11127,,A,,In vivo,Bioavailability in rat of PMEA prodrug,0,,,22224,10116.0,Autocuration,1,CHEMBL622203,BAO_0000218,,
11128,,A,,In vivo,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,1,,,50597,10116.0,Intermediate,1,CHEMBL625522,BAO_0000218,,
11129,,A,,In vivo,Serum conc at 3 hours following 25 mg/kg dose,0,,,22224,9544.0,Autocuration,1,CHEMBL622868,BAO_0000218,,
11130,,A,,In vivo,Urine conc 0-5 hours following 25 mg/kg dose,0,,,22224,9544.0,Autocuration,1,CHEMBL622869,BAO_0000218,1088.0,
11131,,A,,In vivo,Urine conc 0-24 hours following 25 mg/kg dose,0,,,22224,9544.0,Autocuration,1,CHEMBL622870,BAO_0000218,1088.0,
11132,,A,,In vivo,Oral bioavailability in African green monkeys; 20-25,0,,,22224,9534.0,Autocuration,1,CHEMBL622871,BAO_0000218,,
11133,,A,,In vivo,Oral bioavailability in cynomolgus monkey.,1,,,100710,9541.0,Intermediate,1,CHEMBL620560,BAO_0000218,,
11134,,A,,In vivo,Oral bioavailability in dog,0,,,22224,9615.0,Autocuration,1,CHEMBL620561,BAO_0000218,,
11135,,A,,In vivo,Oral bioavailability in dog at 10 mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL620562,BAO_0000218,,
11136,,A,,In vivo,Oral bioavailability in hamster at 10 mg/kg oral dose,1,,,100712,10026.0,Intermediate,1,CHEMBL620563,BAO_0000218,,
11137,,A,,In vivo,Oral bioavailability in rat at 10 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL620564,BAO_0000218,,
11138,,A,,In vivo,Oral bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL872265,BAO_0000218,,
11139,,A,,In vivo,Oral bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL620565,BAO_0000218,,
11140,,A,,In vivo,Oral bioavailability,0,,,22224,9347.0,Autocuration,1,CHEMBL620566,BAO_0000218,,
11141,,A,,In vivo,Oral bioavailability was determined; range 49-102%,0,,,22224,,Autocuration,1,CHEMBL620567,BAO_0000218,,
11142,,A,,In vivo,Oral bioavailability was determined in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL620568,BAO_0000218,,
11143,,A,,In vivo,Oral bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL620569,BAO_0000218,,
11144,,A,,In vivo,Oral bioavailability,0,,,22224,9347.0,Autocuration,1,CHEMBL620570,BAO_0000218,,
11145,,A,,In vivo,Oral bioavailability was determined; Not orally available,0,,,22224,,Autocuration,1,CHEMBL620571,BAO_0000218,,
11146,,A,,In vivo,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),1,,,50594,10090.0,Intermediate,1,CHEMBL620572,BAO_0000218,,
11147,,A,,In vivo,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),0,,,22224,10090.0,Autocuration,1,CHEMBL620573,BAO_0000218,,
11148,,A,,In vivo,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,0,,,22224,10090.0,Autocuration,1,CHEMBL620574,BAO_0000218,,
11149,,A,,In vivo,Oral bioavailability in Rhesus monkey,0,,,22224,9544.0,Autocuration,1,CHEMBL620575,BAO_0000218,,
11150,,A,,In vivo,Oral bioavailability in dog (female mongrel),0,,,22224,9615.0,Autocuration,1,CHEMBL620576,BAO_0000218,,
11151,,A,,In vivo,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,0,,,22224,,Autocuration,1,CHEMBL875846,BAO_0000218,,
11152,,A,,In vivo,Oral bioavailability in dog,0,,,22224,9615.0,Autocuration,1,CHEMBL620577,BAO_0000218,,
11153,,A,,In vivo,Percentage Bioavailability was evaluated.,0,,,22224,,Autocuration,1,CHEMBL620578,BAO_0000218,,
11154,,A,,In vivo,Bioavailability in rat administered i.d.,0,,,22224,10116.0,Autocuration,1,CHEMBL620579,BAO_0000218,,
11155,,A,,In vivo,Bioavailability,0,,,22224,9347.0,Autocuration,1,CHEMBL621248,BAO_0000218,,
11156,,A,,In vivo,Bioavailability in dog (male Beagle) i.v. administration,0,,,22224,9615.0,Autocuration,1,CHEMBL625390,BAO_0000218,,
11157,,A,,In vivo,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",0,,,22224,10116.0,Autocuration,1,CHEMBL625391,BAO_0000218,,
11158,,A,,In vivo,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),0,,,22224,9443.0,Autocuration,1,CHEMBL872266,BAO_0000218,,
11159,,A,,In vivo,Oral bioavailability in rat (Sprague-Dawley) (male),0,,,22224,10116.0,Autocuration,1,CHEMBL625392,BAO_0000218,,
11160,,A,,In vivo,The oral bioavailability was measured on rats after oral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625393,BAO_0000218,,
11161,,A,,In vivo,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625394,BAO_0000218,,
11162,,A,,In vivo,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,,,50797,9544.0,Intermediate,1,CHEMBL625395,BAO_0000218,,
11163,,A,,In vivo,Bioavailability in rat (dose 10 mg/kg i.d.),0,,,22224,10116.0,Autocuration,1,CHEMBL625396,BAO_0000218,,
11164,,A,,In vivo,Bioavailability in dog (male Beagle) i.v. administration,0,,,22224,9615.0,Autocuration,1,CHEMBL625397,BAO_0000218,,
11165,,A,,In vivo,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625398,BAO_0000218,,
11166,,A,,In vivo,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625399,BAO_0000218,178.0,
11167,,A,,In vivo,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL626074,BAO_0000218,2037.0,
11168,,A,,In vivo,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL626075,BAO_0000218,,
11169,,A,,In vivo,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626076,BAO_0000218,1969.0,
11170,,A,,In vivo,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,,,50797,9544.0,Intermediate,1,CHEMBL626077,BAO_0000218,1969.0,
11171,,A,,In vivo,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),1,,,50597,10116.0,Intermediate,1,CHEMBL626078,BAO_0000218,178.0,
11172,,A,,In vivo,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),0,,,22224,,Autocuration,1,CHEMBL625846,BAO_0000218,178.0,
11173,,A,,In vivo,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),0,,,22224,,Autocuration,1,CHEMBL625847,BAO_0000218,178.0,
11174,,A,,In vivo,Maximum concentration observed in rats at an oral dose of 50 mg/kg,1,,,50597,10116.0,Expert,1,CHEMBL625848,BAO_0000218,,
11175,,A,,In vivo,Maximum concentration of compound in plasma administered orally to rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625849,BAO_0000218,1969.0,
11176,,A,,In vivo,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1,,,50588,9615.0,Intermediate,1,CHEMBL626023,BAO_0000218,1969.0,
11177,,A,,In vivo,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1,,,50588,9615.0,Intermediate,1,CHEMBL626024,BAO_0000218,1969.0,
11178,,A,,In vivo,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1,,,50588,9615.0,Intermediate,1,CHEMBL626025,BAO_0000218,1969.0,
11179,,A,,In vivo,Maximum concentration after 10 mg/kg by oral administration,0,,,22224,,Autocuration,1,CHEMBL626026,BAO_0000218,,
11180,,A,,In vivo,Maximum concentration at a dose of 1.5 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626027,BAO_0000218,,
11181,,A,,In vivo,Maximum concentration at a dose of 2.0 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626028,BAO_0000218,,
11182,,A,,In vivo,Maximum concentration in dog plasma,1,,,50588,9615.0,Intermediate,1,CHEMBL626029,BAO_0000218,1969.0,
11183,,A,,In vivo,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,0,,,22224,,Autocuration,1,CHEMBL626030,BAO_0000218,1969.0,
11184,,A,,In vivo,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,0,,,22224,,Autocuration,1,CHEMBL626031,BAO_0000218,1969.0,
11185,,A,,In vivo,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,0,,,22224,,Autocuration,1,CHEMBL626032,BAO_0000218,1969.0,
11186,,A,,In vivo,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,0,,,22224,,Autocuration,1,CHEMBL626033,BAO_0000218,1969.0,
11187,,A,,In vivo,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,0,,,22224,,Autocuration,1,CHEMBL626034,BAO_0000218,1969.0,
11188,,A,,In vivo,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL626035,BAO_0000218,1969.0,
11189,,A,,In vivo,Maximum concentration in plasma at Tmax,0,,,22224,,Autocuration,1,CHEMBL626036,BAO_0000218,1969.0,
11190,,A,,In vivo,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1,,,50588,9615.0,Expert,1,CHEMBL626037,BAO_0000218,1969.0,
11191,,A,,In vivo,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1,,,100712,10026.0,Intermediate,1,CHEMBL626038,BAO_0000218,1969.0,
11192,,A,,In vivo,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626039,BAO_0000218,1969.0,
11193,,A,,In vivo,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626040,BAO_0000218,1969.0,
11194,,A,,In vivo,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1,,,50592,9986.0,Intermediate,1,CHEMBL626041,BAO_0000218,1969.0,
11195,,A,,In vivo,Maximum concentration was calculated,0,,,22224,,Autocuration,1,CHEMBL626042,BAO_0000218,,
11196,,A,,In vivo,Maximum concentration was calculated.,0,,,22224,,Autocuration,1,CHEMBL626043,BAO_0000218,,
11197,,A,,In vivo,Maximum concentration at a peroral dose of 10 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626044,BAO_0000218,,
11198,,A,,In vivo,Maximum concentration of the drug at 10 uM/dg administered perorally,0,,,22224,,Autocuration,1,CHEMBL626045,BAO_0000218,,
11199,,A,,In vivo,Maximum concentration of the drug at 2 uM/dg administered intravenously,0,,,22224,,Autocuration,1,CHEMBL626046,BAO_0000218,,
11200,,A,,In vivo,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1,,,50588,9615.0,Intermediate,1,CHEMBL626047,BAO_0000218,1969.0,
11201,,A,,In vivo,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1,,,100712,10026.0,Intermediate,1,CHEMBL626048,BAO_0000218,1969.0,
11202,,A,,In vivo,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1,,,50597,10116.0,Intermediate,1,CHEMBL626049,BAO_0000218,1969.0,
11203,,A,,In vivo,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626050,BAO_0000218,1969.0,
11204,,A,,In vivo,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL874541,BAO_0000218,1969.0,
11205,,A,,In vivo,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1,,,100712,10026.0,Intermediate,1,CHEMBL622826,BAO_0000218,1969.0,
11206,,A,,In vivo,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1,,,100712,10026.0,Intermediate,1,CHEMBL622827,BAO_0000218,1969.0,
11207,,A,,In vivo,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL622828,BAO_0000218,1969.0,
11208,,A,,In vivo,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1,,,50597,10116.0,Intermediate,1,CHEMBL622829,BAO_0000218,1969.0,
11209,,A,,In vivo,Maximum concentration reached following intravenous administration in male rat,1,,,50597,10116.0,Intermediate,1,CHEMBL876806,BAO_0000218,,
11210,,A,,In vivo,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622830,BAO_0000218,,
11211,,A,,In vivo,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622831,BAO_0000218,,
11212,,A,,In vivo,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626794,BAO_0000218,,
11213,,A,,In vivo,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626795,BAO_0000218,,
11214,,A,,In vivo,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626796,BAO_0000218,,
11215,,A,,In vivo,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626797,BAO_0000218,,
11216,,A,,In vivo,Maximum drug concentration is determined after oral dosing in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL626798,BAO_0000218,,
11217,,A,,In vivo,Maximum observed concentration in oral (5 mg/kg) fasted dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626799,BAO_0000218,,
11218,,A,,In vivo,Maximum observed concentration in oral (5 mg/kg) fed dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626800,BAO_0000218,,
11219,,A,,In vivo,Maximum plasma concentration,0,,,22224,,Autocuration,1,CHEMBL626801,BAO_0000218,1969.0,
11220,,A,,In vivo,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1,,,50597,10116.0,Intermediate,1,CHEMBL876816,BAO_0000218,1969.0,
11221,,A,,In vivo,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626802,BAO_0000218,1969.0,
11222,,A,,In vivo,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626803,BAO_0000218,1969.0,
11223,,A,,In vivo,Maximum plasma concentration following oral administration of 30 umol/kg,0,,,22224,,Autocuration,1,CHEMBL626804,BAO_0000218,1969.0,
11224,,A,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626805,BAO_0000218,1969.0,
11225,,A,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626309,BAO_0000218,1969.0,
11226,,A,,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626310,BAO_0000218,1969.0,
11227,,A,,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626311,BAO_0000218,1969.0,
11228,,A,,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626312,BAO_0000218,1969.0,
11229,,A,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626313,BAO_0000218,995.0,
11230,,A,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626314,BAO_0000218,995.0,
11231,,A,,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626315,BAO_0000218,995.0,
11232,,A,,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626316,BAO_0000218,995.0,
11233,,A,,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,,50597,10116.0,Intermediate,1,CHEMBL626317,BAO_0000218,995.0,
11234,,A,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,50597,10116.0,Intermediate,1,CHEMBL626318,BAO_0000218,,
11235,,A,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,50597,10116.0,Intermediate,1,CHEMBL626319,BAO_0000218,,
11236,,A,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,50597,10116.0,Intermediate,1,CHEMBL626320,BAO_0000218,,
11237,,A,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,50597,10116.0,Intermediate,1,CHEMBL875053,BAO_0000218,,
11238,,A,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,50597,10116.0,Intermediate,1,CHEMBL626321,BAO_0000218,,
11239,,A,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,50597,10116.0,Intermediate,1,CHEMBL626322,BAO_0000218,,
11240,,A,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,50597,10116.0,Intermediate,1,CHEMBL626323,BAO_0000218,,
11241,,A,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,50597,10116.0,Intermediate,1,CHEMBL626324,BAO_0000218,,
11242,,A,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,50597,10116.0,Intermediate,1,CHEMBL626325,BAO_0000218,,
11243,,A,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,50597,10116.0,Intermediate,1,CHEMBL626326,BAO_0000218,,
11244,,A,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),1,,,50597,10116.0,Intermediate,1,CHEMBL626327,BAO_0000218,,
11245,,A,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),1,,,50597,10116.0,Intermediate,1,CHEMBL626328,BAO_0000218,,
11246,,A,,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL626329,BAO_0000218,178.0,
11247,,A,,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL626330,BAO_0000218,178.0,
11248,,A,,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL626331,BAO_0000218,178.0,
11249,,A,,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL626332,BAO_0000218,178.0,
11250,,A,,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL626333,BAO_0000218,178.0,
11251,,A,,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL626334,BAO_0000218,178.0,
11252,,A,,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL626335,BAO_0000218,178.0,
11253,,A,,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624798,BAO_0000218,178.0,
11254,,A,,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624799,BAO_0000218,955.0,
11255,,A,,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624800,BAO_0000218,955.0,
11256,,A,,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624801,BAO_0000218,955.0,
11257,,A,,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624802,BAO_0000218,955.0,
11258,,A,,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624803,BAO_0000218,955.0,
11259,,A,,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624804,BAO_0000218,955.0,
11260,,A,,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624805,BAO_0000218,955.0,
11261,,A,,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624806,BAO_0000218,955.0,
11262,,A,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624807,BAO_0000218,,
11263,,A,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624808,BAO_0000218,,
11264,,A,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624809,BAO_0000218,,
11265,,A,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624810,BAO_0000218,,
11266,,A,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL877618,BAO_0000218,,
11267,,A,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624811,BAO_0000218,,
11268,,A,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624812,BAO_0000218,,
11269,,A,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624813,BAO_0000218,,
11270,,A,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624814,BAO_0000218,,
11271,,A,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624815,BAO_0000218,,
11272,,A,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624816,BAO_0000218,,
11273,,A,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624817,BAO_0000218,,
11274,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624818,BAO_0000218,,
11275,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL624819,BAO_0000218,,
11276,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624820,BAO_0000218,,
11277,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624821,BAO_0000218,,
11278,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,,,50588,9615.0,Intermediate,1,CHEMBL624822,BAO_0000218,,
11279,,A,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL624823,BAO_0000218,,
11280,,A,,,Observed diffusion coefficient in organic solvent for Escherichia coli,1,,,50212,562.0,Intermediate,1,CHEMBL624824,BAO_0000218,,
11281,,A,,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,,50597,10116.0,Intermediate,1,CHEMBL624825,BAO_0000218,178.0,
11282,,A,,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL624826,BAO_0000218,178.0,
11283,,A,,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,,50597,10116.0,Intermediate,1,CHEMBL876817,BAO_0000218,2081.0,
11284,,A,,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL624827,BAO_0000218,2081.0,
11285,,A,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,,50597,10116.0,Intermediate,1,CHEMBL624828,BAO_0000218,,
11286,,A,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL624829,BAO_0000218,,
11287,,A,,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,,50597,10116.0,Intermediate,1,CHEMBL624830,BAO_0000218,2107.0,
11288,,A,,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL624831,BAO_0000218,2107.0,
11289,,A,,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,,50597,10116.0,Intermediate,1,CHEMBL624832,BAO_0000218,2081.0,
11290,,A,,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL624833,BAO_0000218,2081.0,
11291,,A,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL624834,BAO_0000218,,
11292,,A,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,,50597,10116.0,Intermediate,1,CHEMBL624835,BAO_0000218,,
11293,,A,,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,,50597,10116.0,Intermediate,1,CHEMBL624836,BAO_0000218,2106.0,
11294,,A,,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL624837,BAO_0000218,2106.0,
11295,,A,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL624838,BAO_0000218,178.0,
11296,,A,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622188,BAO_0000218,178.0,
11297,,A,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622189,BAO_0000218,948.0,
11298,,A,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,1,,,50597,10116.0,Intermediate,1,CHEMBL622190,BAO_0000218,948.0,
11299,,A,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625170,BAO_0000218,948.0,
11300,,A,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625171,BAO_0000218,2113.0,
11301,,A,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625172,BAO_0000218,2113.0,
11302,,A,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625173,BAO_0000218,2113.0,
11303,,A,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625174,BAO_0000218,2107.0,
11304,,A,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625175,BAO_0000218,2107.0,
11305,,A,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,1,,,50597,10116.0,Intermediate,1,CHEMBL625176,BAO_0000218,2107.0,
11306,,A,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625177,BAO_0000218,2048.0,
11307,,A,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625178,BAO_0000218,2048.0,
11308,,A,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,1,,,50597,10116.0,Intermediate,1,CHEMBL625179,BAO_0000218,2048.0,
11309,,A,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625180,BAO_0000218,2048.0,
11310,,A,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",0,,,22224,,Autocuration,1,CHEMBL625181,BAO_0000218,,
11311,,A,,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,1,,,50594,10090.0,Intermediate,1,CHEMBL625182,BAO_0000218,1088.0,
11312,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625183,BAO_0000218,,
11313,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL875848,BAO_0000218,,
11314,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622260,BAO_0000218,,
11315,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622261,BAO_0000218,,
11316,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622262,BAO_0000218,,
11317,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622263,BAO_0000218,2113.0,
11318,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622418,BAO_0000218,2113.0,
11319,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL622419,BAO_0000218,2107.0,
11320,,A,,In vivo,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL623388,BAO_0000218,,
11321,,A,,In vivo,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL623389,BAO_0000218,2107.0,
11322,,A,,In vivo,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL623390,BAO_0000218,,
11323,,A,,In vivo,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL623391,BAO_0000218,,
11324,,A,,In vivo,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL623392,BAO_0000218,178.0,
11325,,A,,In vivo,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL623393,BAO_0000218,2037.0,
11326,,A,,In vivo,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL623394,BAO_0000218,,
11327,,A,,In vivo,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL618885,BAO_0000218,,
11328,,A,,In vivo,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL618886,BAO_0000218,2107.0,
11329,,A,,In vivo,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL618887,BAO_0000218,,
11330,,A,,In vivo,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL619535,BAO_0000218,,
11331,,A,,In vivo,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL619536,BAO_0000218,178.0,
11332,,A,,In vivo,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL619537,BAO_0000218,2037.0,
11333,,A,,In vivo,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL619705,BAO_0000218,,
11334,,A,,In vivo,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL619706,BAO_0000218,,
11335,,A,,In vivo,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL619707,BAO_0000218,2107.0,
11336,,A,,In vivo,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL619708,BAO_0000218,,
11337,,A,,In vivo,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625219,BAO_0000218,,
11338,,A,,In vivo,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625220,BAO_0000218,178.0,
11339,,A,,In vivo,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625221,BAO_0000218,2037.0,
11340,,A,,In vivo,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625222,BAO_0000218,,
11341,,A,,In vivo,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625223,BAO_0000218,,
11342,,A,,In vivo,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625224,BAO_0000218,2107.0,
11343,,A,,In vivo,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,,50594,10090.0,Intermediate,1,CHEMBL625225,BAO_0000218,,
11344,,A,,In vivo,Biodistribution in Rat blood after 24 hours of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625226,BAO_0000218,178.0,
11345,,A,,In vivo,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL625227,BAO_0000218,178.0,
11346,,A,,In vivo,Biodistribution in Rat blood after 30 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625228,BAO_0000218,178.0,
11347,,A,,In vivo,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL875354,BAO_0000218,178.0,
11348,,A,,In vivo,Biodistribution in Rat blood after 5 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625229,BAO_0000218,178.0,
11349,,A,,In vivo,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL625230,BAO_0000218,178.0,
11350,,A,,In vivo,Biodistribution in Rat heart after 24 hours of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625231,BAO_0000218,948.0,
11351,,A,,In vivo,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL625900,BAO_0000218,948.0,
11352,,A,,In vivo,Biodistribution in Rat heart after 30 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625901,BAO_0000218,948.0,
11353,,A,,In vivo,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL625902,BAO_0000218,948.0,
11354,,A,,In vivo,Biodistribution in Rat heart after 5 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625903,BAO_0000218,948.0,
11355,,A,,In vivo,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL625904,BAO_0000218,948.0,
11356,,A,,In vivo,Biodistribution in Rat liver after 24 hours of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625905,BAO_0000218,2107.0,
11357,,A,,In vivo,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL627861,BAO_0000218,2107.0,
11358,,A,,In vivo,Biodistribution in Rat liver after 30 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627862,BAO_0000218,2107.0,
11359,,A,,In vivo,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL627863,BAO_0000218,2107.0,
11360,,A,,In vivo,Biodistribution in Rat liver after 30 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL627769,BAO_0000218,2107.0,
11361,,A,,In vivo,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1,,,50588,9615.0,Intermediate,1,CHEMBL627770,BAO_0000218,1969.0,
11362,,A,,In vivo,Cmax in cynomolgus monkey (PO dose),1,,,100710,9541.0,Intermediate,1,CHEMBL627771,BAO_0000218,,
11363,,A,,In vivo,Cmax in rat (PO dose),1,,,50597,10116.0,Intermediate,1,CHEMBL627772,BAO_0000218,,
11364,,A,,In vivo,Cmax in rat (PO dose),1,,,50597,10116.0,Intermediate,1,CHEMBL627773,BAO_0000218,,
11365,,A,,In vivo,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621922,BAO_0000218,1969.0,
11366,,A,,In vivo,Cmax in rat plasma after oral dose (10 mg/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL621923,BAO_0000218,1969.0,
11367,,A,,In vivo,Cmax in plasma after oral dose (10 mg/kg),0,,,22224,,Autocuration,1,CHEMBL621924,BAO_0000218,1969.0,
11368,,A,,In vivo,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,1,,,50588,9615.0,Intermediate,1,CHEMBL621925,BAO_0000218,1969.0,
11369,,A,,In vivo,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,0,,,22224,314293.0,Autocuration,1,CHEMBL621926,BAO_0000218,1969.0,
11370,,A,,In vivo,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,1,,,50592,9986.0,Intermediate,1,CHEMBL621927,BAO_0000218,1969.0,
11371,,A,,In vivo,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,1,,,50597,10116.0,Intermediate,1,CHEMBL621928,BAO_0000218,1969.0,
11372,,A,,In vivo,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL621929,BAO_0000218,1969.0,
11373,,A,,In vivo,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL621930,BAO_0000218,1969.0,
11374,,A,,In vivo,Maximum plasma concentration after oral dosing in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL621931,BAO_0000218,1969.0,
11375,,A,,In vivo,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL621932,BAO_0000218,1969.0,
11376,,A,,In vivo,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL621933,BAO_0000218,1969.0,
11377,,A,,In vivo,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621934,BAO_0000218,1969.0,
11378,,A,,In vivo,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL621935,BAO_0000218,1969.0,
11379,,A,,In vivo,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL621936,BAO_0000218,1969.0,
11380,,A,,In vivo,Maximum plasma concentration was determined,0,,,22224,,Autocuration,1,CHEMBL621937,BAO_0000218,1969.0,
11381,,A,,In vivo,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL621938,BAO_0000218,1969.0,
11382,,A,,In vivo,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL621939,BAO_0000218,1969.0,
11383,,A,,In vivo,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL621940,BAO_0000218,1969.0,
11384,,A,,In vivo,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL621941,BAO_0000218,1969.0,
11385,,A,,In vivo,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL621942,BAO_0000218,1969.0,
11386,,A,,In vivo,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL626178,BAO_0000218,1969.0,
11387,,A,,In vivo,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL626179,BAO_0000218,1969.0,
11388,,A,,In vivo,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL626180,BAO_0000218,1969.0,
11389,,A,,In vivo,Plasma Cmax in rat (PO dose),1,,,50597,10116.0,Intermediate,1,CHEMBL626181,BAO_0000218,1969.0,
11390,,A,,In vivo,Maximum serum concentration after po dose of 5.22 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626182,BAO_0000218,,
11391,,A,,In vivo,Maximum serum concentration after po dose of 5.46 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626183,BAO_0000218,,
11392,,A,,In vivo,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626184,BAO_0000218,,
11393,,A,,In vivo,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626185,BAO_0000218,,
11394,,A,,In vivo,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,1,,,50588,9615.0,Intermediate,1,CHEMBL626186,BAO_0000218,1969.0,
11395,,A,,In vivo,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,1,,,50588,9615.0,Intermediate,1,CHEMBL877589,BAO_0000218,1969.0,
11396,,A,,In vivo,Maximum concentration of the drug at 1 uM/dg administered intravenously,0,,,22224,,Autocuration,1,CHEMBL626187,BAO_0000218,,
11397,,A,,In vivo,Maximum concentration of the drug at 20 uM/dg administered perorally,0,,,22224,,Autocuration,1,CHEMBL626188,BAO_0000218,,
11398,,A,,In vivo,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,0,,,22224,,Autocuration,1,CHEMBL626189,BAO_0000218,,
11399,,A,,In vivo,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,0,,,22224,,Autocuration,1,CHEMBL626855,BAO_0000218,178.0,
11400,,A,,In vivo,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,0,,,22224,,Autocuration,1,CHEMBL623781,BAO_0000218,178.0,
11401,,A,,In vivo,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,0,,,22224,,Autocuration,1,CHEMBL623782,BAO_0000218,178.0,
11402,,A,,In vivo,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623783,BAO_0000218,1969.0,
11403,,A,,In vivo,Cmax in dog plasma after 1mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL623784,BAO_0000218,1969.0,
11404,,A,,In vivo,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL623785,BAO_0000218,1969.0,
11405,,A,,In vivo,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL623786,BAO_0000218,1969.0,
11406,,A,,In vivo,Oral maximum concentration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623787,BAO_0000218,,
11407,,A,,In vivo,Oral maximum concentration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623788,BAO_0000218,,
11408,,A,,In vivo,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,1,,,50594,10090.0,Intermediate,1,CHEMBL623789,BAO_0000218,1969.0,
11409,,A,,In vivo,Peak concentration in blood after intravenous administration to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623790,BAO_0000218,178.0,
11410,,A,,In vivo,Peak concentration in blood after peroral administration to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623791,BAO_0000218,178.0,
11411,,A,,In vivo,Peak concentration in rat plasma was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL623792,BAO_0000218,1969.0,
11412,,A,,In vivo,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,0,,,22224,314293.0,Autocuration,1,CHEMBL623793,BAO_0000218,1969.0,
11413,,A,,In vivo,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL623794,BAO_0000218,1969.0,
11414,,A,,In vivo,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL623795,BAO_0000218,1969.0,
11415,,A,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623796,BAO_0000218,,
11416,,A,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623797,BAO_0000218,,
11417,,A,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623798,BAO_0000218,,
11418,,A,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623799,BAO_0000218,,
11419,,A,,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624490,BAO_0000218,160.0,
11420,,A,,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624491,BAO_0000218,160.0,
11421,,A,,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624492,BAO_0000218,160.0,
11422,,A,,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624493,BAO_0000218,160.0,
11423,,A,,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL877595,BAO_0000218,160.0,
11424,,A,,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624494,BAO_0000218,160.0,
11425,,A,,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624495,BAO_0000218,160.0,
11426,,A,,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624681,BAO_0000218,160.0,
11427,,A,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624682,BAO_0000218,,
11428,,A,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624683,BAO_0000218,,
11429,,A,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624684,BAO_0000218,,
11430,,A,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624685,BAO_0000218,,
11431,,A,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624686,BAO_0000218,,
11432,,A,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624687,BAO_0000218,,
11433,,A,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624688,BAO_0000218,,
11434,,A,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL627161,BAO_0000218,,
11435,,A,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL622127,BAO_0000218,,
11436,,A,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL622128,BAO_0000218,,
11437,,A,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL874384,BAO_0000218,,
11438,,A,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624898,BAO_0000218,,
11439,,A,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624899,BAO_0000218,,
11440,,A,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624900,BAO_0000218,,
11441,,A,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624901,BAO_0000218,,
11442,,A,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624902,BAO_0000218,,
11443,,A,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624903,BAO_0000218,,
11444,,A,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624904,BAO_0000218,,
11445,,A,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624905,BAO_0000218,,
11446,,A,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624906,BAO_0000218,,
11447,,A,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624907,BAO_0000218,,
11448,,A,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624908,BAO_0000218,,
11449,,A,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624909,BAO_0000218,,
11450,,A,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624910,BAO_0000218,,
11451,,A,,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624911,BAO_0000218,2385.0,
11452,,A,,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL874388,BAO_0000218,2385.0,
11453,,A,,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL624912,BAO_0000218,2385.0,
11454,,A,,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL622930,BAO_0000218,2385.0,
11455,,A,,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623121,BAO_0000218,2385.0,
11456,,A,,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623122,BAO_0000218,2385.0,
11457,,A,,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623123,BAO_0000218,2385.0,
11458,,A,,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623124,BAO_0000218,2385.0,
11459,,A,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623125,BAO_0000218,,
11460,,A,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623126,BAO_0000218,,
11461,,A,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623127,BAO_0000218,,
11462,,A,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623128,BAO_0000218,,
11463,,A,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623129,BAO_0000218,,
11464,,A,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623130,BAO_0000218,,
11465,,A,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623131,BAO_0000218,,
11466,,A,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL623132,BAO_0000218,,
11467,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623133,BAO_0000218,2107.0,
11468,,A,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623134,BAO_0000218,,
11469,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL874389,BAO_0000218,,
11470,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623135,BAO_0000218,,
11471,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623136,BAO_0000218,,
11472,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623137,BAO_0000218,,
11473,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623138,BAO_0000218,,
11474,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623139,BAO_0000218,2113.0,
11475,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623140,BAO_0000218,2113.0,
11476,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623141,BAO_0000218,2107.0,
11477,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623142,BAO_0000218,2107.0,
11478,,A,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL623143,BAO_0000218,,
11479,,A,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,1,,,50594,10090.0,Intermediate,1,CHEMBL623144,BAO_0000218,1088.0,
11480,,A,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL623405,BAO_0000218,1088.0,
11481,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624074,BAO_0000218,,
11482,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624075,BAO_0000218,,
11483,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624076,BAO_0000218,,
11484,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624077,BAO_0000218,,
11485,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624078,BAO_0000218,,
11486,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624079,BAO_0000218,2113.0,
11487,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624261,BAO_0000218,2113.0,
11488,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624262,BAO_0000218,,
11489,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624263,BAO_0000218,,
11490,,A,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624264,BAO_0000218,,
11491,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624265,BAO_0000218,,
11492,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624266,BAO_0000218,,
11493,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624267,BAO_0000218,,
11494,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624268,BAO_0000218,,
11495,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL875227,BAO_0000218,,
11496,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624269,BAO_0000218,2113.0,
11497,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624270,BAO_0000218,2113.0,
11498,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624271,BAO_0000218,,
11499,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624272,BAO_0000218,,
11500,,A,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,,,50597,10116.0,Intermediate,1,CHEMBL624273,BAO_0000218,,
11501,,A,,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624274,BAO_0000218,1088.0,
11502,,A,,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624275,BAO_0000218,1088.0,
11503,,A,,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624276,BAO_0000218,1088.0,
11504,,A,,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624277,BAO_0000218,1088.0,
11505,,A,,,% dose converted to 2-amino-5-chlorophenyl sulfate,0,,,22224,,Autocuration,1,CHEMBL624278,BAO_0000019,,
11506,,A,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),0,,,22224,,Autocuration,1,CHEMBL624279,BAO_0000019,,
11507,,A,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL624280,BAO_0000218,1988.0,
11508,,A,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL624281,BAO_0000218,1988.0,
11509,,A,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL622933,BAO_0000218,1988.0,
11510,,A,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL622934,BAO_0000218,1988.0,
11511,,A,,In vivo,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL622935,BAO_0000218,2107.0,
11512,,A,,In vivo,Biodistribution in Rat liver after 5 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622936,BAO_0000218,2107.0,
11513,,A,,In vivo,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL875228,BAO_0000218,2107.0,
11514,,A,,In vivo,Biodistribution in Rat lung after 24 hours of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL622937,BAO_0000218,2048.0,
11515,,A,,In vivo,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL622938,BAO_0000218,2048.0,
11516,,A,,In vivo,Biodistribution in Rat lung after 30 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL619736,BAO_0000218,2048.0,
11517,,A,,In vivo,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL625117,BAO_0000218,2048.0,
11518,,A,,In vivo,Biodistribution in Rat lung after 5 minutes of iv administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625118,BAO_0000218,2048.0,
11519,,A,,In vivo,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,1,,,50597,10116.0,Intermediate,1,CHEMBL625119,BAO_0000218,2048.0,
11520,,A,,In vivo,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",1,,,50597,10116.0,Intermediate,1,CHEMBL625120,BAO_0000218,2037.0,
11521,,A,,In vivo,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",1,,,50597,10116.0,Intermediate,1,CHEMBL625121,BAO_0000218,,
11522,,A,,In vivo,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",1,,,50597,10116.0,Intermediate,1,CHEMBL625122,BAO_0000218,10000006.0,
11523,,A,,In vivo,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622204,BAO_0000218,178.0,
11524,,A,,In vivo,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL877503,BAO_0000218,178.0,
11525,,A,,In vivo,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627127,BAO_0000218,178.0,
11526,,A,,In vivo,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,0,,,22224,,Autocuration,1,CHEMBL627128,BAO_0000218,10000000.0,
11527,,A,,In vivo,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,0,,,22224,,Autocuration,1,CHEMBL627129,BAO_0000218,10000000.0,
11528,,A,,In vivo,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,0,,,22224,,Autocuration,1,CHEMBL627130,BAO_0000218,10000000.0,
11529,,A,,In vivo,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627131,BAO_0000218,955.0,
11530,,A,,In vivo,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627132,BAO_0000218,955.0,
11531,,A,,In vivo,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627133,BAO_0000218,955.0,
11532,,A,,In vivo,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627134,BAO_0000218,2037.0,
11533,,A,,In vivo,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627135,BAO_0000218,2037.0,
11534,,A,,In vivo,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL627136,BAO_0000218,2037.0,
11535,,A,,In vivo,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628435,BAO_0000218,,
11536,,A,,In vivo,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628436,BAO_0000218,,
11537,,A,,In vivo,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628437,BAO_0000218,,
11538,,A,,In vivo,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628438,BAO_0000218,948.0,
11539,,A,,In vivo,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628439,BAO_0000218,948.0,
11540,,A,,In vivo,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628440,BAO_0000218,948.0,
11541,,A,,In vivo,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628441,BAO_0000218,10000000.0,
11542,,A,,In vivo,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628442,BAO_0000218,10000000.0,
11543,,A,,In vivo,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628443,BAO_0000218,10000000.0,
11544,,A,,In vivo,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628444,BAO_0000218,2113.0,
11545,,A,,In vivo,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628445,BAO_0000218,2113.0,
11546,,A,,In vivo,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL877504,BAO_0000218,2113.0,
11547,,A,,In vivo,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL628446,BAO_0000218,2107.0,
11548,,A,,In vivo,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626874,BAO_0000218,2107.0,
11549,,A,,In vivo,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626875,BAO_0000218,2107.0,
11550,,A,,In vivo,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626876,BAO_0000218,2048.0,
11551,,A,,In vivo,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626877,BAO_0000218,2048.0,
11552,,A,,In vivo,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626878,BAO_0000218,2048.0,
11553,,A,,In vivo,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL626879,BAO_0000218,2385.0,
11554,,A,,In vivo,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,0,,,22224,314293.0,Autocuration,1,CHEMBL626880,BAO_0000218,1969.0,
11555,,A,,In vivo,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,1,,,50594,10090.0,Intermediate,1,CHEMBL626881,BAO_0000218,1969.0,
11556,,A,,In vivo,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626882,BAO_0000218,1969.0,
11557,,A,,In vivo,Peak plasma concentration was measured in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL626883,BAO_0000218,1969.0,
11558,,A,,In vivo,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626884,BAO_0000218,,
11559,,A,,In vivo,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626885,BAO_0000218,,
11560,,A,,In vivo,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626886,BAO_0000218,,
11561,,A,,In vivo,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626887,BAO_0000218,,
11562,,A,,In vivo,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626888,BAO_0000218,,
11563,,A,,In vivo,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626889,BAO_0000218,,
11564,,A,,In vivo,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL626761,BAO_0000218,,
11565,,A,,In vivo,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626762,BAO_0000218,,
11566,,A,,In vivo,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626763,BAO_0000218,,
11567,,A,,In vivo,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626764,BAO_0000218,,
11568,,A,,In vivo,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626765,BAO_0000218,,
11569,,A,,In vivo,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626766,BAO_0000218,,
11570,,A,,In vivo,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626767,BAO_0000218,,
11571,,A,,In vivo,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,1,,,50597,10116.0,Intermediate,1,CHEMBL626768,BAO_0000218,,
11572,,A,,In vivo,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626769,BAO_0000218,,
11573,,A,,In vivo,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,1,,,50588,9615.0,Intermediate,1,CHEMBL874463,BAO_0000218,,
11574,,A,,In vivo,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL626770,BAO_0000218,,
11575,,A,,In vivo,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,0,,,22224,314293.0,Autocuration,1,CHEMBL626771,BAO_0000218,,
11576,,A,,In vivo,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626772,BAO_0000218,,
11577,,A,,In vivo,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,1,,,100710,9541.0,Intermediate,1,CHEMBL626773,BAO_0000218,,
11578,,A,,In vivo,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,1,,,50594,10090.0,Intermediate,1,CHEMBL626774,BAO_0000218,,
11579,,A,,In vivo,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL626775,BAO_0000218,,
11580,,A,,In vivo,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL626776,BAO_0000218,,
11581,,A,,In vivo,Maximum concentration (Cmax) in rat when administered orally,1,,,50597,10116.0,Intermediate,1,CHEMBL626777,BAO_0000218,,
11582,,A,,In vivo,Maximal concentration in monkey plasma after 25 mg/kg oral dose,0,,,22224,314293.0,Autocuration,1,CHEMBL626778,BAO_0000218,1969.0,
11583,,A,,In vivo,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",0,,,22224,10116.0,Autocuration,1,CHEMBL626779,BAO_0000218,,
11584,,A,,In vivo,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",0,,,22224,10116.0,Autocuration,1,CHEMBL626780,BAO_0000218,,
11585,,A,,In vivo,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,0,,,22224,,Autocuration,1,CHEMBL626781,BAO_0000218,1969.0,
11586,,A,,In vivo,Pharmacokinetic profile Cmax was evaluated in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL632164,BAO_0000218,,
11587,,A,,In vivo,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL632165,BAO_0000218,,
11588,,A,,In vivo,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),1,,,50594,10090.0,Intermediate,1,CHEMBL632166,BAO_0000218,,
11589,,A,,In vivo,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL632167,BAO_0000218,,
11590,,A,,In vivo,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),1,,,50594,10090.0,Intermediate,1,CHEMBL632168,BAO_0000218,,
11591,,A,,In vivo,Cmax in rat plasma,0,,,22224,10116.0,Autocuration,1,CHEMBL632169,BAO_0000218,1969.0,
11592,,A,,In vivo,Cmax in dog plasma after 30mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL632170,BAO_0000218,1969.0,
11593,,A,,In vivo,Cmax in rat plasma after 30mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL632171,BAO_0000218,1969.0,
11594,,A,,In vivo,Plasma level in rats at 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632172,BAO_0000218,1969.0,
11595,,A,,In vivo,Tested for maximum plasma concentration in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL632173,BAO_0000218,1969.0,
11596,,A,,In vivo,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL632174,BAO_0000218,,
11597,,A,,In vivo,The Cmax values in female wistar rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL632175,BAO_0000218,,
11598,,A,,In vivo,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,1,,,50588,9615.0,Intermediate,1,CHEMBL632176,BAO_0000218,1969.0,
11599,,A,,In vivo,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL632177,BAO_0000218,1969.0,
11600,,A,,In vivo,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,1,,,50597,10116.0,Intermediate,1,CHEMBL632178,BAO_0000218,1969.0,
11601,,A,,In vivo,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL632179,BAO_0000218,,
11602,,A,,In vivo,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL632180,BAO_0000218,178.0,
11603,,A,,In vivo,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL632181,BAO_0000218,178.0,
11604,,A,,In vivo,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL632182,BAO_0000218,178.0,
11605,,A,,In vivo,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,0,,,22224,10090.0,Autocuration,1,CHEMBL632183,BAO_0000218,178.0,
11606,,A,,In vivo,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL632184,BAO_0000218,,
11607,,A,,In vivo,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL874470,BAO_0000218,,
11608,,A,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL631302,BAO_0000218,,
11609,,A,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL631303,BAO_0000218,,
11610,,A,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL631304,BAO_0000218,,
11611,,A,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL631305,BAO_0000218,,
11612,,A,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL631306,BAO_0000218,,
11613,,A,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL631307,BAO_0000218,,
11614,,A,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL631308,BAO_0000218,,
11615,,A,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625557,BAO_0000218,,
11616,,A,,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625558,BAO_0000218,2106.0,
11617,,A,,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625559,BAO_0000218,2106.0,
11618,,A,,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625560,BAO_0000218,2106.0,
11619,,A,,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625561,BAO_0000218,2106.0,
11620,,A,,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625562,BAO_0000218,2106.0,
11621,,A,,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL875320,BAO_0000218,2106.0,
11622,,A,,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625563,BAO_0000218,2106.0,
11623,,A,,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625564,BAO_0000218,2106.0,
11624,,A,,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625565,BAO_0000218,995.0,
11625,,A,,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625566,BAO_0000218,995.0,
11626,,A,,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625567,BAO_0000218,995.0,
11627,,A,,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL625568,BAO_0000218,995.0,
11628,,A,,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL628217,BAO_0000218,995.0,
11629,,A,,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL628218,BAO_0000218,995.0,
11630,,A,,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL628219,BAO_0000218,995.0,
11631,,A,,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",1,,,50597,10116.0,Intermediate,1,CHEMBL628220,BAO_0000218,995.0,
11632,,A,,,Distribution in the blood after 120 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628221,BAO_0000019,,
11633,,A,,,Distribution in the blood after 15 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628222,BAO_0000019,,
11634,,A,,,Distribution in the blood after 30 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628223,BAO_0000019,,
11635,,A,,,Distribution in the blood after 5 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628224,BAO_0000019,,
11636,,A,,,Distribution in the blood after 60 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628225,BAO_0000019,,
11637,,A,,,Distribution in the blood after 90 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628226,BAO_0000019,,
11638,,A,,,Distribution in the bone after 120 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628227,BAO_0000019,,
11639,,A,,,Distribution in the bone after 15 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL875481,BAO_0000019,,
11640,,A,,,Distribution in the bone after 30 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628228,BAO_0000019,,
11641,,A,,,Distribution in the bone after 5 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628229,BAO_0000019,,
11642,,A,,,Distribution in the bone after 60 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628230,BAO_0000019,,
11643,,A,,,Distribution in the bone after 90 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628231,BAO_0000019,,
11644,,A,,,Distribution in the heart after 120 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628232,BAO_0000019,,
11645,,A,,,Distribution in the heart after 15 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628233,BAO_0000019,,
11646,,A,,,Distribution in the heart after 30 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628234,BAO_0000019,,
11647,,A,,,Distribution in the heart after 5 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628235,BAO_0000019,,
11648,,A,,,Distribution in the heart after 60 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628236,BAO_0000019,,
11649,,A,,,Distribution in the heart after 90 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628237,BAO_0000019,,
11650,,A,,,Distribution in the kidneys after 120 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628238,BAO_0000019,,
11651,,A,,,Distribution in the kidneys after 15 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628239,BAO_0000019,,
11652,,A,,,Distribution in the kidneys after 30 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628240,BAO_0000019,,
11653,,A,,,Distribution in the kidneys after 5 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628241,BAO_0000019,,
11654,,A,,,Distribution in the kidneys after 60 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628242,BAO_0000019,,
11655,,A,,,Distribution in the kidneys after 90 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL875482,BAO_0000019,,
11656,,A,,,Distribution in the liver after 120 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628243,BAO_0000019,,
11657,,A,,,Distribution in the liver after 15 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628244,BAO_0000019,,
11658,,A,,,Distribution in the liver after 30 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628245,BAO_0000019,,
11659,,A,,,Distribution in the liver after 5 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628246,BAO_0000019,,
11660,,A,,,Distribution in the liver after 60 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628247,BAO_0000019,,
11661,,A,,,Distribution in the liver after 90 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628248,BAO_0000019,,
11662,,A,,,Distribution in the lung after 120 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628249,BAO_0000019,,
11663,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",1,,,50594,10090.0,Intermediate,1,CHEMBL625452,BAO_0000218,,
11664,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",1,,,50594,10090.0,Intermediate,1,CHEMBL625453,BAO_0000218,,
11665,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",1,,,50594,10090.0,Intermediate,1,CHEMBL625454,BAO_0000218,,
11666,,A,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",1,,,50594,10090.0,Intermediate,1,CHEMBL623844,BAO_0000218,,
11667,,A,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623845,BAO_0000218,,
11668,,A,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623846,BAO_0000218,,
11669,,A,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,0,,,22224,,Autocuration,1,CHEMBL623847,BAO_0000218,,
11670,,A,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,,,100710,9541.0,Intermediate,1,CHEMBL623848,BAO_0000218,,
11671,,A,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,,,100710,9541.0,Intermediate,1,CHEMBL623849,BAO_0000218,,
11672,,A,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,,,100710,9541.0,Intermediate,1,CHEMBL623850,BAO_0000218,,
11673,,A,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,,,100710,9541.0,Intermediate,1,CHEMBL623851,BAO_0000218,,
11674,,A,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL623852,BAO_0000218,,
11675,,A,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,1,,,50506,9669.0,Intermediate,1,CHEMBL624551,BAO_0000218,,
11676,,A,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",1,,,50506,9669.0,Intermediate,1,CHEMBL624552,BAO_0000218,,
11677,,A,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL624553,BAO_0000218,,
11678,,A,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,0,,,22224,314293.0,Autocuration,1,CHEMBL624554,BAO_0000218,,
11679,,A,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624555,BAO_0000218,,
11680,,A,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,,,50597,10116.0,Intermediate,1,CHEMBL624741,BAO_0000218,,
11681,,A,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",1,,,50588,9615.0,Intermediate,1,CHEMBL624742,BAO_0000218,,
11682,,A,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",1,,,100712,10026.0,Intermediate,1,CHEMBL624743,BAO_0000218,,
11683,,A,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",1,,,50597,10116.0,Intermediate,1,CHEMBL877606,BAO_0000218,,
11684,,A,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,0,,,22224,,Autocuration,1,CHEMBL624744,BAO_0000218,,
11685,,A,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,0,,,22224,,Autocuration,1,CHEMBL624745,BAO_0000218,178.0,
11686,,A,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,0,,,22224,,Autocuration,1,CHEMBL624746,BAO_0000218,178.0,
11687,,A,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,0,,,22224,,Autocuration,1,CHEMBL624747,BAO_0000218,178.0,
11688,,A,,,Oral absorption expressed as Area under curve was determined,0,,,22224,,Autocuration,1,CHEMBL624748,BAO_0000019,,
11689,,A,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL622504,BAO_0000218,,
11690,,A,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",1,,,50588,9615.0,Intermediate,1,CHEMBL622505,BAO_0000218,,
11691,,A,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",1,,,100712,10026.0,Intermediate,1,CHEMBL622506,BAO_0000218,,
11692,,A,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",1,,,100712,10026.0,Intermediate,1,CHEMBL622507,BAO_0000218,,
11693,,A,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",1,,,50597,10116.0,Intermediate,1,CHEMBL622508,BAO_0000218,,
11694,,A,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,0,,,22224,,Autocuration,1,CHEMBL622509,BAO_0000019,,
11695,,A,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622510,BAO_0000218,,
11696,,A,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),1,,,50597,10116.0,Intermediate,1,CHEMBL622511,BAO_0000218,,
11697,,A,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,1,,,100710,9541.0,Intermediate,1,CHEMBL622512,BAO_0000218,,
11698,,A,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,1,,,100710,9541.0,Intermediate,1,CHEMBL622513,BAO_0000218,,
11699,,A,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,1,,,100710,9541.0,Intermediate,1,CHEMBL622514,BAO_0000218,,
11700,,A,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,1,,,50588,9615.0,Intermediate,1,CHEMBL622515,BAO_0000218,,
11701,,A,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,1,,,50588,9615.0,Intermediate,1,CHEMBL622516,BAO_0000218,,
11702,,A,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL622517,BAO_0000218,,
11703,,A,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL622518,BAO_0000218,,
11704,,A,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL622519,BAO_0000218,,
11705,,A,,In vivo,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622520,BAO_0000218,2385.0,
11706,,A,,In vivo,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL622521,BAO_0000218,2385.0,
11707,,A,,In vivo,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50594,10090.0,Intermediate,1,CHEMBL625113,BAO_0000218,14.0,
11708,,A,,In vivo,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625114,BAO_0000218,14.0,
11709,,A,,In vivo,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL874397,BAO_0000218,14.0,
11710,,A,,In vivo,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625115,BAO_0000218,2106.0,
11711,,A,,In vivo,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL625116,BAO_0000218,2106.0,
11712,,A,,In vivo,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623932,BAO_0000218,2106.0,
11713,,A,,In vivo,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623933,BAO_0000218,2435.0,
11714,,A,,In vivo,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623934,BAO_0000218,2435.0,
11715,,A,,In vivo,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623935,BAO_0000218,2435.0,
11716,,A,,In vivo,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623936,BAO_0000218,2046.0,
11717,,A,,In vivo,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623937,BAO_0000218,2046.0,
11718,,A,,In vivo,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,50597,10116.0,Intermediate,1,CHEMBL623938,BAO_0000218,2046.0,
11719,,A,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,,50594,10090.0,Intermediate,1,CHEMBL623939,BAO_0000218,,
11720,,A,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL623940,BAO_0000218,,
11721,,A,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL623941,BAO_0000218,,
11722,,A,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL627216,BAO_0000218,,
11723,,A,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL623942,BAO_0000218,,
11724,,A,,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,,50594,10090.0,Intermediate,1,CHEMBL618793,BAO_0000218,955.0,
11725,,A,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618794,BAO_0000218,955.0,
11726,,A,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618795,BAO_0000218,955.0,
11727,,A,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618796,BAO_0000218,,
11728,,A,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618797,BAO_0000218,,
11729,,A,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,1,,,50594,10090.0,Intermediate,1,CHEMBL618798,BAO_0000218,2113.0,
11730,,A,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,,50594,10090.0,Intermediate,1,CHEMBL618799,BAO_0000218,2113.0,
11731,,A,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618800,BAO_0000218,2113.0,
11732,,A,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618801,BAO_0000218,2113.0,
11733,,A,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618802,BAO_0000218,2113.0,
11734,,A,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618803,BAO_0000218,2113.0,
11735,,A,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,1,,,50594,10090.0,Intermediate,1,CHEMBL618804,BAO_0000218,2107.0,
11736,,A,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,,50594,10090.0,Intermediate,1,CHEMBL618805,BAO_0000218,2107.0,
11737,,A,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618806,BAO_0000218,2107.0,
11738,,A,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618807,BAO_0000218,2107.0,
11739,,A,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618808,BAO_0000218,2107.0,
11740,,A,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618809,BAO_0000218,2107.0,
11741,,A,,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,,50594,10090.0,Intermediate,1,CHEMBL618810,BAO_0000218,2385.0,
11742,,A,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618811,BAO_0000218,2385.0,
11743,,A,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL875844,BAO_0000218,2385.0,
11744,,A,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618812,BAO_0000218,2385.0,
11745,,A,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618813,BAO_0000218,2385.0,
11746,,A,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,,50594,10090.0,Intermediate,1,CHEMBL618814,BAO_0000218,,
11747,,A,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618815,BAO_0000218,,
11748,,A,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618816,BAO_0000218,,
11749,,A,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL618817,BAO_0000218,,
11750,,A,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL620544,BAO_0000218,,
11751,,A,,In vivo,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL626230,BAO_0000218,,
11752,,A,,In vivo,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL626231,BAO_0000218,,
11753,,A,,In vivo,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL626232,BAO_0000218,,
11754,,A,,In vivo,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL626233,BAO_0000218,1969.0,
11755,,A,,In vivo,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626234,BAO_0000218,1969.0,
11756,,A,,In vivo,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL875341,BAO_0000218,1969.0,
11757,,A,,In vivo,The maximum plasma concentration (100 mg/kg) administered orally in human,1,,,50587,9606.0,Intermediate,1,CHEMBL626235,BAO_0000218,1969.0,
11758,,A,,In vivo,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,0,,,22224,9481.0,Autocuration,1,CHEMBL626236,BAO_0000218,1969.0,
11759,,A,,In vivo,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL626237,BAO_0000218,1969.0,
11760,,A,,In vivo,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626238,BAO_0000218,1969.0,
11761,,A,,In vivo,The maximum plasma concentration (200 mg/kg) administered orally in human,1,,,50587,9606.0,Intermediate,1,CHEMBL622412,BAO_0000218,1969.0,
11762,,A,,In vivo,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623114,BAO_0000218,1969.0,
11763,,A,,In vivo,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,0,,,22224,9481.0,Autocuration,1,CHEMBL623115,BAO_0000218,1969.0,
11764,,A,,In vivo,The maximum plasma concentration (25 mg/kg) administered orally in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL623116,BAO_0000218,1969.0,
11765,,A,,In vivo,The maximum plasma concentration (30 mg/kg) administered orally in dog,0,,,22224,9615.0,Autocuration,1,CHEMBL623117,BAO_0000218,1969.0,
11766,,A,,In vivo,The maximum plasma concentration (400 mg/kg) administered orally in human,1,,,50587,9606.0,Intermediate,1,CHEMBL623118,BAO_0000218,1969.0,
11767,,A,,In vivo,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623119,BAO_0000218,1969.0,
11768,,A,,In vivo,The maximum plasma concentration (50 mg/kg) administered orally in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623120,BAO_0000218,1969.0,
11769,,A,,In vivo,The maximum plasma concentration (800 mg/kg) administered orally in human,1,,,50587,9606.0,Intermediate,1,CHEMBL623286,BAO_0000218,1969.0,
11770,,A,,In vivo,The maximum plasma concentration was measured on rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623287,BAO_0000218,1969.0,
11771,,A,,In vivo,The maximum plasma concentration was measured on rats after oral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623288,BAO_0000218,1969.0,
11772,,A,,In vivo,Plasma drug Cmax in rat (PO dose),1,,,50597,10116.0,Intermediate,1,CHEMBL623289,BAO_0000218,1969.0,
11773,,A,,In vivo,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,0,,,22224,,Autocuration,1,CHEMBL623290,BAO_0000218,,
11774,,A,,In vivo,maximum Plasma concentration in Dog was determined after Peroral administration,1,,,50588,9615.0,Intermediate,1,CHEMBL623291,BAO_0000218,1969.0,
11775,,A,,In vivo,maximum Plasma concentration in Rats was determined after Peroral administration,1,,,50597,10116.0,Intermediate,1,CHEMBL623292,BAO_0000218,1969.0,
11776,,A,,In vivo,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623293,BAO_0000218,1969.0,
11777,,A,,In vivo,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL623294,BAO_0000218,1969.0,
11778,,A,,In vivo,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623295,BAO_0000218,1969.0,
11779,,A,,In vivo,maximum concentration was measured when administered through oral route in mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623296,BAO_0000218,,
11780,,A,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,1,,,50594,10090.0,Intermediate,1,CHEMBL875349,BAO_0000218,,
11781,,A,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,0,,,22224,314293.0,Autocuration,1,CHEMBL623297,BAO_0000019,,
11782,,A,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,0,,,22224,314293.0,Autocuration,1,CHEMBL623298,BAO_0000019,,
11783,,A,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,0,,,22224,314293.0,Autocuration,1,CHEMBL623299,BAO_0000019,,
11784,,A,,,Pharmacokinetic parameter was evaluated in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623300,BAO_0000218,,
11785,,A,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,1,,,50594,10090.0,Intermediate,1,CHEMBL623301,BAO_0000218,,
11786,,A,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,1,,,50594,10090.0,Intermediate,1,CHEMBL623302,BAO_0000218,,
11787,,A,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,1,,,50594,10090.0,Intermediate,1,CHEMBL623303,BAO_0000218,,
11788,,A,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,1,,,50594,10090.0,Intermediate,1,CHEMBL623304,BAO_0000218,,
11789,,A,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,1,,,50594,10090.0,Intermediate,1,CHEMBL623305,BAO_0000218,,
11790,,A,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623306,BAO_0000218,1969.0,
11791,,A,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623307,BAO_0000218,1969.0,
11792,,A,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,1,,,50597,10116.0,Intermediate,1,CHEMBL623308,BAO_0000218,1969.0,
11793,,A,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,1,,,50594,10090.0,Intermediate,1,CHEMBL623309,BAO_0000218,1969.0,
11794,,A,,,Plasma Concentration after 120 min of oral administration to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623310,BAO_0000218,,
11795,,A,,,Plasma Concentration after 30 min of oral administration to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL623311,BAO_0000218,,
11796,,A,,,Plasma Concentration after 60 min of oral administration to mice,1,,,100710,9541.0,Intermediate,1,CHEMBL623312,BAO_0000218,,
11797,,A,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,1,,,50594,10090.0,Intermediate,1,CHEMBL875350,BAO_0000218,,
11798,,A,,,Plasma Concentration after 90 min of oral administration to mice,1,,,50594,10090.0,Intermediate,1,CHEMBL628635,BAO_0000218,,
11799,,A,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628636,BAO_0000218,,
11800,,A,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628637,BAO_0000218,,
11801,,A,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628058,BAO_0000218,,
11802,,A,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,1,,,50597,10116.0,Intermediate,1,CHEMBL628059,BAO_0000218,,
11803,,A,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,1,,,50597,10116.0,Intermediate,1,CHEMBL628060,BAO_0000218,,
11804,,A,,,Distribution in the lung after 15 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628061,BAO_0000019,,
11805,,A,,,Distribution in the lung after 30 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628062,BAO_0000019,,
11806,,A,,,Distribution in the lung after 5 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628063,BAO_0000019,,
11807,,A,,,Distribution in the lung after 60 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628064,BAO_0000019,,
11808,,A,,,Distribution in the lung after 90 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628065,BAO_0000019,,
11809,,A,,,Distribution in the muscle after 120 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628066,BAO_0000019,2385.0,
11810,,A,,,Distribution in the muscle after 15 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628067,BAO_0000019,2385.0,
11811,,A,,,Distribution in the muscle after 30 min of intravenous administration,1,,,50594,10090.0,Intermediate,1,CHEMBL874646,BAO_0000218,2385.0,
11812,,A,,,Distribution in the muscle after 5 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628068,BAO_0000019,2385.0,
11813,,A,,,Distribution in the muscle after 60 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628069,BAO_0000019,2385.0,
11814,,A,,,Distribution in the muscle after 90 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628070,BAO_0000019,2385.0,
11815,,A,,,Distribution in the spleen after 120 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628071,BAO_0000019,2106.0,
11816,,A,,,Distribution in the spleen after 15 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628072,BAO_0000019,2106.0,
11817,,A,,,Distribution in the spleen after 30 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628073,BAO_0000019,2106.0,
11818,,A,,,Distribution in the spleen after 5 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628074,BAO_0000019,2106.0,
11819,,A,,,Distribution in the spleen after 60 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628075,BAO_0000019,2106.0,
11820,,A,,,Distribution in the spleen after 90 min of intravenous administration,0,,,22224,,Autocuration,1,CHEMBL628076,BAO_0000019,2106.0,
11821,,A,,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628077,BAO_0000218,1235.0,
11822,,A,,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628078,BAO_0000218,178.0,
11823,,A,,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628079,BAO_0000218,2107.0,
11824,,A,,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628080,BAO_0000218,992.0,
11825,,A,,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628081,BAO_0000218,2046.0,
11826,,A,,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628082,BAO_0000218,1235.0,
11827,,A,,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL874647,BAO_0000218,178.0,
11828,,A,,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626406,BAO_0000218,2107.0,
11829,,A,,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626407,BAO_0000218,992.0,
11830,,A,,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626408,BAO_0000218,2046.0,
11831,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",1,,,50597,10116.0,Intermediate,1,CHEMBL626409,BAO_0000218,178.0,
11832,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",1,,,50597,10116.0,Intermediate,1,CHEMBL626410,BAO_0000218,178.0,
11833,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",1,,,50597,10116.0,Intermediate,1,CHEMBL626411,BAO_0000218,178.0,
11834,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",1,,,50597,10116.0,Intermediate,1,CHEMBL626412,BAO_0000218,178.0,
11835,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",1,,,50597,10116.0,Intermediate,1,CHEMBL626413,BAO_0000218,178.0,
11836,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",1,,,50597,10116.0,Intermediate,1,CHEMBL626414,BAO_0000218,178.0,
11837,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",1,,,50597,10116.0,Intermediate,1,CHEMBL626415,BAO_0000218,178.0,
11838,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",1,,,50597,10116.0,Intermediate,1,CHEMBL626416,BAO_0000218,178.0,
11839,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",1,,,50597,10116.0,Intermediate,1,CHEMBL627062,BAO_0000218,178.0,
11840,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",1,,,50597,10116.0,Intermediate,1,CHEMBL627063,BAO_0000218,178.0,
11841,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",1,,,50597,10116.0,Intermediate,1,CHEMBL627064,BAO_0000218,178.0,
11842,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",1,,,50597,10116.0,Intermediate,1,CHEMBL627227,BAO_0000218,178.0,
11843,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",1,,,50597,10116.0,Intermediate,1,CHEMBL627228,BAO_0000218,178.0,
11844,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",1,,,50597,10116.0,Intermediate,1,CHEMBL627229,BAO_0000218,178.0,
11845,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",1,,,50597,10116.0,Intermediate,1,CHEMBL625792,BAO_0000218,178.0,
11846,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",1,,,50597,10116.0,Intermediate,1,CHEMBL625793,BAO_0000218,178.0,
11847,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",1,,,50597,10116.0,Intermediate,1,CHEMBL625794,BAO_0000218,178.0,
11848,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",1,,,50597,10116.0,Intermediate,1,CHEMBL625795,BAO_0000218,178.0,
11849,,A,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,1,,,50594,10090.0,Intermediate,1,CHEMBL625796,BAO_0000218,,
11850,,A,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625797,BAO_0000218,,
11851,,A,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625798,BAO_0000218,,
11852,,A,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL875613,BAO_0000218,,
11853,,A,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL625799,BAO_0000218,,
11854,,A,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL625800,BAO_0000218,,
11855,,A,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL625801,BAO_0000218,,
11856,,A,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL625802,BAO_0000218,,
11857,,A,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL625803,BAO_0000218,,
11858,,A,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,0,,,22224,,Autocuration,1,CHEMBL625804,BAO_0000019,,
11859,,A,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL622530,BAO_0000218,,
11860,,A,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,1,,,50594,10090.0,Intermediate,1,CHEMBL622531,BAO_0000218,,
11861,,A,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL622532,BAO_0000218,,
11862,,A,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL623176,BAO_0000218,,
11863,,A,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL623177,BAO_0000218,,
11864,,A,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL623178,BAO_0000218,,
11865,,A,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,1,,,50594,10090.0,Intermediate,1,CHEMBL623179,BAO_0000218,,
11866,,A,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL623180,BAO_0000218,,
11867,,A,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL623181,BAO_0000218,,
11868,,A,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL624131,BAO_0000218,,
11869,,A,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL624132,BAO_0000218,,
11870,,A,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL624133,BAO_0000218,,
11871,,A,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,1,,,50594,10090.0,Intermediate,1,CHEMBL624846,BAO_0000218,,
11872,,A,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL624847,BAO_0000218,,
11873,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL624848,BAO_0000218,,
11874,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL625012,BAO_0000218,,
11875,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL625013,BAO_0000218,,
11876,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,1,,,50594,10090.0,Intermediate,1,CHEMBL625014,BAO_0000218,,
11877,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL625015,BAO_0000218,,
11878,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL625016,BAO_0000218,,
11879,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,1,,,50594,10090.0,Intermediate,1,CHEMBL625017,BAO_0000218,,
11880,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL625018,BAO_0000218,,
11881,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL625019,BAO_0000218,,
11882,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL625020,BAO_0000218,,
11883,,A,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,1,,,50594,10090.0,Intermediate,1,CHEMBL625021,BAO_0000218,,
11884,,A,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625022,BAO_0000218,,
11885,,A,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,1,,,50594,10090.0,Intermediate,1,CHEMBL625023,BAO_0000218,,
11886,,A,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,1,,,100710,9541.0,Intermediate,1,CHEMBL625024,BAO_0000218,,
11887,,A,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,1,,,100710,9541.0,Intermediate,1,CHEMBL627626,BAO_0000218,,
11888,,A,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,0,,,22224,,Autocuration,1,CHEMBL627627,BAO_0000218,955.0,
11889,,A,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,0,,,22224,,Autocuration,1,CHEMBL627628,BAO_0000218,1977.0,
11890,,A,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,0,,,22224,,Autocuration,1,CHEMBL627629,BAO_0000218,955.0,
11891,,A,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,0,,,22224,,Autocuration,1,CHEMBL627630,BAO_0000218,1977.0,
11892,,A,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),0,,,22224,,Autocuration,1,CHEMBL627631,BAO_0000019,,
11893,,A,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),0,,,22224,,Autocuration,1,CHEMBL629515,BAO_0000218,,
11894,,A,,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,,50594,10090.0,Intermediate,1,CHEMBL629516,BAO_0000218,2106.0,
11895,,A,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL629517,BAO_0000218,2106.0,
11896,,A,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL629518,BAO_0000218,2106.0,
11897,,A,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,,50594,10090.0,Intermediate,1,CHEMBL877499,BAO_0000218,,
11898,,A,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL629519,BAO_0000218,,
11899,,A,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL629520,BAO_0000218,,
11900,,A,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,,50594,10090.0,Intermediate,1,CHEMBL629521,BAO_0000218,,
11901,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL629522,BAO_0000218,,
11902,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),1,,,50594,10090.0,Intermediate,1,CHEMBL629523,BAO_0000218,,
11903,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),1,,,50594,10090.0,Intermediate,1,CHEMBL629524,BAO_0000218,,
11904,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL629525,BAO_0000218,,
11905,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL629526,BAO_0000218,,
11906,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),1,,,50594,10090.0,Intermediate,1,CHEMBL629527,BAO_0000218,,
11907,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),1,,,50594,10090.0,Intermediate,1,CHEMBL629528,BAO_0000218,,
11908,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL629529,BAO_0000218,,
11909,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL629530,BAO_0000218,,
11910,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),1,,,50594,10090.0,Intermediate,1,CHEMBL629531,BAO_0000218,,
11911,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),1,,,50594,10090.0,Intermediate,1,CHEMBL628656,BAO_0000218,,
11912,,A,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL628657,BAO_0000218,,
11913,,A,,In vivo,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628658,BAO_0000218,,
11914,,A,,In vivo,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628659,BAO_0000218,,
11915,,A,,In vivo,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL877500,BAO_0000218,,
11916,,A,,In vivo,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628660,BAO_0000218,,
11917,,A,,In vivo,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628661,BAO_0000218,,
11918,,A,,In vivo,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628662,BAO_0000218,,
11919,,A,,In vivo,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628663,BAO_0000218,,
11920,,A,,In vivo,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628664,BAO_0000218,,
11921,,A,,In vivo,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628665,BAO_0000218,178.0,
11922,,A,,In vivo,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628666,BAO_0000218,178.0,
11923,,A,,In vivo,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628667,BAO_0000218,178.0,
11924,,A,,In vivo,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628668,BAO_0000218,178.0,
11925,,A,,In vivo,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628669,BAO_0000218,178.0,
11926,,A,,In vivo,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628670,BAO_0000218,178.0,
11927,,A,,In vivo,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628671,BAO_0000218,178.0,
11928,,A,,In vivo,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL628672,BAO_0000218,10000001.0,
11929,,A,,In vivo,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL630300,BAO_0000218,10000001.0,
11930,,A,,In vivo,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629787,BAO_0000218,10000001.0,
11931,,A,,In vivo,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629788,BAO_0000218,10000001.0,
11932,,A,,In vivo,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629789,BAO_0000218,955.0,
11933,,A,,In vivo,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629790,BAO_0000218,955.0,
11934,,A,,In vivo,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629791,BAO_0000218,955.0,
11935,,A,,In vivo,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629792,BAO_0000218,955.0,
11936,,A,,In vivo,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629793,BAO_0000218,955.0,
11937,,A,,In vivo,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629794,BAO_0000218,955.0,
11938,,A,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,1,,,50597,10116.0,Intermediate,1,CHEMBL874459,BAO_0000218,,
11939,,A,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,1,,,50597,10116.0,Intermediate,1,CHEMBL629795,BAO_0000218,,
11940,,A,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,1,,,50597,10116.0,Intermediate,1,CHEMBL629796,BAO_0000218,,
11941,,A,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,1,,,50597,10116.0,Intermediate,1,CHEMBL629797,BAO_0000218,,
11942,,A,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,1,,,50597,10116.0,Intermediate,1,CHEMBL629798,BAO_0000218,,
11943,,A,,In vivo,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629799,BAO_0000218,2369.0,
11944,,A,,In vivo,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629800,BAO_0000218,2369.0,
11945,,A,,In vivo,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629801,BAO_0000218,2369.0,
11946,,A,,In vivo,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,1,,,50597,10116.0,Intermediate,1,CHEMBL629802,BAO_0000218,2369.0,
11947,,A,,In vivo,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629803,BAO_0000218,2369.0,
11948,,A,,In vivo,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629804,BAO_0000218,178.0,
11949,,A,,In vivo,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629805,BAO_0000218,178.0,
11950,,A,,In vivo,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629806,BAO_0000218,178.0,
11951,,A,,In vivo,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629807,BAO_0000218,178.0,
11952,,A,,In vivo,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629808,BAO_0000218,178.0,
11953,,A,,In vivo,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629809,BAO_0000218,955.0,
11954,,A,,In vivo,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629810,BAO_0000218,955.0,
11955,,A,,In vivo,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629811,BAO_0000218,955.0,
11956,,A,,In vivo,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629812,BAO_0000218,955.0,
11957,,A,,In vivo,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629813,BAO_0000218,955.0,
11958,,A,,In vivo,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL874460,BAO_0000218,955.0,
11959,,A,,In vivo,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629814,BAO_0000218,,
11960,,A,,In vivo,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629815,BAO_0000218,,
11961,,A,,In vivo,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629816,BAO_0000218,,
11962,,A,,In vivo,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL629817,BAO_0000218,,
11963,,A,,In vivo,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL626643,BAO_0000218,2113.0,
11964,,A,,In vivo,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL626644,BAO_0000218,2113.0,
11965,,A,,In vivo,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL626806,BAO_0000218,2113.0,
11966,,A,,In vivo,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL626807,BAO_0000218,2113.0,
11967,,A,,In vivo,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627261,BAO_0000218,2107.0,
11968,,A,,In vivo,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627262,BAO_0000218,2107.0,
11969,,A,,In vivo,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627263,BAO_0000218,2107.0,
11970,,A,,In vivo,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627264,BAO_0000218,2107.0,
11971,,A,,In vivo,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627265,BAO_0000218,2048.0,
11972,,A,,In vivo,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627266,BAO_0000218,2048.0,
11973,,A,,In vivo,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627267,BAO_0000218,2048.0,
11974,,A,,In vivo,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627268,BAO_0000218,2048.0,
11975,,A,,In vivo,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627269,BAO_0000218,2385.0,
11976,,A,,In vivo,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627270,BAO_0000218,2385.0,
11977,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",1,,,50597,10116.0,Intermediate,1,CHEMBL627271,BAO_0000218,,
11978,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",1,,,50597,10116.0,Intermediate,1,CHEMBL627946,BAO_0000218,,
11979,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",1,,,50597,10116.0,Intermediate,1,CHEMBL875472,BAO_0000218,,
11980,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",1,,,50597,10116.0,Intermediate,1,CHEMBL627947,BAO_0000218,,
11981,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",1,,,50597,10116.0,Intermediate,1,CHEMBL627948,BAO_0000218,,
11982,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",1,,,50597,10116.0,Intermediate,1,CHEMBL628113,BAO_0000218,,
11983,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",1,,,50597,10116.0,Intermediate,1,CHEMBL628114,BAO_0000218,,
11984,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",1,,,50597,10116.0,Intermediate,1,CHEMBL628115,BAO_0000218,,
11985,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",1,,,50597,10116.0,Intermediate,1,CHEMBL628116,BAO_0000218,,
11986,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",1,,,50597,10116.0,Intermediate,1,CHEMBL628117,BAO_0000218,,
11987,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",1,,,50597,10116.0,Intermediate,1,CHEMBL628118,BAO_0000218,,
11988,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",1,,,50597,10116.0,Intermediate,1,CHEMBL628119,BAO_0000218,,
11989,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",1,,,50597,10116.0,Intermediate,1,CHEMBL628120,BAO_0000218,,
11990,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",1,,,50597,10116.0,Intermediate,1,CHEMBL628121,BAO_0000218,,
11991,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",1,,,50597,10116.0,Intermediate,1,CHEMBL628122,BAO_0000218,,
11992,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",1,,,50597,10116.0,Intermediate,1,CHEMBL627297,BAO_0000218,,
11993,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",1,,,50597,10116.0,Intermediate,1,CHEMBL627298,BAO_0000218,,
11994,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",1,,,50597,10116.0,Intermediate,1,CHEMBL627299,BAO_0000218,,
11995,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",1,,,50597,10116.0,Intermediate,1,CHEMBL627300,BAO_0000218,,
11996,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",1,,,50597,10116.0,Intermediate,1,CHEMBL627301,BAO_0000218,,
11997,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",1,,,50597,10116.0,Intermediate,1,CHEMBL627302,BAO_0000218,,
11998,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",1,,,50597,10116.0,Intermediate,1,CHEMBL627303,BAO_0000218,,
11999,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",1,,,50597,10116.0,Intermediate,1,CHEMBL627304,BAO_0000218,,
12000,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",1,,,50597,10116.0,Intermediate,1,CHEMBL627305,BAO_0000218,,
12001,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",1,,,50597,10116.0,Intermediate,1,CHEMBL627306,BAO_0000218,,
12002,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",1,,,50597,10116.0,Intermediate,1,CHEMBL623982,BAO_0000218,,
12003,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",1,,,50597,10116.0,Intermediate,1,CHEMBL623983,BAO_0000218,,
12004,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",1,,,50597,10116.0,Intermediate,1,CHEMBL623984,BAO_0000218,,
12005,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",1,,,50597,10116.0,Intermediate,1,CHEMBL623985,BAO_0000218,,
12006,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",1,,,50597,10116.0,Intermediate,1,CHEMBL623986,BAO_0000218,,
12007,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",1,,,50597,10116.0,Intermediate,1,CHEMBL623987,BAO_0000218,,
12008,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",1,,,50597,10116.0,Intermediate,1,CHEMBL623988,BAO_0000218,,
12009,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",1,,,50597,10116.0,Intermediate,1,CHEMBL623989,BAO_0000218,,
12010,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",1,,,50597,10116.0,Intermediate,1,CHEMBL622215,BAO_0000218,,
12011,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",1,,,50597,10116.0,Intermediate,1,CHEMBL622216,BAO_0000218,,
12012,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",1,,,50597,10116.0,Intermediate,1,CHEMBL877481,BAO_0000218,,
12013,,A,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),0,,,22224,,Autocuration,1,CHEMBL622217,BAO_0000218,,
12014,,A,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),1,,,50594,10090.0,Intermediate,1,CHEMBL622218,BAO_0000218,,
12015,,A,,,Pharmacokinetic profile AUC was evaluated in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622219,BAO_0000218,,
12016,,A,,,Pharmacokinetic property (Area under curve),0,,,22224,,Autocuration,1,CHEMBL622220,BAO_0000019,,
12017,,A,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",1,,,50588,9615.0,Intermediate,1,CHEMBL622221,BAO_0000218,,
12018,,A,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",1,,,50594,10090.0,Intermediate,1,CHEMBL622222,BAO_0000218,,
12019,,A,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",1,,,50588,9615.0,Intermediate,1,CHEMBL622223,BAO_0000218,,
12020,,A,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",1,,,50594,10090.0,Intermediate,1,CHEMBL622224,BAO_0000218,,
12021,,A,,,Plasma concentration (AUC) was determined,0,,,22224,,Autocuration,1,CHEMBL622225,BAO_0000019,,
12022,,A,,,Plasma concentration (AUC) was determined; Not detectable,0,,,22224,,Autocuration,1,CHEMBL622226,BAO_0000019,,
12023,,A,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),1,,,50512,10141.0,Intermediate,1,CHEMBL624154,BAO_0000218,,
12024,,A,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624155,BAO_0000218,,
12025,,A,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,,,50597,10116.0,Intermediate,1,CHEMBL624156,BAO_0000218,,
12026,,A,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624157,BAO_0000218,,
12027,,A,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624158,BAO_0000218,,
12028,,A,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,1,,,50597,10116.0,Intermediate,1,CHEMBL624159,BAO_0000218,,
12029,,A,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,1,,,50597,10116.0,Intermediate,1,CHEMBL624160,BAO_0000218,,
12030,,A,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,1,,,50597,10116.0,Intermediate,1,CHEMBL624161,BAO_0000218,,
12031,,A,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,1,,,50597,10116.0,Intermediate,1,CHEMBL624162,BAO_0000218,,
12032,,A,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624163,BAO_0000218,,
12033,,A,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL624164,BAO_0000218,,
12034,,A,,,The AUC(0-infinity) values in female wistar rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL624165,BAO_0000218,,
12035,,A,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL624166,BAO_0000218,,
12036,,A,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",1,,,50597,10116.0,Intermediate,1,CHEMBL624167,BAO_0000218,,
12037,,A,,,The AUC(0-t)values in female wistar rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL624168,BAO_0000218,,
12038,,A,,,The Area under the concentration time curve of compound was measured on rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624169,BAO_0000218,,
12039,,A,,,The area under curve (100 mg/kg) administered orally in humans,1,,,50587,9606.0,Intermediate,1,CHEMBL624170,BAO_0000218,,
12040,,A,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,0,,,22224,9481.0,Autocuration,1,CHEMBL624171,BAO_0000218,,
12041,,A,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL624172,BAO_0000218,,
12042,,A,,,The area under curve (15 mg/kg) administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624173,BAO_0000218,,
12043,,A,,,The area under curve (200 mg/kg) administered orally in humans,1,,,50587,9606.0,Intermediate,1,CHEMBL877488,BAO_0000218,,
12044,,A,,,The area under curve (25 mg/kg) administered intravenously in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624174,BAO_0000218,,
12045,,A,,,The area under curve (25 mg/kg) administered orally in marmoset,0,,,22224,9481.0,Autocuration,1,CHEMBL624175,BAO_0000218,,
12046,,A,,,The area under curve (25 mg/kg) administered orally in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL624176,BAO_0000218,,
12047,,A,,,The area under curve (30 mg/kg) administered orally in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624177,BAO_0000218,,
12048,,A,,,The area under curve (400 mg/kg) administered orally in humans,1,,,50587,9606.0,Intermediate,1,CHEMBL624178,BAO_0000218,,
12049,,A,,,The area under curve (50 mg/kg) administered orally in fasted rat,1,,,50597,10116.0,Intermediate,1,CHEMBL624179,BAO_0000218,,
12050,,A,,,The area under curve (50 mg/kg) administered orally in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627689,BAO_0000218,,
12051,,A,,,The area under curve (800 mg/kg) administered orally in humans,1,,,50587,9606.0,Intermediate,1,CHEMBL627690,BAO_0000218,,
12052,,A,,,The compound was evaluated for area under the curve,0,,,22224,,Autocuration,1,CHEMBL627691,BAO_0000019,,
12053,,A,,,The compound was evaluated for area under the curve in marmosets,0,,,22224,9481.0,Autocuration,1,CHEMBL627692,BAO_0000019,,
12054,,A,,,The compound was evaluated for area under the curve in marmosets,0,,,22224,9481.0,Autocuration,1,CHEMBL627693,BAO_0000019,,
12055,,A,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627694,BAO_0000218,,
12056,,A,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627695,BAO_0000218,,
12057,,A,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),0,,,22224,,Autocuration,1,CHEMBL627696,BAO_0000218,,
12058,,A,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627697,BAO_0000218,,
12059,,A,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627698,BAO_0000218,,
12060,,A,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627699,BAO_0000218,,
12061,,A,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627700,BAO_0000218,,
12062,,A,,,Total drug exposure is determined after oral dosing in rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL627701,BAO_0000218,,
12063,,A,,,Total drug exposure (5 mg/kg) when administered intravenously,0,,,22224,,Autocuration,1,CHEMBL627702,BAO_0000218,,
12064,,A,,,Total drug exposure (5 mg/kg) when administered orally,0,,,22224,,Autocuration,1,CHEMBL627703,BAO_0000218,,
12065,,A,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL626873,BAO_0000218,,
12066,,A,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL629583,BAO_0000218,,
12067,,A,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL629584,BAO_0000218,,
12068,,A,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL629585,BAO_0000218,,
12069,,A,,In vivo,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629586,BAO_0000218,955.0,
12070,,A,,In vivo,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629587,BAO_0000218,955.0,
12071,,A,,In vivo,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629588,BAO_0000218,,
12072,,A,,In vivo,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629589,BAO_0000218,,
12073,,A,,In vivo,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629590,BAO_0000218,,
12074,,A,,In vivo,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629591,BAO_0000218,,
12075,,A,,In vivo,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629592,BAO_0000218,,
12076,,A,,In vivo,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629593,BAO_0000218,,
12077,,A,,In vivo,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629594,BAO_0000218,,
12078,,A,,In vivo,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL629595,BAO_0000218,948.0,
12079,,A,,In vivo,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL630290,BAO_0000218,948.0,
12080,,A,,In vivo,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627137,BAO_0000218,948.0,
12081,,A,,In vivo,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627138,BAO_0000218,948.0,
12082,,A,,In vivo,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627139,BAO_0000218,948.0,
12083,,A,,In vivo,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627140,BAO_0000218,948.0,
12084,,A,,In vivo,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627141,BAO_0000218,948.0,
12085,,A,,In vivo,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627142,BAO_0000218,2113.0,
12086,,A,,In vivo,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627143,BAO_0000218,2113.0,
12087,,A,,In vivo,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL874449,BAO_0000218,2113.0,
12088,,A,,In vivo,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627144,BAO_0000218,2113.0,
12089,,A,,In vivo,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627145,BAO_0000218,2113.0,
12090,,A,,In vivo,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627146,BAO_0000218,2113.0,
12091,,A,,In vivo,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627147,BAO_0000218,2113.0,
12092,,A,,In vivo,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627148,BAO_0000218,2107.0,
12093,,A,,In vivo,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627149,BAO_0000218,2048.0,
12094,,A,,In vivo,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL632160,BAO_0000218,2048.0,
12095,,A,,In vivo,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL632161,BAO_0000218,2048.0,
12096,,A,,In vivo,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL632162,BAO_0000218,2048.0,
12097,,A,,In vivo,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL632163,BAO_0000218,2048.0,
12098,,A,,In vivo,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL874469,BAO_0000218,2048.0,
12099,,A,,In vivo,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627182,BAO_0000218,2048.0,
12100,,A,,In vivo,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627183,BAO_0000218,2385.0,
12101,,A,,In vivo,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627184,BAO_0000218,2385.0,
12102,,A,,In vivo,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627185,BAO_0000218,2385.0,
12103,,A,,In vivo,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627186,BAO_0000218,2385.0,
12104,,A,,In vivo,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627187,BAO_0000218,2385.0,
12105,,A,,In vivo,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627188,BAO_0000218,2385.0,
12106,,A,,In vivo,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627189,BAO_0000218,2385.0,
12107,,A,,In vivo,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627190,BAO_0000218,,
12108,,A,,In vivo,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627191,BAO_0000218,2107.0,
12109,,A,,In vivo,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627192,BAO_0000218,2107.0,
12110,,A,,In vivo,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL627193,BAO_0000218,2107.0,
12111,,A,,In vivo,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL874590,BAO_0000218,2385.0,
12112,,A,,In vivo,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627194,BAO_0000218,2385.0,
12113,,A,,In vivo,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627195,BAO_0000218,2385.0,
12114,,A,,In vivo,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627196,BAO_0000218,992.0,
12115,,A,,In vivo,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627197,BAO_0000218,992.0,
12116,,A,,In vivo,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627198,BAO_0000218,992.0,
12117,,A,,In vivo,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,1,,,50597,10116.0,Intermediate,1,CHEMBL627199,BAO_0000218,992.0,
12118,,A,,In vivo,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627200,BAO_0000218,992.0,
12119,,A,,In vivo,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627201,BAO_0000218,1969.0,
12120,,A,,In vivo,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627202,BAO_0000218,1969.0,
12121,,A,,In vivo,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627203,BAO_0000218,1969.0,
12122,,A,,In vivo,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627204,BAO_0000218,1969.0,
12123,,A,,In vivo,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627205,BAO_0000218,2106.0,
12124,,A,,In vivo,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627206,BAO_0000218,2106.0,
12125,,A,,In vivo,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627207,BAO_0000218,2106.0,
12126,,A,,In vivo,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627208,BAO_0000218,2106.0,
12127,,A,,In vivo,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627209,BAO_0000218,2046.0,
12128,,A,,In vivo,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627210,BAO_0000218,2046.0,
12129,,A,,In vivo,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627211,BAO_0000218,2046.0,
12130,,A,,In vivo,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627212,BAO_0000218,2046.0,
12131,,A,,In vivo,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL627213,BAO_0000218,995.0,
12132,,A,,In vivo,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL626599,BAO_0000218,995.0,
12133,,A,,In vivo,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL626600,BAO_0000218,995.0,
12134,,A,,In vivo,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,,50597,10116.0,Intermediate,1,CHEMBL626601,BAO_0000218,995.0,
12135,,A,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,0,,,22224,,Autocuration,1,CHEMBL627484,BAO_0000019,,
12136,,A,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),1,,,100710,9541.0,Intermediate,1,CHEMBL627485,BAO_0000218,1969.0,
12137,,A,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,1,,,100710,9541.0,Intermediate,1,CHEMBL628147,BAO_0000218,1969.0,
12138,,A,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,1,,,100710,9541.0,Intermediate,1,CHEMBL628148,BAO_0000218,1969.0,
12139,,A,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),1,,,50588,9615.0,Intermediate,1,CHEMBL628149,BAO_0000218,1969.0,
12140,,A,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,1,,,50588,9615.0,Intermediate,1,CHEMBL628150,BAO_0000218,1969.0,
12141,,A,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,1,,,50588,9615.0,Intermediate,1,CHEMBL628318,BAO_0000218,1969.0,
12142,,A,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,1,,,50588,9615.0,Intermediate,1,CHEMBL628319,BAO_0000218,1969.0,
12143,,A,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",1,,,50588,9615.0,Intermediate,1,CHEMBL875609,BAO_0000218,,
12144,,A,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,0,,,22224,,Autocuration,1,CHEMBL628320,BAO_0000019,,
12145,,A,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,0,,,22224,,Autocuration,1,CHEMBL628321,BAO_0000019,,
12146,,A,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,0,,,22224,,Autocuration,1,CHEMBL628322,BAO_0000019,,
12147,,A,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,0,,,22224,,Autocuration,1,CHEMBL628323,BAO_0000019,,
12148,,A,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,0,,,22224,,Autocuration,1,CHEMBL628324,BAO_0000019,,
12149,,A,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,0,,,22224,,Autocuration,1,CHEMBL628325,BAO_0000019,,
12150,,A,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,0,,,22224,,Autocuration,1,CHEMBL628326,BAO_0000019,,
12151,,A,,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL628327,BAO_0000218,1236.0,
12152,,A,,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL628328,BAO_0000218,1236.0,
12153,,A,,,"Concentration of compound in blood of dog 1, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL628329,BAO_0000218,178.0,
12154,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",1,,,50597,10116.0,Intermediate,1,CHEMBL628330,BAO_0000218,2107.0,
12155,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",1,,,50597,10116.0,Intermediate,1,CHEMBL628331,BAO_0000218,2107.0,
12156,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",1,,,50597,10116.0,Intermediate,1,CHEMBL628332,BAO_0000218,2107.0,
12157,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",1,,,50597,10116.0,Intermediate,1,CHEMBL628333,BAO_0000218,2107.0,
12158,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",1,,,50597,10116.0,Intermediate,1,CHEMBL628334,BAO_0000218,2107.0,
12159,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",1,,,50597,10116.0,Intermediate,1,CHEMBL628335,BAO_0000218,2107.0,
12160,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",1,,,50597,10116.0,Intermediate,1,CHEMBL628336,BAO_0000218,2107.0,
12161,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",1,,,50597,10116.0,Intermediate,1,CHEMBL628337,BAO_0000218,2107.0,
12162,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",1,,,50597,10116.0,Intermediate,1,CHEMBL628338,BAO_0000218,2107.0,
12163,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",1,,,50597,10116.0,Intermediate,1,CHEMBL875610,BAO_0000218,2107.0,
12164,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",1,,,50597,10116.0,Intermediate,1,CHEMBL628339,BAO_0000218,2107.0,
12165,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",1,,,50597,10116.0,Intermediate,1,CHEMBL628340,BAO_0000218,2107.0,
12166,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",1,,,50597,10116.0,Intermediate,1,CHEMBL628341,BAO_0000218,2107.0,
12167,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",1,,,50597,10116.0,Intermediate,1,CHEMBL622214,BAO_0000218,2107.0,
12168,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",1,,,50597,10116.0,Intermediate,1,CHEMBL623167,BAO_0000218,2107.0,
12169,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",1,,,50597,10116.0,Intermediate,1,CHEMBL623168,BAO_0000218,2107.0,
12170,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",1,,,50597,10116.0,Intermediate,1,CHEMBL623169,BAO_0000218,2107.0,
12171,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",1,,,50597,10116.0,Intermediate,1,CHEMBL623170,BAO_0000218,2107.0,
12172,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",1,,,50597,10116.0,Intermediate,1,CHEMBL627224,BAO_0000218,2048.0,
12173,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",1,,,50597,10116.0,Intermediate,1,CHEMBL875634,BAO_0000218,2048.0,
12174,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",1,,,50597,10116.0,Intermediate,1,CHEMBL627225,BAO_0000218,2048.0,
12175,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",1,,,50597,10116.0,Intermediate,1,CHEMBL627226,BAO_0000218,2048.0,
12176,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",1,,,50597,10116.0,Intermediate,1,CHEMBL626083,BAO_0000218,2048.0,
12177,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",1,,,50597,10116.0,Intermediate,1,CHEMBL626084,BAO_0000218,2048.0,
12178,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",1,,,50597,10116.0,Intermediate,1,CHEMBL626085,BAO_0000218,2048.0,
12179,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",1,,,50597,10116.0,Intermediate,1,CHEMBL626086,BAO_0000218,2048.0,
12180,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",1,,,50597,10116.0,Intermediate,1,CHEMBL626087,BAO_0000218,2048.0,
12181,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",1,,,50597,10116.0,Intermediate,1,CHEMBL626088,BAO_0000218,2048.0,
12182,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",1,,,50597,10116.0,Intermediate,1,CHEMBL626089,BAO_0000218,2048.0,
12183,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",1,,,50597,10116.0,Intermediate,1,CHEMBL626090,BAO_0000218,2048.0,
12184,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",1,,,50597,10116.0,Intermediate,1,CHEMBL626091,BAO_0000218,2048.0,
12185,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",1,,,50597,10116.0,Intermediate,1,CHEMBL626092,BAO_0000218,2048.0,
12186,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",1,,,50597,10116.0,Intermediate,1,CHEMBL626093,BAO_0000218,2048.0,
12187,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",1,,,50597,10116.0,Intermediate,1,CHEMBL626094,BAO_0000218,2048.0,
12188,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",1,,,50597,10116.0,Intermediate,1,CHEMBL626095,BAO_0000218,2048.0,
12189,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",1,,,50597,10116.0,Intermediate,1,CHEMBL626096,BAO_0000218,2048.0,
12190,,A,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL626097,BAO_0000218,,
12191,,A,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626098,BAO_0000218,,
12192,,A,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,0,,,22224,,Autocuration,1,CHEMBL626099,BAO_0000218,1969.0,
12193,,A,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,0,,,22224,,Autocuration,1,CHEMBL626100,BAO_0000218,1969.0,
12194,,A,,,AUC 0-inf in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626101,BAO_0000218,1969.0,
12195,,A,,,AUC 0-inf in guinea pig,1,,,50512,10141.0,Intermediate,1,CHEMBL626102,BAO_0000218,1969.0,
12196,,A,,,AUC 0-t in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL626103,BAO_0000218,1969.0,
12197,,A,,,AUC 0-t in guinea pig,1,,,50512,10141.0,Intermediate,1,CHEMBL628391,BAO_0000218,1969.0,
12198,,A,,,The compound was tested for brain to plasma partition in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628392,BAO_0000218,,
12199,,A,,,The compound was tested for brain to plasma partition in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL628393,BAO_0000218,,
12200,,A,,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,0,,,22224,,Autocuration,1,CHEMBL628394,BAO_0000019,178.0,
12201,,A,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,1,,,50588,9615.0,Intermediate,1,CHEMBL628395,BAO_0000218,,
12202,,A,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,0,,,22224,314293.0,Autocuration,1,CHEMBL628396,BAO_0000218,,
12203,,A,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,1,,,50592,9986.0,Intermediate,1,CHEMBL628397,BAO_0000218,,
12204,,A,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,1,,,50597,10116.0,Intermediate,1,CHEMBL628398,BAO_0000218,,
12205,,A,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,1,,,50797,9544.0,Intermediate,1,CHEMBL628399,BAO_0000218,,
12206,,A,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,1,,,50588,9615.0,Intermediate,1,CHEMBL628400,BAO_0000218,,
12207,,A,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL874907,BAO_0000218,,
12208,,A,,,Area under curve of the compound was determined,0,,,22224,,Autocuration,1,CHEMBL628401,BAO_0000019,,
12209,,A,,,AUC in monkeys at a dose of 1 mg/kg,0,,,22224,314293.0,Autocuration,1,CHEMBL628402,BAO_0000218,1969.0,
12210,,A,,,AUC in rats at a dose of 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL628403,BAO_0000218,1969.0,
12211,,A,,,Compound was evaluated for the overall absorbance loss at pH of 2,0,,,22224,,Autocuration,1,CHEMBL628404,BAO_0000019,,
12212,,A,,,Compound was evaluated for the overall absorbance loss at pH of 4,0,,,22224,,Autocuration,1,CHEMBL628405,BAO_0000019,,
12213,,A,,,Compound was evaluated for the overall absorbance loss at pH of 7,0,,,22224,,Autocuration,1,CHEMBL628406,BAO_0000019,,
12214,,A,,,Compound was evaluated for its absorption in the rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628407,BAO_0000218,,
12215,,A,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628408,BAO_0000218,1088.0,
12216,,A,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,1,,,50597,10116.0,Intermediate,1,CHEMBL629171,BAO_0000218,1088.0,
12217,,A,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1,,,50597,10116.0,Intermediate,1,CHEMBL629172,BAO_0000218,1088.0,
12218,,A,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,1,,,50597,10116.0,Intermediate,1,CHEMBL629173,BAO_0000218,1088.0,
12219,,A,,,In vitro percent permeability into rat ileum,1,,,50597,10116.0,Intermediate,1,CHEMBL629174,BAO_0000218,,
12220,,A,,,In vitro percent permeability into rat ileum; Range is 10-17,1,,,50597,10116.0,Intermediate,1,CHEMBL629175,BAO_0000218,,
12221,,A,,,In vitro percent permeability into rat ileum; Range is 10-18,1,,,50597,10116.0,Intermediate,1,CHEMBL629176,BAO_0000218,,
12222,,A,,,In vitro percent permeability into rat ileum; Range is 10-19,1,,,50597,10116.0,Intermediate,1,CHEMBL629177,BAO_0000218,,
12223,,A,,,In vitro percent permeability into rat ileum; Range is 12-15,1,,,50597,10116.0,Intermediate,1,CHEMBL629178,BAO_0000218,,
12224,,A,,,In vitro percent permeability into rat ileum; Range is 13-19,1,,,50597,10116.0,Intermediate,1,CHEMBL631869,BAO_0000218,,
12225,,A,,,In vitro percent permeability into rat ileum; Range is 14-17,1,,,50597,10116.0,Intermediate,1,CHEMBL631870,BAO_0000218,,
12226,,A,,,In vitro percent permeability into rat ileum; Range is 15-18,1,,,50597,10116.0,Intermediate,1,CHEMBL631871,BAO_0000218,,
12227,,A,,,In vitro percent permeability into rat ileum; Range is 2-5,1,,,50597,10116.0,Intermediate,1,CHEMBL631872,BAO_0000218,,
12228,,A,,,In vitro percent permeability into rat ileum; Range is 23-42,0,,,22224,,Autocuration,1,CHEMBL875775,BAO_0000221,2116.0,
12229,,A,,,In vitro percent permeability into rat ileum; Range is 28-36,1,,,50597,10116.0,Intermediate,1,CHEMBL631873,BAO_0000218,,
12230,,A,,,In vitro percent permeability into rat ileum; Range is 29-35,1,,,50597,10116.0,Intermediate,1,CHEMBL631874,BAO_0000218,,
12231,,A,,,In vitro percent permeability into rat ileum; Range is 46-66,1,,,50597,10116.0,Intermediate,1,CHEMBL631875,BAO_0000218,,
12232,,A,,,In vitro percent permeability into rat ileum; Range is 50-68,1,,,50597,10116.0,Intermediate,1,CHEMBL631876,BAO_0000218,,
12233,,A,,,In vitro percent permeability into rat ileum; Range is 78-81,1,,,50597,10116.0,Intermediate,1,CHEMBL631877,BAO_0000218,,
12234,,A,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,1,,,50597,10116.0,Intermediate,1,CHEMBL631878,BAO_0000218,,
12235,,A,,,In vitro percent permeability into rat ileum; nd indicates not detected,1,,,50597,10116.0,Intermediate,1,CHEMBL631879,BAO_0000218,,
12236,,A,,,In vitro percent permeability into rat ileum; nt indicates not detected,1,,,50597,10116.0,Intermediate,1,CHEMBL631880,BAO_0000218,,
12237,,A,,,In vitro percent permeability into rat ileum; nt indicates not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL631881,BAO_0000218,,
12238,,A,,,Compound was tested for oral absorption in bile-duct cannulated rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631882,BAO_0000218,,
12239,,A,,,Compound was tested for oral absorption in bile-duct cannulated rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL630749,BAO_0000218,,
12240,,A,,,Oral absorption using Caco-2 cell monolayers.,1,,,50587,9606.0,Intermediate,1,CHEMBL630750,BAO_0000218,,
12241,,A,,,Percent of the drug absorbed after administration to humans was determined,1,,,50587,9606.0,Intermediate,1,CHEMBL630253,BAO_0000218,,
12242,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL630254,BAO_0000218,1969.0,
12243,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL630255,BAO_0000218,1969.0,
12244,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL630256,BAO_0000218,1969.0,
12245,,A,,In vivo,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL875781,BAO_0000218,2107.0,
12246,,A,,In vivo,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL630257,BAO_0000218,2107.0,
12247,,A,,In vivo,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,,50597,10116.0,Intermediate,1,CHEMBL630258,BAO_0000218,2107.0,
12248,,A,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",1,,,50597,10116.0,Intermediate,1,CHEMBL630259,BAO_0000218,,
12249,,A,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",1,,,50597,10116.0,Intermediate,1,CHEMBL630260,BAO_0000218,2435.0,
12250,,A,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",1,,,50597,10116.0,Intermediate,1,CHEMBL630261,BAO_0000218,2435.0,
12251,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,1,,,50597,10116.0,Intermediate,1,CHEMBL630262,BAO_0000218,,
12252,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL630263,BAO_0000218,,
12253,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630264,BAO_0000218,,
12254,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630265,BAO_0000218,,
12255,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630266,BAO_0000218,,
12256,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630267,BAO_0000218,2113.0,
12257,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630268,BAO_0000218,2113.0,
12258,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL630269,BAO_0000218,,
12259,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630270,BAO_0000218,,
12260,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL630141,BAO_0000218,2048.0,
12261,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630142,BAO_0000218,2048.0,
12262,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630143,BAO_0000218,2385.0,
12263,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630144,BAO_0000218,2385.0,
12264,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630145,BAO_0000218,2367.0,
12265,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630146,BAO_0000218,2367.0,
12266,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,1,,,50597,10116.0,Intermediate,1,CHEMBL630147,BAO_0000218,,
12267,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630148,BAO_0000218,,
12268,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630149,BAO_0000218,,
12269,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL630150,BAO_0000218,2106.0,
12270,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL630151,BAO_0000218,2106.0,
12271,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL632031,BAO_0000218,2046.0,
12272,,A,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,1,,,50597,10116.0,Intermediate,1,CHEMBL632032,BAO_0000218,2046.0,
12273,,A,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL632033,BAO_0000218,,
12274,,A,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL632034,BAO_0000218,,
12275,,A,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL632035,BAO_0000218,2385.0,
12276,,A,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL632036,BAO_0000218,,
12277,,A,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,1,,,50597,10116.0,Intermediate,1,CHEMBL632037,BAO_0000218,2046.0,
12278,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL632038,BAO_0000218,178.0,
12279,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL632039,BAO_0000218,178.0,
12280,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL632040,BAO_0000218,178.0,
12281,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL632041,BAO_0000218,178.0,
12282,,A,,,"Concentration of compound in blood of dog 2, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632042,BAO_0000218,178.0,
12283,,A,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632043,BAO_0000218,,
12284,,A,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632044,BAO_0000218,,
12285,,A,,,"Concentration of compound in liver of dog 1, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632045,BAO_0000218,2107.0,
12286,,A,,,"Concentration of compound in liver of dog 2, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632046,BAO_0000218,2107.0,
12287,,A,,,"Concentration of compound in lung of dog 1, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632047,BAO_0000218,2048.0,
12288,,A,,,"Concentration of compound in lung of dog 2, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632048,BAO_0000218,2048.0,
12289,,A,,,"Concentration of compound in muscle of dog 1, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632049,BAO_0000218,2385.0,
12290,,A,,,"Concentration of compound in muscle of dog 2, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL876418,BAO_0000218,2385.0,
12291,,A,,,"Concentration of compound in spleen of dog 1,after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632050,BAO_0000218,2106.0,
12292,,A,,,"Concentration of compound in spleen of dog 2, after administering intravenously",1,,,50588,9615.0,Intermediate,1,CHEMBL632051,BAO_0000218,2106.0,
12293,,F,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,0,,,22224,,Autocuration,1,CHEMBL632052,BAO_0000218,,
12294,,F,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,0,,,22224,,Autocuration,1,CHEMBL632053,BAO_0000218,,
12295,,A,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,0,,,22224,,Autocuration,1,CHEMBL632054,BAO_0000218,,
12296,,F,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,0,,,22224,,Autocuration,1,CHEMBL632055,BAO_0000218,,
12297,,F,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,0,,,22224,,Autocuration,1,CHEMBL631181,BAO_0000218,,
12298,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,0,,,22224,,Autocuration,1,CHEMBL631182,BAO_0000218,,
12299,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,0,,,22224,,Autocuration,1,CHEMBL631183,BAO_0000218,,
12300,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,0,,,22224,,Autocuration,1,CHEMBL631184,BAO_0000218,,
12301,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,0,,,22224,,Autocuration,1,CHEMBL629774,BAO_0000218,,
12302,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,0,,,22224,,Autocuration,1,CHEMBL629775,BAO_0000218,,
12303,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,0,,,22224,,Autocuration,1,CHEMBL876549,BAO_0000218,,
12304,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,0,,,22224,,Autocuration,1,CHEMBL628172,BAO_0000218,,
12305,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,0,,,22224,,Autocuration,1,CHEMBL628173,BAO_0000218,,
12306,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,0,,,22224,,Autocuration,1,CHEMBL628174,BAO_0000218,,
12307,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,0,,,22224,,Autocuration,1,CHEMBL628175,BAO_0000218,,
12308,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,0,,,22224,,Autocuration,1,CHEMBL628176,BAO_0000218,,
12309,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,0,,,22224,,Autocuration,1,CHEMBL628177,BAO_0000218,,
12310,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,0,,,22224,,Autocuration,1,CHEMBL628178,BAO_0000218,,
12311,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,0,,,22224,,Autocuration,1,CHEMBL628179,BAO_0000218,,
12312,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,0,,,22224,,Autocuration,1,CHEMBL628180,BAO_0000218,,
12313,,A,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,0,,,22224,,Autocuration,1,CHEMBL628181,BAO_0000218,,
12314,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,0,,,22224,,Autocuration,1,CHEMBL628182,BAO_0000218,,
12315,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,0,,,22224,,Autocuration,1,CHEMBL628183,BAO_0000218,,
12316,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,0,,,22224,,Autocuration,1,CHEMBL628184,BAO_0000218,,
12317,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,0,,,22224,,Autocuration,1,CHEMBL628185,BAO_0000218,,
12318,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,0,,,22224,,Autocuration,1,CHEMBL875617,BAO_0000218,,
12319,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,0,,,22224,,Autocuration,1,CHEMBL628186,BAO_0000218,,
12320,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,0,,,22224,,Autocuration,1,CHEMBL628187,BAO_0000218,,
12321,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,0,,,22224,,Autocuration,1,CHEMBL628188,BAO_0000218,,
12322,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,0,,,22224,,Autocuration,1,CHEMBL628189,BAO_0000218,,
12323,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,0,,,22224,,Autocuration,1,CHEMBL628190,BAO_0000218,,
12324,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,0,,,22224,,Autocuration,1,CHEMBL628191,BAO_0000218,,
12325,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,0,,,22224,,Autocuration,1,CHEMBL626513,BAO_0000218,,
12326,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",1,,,50597,10116.0,Intermediate,1,CHEMBL626514,BAO_0000218,2046.0,
12327,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",1,,,50597,10116.0,Intermediate,1,CHEMBL626515,BAO_0000218,2046.0,
12328,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",1,,,50597,10116.0,Intermediate,1,CHEMBL626516,BAO_0000218,2046.0,
12329,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",1,,,50597,10116.0,Intermediate,1,CHEMBL626517,BAO_0000218,2046.0,
12330,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",1,,,50597,10116.0,Intermediate,1,CHEMBL626518,BAO_0000218,2046.0,
12331,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",1,,,50597,10116.0,Intermediate,1,CHEMBL626519,BAO_0000218,2046.0,
12332,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",1,,,50597,10116.0,Intermediate,1,CHEMBL626520,BAO_0000218,2046.0,
12333,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",1,,,50597,10116.0,Intermediate,1,CHEMBL626521,BAO_0000218,2046.0,
12334,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",1,,,50597,10116.0,Intermediate,1,CHEMBL626522,BAO_0000218,2046.0,
12335,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",1,,,50597,10116.0,Intermediate,1,CHEMBL626523,BAO_0000218,2046.0,
12336,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",1,,,50597,10116.0,Intermediate,1,CHEMBL626524,BAO_0000218,2046.0,
12337,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",1,,,50597,10116.0,Intermediate,1,CHEMBL626688,BAO_0000218,2046.0,
12338,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",1,,,50597,10116.0,Intermediate,1,CHEMBL626689,BAO_0000218,2046.0,
12339,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",1,,,50597,10116.0,Intermediate,1,CHEMBL626690,BAO_0000218,2046.0,
12340,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",1,,,50597,10116.0,Intermediate,1,CHEMBL626691,BAO_0000218,2046.0,
12341,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",1,,,50597,10116.0,Intermediate,1,CHEMBL627319,BAO_0000218,2046.0,
12342,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",1,,,50597,10116.0,Intermediate,1,CHEMBL624052,BAO_0000218,2046.0,
12343,,A,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",1,,,50597,10116.0,Intermediate,1,CHEMBL624053,BAO_0000218,2046.0,
12344,,A,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624054,BAO_0000218,,
12345,,A,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624055,BAO_0000218,,
12346,,A,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624056,BAO_0000218,,
12347,,A,,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL624057,BAO_0000218,995.0,
12348,,A,,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622281,BAO_0000218,995.0,
12349,,A,,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622282,BAO_0000218,995.0,
12350,,A,,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622283,BAO_0000218,995.0,
12351,,A,,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622284,BAO_0000218,995.0,
12352,,A,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622285,BAO_0000218,995.0,
12353,,A,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622286,BAO_0000218,995.0,
12354,,P,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,0,,,22224,,Autocuration,1,CHEMBL622287,BAO_0000100,,
12355,,A,,,Partition coefficient (logD7.4),1,,,50594,10090.0,Intermediate,1,CHEMBL622288,BAO_0000218,,
12356,,A,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",1,,,50594,10090.0,Intermediate,1,CHEMBL622289,BAO_0000218,,
12357,,A,,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",1,,,50594,10090.0,Intermediate,1,CHEMBL622290,BAO_0000218,955.0,
12358,,A,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,1,,,50594,10090.0,Intermediate,1,CHEMBL622291,BAO_0000218,,
12359,,A,,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,1,,,50594,10090.0,Intermediate,1,CHEMBL622292,BAO_0000218,955.0,
12360,,A,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",1,,,50594,10090.0,Intermediate,1,CHEMBL622293,BAO_0000218,,
12361,,A,,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",1,,,50594,10090.0,Intermediate,1,CHEMBL622294,BAO_0000218,955.0,
12362,,A,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,1,,,50594,10090.0,Intermediate,1,CHEMBL622295,BAO_0000218,,
12363,,A,,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,1,,,50597,10116.0,Intermediate,1,CHEMBL622296,BAO_0000218,955.0,
12364,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL874409,BAO_0000218,1969.0,
12365,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622297,BAO_0000218,1969.0,
12366,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622298,BAO_0000218,1969.0,
12367,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622299,BAO_0000218,1969.0,
12368,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622300,BAO_0000218,1969.0,
12369,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622301,BAO_0000218,1969.0,
12370,,A,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622302,BAO_0000218,1969.0,
12371,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622303,BAO_0000218,1969.0,
12372,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622304,BAO_0000218,1969.0,
12373,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622305,BAO_0000218,1969.0,
12374,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL622306,BAO_0000218,1969.0,
12375,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626864,BAO_0000218,1969.0,
12376,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL626865,BAO_0000218,1969.0,
12377,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626866,BAO_0000218,1969.0,
12378,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL626867,BAO_0000218,1969.0,
12379,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL626868,BAO_0000218,1969.0,
12380,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626869,BAO_0000218,1969.0,
12381,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL626870,BAO_0000218,1969.0,
12382,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626871,BAO_0000218,1969.0,
12383,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL626872,BAO_0000218,1969.0,
12384,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1,,,50597,10116.0,Intermediate,1,CHEMBL632185,BAO_0000218,1969.0,
12385,,A,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL632186,BAO_0000218,1969.0,
12386,,A,,,Amount of acetic acid produced by the compound,0,,,22224,,Autocuration,1,CHEMBL629310,BAO_0000019,,
12387,,A,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,0,,,22224,,Autocuration,1,CHEMBL629311,BAO_0000019,,
12388,,A,,,Log of (Cbrain/Cblood) in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL629312,BAO_0000218,,
12389,,A,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629313,BAO_0000221,,
12390,,A,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629314,BAO_0000221,,
12391,,A,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629315,BAO_0000221,,
12392,,B,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629316,BAO_0000219,,
12393,,A,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629317,BAO_0000221,,
12394,,A,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629318,BAO_0000019,,
12395,,A,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL877497,BAO_0000019,,
12396,,A,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629319,BAO_0000019,,
12397,,A,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629320,BAO_0000019,,
12398,,A,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629496,BAO_0000019,,
12399,,A,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629497,BAO_0000019,,
12400,,A,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629498,BAO_0000019,,
12401,,A,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629499,BAO_0000019,,
12402,,A,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629500,BAO_0000019,,
12403,,A,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629501,BAO_0000019,,
12404,,A,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),0,,,22224,,Autocuration,1,CHEMBL629502,BAO_0000019,,
12405,,F,,In vivo,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,0,,,22224,,Autocuration,1,CHEMBL629503,BAO_0000218,,
12406,,A,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL629504,BAO_0000218,,
12407,,A,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,0,,,22224,,Autocuration,1,CHEMBL629505,BAO_0000019,,
12408,,A,,,Compound was evaluated for total body clearance,0,,,22224,,Autocuration,1,CHEMBL629506,BAO_0000019,,
12409,,A,,,Compound was evaluated for volume of distribution at steady state,0,,,22224,,Autocuration,1,CHEMBL629507,BAO_0000019,,
12410,,A,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,0,,,22224,,Autocuration,1,CHEMBL877498,BAO_0000019,,
12411,,A,,,Percentage of the diamine which is monoprotonated at pH 7.4,0,,,22224,,Autocuration,1,CHEMBL629508,BAO_0000019,,
12412,,A,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,0,,,22224,,Autocuration,1,CHEMBL629509,BAO_0000019,,
12413,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL629510,BAO_0000218,178.0,
12414,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL629511,BAO_0000218,178.0,
12415,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL629512,BAO_0000218,178.0,
12416,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL629513,BAO_0000218,178.0,
12417,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL629514,BAO_0000218,178.0,
12418,,A,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL628447,BAO_0000218,178.0,
12419,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL628448,BAO_0000218,178.0,
12420,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL628449,BAO_0000218,178.0,
12421,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631119,BAO_0000218,178.0,
12422,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631120,BAO_0000218,178.0,
12423,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631121,BAO_0000218,178.0,
12424,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,1,,,50597,10116.0,Intermediate,1,CHEMBL874458,BAO_0000218,178.0,
12425,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631122,BAO_0000218,178.0,
12426,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631123,BAO_0000218,178.0,
12427,,A,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631124,BAO_0000218,178.0,
12428,,A,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631125,BAO_0000218,178.0,
12429,,A,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631290,BAO_0000218,178.0,
12430,,A,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631291,BAO_0000218,178.0,
12431,,A,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631292,BAO_0000218,178.0,
12432,,A,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631293,BAO_0000218,178.0,
12433,,A,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631294,BAO_0000218,178.0,
12434,,A,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631295,BAO_0000218,178.0,
12435,,A,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631296,BAO_0000218,178.0,
12436,,A,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,,,50597,10116.0,Intermediate,1,CHEMBL631297,BAO_0000218,178.0,
12437,,A,,,Maximum biodistribution (Bmax) was determined.,0,,,22224,,Autocuration,1,CHEMBL631298,BAO_0000218,,
12438,,A,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,1,,,50594,10090.0,Intermediate,1,CHEMBL631299,BAO_0000218,,
12439,,A,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,1,,,50594,10090.0,Intermediate,1,CHEMBL631300,BAO_0000218,,
12440,,A,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,1,,,50594,10090.0,Intermediate,1,CHEMBL631301,BAO_0000218,,
12441,,A,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,1,,,50594,10090.0,Intermediate,1,CHEMBL630291,BAO_0000218,,
12442,,A,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,0,,,22224,,Autocuration,1,CHEMBL630292,BAO_0000218,,
12443,,A,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,0,,,22224,,Autocuration,1,CHEMBL630293,BAO_0000218,,
12444,,A,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL630294,BAO_0000218,,
12445,,A,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,0,,,22224,,Autocuration,1,CHEMBL630295,BAO_0000218,,
12446,,A,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,0,,,22224,,Autocuration,1,CHEMBL630296,BAO_0000218,,
12447,,A,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL626782,BAO_0000218,,
12448,,A,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL626783,BAO_0000218,,
12449,,A,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,0,,,22224,,Autocuration,1,CHEMBL626784,BAO_0000218,,
12450,,A,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,0,,,22224,,Autocuration,1,CHEMBL626785,BAO_0000218,,
12451,,A,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL626786,BAO_0000218,,
12452,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,0,,,22224,,Autocuration,1,CHEMBL626787,BAO_0000218,,
12453,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,0,,,22224,,Autocuration,1,CHEMBL626788,BAO_0000218,,
12454,,A,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,0,,,22224,,Autocuration,1,CHEMBL625927,BAO_0000218,,
12455,,A,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL625928,BAO_0000218,178.0,
12456,,A,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,,50597,10116.0,Intermediate,1,CHEMBL625929,BAO_0000218,178.0,
12457,,A,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,1,,,50597,10116.0,Intermediate,1,CHEMBL625930,BAO_0000218,178.0,
12458,,A,,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",1,,,50597,10116.0,Intermediate,1,CHEMBL625931,BAO_0000218,178.0,
12459,,A,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,1,,,50597,10116.0,Intermediate,1,CHEMBL627230,BAO_0000218,178.0,
12460,,A,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627231,BAO_0000218,178.0,
12461,,A,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,,50597,10116.0,Intermediate,1,CHEMBL627232,BAO_0000218,178.0,
12462,,A,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,1,,,50597,10116.0,Intermediate,1,CHEMBL627233,BAO_0000218,178.0,
12463,,A,,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL875470,BAO_0000218,178.0,
12464,,A,,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627234,BAO_0000218,178.0,
12465,,A,,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627235,BAO_0000218,178.0,
12466,,A,,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627236,BAO_0000218,178.0,
12467,,A,,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627237,BAO_0000218,178.0,
12468,,A,,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627238,BAO_0000218,178.0,
12469,,A,,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627239,BAO_0000218,178.0,
12470,,A,,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627240,BAO_0000218,178.0,
12471,,A,,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627241,BAO_0000218,178.0,
12472,,A,,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627242,BAO_0000218,178.0,
12473,,A,,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,1,,,50597,10116.0,Intermediate,1,CHEMBL627243,BAO_0000218,178.0,
12474,,A,,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,,50597,10116.0,Intermediate,1,CHEMBL627244,BAO_0000218,178.0,
12475,,A,,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627245,BAO_0000218,178.0,
12476,,A,,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627246,BAO_0000218,178.0,
12477,,A,,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627247,BAO_0000218,178.0,
12478,,A,,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627248,BAO_0000218,178.0,
12479,,A,,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627249,BAO_0000218,178.0,
12480,,A,,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL625569,BAO_0000218,178.0,
12481,,A,,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL625570,BAO_0000218,178.0,
12482,,A,,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL625571,BAO_0000218,178.0,
12483,,A,,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,,50597,10116.0,Intermediate,1,CHEMBL625572,BAO_0000218,178.0,
12484,,A,,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,,50597,10116.0,Intermediate,1,CHEMBL625573,BAO_0000218,178.0,
12485,,A,,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625574,BAO_0000218,178.0,
12486,,A,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,,50597,10116.0,Intermediate,1,CHEMBL626245,BAO_0000218,178.0,
12487,,A,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626246,BAO_0000218,178.0,
12488,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,0,,,22224,,Autocuration,1,CHEMBL626247,BAO_0000218,,
12489,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,0,,,22224,,Autocuration,1,CHEMBL626248,BAO_0000218,,
12490,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,0,,,22224,,Autocuration,1,CHEMBL626249,BAO_0000218,,
12491,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,0,,,22224,,Autocuration,1,CHEMBL626420,BAO_0000218,,
12492,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,0,,,22224,,Autocuration,1,CHEMBL626421,BAO_0000218,,
12493,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,0,,,22224,,Autocuration,1,CHEMBL626422,BAO_0000218,,
12494,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,0,,,22224,,Autocuration,1,CHEMBL626423,BAO_0000218,,
12495,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,0,,,22224,,Autocuration,1,CHEMBL626424,BAO_0000218,,
12496,,A,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,1,,,50588,9615.0,Intermediate,1,CHEMBL626425,BAO_0000218,,
12497,,A,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,1,,,50597,10116.0,Intermediate,1,CHEMBL875476,BAO_0000218,,
12498,,A,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,1,,,100710,9541.0,Intermediate,1,CHEMBL626426,BAO_0000218,,
12499,,P,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,0,,,22224,,Autocuration,1,CHEMBL626427,BAO_0000100,,
12500,,P,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,0,,,22224,,Autocuration,1,CHEMBL626428,BAO_0000100,,
12501,,A,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,0,,,22224,,Autocuration,1,CHEMBL626429,BAO_0000019,,
12502,,A,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,0,,,22224,,Autocuration,1,CHEMBL625025,BAO_0000019,1088.0,
12503,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625026,BAO_0000218,178.0,
12504,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625027,BAO_0000218,178.0,
12505,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL874410,BAO_0000218,178.0,
12506,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625028,BAO_0000218,178.0,
12507,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625029,BAO_0000218,178.0,
12508,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625030,BAO_0000218,178.0,
12509,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625031,BAO_0000218,178.0,
12510,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625032,BAO_0000218,178.0,
12511,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625033,BAO_0000218,178.0,
12512,,A,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL625034,BAO_0000218,178.0,
12513,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624872,BAO_0000218,948.0,
12514,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624873,BAO_0000218,948.0,
12515,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624874,BAO_0000218,948.0,
12516,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624875,BAO_0000218,948.0,
12517,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624876,BAO_0000218,948.0,
12518,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624877,BAO_0000218,948.0,
12519,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624878,BAO_0000218,948.0,
12520,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624879,BAO_0000218,948.0,
12521,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624880,BAO_0000218,948.0,
12522,,A,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624881,BAO_0000218,948.0,
12523,,A,,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",1,,,50597,10116.0,Intermediate,1,CHEMBL624882,BAO_0000218,948.0,
12524,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624883,BAO_0000218,2113.0,
12525,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624884,BAO_0000218,2113.0,
12526,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624885,BAO_0000218,2113.0,
12527,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624886,BAO_0000218,2113.0,
12528,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624887,BAO_0000218,2113.0,
12529,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624888,BAO_0000218,2113.0,
12530,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624889,BAO_0000218,2113.0,
12531,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624890,BAO_0000218,2113.0,
12532,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL621964,BAO_0000218,2113.0,
12533,,A,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL621965,BAO_0000218,2113.0,
12534,,A,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL621966,BAO_0000218,2107.0,
12535,,A,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL621967,BAO_0000218,2107.0,
12536,,A,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL622164,BAO_0000218,2107.0,
12537,,A,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),0,,,22224,,Autocuration,1,CHEMBL623097,BAO_0000019,,
12538,,A,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),0,,,22224,,Autocuration,1,CHEMBL623098,BAO_0000019,,
12539,,A,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,0,,,22224,,Autocuration,1,CHEMBL623099,BAO_0000019,,
12540,,A,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,0,,,22224,,Autocuration,1,CHEMBL623100,BAO_0000019,,
12541,,A,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",1,,,50597,10116.0,Intermediate,1,CHEMBL628673,BAO_0000218,,
12542,,A,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",1,,,50597,10116.0,Intermediate,1,CHEMBL628674,BAO_0000218,,
12543,,A,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",1,,,50597,10116.0,Intermediate,1,CHEMBL628675,BAO_0000218,,
12544,,A,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",1,,,50597,10116.0,Intermediate,1,CHEMBL627644,BAO_0000218,,
12545,,A,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",1,,,50597,10116.0,Intermediate,1,CHEMBL627645,BAO_0000218,,
12546,,A,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",1,,,50597,10116.0,Intermediate,1,CHEMBL627646,BAO_0000218,,
12547,,A,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",1,,,50597,10116.0,Intermediate,1,CHEMBL627647,BAO_0000218,,
12548,,A,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",1,,,50597,10116.0,Intermediate,1,CHEMBL627648,BAO_0000218,,
12549,,A,,,Free level in rat plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL627649,BAO_0000218,,
12550,,A,,,Level reaching in blood plasma of rat or human was determined,0,,,22224,,Autocuration,1,CHEMBL628313,BAO_0000019,,
12551,,A,,,Log (Cbrain/Cblood) in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628314,BAO_0000218,,
12552,,A,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,0,,,22224,,Autocuration,1,CHEMBL628315,BAO_0000019,,
12553,,A,,,Mean percentage of compound transport through membrane; expressed as membrane transport,0,,,22224,,Autocuration,1,CHEMBL628316,BAO_0000019,,
12554,,A,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,0,,,22224,,Autocuration,1,CHEMBL628317,BAO_0000218,,
12555,,A,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,0,,,22224,,Autocuration,1,CHEMBL628473,BAO_0000019,,
12556,,A,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",0,,,22224,,Autocuration,1,CHEMBL628474,BAO_0000019,,
12557,,A,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,0,,,22224,,Autocuration,1,CHEMBL628475,BAO_0000019,,
12558,,A,,,Net water uptake by a carrier mediated transport (%cm) mechanism,0,,,22224,,Autocuration,1,CHEMBL628476,BAO_0000019,,
12559,,A,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL628477,BAO_0000218,,
12560,,A,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,1,,,50506,9669.0,Intermediate,1,CHEMBL628478,BAO_0000218,,
12561,,A,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",1,,,50506,9669.0,Intermediate,1,CHEMBL628479,BAO_0000218,,
12562,,A,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL628480,BAO_0000218,,
12563,,A,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",0,,,22224,314293.0,Autocuration,1,CHEMBL628481,BAO_0000218,,
12564,,A,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL628482,BAO_0000218,,
12565,,A,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,,,50597,10116.0,Intermediate,1,CHEMBL628483,BAO_0000218,,
12566,,A,,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1,,,50597,10116.0,Intermediate,1,CHEMBL628484,BAO_0000218,1969.0,
12567,,A,,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,,,50597,10116.0,Intermediate,1,CHEMBL628485,BAO_0000218,1969.0,
12568,,A,,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",1,,,100710,9541.0,Intermediate,1,CHEMBL628486,BAO_0000218,1969.0,
12569,,A,,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",1,,,50587,9606.0,Intermediate,1,CHEMBL628487,BAO_0000218,1969.0,
12570,,A,,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1,,,50597,10116.0,Intermediate,1,CHEMBL628488,BAO_0000218,1969.0,
12571,,A,,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,,,50597,10116.0,Intermediate,1,CHEMBL628489,BAO_0000218,1969.0,
12572,,A,,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,,,50597,10116.0,Intermediate,1,CHEMBL628490,BAO_0000218,1969.0,
12573,,A,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,,,100710,9541.0,Intermediate,1,CHEMBL628491,BAO_0000218,,
12574,,A,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,,,100710,9541.0,Intermediate,1,CHEMBL877507,BAO_0000218,,
12575,,A,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,0,,,22224,,Autocuration,1,CHEMBL628492,BAO_0000218,,
12576,,A,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),0,,,22224,314293.0,Autocuration,1,CHEMBL628493,BAO_0000019,,
12577,,A,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),0,,,22224,314293.0,Autocuration,1,CHEMBL628494,BAO_0000019,,
12578,,A,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),0,,,22224,314293.0,Autocuration,1,CHEMBL628495,BAO_0000019,,
12579,,A,,,Permeability in Caco-2 assay at 10E-6,1,,,50587,9606.0,Intermediate,1,CHEMBL628496,BAO_0000218,,
12580,,A,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,0,,,22224,,Autocuration,1,CHEMBL628497,BAO_0000218,955.0,
12581,,A,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,0,,,22224,,Autocuration,1,CHEMBL628498,BAO_0000218,955.0,
12582,,A,,,Plasma protein binding was determined,0,,,22224,,Autocuration,1,CHEMBL628499,BAO_0000019,,
12583,,A,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL627656,BAO_0000218,,
12584,,A,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,0,,,22224,,Autocuration,1,CHEMBL627657,BAO_0000218,,
12585,,A,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,0,,,22224,,Autocuration,1,CHEMBL626808,BAO_0000218,,
12586,,A,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL626809,BAO_0000218,,
12587,,A,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL626810,BAO_0000218,,
12588,,A,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,0,,,22224,,Autocuration,1,CHEMBL626811,BAO_0000218,,
12589,,A,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,0,,,22224,,Autocuration,1,CHEMBL874465,BAO_0000218,,
12590,,A,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL626812,BAO_0000218,,
12591,,A,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL626813,BAO_0000218,,
12592,,A,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,0,,,22224,,Autocuration,1,CHEMBL626814,BAO_0000218,,
12593,,A,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,0,,,22224,,Autocuration,1,CHEMBL626815,BAO_0000019,,
12594,,A,,,Partition coefficient (logP),0,,,22224,,Autocuration,1,CHEMBL628566,BAO_0000019,,
12595,,P,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),0,,,22229,,Autocuration,1,CHEMBL628567,BAO_0000100,,
12596,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL628568,BAO_0000100,,
12597,,A,,In vivo,C max in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL628569,BAO_0000218,,
12598,,A,,In vivo,C max in guinea pig,1,,,50512,10141.0,Intermediate,1,CHEMBL628570,BAO_0000218,,
12599,,A,,In vivo,C max value was evaluated,0,,,22224,,Autocuration,1,CHEMBL628571,BAO_0000218,,
12600,,A,,In vivo,Cmax value after oral dose of 0.1 mg//kg,0,,,22224,,Autocuration,1,CHEMBL628572,BAO_0000218,,
12601,,A,,In vivo,Cmax value after oral dose of 0.3 mg/kg,0,,,22224,,Autocuration,1,CHEMBL628573,BAO_0000218,,
12602,,A,,In vivo,Cmax value after oral dose of 1 mg/kg,0,,,22224,,Autocuration,1,CHEMBL628574,BAO_0000218,,
12603,,A,,In vivo,Cmax value after oral dose of 10 mg/kg,0,,,22224,,Autocuration,1,CHEMBL628575,BAO_0000218,,
12604,,A,,In vivo,Cmax value after oral dose of 23.4 mg/kg,0,,,22224,,Autocuration,1,CHEMBL628576,BAO_0000218,,
12605,,A,,In vivo,Cmax value after oral dose of 3 mg/kg,0,,,22224,,Autocuration,1,CHEMBL628577,BAO_0000218,,
12606,,A,,In vivo,Cmax value after oral dose of 3.87 mg/kg,0,,,22224,,Autocuration,1,CHEMBL628578,BAO_0000218,,
12607,,A,,In vivo,Cmax value in female Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL874466,BAO_0000218,,
12608,,A,,In vivo,Cmax value in male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL628579,BAO_0000218,,
12609,,A,,In vivo,Cmax value in rat plasma when administered 20 mg/kg perorally,1,,,50597,10116.0,Intermediate,1,CHEMBL628580,BAO_0000218,1969.0,
12610,,A,,In vivo,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,,,50588,9615.0,Intermediate,1,CHEMBL628581,BAO_0000218,1969.0,
12611,,A,,In vivo,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,,,50588,9615.0,Intermediate,1,CHEMBL628582,BAO_0000218,1969.0,
12612,,A,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,1,,,50588,9615.0,Intermediate,1,CHEMBL628583,BAO_0000218,,
12613,,A,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,0,,,22224,314293.0,Autocuration,1,CHEMBL625782,BAO_0000218,,
12614,,A,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,1,,,50592,9986.0,Intermediate,1,CHEMBL625783,BAO_0000218,,
12615,,A,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,1,,,50597,10116.0,Intermediate,1,CHEMBL625784,BAO_0000218,,
12616,,A,,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,1,,,50797,9544.0,Intermediate,1,CHEMBL625785,BAO_0000218,1969.0,
12617,,A,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625786,BAO_0000218,,
12618,,A,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,0,,,22224,,Autocuration,1,CHEMBL874467,BAO_0000019,,
12619,,A,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",1,,,50588,9615.0,Intermediate,1,CHEMBL625787,BAO_0000218,,
12620,,A,,,cytotoxicity against HIV protease enzyme.,1,,,50677,12721.0,Intermediate,1,CHEMBL625964,BAO_0000218,,
12621,,A,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,1,,,50594,10090.0,Intermediate,1,CHEMBL625965,BAO_0000218,,
12622,,A,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,1,,,50594,10090.0,Intermediate,1,CHEMBL625966,BAO_0000218,,
12623,,A,,In vivo,The plasma clearance in dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL625967,BAO_0000218,1969.0,
12624,,A,,In vivo,The plasma clearance in rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL625968,BAO_0000218,1969.0,
12625,,A,,In vivo,Clearance from plasma in male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625969,BAO_0000218,1969.0,
12626,,A,,In vivo,Clearance from plasma in male cynomolgus monkeys,1,,,100710,9541.0,Intermediate,1,CHEMBL625970,BAO_0000218,1969.0,
12627,,A,,In vivo,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",1,,,50588,9615.0,Intermediate,1,CHEMBL625971,BAO_0000218,1969.0,
12628,,A,,In vivo,Clearance of compound in dog plasma,1,,,50588,9615.0,Intermediate,1,CHEMBL625972,BAO_0000218,1969.0,
12629,,A,,In vivo,Clearance of compound in human plasma,1,,,50587,9606.0,Intermediate,1,CHEMBL625973,BAO_0000218,1969.0,
12630,,A,,In vivo,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL625974,BAO_0000218,,
12631,,A,,In vivo,Clearance of compound when administered intravenously as an individual dose to a single dog.,1,,,50588,9615.0,Intermediate,1,CHEMBL625975,BAO_0000218,,
12632,,A,,In vivo,"Clearance (10 mg/kg, intravenously) in dog plasma",1,,,50588,9615.0,Intermediate,1,CHEMBL625976,BAO_0000218,1969.0,
12633,,A,,In vivo,Clearance value in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625977,BAO_0000218,,
12634,,A,,In vivo,Clearance value in guinea pig,1,,,50512,10141.0,Intermediate,1,CHEMBL625978,BAO_0000218,,
12635,,A,,In vivo,Clearance values in rats after iv administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL874468,BAO_0000218,,
12636,,A,,In vivo,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,0,,,22224,,Autocuration,1,CHEMBL625421,BAO_0000218,1969.0,
12637,,A,,In vivo,In vivo clearance (5 mg/kg) was determined in rabbits,1,,,50592,9986.0,Intermediate,1,CHEMBL625422,BAO_0000218,,
12638,,A,,In vivo,Plasma Clearance rate was determined for the compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625423,BAO_0000218,,
12639,,A,,In vivo,Plasma Clearance rate was determined for the compound in squirrel monkeys,0,,,22224,9520.0,Autocuration,1,CHEMBL625424,BAO_0000218,,
12640,,A,,In vivo,Plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625425,BAO_0000218,,
12641,,A,,In vivo,Plasma clearance of the compound,0,,,22224,,Autocuration,1,CHEMBL625426,BAO_0000218,,
12642,,A,,In vivo,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,1,,,50512,10141.0,Intermediate,1,CHEMBL625427,BAO_0000218,,
12643,,A,,In vivo,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,1,,,50512,10141.0,Intermediate,1,CHEMBL625428,BAO_0000218,,
12644,,A,,In vivo,Plasma clearance was determined,0,,,22224,,Autocuration,1,CHEMBL625429,BAO_0000218,,
12645,,A,,In vivo,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,1,,,50588,9615.0,Intermediate,1,CHEMBL625430,BAO_0000218,,
12646,,A,,In vivo,Plasma clearance rate was determined for the compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625431,BAO_0000218,,
12647,,A,,In vivo,Plasma clearance rate was determined for the compound in squirrel monkeys,0,,,22224,9520.0,Autocuration,1,CHEMBL627307,BAO_0000218,,
12648,,A,,In vivo,Slow clearance (CL) was determined,0,,,22224,,Autocuration,1,CHEMBL627308,BAO_0000218,,
12649,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,0,,,22224,,Autocuration,1,CHEMBL627309,BAO_0000218,,
12650,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,0,,,22224,,Autocuration,1,CHEMBL627310,BAO_0000218,,
12651,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,0,,,22224,,Autocuration,1,CHEMBL627311,BAO_0000218,,
12652,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,0,,,22224,,Autocuration,1,CHEMBL627312,BAO_0000218,,
12653,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,0,,,22224,,Autocuration,1,CHEMBL627313,BAO_0000218,,
12654,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,0,,,22224,,Autocuration,1,CHEMBL627314,BAO_0000218,,
12655,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,0,,,22224,,Autocuration,1,CHEMBL627315,BAO_0000218,,
12656,,A,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,0,,,22224,,Autocuration,1,CHEMBL627316,BAO_0000218,,
12657,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,0,,,22224,,Autocuration,1,CHEMBL627317,BAO_0000218,,
12658,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,0,,,22224,,Autocuration,1,CHEMBL627318,BAO_0000218,,
12659,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,0,,,22224,,Autocuration,1,CHEMBL627999,BAO_0000218,,
12660,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,0,,,22224,,Autocuration,1,CHEMBL628000,BAO_0000218,,
12661,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,0,,,22224,,Autocuration,1,CHEMBL628001,BAO_0000218,,
12662,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,0,,,22224,,Autocuration,1,CHEMBL628002,BAO_0000218,,
12663,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,0,,,22224,,Autocuration,1,CHEMBL625610,BAO_0000218,,
12664,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,0,,,22224,,Autocuration,1,CHEMBL625611,BAO_0000218,,
12665,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,0,,,22224,,Autocuration,1,CHEMBL625612,BAO_0000218,,
12666,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,0,,,22224,,Autocuration,1,CHEMBL625613,BAO_0000218,,
12667,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,0,,,22224,,Autocuration,1,CHEMBL875479,BAO_0000218,,
12668,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,0,,,22224,,Autocuration,1,CHEMBL625614,BAO_0000218,,
12669,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,0,,,22224,,Autocuration,1,CHEMBL625615,BAO_0000218,,
12670,,A,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,0,,,22224,,Autocuration,1,CHEMBL626302,BAO_0000218,,
12671,,A,,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626303,BAO_0000218,178.0,
12672,,A,,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,,50597,10116.0,Intermediate,1,CHEMBL627420,BAO_0000218,178.0,
12673,,A,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,1,,,50597,10116.0,Intermediate,1,CHEMBL627421,BAO_0000218,,
12674,,A,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,1,,,50597,10116.0,Intermediate,1,CHEMBL625695,BAO_0000218,,
12675,,A,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,1,,,50597,10116.0,Intermediate,1,CHEMBL625696,BAO_0000218,,
12676,,A,,,Distribution of compound in mice brain was measured after 1 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL875606,BAO_0000218,955.0,
12677,,A,,,Distribution of compound in mice brain was measured after 24 hr r,1,,,50594,10090.0,Intermediate,1,CHEMBL625697,BAO_0000218,955.0,
12678,,A,,,Distribution of compound in mice brain was measured after 2 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL625698,BAO_0000218,955.0,
12679,,A,,,Distribution of compound in mice brain was measured after 3 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL625699,BAO_0000218,955.0,
12680,,A,,,Distribution of compound in mice brain was measured after 6 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL625700,BAO_0000218,955.0,
12681,,A,,,Distribution of compound in mice liver was measured after 1 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL625701,BAO_0000218,,
12682,,A,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,1,,,50594,10090.0,Intermediate,1,CHEMBL625702,BAO_0000218,,
12683,,A,,,Distribution of compound in mice liver was measured after 2 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL625703,BAO_0000218,,
12684,,A,,,Distribution of compound in mice liver was measured after 3 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL625704,BAO_0000218,,
12685,,A,,,Distribution of compound in mice liver was measured after 6 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL625705,BAO_0000218,,
12686,,A,,,Distribution in dog adrenal medulla 30 min after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL625706,BAO_0000218,1236.0,
12687,,A,,,Distribution in dog adrenal medulla 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL625707,BAO_0000218,1236.0,
12688,,A,,,Distribution in female dog Ovary 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL625708,BAO_0000218,,
12689,,A,,,Distribution in female dog Ovary 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL625709,BAO_0000218,,
12690,,A,,,Distribution in female dog adipose 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624180,BAO_0000218,,
12691,,A,,,Distribution in female dog adipose 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624181,BAO_0000218,,
12692,,A,,,Distribution in female dog adrenal cortex 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624182,BAO_0000218,1235.0,
12693,,A,,,Distribution in female dog adrenal cortex 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624183,BAO_0000218,1235.0,
12694,,A,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624184,BAO_0000218,2107.0,
12695,,A,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL877489,BAO_0000218,2107.0,
12696,,A,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624185,BAO_0000218,2107.0,
12697,,A,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624186,BAO_0000218,2107.0,
12698,,A,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624187,BAO_0000218,2107.0,
12699,,A,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624188,BAO_0000218,2107.0,
12700,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624189,BAO_0000218,2048.0,
12701,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624190,BAO_0000218,2048.0,
12702,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624191,BAO_0000218,2048.0,
12703,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624192,BAO_0000218,2048.0,
12704,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624193,BAO_0000218,2048.0,
12705,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624194,BAO_0000218,2048.0,
12706,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624891,BAO_0000218,2048.0,
12707,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624892,BAO_0000218,2048.0,
12708,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL624893,BAO_0000218,2048.0,
12709,,A,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627632,BAO_0000218,2048.0,
12710,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627633,BAO_0000218,,
12711,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627634,BAO_0000218,,
12712,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627635,BAO_0000218,,
12713,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627636,BAO_0000218,,
12714,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626816,BAO_0000218,,
12715,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626817,BAO_0000218,,
12716,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626818,BAO_0000218,,
12717,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626819,BAO_0000218,,
12718,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626820,BAO_0000218,,
12719,,A,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626821,BAO_0000218,,
12720,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626822,BAO_0000218,2046.0,
12721,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626823,BAO_0000218,2046.0,
12722,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626824,BAO_0000218,2046.0,
12723,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626825,BAO_0000218,2046.0,
12724,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626826,BAO_0000218,2046.0,
12725,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626827,BAO_0000218,2046.0,
12726,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626828,BAO_0000218,2046.0,
12727,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626829,BAO_0000218,2046.0,
12728,,A,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626830,BAO_0000218,2046.0,
12729,,A,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627150,BAO_0000218,,
12730,,A,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627151,BAO_0000218,,
12731,,A,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627152,BAO_0000218,,
12732,,A,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL627153,BAO_0000218,,
12733,,A,,,Rate of acetate production by the compound was determined,0,,,22224,,Autocuration,1,CHEMBL627154,BAO_0000019,,
12734,,A,,,Rate of acetate production by the compound was determined; Not determined,0,,,22224,,Autocuration,1,CHEMBL627155,BAO_0000019,,
12735,,A,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,0,,,22224,,Autocuration,1,CHEMBL627156,BAO_0000019,,
12736,,A,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,0,,,22224,,Autocuration,1,CHEMBL627157,BAO_0000019,,
12737,,A,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1,,,50592,9986.0,Intermediate,1,CHEMBL627158,BAO_0000218,,
12738,,A,,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1,,,50592,9986.0,Intermediate,1,CHEMBL627159,BAO_0000218,1969.0,
12739,,A,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1,,,50594,10090.0,Intermediate,1,CHEMBL627160,BAO_0000218,,
12740,,A,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL628540,BAO_0000218,,
12741,,A,,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL628541,BAO_0000218,1969.0,
12742,,A,,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL628542,BAO_0000218,1969.0,
12743,,P,,,Solubility after at a pH 1.2,0,,,22229,,Autocuration,1,CHEMBL628543,BAO_0000100,,
12744,,P,,,Solubility after at pH 1.2,0,,,22229,,Autocuration,1,CHEMBL628544,BAO_0000100,,
12745,,P,,,Solubility after injection of water,0,,,22229,,Autocuration,1,CHEMBL628545,BAO_0000100,,
12746,,A,,,Statistical significance of IC 50 values; Expressed as R value,0,,,22224,,Autocuration,1,CHEMBL628546,BAO_0000019,,
12747,,A,,,Systemic availability with respect to methyldopa was determined,0,,,22224,,Autocuration,1,CHEMBL874455,BAO_0000019,,
12748,,A,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL628547,BAO_0000218,,
12749,,A,,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL628548,BAO_0000218,1969.0,
12750,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",1,,,50592,9986.0,Intermediate,1,CHEMBL628549,BAO_0000218,1988.0,
12751,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",1,,,50592,9986.0,Intermediate,1,CHEMBL628550,BAO_0000218,1988.0,
12752,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",1,,,50592,9986.0,Intermediate,1,CHEMBL628551,BAO_0000218,1988.0,
12753,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",1,,,50592,9986.0,Intermediate,1,CHEMBL628552,BAO_0000218,1088.0,
12754,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",1,,,50592,9986.0,Intermediate,1,CHEMBL628553,BAO_0000218,1088.0,
12755,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",1,,,50592,9986.0,Intermediate,1,CHEMBL628554,BAO_0000218,1088.0,
12756,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",1,,,50592,9986.0,Intermediate,1,CHEMBL628555,BAO_0000218,1088.0,
12757,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",1,,,50592,9986.0,Intermediate,1,CHEMBL628556,BAO_0000218,1088.0,
12758,,A,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",1,,,50592,9986.0,Intermediate,1,CHEMBL628557,BAO_0000218,2113.0,
12759,,A,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",1,,,50592,9986.0,Intermediate,1,CHEMBL628558,BAO_0000218,1988.0,
12760,,A,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",1,,,50592,9986.0,Intermediate,1,CHEMBL628559,BAO_0000218,1988.0,
12761,,A,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",1,,,50592,9986.0,Intermediate,1,CHEMBL628560,BAO_0000218,1988.0,
12762,,A,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",1,,,50592,9986.0,Intermediate,1,CHEMBL874456,BAO_0000218,1088.0,
12763,,A,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",1,,,50592,9986.0,Intermediate,1,CHEMBL628561,BAO_0000218,1988.0,
12764,,A,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",1,,,50592,9986.0,Intermediate,1,CHEMBL628562,BAO_0000218,1988.0,
12765,,A,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",1,,,50592,9986.0,Intermediate,1,CHEMBL628563,BAO_0000218,1088.0,
12766,,A,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",1,,,50592,9986.0,Intermediate,1,CHEMBL628564,BAO_0000218,1088.0,
12767,,A,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",1,,,50592,9986.0,Intermediate,1,CHEMBL628565,BAO_0000218,1088.0,
12768,,A,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",1,,,50592,9986.0,Intermediate,1,CHEMBL631248,BAO_0000218,1088.0,
12769,,A,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",1,,,50592,9986.0,Intermediate,1,CHEMBL631249,BAO_0000218,1088.0,
12770,,A,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",1,,,50592,9986.0,Intermediate,1,CHEMBL627214,BAO_0000218,2113.0,
12771,,A,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",1,,,50592,9986.0,Intermediate,1,CHEMBL874591,BAO_0000218,1988.0,
12772,,A,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",1,,,50592,9986.0,Intermediate,1,CHEMBL627215,BAO_0000218,1988.0,
12773,,A,,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,1,,,50592,9986.0,Intermediate,1,CHEMBL625471,BAO_0000218,1988.0,
12774,,A,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,1,,,50592,9986.0,Intermediate,1,CHEMBL625472,BAO_0000218,,
12775,,A,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,1,,,50592,9986.0,Intermediate,1,CHEMBL625473,BAO_0000218,,
12776,,A,,In vivo,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL625474,BAO_0000218,,
12777,,A,,In vivo,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL625475,BAO_0000218,,
12778,,A,,In vivo,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625476,BAO_0000218,,
12779,,A,,In vivo,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625477,BAO_0000218,,
12780,,A,,In vivo,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625478,BAO_0000218,,
12781,,A,,In vitro,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,1,,,50597,10116.0,Intermediate,1,CHEMBL625479,BAO_0000218,,
12782,,A,,In vitro,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,1,,,50597,10116.0,Intermediate,1,CHEMBL625480,BAO_0000218,,
12783,,A,,In vivo,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,1,,,50597,10116.0,Intermediate,1,CHEMBL625481,BAO_0000218,1969.0,
12784,,A,,In vivo,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625482,BAO_0000218,,
12785,,A,,In vivo,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625483,BAO_0000218,,
12786,,A,,In vivo,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625484,BAO_0000218,,
12787,,A,,In vivo,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625485,BAO_0000218,,
12788,,A,,In vivo,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625486,BAO_0000218,1969.0,
12789,,A,,In vivo,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625487,BAO_0000218,1969.0,
12790,,A,,In vivo,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625488,BAO_0000218,1969.0,
12791,,A,,In vivo,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625489,BAO_0000218,1969.0,
12792,,A,,In vivo,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625490,BAO_0000218,1969.0,
12793,,A,,In vivo,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625491,BAO_0000218,1969.0,
12794,,A,,In vivo,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625492,BAO_0000218,1969.0,
12795,,A,,In vivo,plasma clearance in human,1,,,50587,9606.0,Intermediate,1,CHEMBL625493,BAO_0000218,1969.0,
12796,,A,,In vivo,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625494,BAO_0000218,,
12797,,A,,In vivo,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625495,BAO_0000218,,
12798,,A,,In vivo,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625496,BAO_0000218,,
12799,,P,,,1-Octanol/water partition coefficient measured at 7.4,0,,,22229,,Autocuration,1,CHEMBL625497,BAO_0000100,,
12800,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625498,BAO_0000100,,
12801,,A,,,Partition coefficient (logP),0,,,22224,,Autocuration,1,CHEMBL625499,BAO_0000019,,
12802,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625500,BAO_0000100,,
12803,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625501,BAO_0000100,,
12804,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625502,BAO_0000100,,
12805,,P,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),0,,,22229,,Autocuration,1,CHEMBL625503,BAO_0000100,,
12806,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625504,BAO_0000100,,
12807,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625505,BAO_0000100,,
12808,,P,,,Calculated partition coefficient of the compound,0,,,22229,,Autocuration,1,CHEMBL625506,BAO_0000100,,
12809,,A,,,Partition coefficient (logP),0,,,22224,,Autocuration,1,CHEMBL625507,BAO_0000019,,
12810,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625508,BAO_0000100,,
12811,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625509,BAO_0000100,,
12812,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625510,BAO_0000100,,
12813,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL883125,BAO_0000100,,
12814,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625511,BAO_0000100,,
12815,,A,,,Partition coefficient of the compound,0,,,22224,,Autocuration,1,CHEMBL874650,BAO_0000019,,
12816,,A,,,Partition coefficient of the compound,0,,,22224,,Autocuration,1,CHEMBL625512,BAO_0000019,,
12817,,A,,,Partition coefficient of compound was determined,0,,,22224,,Autocuration,1,CHEMBL625513,BAO_0000019,,
12818,,A,,,Partition coefficient was determined,0,,,22224,,Autocuration,1,CHEMBL625514,BAO_0000019,,
12819,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625515,BAO_0000100,,
12820,,P,,,partition coefficient of compound was determined,0,,,22229,,Autocuration,1,CHEMBL625516,BAO_0000100,,
12821,,A,,In vivo,The total body administered intravenously in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL625517,BAO_0000218,,
12822,,A,,In vivo,The total body administered intravenously in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625518,BAO_0000218,,
12823,,A,,,Time taken for the administration to female NIH mice weighing 25-30 g.,1,,,50594,10090.0,Intermediate,1,CHEMBL625519,BAO_0000218,,
12824,,A,,,Time taken for the administration,0,,,22224,,Autocuration,1,CHEMBL625520,BAO_0000019,,
12825,,A,,In vivo,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,1,,,50588,9615.0,Intermediate,1,CHEMBL874651,BAO_0000218,,
12826,,A,,In vivo,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,0,,,22224,314293.0,Autocuration,1,CHEMBL625521,BAO_0000218,,
12827,,A,,In vivo,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,1,,,50592,9986.0,Intermediate,1,CHEMBL623171,BAO_0000218,,
12828,,A,,In vivo,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,1,,,50597,10116.0,Intermediate,1,CHEMBL623853,BAO_0000218,,
12829,,A,,,Plasma clearance for the compound was determined.,0,,,22224,,Autocuration,1,CHEMBL623854,BAO_0000019,,
12830,,P,,,CLog P value of the compound,0,,,22224,,Autocuration,1,CHEMBL874405,BAO_0000100,,
12831,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL623855,BAO_0000100,,
12832,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL623856,BAO_0000100,,
12833,,P,,,ClogP value of the compound; nd ='no data',0,,,22224,,Autocuration,1,CHEMBL623857,BAO_0000100,,
12834,,P,,,ClogP value of the compound; nd ='not determined',0,,,22224,,Autocuration,1,CHEMBL623858,BAO_0000100,,
12835,,P,,,CLog P was determined,0,,,22224,,Autocuration,1,CHEMBL623859,BAO_0000100,,
12836,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL839829,BAO_0000100,,
12837,,A,,,CLogP was calculated,0,,,22224,,Autocuration,1,CHEMBL623860,BAO_0000019,,
12838,,A,,,CLogP value was determined,0,,,22224,,Autocuration,1,CHEMBL623861,BAO_0000019,,
12839,,A,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,0,,,22224,,Autocuration,1,CHEMBL623862,BAO_0000019,,
12840,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL874406,BAO_0000100,,
12841,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL623863,BAO_0000100,,
12842,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624021,BAO_0000100,,
12843,,A,,,Distribution in female dog adrenal medulla 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624022,BAO_0000218,1236.0,
12844,,A,,,Distribution in female dog adrenal medulla 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624023,BAO_0000218,1236.0,
12845,,A,,,Distribution in female dog bile 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624024,BAO_0000218,,
12846,,A,,,Distribution in female dog bile 72 hr after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624025,BAO_0000218,,
12847,,A,,,Distribution in female dog blood 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624026,BAO_0000218,,
12848,,A,,,Distribution in female dog blood 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624027,BAO_0000218,,
12849,,A,,,Distribution in female dog heart 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624028,BAO_0000218,,
12850,,A,,,Distribution in female dog heart 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624029,BAO_0000218,,
12851,,A,,,Distribution in female dog kidney 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624030,BAO_0000218,,
12852,,A,,,Distribution in female dog kidney 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624031,BAO_0000218,,
12853,,A,,,Distribution in female dog large intestine 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624032,BAO_0000218,160.0,
12854,,A,,,Distribution in female dog large intestine 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL874407,BAO_0000218,160.0,
12855,,A,,,Distribution in female dog liver 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624033,BAO_0000218,,
12856,,A,,,Distribution in female dog liver 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624034,BAO_0000218,,
12857,,A,,,Distribution in female dog lung 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624035,BAO_0000218,,
12858,,A,,,Distribution in female dog lung 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624036,BAO_0000218,,
12859,,A,,,Distribution in female dog muscle 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624037,BAO_0000218,2385.0,
12860,,A,,,Distribution in female dog muscle 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624038,BAO_0000218,2385.0,
12861,,A,,,Distribution in female dog pancreas 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624039,BAO_0000218,,
12862,,A,,,Distribution in female dog pancreas 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624040,BAO_0000218,,
12863,,A,,,Distribution in female dog small intestine 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624041,BAO_0000218,160.0,
12864,,A,,,Distribution in female dog small intestine 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624042,BAO_0000218,160.0,
12865,,A,,,Distribution in female dog spleen 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624043,BAO_0000218,2106.0,
12866,,A,,,Distribution in female dog spleen 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624044,BAO_0000218,2106.0,
12867,,A,,,Distribution in female dog stomach 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624045,BAO_0000218,945.0,
12868,,A,,,Distribution in female dog stomach 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624046,BAO_0000218,945.0,
12869,,A,,,Distribution in female dog thyroid 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624047,BAO_0000218,2046.0,
12870,,A,,,Distribution in female dog thyroid 72 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624048,BAO_0000218,2046.0,
12871,,A,,,Distribution in female dog urine 24 hours after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL874408,BAO_0000218,1088.0,
12872,,A,,,Distribution in female dog urine 72 hr after administration.,1,,,50588,9615.0,Intermediate,1,CHEMBL624049,BAO_0000218,1088.0,
12873,,A,,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,0,,,22224,,Autocuration,1,CHEMBL624050,BAO_0000218,1969.0,
12874,,A,,,Plasma concentration at 7 hr after intravenous dosing,0,,,22224,,Autocuration,1,CHEMBL624051,BAO_0000019,,
12875,,A,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623278,BAO_0000218,,
12876,,A,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623279,BAO_0000218,,
12877,,A,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623280,BAO_0000218,,
12878,,A,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623963,BAO_0000218,,
12879,,A,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623964,BAO_0000218,,
12880,,A,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623965,BAO_0000218,,
12881,,A,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623966,BAO_0000218,,
12882,,A,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,1,,,50597,10116.0,Intermediate,1,CHEMBL874415,BAO_0000218,,
12883,,A,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623967,BAO_0000218,,
12884,,A,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623968,BAO_0000218,,
12885,,A,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL623969,BAO_0000218,,
12886,,A,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL628409,BAO_0000218,,
12887,,A,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL628410,BAO_0000218,,
12888,,A,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL628411,BAO_0000218,,
12889,,A,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,1,,,50597,10116.0,Intermediate,1,CHEMBL628412,BAO_0000218,,
12890,,A,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,0,,,22224,,Autocuration,1,CHEMBL628413,BAO_0000019,,
12891,,A,,,The concentration in plasmat; Not determined,0,,,22224,,Autocuration,1,CHEMBL628414,BAO_0000019,1969.0,
12892,,A,,,Tissue level at 10 mg/kg/po in wistar rats in blood,1,,,50597,10116.0,Intermediate,1,CHEMBL628415,BAO_0000218,,
12893,,A,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,1,,,50597,10116.0,Intermediate,1,CHEMBL628416,BAO_0000218,,
12894,,A,,,Tissue level at 10 mg/kg/po in wistar rats in heart,1,,,50597,10116.0,Intermediate,1,CHEMBL628417,BAO_0000218,,
12895,,A,,,Tissue level at 10 mg/kg/po in wistar rats in liver,1,,,50597,10116.0,Intermediate,1,CHEMBL874908,BAO_0000218,2107.0,
12896,,A,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,1,,,50597,10116.0,Intermediate,1,CHEMBL628418,BAO_0000218,,
12897,,A,,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,1,,,50597,10116.0,Intermediate,1,CHEMBL628419,BAO_0000218,2385.0,
12898,,A,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,1,,,50597,10116.0,Intermediate,1,CHEMBL628420,BAO_0000218,,
12899,,A,,,Water solubility at 37 degree C.,0,,,22224,,Autocuration,1,CHEMBL628421,BAO_0000019,,
12900,,P,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,0,,,22229,,Autocuration,1,CHEMBL626726,BAO_0000100,,
12901,,P,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,0,,,22229,,Autocuration,1,CHEMBL626727,BAO_0000100,,
12902,,A,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626728,BAO_0000218,178.0,
12903,,A,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626729,BAO_0000218,178.0,
12904,,A,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626730,BAO_0000218,178.0,
12905,,A,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626731,BAO_0000218,178.0,
12906,,A,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626732,BAO_0000218,178.0,
12907,,A,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626733,BAO_0000218,948.0,
12908,,A,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626734,BAO_0000218,948.0,
12909,,A,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626735,BAO_0000218,948.0,
12910,,A,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL874909,BAO_0000218,948.0,
12911,,A,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626736,BAO_0000218,948.0,
12912,,A,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL626737,BAO_0000218,2113.0,
12913,,A,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630999,BAO_0000218,2113.0,
12914,,A,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631000,BAO_0000218,2113.0,
12915,,A,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631001,BAO_0000218,2113.0,
12916,,A,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631002,BAO_0000218,2113.0,
12917,,A,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631003,BAO_0000218,2107.0,
12918,,A,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631004,BAO_0000218,2107.0,
12919,,A,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631005,BAO_0000218,2107.0,
12920,,A,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631006,BAO_0000218,2107.0,
12921,,A,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631007,BAO_0000218,2107.0,
12922,,A,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631008,BAO_0000218,2048.0,
12923,,A,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631009,BAO_0000218,2048.0,
12924,,A,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631010,BAO_0000218,2048.0,
12925,,A,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631011,BAO_0000218,2048.0,
12926,,A,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL631012,BAO_0000218,2048.0,
12927,,A,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630271,BAO_0000218,2046.0,
12928,,A,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630272,BAO_0000218,2046.0,
12929,,A,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630273,BAO_0000218,2046.0,
12930,,A,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630274,BAO_0000218,2046.0,
12931,,A,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630275,BAO_0000218,2046.0,
12932,,A,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL875782,BAO_0000218,,
12933,,A,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630276,BAO_0000218,,
12934,,A,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630277,BAO_0000218,,
12935,,A,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630278,BAO_0000218,,
12936,,A,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,1,,,50597,10116.0,Intermediate,1,CHEMBL630279,BAO_0000218,,
12937,,A,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL630280,BAO_0000019,,
12938,,A,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL630281,BAO_0000019,,
12939,,A,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,1,,,50592,9986.0,Intermediate,1,CHEMBL630282,BAO_0000218,,
12940,,A,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,1,,,50592,9986.0,Intermediate,1,CHEMBL630283,BAO_0000218,,
12941,,A,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),0,,,22224,,Autocuration,1,CHEMBL630284,BAO_0000019,,
12942,,A,,,Alkylating activity was determined,0,,,22224,,Autocuration,1,CHEMBL630285,BAO_0000019,,
12943,,A,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),0,,,22224,,Autocuration,1,CHEMBL630286,BAO_0000251,,
12944,,A,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",1,,,50592,9986.0,Intermediate,1,CHEMBL630069,BAO_0000218,,
12945,,A,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",1,,,50592,9986.0,Intermediate,1,CHEMBL630070,BAO_0000218,,
12946,,A,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",1,,,50592,9986.0,Intermediate,1,CHEMBL630071,BAO_0000218,,
12947,,A,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",1,,,50592,9986.0,Intermediate,1,CHEMBL630072,BAO_0000218,,
12948,,A,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",1,,,50592,9986.0,Intermediate,1,CHEMBL875110,BAO_0000218,,
12949,,A,,,Compound was tested for antidiuretic activity in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630073,BAO_0000218,,
12950,,A,,,Compound was tested for inactivation kinetic values,0,,,22224,,Autocuration,1,CHEMBL630074,BAO_0000019,,
12951,,A,,In vivo,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,0,,,22224,,Autocuration,1,CHEMBL630075,BAO_0000218,,
12952,,A,,,Dissociation rate calculated from the first-order equation using the t1/2 value,0,,,22224,,Autocuration,1,CHEMBL630076,BAO_0000019,,
12953,,P,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,0,,,22229,,Autocuration,1,CHEMBL630077,BAO_0000100,,
12954,,P,,,Aqueous solubility was measured,0,,,22229,,Autocuration,1,CHEMBL630078,BAO_0000100,,
12955,,P,,,Aqueous solubility was measured at a pH 4,0,,,22229,,Autocuration,1,CHEMBL630079,BAO_0000100,,
12956,,P,,,Aqueous solubility (pH 7),0,,,22229,,Autocuration,1,CHEMBL630080,BAO_0000100,,
12957,,P,,,Aqueous solubility was measured at a pH 9,0,,,22229,,Autocuration,1,CHEMBL630081,BAO_0000100,,
12958,,A,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",0,,,22224,,Autocuration,1,CHEMBL630082,BAO_0000019,,
12959,,A,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",0,,,22224,,Autocuration,1,CHEMBL630083,BAO_0000019,,
12960,,A,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",0,,,22224,,Autocuration,1,CHEMBL630084,BAO_0000019,,
12961,,P,,,Aqueous solubility of the compound,0,,,22229,,Autocuration,1,CHEMBL629198,BAO_0000100,,
12962,,P,,,Aqueous solubility at 37 degree Celsius at pH 7.38,0,,,22229,,Autocuration,1,CHEMBL629199,BAO_0000100,,
12963,,P,,,Aqueous solubility in pH 7.4 phosphate buffer,0,,,22229,,Autocuration,1,CHEMBL629200,BAO_0000100,,
12964,,A,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,1,,,50588,9615.0,Intermediate,1,CHEMBL629201,BAO_0000218,,
12965,,A,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,1,,,50588,9615.0,Intermediate,1,CHEMBL629202,BAO_0000218,,
12966,,A,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,1,,,50587,9606.0,Intermediate,1,CHEMBL875111,BAO_0000218,,
12967,,A,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,1,,,50587,9606.0,Intermediate,1,CHEMBL629203,BAO_0000218,,
12968,,A,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,1,,,50587,9606.0,Intermediate,1,CHEMBL629204,BAO_0000218,,
12969,,A,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,1,,,50587,9606.0,Intermediate,1,CHEMBL629205,BAO_0000218,,
12970,,A,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,1,,,50587,9606.0,Intermediate,1,CHEMBL629206,BAO_0000218,,
12971,,A,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,0,,,22224,,Autocuration,1,CHEMBL631185,BAO_0000019,,
12972,,A,,,Compound was evaluated for the average bile flow rat in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL631186,BAO_0000218,,
12973,,A,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",1,,,50592,9986.0,Intermediate,1,CHEMBL631187,BAO_0000218,,
12974,,A,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",1,,,50592,9986.0,Intermediate,1,CHEMBL631188,BAO_0000218,,
12975,,A,,,Average half life period was determined,0,,,22224,,Autocuration,1,CHEMBL876419,BAO_0000019,,
12976,,A,,,Average half life period was determined,0,,,22224,,Autocuration,1,CHEMBL631189,BAO_0000019,,
12977,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL631190,BAO_0000218,,
12978,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL631191,BAO_0000218,,
12979,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL631192,BAO_0000218,,
12980,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL632400,BAO_0000218,,
12981,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL630564,BAO_0000218,,
12982,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL630565,BAO_0000218,,
12983,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL630566,BAO_0000218,,
12984,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL631229,BAO_0000218,,
12985,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL631230,BAO_0000218,,
12986,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL876428,BAO_0000100,,
12987,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL631231,BAO_0000100,,
12988,,P,,,Calculated partition coefficient (clogP) (MacLogP),0,,,22229,,Autocuration,1,CHEMBL631232,BAO_0000100,,
12989,,A,,,Hydrophilicity was determined,0,,,22224,,Autocuration,1,CHEMBL631233,BAO_0000019,,
12990,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL631234,BAO_0000100,,
12991,,A,,,Increased absorption was determined,0,,,22224,,Autocuration,1,CHEMBL883126,BAO_0000019,,
12992,,P,,,Lipophilicity value was evaluated,0,,,22224,,Autocuration,1,CHEMBL631235,BAO_0000100,,
12993,,P,,,Log P value of the compound.,0,,,22224,,Autocuration,1,CHEMBL631236,BAO_0000100,,
12994,,A,,,Partition coefficient of compound was determined,0,,,22224,,Autocuration,1,CHEMBL631237,BAO_0000019,,
12995,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL631238,BAO_0000100,,
12996,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL876429,BAO_0000100,,
12997,,A,,,Partition coefficient was measured by medchem software; Not calculated,0,,,22224,,Autocuration,1,CHEMBL631414,BAO_0000019,,
12998,,P,,,Partition coefficient was measured by octanol-water using standard shake-flask method,0,,,22224,,Autocuration,1,CHEMBL631415,BAO_0000100,,
12999,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL631416,BAO_0000100,,
13000,,A,,,Partition coefficient (logP),0,,,22224,,Autocuration,1,CHEMBL631417,BAO_0000019,,
13001,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL631418,BAO_0000100,,
13002,,P,,,The Octanol/Water partition coefficient CLogP,0,,,22229,,Autocuration,1,CHEMBL631419,BAO_0000100,,
13003,,A,,,The pharmacokinetic parameter C Log p was reported,0,,,22224,,Autocuration,1,CHEMBL631420,BAO_0000019,,
13004,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL631421,BAO_0000100,,
13005,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL631422,BAO_0000100,,
13006,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL631423,BAO_0000100,,
13007,,A,,In vivo,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL876430,BAO_0000218,1969.0,
13008,,A,,In vivo,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631424,BAO_0000218,1969.0,
13009,,A,,In vivo,Compound was administered intravenously in dog to evaluate plasma clearance values,1,,,50588,9615.0,Intermediate,1,CHEMBL631425,BAO_0000218,1969.0,
13010,,A,,In vivo,Compound was administered intravenously in monkey to evaluate plasma clearance values,0,,,22224,314293.0,Autocuration,1,CHEMBL631426,BAO_0000218,1969.0,
13011,,A,,In vivo,Compound was administered intravenously in mouse to evaluate plasma clearance values,1,,,50594,10090.0,Intermediate,1,CHEMBL631427,BAO_0000218,1969.0,
13012,,A,,In vivo,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,1,,,50588,9615.0,Intermediate,1,CHEMBL631428,BAO_0000218,1969.0,
13013,,A,,In vitro,Intrinsic clearance in Rhesus liver microsome,1,,,50797,9544.0,Intermediate,1,CHEMBL631429,BAO_0000218,2107.0,
13014,,A,,In vitro,Intrinsic clearance in dog liver microsome,1,,,50588,9615.0,Intermediate,1,CHEMBL631430,BAO_0000218,2107.0,
13015,,A,,In vitro,Intrinsic clearance in rat liver microsome,1,,,50597,10116.0,Intermediate,1,CHEMBL631431,BAO_0000218,2107.0,
13016,,A,,In vivo,Low plasma clearance was calculated in rhesus monkey,1,,,50797,9544.0,Intermediate,1,CHEMBL631432,BAO_0000218,1969.0,
13017,,A,,In vivo,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,,50588,9615.0,Intermediate,1,CHEMBL631433,BAO_0000218,,
13018,,A,,In vivo,Plasma clearance after intravenous dose of 0.3 mg/kg,0,,,22224,,Autocuration,1,CHEMBL631434,BAO_0000218,,
13019,,A,,In vivo,Plasma clearance after intravenous dose of 1 mg/kg,0,,,22224,,Autocuration,1,CHEMBL631435,BAO_0000218,,
13020,,A,,In vivo,Plasma clearance after intravenous dose of 3 mg/kg,0,,,22224,,Autocuration,1,CHEMBL631436,BAO_0000218,,
13021,,A,,In vivo,Plasma clearance after intravenous dose of 3.87 mg/kg,0,,,22224,,Autocuration,1,CHEMBL631437,BAO_0000218,,
13022,,A,,In vivo,Plasma clearance after peroral administration at 10 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631438,BAO_0000218,,
13023,,A,,In vivo,Plasma clearance after peroral administration at 10 mpk in Rhesus,1,,,50797,9544.0,Intermediate,1,CHEMBL876431,BAO_0000218,,
13024,,A,,In vivo,Plasma clearance after peroral administration at 10 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL631439,BAO_0000218,,
13025,,A,,In vivo,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631440,BAO_0000218,,
13026,,A,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),0,,,22224,,Autocuration,1,CHEMBL631441,BAO_0000019,,
13027,,A,,,Critical Micellar concentration was determined,0,,,22224,,Autocuration,1,CHEMBL631442,BAO_0000019,,
13028,,A,,,Critical Micellar concentration of the compound. was determined,0,,,22224,,Autocuration,1,CHEMBL626525,BAO_0000019,,
13029,,A,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,0,,,22224,,Autocuration,1,CHEMBL627168,BAO_0000019,,
13030,,A,,,Critical micellar concentration was measured in water by the dye solubilization method,0,,,22224,,Autocuration,1,CHEMBL875618,BAO_0000019,,
13031,,B,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,0,,,22224,,Autocuration,1,CHEMBL626612,BAO_0000019,,
13032,,A,,,CMR value (relative to BAY K 8644),0,,,22224,,Autocuration,1,CHEMBL626613,BAO_0000019,,
13033,,A,,,Carbamoylating activity was determined,0,,,22224,,Autocuration,1,CHEMBL626614,BAO_0000019,,
13034,,A,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL626615,BAO_0000218,,
13035,,A,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,0,,,22224,,Autocuration,1,CHEMBL626616,BAO_0000019,,
13036,,A,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,0,,,22224,,Autocuration,1,CHEMBL626617,BAO_0000019,,
13037,,A,,In vivo,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,1,,,50588,9615.0,Intermediate,1,CHEMBL626618,BAO_0000218,1969.0,
13038,,A,,In vivo,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,1,,,50597,10116.0,Intermediate,1,CHEMBL626619,BAO_0000218,1969.0,
13039,,A,,In vivo,"Clearance rate at 0.46 mg/kg, iv, in dogs",1,,,50588,9615.0,Intermediate,1,CHEMBL626620,BAO_0000218,,
13040,,A,,In vivo,"Clearance rate at 5.5 mg/kg, iv, in rat",1,,,50597,10116.0,Intermediate,1,CHEMBL626621,BAO_0000218,,
13041,,A,,In vivo,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,1,,,100710,9541.0,Intermediate,1,CHEMBL626622,BAO_0000218,,
13042,,A,,In vivo,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,1,,,100710,9541.0,Intermediate,1,CHEMBL626623,BAO_0000218,,
13043,,A,,In vivo,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,1,,,50588,9615.0,Intermediate,1,CHEMBL626624,BAO_0000218,,
13044,,A,,In vivo,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL626625,BAO_0000218,,
13045,,A,,Ex vivo,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,,,50597,10116.0,Intermediate,1,CHEMBL626626,BAO_0000218,2107.0,
13046,,A,,In vivo,Tested for the total clearance of the compound,0,,,22224,,Autocuration,1,CHEMBL626627,BAO_0000218,,
13047,,A,,In vivo,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,1,,,50588,9615.0,Intermediate,1,CHEMBL626628,BAO_0000218,,
13048,,A,,In vivo,Total body clearance was determined,0,,,22224,,Autocuration,1,CHEMBL626629,BAO_0000218,,
13049,,A,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626630,BAO_0000218,,
13050,,A,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626631,BAO_0000218,,
13051,,P,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,0,,,22229,,Autocuration,1,CHEMBL626632,BAO_0000100,,
13052,,P,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,0,,,22229,,Autocuration,1,CHEMBL626633,BAO_0000100,,
13053,,P,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,0,,,22229,,Autocuration,1,CHEMBL626634,BAO_0000100,,
13054,,P,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,0,,,22229,,Autocuration,1,CHEMBL626635,BAO_0000100,,
13055,,P,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,0,,,22229,,Autocuration,1,CHEMBL626636,BAO_0000100,,
13056,,P,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,0,,,22229,,Autocuration,1,CHEMBL626637,BAO_0000100,,
13057,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),1,,,50339,4754.0,Intermediate,1,CHEMBL626638,BAO_0000218,,
13058,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,1,,,50339,4754.0,Intermediate,1,CHEMBL626639,BAO_0000218,,
13059,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,1,,,50339,4754.0,Intermediate,1,CHEMBL626640,BAO_0000218,,
13060,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,1,,,50339,4754.0,Intermediate,1,CHEMBL626641,BAO_0000218,,
13061,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,1,,,50339,4754.0,Intermediate,1,CHEMBL627272,BAO_0000218,,
13062,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,1,,,50339,4754.0,Intermediate,1,CHEMBL627273,BAO_0000218,,
13063,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),1,,,50339,4754.0,Intermediate,1,CHEMBL627441,BAO_0000218,,
13064,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),1,,,50339,4754.0,Intermediate,1,CHEMBL628355,BAO_0000218,,
13065,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),1,,,50339,4754.0,Intermediate,1,CHEMBL628356,BAO_0000218,,
13066,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),1,,,50339,4754.0,Intermediate,1,CHEMBL628357,BAO_0000218,,
13067,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),1,,,50339,4754.0,Intermediate,1,CHEMBL628358,BAO_0000218,,
13068,,A,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),1,,,50339,4754.0,Intermediate,1,CHEMBL622307,BAO_0000218,,
13069,,A,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,0,,,22224,,Autocuration,1,CHEMBL622527,BAO_0000019,,
13070,,A,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,0,,,22224,,Autocuration,1,CHEMBL622528,BAO_0000019,,
13071,,A,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,0,,,22224,,Autocuration,1,CHEMBL622529,BAO_0000019,,
13072,,A,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,0,,,22224,,Autocuration,1,CHEMBL622992,BAO_0000019,,
13073,,A,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,0,,,22224,,Autocuration,1,CHEMBL622993,BAO_0000019,,
13074,,A,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,0,,,22224,,Autocuration,1,CHEMBL622994,BAO_0000019,,
13075,,A,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",1,,,50597,10116.0,Intermediate,1,CHEMBL622995,BAO_0000218,,
13076,,A,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",1,,,50597,10116.0,Intermediate,1,CHEMBL622996,BAO_0000218,,
13077,,A,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",1,,,50597,10116.0,Intermediate,1,CHEMBL622997,BAO_0000218,,
13078,,A,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",1,,,50597,10116.0,Intermediate,1,CHEMBL622998,BAO_0000218,,
13079,,A,,,Cp max following ip administration at 1 mg/kg,0,,,22224,,Autocuration,1,CHEMBL622999,BAO_0000218,,
13080,,A,,In vivo,Maximum concentration in plasma was reported at 0.5 hour,0,,,22224,,Autocuration,1,CHEMBL623000,BAO_0000218,1969.0,
13081,,A,,In vivo,Maximum concentration in plasma was reported at 2 hour,0,,,22224,,Autocuration,1,CHEMBL623001,BAO_0000218,1969.0,
13082,,A,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,1,,,50594,10090.0,Intermediate,1,CHEMBL623002,BAO_0000218,,
13083,,P,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),0,,,22229,,Autocuration,1,CHEMBL623003,BAO_0000100,,
13084,,A,,,Steady state concentration was evaluated,0,,,22224,,Autocuration,1,CHEMBL623004,BAO_0000019,,
13085,,A,,,Partition coefficient (logP),0,,,22224,,Autocuration,1,CHEMBL623005,BAO_0000019,,
13086,,A,,,Partition coefficient (logD7.4),0,,,22224,,Autocuration,1,CHEMBL623006,BAO_0000019,,
13087,,A,,In vivo,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623007,BAO_0000218,2107.0,
13088,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623008,BAO_0000218,10000001.0,
13089,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL876654,BAO_0000218,2037.0,
13090,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623009,BAO_0000218,,
13091,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623010,BAO_0000218,,
13092,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623011,BAO_0000218,948.0,
13093,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623012,BAO_0000218,160.0,
13094,,A,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL623013,BAO_0000019,,
13095,,A,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL623014,BAO_0000019,,
13096,,A,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL623015,BAO_0000019,1088.0,
13097,,A,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL623016,BAO_0000019,1088.0,
13098,,A,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL624858,BAO_0000019,1088.0,
13099,,A,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,1,,,50597,10116.0,Intermediate,1,CHEMBL624859,BAO_0000218,,
13100,,A,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624860,BAO_0000218,,
13101,,A,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,,,50597,10116.0,Intermediate,1,CHEMBL624861,BAO_0000218,,
13102,,A,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,1,,,50597,10116.0,Intermediate,1,CHEMBL624862,BAO_0000218,,
13103,,A,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,1,,,50597,10116.0,Intermediate,1,CHEMBL624863,BAO_0000218,,
13104,,A,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,,,50597,10116.0,Intermediate,1,CHEMBL876655,BAO_0000218,,
13105,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,1,,,50588,9615.0,Intermediate,1,CHEMBL624864,BAO_0000218,,
13106,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,1,,,50588,9615.0,Intermediate,1,CHEMBL624865,BAO_0000218,,
13107,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,,,50588,9615.0,Intermediate,1,CHEMBL624866,BAO_0000218,,
13108,,F,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,1,,,50588,9615.0,Expert,1,CHEMBL624867,BAO_0000218,,
13109,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,1,,,50588,9615.0,Intermediate,1,CHEMBL624868,BAO_0000218,,
13110,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,1,,,50588,9615.0,Intermediate,1,CHEMBL628450,BAO_0000218,,
13111,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,1,,,50588,9615.0,Intermediate,1,CHEMBL628451,BAO_0000218,,
13112,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,1,,,50588,9615.0,Intermediate,1,CHEMBL628452,BAO_0000218,,
13113,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,,,50588,9615.0,Intermediate,1,CHEMBL628453,BAO_0000218,,
13114,,A,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL628454,BAO_0000218,,
13115,,A,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,1,,,50588,9615.0,Intermediate,1,CHEMBL628455,BAO_0000218,,
13116,,A,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,1,,,50588,9615.0,Intermediate,1,CHEMBL628456,BAO_0000218,,
13117,,A,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,,,50588,9615.0,Intermediate,1,CHEMBL628457,BAO_0000218,,
13118,,A,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,1,,,50588,9615.0,Intermediate,1,CHEMBL877505,BAO_0000218,,
13119,,A,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,1,,,50588,9615.0,Intermediate,1,CHEMBL628458,BAO_0000218,,
13120,,A,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,1,,,50588,9615.0,Intermediate,1,CHEMBL628459,BAO_0000218,,
13121,,A,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,1,,,50588,9615.0,Intermediate,1,CHEMBL628460,BAO_0000218,,
13122,,A,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,1,,,50588,9615.0,Intermediate,1,CHEMBL628461,BAO_0000218,,
13123,,B,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",0,,,22224,,Autocuration,1,CHEMBL628462,BAO_0000218,,
13124,,A,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,,,50588,9615.0,Intermediate,1,CHEMBL628463,BAO_0000218,,
13125,,F,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",1,,,50597,10116.0,Expert,1,CHEMBL625666,BAO_0000218,,
13126,,B,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,0,,,22224,,Autocuration,1,CHEMBL625667,BAO_0000218,,
13127,,A,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,,,50597,10116.0,Expert,1,CHEMBL625668,BAO_0000218,,
13128,,A,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625669,BAO_0000218,,
13129,,A,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,0,,,22224,,Autocuration,1,CHEMBL625670,BAO_0000019,,
13130,,A,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625671,BAO_0000218,,
13131,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,1,,,50602,10298.0,Intermediate,1,CHEMBL625672,BAO_0000218,,
13132,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,1,,,50602,10298.0,Intermediate,1,CHEMBL625673,BAO_0000218,,
13133,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,1,,,50602,10298.0,Intermediate,1,CHEMBL625674,BAO_0000218,,
13134,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,1,,,50602,10298.0,Intermediate,1,CHEMBL625675,BAO_0000218,,
13135,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,1,,,50602,10298.0,Intermediate,1,CHEMBL627637,BAO_0000218,,
13136,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,1,,,50602,10298.0,Intermediate,1,CHEMBL627638,BAO_0000218,,
13137,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,1,,,50602,10298.0,Intermediate,1,CHEMBL627639,BAO_0000218,,
13138,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,1,,,50602,10298.0,Intermediate,1,CHEMBL627640,BAO_0000218,,
13139,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,1,,,50602,10298.0,Intermediate,1,CHEMBL627641,BAO_0000218,,
13140,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,1,,,50602,10298.0,Intermediate,1,CHEMBL627642,BAO_0000218,,
13141,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,1,,,50602,10298.0,Intermediate,1,CHEMBL877506,BAO_0000218,,
13142,,A,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,1,,,50594,10090.0,Intermediate,1,CHEMBL627275,BAO_0000218,,
13143,,A,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",1,,,50506,9669.0,Intermediate,1,CHEMBL627643,BAO_0000218,,
13144,,A,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",1,,,50506,9669.0,Intermediate,1,CHEMBL631246,BAO_0000218,,
13145,,A,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",1,,,50506,9669.0,Intermediate,1,CHEMBL631247,BAO_0000218,,
13146,,A,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,1,,,50506,9669.0,Intermediate,1,CHEMBL629532,BAO_0000218,,
13147,,A,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,1,,,50506,9669.0,Intermediate,1,CHEMBL629533,BAO_0000218,,
13148,,A,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,1,,,50506,9669.0,Intermediate,1,CHEMBL629534,BAO_0000218,,
13149,,A,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,1,,,50506,9669.0,Intermediate,1,CHEMBL629535,BAO_0000218,,
13150,,A,,,Pharmacokinetic parameter :drug bound to plasma was reported,0,,,22224,,Autocuration,1,CHEMBL625932,BAO_0000019,,
13151,,A,,,compound was evaluated for drug bound in plasma,0,,,22224,,Autocuration,1,CHEMBL625933,BAO_0000019,,
13152,,A,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,1,,,50597,10116.0,Intermediate,1,CHEMBL625934,BAO_0000218,,
13153,,A,,,Bioavailability,0,,,22224,9347.0,Autocuration,1,CHEMBL625935,BAO_0000218,,
13154,,A,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,1,,,50597,10116.0,Intermediate,1,CHEMBL625936,BAO_0000218,,
13155,,A,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL625937,BAO_0000218,,
13156,,A,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1,,,50588,9615.0,Intermediate,1,CHEMBL625938,BAO_0000218,,
13157,,A,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,1,,,50597,10116.0,Intermediate,1,CHEMBL625939,BAO_0000218,1970.0,
13158,,A,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,1,,,50597,10116.0,Intermediate,1,CHEMBL625940,BAO_0000218,1970.0,
13159,,A,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,1,,,50597,10116.0,Intermediate,1,CHEMBL874464,BAO_0000218,1970.0,
13160,,A,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,1,,,50597,10116.0,Intermediate,1,CHEMBL625941,BAO_0000218,1970.0,
13161,,A,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,1,,,50597,10116.0,Intermediate,1,CHEMBL625942,BAO_0000218,1970.0,
13162,,A,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,1,,,50597,10116.0,Intermediate,1,CHEMBL625943,BAO_0000218,1970.0,
13163,,A,,,In vitro protein binding in human serum at 5 ug/ml,1,,,50587,9606.0,Intermediate,1,CHEMBL625944,BAO_0000218,1977.0,
13164,,A,,,Serum protein binding ability was measured,0,,,22224,,Autocuration,1,CHEMBL625945,BAO_0000019,,
13165,,A,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),0,,,22224,,Autocuration,1,CHEMBL625946,BAO_0000019,,
13166,,A,,In vivo,Oral bioavailability in dog,0,,,22224,9615.0,Autocuration,1,CHEMBL625947,BAO_0000218,,
13167,,A,,In vivo,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,1,,,50597,10116.0,Intermediate,1,CHEMBL625948,BAO_0000218,,
13168,,A,,In vivo,Absolute oral bioavailability at an iv dose of 14 mg/kg,0,,,22224,,Autocuration,1,CHEMBL625949,BAO_0000218,,
13169,,A,,In vivo,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,0,,,22224,,Autocuration,1,CHEMBL625950,BAO_0000218,,
13170,,A,,In vivo,Oral bioavailability (dose 15 mg/kg i.v.),0,,,22224,9347.0,Autocuration,1,CHEMBL625951,BAO_0000218,,
13171,,A,,In vivo,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,0,,,22224,,Autocuration,1,CHEMBL625952,BAO_0000218,,
13172,,A,,In vivo,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,0,,,22224,,Autocuration,1,CHEMBL625953,BAO_0000218,,
13173,,A,,In vivo,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,0,,,22224,,Autocuration,1,CHEMBL625954,BAO_0000218,,
13174,,A,,In vivo,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,0,,,22224,,Autocuration,1,CHEMBL882959,BAO_0000218,,
13175,,A,,In vivo,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,1,,,50588,9615.0,Intermediate,1,CHEMBL625955,BAO_0000218,,
13176,,A,,In vivo,Bioavailability in ferret,0,,,22224,9669.0,Autocuration,1,CHEMBL625956,BAO_0000218,,
13177,,A,,In vivo,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,1,,,100710,9541.0,Intermediate,1,CHEMBL625957,BAO_0000218,,
13178,,A,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625958,BAO_0000218,,
13179,,A,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625959,BAO_0000218,,
13180,,A,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626642,BAO_0000218,,
13181,,A,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631330,BAO_0000218,,
13182,,A,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631331,BAO_0000218,,
13183,,A,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL631332,BAO_0000218,,
13184,,A,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL631333,BAO_0000218,,
13185,,A,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632018,BAO_0000218,,
13186,,A,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632019,BAO_0000218,,
13187,,A,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632020,BAO_0000218,,
13188,,A,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632021,BAO_0000218,,
13189,,A,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632022,BAO_0000218,,
13190,,A,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632023,BAO_0000218,,
13191,,A,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632024,BAO_0000218,,
13192,,A,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL874472,BAO_0000218,,
13193,,A,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632025,BAO_0000218,,
13194,,A,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632026,BAO_0000218,,
13195,,A,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632027,BAO_0000218,,
13196,,A,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL632028,BAO_0000218,,
13197,,A,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626430,BAO_0000218,,
13198,,A,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626431,BAO_0000218,,
13199,,A,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626432,BAO_0000218,,
13200,,A,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626433,BAO_0000218,,
13201,,A,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626434,BAO_0000218,,
13202,,A,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627280,BAO_0000218,,
13203,,A,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627281,BAO_0000218,,
13204,,A,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627282,BAO_0000218,,
13205,,A,,,Total body clearance was measured at given dose,0,,,22224,,Autocuration,1,CHEMBL627283,BAO_0000019,,
13206,,A,,,Total body clearance was measured at given dose.,0,,,22224,,Autocuration,1,CHEMBL627284,BAO_0000218,,
13207,,A,,,Metabolic clearance from the body in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627285,BAO_0000218,,
13208,,A,,In vivo,Renal clearance from the body,0,,,22224,,Autocuration,1,CHEMBL627286,BAO_0000218,,
13209,,A,,In vivo,Renal clearance from the body in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL875477,BAO_0000218,,
13210,,A,,In vivo,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627287,BAO_0000218,,
13211,,A,,In vivo,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL627288,BAO_0000218,,
13212,,A,,,Total clearance from the body in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL627289,BAO_0000218,,
13213,,A,,In vivo,Clearance into cortex from rat plasma or PBS,1,,,50597,10116.0,Intermediate,1,CHEMBL627290,BAO_0000218,1969.0,
13214,,A,,In vivo,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL627291,BAO_0000218,,
13215,,A,,In vivo,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL627292,BAO_0000218,,
13216,,A,,In vivo,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL627293,BAO_0000218,,
13217,,A,,In vivo,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL627294,BAO_0000218,,
13218,,A,,In vivo,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,0,,,22224,,Autocuration,1,CHEMBL875478,BAO_0000218,,
13219,,A,,In vivo,Clearance was determined,0,,,22224,,Autocuration,1,CHEMBL627295,BAO_0000218,,
13220,,A,,In vivo,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,1,,,50594,10090.0,Intermediate,1,CHEMBL627296,BAO_0000218,,
13221,,A,,In vivo,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,1,,,50592,9986.0,Intermediate,1,CHEMBL626119,BAO_0000218,,
13222,,A,,In vivo,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,1,,,50597,10116.0,Intermediate,1,CHEMBL626120,BAO_0000218,,
13223,,A,,In vivo,Clearance in rat after iv dose (100 ug/kg),1,,,50597,10116.0,Intermediate,1,CHEMBL626121,BAO_0000218,,
13224,,A,,In vivo,Clearance in guinea pig,0,,,22224,10141.0,Autocuration,1,CHEMBL626122,BAO_0000218,,
13225,,A,,In vivo,Compound was evaluated for clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626123,BAO_0000218,,
13226,,A,,In vivo,Compound was evaluated for the clearance in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL623456,BAO_0000218,,
13227,,A,,In vivo,Compound was evaluated for the clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623457,BAO_0000218,,
13228,,A,,In vivo,Compound was tested in vivo for clearance after iv administration in the rat,1,,,50597,10116.0,Intermediate,1,CHEMBL623458,BAO_0000218,,
13229,,A,,In vivo,IV clearance determined at an iv dose of 14 mg/kg,0,,,22224,,Autocuration,1,CHEMBL623459,BAO_0000218,,
13230,,A,,In vivo,IV clearance determined at an iv dose of 15.2 mg/kg,0,,,22224,,Autocuration,1,CHEMBL875484,BAO_0000218,,
13231,,A,,In vivo,IV clearance determined at an iv dose of 15 mg/kg,0,,,22224,,Autocuration,1,CHEMBL623460,BAO_0000218,,
13232,,A,,In vivo,IV clearance determined at an peroral dose of 30 mg/kg.,0,,,22224,,Autocuration,1,CHEMBL623461,BAO_0000218,,
13233,,A,,In vivo,IV clearance determined at an peroral dose of 30.2 mg/kg.,0,,,22224,,Autocuration,1,CHEMBL623462,BAO_0000218,,
13234,,A,,In vivo,IV clearance determined at an peroral dose of 30.3 mg/kg.,0,,,22224,,Autocuration,1,CHEMBL627386,BAO_0000218,,
13235,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627387,BAO_0000218,2113.0,
13236,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627388,BAO_0000218,2107.0,
13237,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627389,BAO_0000218,2048.0,
13238,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627390,BAO_0000218,2385.0,
13239,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627391,BAO_0000218,1969.0,
13240,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627392,BAO_0000218,,
13241,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627393,BAO_0000218,2106.0,
13242,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627394,BAO_0000218,3126.0,
13243,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627395,BAO_0000218,10000001.0,
13244,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL875485,BAO_0000218,2037.0,
13245,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627396,BAO_0000218,,
13246,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627397,BAO_0000218,,
13247,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627398,BAO_0000218,948.0,
13248,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627399,BAO_0000218,10000001.0,
13249,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627400,BAO_0000218,2113.0,
13250,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627401,BAO_0000218,2107.0,
13251,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627402,BAO_0000218,2048.0,
13252,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627403,BAO_0000218,2385.0,
13253,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL627404,BAO_0000218,1969.0,
13254,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623101,BAO_0000218,,
13255,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL877480,BAO_0000218,2106.0,
13256,,A,,In vivo,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623102,BAO_0000218,3126.0,
13257,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623103,BAO_0000218,10000001.0,
13258,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623104,BAO_0000218,2037.0,
13259,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623105,BAO_0000218,,
13260,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623106,BAO_0000218,,
13261,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623107,BAO_0000218,948.0,
13262,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623108,BAO_0000218,160.0,
13263,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623109,BAO_0000218,2113.0,
13264,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623110,BAO_0000218,2107.0,
13265,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL623111,BAO_0000218,2048.0,
13266,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625060,BAO_0000218,2385.0,
13267,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625061,BAO_0000218,1969.0,
13268,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625062,BAO_0000218,,
13269,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625063,BAO_0000218,2106.0,
13270,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625064,BAO_0000218,3126.0,
13271,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625065,BAO_0000218,10000001.0,
13272,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625066,BAO_0000218,2037.0,
13273,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625067,BAO_0000218,,
13274,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625068,BAO_0000218,,
13275,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622159,BAO_0000218,948.0,
13276,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622160,BAO_0000218,160.0,
13277,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622161,BAO_0000218,2113.0,
13278,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622162,BAO_0000218,2048.0,
13279,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622163,BAO_0000218,2385.0,
13280,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622313,BAO_0000218,1969.0,
13281,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622314,BAO_0000218,,
13282,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622315,BAO_0000218,2106.0,
13283,,A,,In vivo,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622316,BAO_0000218,3126.0,
13284,,A,,,Normal diffusion coefficient in water for Escherichia coli,1,,,50212,562.0,Intermediate,1,CHEMBL877486,BAO_0000218,,
13285,,A,,,Average max percent decrease in RVR (renal vascular resistance) was determined,0,,,22224,,Autocuration,1,CHEMBL622317,BAO_0000019,,
13286,,A,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,0,,,22224,,Autocuration,1,CHEMBL622318,BAO_0000019,,
13287,,A,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,0,,,22224,,Autocuration,1,CHEMBL622319,BAO_0000019,,
13288,,A,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,0,,,22224,,Autocuration,1,CHEMBL622320,BAO_0000019,,
13289,,A,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,0,,,22224,,Autocuration,1,CHEMBL622321,BAO_0000019,,
13290,,A,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,0,,,22224,,Autocuration,1,CHEMBL622322,BAO_0000019,,
13291,,A,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,0,,,22224,,Autocuration,1,CHEMBL622323,BAO_0000019,,
13292,,A,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622324,BAO_0000218,,
13293,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622325,BAO_0000218,1088.0,
13294,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622326,BAO_0000218,1088.0,
13295,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL877487,BAO_0000218,1088.0,
13296,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622327,BAO_0000218,1088.0,
13297,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622328,BAO_0000218,1088.0,
13298,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622329,BAO_0000218,1088.0,
13299,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622330,BAO_0000218,1088.0,
13300,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622331,BAO_0000218,1088.0,
13301,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622332,BAO_0000218,1088.0,
13302,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL622333,BAO_0000218,1088.0,
13303,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL627658,BAO_0000218,1088.0,
13304,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL630428,BAO_0000218,1088.0,
13305,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL630429,BAO_0000218,1088.0,
13306,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL630430,BAO_0000218,1088.0,
13307,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL630431,BAO_0000218,1088.0,
13308,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL630432,BAO_0000218,1088.0,
13309,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL630433,BAO_0000218,1088.0,
13310,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL630434,BAO_0000218,1088.0,
13311,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629372,BAO_0000218,1088.0,
13312,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629553,BAO_0000218,1088.0,
13313,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629554,BAO_0000218,1088.0,
13314,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL874447,BAO_0000218,1088.0,
13315,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629555,BAO_0000218,1088.0,
13316,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629556,BAO_0000218,1088.0,
13317,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629557,BAO_0000218,1088.0,
13318,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629558,BAO_0000218,1088.0,
13319,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629559,BAO_0000218,1088.0,
13320,,A,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629560,BAO_0000218,1088.0,
13321,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629561,BAO_0000218,1088.0,
13322,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629562,BAO_0000218,1088.0,
13323,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629563,BAO_0000218,1088.0,
13324,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629564,BAO_0000218,1088.0,
13325,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629565,BAO_0000218,1088.0,
13326,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629566,BAO_0000218,1088.0,
13327,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629567,BAO_0000218,1088.0,
13328,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629568,BAO_0000218,1088.0,
13329,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629569,BAO_0000218,1088.0,
13330,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL629570,BAO_0000218,1088.0,
13331,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL629571,BAO_0000218,1088.0,
13332,,A,,In vivo,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,0,,,22224,10116.0,Autocuration,1,CHEMBL629572,BAO_0000218,,
13333,,A,,In vivo,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,0,,,22224,10116.0,Autocuration,1,CHEMBL629573,BAO_0000218,,
13334,,A,,In vivo,Bioavailability (dose 20 mg/kg),0,,,22224,9347.0,Autocuration,1,CHEMBL629574,BAO_0000218,,
13335,,A,,In vivo,Bioavailability in dog,0,,,22224,9615.0,Autocuration,1,CHEMBL629575,BAO_0000218,,
13336,,A,,In vivo,Bioavailability in rat (Sprague-Dawley) (male),0,,,22224,10116.0,Autocuration,1,CHEMBL874448,BAO_0000218,,
13337,,A,,In vivo,Bioavailability in monkey (dose 10 mg/kg i.d.),0,,,22224,9443.0,Autocuration,1,CHEMBL629576,BAO_0000218,,
13338,,A,,In vivo,Bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL629577,BAO_0000218,,
13339,,A,,In vivo,Bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL629578,BAO_0000218,,
13340,,A,,In vivo,Bioavailability in dog (dose 3.0 mg/kg p.o.),0,,,22224,9615.0,Autocuration,1,CHEMBL629579,BAO_0000218,,
13341,,A,,In vivo,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,0,,,22224,9615.0,Autocuration,1,CHEMBL882958,BAO_0000218,,
13342,,A,,In vivo,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,1,,,50505,9598.0,Intermediate,1,CHEMBL629580,BAO_0000218,,
13343,,A,,In vivo,Bioavailability,0,,,22224,9347.0,Autocuration,1,CHEMBL629581,BAO_0000218,,
13344,,A,,In vivo,Bioavailability in squirrel monkey,0,,,22224,9520.0,Autocuration,1,CHEMBL629582,BAO_0000218,,
13345,,A,,In vivo,Bioavailability was evaluated in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL628522,BAO_0000218,,
13346,,A,,In vivo,Bioavailability was evaluated in hamster,1,,,100712,10026.0,Intermediate,1,CHEMBL625432,BAO_0000218,,
13347,,A,,In vivo,Bioavailability in rat,0,,,22224,10116.0,Autocuration,1,CHEMBL625433,BAO_0000218,,
13348,,A,,In vivo,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625434,BAO_0000218,1969.0,
13349,,A,,In vivo,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,1,,,50597,10116.0,Intermediate,1,CHEMBL625435,BAO_0000218,1969.0,
13350,,A,,In vivo,Bioavailability in rat (dose 10 mg/kg p.o.),0,,,22224,10116.0,Autocuration,1,CHEMBL625436,BAO_0000218,,
13351,,A,,In vivo,Bioavailability was measured in cynomolgus monkeys.,1,,,100710,9541.0,Intermediate,1,CHEMBL874588,BAO_0000218,,
13352,,A,,In vivo,Bioavailability was measured in nude mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL625437,BAO_0000218,,
13353,,A,,In vivo,Bioavailability in ferret (dose 10 mg/kg i.d.),0,,,22224,9669.0,Autocuration,1,CHEMBL625438,BAO_0000218,,
13354,,A,,In vivo,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),0,,,22224,314293.0,Autocuration,1,CHEMBL625439,BAO_0000218,,
13355,,A,,In vivo,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",0,,,22224,314293.0,Autocuration,1,CHEMBL625440,BAO_0000218,,
13356,,A,,In vivo,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),0,,,22224,314293.0,Autocuration,1,CHEMBL625441,BAO_0000218,,
13357,,A,,In vivo,Bioavailability in rat (dose 10 mg/kg i.d.),0,,,22224,10116.0,Autocuration,1,CHEMBL625442,BAO_0000218,,
13358,,A,,In vivo,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,,,50597,10116.0,Intermediate,1,CHEMBL625443,BAO_0000218,,
13359,,A,,In vivo,Bioavailability was determined; extremely poor,0,,,22224,,Autocuration,1,CHEMBL625444,BAO_0000218,,
13360,,A,,In vivo,% bioavailability in mice after oral administration of prodrug,1,,,50594,10090.0,Intermediate,1,CHEMBL625445,BAO_0000218,,
13361,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,1,,,50588,9615.0,Intermediate,1,CHEMBL625446,BAO_0000218,,
13362,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,1,,,50588,9615.0,Intermediate,1,CHEMBL882960,BAO_0000218,,
13363,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,1,,,50588,9615.0,Intermediate,1,CHEMBL625447,BAO_0000218,,
13364,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,1,,,50588,9615.0,Intermediate,1,CHEMBL625448,BAO_0000218,,
13365,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,1,,,50588,9615.0,Intermediate,1,CHEMBL625449,BAO_0000218,,
13366,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),1,,,50588,9615.0,Intermediate,1,CHEMBL874589,BAO_0000218,,
13367,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,1,,,50588,9615.0,Intermediate,1,CHEMBL625450,BAO_0000218,,
13368,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,1,,,50588,9615.0,Intermediate,1,CHEMBL625451,BAO_0000218,,
13369,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,1,,,50588,9615.0,Intermediate,1,CHEMBL626584,BAO_0000218,,
13370,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,1,,,50588,9615.0,Intermediate,1,CHEMBL626585,BAO_0000218,,
13371,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,1,,,50588,9615.0,Intermediate,1,CHEMBL626586,BAO_0000218,,
13372,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,1,,,50588,9615.0,Intermediate,1,CHEMBL626587,BAO_0000218,,
13373,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,1,,,50588,9615.0,Intermediate,1,CHEMBL626588,BAO_0000218,,
13374,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,1,,,50588,9615.0,Intermediate,1,CHEMBL626589,BAO_0000218,,
13375,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,1,,,50588,9615.0,Intermediate,1,CHEMBL626590,BAO_0000218,,
13376,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,1,,,50588,9615.0,Intermediate,1,CHEMBL626591,BAO_0000218,,
13377,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,1,,,50588,9615.0,Intermediate,1,CHEMBL627181,BAO_0000218,,
13378,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,1,,,50588,9615.0,Intermediate,1,CHEMBL628083,BAO_0000218,,
13379,,A,,In vivo,IV clearance determined at an peroral dose of 15 mg/kg.,0,,,22224,,Autocuration,1,CHEMBL628084,BAO_0000218,,
13380,,F,,In vivo,Mouse oral clearance was measured against Hymenolepiasis nana.,1,,,50064,102285.0,Expert,1,CHEMBL628085,BAO_0000218,,
13381,,F,,In vivo,Mouse oral clearance was measured against Nematospiroides dubius,1,,,50545,6339.0,Expert,1,CHEMBL628086,BAO_0000218,,
13382,,F,,In vivo,Mouse oral clearance was measured against N. dubius; NT is Not Tested,0,,,22224,,Autocuration,1,CHEMBL628087,BAO_0000218,,
13383,,A,,In vivo,Mouse oral clearance was measured against N. nana; NT is Not Tested,1,,,50594,10090.0,Intermediate,1,CHEMBL628088,BAO_0000218,,
13384,,B,,In vivo,Mouse oral clearance was measured against N. nana; NT is Not Tested,0,,,22224,,Autocuration,1,CHEMBL628089,BAO_0000218,,
13385,,A,,In vivo,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL628090,BAO_0000218,,
13386,,A,,In vivo,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL628091,BAO_0000218,,
13387,,A,,In vivo,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL628092,BAO_0000218,,
13388,,A,,In vivo,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL628093,BAO_0000218,,
13389,,A,,In vivo,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL875607,BAO_0000218,,
13390,,A,,In vivo,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL625710,BAO_0000218,,
13391,,A,,In vivo,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL625711,BAO_0000218,,
13392,,A,,In vivo,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL625712,BAO_0000218,,
13393,,A,,In vivo,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,0,,,22224,,Autocuration,1,CHEMBL625713,BAO_0000218,,
13394,,A,,In vivo,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,1,,,50588,9615.0,Intermediate,1,CHEMBL625714,BAO_0000218,,
13395,,A,,In vivo,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,1,,,50797,9544.0,Intermediate,1,CHEMBL625715,BAO_0000218,,
13396,,A,,In vivo,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625716,BAO_0000218,,
13397,,A,,In vivo,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL625717,BAO_0000218,,
13398,,A,,In vivo,Plasma clearance was determined for the compound in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625718,BAO_0000218,,
13399,,A,,In vivo,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,1,,,50597,10116.0,Intermediate,1,CHEMBL625719,BAO_0000218,,
13400,,A,,In vivo,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,1,,,50597,10116.0,Intermediate,1,CHEMBL625720,BAO_0000218,,
13401,,A,,In vivo,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,1,,,50597,10116.0,Intermediate,1,CHEMBL625721,BAO_0000218,,
13402,,A,,In vivo,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,1,,,50597,10116.0,Intermediate,1,CHEMBL625722,BAO_0000218,,
13403,,A,,In vivo,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,1,,,50597,10116.0,Intermediate,1,CHEMBL625723,BAO_0000218,,
13404,,A,,In vivo,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,1,,,50545,6339.0,Intermediate,1,CHEMBL625724,BAO_0000218,,
13405,,A,,In vivo,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,1,,,50545,6339.0,Intermediate,1,CHEMBL625725,BAO_0000218,,
13406,,A,,In vivo,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,1,,,50545,6339.0,Intermediate,1,CHEMBL625726,BAO_0000218,,
13407,,A,,In vivo,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,1,,,50545,6339.0,Intermediate,1,CHEMBL875608,BAO_0000218,,
13408,,A,,In vivo,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,1,,,50545,6339.0,Intermediate,1,CHEMBL625727,BAO_0000218,,
13409,,A,,In vivo,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,0,,,22224,10116.0,Autocuration,1,CHEMBL625728,BAO_0000218,1088.0,
13410,,A,,In vivo,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,0,,,22224,10116.0,Autocuration,1,CHEMBL625729,BAO_0000218,,
13411,,A,,In vivo,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,0,,,22224,10116.0,Autocuration,1,CHEMBL625730,BAO_0000218,,
13412,,A,,In vivo,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,0,,,22224,10116.0,Autocuration,1,CHEMBL625731,BAO_0000218,1088.0,
13413,,A,,In vivo,Urinary clearance was determined in rat at 25 mg/kg os dosage,0,,,22224,10116.0,Autocuration,1,CHEMBL626417,BAO_0000218,1088.0,
13414,,A,,In vivo,Urinary clearance was determined at 100 mg/kg oral dosage in human,1,,,50587,9606.0,Intermediate,1,CHEMBL626418,BAO_0000218,1088.0,
13415,,A,,In vivo,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,1,,,50588,9615.0,Intermediate,1,CHEMBL626419,BAO_0000218,1088.0,
13416,,A,,In vivo,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,,,50588,9615.0,Intermediate,1,CHEMBL626592,BAO_0000218,1969.0,
13417,,A,,In vivo,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,,,50597,10116.0,Intermediate,1,CHEMBL626593,BAO_0000218,1969.0,
13418,,A,,In vivo,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,,,50597,10116.0,Intermediate,1,CHEMBL626594,BAO_0000218,,
13419,,A,,In vivo,Clearance rate in dogs,1,,,50588,9615.0,Intermediate,1,CHEMBL625035,BAO_0000218,,
13420,,A,,In vitro,Compound was measured for intrinsic clearance,0,,,22224,,Autocuration,1,CHEMBL625036,BAO_0000019,,
13421,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625037,BAO_0000100,,
13422,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625038,BAO_0000100,,
13423,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625039,BAO_0000100,,
13424,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625040,BAO_0000100,,
13425,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625041,BAO_0000100,,
13426,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625042,BAO_0000100,,
13427,,A,,,Partition coefficient of the compound,0,,,22224,,Autocuration,1,CHEMBL874411,BAO_0000019,,
13428,,A,,,Permeability,0,,,22224,,Autocuration,1,CHEMBL625043,BAO_0000019,,
13429,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625044,BAO_0000100,,
13430,,A,,,Partition coefficient (logD),0,,,22224,,Autocuration,1,CHEMBL625045,BAO_0000019,,
13431,,P,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),0,,,22229,,Autocuration,1,CHEMBL625046,BAO_0000100,,
13432,,P,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),0,,,22229,,Autocuration,1,CHEMBL625047,BAO_0000100,,
13433,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625048,BAO_0000100,,
13434,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625049,BAO_0000100,,
13435,,P,,,Calculated logarithm of partition coefficient (P) was determined,0,,,22229,,Autocuration,1,CHEMBL625050,BAO_0000100,,
13436,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625051,BAO_0000100,,
13437,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL874412,BAO_0000100,,
13438,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625052,BAO_0000100,,
13439,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL625053,BAO_0000100,,
13440,,A,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,0,,,22224,,Autocuration,1,CHEMBL623250,BAO_0000019,,
13441,,A,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,0,,,22224,,Autocuration,1,CHEMBL623251,BAO_0000019,,
13442,,A,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,0,,,22224,,Autocuration,1,CHEMBL623252,BAO_0000019,,
13443,,A,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,0,,,22224,,Autocuration,1,CHEMBL623253,BAO_0000019,,
13444,,A,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,0,,,22224,,Autocuration,1,CHEMBL623254,BAO_0000019,,
13445,,A,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,0,,,22224,,Autocuration,1,CHEMBL623255,BAO_0000019,,
13446,,A,,,Percent degradation of compound at a pH of 1 over a 18 hr period,0,,,22224,,Autocuration,1,CHEMBL626831,BAO_0000019,,
13447,,A,,,Percent degradation of compound at pH of 1 over an 18 hr period,0,,,22224,,Autocuration,1,CHEMBL877494,BAO_0000019,,
13448,,A,,,Delta Logarithm of Partition Coefficient value was determined.,0,,,22224,,Autocuration,1,CHEMBL626832,BAO_0000019,,
13449,,A,,,Delta logPoct-cyc,0,,,22224,,Autocuration,1,CHEMBL626833,BAO_0000019,,
13450,,P,,,Lipophilicity estimated on reversed phase TLC,0,,,22224,,Autocuration,1,CHEMBL626834,BAO_0000100,,
13451,,A,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,0,,,22224,,Autocuration,1,CHEMBL626835,BAO_0000019,,
13452,,A,,,Delta logPoct-cyc,0,,,22224,,Autocuration,1,CHEMBL626836,BAO_0000019,,
13453,,P,,,Change in logarithm of partition coefficient of the compound,0,,,22229,,Autocuration,1,CHEMBL626837,BAO_0000100,,
13454,,A,,,Delta logD (pH 6.5),0,,,22224,,Autocuration,1,CHEMBL626838,BAO_0000019,,
13455,,P,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",0,,,22224,,Autocuration,1,CHEMBL626839,BAO_0000100,,
13456,,A,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,0,,,22224,,Autocuration,1,CHEMBL626840,BAO_0000019,,
13457,,A,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),0,,,22224,,Autocuration,1,CHEMBL626841,BAO_0000019,,
13458,,A,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,0,,,22224,,Autocuration,1,CHEMBL626842,BAO_0000219,,
13459,,A,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,0,,,22224,,Autocuration,1,CHEMBL626843,BAO_0000219,,
13460,,A,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,1,,,50597,10116.0,Intermediate,1,CHEMBL626844,BAO_0000218,,
13461,,A,,,Amount of deuterium retained was reported after normal workup in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL877495,BAO_0000218,,
13462,,A,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,1,,,50597,10116.0,Intermediate,1,CHEMBL626845,BAO_0000218,,
13463,,A,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,1,,,50597,10116.0,Intermediate,1,CHEMBL626846,BAO_0000218,,
13464,,A,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,1,,,50597,10116.0,Intermediate,1,CHEMBL626847,BAO_0000218,,
13465,,A,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,1,,,50597,10116.0,Intermediate,1,CHEMBL628677,BAO_0000218,,
13466,,A,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,1,,,50597,10116.0,Intermediate,1,CHEMBL628678,BAO_0000218,,
13467,,A,,,Compound was subjected to electrochemical oxidation,0,,,22224,,Autocuration,1,CHEMBL628679,BAO_0000019,,
13468,,A,,,Compound was subjected to photochemical oxidation,0,,,22224,,Autocuration,1,CHEMBL628680,BAO_0000019,,
13469,,A,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,0,,,22224,,Autocuration,1,CHEMBL628681,BAO_0000019,,
13470,,A,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,0,,,22224,,Autocuration,1,CHEMBL628682,BAO_0000019,,
13471,,A,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,0,,,22224,,Autocuration,1,CHEMBL628683,BAO_0000019,,
13472,,A,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,1,,,50597,10116.0,Intermediate,1,CHEMBL628684,BAO_0000218,,
13473,,P,,,Dissociation constant (pKa),0,,,22229,,Autocuration,1,CHEMBL877501,BAO_0000100,,
13474,,P,,,Dissociation constant value of the compound; ND means not determined.,0,,,22224,,Autocuration,1,CHEMBL628685,BAO_0000100,,
13475,,A,,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL628686,BAO_0000218,178.0,
13476,,A,,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL628687,BAO_0000218,178.0,
13477,,A,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL628688,BAO_0000218,,
13478,,A,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL628689,BAO_0000218,,
13479,,A,,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL628690,BAO_0000218,2107.0,
13480,,A,,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL629363,BAO_0000218,2107.0,
13481,,A,,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL629364,BAO_0000218,2106.0,
13482,,A,,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL629365,BAO_0000218,2106.0,
13483,,A,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL629366,BAO_0000218,,
13484,,A,,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL629367,BAO_0000218,1088.0,
13485,,A,,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL629368,BAO_0000218,1988.0,
13486,,A,,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1,,,50597,10116.0,Intermediate,1,CHEMBL877502,BAO_0000218,1088.0,
13487,,A,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,1,,,50594,10090.0,Intermediate,1,CHEMBL629369,BAO_0000218,2037.0,
13488,,A,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,1,,,50594,10090.0,Intermediate,1,CHEMBL629370,BAO_0000218,955.0,
13489,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL629371,BAO_0000218,1088.0,
13490,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL626276,BAO_0000218,1088.0,
13491,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL626277,BAO_0000218,1088.0,
13492,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL631250,BAO_0000218,1088.0,
13493,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL631251,BAO_0000218,1088.0,
13494,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL631252,BAO_0000218,1088.0,
13495,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL631253,BAO_0000218,1088.0,
13496,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL631254,BAO_0000218,1088.0,
13497,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL631255,BAO_0000218,1088.0,
13498,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL631256,BAO_0000218,1088.0,
13499,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL631257,BAO_0000218,1088.0,
13500,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628009,BAO_0000218,1088.0,
13501,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628010,BAO_0000218,1088.0,
13502,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628011,BAO_0000218,1088.0,
13503,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628012,BAO_0000218,1088.0,
13504,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628013,BAO_0000218,1088.0,
13505,,A,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628014,BAO_0000218,1088.0,
13506,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628015,BAO_0000218,1088.0,
13507,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628016,BAO_0000218,1088.0,
13508,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL874461,BAO_0000218,1088.0,
13509,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628017,BAO_0000218,1088.0,
13510,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628018,BAO_0000218,1088.0,
13511,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628019,BAO_0000218,1088.0,
13512,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628020,BAO_0000218,1088.0,
13513,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628021,BAO_0000218,1088.0,
13514,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628022,BAO_0000218,1088.0,
13515,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1,,,50588,9615.0,Intermediate,1,CHEMBL628023,BAO_0000218,1088.0,
13516,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL628024,BAO_0000218,1088.0,
13517,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL628025,BAO_0000218,1088.0,
13518,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL628026,BAO_0000218,1088.0,
13519,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL628027,BAO_0000218,1088.0,
13520,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",0,,,22224,314293.0,Autocuration,1,CHEMBL628028,BAO_0000218,1088.0,
13521,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628029,BAO_0000218,1088.0,
13522,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628030,BAO_0000218,1088.0,
13523,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628031,BAO_0000218,1088.0,
13524,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628032,BAO_0000218,1088.0,
13525,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628033,BAO_0000218,1088.0,
13526,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628034,BAO_0000218,1088.0,
13527,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628035,BAO_0000218,1088.0,
13528,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL628036,BAO_0000218,1088.0,
13529,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL874462,BAO_0000218,1088.0,
13530,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,1,,,50588,9615.0,Intermediate,1,CHEMBL628037,BAO_0000218,,
13531,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,1,,,50588,9615.0,Intermediate,1,CHEMBL628123,BAO_0000218,,
13532,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,1,,,50588,9615.0,Intermediate,1,CHEMBL628124,BAO_0000218,,
13533,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,1,,,50588,9615.0,Intermediate,1,CHEMBL628125,BAO_0000218,,
13534,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,1,,,50588,9615.0,Intermediate,1,CHEMBL628126,BAO_0000218,,
13535,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),1,,,50588,9615.0,Intermediate,1,CHEMBL628127,BAO_0000218,,
13536,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,1,,,50588,9615.0,Intermediate,1,CHEMBL628128,BAO_0000218,,
13537,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,1,,,50588,9615.0,Intermediate,1,CHEMBL628129,BAO_0000218,,
13538,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,1,,,50588,9615.0,Intermediate,1,CHEMBL628130,BAO_0000218,,
13539,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,1,,,50588,9615.0,Intermediate,1,CHEMBL628131,BAO_0000218,,
13540,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,1,,,50588,9615.0,Intermediate,1,CHEMBL628132,BAO_0000218,,
13541,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,1,,,50588,9615.0,Intermediate,1,CHEMBL628133,BAO_0000218,,
13542,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,1,,,50588,9615.0,Intermediate,1,CHEMBL628134,BAO_0000218,,
13543,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,1,,,50588,9615.0,Intermediate,1,CHEMBL628135,BAO_0000218,,
13544,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,1,,,50588,9615.0,Intermediate,1,CHEMBL628136,BAO_0000218,,
13545,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,1,,,50588,9615.0,Intermediate,1,CHEMBL628137,BAO_0000218,,
13546,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,1,,,50588,9615.0,Intermediate,1,CHEMBL628138,BAO_0000218,,
13547,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,1,,,50588,9615.0,Intermediate,1,CHEMBL628139,BAO_0000218,,
13548,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,1,,,50588,9615.0,Intermediate,1,CHEMBL628140,BAO_0000218,,
13549,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,1,,,50588,9615.0,Intermediate,1,CHEMBL628141,BAO_0000218,,
13550,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,1,,,50588,9615.0,Intermediate,1,CHEMBL628142,BAO_0000218,,
13551,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,1,,,50588,9615.0,Intermediate,1,CHEMBL628143,BAO_0000218,,
13552,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,1,,,50588,9615.0,Intermediate,1,CHEMBL628144,BAO_0000218,,
13553,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,1,,,50588,9615.0,Intermediate,1,CHEMBL628145,BAO_0000218,,
13554,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,1,,,50588,9615.0,Intermediate,1,CHEMBL628146,BAO_0000218,,
13555,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,1,,,50588,9615.0,Intermediate,1,CHEMBL625355,BAO_0000218,,
13556,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,1,,,50588,9615.0,Intermediate,1,CHEMBL625356,BAO_0000218,,
13557,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,1,,,50588,9615.0,Intermediate,1,CHEMBL625357,BAO_0000218,,
13558,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,1,,,50588,9615.0,Intermediate,1,CHEMBL625527,BAO_0000218,,
13559,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),1,,,50588,9615.0,Intermediate,1,CHEMBL875473,BAO_0000218,,
13560,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,1,,,50588,9615.0,Intermediate,1,CHEMBL625528,BAO_0000218,,
13561,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,1,,,50597,10116.0,Intermediate,1,CHEMBL626304,BAO_0000218,,
13562,,A,,In vivo,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,1,,,50588,9615.0,Intermediate,1,CHEMBL624138,BAO_0000218,1637.0,
13563,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624139,BAO_0000100,,
13564,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624140,BAO_0000100,,
13565,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624141,BAO_0000100,,
13566,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624142,BAO_0000100,,
13567,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624143,BAO_0000100,,
13568,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624144,BAO_0000100,,
13569,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624145,BAO_0000100,,
13570,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624146,BAO_0000100,,
13571,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624147,BAO_0000100,,
13572,,P,,,Calculated partition coefficient (clogP) (MacLogP),0,,,22229,,Autocuration,1,CHEMBL883123,BAO_0000100,,
13573,,A,,,Partition coefficient (logP),0,,,22224,,Autocuration,1,CHEMBL624148,BAO_0000019,,
13574,,A,,,Kinetic parameter was determined,0,,,22224,,Autocuration,1,CHEMBL874416,BAO_0000019,,
13575,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624149,BAO_0000100,,
13576,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL624150,BAO_0000100,,
13577,,P,,,Lipophilicity was determined,0,,,22224,,Autocuration,1,CHEMBL624151,BAO_0000100,,
13578,,P,,,Lipophilicity was determined,0,,,22224,,Autocuration,1,CHEMBL624152,BAO_0000100,,
13579,,P,,,Lipophilicity was determined,0,,,22224,,Autocuration,1,CHEMBL622139,BAO_0000100,,
13580,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL622140,BAO_0000100,,
13581,,P,,,Lipophilicity was determined,0,,,22224,,Autocuration,1,CHEMBL622141,BAO_0000100,,
13582,,P,,,Lipophilicity in octanol-water,0,,,22224,,Autocuration,1,CHEMBL622142,BAO_0000100,,
13583,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL622143,BAO_0000100,,
13584,,P,,,Octanol-water partition coefficient was determined,0,,,22229,,Autocuration,1,CHEMBL622144,BAO_0000100,,
13585,,A,,,Partition coefficient (logP),0,,,22224,,Autocuration,1,CHEMBL877473,BAO_0000019,,
13586,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL622145,BAO_0000100,,
13587,,A,,,Partition coefficient was determined; ND means not determined,0,,,22224,,Autocuration,1,CHEMBL622146,BAO_0000019,,
13588,,P,,,Calculated partition coefficient (clogP),0,,,22229,,Autocuration,1,CHEMBL622147,BAO_0000100,,
13589,,A,,,Partition coefficient of the compound,0,,,22224,,Autocuration,1,CHEMBL622148,BAO_0000019,,
13590,,A,,,Permeability was determined,0,,,22224,,Autocuration,1,CHEMBL883124,BAO_0000019,,
13591,,P,,,The compound was evaluated for the partition coefficient,0,,,22229,,Autocuration,1,CHEMBL622149,BAO_0000100,,
13592,,A,,,Partition coefficient (logP),0,,,22224,,Autocuration,1,CHEMBL622150,BAO_0000019,,
13593,,P,,,The lipophilicity was reported,0,,,22224,,Autocuration,1,CHEMBL622151,BAO_0000100,,
13594,,P,,,logarithm of the octanol-water partition coefficient for the compound,0,,,22229,,Autocuration,1,CHEMBL622152,BAO_0000100,,
13595,,A,,,Clogp value was determined,0,,,22224,,Autocuration,1,CHEMBL622153,BAO_0000019,,
13596,,A,,In vivo,Clp at a dose of 1.5 mg/kg,0,,,22224,,Autocuration,1,CHEMBL877474,BAO_0000218,,
13597,,A,,In vivo,Clp at a dose of 2.0 mg/kg,0,,,22224,,Autocuration,1,CHEMBL622154,BAO_0000218,,
13598,,A,,In vivo,"Clp, plasma clearance at a dose of 10 mg/kg",0,,,22224,,Autocuration,1,CHEMBL622155,BAO_0000218,1969.0,
13599,,A,,In vivo,"Clp, plasma clearance at a dose of 50 mg/kg",0,,,22224,,Autocuration,1,CHEMBL622156,BAO_0000218,1969.0,
13600,,A,,In vivo,Compound was tested for plasma clearance in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622157,BAO_0000218,1969.0,
13601,,A,,In vivo,Compound was tested for plasma clearance in rat; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622158,BAO_0000218,1969.0,
13602,,A,,In vivo,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL622807,BAO_0000218,,
13603,,A,,In vivo,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,1,,,50797,9544.0,Intermediate,1,CHEMBL622808,BAO_0000218,,
13604,,A,,In vivo,Plasma clearance by iv administration at a dose 0.003 ug/mL,0,,,22224,,Autocuration,1,CHEMBL622809,BAO_0000218,,
13605,,A,,In vivo,Plasma clearance determined,0,,,22224,,Autocuration,1,CHEMBL622810,BAO_0000218,,
13606,,A,,In vivo,Plasma clearance after iv administration at 3 mg/kg in hamster,1,,,100712,10026.0,Intermediate,1,CHEMBL876653,BAO_0000218,,
13607,,A,,In vivo,Plasma clearance after iv administration at 4 mg/kg in hamster,1,,,100712,10026.0,Intermediate,1,CHEMBL622811,BAO_0000218,,
13608,,A,,In vivo,Rate of clearance in rat was determined,1,,,50597,10116.0,Intermediate,1,CHEMBL622986,BAO_0000218,,
13609,,A,,In vivo,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622987,BAO_0000218,1969.0,
13610,,A,,In vivo,Total plasma clearance after iv dose of 5.10 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622988,BAO_0000218,1969.0,
13611,,A,,In vivo,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622989,BAO_0000218,1969.0,
13612,,A,,In vivo,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622990,BAO_0000218,1969.0,
13613,,A,,In vivo,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,0,,,22224,314293.0,Autocuration,1,CHEMBL622991,BAO_0000218,1969.0,
13614,,A,,In vivo,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622227,BAO_0000218,1969.0,
13615,,A,,In vivo,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL622228,BAO_0000218,1969.0,
13616,,A,,In vivo,Clpl value in rat,1,,,50597,10116.0,Intermediate,1,CHEMBL622229,BAO_0000218,,
13617,,A,,In vivo,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,1,,,50512,10141.0,Intermediate,1,CHEMBL622230,BAO_0000218,,
13618,,A,,In vivo,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,1,,,50597,10116.0,Intermediate,1,CHEMBL622231,BAO_0000218,,
13619,,A,,In vivo,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,1,,,100710,9541.0,Intermediate,1,CHEMBL622232,BAO_0000218,,
13620,,A,,In vivo,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,0,,,22224,,Autocuration,1,CHEMBL622233,BAO_0000218,,
13621,,A,,In vivo,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,0,,,22224,,Autocuration,1,CHEMBL622234,BAO_0000218,,
13622,,A,,In vivo,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,0,,,22224,,Autocuration,1,CHEMBL622235,BAO_0000218,,
13623,,A,,In vivo,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,0,,,22224,,Autocuration,1,CHEMBL622236,BAO_0000218,,
13624,,A,,In vivo,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,0,,,22224,,Autocuration,1,CHEMBL622237,BAO_0000218,,
13625,,A,,In vivo,Cmax in minutes at a po dose of 10.0(pmol/g/h).,0,,,22224,,Autocuration,1,CHEMBL877482,BAO_0000218,,
13626,,A,,In vivo,Cmax in minutes at a po dose of 20.0(pmol/g/h).,0,,,22224,,Autocuration,1,CHEMBL622238,BAO_0000218,,
13627,,A,,In vivo,Cmax in minutes at a po dose of 40.0(pmol/g/h).,0,,,22224,,Autocuration,1,CHEMBL622239,BAO_0000218,,
13628,,A,,In vivo,Cmax was calculated as maximum concentration reached in the blood,0,,,22224,,Autocuration,1,CHEMBL622240,BAO_0000218,178.0,
13629,,A,,In vivo,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,0,,,22224,,Autocuration,1,CHEMBL622241,BAO_0000218,178.0,
13630,,A,,In vivo,Cmax was determine after peroral administration at 10 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631013,BAO_0000218,,
13631,,A,,In vivo,Cmax was determine after peroral administration at 10 mpk in Rhesus,1,,,50797,9544.0,Intermediate,1,CHEMBL631014,BAO_0000218,,
13632,,A,,In vivo,Cmax was determine after peroral administration at 10 mpk in dog,1,,,50588,9615.0,Intermediate,1,CHEMBL631015,BAO_0000218,,
13633,,A,,In vivo,Cmax was determine after peroral administration at 160 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631016,BAO_0000218,,
13634,,A,,In vivo,Cmax was determine after peroral administration at 20 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631017,BAO_0000218,,
13635,,A,,In vivo,Cmax was determine after peroral administration at 50 mpk in Rat,1,,,50597,10116.0,Intermediate,1,CHEMBL631018,BAO_0000218,,
13636,,A,,In vivo,Cmax was determined,0,,,22224,,Autocuration,1,CHEMBL631019,BAO_0000218,,
13637,,A,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,1,,,50594,10090.0,Intermediate,1,CHEMBL875761,BAO_0000218,955.0,
13638,,A,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,1,,,50594,10090.0,Intermediate,1,CHEMBL631020,BAO_0000218,955.0,
13639,,A,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,1,,,50594,10090.0,Intermediate,1,CHEMBL631669,BAO_0000218,955.0,
13640,,A,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,1,,,50594,10090.0,Intermediate,1,CHEMBL631670,BAO_0000218,955.0,
13641,,A,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,1,,,50594,10090.0,Intermediate,1,CHEMBL631671,BAO_0000218,2435.0,
13642,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,1,,,50597,10116.0,Intermediate,1,CHEMBL631672,BAO_0000218,178.0,
13643,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,1,,,50597,10116.0,Intermediate,1,CHEMBL631673,BAO_0000218,178.0,
13644,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,1,,,50597,10116.0,Intermediate,1,CHEMBL631856,BAO_0000218,178.0,
13645,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,1,,,50597,10116.0,Intermediate,1,CHEMBL631857,BAO_0000218,178.0,
13646,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,1,,,50597,10116.0,Intermediate,1,CHEMBL631858,BAO_0000218,178.0,
13647,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,1,,,50597,10116.0,Intermediate,1,CHEMBL631859,BAO_0000218,178.0,
13648,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,1,,,50597,10116.0,Intermediate,1,CHEMBL631860,BAO_0000218,178.0,
13649,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,1,,,50597,10116.0,Intermediate,1,CHEMBL631861,BAO_0000218,178.0,
13650,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,1,,,50597,10116.0,Intermediate,1,CHEMBL631862,BAO_0000218,178.0,
13651,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,1,,,50597,10116.0,Intermediate,1,CHEMBL631863,BAO_0000218,178.0,
13652,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,1,,,50597,10116.0,Intermediate,1,CHEMBL631864,BAO_0000218,178.0,
13653,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,1,,,50597,10116.0,Intermediate,1,CHEMBL631865,BAO_0000218,178.0,
13654,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,1,,,50597,10116.0,Intermediate,1,CHEMBL631866,BAO_0000218,178.0,
13655,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,1,,,50597,10116.0,Intermediate,1,CHEMBL629360,BAO_0000218,178.0,
13656,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,1,,,50597,10116.0,Intermediate,1,CHEMBL629361,BAO_0000218,178.0,
13657,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,1,,,50597,10116.0,Intermediate,1,CHEMBL629362,BAO_0000218,178.0,
13658,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,1,,,50597,10116.0,Intermediate,1,CHEMBL630740,BAO_0000218,178.0,
13659,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,1,,,50597,10116.0,Intermediate,1,CHEMBL630741,BAO_0000218,178.0,
13660,,A,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,1,,,50597,10116.0,Intermediate,1,CHEMBL630742,BAO_0000218,178.0,
13661,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,1,,,50597,10116.0,Intermediate,1,CHEMBL630743,BAO_0000218,,
13662,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,1,,,50597,10116.0,Intermediate,1,CHEMBL630744,BAO_0000218,,
13663,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,1,,,50597,10116.0,Intermediate,1,CHEMBL630745,BAO_0000218,,
13664,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,1,,,50597,10116.0,Intermediate,1,CHEMBL630746,BAO_0000218,,
13665,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,1,,,50597,10116.0,Intermediate,1,CHEMBL630747,BAO_0000218,,
13666,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,1,,,50597,10116.0,Intermediate,1,CHEMBL630748,BAO_0000218,,
13667,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,1,,,50597,10116.0,Intermediate,1,CHEMBL632056,BAO_0000218,,
13668,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,1,,,50597,10116.0,Intermediate,1,CHEMBL632057,BAO_0000218,,
13669,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,1,,,50597,10116.0,Intermediate,1,CHEMBL632058,BAO_0000218,,
13670,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,1,,,50597,10116.0,Intermediate,1,CHEMBL632059,BAO_0000218,,
13671,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,1,,,50597,10116.0,Intermediate,1,CHEMBL632060,BAO_0000218,,
13672,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,1,,,50597,10116.0,Intermediate,1,CHEMBL632061,BAO_0000218,,
13673,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,1,,,50597,10116.0,Intermediate,1,CHEMBL629207,BAO_0000218,,
13674,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,1,,,50597,10116.0,Intermediate,1,CHEMBL629208,BAO_0000218,,
13675,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,1,,,50597,10116.0,Intermediate,1,CHEMBL629209,BAO_0000218,,
13676,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,1,,,50597,10116.0,Intermediate,1,CHEMBL629210,BAO_0000218,,
13677,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,1,,,50597,10116.0,Intermediate,1,CHEMBL629211,BAO_0000218,,
13678,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,1,,,50597,10116.0,Intermediate,1,CHEMBL629212,BAO_0000218,,
13679,,A,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,1,,,50597,10116.0,Intermediate,1,CHEMBL629213,BAO_0000218,,
13680,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629214,BAO_0000218,1088.0,
13681,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL629215,BAO_0000218,1088.0,
13682,,A,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",1,,,50597,10116.0,Intermediate,1,CHEMBL635154,BAO_0000218,1088.0,
13683,,A,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL629216,BAO_0000218,,
13684,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL629217,BAO_0000218,,
13685,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL629218,BAO_0000218,,
13686,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL629219,BAO_0000218,,
13687,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL629220,BAO_0000218,,
13688,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL629221,BAO_0000218,,
13689,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631127,BAO_0000218,,
13690,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL631128,BAO_0000218,,
13691,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631129,BAO_0000218,,
13692,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631130,BAO_0000218,,
13693,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631131,BAO_0000218,,
13694,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL631132,BAO_0000218,,
13695,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631133,BAO_0000218,,
13696,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL631134,BAO_0000218,,
13697,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL875120,BAO_0000218,,
13698,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631135,BAO_0000218,,
13699,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631136,BAO_0000218,,
13700,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL631137,BAO_0000218,,
13701,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631138,BAO_0000218,,
13702,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,1,,,50597,10116.0,Intermediate,1,CHEMBL631139,BAO_0000218,,
13703,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631140,BAO_0000218,,
13704,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631141,BAO_0000218,,
13705,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631142,BAO_0000218,,
13706,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,,,50597,10116.0,Intermediate,1,CHEMBL631143,BAO_0000218,,
13707,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,,50597,10116.0,Intermediate,1,CHEMBL631144,BAO_0000218,,
13708,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL631145,BAO_0000218,,
13709,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631146,BAO_0000218,,
13710,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL631147,BAO_0000218,,
13711,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631148,BAO_0000218,,
13712,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631149,BAO_0000218,,
13713,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631150,BAO_0000218,,
13714,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631151,BAO_0000218,,
13715,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631152,BAO_0000218,,
13716,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631443,BAO_0000218,,
13717,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631444,BAO_0000218,,
13718,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631445,BAO_0000218,,
13719,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,,,50588,9615.0,Intermediate,1,CHEMBL631446,BAO_0000218,,
13720,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631447,BAO_0000218,,
13721,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631448,BAO_0000218,,
13722,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,1,,,50588,9615.0,Intermediate,1,CHEMBL631449,BAO_0000218,,
13723,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL631450,BAO_0000218,,
13724,,A,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,,,50588,9615.0,Intermediate,1,CHEMBL629724,BAO_0000218,,
13725,,A,,In vivo,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL629725,BAO_0000218,14.0,
13726,,A,,In vivo,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL629726,BAO_0000218,14.0,
13727,,A,,In vivo,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL629727,BAO_0000218,2106.0,
13728,,A,,In vivo,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630404,BAO_0000218,2106.0,
13729,,A,,In vivo,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630405,BAO_0000218,2106.0,
13730,,A,,In vivo,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630406,BAO_0000218,2106.0,
13731,,A,,In vivo,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630407,BAO_0000218,945.0,
13732,,A,,In vivo,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630573,BAO_0000218,945.0,
13733,,A,,In vivo,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630574,BAO_0000218,945.0,
13734,,A,,In vivo,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630575,BAO_0000218,945.0,
13735,,A,,In vivo,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630576,BAO_0000218,,
13736,,A,,In vivo,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630577,BAO_0000218,,
13737,,A,,In vivo,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630578,BAO_0000218,,
13738,,A,,In vivo,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,,50594,10090.0,Intermediate,1,CHEMBL630579,BAO_0000218,,
13739,,A,,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),1,,,50594,10090.0,Intermediate,1,CHEMBL630580,BAO_0000218,2113.0,
13740,,A,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,1,,,50594,10090.0,Intermediate,1,CHEMBL630581,BAO_0000218,2113.0,
13741,,A,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),1,,,50594,10090.0,Intermediate,1,CHEMBL630582,BAO_0000218,2113.0,
13742,,A,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,1,,,50594,10090.0,Intermediate,1,CHEMBL630583,BAO_0000218,,
13743,,A,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),1,,,50594,10090.0,Intermediate,1,CHEMBL630584,BAO_0000218,,
13744,,A,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,1,,,50594,10090.0,Intermediate,1,CHEMBL630585,BAO_0000218,,
13745,,A,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),1,,,50594,10090.0,Intermediate,1,CHEMBL630586,BAO_0000218,,
13746,,A,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,1,,,50594,10090.0,Intermediate,1,CHEMBL630587,BAO_0000218,,
13747,,A,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),1,,,50594,10090.0,Intermediate,1,CHEMBL630588,BAO_0000218,,
13748,,A,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,1,,,50594,10090.0,Intermediate,1,CHEMBL630589,BAO_0000218,,
13749,,A,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),1,,,50594,10090.0,Intermediate,1,CHEMBL630590,BAO_0000218,,
13750,,A,,,Removal of 238-Plutonium(IV) in feces at 24 h,0,,,22224,,Autocuration,1,CHEMBL630591,BAO_0000019,1988.0,
13751,,A,,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),0,,,22224,,Autocuration,1,CHEMBL630592,BAO_0000019,1988.0,
13752,,A,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,0,,,22224,,Autocuration,1,CHEMBL630593,BAO_0000019,,
13753,,A,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),0,,,22224,,Autocuration,1,CHEMBL630594,BAO_0000019,,
13754,,A,,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),0,,,22224,,Autocuration,1,CHEMBL630595,BAO_0000019,1088.0,
13755,,A,,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),0,,,22224,,Autocuration,1,CHEMBL630596,BAO_0000019,1088.0,
13756,,A,,,Removal of 238-Plutonium(IV) in urine after 0-24 h,0,,,22224,,Autocuration,1,CHEMBL630597,BAO_0000019,1088.0,
13757,,A,,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),0,,,22224,,Autocuration,1,CHEMBL630598,BAO_0000019,1088.0,
13758,,A,,,Removal of 238-Plutonium(IV) in urine after 0-4 h,0,,,22224,,Autocuration,1,CHEMBL630599,BAO_0000019,1088.0,
13759,,A,,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),0,,,22224,,Autocuration,1,CHEMBL630600,BAO_0000019,1088.0,
13760,,A,,,Removal of 238-Plutonium(IV) in urine after 4-24 h,0,,,22224,,Autocuration,1,CHEMBL630601,BAO_0000019,1088.0,
13761,,A,,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),0,,,22224,,Autocuration,1,CHEMBL630602,BAO_0000019,1088.0,
13762,,A,,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),0,,,22224,,Autocuration,1,CHEMBL630603,BAO_0000019,1088.0,
13763,,A,,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),0,,,22224,,Autocuration,1,CHEMBL630604,BAO_0000019,1088.0,
13764,,A,,In vivo,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL624869,BAO_0000218,178.0,
13765,,A,,In vivo,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL624870,BAO_0000218,178.0,
13766,,A,,In vivo,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL623189,BAO_0000218,178.0,
13767,,A,,In vivo,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623190,BAO_0000218,178.0,
13768,,A,,In vivo,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623191,BAO_0000218,178.0,
13769,,A,,In vivo,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623192,BAO_0000218,,
13770,,A,,In vivo,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623193,BAO_0000218,,
13771,,A,,In vivo,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL623194,BAO_0000218,,
13772,,A,,In vivo,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623195,BAO_0000218,,
13773,,A,,In vivo,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623196,BAO_0000218,,
13774,,A,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623197,BAO_0000218,,
13775,,A,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623198,BAO_0000218,,
13776,,A,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623199,BAO_0000218,,
13777,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623200,BAO_0000218,2385.0,
13778,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623201,BAO_0000218,2385.0,
13779,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623202,BAO_0000218,2385.0,
13780,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623203,BAO_0000218,2385.0,
13781,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623204,BAO_0000218,2385.0,
13782,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623205,BAO_0000218,2385.0,
13783,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623206,BAO_0000218,2385.0,
13784,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623207,BAO_0000218,2385.0,
13785,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623208,BAO_0000218,2385.0,
13786,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623209,BAO_0000218,2385.0,
13787,,A,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623210,BAO_0000218,2385.0,
13788,,A,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623211,BAO_0000218,,
13789,,A,,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,1,,,50597,10116.0,Intermediate,1,CHEMBL623212,BAO_0000218,995.0,
13790,,A,,,Tested in vitro for intrinsic activity relative to quinpirole,0,,,22224,,Autocuration,1,CHEMBL623213,BAO_0000019,,
13791,,A,,,"Relative ion enhancement, determined in pulsed ultrafiltration",0,,,22224,,Autocuration,1,CHEMBL623214,BAO_0000019,,
13792,,A,,,% ionization at the pH 7.4 at 37 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL623215,BAO_0000019,,
13793,,A,,,Percentage ionization was measured,0,,,22224,,Autocuration,1,CHEMBL623216,BAO_0000019,,
13794,,A,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,1,,,50591,9913.0,Intermediate,1,CHEMBL623217,BAO_0000218,,
13795,,A,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,0,,,22224,,Autocuration,1,CHEMBL623218,BAO_0000019,,
13796,,A,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,0,,,22224,,Autocuration,1,CHEMBL623913,BAO_0000019,,
13797,,A,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,0,,,22224,,Autocuration,1,CHEMBL623914,BAO_0000019,,
13798,,P,,,Compound was evaluated for the partition coefficient in octanol/water,0,,,22229,,Autocuration,1,CHEMBL623915,BAO_0000100,,
13799,,P,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),0,,,22229,,Autocuration,1,CHEMBL624080,BAO_0000100,,
13800,,A,,,Equilibrium constant measured by the pulse radiolysis at pH 7,0,,,22224,,Autocuration,1,CHEMBL624081,BAO_0000019,,
13801,,A,,,In vitro hydrolytic rate constant determined in human blood,1,,,50587,9606.0,Intermediate,1,CHEMBL624082,BAO_0000218,,
13802,,A,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,1,,,50587,9606.0,Intermediate,1,CHEMBL625054,BAO_0000218,,
13803,,A,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,0,,,22224,,Autocuration,1,CHEMBL877485,BAO_0000019,,
13804,,A,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,1,,,50594,10090.0,Intermediate,1,CHEMBL625055,BAO_0000218,,
13805,,A,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,1,,,50594,10090.0,Intermediate,1,CHEMBL625056,BAO_0000218,,
13806,,A,,,In vitro oxidation of compound in presence of human plasma,1,,,50587,9606.0,Intermediate,1,CHEMBL625057,BAO_0000218,,
13807,,A,,,In vitro oxidation of compound in presence of hydrogen peroxide,0,,,22224,,Autocuration,1,CHEMBL625058,BAO_0000019,,
13808,,A,,,In vitro oxidation of compound in presence of mouse brain homogenate,1,,,50594,10090.0,Intermediate,1,CHEMBL625059,BAO_0000218,,
13809,,A,,,In vitro oxidation of compound in presence of mouse liver homogenate,1,,,50594,10090.0,Intermediate,1,CHEMBL629536,BAO_0000218,,
13810,,A,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629537,BAO_0000218,,
13811,,A,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629538,BAO_0000218,,
13812,,A,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629539,BAO_0000218,,
13813,,A,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL874445,BAO_0000218,,
13814,,A,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629540,BAO_0000218,,
13815,,A,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629541,BAO_0000218,,
13816,,A,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629542,BAO_0000218,,
13817,,A,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL630243,BAO_0000218,,
13818,,A,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL630244,BAO_0000218,,
13819,,A,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL630245,BAO_0000218,,
13820,,A,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL630246,BAO_0000218,,
13821,,A,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL630247,BAO_0000218,,
13822,,A,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL630248,BAO_0000218,,
13823,,A,,In vivo,Biodistribution in rat blood at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630249,BAO_0000218,178.0,
13824,,A,,In vivo,Biodistribution in rat blood at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630250,BAO_0000218,178.0,
13825,,A,,In vivo,Biodistribution in rat blood at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630251,BAO_0000218,178.0,
13826,,A,,In vivo,Biodistribution in rat blood at 3 hr after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630252,BAO_0000218,178.0,
13827,,A,,In vivo,Biodistribution in rat blood at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630408,BAO_0000218,178.0,
13828,,A,,In vivo,Biodistribution in rat cerebellum at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630409,BAO_0000218,2037.0,
13829,,A,,In vivo,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL874446,BAO_0000218,2037.0,
13830,,A,,In vivo,Biodistribution in rat cerebellum at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630410,BAO_0000218,2037.0,
13831,,A,,In vivo,Biodistribution in rat cerebellum at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630411,BAO_0000218,2037.0,
13832,,A,,In vivo,Biodistribution in rat cerebellum at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630412,BAO_0000218,2037.0,
13833,,A,,In vivo,Biodistribution in rat cerebellum at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630413,BAO_0000218,2037.0,
13834,,A,,In vivo,Biodistribution in rat cerebellum at 3 hr after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630414,BAO_0000218,2037.0,
13835,,A,,In vivo,Biodistribution in rat cerebellum at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630415,BAO_0000218,2037.0,
13836,,A,,In vivo,Biodistribution in rat cortex at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630416,BAO_0000218,,
13837,,A,,In vivo,Biodistribution in rat cortex at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630417,BAO_0000218,,
13838,,A,,In vivo,Biodistribution in rat cortex at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630418,BAO_0000218,,
13839,,A,,In vivo,Biodistribution in rat cortex at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630419,BAO_0000218,,
13840,,A,,In vivo,Biodistribution in rat cortex at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630420,BAO_0000218,,
13841,,A,,In vivo,Biodistribution in rat cortex at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630421,BAO_0000218,,
13842,,A,,In vivo,Biodistribution in rat cortex at 3 hr after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630422,BAO_0000218,,
13843,,A,,In vivo,Biodistribution in rat cortex at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630423,BAO_0000218,,
13844,,A,,In vivo,Biodistribution in rat heart at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630424,BAO_0000218,948.0,
13845,,A,,In vivo,Biodistribution in rat heart at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630425,BAO_0000218,948.0,
13846,,A,,In vivo,Biodistribution in rat heart at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL629462,BAO_0000218,948.0,
13847,,A,,In vivo,Biodistribution in rat heart at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630426,BAO_0000218,948.0,
13848,,A,,In vivo,Biodistribution in rat heart at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630427,BAO_0000218,948.0,
13849,,A,,In vivo,Biodistribution in rat heart at 3 hr after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625877,BAO_0000218,948.0,
13850,,A,,In vivo,Biodistribution in rat heart at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625878,BAO_0000218,948.0,
13851,,A,,In vivo,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625879,BAO_0000218,10000000.0,
13852,,A,,In vivo,Biodistribution in rat hippocampus at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625880,BAO_0000218,10000000.0,
13853,,A,,In vivo,Biodistribution in rat hippocampus at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625881,BAO_0000218,10000000.0,
13854,,A,,In vivo,Biodistribution in rat hippocampus at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625882,BAO_0000218,10000000.0,
13855,,A,,In vivo,Biodistribution in rat hippocampus at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625883,BAO_0000218,10000000.0,
13856,,A,,In vivo,Biodistribution in rat kidney at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625884,BAO_0000218,2113.0,
13857,,A,,In vivo,Biodistribution in rat kidney at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625885,BAO_0000218,2113.0,
13858,,A,,In vivo,Biodistribution in rat kidney at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628649,BAO_0000218,2113.0,
13859,,A,,In vivo,Biodistribution in rat kidney at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628650,BAO_0000218,2113.0,
13860,,A,,In vivo,Biodistribution in rat kidney at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628651,BAO_0000218,2113.0,
13861,,A,,In vivo,Biodistribution in rat kidney at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628652,BAO_0000218,2113.0,
13862,,A,,In vivo,Biodistribution in rat kidney at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628653,BAO_0000218,2113.0,
13863,,A,,In vivo,Biodistribution in rat liver at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628654,BAO_0000218,2107.0,
13864,,A,,In vivo,Biodistribution in rat liver at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628655,BAO_0000218,2107.0,
13865,,A,,In vivo,Biodistribution in rat liver at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625238,BAO_0000218,2107.0,
13866,,A,,In vivo,Biodistribution in rat liver at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625239,BAO_0000218,2107.0,
13867,,A,,In vivo,Biodistribution in rat liver at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625240,BAO_0000218,2107.0,
13868,,A,,In vivo,Biodistribution in rat liver at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625241,BAO_0000218,2107.0,
13869,,A,,In vivo,Biodistribution in rat liver at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625242,BAO_0000218,2107.0,
13870,,A,,In vivo,Biodistribution in rat lung at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL874587,BAO_0000218,2048.0,
13871,,A,,In vivo,Biodistribution in rat lung at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625405,BAO_0000218,2048.0,
13872,,A,,In vivo,Biodistribution in rat lung at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625406,BAO_0000218,2048.0,
13873,,A,,In vivo,Biodistribution in rat lung at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625407,BAO_0000218,2048.0,
13874,,A,,In vivo,Biodistribution in rat lung at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625408,BAO_0000218,2048.0,
13875,,A,,In vivo,Biodistribution in rat lung at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL625409,BAO_0000218,2048.0,
13876,,A,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,1,,,50597,10116.0,Intermediate,1,CHEMBL625410,BAO_0000218,1515.0,
13877,,A,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,1,,,50597,10116.0,Intermediate,1,CHEMBL625411,BAO_0000218,1515.0,
13878,,A,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,1,,,50597,10116.0,Intermediate,1,CHEMBL625412,BAO_0000218,1515.0,
13879,,A,,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,1,,,50597,10116.0,Intermediate,1,CHEMBL625413,BAO_0000218,1515.0,
13880,,A,,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,1,,,50597,10116.0,Intermediate,1,CHEMBL625414,BAO_0000218,1515.0,
13881,,A,,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,1,,,50597,10116.0,Intermediate,1,CHEMBL625415,BAO_0000218,1515.0,
13882,,A,,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,1,,,50597,10116.0,Intermediate,1,CHEMBL625416,BAO_0000218,1515.0,
13883,,A,,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625417,BAO_0000218,1088.0,
13884,,A,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,1,,,50597,10116.0,Intermediate,1,CHEMBL625418,BAO_0000218,1988.0,
13885,,A,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,1,,,50597,10116.0,Intermediate,1,CHEMBL625419,BAO_0000218,1088.0,
13886,,A,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL625420,BAO_0000218,,
13887,,A,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL626996,BAO_0000218,,
13888,,A,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",1,,,50597,10116.0,Intermediate,1,CHEMBL626997,BAO_0000218,1988.0,
13889,,A,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",1,,,50597,10116.0,Intermediate,1,CHEMBL626998,BAO_0000218,1088.0,
13890,,A,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",1,,,50597,10116.0,Intermediate,1,CHEMBL626999,BAO_0000218,,
13891,,A,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,1,,,50594,10090.0,Intermediate,1,CHEMBL627000,BAO_0000218,,
13892,,A,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,1,,,50594,10090.0,Intermediate,1,CHEMBL627001,BAO_0000218,,
13893,,A,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,1,,,50594,10090.0,Intermediate,1,CHEMBL627002,BAO_0000218,,
13894,,A,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,1,,,50594,10090.0,Intermediate,1,CHEMBL627003,BAO_0000218,,
13895,,A,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627004,BAO_0000218,1088.0,
13896,,A,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627005,BAO_0000218,1088.0,
13897,,A,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL874594,BAO_0000218,1088.0,
13898,,A,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627006,BAO_0000218,1088.0,
13899,,A,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627007,BAO_0000218,1088.0,
13900,,A,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627884,BAO_0000218,1088.0,
13901,,A,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627885,BAO_0000218,1088.0,
13902,,A,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627886,BAO_0000218,1088.0,
13903,,A,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627887,BAO_0000218,1088.0,
13904,,A,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627888,BAO_0000218,1088.0,
13905,,A,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL628057,BAO_0000218,1088.0,
13906,,A,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL627405,BAO_0000218,1088.0,
13907,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627406,BAO_0000218,1088.0,
13908,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627407,BAO_0000218,1088.0,
13909,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627408,BAO_0000218,1088.0,
13910,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627409,BAO_0000218,1088.0,
13911,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL875486,BAO_0000218,1088.0,
13912,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627410,BAO_0000218,1088.0,
13913,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627411,BAO_0000218,1088.0,
13914,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627412,BAO_0000218,1088.0,
13915,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627413,BAO_0000218,1088.0,
13916,,A,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627414,BAO_0000218,1088.0,
13917,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627415,BAO_0000218,1088.0,
13918,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627416,BAO_0000218,1088.0,
13919,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627417,BAO_0000218,1088.0,
13920,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627418,BAO_0000218,1088.0,
13921,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627419,BAO_0000218,1088.0,
13922,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627320,BAO_0000218,1088.0,
13923,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627321,BAO_0000218,1088.0,
13924,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627322,BAO_0000218,2113.0,
13925,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627323,BAO_0000218,2113.0,
13926,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL627491,BAO_0000218,2113.0,
13927,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627492,BAO_0000218,2113.0,
13928,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627493,BAO_0000218,2113.0,
13929,,A,,In vivo,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627494,BAO_0000218,2107.0,
13930,,A,,In vivo,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627495,BAO_0000218,2107.0,
13931,,A,,In vivo,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL627496,BAO_0000218,2107.0,
13932,,A,,In vivo,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627497,BAO_0000218,2107.0,
13933,,A,,In vivo,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627498,BAO_0000218,2107.0,
13934,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627499,BAO_0000218,2048.0,
13935,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL627500,BAO_0000218,2048.0,
13936,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL627501,BAO_0000218,2048.0,
13937,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625616,BAO_0000218,2048.0,
13938,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625617,BAO_0000218,2048.0,
13939,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625618,BAO_0000218,2385.0,
13940,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625619,BAO_0000218,2385.0,
13941,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL625620,BAO_0000218,2385.0,
13942,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625621,BAO_0000218,2385.0,
13943,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625622,BAO_0000218,2385.0,
13944,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625788,BAO_0000218,2106.0,
13945,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625789,BAO_0000218,2106.0,
13946,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL625790,BAO_0000218,2106.0,
13947,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL625791,BAO_0000218,2106.0,
13948,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL622334,BAO_0000218,2106.0,
13949,,A,,In vivo,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL622335,BAO_0000218,2046.0,
13950,,A,,In vivo,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL622336,BAO_0000218,2046.0,
13951,,A,,In vivo,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL622337,BAO_0000218,2046.0,
13952,,A,,In vivo,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL622338,BAO_0000218,2046.0,
13953,,A,,In vivo,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL622339,BAO_0000218,2046.0,
13954,,A,,In vivo,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL624153,BAO_0000218,,
13955,,A,,In vivo,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL628430,BAO_0000218,,
13956,,A,,In vivo,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL628431,BAO_0000218,,
13957,,A,,In vivo,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL628432,BAO_0000218,,
13958,,A,,In vivo,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL628433,BAO_0000218,,
13959,,A,,In vivo,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,,50597,10116.0,Intermediate,1,CHEMBL628434,BAO_0000218,2106.0,
13960,,A,,In vivo,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,,50597,10116.0,Intermediate,1,CHEMBL626789,BAO_0000218,2106.0,
13961,,A,,In vivo,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",1,,,50597,10116.0,Intermediate,1,CHEMBL626790,BAO_0000218,2106.0,
13962,,A,,In vivo,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,,50597,10116.0,Intermediate,1,CHEMBL626791,BAO_0000218,2106.0,
13963,,A,,In vivo,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,,50597,10116.0,Intermediate,1,CHEMBL626792,BAO_0000218,2106.0,
13964,,A,,In vivo,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,,50597,10116.0,Intermediate,1,CHEMBL626793,BAO_0000218,2106.0,
13965,,A,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627436,BAO_0000218,,
13966,,A,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627437,BAO_0000218,,
13967,,A,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627438,BAO_0000218,,
13968,,A,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627439,BAO_0000218,,
13969,,A,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627440,BAO_0000218,,
13970,,A,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627602,BAO_0000218,,
13971,,A,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627603,BAO_0000218,,
13972,,A,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627604,BAO_0000218,,
13973,,A,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627605,BAO_0000218,,
13974,,A,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627606,BAO_0000218,,
13975,,A,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627607,BAO_0000218,,
13976,,A,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627608,BAO_0000218,,
13977,,A,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627609,BAO_0000218,,
13978,,A,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627610,BAO_0000218,,
13979,,A,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627611,BAO_0000218,,
13980,,A,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL627612,BAO_0000218,,
13981,,P,,,Octanol:water partition coefficient is evaluated,0,,,22229,,Autocuration,1,CHEMBL627613,BAO_0000100,,
13982,,P,,,Partition coefficient in 1-octanol/water system,0,,,22224,,Autocuration,1,CHEMBL627614,BAO_0000100,,
13983,,P,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,0,,,22224,,Autocuration,1,CHEMBL627615,BAO_0000100,,
13984,,P,,,Partition coefficient in octanol/water system was determined,0,,,22224,,Autocuration,1,CHEMBL627616,BAO_0000100,,
13985,,P,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,0,,,22224,,Autocuration,1,CHEMBL627617,BAO_0000100,,
13986,,A,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,0,,,22224,,Autocuration,1,CHEMBL627618,BAO_0000019,,
13987,,A,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",0,,,22224,,Autocuration,1,CHEMBL627619,BAO_0000019,,
13988,,A,,,Pseudo-first-order rate constant of the compound,0,,,22224,,Autocuration,1,CHEMBL627620,BAO_0000019,,
13989,,A,,,Pseudo-first-order rate constant with 1-min time point,0,,,22224,,Autocuration,1,CHEMBL627621,BAO_0000019,,
13990,,A,,,Pseudo-first-order rate constant without 1-min time point,0,,,22224,,Autocuration,1,CHEMBL627622,BAO_0000019,,
13991,,A,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,0,,,22224,,Autocuration,1,CHEMBL627623,BAO_0000019,,
13992,,A,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,0,,,22224,,Autocuration,1,CHEMBL627624,BAO_0000019,,
13993,,A,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,0,,,22224,,Autocuration,1,CHEMBL627625,BAO_0000019,,
13994,,A,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,0,,,22224,,Autocuration,1,CHEMBL628523,BAO_0000019,,
13995,,A,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,0,,,22224,,Autocuration,1,CHEMBL628524,BAO_0000019,,
13996,,A,,,The efflux rate constant of the compound,0,,,22224,,Autocuration,1,CHEMBL628525,BAO_0000019,,
13997,,A,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,0,,,22224,,Autocuration,1,CHEMBL625732,BAO_0000019,,
13998,,A,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,0,,,22224,,Autocuration,1,CHEMBL625733,BAO_0000019,,
13999,,F,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,0,,,22224,,Autocuration,1,CHEMBL625734,BAO_0000019,,
14000,,A,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,0,,,22224,,Autocuration,1,CHEMBL625913,BAO_0000019,,
14001,,A,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,0,,,22224,,Autocuration,1,CHEMBL625914,BAO_0000019,,
14002,,A,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,0,,,22224,,Autocuration,1,CHEMBL625915,BAO_0000019,,
14003,,A,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,0,,,22224,,Autocuration,1,CHEMBL625916,BAO_0000019,,
14004,,A,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),0,,,22224,,Autocuration,1,CHEMBL625917,BAO_0000019,,
14005,,A,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL625918,BAO_0000019,,
14006,,A,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL625919,BAO_0000019,,
14007,,A,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL625920,BAO_0000019,,
14008,,A,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL874453,BAO_0000019,,
14009,,A,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL625921,BAO_0000019,,
14010,,A,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,0,,,22224,,Autocuration,1,CHEMBL625922,BAO_0000019,,
14011,,A,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL625923,BAO_0000019,,
14012,,A,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL625924,BAO_0000019,,
14013,,A,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL625925,BAO_0000019,,
14014,,A,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL625926,BAO_0000019,,
14015,,A,,In vivo,Biodistribution in rat lung at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL627704,BAO_0000218,2048.0,
14016,,A,,In vivo,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL627705,BAO_0000218,,
14017,,A,,In vivo,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL627706,BAO_0000218,,
14018,,A,,In vivo,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL627707,BAO_0000218,,
14019,,A,,In vivo,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL627708,BAO_0000218,,
14020,,A,,In vivo,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628361,BAO_0000218,,
14021,,A,,In vivo,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628362,BAO_0000218,,
14022,,A,,In vivo,Biodistribution in rat striatum at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628363,BAO_0000218,2435.0,
14023,,A,,In vivo,Biodistribution in rat striatum at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628364,BAO_0000218,2435.0,
14024,,A,,In vivo,Biodistribution in rat striatum at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628365,BAO_0000218,2435.0,
14025,,A,,In vivo,Biodistribution in rat striatum at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL874454,BAO_0000218,2435.0,
14026,,A,,In vivo,Biodistribution in rat striatum at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628531,BAO_0000218,2435.0,
14027,,A,,In vivo,Biodistribution in rat striatum at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628532,BAO_0000218,2435.0,
14028,,A,,In vivo,Biodistribution in rat striatum at 3 hr after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628533,BAO_0000218,2435.0,
14029,,A,,In vivo,Biodistribution in rat striatum at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628534,BAO_0000218,2435.0,
14030,,A,,In vivo,Biodistribution in rat thyroid at 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628535,BAO_0000218,2046.0,
14031,,A,,In vivo,Biodistribution in rat thyroid at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628536,BAO_0000218,2046.0,
14032,,A,,In vivo,Biodistribution in rat thyroid at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628537,BAO_0000218,2046.0,
14033,,A,,In vivo,Biodistribution in rat thyroid at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628538,BAO_0000218,2046.0,
14034,,A,,In vivo,Biodistribution in rat thyroid at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628539,BAO_0000218,2046.0,
14035,,A,,In vivo,Biodistribution in rat thyroid at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630297,BAO_0000218,2046.0,
14036,,A,,In vivo,Biodistribution in rat thyroid at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630298,BAO_0000218,2046.0,
14037,,A,,In vivo,Biodistribution in rest of brain of rat 120 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL630299,BAO_0000218,955.0,
14038,,A,,In vivo,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628094,BAO_0000218,955.0,
14039,,A,,In vivo,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628095,BAO_0000218,955.0,
14040,,A,,In vivo,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL874648,BAO_0000218,955.0,
14041,,A,,In vivo,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628096,BAO_0000218,955.0,
14042,,A,,In vivo,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628097,BAO_0000218,955.0,
14043,,A,,In vivo,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,1,,,50597,10116.0,Intermediate,1,CHEMBL628098,BAO_0000218,955.0,
14044,,A,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",0,,,22224,,Autocuration,1,CHEMBL628099,BAO_0000019,,
14045,,A,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",0,,,22224,,Autocuration,1,CHEMBL628100,BAO_0000019,,
14046,,A,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),0,,,22224,,Autocuration,1,CHEMBL628101,BAO_0000019,,
14047,,A,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",0,,,22224,,Autocuration,1,CHEMBL628102,BAO_0000019,,
14048,,A,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",0,,,22224,,Autocuration,1,CHEMBL628103,BAO_0000019,,
14049,,A,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",0,,,22224,,Autocuration,1,CHEMBL628104,BAO_0000019,,
14050,,A,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",0,,,22224,,Autocuration,1,CHEMBL628105,BAO_0000019,,
14051,,A,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",0,,,22224,,Autocuration,1,CHEMBL628106,BAO_0000019,,
14052,,A,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1,,,50597,10116.0,Intermediate,1,CHEMBL628107,BAO_0000218,1088.0,
14053,,F,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,0,,,22224,,Autocuration,1,CHEMBL628108,BAO_0000218,1088.0,
14054,,A,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1,,,50597,10116.0,Intermediate,1,CHEMBL628109,BAO_0000218,1088.0,
14055,,F,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,0,,,22224,,Autocuration,1,CHEMBL625299,BAO_0000218,1088.0,
14056,,A,,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,1,,,50597,10116.0,Intermediate,1,CHEMBL625300,BAO_0000218,1088.0,
14057,,A,,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,1,,,50597,10116.0,Intermediate,1,CHEMBL625301,BAO_0000218,1088.0,
14058,,A,,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,1,,,50597,10116.0,Intermediate,1,CHEMBL625302,BAO_0000218,1088.0,
14059,,A,,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,1,,,50597,10116.0,Intermediate,1,CHEMBL874649,BAO_0000218,1088.0,
14060,,A,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,1,,,50597,10116.0,Intermediate,1,CHEMBL625303,BAO_0000218,,
14061,,A,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL625463,BAO_0000218,,
14062,,A,,,In vitro metabolism in human liver microsomes,1,,,50587,9606.0,Intermediate,1,CHEMBL625464,BAO_0000218,2107.0,
14063,,A,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,1,,,50587,9606.0,Intermediate,1,CHEMBL625465,BAO_0000218,,
14064,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625466,BAO_0000218,1088.0,
14065,,A,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625467,BAO_0000218,1088.0,
14066,,A,,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625468,BAO_0000218,1088.0,
14067,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625469,BAO_0000218,1088.0,
14068,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625470,BAO_0000218,1088.0,
14069,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL632418,BAO_0000218,1088.0,
14070,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627250,BAO_0000218,1088.0,
14071,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627251,BAO_0000218,1088.0,
14072,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627252,BAO_0000218,1088.0,
14073,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627253,BAO_0000218,1088.0,
14074,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627254,BAO_0000218,1088.0,
14075,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL875471,BAO_0000218,1088.0,
14076,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627255,BAO_0000218,1088.0,
14077,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627256,BAO_0000218,1088.0,
14078,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627257,BAO_0000218,1088.0,
14079,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627258,BAO_0000218,1088.0,
14080,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627259,BAO_0000218,1088.0,
14081,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627260,BAO_0000218,1088.0,
14082,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623256,BAO_0000218,1088.0,
14083,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL874413,BAO_0000218,1088.0,
14084,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623257,BAO_0000218,1088.0,
14085,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623258,BAO_0000218,1088.0,
14086,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623259,BAO_0000218,1088.0,
14087,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623260,BAO_0000218,1088.0,
14088,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623261,BAO_0000218,1088.0,
14089,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623262,BAO_0000218,1088.0,
14090,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623263,BAO_0000218,1088.0,
14091,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623264,BAO_0000218,1088.0,
14092,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623265,BAO_0000218,1088.0,
14093,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623266,BAO_0000218,1088.0,
14094,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623267,BAO_0000218,1088.0,
14095,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623268,BAO_0000218,1088.0,
14096,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623269,BAO_0000218,1088.0,
14097,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623270,BAO_0000218,1088.0,
14098,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623271,BAO_0000218,1088.0,
14099,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623272,BAO_0000218,1088.0,
14100,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623273,BAO_0000218,1088.0,
14101,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623274,BAO_0000218,1088.0,
14102,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL874414,BAO_0000218,1088.0,
14103,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623275,BAO_0000218,1088.0,
14104,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL629150,BAO_0000218,1088.0,
14105,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623276,BAO_0000218,1088.0,
14106,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623277,BAO_0000218,1088.0,
14107,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623112,BAO_0000218,1088.0,
14108,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623113,BAO_0000218,1088.0,
14109,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623800,BAO_0000218,1088.0,
14110,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623801,BAO_0000218,1088.0,
14111,,A,,In vivo,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,,50597,10116.0,Intermediate,1,CHEMBL623802,BAO_0000218,2106.0,
14112,,A,,In vivo,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623803,BAO_0000218,995.0,
14113,,A,,In vivo,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623970,BAO_0000218,995.0,
14114,,A,,In vivo,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL623971,BAO_0000218,995.0,
14115,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623972,BAO_0000218,178.0,
14116,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623973,BAO_0000218,178.0,
14117,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623974,BAO_0000218,178.0,
14118,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623975,BAO_0000218,178.0,
14119,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623976,BAO_0000218,955.0,
14120,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623977,BAO_0000218,955.0,
14121,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623978,BAO_0000218,955.0,
14122,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623979,BAO_0000218,955.0,
14123,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623980,BAO_0000218,,
14124,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL623981,BAO_0000218,,
14125,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL626278,BAO_0000218,,
14126,,A,,In vivo,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),1,,,50597,10116.0,Intermediate,1,CHEMBL626279,BAO_0000218,,
14127,,A,,In vivo,Biodistribution in mice bladder plus excreted urine was determined,1,,,50594,10090.0,Intermediate,1,CHEMBL626280,BAO_0000218,,
14128,,A,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626281,BAO_0000218,,
14129,,A,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626282,BAO_0000218,,
14130,,A,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626283,BAO_0000218,,
14131,,A,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626284,BAO_0000218,,
14132,,A,,,"Percentage biodistribution in mouse brain, 10 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626285,BAO_0000218,955.0,
14133,,A,,,"Percentage biodistribution in mouse brain, 30 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626286,BAO_0000218,955.0,
14134,,A,,,"Percentage biodistribution in mouse brain, 5 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626287,BAO_0000218,955.0,
14135,,A,,,"Percentage biodistribution in mouse brain, 60 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626288,BAO_0000218,955.0,
14136,,A,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626289,BAO_0000218,,
14137,,A,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626290,BAO_0000218,,
14138,,A,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626291,BAO_0000218,,
14139,,A,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL839888,BAO_0000218,,
14140,,A,,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626292,BAO_0000218,160.0,
14141,,A,,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626293,BAO_0000218,160.0,
14142,,A,,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626294,BAO_0000218,160.0,
14143,,A,,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL626295,BAO_0000218,160.0,
14144,,A,,,"Percentage biodistribution in mouse liver, 10 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL627659,BAO_0000218,2107.0,
14145,,A,,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL627660,BAO_0000218,2107.0,
14146,,A,,,"Percentage biodistribution in mouse liver, 5 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL627661,BAO_0000218,2107.0,
14147,,A,,In vivo,Biodistribution in mice liver at 60 minutes of post injection,1,,,50594,10090.0,Intermediate,1,CHEMBL627662,BAO_0000218,2107.0,
14148,,A,,In vivo,Biodistribution in mice lungs at 10 min of post injection,1,,,50594,10090.0,Intermediate,1,CHEMBL627663,BAO_0000218,2048.0,
14149,,A,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL627664,BAO_0000218,,
14150,,A,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",1,,,50594,10090.0,Intermediate,1,CHEMBL627665,BAO_0000218,,
14151,,A,,In vivo,Biodistribution in mice lungs at 60 min of post injection,1,,,50594,10090.0,Intermediate,1,CHEMBL627666,BAO_0000218,2048.0,
14152,,A,,,Percentage biodistribution in mouse spleen,1,,,50594,10090.0,Intermediate,1,CHEMBL627667,BAO_0000218,2106.0,
14153,,A,,,Percentage biodistribution in mouse stomach,1,,,50594,10090.0,Intermediate,1,CHEMBL627668,BAO_0000218,945.0,
14154,,A,,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,1,,,50594,10090.0,Intermediate,1,CHEMBL627669,BAO_0000218,1088.0,
14155,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,0,,,22224,,Autocuration,1,CHEMBL627670,BAO_0000218,1255.0,
14156,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,0,,,22224,,Autocuration,1,CHEMBL627671,BAO_0000218,178.0,
14157,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,0,,,22224,,Autocuration,1,CHEMBL627672,BAO_0000218,1474.0,
14158,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,0,,,22224,,Autocuration,1,CHEMBL627673,BAO_0000218,,
14159,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,0,,,22224,,Autocuration,1,CHEMBL627674,BAO_0000218,2113.0,
14160,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,0,,,22224,,Autocuration,1,CHEMBL627675,BAO_0000218,2107.0,
14161,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,0,,,22224,,Autocuration,1,CHEMBL627676,BAO_0000218,2048.0,
14162,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,0,,,22224,,Autocuration,1,CHEMBL627677,BAO_0000218,2385.0,
14163,,A,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL627678,BAO_0000019,,
14164,,A,,,Affinity for protein binding expressed as association constant in fresh rat serum,1,,,50597,10116.0,Intermediate,1,CHEMBL627679,BAO_0000218,1977.0,
14165,,A,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,0,,,22224,,Autocuration,1,CHEMBL627680,BAO_0000019,,
14166,,A,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,0,,,22224,,Autocuration,1,CHEMBL627681,BAO_0000019,,
14167,,A,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,0,,,22224,,Autocuration,1,CHEMBL627682,BAO_0000019,,
14168,,A,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,0,,,22224,,Autocuration,1,CHEMBL627683,BAO_0000019,,
14169,,A,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,0,,,22224,,Autocuration,1,CHEMBL627684,BAO_0000019,,
14170,,A,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",0,,,22224,,Autocuration,1,CHEMBL874441,BAO_0000019,,
14171,,A,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,0,,,22224,,Autocuration,1,CHEMBL627685,BAO_0000019,,
14172,,A,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",0,,,22224,,Autocuration,1,CHEMBL627686,BAO_0000019,,
14173,,A,,,Apparent rate constant Koff for inactivation of dTMP synthase.,0,,,22224,,Autocuration,1,CHEMBL627687,BAO_0000019,,
14174,,A,,,The irreversible inhibitor activity by second order rate equation.,0,,,22224,,Autocuration,1,CHEMBL627688,BAO_0000019,,
14175,,A,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL628038,BAO_0000218,,
14176,,A,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL628039,BAO_0000218,,
14177,,A,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,1,,,50597,10116.0,Intermediate,1,CHEMBL628040,BAO_0000218,,
14178,,A,,,Dissociation rate calculated from the first-order equation using t1/2 value,0,,,22224,,Autocuration,1,CHEMBL628041,BAO_0000019,,
14179,,A,,,The compound was tested for Binding constant against DNA,0,,,22224,,Autocuration,1,CHEMBL630226,BAO_0000019,,
14180,,A,,,First order rate constant for cyclization of the compound,0,,,22224,,Autocuration,1,CHEMBL628042,BAO_0000019,,
14181,,A,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,0,,,22224,,Autocuration,1,CHEMBL625232,BAO_0000019,,
14182,,A,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,0,,,22224,,Autocuration,1,CHEMBL625233,BAO_0000019,,
14183,,A,,,Hydrolysis rate constant was determined,0,,,22224,,Autocuration,1,CHEMBL625979,BAO_0000019,,
14184,,A,,,Observed first order rate constant,0,,,22224,,Autocuration,1,CHEMBL625980,BAO_0000019,,
14185,,A,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,0,,,22224,,Autocuration,1,CHEMBL625981,BAO_0000019,,
14186,,A,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,0,,,22224,,Autocuration,1,CHEMBL625982,BAO_0000019,,
14187,,A,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL625983,BAO_0000019,,
14188,,A,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625984,BAO_0000019,,
14189,,A,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625985,BAO_0000019,,
14190,,A,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625986,BAO_0000019,,
14191,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625987,BAO_0000019,,
14192,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625988,BAO_0000019,,
14193,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625989,BAO_0000019,,
14194,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625990,BAO_0000019,,
14195,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625991,BAO_0000019,,
14196,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625992,BAO_0000019,,
14197,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL625993,BAO_0000019,,
14198,,A,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL631973,BAO_0000019,,
14199,,A,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632143,BAO_0000019,,
14200,,A,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632144,BAO_0000019,,
14201,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632145,BAO_0000019,,
14202,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632146,BAO_0000019,,
14203,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632147,BAO_0000019,,
14204,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632148,BAO_0000019,,
14205,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632149,BAO_0000019,,
14206,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632150,BAO_0000019,,
14207,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL632151,BAO_0000019,,
14208,,A,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,1,,,50587,9606.0,Intermediate,1,CHEMBL632152,BAO_0000218,,
14209,,A,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,1,,,50587,9606.0,Intermediate,1,CHEMBL632153,BAO_0000218,,
14210,,A,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,1,,,50587,9606.0,Intermediate,1,CHEMBL632154,BAO_0000218,,
14211,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,1,,,50602,10298.0,Intermediate,1,CHEMBL632155,BAO_0000218,,
14212,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,1,,,50602,10298.0,Intermediate,1,CHEMBL632156,BAO_0000218,,
14213,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,1,,,50602,10298.0,Intermediate,1,CHEMBL632157,BAO_0000218,,
14214,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,1,,,50602,10298.0,Intermediate,1,CHEMBL632158,BAO_0000218,,
14215,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,1,,,50602,10298.0,Intermediate,1,CHEMBL632159,BAO_0000218,,
14216,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,1,,,50602,10298.0,Intermediate,1,CHEMBL626305,BAO_0000218,,
14217,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,1,,,50602,10298.0,Intermediate,1,CHEMBL626306,BAO_0000218,,
14218,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,1,,,50602,10298.0,Intermediate,1,CHEMBL626307,BAO_0000218,,
14219,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,1,,,50602,10298.0,Intermediate,1,CHEMBL626308,BAO_0000218,,
14220,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,1,,,50602,10298.0,Intermediate,1,CHEMBL626479,BAO_0000218,,
14221,,A,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,1,,,50602,10298.0,Intermediate,1,CHEMBL626480,BAO_0000218,,
14222,,P,,,Calculated partition coefficient (clogP) (MlogP),0,,,22229,,Autocuration,1,CHEMBL626481,BAO_0000100,,
14223,,A,,,Equipotent potent ratio relative to carbachol (nicotinic activity),0,,,22224,,Autocuration,1,CHEMBL626482,BAO_0000019,,
14224,,A,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",1,,,50588,9615.0,Intermediate,1,CHEMBL626483,BAO_0000218,,
14225,,A,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",1,,,50588,9615.0,Intermediate,1,CHEMBL626484,BAO_0000218,,
14226,,P,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,0,,,22229,,Autocuration,1,CHEMBL626485,BAO_0000100,,
14227,,P,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,0,,,22229,,Autocuration,1,CHEMBL626486,BAO_0000100,,
14228,,P,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,0,,,22229,,Autocuration,1,CHEMBL626487,BAO_0000100,,
14229,,A,,In vivo,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,,,50588,9615.0,Intermediate,1,CHEMBL626488,BAO_0000218,1969.0,
14230,,A,,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,1,,,50597,10116.0,Intermediate,1,CHEMBL626489,BAO_0000218,1977.0,
14231,,A,,,Area under the MAP curve measured over 5 min; ND means Not determined,0,,,22224,,Autocuration,1,CHEMBL626490,BAO_0000019,,
14232,,P,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,0,,,22224,,Autocuration,1,CHEMBL626491,BAO_0000100,,
14233,,P,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,0,,,22229,,Autocuration,1,CHEMBL626492,BAO_0000100,,
14234,,A,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,0,,,22224,,Autocuration,1,CHEMBL626493,BAO_0000019,,
14235,,A,,In vivo,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL626494,BAO_0000218,,
14236,,A,,In vivo,Half life after oral tested,0,,,22224,,Autocuration,1,CHEMBL626495,BAO_0000218,,
14237,,A,,,Half life was determined in plasma of rat; NT indicates not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL626496,BAO_0000218,1969.0,
14238,,A,,In vivo,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL626497,BAO_0000218,,
14239,,A,,In vivo,Oral bioavailability after oral tested,0,,,22224,,Autocuration,1,CHEMBL626498,BAO_0000218,,
14240,,A,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),1,,,50597,10116.0,Intermediate,1,CHEMBL626499,BAO_0000218,,
14241,,A,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),1,,,50597,10116.0,Intermediate,1,CHEMBL626500,BAO_0000218,,
14242,,A,,,half life was determined in plasma of rat; NT indicates not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL626501,BAO_0000218,1969.0,
14243,,A,,,half life was determined in plasma of rat; NT means not tested,1,,,50597,10116.0,Intermediate,1,CHEMBL626502,BAO_0000218,1969.0,
14244,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,1,,,50597,10116.0,Intermediate,1,CHEMBL626503,BAO_0000218,,
14245,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,1,,,50597,10116.0,Intermediate,1,CHEMBL626504,BAO_0000218,,
14246,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,1,,,50597,10116.0,Intermediate,1,CHEMBL626505,BAO_0000218,,
14247,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,1,,,50597,10116.0,Intermediate,1,CHEMBL626506,BAO_0000218,,
14248,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,1,,,50597,10116.0,Intermediate,1,CHEMBL626507,BAO_0000218,,
14249,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,1,,,50597,10116.0,Intermediate,1,CHEMBL626508,BAO_0000218,,
14250,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,1,,,50597,10116.0,Intermediate,1,CHEMBL626509,BAO_0000218,,
14251,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,1,,,50597,10116.0,Intermediate,1,CHEMBL875480,BAO_0000218,,
14252,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,1,,,50597,10116.0,Intermediate,1,CHEMBL626510,BAO_0000218,,
14253,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,1,,,50597,10116.0,Intermediate,1,CHEMBL626511,BAO_0000218,,
14254,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,1,,,50597,10116.0,Intermediate,1,CHEMBL626512,BAO_0000218,,
14255,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,1,,,50597,10116.0,Intermediate,1,CHEMBL628208,BAO_0000218,,
14256,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,1,,,50597,10116.0,Intermediate,1,CHEMBL628209,BAO_0000218,,
14257,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,1,,,50597,10116.0,Intermediate,1,CHEMBL628210,BAO_0000218,,
14258,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,1,,,50597,10116.0,Intermediate,1,CHEMBL628211,BAO_0000218,,
14259,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,1,,,50597,10116.0,Intermediate,1,CHEMBL628212,BAO_0000218,,
14260,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,1,,,50597,10116.0,Intermediate,1,CHEMBL628213,BAO_0000218,,
14261,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628214,BAO_0000218,1088.0,
14262,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628215,BAO_0000218,1088.0,
14263,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628216,BAO_0000218,1088.0,
14264,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626595,BAO_0000218,1088.0,
14265,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626596,BAO_0000218,1088.0,
14266,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626597,BAO_0000218,1088.0,
14267,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626598,BAO_0000218,1088.0,
14268,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL622242,BAO_0000218,1088.0,
14269,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL622243,BAO_0000218,1088.0,
14270,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL622244,BAO_0000218,1088.0,
14271,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL622245,BAO_0000218,1088.0,
14272,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL622246,BAO_0000218,1088.0,
14273,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL622247,BAO_0000218,1088.0,
14274,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL622248,BAO_0000218,1088.0,
14275,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL877483,BAO_0000218,1088.0,
14276,,A,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL622249,BAO_0000218,1088.0,
14277,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622250,BAO_0000218,1088.0,
14278,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622251,BAO_0000218,1088.0,
14279,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622252,BAO_0000218,1088.0,
14280,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622253,BAO_0000218,1088.0,
14281,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622254,BAO_0000218,1088.0,
14282,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622255,BAO_0000218,1088.0,
14283,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622256,BAO_0000218,1088.0,
14284,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622257,BAO_0000218,1088.0,
14285,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622258,BAO_0000218,1088.0,
14286,,A,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622259,BAO_0000218,1088.0,
14287,,A,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622927,BAO_0000218,1088.0,
14288,,A,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622928,BAO_0000218,1088.0,
14289,,A,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL622929,BAO_0000218,1088.0,
14290,,A,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL623182,BAO_0000218,1088.0,
14291,,A,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL623183,BAO_0000218,1088.0,
14292,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623184,BAO_0000218,1088.0,
14293,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623185,BAO_0000218,1088.0,
14294,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL877484,BAO_0000218,1088.0,
14295,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL627274,BAO_0000218,1088.0,
14296,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623186,BAO_0000218,1088.0,
14297,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623187,BAO_0000218,1088.0,
14298,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL623188,BAO_0000218,1088.0,
14299,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628055,BAO_0000218,1088.0,
14300,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628056,BAO_0000218,1088.0,
14301,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628200,BAO_0000218,1088.0,
14302,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628201,BAO_0000218,1088.0,
14303,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628202,BAO_0000218,1088.0,
14304,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628203,BAO_0000218,1088.0,
14305,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628204,BAO_0000218,1088.0,
14306,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628205,BAO_0000218,1088.0,
14307,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628206,BAO_0000218,1088.0,
14308,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),0,,,22224,,Autocuration,1,CHEMBL628207,BAO_0000218,2367.0,
14309,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,0,,,22224,,Autocuration,1,CHEMBL627220,BAO_0000218,2367.0,
14310,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,0,,,22224,,Autocuration,1,CHEMBL627221,BAO_0000218,2385.0,
14311,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),0,,,22224,,Autocuration,1,CHEMBL627222,BAO_0000218,2367.0,
14312,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,0,,,22224,,Autocuration,1,CHEMBL627223,BAO_0000218,,
14313,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,0,,,22224,,Autocuration,1,CHEMBL632062,BAO_0000218,2385.0,
14314,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,0,,,22224,,Autocuration,1,CHEMBL632063,BAO_0000218,2106.0,
14315,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,0,,,22224,,Autocuration,1,CHEMBL632064,BAO_0000218,1255.0,
14316,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,0,,,22224,,Autocuration,1,CHEMBL632065,BAO_0000218,178.0,
14317,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,0,,,22224,,Autocuration,1,CHEMBL632066,BAO_0000218,1474.0,
14318,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,0,,,22224,,Autocuration,1,CHEMBL632067,BAO_0000218,,
14319,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,0,,,22224,,Autocuration,1,CHEMBL629188,BAO_0000218,2113.0,
14320,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,0,,,22224,,Autocuration,1,CHEMBL629189,BAO_0000218,2107.0,
14321,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,0,,,22224,,Autocuration,1,CHEMBL629190,BAO_0000218,2048.0,
14322,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,0,,,22224,,Autocuration,1,CHEMBL629191,BAO_0000218,2385.0,
14323,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),0,,,22224,,Autocuration,1,CHEMBL629192,BAO_0000218,2367.0,
14324,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,0,,,22224,,Autocuration,1,CHEMBL629193,BAO_0000218,2385.0,
14325,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),0,,,22224,,Autocuration,1,CHEMBL629194,BAO_0000218,2367.0,
14326,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,0,,,22224,,Autocuration,1,CHEMBL629195,BAO_0000218,,
14327,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,0,,,22224,,Autocuration,1,CHEMBL629373,BAO_0000218,2385.0,
14328,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,0,,,22224,,Autocuration,1,CHEMBL629374,BAO_0000218,2106.0,
14329,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,0,,,22224,,Autocuration,1,CHEMBL629375,BAO_0000218,2367.0,
14330,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,0,,,22224,,Autocuration,1,CHEMBL629376,BAO_0000218,1255.0,
14331,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,0,,,22224,,Autocuration,1,CHEMBL629377,BAO_0000218,178.0,
14332,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,0,,,22224,,Autocuration,1,CHEMBL629378,BAO_0000218,1474.0,
14333,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,0,,,22224,,Autocuration,1,CHEMBL629379,BAO_0000218,,
14334,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,0,,,22224,,Autocuration,1,CHEMBL629151,BAO_0000218,2113.0,
14335,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,0,,,22224,,Autocuration,1,CHEMBL629152,BAO_0000218,2107.0,
14336,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,0,,,22224,,Autocuration,1,CHEMBL629153,BAO_0000218,2048.0,
14337,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,0,,,22224,,Autocuration,1,CHEMBL629154,BAO_0000218,2385.0,
14338,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),0,,,22224,,Autocuration,1,CHEMBL629155,BAO_0000218,2367.0,
14339,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,0,,,22224,,Autocuration,1,CHEMBL629156,BAO_0000218,2367.0,
14340,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,0,,,22224,,Autocuration,1,CHEMBL629157,BAO_0000218,2385.0,
14341,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),0,,,22224,,Autocuration,1,CHEMBL629158,BAO_0000218,2367.0,
14342,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,0,,,22224,,Autocuration,1,CHEMBL629159,BAO_0000218,,
14343,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,0,,,22224,,Autocuration,1,CHEMBL629160,BAO_0000218,2385.0,
14344,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,0,,,22224,,Autocuration,1,CHEMBL629161,BAO_0000218,2106.0,
14345,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,0,,,22224,,Autocuration,1,CHEMBL629162,BAO_0000218,1255.0,
14346,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,0,,,22224,,Autocuration,1,CHEMBL629163,BAO_0000218,178.0,
14347,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,0,,,22224,,Autocuration,1,CHEMBL629164,BAO_0000218,1474.0,
14348,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,0,,,22224,,Autocuration,1,CHEMBL629165,BAO_0000218,,
14349,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,0,,,22224,,Autocuration,1,CHEMBL629166,BAO_0000218,2107.0,
14350,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,0,,,22224,,Autocuration,1,CHEMBL629167,BAO_0000218,2048.0,
14351,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,0,,,22224,,Autocuration,1,CHEMBL629168,BAO_0000218,2385.0,
14352,,A,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,0,,,22224,,Autocuration,1,CHEMBL629169,BAO_0000019,,
14353,,A,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,0,,,22224,,Autocuration,1,CHEMBL629170,BAO_0000019,,
14354,,A,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,0,,,22224,,Autocuration,1,CHEMBL631153,BAO_0000019,,
14355,,A,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,0,,,22224,,Autocuration,1,CHEMBL875121,BAO_0000019,,
14356,,A,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,0,,,22224,,Autocuration,1,CHEMBL631154,BAO_0000019,,
14357,,A,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,0,,,22224,,Autocuration,1,CHEMBL631155,BAO_0000019,,
14358,,A,,,Hydrolysis rate constant was determined,0,,,22224,,Autocuration,1,CHEMBL631156,BAO_0000019,,
14359,,A,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",0,,,22224,,Autocuration,1,CHEMBL631157,BAO_0000019,,
14360,,A,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",0,,,22224,,Autocuration,1,CHEMBL631158,BAO_0000019,,
14361,,A,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",0,,,22224,,Autocuration,1,CHEMBL631159,BAO_0000019,,
14362,,A,,,Observed second order rate constant,0,,,22224,,Autocuration,1,CHEMBL631160,BAO_0000019,,
14363,,A,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,0,,,22224,,Autocuration,1,CHEMBL631161,BAO_0000019,,
14364,,A,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,0,,,22224,,Autocuration,1,CHEMBL631162,BAO_0000019,,
14365,,A,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,0,,,22224,,Autocuration,1,CHEMBL630313,BAO_0000019,,
14366,,A,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",0,,,22224,,Autocuration,1,CHEMBL630314,BAO_0000019,,
14367,,A,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",0,,,22224,,Autocuration,1,CHEMBL630315,BAO_0000019,,
14368,,A,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630316,BAO_0000019,,
14369,,A,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630986,BAO_0000019,,
14370,,A,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630987,BAO_0000019,,
14371,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630988,BAO_0000019,,
14372,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630989,BAO_0000019,,
14373,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630990,BAO_0000019,,
14374,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630991,BAO_0000019,,
14375,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630992,BAO_0000019,,
14376,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630993,BAO_0000019,,
14377,,A,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,0,,,22224,,Autocuration,1,CHEMBL630994,BAO_0000019,,
14378,,A,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,1,,,50597,10116.0,Intermediate,1,CHEMBL630995,BAO_0000218,,
14379,,A,,,Association constant for compound at 31 degree C was determined,0,,,22224,,Autocuration,1,CHEMBL629252,BAO_0000019,,
14380,,A,,,Calculated antagonist equilibrium dissociation constant of the compound,0,,,22224,,Autocuration,1,CHEMBL629253,BAO_0000019,,
14381,,A,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,0,,,22224,,Autocuration,1,CHEMBL629944,BAO_0000019,,
14382,,A,,,Dissociation constants vs LTE4 on guinea pig trachea,1,,,50512,10141.0,Intermediate,1,CHEMBL629945,BAO_0000218,3126.0,
14383,,A,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",0,,,22224,,Autocuration,1,CHEMBL629946,BAO_0000019,,
14384,,A,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",0,,,22224,,Autocuration,1,CHEMBL629947,BAO_0000019,,
14385,,A,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",0,,,22224,,Autocuration,1,CHEMBL629948,BAO_0000019,,
14386,,A,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",0,,,22224,,Autocuration,1,CHEMBL856024,BAO_0000019,,
14387,,A,,,Affinity constant KD value was derived from TMP,0,,,22224,,Autocuration,1,CHEMBL629949,BAO_0000019,,
14388,,A,,,Apparent dissociation (binding) rate constant was evaluated,0,,,22224,,Autocuration,1,CHEMBL629950,BAO_0000019,,
14389,,P,,,Dissociation constant (KD) of the compound,0,,,22224,,Autocuration,1,CHEMBL630127,BAO_0000100,,
14390,,P,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,0,,,22224,,Autocuration,1,CHEMBL630128,BAO_0000100,,
14391,,P,,,Dissociation constant from ESR titration experiments,0,,,22224,,Autocuration,1,CHEMBL630129,BAO_0000100,,
14392,,,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),0,,,22224,,Autocuration,1,CHEMBL630130,BAO_0000019,,
14393,,P,,,Dissociation constant was evaluated.,0,,,22224,,Autocuration,1,CHEMBL875234,BAO_0000100,,
14394,,P,,,Dissociation constant was reported,0,,,22224,,Autocuration,1,CHEMBL630131,BAO_0000100,,
14395,,A,,,Dissociation constant was determined in rat pituitary cells.,1,,,50597,10116.0,Intermediate,1,CHEMBL630132,BAO_0000218,,
14396,,A,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,0,,,22224,,Autocuration,1,CHEMBL630133,BAO_0000019,,
14397,,A,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,0,,,22224,,Autocuration,1,CHEMBL630134,BAO_0000019,,
14398,,A,,,Equilibrium dissociation constant of the compound,0,,,22224,,Autocuration,1,CHEMBL630135,BAO_0000019,,
14399,,A,,,Equilibrium dissociation constant was determined,0,,,22224,,Autocuration,1,CHEMBL630136,BAO_0000019,,
14400,,A,,,Kinetic constant KD was evaluated,0,,,22224,,Autocuration,1,CHEMBL630137,BAO_0000019,,
14401,,A,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,0,,,22224,,Autocuration,1,CHEMBL630138,BAO_0000019,,
14402,,A,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,0,,,22224,,Autocuration,1,CHEMBL630139,BAO_0000019,,
14403,,A,,,Rate constant for hydrolysis in aqueous acetone.,0,,,22224,,Autocuration,1,CHEMBL630140,BAO_0000019,,
14404,,A,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,0,,,22224,,Autocuration,1,CHEMBL875235,BAO_0000019,,
14405,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,1,,,50597,10116.0,Intermediate,1,CHEMBL876439,BAO_0000218,,
14406,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,1,,,50597,10116.0,Intermediate,1,CHEMBL630605,BAO_0000218,,
14407,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,1,,,50597,10116.0,Intermediate,1,CHEMBL630606,BAO_0000218,,
14408,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,1,,,50597,10116.0,Intermediate,1,CHEMBL630607,BAO_0000218,,
14409,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,1,,,50597,10116.0,Intermediate,1,CHEMBL630608,BAO_0000218,,
14410,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,1,,,50597,10116.0,Intermediate,1,CHEMBL630609,BAO_0000218,,
14411,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,1,,,50597,10116.0,Intermediate,1,CHEMBL630610,BAO_0000218,,
14412,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,1,,,50597,10116.0,Intermediate,1,CHEMBL630611,BAO_0000218,,
14413,,A,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,1,,,50597,10116.0,Intermediate,1,CHEMBL629552,BAO_0000218,,
14414,,A,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629733,BAO_0000218,,
14415,,A,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629734,BAO_0000218,,
14416,,A,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629735,BAO_0000218,,
14417,,A,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629736,BAO_0000218,,
14418,,A,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629737,BAO_0000218,,
14419,,A,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629738,BAO_0000218,,
14420,,A,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629739,BAO_0000218,,
14421,,A,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL629740,BAO_0000218,,
14422,,A,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629741,BAO_0000218,,
14423,,A,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629742,BAO_0000218,,
14424,,A,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629743,BAO_0000218,,
14425,,A,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629744,BAO_0000218,,
14426,,A,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629745,BAO_0000218,,
14427,,A,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629746,BAO_0000218,,
14428,,A,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629747,BAO_0000218,,
14429,,A,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629748,BAO_0000218,,
14430,,A,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629749,BAO_0000218,,
14431,,A,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629750,BAO_0000218,,
14432,,A,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629751,BAO_0000218,,
14433,,A,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629752,BAO_0000218,,
14434,,A,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629753,BAO_0000218,,
14435,,A,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629754,BAO_0000218,,
14436,,A,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629755,BAO_0000218,,
14437,,A,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629756,BAO_0000218,,
14438,,A,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629757,BAO_0000218,,
14439,,A,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629758,BAO_0000218,,
14440,,A,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629759,BAO_0000218,,
14441,,A,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL629760,BAO_0000218,,
14442,,A,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,,,50597,10116.0,Intermediate,1,CHEMBL876443,BAO_0000218,,
14443,,A,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,1,,,50588,9615.0,Intermediate,1,CHEMBL629761,BAO_0000218,,
14444,,A,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,1,,,50588,9615.0,Intermediate,1,CHEMBL629762,BAO_0000218,,
14445,,A,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL629763,BAO_0000218,,
14446,,A,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL629764,BAO_0000218,,
14447,,A,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL629765,BAO_0000218,,
14448,,A,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL629766,BAO_0000218,,
14449,,A,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL629767,BAO_0000218,,
14450,,A,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,1,,,50588,9615.0,Intermediate,1,CHEMBL629768,BAO_0000218,,
14451,,A,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL629769,BAO_0000218,,
14452,,A,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,1,,,50588,9615.0,Intermediate,1,CHEMBL629770,BAO_0000218,,
14453,,A,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,1,,,50588,9615.0,Intermediate,1,CHEMBL629771,BAO_0000218,,
14454,,A,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL629772,BAO_0000218,,
14455,,A,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL629773,BAO_0000218,,
14456,,A,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL625455,BAO_0000218,,
14457,,A,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL625456,BAO_0000218,,
14458,,A,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,1,,,50594,10090.0,Intermediate,1,CHEMBL625457,BAO_0000218,,
14459,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625458,BAO_0000218,1088.0,
14460,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625459,BAO_0000218,1088.0,
14461,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL875483,BAO_0000218,1088.0,
14462,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL634779,BAO_0000218,1088.0,
14463,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625460,BAO_0000218,1088.0,
14464,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626117,BAO_0000218,1088.0,
14465,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626118,BAO_0000218,1088.0,
14466,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628342,BAO_0000218,1088.0,
14467,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628343,BAO_0000218,1088.0,
14468,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628344,BAO_0000218,1088.0,
14469,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628345,BAO_0000218,1088.0,
14470,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628346,BAO_0000218,1088.0,
14471,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628347,BAO_0000218,1088.0,
14472,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628348,BAO_0000218,1088.0,
14473,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628349,BAO_0000218,1088.0,
14474,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL875611,BAO_0000218,1088.0,
14475,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628350,BAO_0000218,1088.0,
14476,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628351,BAO_0000218,1088.0,
14477,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628352,BAO_0000218,1088.0,
14478,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628353,BAO_0000218,1088.0,
14479,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628354,BAO_0000218,1088.0,
14480,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626667,BAO_0000218,1088.0,
14481,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626668,BAO_0000218,1088.0,
14482,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626669,BAO_0000218,1088.0,
14483,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626670,BAO_0000218,1088.0,
14484,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626671,BAO_0000218,1088.0,
14485,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626672,BAO_0000218,1088.0,
14486,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626673,BAO_0000218,1088.0,
14487,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626674,BAO_0000218,1088.0,
14488,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626675,BAO_0000218,1088.0,
14489,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626676,BAO_0000218,1088.0,
14490,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626677,BAO_0000218,1088.0,
14491,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626678,BAO_0000218,1088.0,
14492,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626679,BAO_0000218,1088.0,
14493,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL875612,BAO_0000218,1088.0,
14494,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626680,BAO_0000218,1088.0,
14495,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626681,BAO_0000218,1088.0,
14496,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626682,BAO_0000218,1088.0,
14497,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626683,BAO_0000218,1088.0,
14498,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626684,BAO_0000218,1088.0,
14499,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626685,BAO_0000218,1088.0,
14500,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626686,BAO_0000218,1088.0,
14501,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626687,BAO_0000218,1088.0,
14502,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL624978,BAO_0000218,1088.0,
14503,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL624979,BAO_0000218,1088.0,
14504,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL624980,BAO_0000218,1088.0,
14505,,A,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL624981,BAO_0000218,1088.0,
14506,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL624982,BAO_0000218,1088.0,
14507,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),0,,,22224,,Autocuration,1,CHEMBL627564,BAO_0000218,2367.0,
14508,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),0,,,22224,,Autocuration,1,CHEMBL627565,BAO_0000218,2367.0,
14509,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,0,,,22224,,Autocuration,1,CHEMBL627566,BAO_0000218,,
14510,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,0,,,22224,,Autocuration,1,CHEMBL627567,BAO_0000218,2385.0,
14511,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,0,,,22224,,Autocuration,1,CHEMBL627568,BAO_0000218,2106.0,
14512,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,0,,,22224,,Autocuration,1,CHEMBL627569,BAO_0000218,2113.0,
14513,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,0,,,22224,,Autocuration,1,CHEMBL627570,BAO_0000218,1255.0,
14514,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,0,,,22224,,Autocuration,1,CHEMBL627571,BAO_0000218,178.0,
14515,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,0,,,22224,,Autocuration,1,CHEMBL627572,BAO_0000218,1474.0,
14516,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,0,,,22224,,Autocuration,1,CHEMBL627573,BAO_0000218,,
14517,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,0,,,22224,,Autocuration,1,CHEMBL627574,BAO_0000218,2113.0,
14518,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,0,,,22224,,Autocuration,1,CHEMBL627575,BAO_0000218,2107.0,
14519,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,0,,,22224,,Autocuration,1,CHEMBL627576,BAO_0000218,2048.0,
14520,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,0,,,22224,,Autocuration,1,CHEMBL627577,BAO_0000218,2385.0,
14521,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),0,,,22224,,Autocuration,1,CHEMBL627578,BAO_0000218,2367.0,
14522,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,0,,,22224,,Autocuration,1,CHEMBL627579,BAO_0000218,2367.0,
14523,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,0,,,22224,,Autocuration,1,CHEMBL627580,BAO_0000218,2385.0,
14524,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),0,,,22224,,Autocuration,1,CHEMBL627581,BAO_0000218,2367.0,
14525,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,0,,,22224,,Autocuration,1,CHEMBL627582,BAO_0000218,,
14526,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,0,,,22224,,Autocuration,1,CHEMBL627583,BAO_0000218,2385.0,
14527,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,0,,,22224,,Autocuration,1,CHEMBL627584,BAO_0000218,2106.0,
14528,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,0,,,22224,,Autocuration,1,CHEMBL627585,BAO_0000218,2367.0,
14529,,A,,In vivo,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,0,,,22224,,Autocuration,1,CHEMBL627586,BAO_0000218,2385.0,
14530,,A,,In vivo,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL627587,BAO_0000218,,
14531,,A,,In vivo,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL627588,BAO_0000218,,
14532,,A,,In vivo,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628250,BAO_0000218,,
14533,,A,,In vivo,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628251,BAO_0000218,,
14534,,A,,In vivo,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628252,BAO_0000218,10000000.0,
14535,,A,,In vivo,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628253,BAO_0000218,10000000.0,
14536,,A,,In vivo,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628254,BAO_0000218,1898.0,
14537,,A,,In vivo,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL877493,BAO_0000218,1898.0,
14538,,A,,In vivo,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628255,BAO_0000218,,
14539,,A,,In vivo,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628256,BAO_0000218,,
14540,,A,,In vivo,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628257,BAO_0000218,10000000.0,
14541,,A,,In vivo,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628258,BAO_0000218,1898.0,
14542,,A,,In vivo,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628259,BAO_0000218,,
14543,,A,,In vivo,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL628429,BAO_0000218,,
14544,,A,,In vivo,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,,,50597,10116.0,Intermediate,1,CHEMBL626862,BAO_0000218,10000000.0,
14545,,A,,In vivo,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL626863,BAO_0000218,1898.0,
14546,,A,,In vivo,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,1,,,50597,10116.0,Intermediate,1,CHEMBL625886,BAO_0000218,2037.0,
14547,,A,,In vivo,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,1,,,50597,10116.0,Intermediate,1,CHEMBL625887,BAO_0000218,2037.0,
14548,,A,,In vivo,Biodistribution of the [11C]-radiolabeled compound in rat cortex,1,,,50597,10116.0,Intermediate,1,CHEMBL625888,BAO_0000218,,
14549,,A,,In vivo,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,1,,,50597,10116.0,Intermediate,1,CHEMBL625889,BAO_0000218,,
14550,,A,,In vivo,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,1,,,50597,10116.0,Intermediate,1,CHEMBL625890,BAO_0000218,10000000.0,
14551,,A,,In vivo,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,1,,,50597,10116.0,Intermediate,1,CHEMBL625891,BAO_0000218,10000000.0,
14552,,A,,In vivo,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,1,,,50597,10116.0,Intermediate,1,CHEMBL625892,BAO_0000218,1898.0,
14553,,A,,In vivo,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,1,,,50597,10116.0,Intermediate,1,CHEMBL625893,BAO_0000218,1898.0,
14554,,A,,In vivo,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,1,,,50597,10116.0,Intermediate,1,CHEMBL625894,BAO_0000218,2037.0,
14555,,A,,In vivo,Biodistribution of the [18F]-radiolabeled compound in rat cortex,1,,,50597,10116.0,Intermediate,1,CHEMBL625895,BAO_0000218,,
14556,,A,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,0,,,22224,,Autocuration,1,CHEMBL625896,BAO_0000019,,
14557,,A,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",0,,,22224,,Autocuration,1,CHEMBL625897,BAO_0000019,,
14558,,A,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",0,,,22224,,Autocuration,1,CHEMBL625898,BAO_0000019,,
14559,,A,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",0,,,22224,,Autocuration,1,CHEMBL625899,BAO_0000019,,
14560,,A,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,0,,,22224,,Autocuration,1,CHEMBL626124,BAO_0000019,,
14561,,A,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,1,,,50212,562.0,Intermediate,1,CHEMBL628500,BAO_0000218,,
14562,,A,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",1,,,50597,10116.0,Intermediate,1,CHEMBL857856,BAO_0000218,,
14563,,A,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",1,,,50597,10116.0,Intermediate,1,CHEMBL628501,BAO_0000218,,
14564,,A,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",0,,,22224,,Autocuration,1,CHEMBL628502,BAO_0000019,,
14565,,A,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,0,,,22224,,Autocuration,1,CHEMBL628503,BAO_0000019,,
14566,,A,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL628504,BAO_0000019,,
14567,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",0,,,22224,,Autocuration,1,CHEMBL628505,BAO_0000019,,
14568,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",0,,,22224,,Autocuration,1,CHEMBL874452,BAO_0000019,,
14569,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",0,,,22224,,Autocuration,1,CHEMBL628506,BAO_0000019,,
14570,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",0,,,22224,,Autocuration,1,CHEMBL628507,BAO_0000019,,
14571,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",0,,,22224,,Autocuration,1,CHEMBL628508,BAO_0000019,,
14572,,A,,,Michaelis constant (KM) was evaluated,0,,,22224,,Autocuration,1,CHEMBL628509,BAO_0000019,,
14573,,A,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,0,,,22224,,Autocuration,1,CHEMBL628510,BAO_0000019,,
14574,,B,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,0,,,22224,,Autocuration,1,CHEMBL628511,BAO_0000019,,
14575,,B,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,0,,,22224,,Autocuration,1,CHEMBL628512,BAO_0000019,,
14576,,B,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,0,,,22224,,Autocuration,1,CHEMBL628513,BAO_0000019,,
14577,,B,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,0,,,22224,,Autocuration,1,CHEMBL628514,BAO_0000019,,
14578,,A,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,0,,,22224,,Autocuration,1,CHEMBL628515,BAO_0000019,,
14579,,A,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,0,,,22224,,Autocuration,1,CHEMBL628516,BAO_0000019,,
14580,,A,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),0,,,22224,,Autocuration,1,CHEMBL628517,BAO_0000019,,
14581,,A,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),0,,,22224,,Autocuration,1,CHEMBL628518,BAO_0000019,,
14582,,A,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,0,,,22224,,Autocuration,1,CHEMBL628519,BAO_0000019,,
14583,,A,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,0,,,22224,,Autocuration,1,CHEMBL628520,BAO_0000019,,
14584,,A,,,Binding constant was determined,0,,,22224,,Autocuration,1,CHEMBL628521,BAO_0000019,,
14585,,A,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL630443,BAO_0000019,,
14586,,A,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,0,,,22224,,Autocuration,1,CHEMBL630444,BAO_0000019,,
14587,,A,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,0,,,22224,,Autocuration,1,CHEMBL857732,BAO_0000019,,
14588,,P,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,0,,,22224,,Autocuration,1,CHEMBL630445,BAO_0000100,,
14589,,A,,,Catalytic rate constant of the compound,0,,,22224,,Autocuration,1,CHEMBL630446,BAO_0000019,,
14590,,B,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,0,,,22224,,Autocuration,1,CHEMBL630447,BAO_0000019,,
14591,,A,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),0,,,22224,,Autocuration,1,CHEMBL630448,BAO_0000019,,
14592,,A,,,Catalytic rate constant against phospholipase A2 was determined,0,,,22224,,Autocuration,1,CHEMBL630449,BAO_0000019,,
14593,,A,,,"Compound was evaluated for catalytic constant, Kcat",0,,,22224,,Autocuration,1,CHEMBL630450,BAO_0000019,,
14594,,A,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,0,,,22224,,Autocuration,1,CHEMBL630451,BAO_0000019,,
14595,,A,,,Kcat calculated from 0.693/T1/2,0,,,22224,,Autocuration,1,CHEMBL630452,BAO_0000019,,
14596,,A,,,Kcat was determined,0,,,22224,,Autocuration,1,CHEMBL630453,BAO_0000019,,
14597,,A,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,0,,,22224,,Autocuration,1,CHEMBL630454,BAO_0000019,,
14598,,A,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,0,,,22224,,Autocuration,1,CHEMBL630455,BAO_0000019,,
14599,,A,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,0,,,22224,,Autocuration,1,CHEMBL631487,BAO_0000019,,
14600,,A,,,Kcat value was determined,0,,,22224,,Autocuration,1,CHEMBL631488,BAO_0000019,,
14601,,A,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,0,,,22224,,Autocuration,1,CHEMBL876440,BAO_0000019,,
14602,,A,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,0,,,22224,,Autocuration,1,CHEMBL631489,BAO_0000019,,
14603,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",0,,,22224,,Autocuration,1,CHEMBL857742,BAO_0000019,,
14604,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",0,,,22224,,Autocuration,1,CHEMBL631490,BAO_0000019,,
14605,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",0,,,22224,,Autocuration,1,CHEMBL631491,BAO_0000019,,
14606,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",0,,,22224,,Autocuration,1,CHEMBL631492,BAO_0000019,,
14607,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",0,,,22224,,Autocuration,1,CHEMBL631493,BAO_0000019,,
14608,,A,,,Kinetic parameter for rate of conversion to PABA was determined,0,,,22224,,Autocuration,1,CHEMBL631494,BAO_0000019,,
14609,,A,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,0,,,22224,,Autocuration,1,CHEMBL631495,BAO_0000019,,
14610,,A,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL631496,BAO_0000218,1988.0,
14611,,A,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL631497,BAO_0000218,1088.0,
14612,,A,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL631498,BAO_0000218,1088.0,
14613,,A,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL629776,BAO_0000218,1088.0,
14614,,A,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL629777,BAO_0000218,1088.0,
14615,,A,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1,,,50597,10116.0,Intermediate,1,CHEMBL629778,BAO_0000218,1088.0,
14616,,A,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630456,BAO_0000218,,
14617,,A,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630457,BAO_0000218,,
14618,,A,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630458,BAO_0000218,,
14619,,A,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630459,BAO_0000218,,
14620,,A,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630460,BAO_0000218,,
14621,,A,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL876550,BAO_0000218,,
14622,,A,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630461,BAO_0000218,,
14623,,A,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630462,BAO_0000218,,
14624,,A,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630463,BAO_0000218,,
14625,,A,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630464,BAO_0000218,,
14626,,A,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630465,BAO_0000218,,
14627,,A,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630466,BAO_0000218,,
14628,,A,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630467,BAO_0000218,,
14629,,A,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630633,BAO_0000218,,
14630,,A,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630634,BAO_0000218,,
14631,,A,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630635,BAO_0000218,,
14632,,A,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630636,BAO_0000218,,
14633,,A,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,1,,,50597,10116.0,Intermediate,1,CHEMBL630637,BAO_0000218,,
14634,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1,,,50592,9986.0,Intermediate,1,CHEMBL630638,BAO_0000218,1988.0,
14635,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1,,,50592,9986.0,Intermediate,1,CHEMBL630639,BAO_0000218,1988.0,
14636,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1,,,50592,9986.0,Intermediate,1,CHEMBL630640,BAO_0000218,1988.0,
14637,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1,,,50592,9986.0,Intermediate,1,CHEMBL876551,BAO_0000218,1988.0,
14638,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",1,,,50592,9986.0,Intermediate,1,CHEMBL630641,BAO_0000218,1088.0,
14639,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1,,,50592,9986.0,Intermediate,1,CHEMBL630642,BAO_0000218,1088.0,
14640,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1,,,50592,9986.0,Intermediate,1,CHEMBL630643,BAO_0000218,1088.0,
14641,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1,,,50592,9986.0,Intermediate,1,CHEMBL630644,BAO_0000218,1088.0,
14642,,A,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1,,,50592,9986.0,Intermediate,1,CHEMBL630645,BAO_0000218,1088.0,
14643,,A,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1,,,50592,9986.0,Intermediate,1,CHEMBL625599,BAO_0000218,1988.0,
14644,,A,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1,,,50592,9986.0,Intermediate,1,CHEMBL625600,BAO_0000218,1988.0,
14645,,A,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1,,,50592,9986.0,Intermediate,1,CHEMBL625601,BAO_0000218,1988.0,
14646,,A,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1,,,50592,9986.0,Intermediate,1,CHEMBL625602,BAO_0000218,1988.0,
14647,,A,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",1,,,50592,9986.0,Intermediate,1,CHEMBL627470,BAO_0000218,1088.0,
14648,,A,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1,,,50592,9986.0,Intermediate,1,CHEMBL627471,BAO_0000218,1088.0,
14649,,A,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1,,,50592,9986.0,Intermediate,1,CHEMBL627472,BAO_0000218,1088.0,
14650,,A,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1,,,50592,9986.0,Intermediate,1,CHEMBL627473,BAO_0000218,1088.0,
14651,,A,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1,,,50592,9986.0,Intermediate,1,CHEMBL627474,BAO_0000218,1088.0,
14652,,A,,In vivo,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627475,BAO_0000218,178.0,
14653,,A,,In vivo,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL627476,BAO_0000218,178.0,
14654,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627477,BAO_0000218,1088.0,
14655,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627478,BAO_0000218,1088.0,
14656,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627479,BAO_0000218,1088.0,
14657,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627480,BAO_0000218,1088.0,
14658,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627481,BAO_0000218,1088.0,
14659,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627482,BAO_0000218,1088.0,
14660,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL627483,BAO_0000218,1088.0,
14661,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL875636,BAO_0000218,1088.0,
14662,,A,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625764,BAO_0000218,1088.0,
14663,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625765,BAO_0000218,1088.0,
14664,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625766,BAO_0000218,1088.0,
14665,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625767,BAO_0000218,1088.0,
14666,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625768,BAO_0000218,1088.0,
14667,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625769,BAO_0000218,1088.0,
14668,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625770,BAO_0000218,1088.0,
14669,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625771,BAO_0000218,1088.0,
14670,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625772,BAO_0000218,1088.0,
14671,,A,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,,,50588,9615.0,Intermediate,1,CHEMBL625773,BAO_0000218,1088.0,
14672,,A,,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625774,BAO_0000218,1088.0,
14673,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625775,BAO_0000218,1088.0,
14674,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625776,BAO_0000218,1088.0,
14675,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625777,BAO_0000218,1088.0,
14676,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625778,BAO_0000218,1088.0,
14677,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625779,BAO_0000218,1088.0,
14678,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625780,BAO_0000218,1088.0,
14679,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL625781,BAO_0000218,1088.0,
14680,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL875637,BAO_0000218,1088.0,
14681,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626473,BAO_0000218,1088.0,
14682,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626474,BAO_0000218,1088.0,
14683,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626475,BAO_0000218,1088.0,
14684,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626476,BAO_0000218,1088.0,
14685,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL634397,BAO_0000218,1088.0,
14686,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL626477,BAO_0000218,1088.0,
14687,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631069,BAO_0000218,1088.0,
14688,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631070,BAO_0000218,1088.0,
14689,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631071,BAO_0000218,1088.0,
14690,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631072,BAO_0000218,1088.0,
14691,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631073,BAO_0000218,1088.0,
14692,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631074,BAO_0000218,1088.0,
14693,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631075,BAO_0000218,1088.0,
14694,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631725,BAO_0000218,1088.0,
14695,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631726,BAO_0000218,1088.0,
14696,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631727,BAO_0000218,1088.0,
14697,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631728,BAO_0000218,1088.0,
14698,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631729,BAO_0000218,1088.0,
14699,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631730,BAO_0000218,1088.0,
14700,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631731,BAO_0000218,1088.0,
14701,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631910,BAO_0000218,1088.0,
14702,,A,,In vivo,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,1,,,50597,10116.0,Intermediate,1,CHEMBL631911,BAO_0000218,10000000.0,
14703,,A,,In vivo,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,1,,,50597,10116.0,Intermediate,1,CHEMBL631912,BAO_0000218,1898.0,
14704,,A,,In vivo,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,1,,,50597,10116.0,Intermediate,1,CHEMBL631913,BAO_0000218,1898.0,
14705,,A,,In vivo,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631914,BAO_0000218,178.0,
14706,,A,,In vivo,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631915,BAO_0000218,178.0,
14707,,A,,In vivo,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL875778,BAO_0000218,178.0,
14708,,A,,In vivo,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631916,BAO_0000218,178.0,
14709,,A,,In vivo,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631917,BAO_0000218,178.0,
14710,,A,,In vivo,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631918,BAO_0000218,178.0,
14711,,A,,In vivo,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631919,BAO_0000218,178.0,
14712,,A,,In vivo,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL631920,BAO_0000218,178.0,
14713,,A,,In vivo,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631921,BAO_0000218,178.0,
14714,,A,,In vivo,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631922,BAO_0000218,178.0,
14715,,A,,In vivo,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL631923,BAO_0000218,178.0,
14716,,A,,In vivo,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631924,BAO_0000218,,
14717,,A,,In vivo,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630234,BAO_0000218,,
14718,,A,,In vivo,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL630235,BAO_0000218,,
14719,,A,,In vivo,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630236,BAO_0000218,,
14720,,A,,In vivo,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630237,BAO_0000218,,
14721,,A,,In vivo,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630238,BAO_0000218,,
14722,,A,,In vivo,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630239,BAO_0000218,,
14723,,A,,In vivo,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL630303,BAO_0000218,,
14724,,A,,In vivo,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630304,BAO_0000218,,
14725,,A,,In vivo,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630305,BAO_0000218,,
14726,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630306,BAO_0000218,2113.0,
14727,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630307,BAO_0000218,2113.0,
14728,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL630308,BAO_0000218,2113.0,
14729,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630309,BAO_0000218,2113.0,
14730,,A,,In vivo,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL629309,BAO_0000218,2113.0,
14731,,A,,In vivo,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL629993,BAO_0000218,2113.0,
14732,,A,,In vivo,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL629994,BAO_0000218,2113.0,
14733,,A,,In vivo,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL629995,BAO_0000218,2113.0,
14734,,A,,In vivo,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631993,BAO_0000218,2113.0,
14735,,A,,In vivo,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631994,BAO_0000218,2113.0,
14736,,A,,In vivo,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631995,BAO_0000218,2113.0,
14737,,A,,In vivo,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL631996,BAO_0000218,2107.0,
14738,,A,,In vivo,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631997,BAO_0000218,2107.0,
14739,,A,,In vivo,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631998,BAO_0000218,2107.0,
14740,,A,,In vivo,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631999,BAO_0000218,2107.0,
14741,,A,,In vivo,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL632000,BAO_0000218,2107.0,
14742,,A,,In vivo,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL632001,BAO_0000218,2107.0,
14743,,A,,In vivo,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL874424,BAO_0000218,2107.0,
14744,,A,,In vivo,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL632002,BAO_0000218,2107.0,
14745,,A,,In vivo,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL632003,BAO_0000218,2107.0,
14746,,A,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,0,,,22224,,Autocuration,1,CHEMBL632004,BAO_0000019,,
14747,,A,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,0,,,22224,,Autocuration,1,CHEMBL632005,BAO_0000019,,
14748,,A,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,0,,,22224,,Autocuration,1,CHEMBL632006,BAO_0000019,,
14749,,A,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,0,,,22224,,Autocuration,1,CHEMBL632007,BAO_0000019,,
14750,,A,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,0,,,22224,,Autocuration,1,CHEMBL632008,BAO_0000019,,
14751,,A,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,0,,,22224,,Autocuration,1,CHEMBL632009,BAO_0000019,,
14752,,A,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,0,,,22224,,Autocuration,1,CHEMBL632010,BAO_0000019,,
14753,,A,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,0,,,22224,,Autocuration,1,CHEMBL857750,BAO_0000019,,
14754,,A,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,0,,,22224,,Autocuration,1,CHEMBL632011,BAO_0000019,,
14755,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",0,,,22224,,Autocuration,1,CHEMBL632012,BAO_0000019,,
14756,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",0,,,22224,,Autocuration,1,CHEMBL632013,BAO_0000019,,
14757,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",0,,,22224,,Autocuration,1,CHEMBL632014,BAO_0000019,,
14758,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",0,,,22224,,Autocuration,1,CHEMBL629622,BAO_0000019,,
14759,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",0,,,22224,,Autocuration,1,CHEMBL629623,BAO_0000019,,
14760,,A,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",0,,,22224,,Autocuration,1,CHEMBL629624,BAO_0000019,,
14761,,A,,,Ratio of Kcat to that of Km was determined,0,,,22224,,Autocuration,1,CHEMBL629625,BAO_0000019,,
14762,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",0,,,22224,,Autocuration,1,CHEMBL629626,BAO_0000019,,
14763,,A,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",0,,,22224,,Autocuration,1,CHEMBL629627,BAO_0000019,,
14764,,A,,,"Compound was evaluated for constant, Kd",0,,,22224,,Autocuration,1,CHEMBL629628,BAO_0000019,,
14765,,A,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,0,,,22224,,Autocuration,1,CHEMBL629629,BAO_0000019,,
14766,,A,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,0,,,22224,,Autocuration,1,CHEMBL629630,BAO_0000019,,
14767,,A,,,Dissociation Constant of compound determined,0,,,22224,,Autocuration,1,CHEMBL856030,BAO_0000019,,
14768,,B,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,0,,,22224,,Autocuration,1,CHEMBL629631,BAO_0000019,,
14769,,B,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,0,,,22224,,Autocuration,1,CHEMBL629632,BAO_0000019,,
14770,,P,,,Dissociation constant of compound with Fructose was determined,0,,,22224,,Autocuration,1,CHEMBL629633,BAO_0000100,,
14771,,P,,,Dissociation constant of compound with Fructose was determined; Not determined,0,,,22224,,Autocuration,1,CHEMBL629634,BAO_0000100,,
14772,,P,,,Dissociation constant of compound with Lactulose was determined,0,,,22224,,Autocuration,1,CHEMBL629635,BAO_0000100,,
14773,,P,,,Dissociation constant of compound with Lactulose was determined; Not determined,0,,,22224,,Autocuration,1,CHEMBL629636,BAO_0000100,,
14774,,P,,,Dissociation constant of the Compound,0,,,22224,,Autocuration,1,CHEMBL629637,BAO_0000100,,
14775,,P,,,Dissociation constant by non-linear regression analysis,0,,,22224,,Autocuration,1,CHEMBL629638,BAO_0000100,,
14776,,P,,,Dissociation constant was determined,0,,,22224,,Autocuration,1,CHEMBL629639,BAO_0000100,,
14777,,P,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,0,,,22224,,Autocuration,1,CHEMBL629640,BAO_0000100,,
14778,,P,,,Dissociation constant was determined,0,,,22224,,Autocuration,1,CHEMBL629641,BAO_0000100,,
14779,,P,,,Dissociation constant was determined,0,,,22224,,Autocuration,1,CHEMBL631344,BAO_0000100,,
14780,,A,,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,1,,,50597,10116.0,Intermediate,1,CHEMBL631345,BAO_0000218,2385.0,
14781,,A,,,The dissociation constant determined by fluorescence displacement assay,0,,,22224,,Autocuration,1,CHEMBL631346,BAO_0000019,,
14782,,A,,,kd value surface plasmon resonance (SPR) method,0,,,22224,,Autocuration,1,CHEMBL631524,BAO_0000019,,
14783,,A,,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,1,,,50597,10116.0,Intermediate,1,CHEMBL631525,BAO_0000218,2385.0,
14784,,F,,,First dissociation constant of the binding of compound to V30M TTR,0,,,22224,,Autocuration,1,CHEMBL631526,BAO_0000019,,
14785,,F,,,Second dissociation constant of the binding of compound to V30M TTR,0,,,22224,,Autocuration,1,CHEMBL631527,BAO_0000019,,
14786,,A,,,"Compound was evaluated for equilibrium constant, Ke",0,,,22224,,Autocuration,1,CHEMBL631528,BAO_0000019,,
14787,,A,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,0,,,22224,,Autocuration,1,CHEMBL631529,BAO_0000019,1898.0,
14788,,A,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,0,,,22224,,Autocuration,1,CHEMBL631530,BAO_0000019,1898.0,
14789,,A,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL631531,BAO_0000019,,
14790,,A,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL631532,BAO_0000019,,
14791,,A,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL631533,BAO_0000019,,
14792,,A,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,,,50594,10090.0,Intermediate,1,CHEMBL876552,BAO_0000218,,
14793,,A,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,1,,,50594,10090.0,Intermediate,1,CHEMBL631534,BAO_0000218,,
14794,,A,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,,,50594,10090.0,Intermediate,1,CHEMBL631535,BAO_0000218,,
14795,,A,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,,,50594,10090.0,Intermediate,1,CHEMBL631536,BAO_0000218,,
14796,,A,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,1,,,50594,10090.0,Intermediate,1,CHEMBL631537,BAO_0000218,,
14797,,A,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,1,,,50594,10090.0,Intermediate,1,CHEMBL631538,BAO_0000218,,
14798,,A,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,1,,,50594,10090.0,Intermediate,1,CHEMBL631539,BAO_0000218,,
14799,,A,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,,,50594,10090.0,Intermediate,1,CHEMBL631540,BAO_0000218,,
14800,,A,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625637,BAO_0000218,,
14801,,A,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,,50597,10116.0,Intermediate,1,CHEMBL625638,BAO_0000218,,
14802,,A,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,,,50597,10116.0,Intermediate,1,CHEMBL625639,BAO_0000218,,
14803,,A,,In vivo,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625640,BAO_0000218,955.0,
14804,,A,,In vivo,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625641,BAO_0000218,955.0,
14805,,A,,In vivo,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625642,BAO_0000218,948.0,
14806,,A,,In vivo,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625643,BAO_0000218,948.0,
14807,,A,,In vivo,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625644,BAO_0000218,2113.0,
14808,,A,,In vivo,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625645,BAO_0000218,2113.0,
14809,,A,,In vivo,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625646,BAO_0000218,2107.0,
14810,,A,,In vivo,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625647,BAO_0000218,2107.0,
14811,,A,,In vivo,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625648,BAO_0000218,2048.0,
14812,,A,,In vivo,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625649,BAO_0000218,2048.0,
14813,,A,,In vivo,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625650,BAO_0000218,2385.0,
14814,,A,,In vivo,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625651,BAO_0000218,2385.0,
14815,,A,,In vivo,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625652,BAO_0000218,14.0,
14816,,A,,In vivo,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625653,BAO_0000218,14.0,
14817,,A,,In vivo,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625654,BAO_0000218,2106.0,
14818,,A,,In vivo,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,,50597,10116.0,Intermediate,1,CHEMBL625655,BAO_0000218,2106.0,
14819,,A,,In vivo,Biodistribution of Compound in rat blood after 15 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625656,BAO_0000218,178.0,
14820,,A,,In vivo,Biodistribution of Compound in rat blood after 2 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625657,BAO_0000218,178.0,
14821,,A,,In vivo,Biodistribution of Compound in rat brain after 15 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625658,BAO_0000218,955.0,
14822,,A,,In vivo,Biodistribution of Compound in rat brain after 2 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625659,BAO_0000218,955.0,
14823,,A,,In vivo,Biodistribution of Compound in rat heart after 15 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625660,BAO_0000218,948.0,
14824,,A,,In vivo,Biodistribution of Compound in rat heart after 2 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625661,BAO_0000218,948.0,
14825,,A,,In vivo,Biodistribution of Compound in rat liver after 15 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625662,BAO_0000218,2107.0,
14826,,A,,In vivo,Biodistribution of Compound in rat liver after 2 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL625663,BAO_0000218,2107.0,
14827,,A,,In vivo,Biodistribution of Compound in rat lung after 15 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL875621,BAO_0000218,2048.0,
14828,,A,,In vivo,Biodistribution of Compound in rat lung after 2 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL628382,BAO_0000218,2048.0,
14829,,A,,In vivo,Biodistribution of Compound in rat muscle after 15 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL628383,BAO_0000218,2385.0,
14830,,A,,In vivo,Biodistribution of Compound in rat muscle after 2 minutes of administration,1,,,50597,10116.0,Intermediate,1,CHEMBL628384,BAO_0000218,2385.0,
14831,,A,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,1,,,50597,10116.0,Intermediate,1,CHEMBL628385,BAO_0000218,,
14832,,A,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,1,,,50597,10116.0,Intermediate,1,CHEMBL875753,BAO_0000218,,
14833,,A,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,1,,,50597,10116.0,Intermediate,1,CHEMBL628386,BAO_0000218,,
14834,,A,,,Organ distribution in rat blood 2 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL628387,BAO_0000218,,
14835,,A,,,Organ distribution in rat blood 2 hr after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL628388,BAO_0000218,,
14836,,A,,,Organ distribution in rat blood 30 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL628389,BAO_0000218,,
14837,,A,,,Organ distribution in rat blood 30 min after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL632756,BAO_0000218,,
14838,,A,,,Organ distribution in rat brain 2 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL628390,BAO_0000218,,
14839,,A,,,Organ distribution in rat brain 2 hr after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631811,BAO_0000218,,
14840,,A,,,Organ distribution in rat brain 30 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631812,BAO_0000218,,
14841,,A,,,Organ distribution in rat heart 2 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631813,BAO_0000218,,
14842,,A,,,Organ distribution in rat heart 2 hr after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631814,BAO_0000218,,
14843,,A,,,Organ distribution in rat heart 30 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631815,BAO_0000218,,
14844,,A,,,Organ distribution in rat kidney 2 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631816,BAO_0000218,,
14845,,A,,,Organ distribution in rat kidney 2 hr after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL875758,BAO_0000218,,
14846,,A,,,Organ distribution in rat kidney 30 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631817,BAO_0000218,,
14847,,A,,,Organ distribution in rat liver 2 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631818,BAO_0000218,2107.0,
14848,,A,,,Organ distribution in rat liver 2 hr after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631819,BAO_0000218,2107.0,
14849,,A,,,Organ distribution in rat liver 30 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631820,BAO_0000218,2107.0,
14850,,A,,,Organ distribution in rat lung 2 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631821,BAO_0000218,,
14851,,A,,,Organ distribution in rat lung 2 hr after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631822,BAO_0000218,,
14852,,A,,,Organ distribution in rat lung 30 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631823,BAO_0000218,,
14853,,A,,,Organ distribution in rat muscle 2 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631824,BAO_0000218,2385.0,
14854,,A,,,Organ distribution in rat muscle 2 hr after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631825,BAO_0000218,2385.0,
14855,,A,,,Organ distribution in rat muscle 30 minutes after intravenous injection,1,,,50597,10116.0,Intermediate,1,CHEMBL631826,BAO_0000218,2385.0,
14856,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL631827,BAO_0000218,,
14857,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),1,,,50594,10090.0,Intermediate,1,CHEMBL631828,BAO_0000218,,
14858,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),1,,,50594,10090.0,Intermediate,1,CHEMBL631829,BAO_0000218,,
14859,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL875759,BAO_0000218,1088.0,
14860,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631830,BAO_0000218,1088.0,
14861,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631831,BAO_0000218,1088.0,
14862,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631832,BAO_0000218,1088.0,
14863,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631833,BAO_0000218,1088.0,
14864,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631834,BAO_0000218,1088.0,
14865,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631835,BAO_0000218,1088.0,
14866,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631836,BAO_0000218,1088.0,
14867,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631837,BAO_0000218,1088.0,
14868,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631838,BAO_0000218,1088.0,
14869,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631839,BAO_0000218,1088.0,
14870,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631840,BAO_0000218,1088.0,
14871,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631841,BAO_0000218,1088.0,
14872,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631842,BAO_0000218,1088.0,
14873,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631843,BAO_0000218,1088.0,
14874,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631844,BAO_0000218,1088.0,
14875,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631845,BAO_0000218,1088.0,
14876,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631846,BAO_0000218,1088.0,
14877,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL875760,BAO_0000218,1088.0,
14878,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL632199,BAO_0000218,1088.0,
14879,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631847,BAO_0000218,1088.0,
14880,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL631848,BAO_0000218,1088.0,
14881,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628707,BAO_0000218,1088.0,
14882,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628708,BAO_0000218,1088.0,
14883,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628709,BAO_0000218,1088.0,
14884,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628710,BAO_0000218,1088.0,
14885,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628711,BAO_0000218,1088.0,
14886,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628712,BAO_0000218,1088.0,
14887,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628713,BAO_0000218,1088.0,
14888,,A,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,,,50597,10116.0,Intermediate,1,CHEMBL628714,BAO_0000218,1088.0,
14889,,A,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",1,,,50597,10116.0,Intermediate,1,CHEMBL628715,BAO_0000218,,
14890,,A,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,0,,,22224,,Autocuration,1,CHEMBL629179,BAO_0000019,,
14891,,A,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,0,,,22224,,Autocuration,1,CHEMBL629180,BAO_0000019,,
14892,,A,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,0,,,22224,,Autocuration,1,CHEMBL875108,BAO_0000019,,
14893,,A,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629181,BAO_0000019,1235.0,
14894,,A,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629182,BAO_0000019,1235.0,
14895,,A,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629183,BAO_0000019,,
14896,,A,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629184,BAO_0000019,,
14897,,A,,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629185,BAO_0000019,1235.0,
14898,,A,,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629186,BAO_0000019,1235.0,
14899,,A,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629187,BAO_0000019,,
14900,,A,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629887,BAO_0000019,,
14901,,A,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629888,BAO_0000019,,
14902,,A,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629889,BAO_0000019,,
14903,,A,,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629890,BAO_0000019,1235.0,
14904,,A,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629891,BAO_0000019,,
14905,,A,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629892,BAO_0000019,,
14906,,A,,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629893,BAO_0000019,1235.0,
14907,,A,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629894,BAO_0000019,,
14908,,A,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,0,,,22224,,Autocuration,1,CHEMBL629895,BAO_0000019,,
14909,,A,,In vivo,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",0,,,22224,9615.0,Autocuration,1,CHEMBL875109,BAO_0000218,,
14910,,A,,In vivo,Absolute bioavailability in male cynomolgus monkeys,0,,,22224,9541.0,Autocuration,1,CHEMBL629896,BAO_0000218,,
14911,,A,,In vivo,Absolute bioavailability in maleSprague-Dawley rats,0,,,22224,10116.0,Autocuration,1,CHEMBL629897,BAO_0000218,,
14912,,A,,In vivo,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL629898,BAO_0000218,2107.0,
14913,,A,,In vivo,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630057,BAO_0000218,2107.0,
14914,,A,,In vivo,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630058,BAO_0000218,2107.0,
14915,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630059,BAO_0000218,2048.0,
14916,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630060,BAO_0000218,2048.0,
14917,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL630061,BAO_0000218,2048.0,
14918,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630062,BAO_0000218,2048.0,
14919,,A,,In vivo,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630063,BAO_0000218,2048.0,
14920,,A,,In vivo,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630064,BAO_0000218,2048.0,
14921,,A,,In vivo,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630065,BAO_0000218,2048.0,
14922,,A,,In vivo,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL630066,BAO_0000218,2048.0,
14923,,A,,In vivo,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630067,BAO_0000218,2048.0,
14924,,A,,In vivo,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630068,BAO_0000218,2048.0,
14925,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631113,BAO_0000218,2385.0,
14926,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631114,BAO_0000218,2385.0,
14927,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL631115,BAO_0000218,2385.0,
14928,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL631116,BAO_0000218,2385.0,
14929,,A,,In vivo,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630528,BAO_0000218,2385.0,
14930,,A,,In vivo,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630529,BAO_0000218,2385.0,
14931,,A,,In vivo,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630530,BAO_0000218,2385.0,
14932,,A,,In vivo,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL630531,BAO_0000218,2385.0,
14933,,A,,In vivo,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630532,BAO_0000218,2385.0,
14934,,A,,In vivo,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630533,BAO_0000218,2385.0,
14935,,A,,In vivo,Biodistribution in normal mice blood after 120 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630534,BAO_0000218,178.0,
14936,,A,,In vivo,Biodistribution in normal mice blood after 24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630535,BAO_0000218,178.0,
14937,,A,,In vivo,Biodistribution in normal mice blood after 4 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630536,BAO_0000218,178.0,
14938,,A,,In vivo,Biodistribution in normal mice bone after 120 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630537,BAO_0000218,10000001.0,
14939,,A,,In vivo,Biodistribution in normal mice bone after 24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630538,BAO_0000218,10000001.0,
14940,,A,,In vivo,Biodistribution in normal mice bone after 4 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630539,BAO_0000218,10000001.0,
14941,,A,,In vivo,Biodistribution in normal mice heart after 120 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630540,BAO_0000218,948.0,
14942,,A,,In vivo,Biodistribution in normal mice heart after 24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630541,BAO_0000218,948.0,
14943,,A,,In vivo,Biodistribution in normal mice heart after 4 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630542,BAO_0000218,948.0,
14944,,A,,In vivo,Biodistribution in normal mice kidney after 120 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630543,BAO_0000218,2113.0,
14945,,A,,In vivo,Biodistribution in normal mice kidney after 24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630544,BAO_0000218,2113.0,
14946,,A,,In vivo,Biodistribution in normal mice kidney after 4 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630545,BAO_0000218,2113.0,
14947,,A,,In vivo,Biodistribution in normal mice liver after 120 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630546,BAO_0000218,2107.0,
14948,,A,,In vivo,Biodistribution in normal mice liver after 24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630547,BAO_0000218,2107.0,
14949,,A,,In vivo,Biodistribution in normal mice liver after 4 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630548,BAO_0000218,2107.0,
14950,,A,,In vivo,Biodistribution in normal mice spleen after 120 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630549,BAO_0000218,2106.0,
14951,,A,,In vivo,Biodistribution in normal mice spleen after 24 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL630550,BAO_0000218,2106.0,
14952,,A,,In vivo,Biodistribution in normal mice spleen after 4 hr,1,,,50594,10090.0,Intermediate,1,CHEMBL876426,BAO_0000218,2106.0,
14953,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630551,BAO_0000218,2106.0,
14954,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630552,BAO_0000218,2106.0,
14955,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL630553,BAO_0000218,2106.0,
14956,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630554,BAO_0000218,2106.0,
14957,,A,,In vivo,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630555,BAO_0000218,2106.0,
14958,,A,,In vivo,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630556,BAO_0000218,2106.0,
14959,,A,,In vivo,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630557,BAO_0000218,2106.0,
14960,,A,,In vivo,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,,50597,10116.0,Intermediate,1,CHEMBL630558,BAO_0000218,2106.0,
14961,,A,,In vivo,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630559,BAO_0000218,2106.0,
14962,,A,,In vivo,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL630560,BAO_0000218,2106.0,
14963,,A,,In vivo,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,,50597,10116.0,Intermediate,1,CHEMBL876427,BAO_0000218,2046.0,
14964,,A,,,The Kel values in female wistar rats.,1,,,50597,10116.0,Intermediate,1,CHEMBL630561,BAO_0000218,,
14965,,A,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL630562,BAO_0000019,,
14966,,A,,,Hydrolysis rate constant of the compound,0,,,22224,,Autocuration,1,CHEMBL630563,BAO_0000019,,
14967,,P,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,0,,,22229,,Autocuration,1,CHEMBL629673,BAO_0000100,,
14968,,A,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",0,,,22224,,Autocuration,1,CHEMBL629674,BAO_0000019,,
14969,,A,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",0,,,22224,,Autocuration,1,CHEMBL629675,BAO_0000019,,
14970,,A,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",0,,,22224,,Autocuration,1,CHEMBL629676,BAO_0000019,,
14971,,A,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",0,,,22224,,Autocuration,1,CHEMBL629677,BAO_0000019,,
14972,,A,,,Apparent inactivation rate constant was evaluated,0,,,22224,,Autocuration,1,CHEMBL629678,BAO_0000019,,
14973,,A,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,0,,,22224,,Autocuration,1,CHEMBL629679,BAO_0000019,,
14974,,A,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,0,,,22224,,Autocuration,1,CHEMBL629680,BAO_0000019,,
14975,,A,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,0,,,22224,,Autocuration,1,CHEMBL629681,BAO_0000019,,
14976,,A,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,0,,,22224,,Autocuration,1,CHEMBL629682,BAO_0000019,,
14977,,A,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,0,,,22224,,Autocuration,1,CHEMBL629683,BAO_0000019,,
14978,,F,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,0,,,22224,,Autocuration,1,CHEMBL629684,BAO_0000019,,
14979,,P,,,Dissociation constant was determined,0,,,22224,,Autocuration,1,CHEMBL629685,BAO_0000100,,
14980,,P,,,Dissociation constant was determined,0,,,22224,,Autocuration,1,CHEMBL629686,BAO_0000100,,
14981,,P,,,Dissociation constant at pH 7.4,0,,,22224,,Autocuration,1,CHEMBL872932,BAO_0000100,,
14982,,P,,,Dissociation constant in presence of 1 mM dithiothreitol,0,,,22224,,Autocuration,1,CHEMBL629687,BAO_0000100,,
14983,,A,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,0,,,22224,,Autocuration,1,CHEMBL872931,BAO_0000019,,
14984,,A,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,0,,,22224,,Autocuration,1,CHEMBL628151,BAO_0000019,,
14985,,A,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,0,,,22224,,Autocuration,1,CHEMBL628152,BAO_0000019,,
14986,,A,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,0,,,22224,,Autocuration,1,CHEMBL628153,BAO_0000019,,
14987,,A,,,Kinetic constant for aromatization of androstenedione,0,,,22224,,Autocuration,1,CHEMBL628154,BAO_0000019,,
14988,,A,,,Kinetic constant for aromatization of testosterone,0,,,22224,,Autocuration,1,CHEMBL628155,BAO_0000019,,
14989,,A,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,0,,,22224,,Autocuration,1,CHEMBL628156,BAO_0000019,,
14990,,A,,,Local inhibition constant was determined,0,,,22224,,Autocuration,1,CHEMBL628157,BAO_0000019,,
14991,,A,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,1,,,50347,4932.0,Intermediate,1,CHEMBL857533,BAO_0000218,,
14992,,P,,,Dissociation constant value of the compound,0,,,22224,,Autocuration,1,CHEMBL628158,BAO_0000100,,
14993,,A,,,In vitro permeability through cornea without epithelium,0,,,22224,,Autocuration,1,CHEMBL628159,BAO_0000019,964.0,
14994,,A,,,In vitro permeability through intact cornea,0,,,22224,,Autocuration,1,CHEMBL875616,BAO_0000019,964.0,
14995,,A,,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,1,,,50592,9986.0,Intermediate,1,CHEMBL628160,BAO_0000218,964.0,
14996,,A,,,Rate of enzyme inactivation for the compound was determined,0,,,22224,,Autocuration,1,CHEMBL628161,BAO_0000019,,
14997,,A,,,In vitro permeability through cornea without epithelium,0,,,22224,,Autocuration,1,CHEMBL628162,BAO_0000019,964.0,
14998,,A,,,In vitro permeability through intact cornea,0,,,22224,,Autocuration,1,CHEMBL628163,BAO_0000019,964.0,
14999,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628164,BAO_0000019,,
15000,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628165,BAO_0000019,,
15001,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628166,BAO_0000019,,
15002,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628167,BAO_0000019,,
15003,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628168,BAO_0000019,,
15004,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628169,BAO_0000019,,
15005,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628170,BAO_0000019,,
15006,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628171,BAO_0000019,,
15007,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL627434,BAO_0000019,,
15008,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL627435,BAO_0000019,,
15009,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628110,BAO_0000019,,
15010,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628111,BAO_0000019,,
15011,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628112,BAO_0000019,,
15012,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628260,BAO_0000019,,
15013,,A,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",0,,,22224,,Autocuration,1,CHEMBL628261,BAO_0000019,,
15014,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),1,,,50594,10090.0,Intermediate,1,CHEMBL628262,BAO_0000218,,
15015,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,1,,,50587,9606.0,Intermediate,1,CHEMBL628263,BAO_0000218,,
15016,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL628264,BAO_0000218,,
15017,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),1,,,50594,10090.0,Intermediate,1,CHEMBL628265,BAO_0000218,,
15018,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),1,,,50594,10090.0,Intermediate,1,CHEMBL628266,BAO_0000218,,
15019,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),1,,,50594,10090.0,Intermediate,1,CHEMBL628267,BAO_0000218,,
15020,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,1,,,50594,10090.0,Intermediate,1,CHEMBL628268,BAO_0000218,,
15021,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),1,,,50594,10090.0,Intermediate,1,CHEMBL628269,BAO_0000218,,
15022,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),1,,,50594,10090.0,Intermediate,1,CHEMBL628270,BAO_0000218,,
15023,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),1,,,50594,10090.0,Intermediate,1,CHEMBL628271,BAO_0000218,,
15024,,A,,In vivo,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),1,,,50594,10090.0,Intermediate,1,CHEMBL628272,BAO_0000218,,
